Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use

ABSTRACT

Formula I (Ia and Ib) compounds wherein (i) X 1  is N and X 2  is S, (ii) X 1  is CR 7  and X 2  is S, (iii) X 1  is N and X 2  is NR 2 , or (iv) X 1  is CR 7  and X 2  is 0, including stereoisomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. Ser. No. 12/787,613, filed 26May 2010, filed under 37 CFR §1.53(b), and claims the benefit under 35USC §119(e) of U.S. Provisional Application Ser. No. 61/181,452 filed on27 May 2009, and Ser. No. 61/287,607 filed on 17 Dec. 2009, all of whichare incorporated by reference in there entireties.

FIELD OF THE INVENTION

The invention relates generally to compounds for treating disordersmediated by lipid kinases such as inflammation, immunological, andcancer, and more specifically to compounds which inhibit PI3 kinaseactivity. The invention also relates to methods of using the compoundsfor in vitro, in situ, and in vivo diagnosis or treatment of mammaliancells, or associated pathological conditions.

BACKGROUND OF THE INVENTION

Phosphatidylinositol (PI), a phospholipid found in cell membranes, playsan important role in intracellular signal transduction. Cell signalingvia 3′-phosphorylated phosphoinositides has been implicated in a varietyof cellular processes, e.g., malignant transformation, growth factorsignaling, inflammation, and immunity (Rameh et al (1999) J. Biol Chem,274:8347-8350). The enzyme responsible for generating thesephosphorylated signaling products, phosphatidylinositol 3-kinase (alsoreferred to as PI 3-kinase or PI3K), was originally identified as anactivity associated with viral oncoproteins and growth factor receptortyrosine kinases that phosphorylate phosphatidylinositol (PI) and itsphosphorylated derivatives at the 3′-hydroxyl of the inositol ring(Panayotou et al (1992) Trends Cell Biol 2:358-60).

Phosphoinositide 3-kinases (PI3K) are lipid kinases that phosphorylatelipids at the 3-hydroxyl residue of the inositol ring ofphosphoinositols (Whitman et al (1988) Nature, 332:664). The3′-phosphorylated phospholipids (PIP3s) generated by PI3-kinases act assecond messengers recruiting kinases with lipid binding domains(including plekstrin homology (PH) regions), such as Akt andphosphoinositide-dependent kinase-1 (PDK1). Binding of Akt to membranePIP3s causes the translocation of Akt to the plasma membrane, bringingAkt into contact with PDK1, which is responsible for activating Akt. Thetumor-suppressor phosphatase, PTEN, dephosphorylates PIP3 and thereforeacts as a negative regulator of Akt activation. The PI3-kinases Akt andPDK1 are important in the regulation of many cellular processesincluding cell cycle regulation, proliferation, survival, apoptosis andmotility and are significant components of the molecular mechanisms ofdiseases such as cancer, diabetes and immune inflammation (Vivanco et al(2002) Nature Rev. Cancer 2:489; Phillips et al (1998) Cancer 83:41).

PI3 kinase is a heterodimer consisting of p85 and p110 subunits (Otsu etal (1991) Cell 65:91-104; Hiles et al (1992) Cell 70:419-29). Fourdistinct Class I PI3Ks have been identified, designated PI3K α (alpha),β (beta), δ (delta), and γ (gamma), each consisting of a distinct 110kDa catalytic subunit and a regulatory subunit. More specifically, threeof the catalytic subunits, i.e., p110 alpha, p110 beta and p110 delta,each interact with the same regulatory subunit, p85; whereas p110 gammainteracts with a distinct regulatory subunit, p101. The patterns ofexpression of each of these PI3Ks in human cells and tissues are alsodistinct.

The p110 delta isoform has been implicated in biological functionsrelated to immune-inflammatory diseases, including signaling from theB-cell receptor, T cell receptor, FcR signaling of mast cells andmonocyte/macrophage, and osteoclast function/RANKL signaling (Deane Jand Fruman D A (2004) Annu Rev. Immunol. 2004. 22:563-98; Janas et al.,The Journal of Immunology, 2008, 180: 739-746; Marone R et al., Biochim.Biophy. Acta 2007, 1784:159-185. Deletion of the PI3K delta gene orselective introduction of a catalytically inactive mutant of PI3K deltacauses a nearly complete ablation of B cell proliferation and signaling,and impairment of signaling through T cells as well.

SUMMARY OF THE INVENTION

The invention relates generally to Formula I compounds with PI3 kinaseinhibitory activity and selective binding to the p110 delta isoformrelative to binding to the p110 alpha isoform. Formula I compounds atleast 10 fold selective in binding to the p110 delta isoform relative tobinding to the p110 alpha isoform.

Formula I compounds have the structures:

and stereoisomers, tautomers, or pharmaceutically acceptable saltsthereof. The various substituents, including X¹, X², mor, R¹, R²,R^(2′), and R³, are as defined herein.

Another aspect of the invention provides a pharmaceutical compositioncomprising a Formula I compound and a pharmaceutically acceptablecarrier, glidant, diluent, or excipient.

Another aspect of the invention provides the use of a Formula I compoundin the manufacture of a medicament for treating a disease or disorderselected from cancer, immune disorders, cardiovascular disease, viralinfection, inflammation, metabolism/endocrine function disorders andneurological disorders, and mediated by the p110 delta isoform of PI3kinase.

The invention also relates to methods of using the Formula I compoundsfor in vitro, in situ, and in vivo diagnosis or treatment of mammaliancells, organisms, or associated pathological conditions, such as cancer,systemic and local inflammation, immune-inflammatory diseases such asrheumatoid arthritis, immune suppression, organ transplant rejection,allergies, ulcerative colitis, Crohn's disease, dermatitis, asthma,systemic lupus erythematosus, Sjögren's Syndrome, multiple sclerosis,scleroderma/systemic sclerosis, idiopathic thrombocytopenic purpura(ITP), anti-neutrophil cytoplasmic antibodies (ANCA) vasculitis, chronicobstructive pulmonary disease (COPD), psoriasis, and for general jointprotective effects.

Another aspect of the invention provides a method of treating a diseaseor disorder which method comprises administering a Formula I compound toa patient with a disease or disorder selected from cancer, immunedisorders, cardiovascular disease, viral infection, inflammation,metabolism/endocrine function disorders and neurological disorders, andmediated by the p110 delta isoform of PI3 kinase. The method may furthercomprise administering an additional therapeutic agent selected from achemotherapeutic agent, an anti-inflammatory agent, an immunomodulatoryagent, a neurotropic factor, an agent for treating cardiovasculardisease, an agent for treating liver disease, an anti-viral agent, anagent for treating blood disorders, an agent for treating diabetes, andan agent for treating immunodeficiency disorders.

Another aspect of the invention provides a kit for treating a conditionmediated by the p110 delta isoform of PI3 kinase, comprising a firstpharmaceutical composition comprising a Formula I compound; andinstructions for use.

DETAILED DESCRIPTION OF EXEMPLARY EMBODIMENTS

Reference will now be made in detail to certain embodiments of theinvention, examples of which are illustrated in the accompanyingstructures and formulas. While the invention will be described inconjunction with the enumerated embodiments, it will be understood thatthey are not intended to limit the invention to those embodiments. Onthe contrary, the invention is intended to cover all alternatives,modifications, and equivalents which may be included within the scope ofthe present invention as defined by the claims. One skilled in the artwill recognize many methods and materials similar or equivalent to thosedescribed herein, which could be used in the practice of the presentinvention. The present invention is in no way limited to the methods andmaterials described. In the event that one or more of the incorporatedliterature, patents, and similar materials differs from or contradictsthis application, including but not limited to defined terms, termusage, described techniques, or the like, this application controls.

DEFINITIONS

The term “alkyl” as used herein refers to a saturated linear orbranched-chain monovalent hydrocarbon radical of one to twelve carbonatoms (C₁-C₁₂), wherein the alkyl radical may be optionally substitutedindependently with one or more substituents described below. In anotherembodiment, an alkyl radical is one to eight carbon atoms (C₁-C₈), orone to six carbon atoms (C₁-C₆). Examples of alkyl groups include, butare not limited to, methyl (Me, —CH₃), ethyl (Et, —CH₂CH₃), 1-propyl(n-Pr, n-propyl, —CH₂CH₂CH₃), 2-propyl (i-Pr, i-propyl, —CH(CH₃)₂),1-butyl (n-Bu, n-butyl, —CH₂CH₂CH₂CH₃), 2-methyl-1-propyl (1-Bu,i-butyl, —CH₂CH(CH₃)₂), 2-butyl (s-Bu, s-butyl, —CH(CH₃)CH₂CH₃),2-methyl-2-propyl (t-Bu, t-butyl, —C(CH₃)₃), 1-pentyl (n-pentyl,—CH₂CH₂CH₂CH₂CH₃), 2-pentyl (—CH(CH₃)CH₂CH₂CH₃), 3-pentyl(—CH(CH₂CH₃)₂), 2-methyl-2-butyl (—C(CH₃)₂CH₂CH₃), 3-methyl-2-butyl(—CH(CH₃)CH(CH₃)₂), 3-methyl-1-butyl (—CH₂CH₂CH(CH₃)₂), 2-methyl-1-butyl(—CH₂CH(CH₃)CH₂CH₃), 1-hexyl (—CH₂CH₂CH₂CH₂CH₂CH₃), 2-hexyl(—CH(CH₃)CH₂CH₂CH₂CH₃), 3-hexyl (—CH(CH₂CH₃)(CH₂CH₂CH₃)),2-methyl-2-pentyl (—C(CH₃)₂CH₂CH₂CH₃), 3-methyl-2-pentyl(—CH(CH₃)CH(CH₃)CH₂CH₃), 4-methyl-2-pentyl (—CH(CH₃)CH₂CH(CH₃)₂),3-methyl-3-pentyl (—C(CH₃)(CH₂CH₃)₂), 2-methyl-3-pentyl(—CH(CH₂CH₃)CH(CH₃)₂), 2,3-dimethyl-2-butyl (—C(CH₃)₂CH(CH₃)₂),3,3-dimethyl-2-butyl (—CH(CH₃)C(CH₃)₃, 1-heptyl, 1-octyl, and the like.

The term “alkylene” as used herein refers to a saturated linear orbranched-chain divalent hydrocarbon radical of one to twelve carbonatoms (C₁-C₁₂), wherein the alkylene radical may be optionallysubstituted independently with one or more substituents described below.In another embodiment, an alkylene radical is one to eight carbon atoms(C₁-C₈), or one to six carbon atoms (C₁-C₆). Examples of alkylene groupsinclude, but are not limited to, methylene (—CH₂—), ethylene (—CH₂CH₂—),propylene (—CH₂CH₂CH₂—), and the like.

The term “alkenyl” refers to linear or branched-chain monovalenthydrocarbon radical of two to eight carbon atoms (C₂-C₈) with at leastone site of unsaturation, i.e., a carbon-carbon, sp² double bond,wherein the alkenyl radical may be optionally substituted independentlywith one or more substituents described herein, and includes radicalshaving “cis” and “trans” orientations, or alternatively, “E” and “Z”orientations. Examples include, but are not limited to, ethylenyl orvinyl (—CH═CH₂), allyl (—CH₂CH═CH₂), and the like.

The term “alkenylene” refers to linear or branched-chain divalenthydrocarbon radical of two to eight carbon atoms (C₂-C₈) with at leastone site of unsaturation, i.e., a carbon-carbon, sp² double bond,wherein the alkenyl radical may be optionally substituted, and includesradicals having “cis” and “trans” orientations, or alternatively, “E”and “Z” orientations. Examples include, but are not limited to,ethylenylene or vinylene (—CH═CH—), allyl (—CH₂CH═CH—), and the like.

The term “alkynyl” refers to a linear or branched monovalent hydrocarbonradical of two to eight carbon atoms (C₂-C₈) with at least one site ofunsaturation, i.e., a carbon-carbon, sp triple bond, wherein the alkynylradical may be optionally substituted independently with one or moresubstituents described herein. Examples include, but are not limited to,ethynyl (—C≡CH), propynyl (propargyl, —CH₂C≡CH), and the like.

The term “alkynylene” refers to a linear or branched divalenthydrocarbon radical of two to eight carbon atoms (C₂-C₈) with at leastone site of unsaturation, i.e., a carbon-carbon, sp triple bond, whereinthe alkynyl radical may be optionally. Examples include, but are notlimited to, ethynylene (—C≡C—), propynylene (propargylene, —CH₂C≡C—),and the like.

The terms “carbocycle”, “carbocyclyl”, “carbocyclic ring” and“cycloalkyl” refer to a monovalent non-aromatic, saturated or partiallyunsaturated ring having 3 to 12 carbon atoms (C₃-C₁₂) as a monocyclicring or 7 to 12 carbon atoms as a bicyclic ring. Bicyclic carbocycleshaving 7 to 12 atoms can be arranged, for example, as a bicyclo [4,5],[5,5], [5,6] or [6,6] system, and bicyclic carbocycles having 9 or 10ring atoms can be arranged as a bicyclo [5,6] or [6,6] system, or asbridged systems such as bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane andbicyclo[3.2.2]nonane. Examples of monocyclic carbocycles include, butare not limited to, cyclopropyl, cyclobutyl, cyclopentyl,1-cyclopent-1-enyl, 1-cyclopent-2-enyl, 1-cyclopent-3-enyl, cyclohexyl,1-cyclohex-1-enyl, 1-cyclohex-2-enyl, 1-cyclohex-3-enyl,cyclohexadienyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl,cycloundecyl, cyclododecyl, adamantanyl, and the like.

“Aryl” means a monovalent aromatic hydrocarbon radical of 6-20 carbonatoms (C₆-C₂₀) derived by the removal of one hydrogen atom from a singlecarbon atom of a parent aromatic ring system. Some aryl groups arerepresented in the exemplary structures as “Ar”. Aryl includes bicyclicradicals comprising an aromatic ring fused to a saturated, partiallyunsaturated ring, or aromatic carbocyclic ring. Typical aryl groupsinclude, but are not limited to, radicals derived from benzene (phenyl),substituted benzenes, naphthalene, anthracene, biphenyl, indenyl,indanyl, 1,2-dihydronaphthalene, 1,2,3,4-tetrahydronaphthyl, and thelike. Aryl groups are optionally substituted independently with one ormore substituents described herein.

“Arylene” means a divalent aromatic hydrocarbon radical of 6-20 carbonatoms (C₆-C₂₀) derived by the removal of two hydrogen atom from a twocarbon atoms of a parent aromatic ring system. Some arylene groups arerepresented in the exemplary structures as “Ar”. Arylene includesbicyclic radicals comprising an aromatic ring fused to a saturated,partially unsaturated ring, or aromatic carbocyclic ring. Typicalarylene groups include, but are not limited to, radicals derived frombenzene (phenylene), substituted benzenes, naphthalene, anthracene,biphenylene, indenylene, indanylene, 1,2-dihydronaphthalene,1,2,3,4-tetrahydronaphthyl, and the like. Arylene groups are optionallysubstituted.

The terms “heterocycle,” “heterocyclyl” and “heterocyclic ring” are usedinterchangeably herein and refer to a saturated or a partiallyunsaturated (i.e., having one or more double and/or triple bonds withinthe ring) carbocyclic radical of 3 to about 20 ring atoms in which atleast one ring atom is a heteroatom selected from nitrogen, oxygen,phosphorus and sulfur, the remaining ring atoms being C, where one ormore ring atoms is optionally substituted independently with one or moresubstituents described below. A heterocycle may be a monocycle having 3to 7 ring members (2 to 6 carbon atoms and 1 to 4 heteroatoms selectedfrom N, O, P, and S) or a bicycle having 7 to 10 ring members (4 to 9carbon atoms and 1 to 6 heteroatoms selected from N, O, P, and S), forexample: a bicyclo[4,5], [5,5], [5,6], or [6,6] system. Heterocycles aredescribed in Paquette, Leo A.; “Principles of Modern HeterocyclicChemistry” (W. A. Benjamin, New York, 1968), particularly Chapters 1, 3,4, 6, 7, and 9; “The Chemistry of Heterocyclic Compounds, A series ofMonographs” (John Wiley & Sons, New York, 1950 to present), inparticular Volumes 13, 14, 16, 19, and 28; and J. Am. Chem. Soc. (1960)82:5566. “Heterocyclyl” also includes radicals where heterocycleradicals are fused with a saturated, partially unsaturated ring, oraromatic carbocyclic or heterocyclic ring. Examples of heterocyclicrings include, but are not limited to, pyrrolidinyl, tetrahydrofuranyl,dihydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, dihydropyranyl,tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino,thioxanyl, piperazinyl, homopiperazinyl, azetidinyl, oxetanyl,thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl,thiazepinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H-pyranyl,4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl, dithianyl,dithiolanyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl,dihydroisoquinolinyl, tetrahydroisoquinolinyl,pyrazolidinylimidazolinyl, imidazolidinyl,2-oxa-5-azabicyclo[2.2.2]octane, 3-oxa-8-azabicyclo[3.2.1]octane,8-oxa-3-azabicyclo[3.2.1]octane, 6-oxa-3-azabicyclo[3.1.1]heptane,2-oxa-5-azabicyclo[2.2.1]heptane, 3-azabicyco[3.1.0]hexanyl,3-azabicyclo[4.1.0]heptanyl, azabicyclo[2.2.2]hexanyl, 3H-indolylquinolizinyl and N-pyridyl ureas. Spiro moieties are also includedwithin the scope of this definition. Examples of a heterocyclic groupwherein 2 ring carbon atoms are substituted with oxo (═O) moieties arepyrimidinonyl and 1,1-dioxo-thiomorpholinyl. The heterocycle groupsherein are optionally substituted independently with one or moresubstituents described herein.

The term “heteroaryl” refers to a monovalent aromatic radical of 5-, 6-,or 7-membered rings, and includes fused ring systems (at least one ofwhich is aromatic) of 5-20 atoms, containing one or more heteroatomsindependently selected from nitrogen, oxygen, and sulfur. Examples ofheteroaryl groups are pyridinyl (including, for example,2-hydroxypyridinyl), imidazolyl, imidazopyridinyl, pyrimidinyl(including, for example, 4-hydroxypyrimidinyl), pyrazolyl, triazolyl,pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl,oxadiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl,isoquinolinyl, tetrahydroisoquinolinyl, indolyl, benzimidazolyl,benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl,pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl,triazolyl, thiadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl,benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl,quinoxalinyl, naphthyridinyl, and furopyridinyl. Heteroaryl groups areoptionally substituted independently with one or more substituentsdescribed herein.

Examples of bicyclic heteroaryl groups include:

The heterocycle or heteroaryl groups may be carbon (carbon-linked), ornitrogen (nitrogen-linked) bonded where such is possible. By way ofexample and not limitation, carbon bonded heterocycles or heteroarylsare bonded at position 2, 3, 4, 5, or 6 of a pyridine, position 3, 4, 5,or 6 of a pyridazine, position 2, 4, 5, or 6 of a pyrimidine, position2, 3, 5, or 6 of a pyrazine, position 2, 3, 4, or 5 of a furan,tetrahydrofuran, thiofuran, thiophene, pyrrole or tetrahydropyrrole,position 2, 4, or 5 of an oxazole, imidazole or thiazole, position 3, 4,or 5 of an isoxazole, pyrazole, or isothiazole, position 2 or 3 of anaziridine, position 2, 3, or 4 of an azetidine, position 2, 3, 4, 5, 6,7, or 8 of a quinoline or position 1, 3, 4, 5, 6, 7, or 8 of anisoquinoline. Ring nitrogen atoms of the heterocycle or heteroarylgroups may be bonded with oxygen to form N-oxides.

By way of example and not limitation, nitrogen bonded heterocycles orheteroaryls are bonded at position 1 of an aziridine, azetidine,pyrrole, pyrrolidine, 2-pyrroline, 3-pyrroline, imidazole,imidazolidine, 2-imidazoline, 3-imidazoline, pyrazole, pyrazoline,2-pyrazoline, 3-pyrazoline, piperidine, piperazine, indole, indoline,1H-indazole, benzimidazole, position 2 of a isoindole, or isoindoline,position 4 of a morpholine, and position 9 of a carbazole, orβ-carboline.

The terms “treat” and “treatment” refer to both therapeutic treatmentand prophylactic or preventative measures, wherein the object is toprevent or slow down (lessen) an undesired physiological change ordisorder, such as the development or spread of cancer. For purposes ofthis invention, beneficial or desired clinical results include, but arenot limited to, alleviation of symptoms, diminishment of extent ofdisease, stabilized (i.e., not worsening) state of disease, delay orslowing of disease progression, amelioration or palliation of thedisease state, and remission (whether partial or total), whetherdetectable or undetectable. “Treatment” can also mean prolongingsurvival as compared to expected survival if not receiving treatment.Those in need of treatment include those already with the condition ordisorder as well as those prone to have the condition or disorder orthose in which the condition or disorder is to be prevented.

The phrase “therapeutically effective amount” means an amount of acompound of the present invention that (i) treats or prevents theparticular disease, condition, or disorder, (ii) attenuates,ameliorates, or eliminates one or more symptoms of the particulardisease, condition, or disorder, or (iii) prevents or delays the onsetof one or more symptoms of the particular disease, condition, ordisorder described herein. In the case of cancer, the therapeuticallyeffective amount of the drug may reduce the number of cancer cells;reduce the tumor size; inhibit (i.e., slow to some extent and preferablystop) cancer cell infiltration into peripheral organs; inhibit (i.e.,slow to some extent and preferably stop) tumor metastasis; inhibit, tosome extent, tumor growth; and/or relieve to some extent one or more ofthe symptoms associated with the cancer. To the extent the drug mayprevent growth and/or kill existing cancer cells, it may be cytostaticand/or cytotoxic. For cancer therapy, efficacy can be measured, forexample, by assessing the time to disease progression (TTP) and/ordetermining the response rate (RR).

“Inflammatory disorder” as used herein can refer to any disease,disorder, or syndrome in which an excessive or unregulated inflammatoryresponse leads to excessive inflammatory symptoms, host tissue damage,or loss of tissue function. “Inflammatory disorder” also refers to apathological state mediated by influx of leukocytes and/or neutrophilchemotaxis.

“Inflammation” as used herein refers to a localized, protective responseelicited by injury or destruction of tissues, which serves to destroy,dilute, or wall off (sequester) both the injurious agent and the injuredtissue. Inflammation is notably associated with influx of leukocytesand/or neutrophil chemotaxis. Inflammation can result from infectionwith pathogenic organisms and viruses and from noninfectious means suchas trauma or reperfusion following myocardial infarction or stroke,immune response to foreign antigen, and autoimmune responses.Accordingly, inflammatory disorders amenable to treatment with Formula Icompounds encompass disorders associated with reactions of the specificdefense system as well as with reactions of the nonspecific defensesystem.

“Specific defense system” refers to the component of the immune systemthat reacts to the presence of specific antigens. Examples ofinflammation resulting from a response of the specific defense systeminclude the classical response to foreign antigens, autoimmune diseases,and delayed type hypersensitivity response mediated by T-cells. Chronicinflammatory diseases, the rejection of solid transplanted tissue andorgans, e.g., kidney and bone marrow transplants, and graft versus hostdisease (GVHD), are further examples of inflammatory reactions of thespecific defense system.

The term “nonspecific defense system” as used herein refers toinflammatory disorders that are mediated by leukocytes that areincapable of immunological memory (e.g., granulocytes, and macrophages).Examples of inflammation that result, at least in part, from a reactionof the nonspecific defense system include inflammation associated withconditions such as adult (acute) respiratory distress syndrome (ARDS) ormultiple organ injury syndromes; reperfusion injury; acuteglomerulonephritis; reactive arthritis; dermatoses with acuteinflammatory components; acute purulent meningitis or other centralnervous system inflammatory disorders such as stroke; thermal injury;inflammatory bowel disease; granulocyte transfusion associatedsyndromes; and cytokine-induced toxicity.

“Autoimmune disease” as used herein refers to any group of disorders inwhich tissue injury is associated with humoral or cell-mediatedresponses to the body's own constituents.

“Allergic disease” as used herein refers to any symptoms, tissue damage,or loss of tissue function resulting from allergy. “Arthritic disease”as used herein refers to any disease that is characterized byinflammatory lesions of the joints attributable to a variety ofetiologies. “Dermatitis” as used herein refers to any of a large familyof diseases of the skin that are characterized by inflammation of theskin attributable to a variety of etiologies. “Transplant rejection” asused herein refers to any immune reaction directed against graftedtissue, such as organs or cells (e.g., bone marrow), characterized by aloss of function of the grafted and surrounding tissues, pain, swelling,leukocytosis, and thrombocytopenia. The therapeutic methods of thepresent invention include methods for the treatment of disordersassociated with inflammatory cell activation.

“Inflammatory cell activation” refers to the induction by a stimulus(including, but not limited to, cytokines, antigens or auto-antibodies)of a proliferative cellular response, the production of solublemediators (including but not limited to cytokines, oxygen radicals,enzymes, prostanoids, or vasoactive amines), or cell surface expressionof new or increased numbers of mediators (including, but not limited to,major histocompatability antigens or cell adhesion molecules) ininflammatory cells (including but not limited to monocytes, macrophages,T lymphocytes, B lymphocytes, granulocytes (i.e., polymorphonuclearleukocytes such as neutrophils, basophils, and eosinophils), mast cells,dendritic cells, Langerhans cells, and endothelial cells). It will beappreciated by persons skilled in the art that the activation of one ora combination of these phenotypes in these cells can contribute to theinitiation, perpetuation, or exacerbation of an inflammatory disorder.

The term “NSAID” is an acronym for “non-steroidal anti-inflammatorydrug” and is a therapeutic agent with analgesic, antipyretic (loweringan elevated body temperature and relieving pain without impairingconsciousness) and, in higher doses, with anti-inflammatory effects(reducing inflammation). The term “non-steroidal” is used to distinguishthese drugs from steroids, which (among a broad range of other effects)have a similar eicosanoid-depressing, anti-inflammatory action. Asanalgesics, NSAIDs are unusual in that they are non-narcotic. NSAIDsinclude aspirin, ibuprofen, and naproxen. NSAIDs are usually indicatedfor the treatment of acute or chronic conditions where pain andinflammation are present. NSAIDs are generally indicated for thesymptomatic relief of the following conditions: rheumatoid arthritis,osteoarthritis, inflammatory arthropathies (e.g. ankylosing spondylitis,psoriatic arthritis, Reiter's syndrome, acute gout, dysmenorrhoea,metastatic bone pain, headache and migraine, postoperative pain,mild-to-moderate pain due to inflammation and tissue injury, pyrexia,ileus, and renal colic. Most NSAIDs act as non-selective inhibitors ofthe enzyme cyclooxygenase, inhibiting both the cyclooxygenase-1 (COX-1)and cyclooxygenase-2 (COX-2) isoenzymes. Cyclooxygenase catalyzes theformation of prostaglandins and thromboxane from arachidonic acid(itself derived from the cellular phospholipid bilayer by phospholipaseA₂). Prostaglandins act (among other things) as messenger molecules inthe process of inflammation. COX-2 inhibitors include celecoxib,etoricoxib, lumiracoxib, parecoxib, rofecoxib, rofecoxib, andvaldecoxib.

The terms “cancer” refers to or describe the physiological condition inmammals that is typically characterized by unregulated cell growth. A“tumor” comprises one or more cancerous cells. Examples of cancerinclude, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma,and leukemia or lymphoid malignancies. More particular examples of suchcancers include squamous cell cancer (e.g., epithelial squamous cellcancer), lung cancer including small-cell lung cancer, non-small celllung cancer (“NSCLC”), adenocarcinoma of the lung and squamous carcinomaof the lung, cancer of the peritoneum, hepatocellular cancer, gastric orstomach cancer including gastrointestinal cancer, pancreatic cancer,glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladdercancer, hepatoma, breast cancer, colon cancer, rectal cancer, colorectalcancer, endometrial or uterine carcinoma, salivary gland carcinoma,kidney or renal cancer, prostate cancer, vulval cancer, thyroid cancer,hepatic carcinoma, anal carcinoma, penile carcinoma, as well as head andneck cancer.

A “chemotherapeutic agent” is a chemical compound useful in thetreatment of cancer, regardless of mechanism of action. Classes ofchemotherapeutic agents include, but are not limited to: alkylatingagents, antimetabolites, spindle poison plant alkaloids,cytotoxic/antitumor antibiotics, topoisomerase inhibitors, antibodies,photosensitizers, and kinase inhibitors. Chemotherapeutic agents includecompounds used in “targeted therapy” and conventional chemotherapy.Examples of chemotherapeutic agents include: erlotinib (TARCEVA®,Genentech/OSI Pharm.), docetaxel (TAXOTERE®, Sanofi-Aventis), 5-FU(fluorouracil, 5-fluorouracil, CAS No. 51-21-8), gemcitabine (GEMZAR®,Lilly), PD-0325901 (CAS No. 391210-10-9, Pfizer), cisplatin(cis-diamine, dichloroplatinum(II), CAS No. 15663-27-1), carboplatin(CAS No. 41575-94-4), paclitaxel (TAXOL®, Bristol-Myers Squibb Oncology,Princeton, N.J.), trastuzumab (HERCEPTIN®, Genentech), temozolomide(4-methyl-5-oxo-2,3,4,6,8-pentazabicyclo[4.3.0]nona-2,7,9-triene-9-carboxamide,CAS No. 85622-93-1, TEMODAR®, TEMODAL®, Schering Plough), tamoxifen((Z)-2-[4-(1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethylethanamine,NOLVADEX®, ISTUBAL®, VALODEX®), and doxorubicin (ADRIAMYCIN®), Akti-1/2,HPPD, and rapamycin.

More examples of chemotherapeutic agents include: oxaliplatin(ELOXATIN®, Sanofi), bortezomib (VELCADE®, Millennium Pharm.), sutent(SUNITINIB®, SU11248, Pfizer), letrozole (FEMARA®, Novartis), imatinibmesylate (GLEEVEC®, Novartis), XL-518 (Mek inhibitor, Exelixis, WO2007/044515), ARRY-886 (Mek inhibitor, AZD6244, Array BioPharma, AstraZeneca), SF-1126 (PI3K inhibitor, Semafore Pharmaceuticals), BEZ-235(PI3K inhibitor, Novartis), XL-147 (PI3K inhibitor, Exelixis), PTK787/ZK222584 (Novartis), fulvestrant (FASLODEX®, AstraZeneca), leucovorin(folinic acid), rapamycin (sirolimus, RAPAMUNE®, Wyeth), lapatinib(TYKERB®, GSK572016, Glaxo Smith Kline), lonafarnib (SARASAR™, SCH66336, Schering Plough), sorafenib (NEXAVAR®, BAY43-9006, Bayer Labs),gefitinib (IRESSA®, AstraZeneca), irinotecan (CAMPTOSAR®, CPT-11,Pfizer), tipifarnib (ZARNESTRA™, Johnson & Johnson), ABRAXANE™(Cremophor-free), albumin-engineered nanoparticle formulations ofpaclitaxel (American Pharmaceutical Partners, Schaumberg, II),vandetanib (rINN, ZD6474, ZACTIMA®, AstraZeneca), chloranmbucil, AG1478,AG1571 (SU 5271; Sugen), temsirolimus (TORISEL®, Wyeth), pazopanib(GlaxoSmithKline), canfosfamide (TELCYTA®, Telik), thiotepa andcyclosphosphamide (CYTOXAN®, NEOSAR®); alkyl sulfonates such asbusulfan, improsulfan and piposulfan; aziridines such as benzodopa,carboquone, meturedopa, and uredopa; ethylenimines and methylamelaminesincluding altretamine, triethylenemelamine, triethylenephosphoramide,triethylenethiophosphoramide and trimethylomelamine; acetogenins(especially bullatacin and bullatacinone); a camptothecin (including thesynthetic analog topotecan); bryostatin; callystatin; CC-1065 (includingits adozelesin, carzelesin and bizelesin synthetic analogs);cryptophycins (particularly cryptophycin 1 and cryptophycin 8);dolastatin; duocarmycin (including the synthetic analogs, KW-2189 andCB1-TM1); eleutherobin; pancratistatin; a sarcodictyin; spongistatin;nitrogen mustards such as chlorambucil, chlornaphazine,chlorophosphamide, estramustine, ifosfamide, mechlorethamine,mechlorethamine oxide hydrochloride, melphalan, novembichin,phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosoureassuch as carmustine, chlorozotocin, fotemustine, lomustine, nimustine,and ranimnustine; antibiotics such as the enediyne antibiotics (e.g.,calicheamicin, calicheamicin gamma1I, calicheamicin omegaI1 (Angew Chem.Intl. Ed. Engl. (1994) 33:183-186); dynemicin, dynemicin A;bisphosphonates, such as clodronate; an esperamicin; as well asneocarzinostatin chromophore and related chromoprotein enediyneantibiotic chromophores), aclacinomysins, actinomycin, authramycin,azaserine, bleomycins, cactinomycin, carabicin, caminomycin,carzinophilin, chromomycinis, dactinomycin, daunorubicin, detorubicin,6-diazo-5-oxo-L-norleucine, morpholino-doxorubicin,cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin anddeoxydoxorubicin), epirubicin, esorubicin, idarubicin, nemorubicin,marcellomycin, mitomycins such as mitomycin C, mycophenolic acid,nogalamycin, olivomycins, peplomycin, porfiromycin, puromycin,quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin,ubenimex, zinostatin, zorubicin; anti-metabolites such as methotrexateand 5-fluorouracil (5-FU); folic acid analogs such as denopterin,methotrexate, pteropterin, trimetrexate; purine analogs such asfludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidineanalogs such as ancitabine, azacitidine, 6-azauridine, carmofur,cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine;androgens such as calusterone, dromostanolone propionate, epitiostanol,mepitiostane, testolactone; anti-adrenals such as aminoglutethimide,mitotane, trilostane; folic acid replenisher such as frolinic acid;aceglatone; aldophosphamide glycoside; aminolevulinic acid; eniluracil;amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine;diaziquone; elformithine; elliptinium acetate; an epothilone; etoglucid;gallium nitrate; hydroxyurea; lentinan; lonidainine; maytansinoids suchas maytansine and ansamitocins; mitoguazone; mitoxantrone; mopidanmol;nitraerine; pentostatin; phenamet; pirarubicin; losoxantrone;podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK® polysaccharidecomplex (JHS Natural Products, Eugene, Oreg.); razoxane; rhizoxin;sizofuran; spirogermanium; tenuazonic acid; triaziquone;2,2′,2″-trichlorotriethylamine; trichothecenes (especially T-2 toxin,verracurin A, roridin A and anguidine); urethan; vindesine; dacarbazine;mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine;arabinoside (“Ara-C”); cyclophosphamide; thiotepa; 6-thioguanine;mercaptopurine; methotrexate; platinum analogs such as cisplatin andcarboplatin; vinblastine; etoposide (VP-16); ifosfamide; mitoxantrone;vincristine; vinorelbine (NAVELBINE®); novantrone; teniposide;edatrexate; daunomycin; aminopterin; capecitabine (XELODA®, Roche);ibandronate; CPT-11; topoisomerase inhibitor RFS 2000;difluoromethylornithine (DMFO); retinoids such as retinoic acid; andpharmaceutically acceptable salts, acids and derivatives of any of theabove.

Also included in the definition of “chemotherapeutic agent” are: (i)anti-hormonal agents that act to regulate or inhibit hormone action ontumors such as anti-estrogens and selective estrogen receptor modulators(SERMs), including, for example, tamoxifen (including NOLVADEX®;tamoxifen citrate), raloxifene, droloxifene, 4-hydroxytamoxifen,trioxifene, keoxifene, LY117018, onapristone, and FARESTON® (toremifinecitrate); (ii) aromatase inhibitors that inhibit the enzyme aromatase,which regulates estrogen production in the adrenal glands, such as, forexample, 4(5)-imidazoles, aminoglutethimide, MEGASE® (megestrolacetate), AROMASIN® (exemestane; Pfizer), formestanie, fadrozole,RIVISOR® (vorozole), FEMARA® (letrozole; Novartis), and ARIMIDEX®(anastrozole; AstraZeneca); (iii) anti-androgens such as flutamide,nilutamide, bicalutamide, leuprolide, and goserelin; as well astroxacitabine (a 1,3-dioxolane nucleoside cytosine analog); (iv) proteinkinase inhibitors such as MEK inhibitors (WO 2007/044515); (v) lipidkinase inhibitors; (vi) antisense oligonucleotides, particularly thosewhich inhibit expression of genes in signaling pathways implicated inaberrant cell proliferation, for example, PKC-alpha, Raf and H-Ras, suchas oblimersen (GENASENSE®, Genta Inc.); (vii) ribozymes such as VEGFexpression inhibitors (e.g., ANGIOZYME®) and HER2 expression inhibitors;(viii) vaccines such as gene therapy vaccines, for example, ALLOVECTIN®,LEUVECTIN®, and VAXID®; PROLEUKIN® rIL-2; topoisomerase 1 inhibitorssuch as LURTOTECAN®; ABARELIX® rmRH; (ix) anti-angiogenic agents such asbevacizumab (AVASTIN®, Genentech); and pharmaceutically acceptablesalts, acids and derivatives of any of the above.

Also included in the definition of “chemotherapeutic agent” aretherapeutic antibodies such as alemtuzumab (Campath), bevacizumab(AVASTIN®, Genentech); cetuximab (ERBITUX®, Imclone); panitumumab(VECTIBIX®, Amgen), rituximab (RITUXAN®, Genentech/Biogen Idec),pertuzumab (OMNITARG™, 2C4, Genentech), trastuzumab (HERCEPTIN®,Genentech), tositumomab (Bexxar, Corixia), and the antibody drugconjugate, gemtuzumab ozogamicin (MYLOTARG®, Wyeth).

Humanized monoclonal antibodies with therapeutic potential aschemotherapeutic agents in combination with the PI3K inhibitors of theinvention include: alemtuzumab, apolizumab, aselizumab, atlizumab,bapineuzumab, bevacizumab, bivatuzumab mertansine, cantuzumabmertansine, cedelizumab, certolizumab pegol, cidfusituzumab, cidtuzumab,daclizumab, eculizumab, efalizumab, epratuzumab, erlizumab, felvizumab,fontolizumab, gemtuzumab ozogamicin, inotuzumab ozogamicin, ipilimumab,labetuzumab, lintuzumab, matuzumab, mepolizumab, motavizumab,motovizumab, natalizumab, nimotuzumab, nolovizumab, numavizumab,ocrelizumab, omalizumab, palivizumab, pascolizumab, pecfusituzumab,pectuzumab, pertuzumab, pexelizumab, ralivizumab, ranibizumab,reslivizumab, reslizumab, resyvizumab, rovelizumab, ruplizumab,sibrotuzumab, siplizumab, sontuzumab, tacatuzumab tetraxetan,tadocizumab, talizumab, tefibazumab, tocilizumab, toralizumab,trastuzumab, tucotuzumab celmoleukin, tucusituzumab, umavizumab,urtoxazumab, and visilizumab.

A “metabolite” is a product produced through metabolism in the body of aspecified compound or salt thereof. Metabolites of a compound may beidentified using routine techniques known in the art and theiractivities determined using tests such as those described herein. Suchproducts may result for example from the oxidation, reduction,hydrolysis, amidation, deamidation, esterification, deesterification,enzymatic cleavage, and the like, of the administered compound.Accordingly, the invention includes metabolites of compounds of theinvention, including compounds produced by a process comprisingcontacting a compound of this invention with a mammal for a period oftime sufficient to yield a metabolic product thereof.

The term “package insert” is used to refer to instructions customarilyincluded in commercial packages of therapeutic products, that containinformation about the indications, usage, dosage, administration,contraindications and/or warnings concerning the use of such therapeuticproducts.

The term “chiral” refers to molecules which have the property ofnon-superimposability of the mirror image partner, while the term“achiral” refers to molecules which are superimposable on their mirrorimage partner.

The term “stereoisomers” refers to compounds which have identicalchemical constitution, but differ with regard to the arrangement of theatoms or groups in space. Stereoisomers include enantiomers anddiastereomers.

“Diastereomer” refers to a stereoisomer with two or more centers ofchirality and whose molecules are not mirror images of one another.Diastereomers have different physical properties, e.g. melting points,boiling points, spectral properties, and reactivities. Mixtures ofdiastereomers may separate under high resolution analytical proceduressuch as electrophoresis and chromatography. Diastereomers includegeometric isomers, cis/trans and E/Z isomers, and atropisomers.

“Enantiomers” refer to two stereoisomers of a compound which arenon-superimposable mirror images of one another.

Stereochemical definitions and conventions used herein generally followS. P. Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984)McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S.,“Stereochemistry of Organic Compounds”, John Wiley & Sons, Inc., NewYork, 1994. The compounds of the invention may contain asymmetric orchiral centers, and therefore exist in different stereoisomeric forms.It is intended that all stereoisomeric forms of the compounds of theinvention, including but not limited to, diastereomers, enantiomers andatropisomers, as well as mixtures thereof such as racemic mixtures, formpart of the present invention. Many organic compounds exist in opticallyactive forms, i.e., they have the ability to rotate the plane ofplane-polarized light. In describing an optically active compound, theprefixes D and L, or R and S, are used to denote the absoluteconfiguration of the molecule about its chiral center(s). The prefixes dand l or (+) and (−) are employed to designate the sign of rotation ofplane-polarized light by the compound, with (−) or l meaning that thecompound is levorotatory. A compound prefixed with (+) or d isdextrorotatory. For a given chemical structure, these stereoisomers areidentical except that they are mirror images of one another. A specificstereoisomer may also be referred to as an enantiomer, and a mixture ofsuch isomers is often called an enantiomeric mixture. A 50:50 mixture ofenantiomers is referred to as a racemic mixture or a racemate, which mayoccur where there has been no stereoselection or stereospecificity in achemical reaction or process. The terms “racemic mixture” and “racemate”refer to an equimolar mixture of two enantiomeric species, devoid ofoptical activity.

The term “tautomer” or “tautomeric form” refers to structural isomers ofdifferent energies which are interconvertible via a low energy barrier.For example, proton tautomers (also known as prototropic tautomers)include interconversions via migration of a proton, such as keto-enoland imine-enamine isomerizations. Valence tautomers includeinterconversions by reorganization of some of the bonding electrons.

The phrase “pharmaceutically acceptable salt” as used herein, refers topharmaceutically acceptable organic or inorganic salts of a compound ofthe invention. Exemplary salts include, but are not limited, to sulfate,citrate, acetate, oxalate, chloride, bromide, iodide, nitrate,bisulfate, phosphate, acid phosphate, isonicotinate, lactate,salicylate, acid citrate, tartrate, oleate, tannate, pantothenate,bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate,gluconate, glucuronate, saccharate, formate, benzoate, glutamate,methanesulfonate “mesylate”, ethanesulfonate, benzenesulfonate,p-toluenesulfonate, and pamoate (i.e.,1,1′-methylene-bis(2-hydroxy-3-naphthoate)) salts. A pharmaceuticallyacceptable salt may involve the inclusion of another molecule such as anacetate ion, a succinate ion or other counter ion. The counter ion maybe any organic or inorganic moiety that stabilizes the charge on theparent compound. Furthermore, a pharmaceutically acceptable salt mayhave more than one charged atom in its structure. Instances wheremultiple charged atoms are part of the pharmaceutically acceptable saltcan have multiple counter ions. Hence, a pharmaceutically acceptablesalt can have one or more charged atoms and/or one or more counter ion.

If the compound of the invention is a base, the desired pharmaceuticallyacceptable salt may be prepared by any suitable method available in theart, for example, treatment of the free base with an inorganic acid,such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid,methanesulfonic acid, phosphoric acid and the like, or with an organicacid, such as acetic acid, trifluoroacetic acid, maleic acid, succinicacid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalicacid, glycolic acid, salicylic acid, a pyranosidyl acid, such asglucuronic acid or galacturonic acid, an alpha hydroxy acid, such ascitric acid or tartaric acid, an amino acid, such as aspartic acid orglutamic acid, an aromatic acid, such as benzoic acid or cinnamic acid,a sulfonic acid, such as p-toluenesulfonic acid or ethanesulfonic acid,or the like.

If the compound of the invention is an acid, the desiredpharmaceutically acceptable salt may be prepared by any suitable method,for example, treatment of the free acid with an inorganic or organicbase, such as an amine (primary, secondary or tertiary), an alkali metalhydroxide or alkaline earth metal hydroxide, or the like. Illustrativeexamples of suitable salts include, but are not limited to, organicsalts derived from amino acids, such as glycine and arginine, ammonia,primary, secondary, and tertiary amines, and cyclic amines, such aspiperidine, morpholine and piperazine, and inorganic salts derived fromsodium, calcium, potassium, magnesium, manganese, iron, copper, zinc,aluminum and lithium.

The phrase “pharmaceutically acceptable” indicates that the substance orcomposition must be compatible chemically and/or toxicologically, withthe other ingredients comprising a formulation, and/or the mammal beingtreated therewith.

A “solvate” refers to an association or complex of one or more solventmolecules and a compound of the invention. Examples of solvents thatform solvates include, but are not limited to, water, isopropanol,ethanol, methanol, DMSO, ethylacetate, acetic acid, and ethanolamine.

The terms “compound of this invention,” and “compounds of the presentinvention” and “compounds of Formula I” include compounds of Formulas Iand stereoisomers, tautomers, solvates, metabolites, andpharmaceutically acceptable salts and prodrugs thereof.

Any formula or structure given herein, including Formula I compounds, isalso intended to represent hydrates, solvates, and polymorphs of suchcompounds, and mixtures thereof.

Any formula or structure given herein, including Formula I compounds, isalso intended to represent isotopically labeled forms of the compoundsas well as unlabeled forms. Isotopically labeled compounds havestructures depicted by the formulas given herein except that one or moreatoms are replaced by an atom having a selected atomic mass or massnumber. Examples of isotopes that can be incorporated into compounds ofthe invention include isotopes of hydrogen, carbon, nitrogen, oxygen,phosphorous, fluorine, and chlorine, such as, but not limited to 2H(deuterium, D), 3H (tritium), 11C, 13C, 14C, 15N, 18F, 31P, 32P, 35S,36Cl, and 125I. Various isotopically labeled compounds of the presentinvention, for example those into which radioactive isotopes such as 3H,13C, and 14C are incorporated. Such isotopically labelled compounds maybe useful in metabolic studies, reaction kinetic studies, detection orimaging techniques, such as positron emission tomography (PET) orsingle-photon emission computed tomography (SPECT) including drug orsubstrate tissue distribution assays, or in radioactive treatment ofpatients. Deuterium labelled or substituted therapeutic compounds of theinvention may have improved DMPK (drug metabolism and pharmacokinetics)properties, relating to distribution, metabolism, and excretion (ADME).Substitution with heavier isotopes such as deuterium may afford certaintherapeutic advantages resulting from greater metabolic stability, forexample increased in vivo half-life or reduced dosage requirements. An18F labeled compound may be useful for PET or SPECT studies.Isotopically labeled compounds of this invention and prodrugs thereofcan generally be prepared by carrying out the procedures disclosed inthe schemes or in the examples and preparations described below bysubstituting a readily available isotopically labeled reagent for anon-isotopically labeled reagent. Further, substitution with heavierisotopes, particularly deuterium (i.e., 2H or D) may afford certaintherapeutic advantages resulting from greater metabolic stability, forexample increased in vivo half-life or reduced dosage requirements or animprovement in therapeutic index. It is understood that deuterium inthis context is regarded as a substituent in the compound of the formula(I). The concentration of such a heavier isotope, specificallydeuterium, may be defined by an isotopic enrichment factor. In thecompounds of this invention any atom not specifically designated as aparticular isotope is meant to represent any stable isotope of thatatom. Unless otherwise stated, when a position is designatedspecifically as “H” or “hydrogen”, the position is understood to havehydrogen at its natural abundance isotopic composition. Accordingly, inthe compounds of this invention any atom specifically designated as adeuterium (D) is meant to represent deuterium.

Formula I Compounds of the Invention

Formula I compounds include compounds selected from Formulas Ia and Ib:

and stereoisomers, tautomers, or pharmaceutically acceptable saltsthereof,

wherein (i) X¹ is N and X² is S, (ii) X¹ is CR⁷ and X² is S, (iii) X¹ isN and X² is NR², or (iv) X¹ is CR⁷ and X² is O;

R¹ is selected from

C₁-C₁₂ alkyl,

C₂-C₈ alkenyl,

C₂-C₈ alkynyl,

C₆-C₂₀ aryl,

C₂-C₂₀ heterocyclyl,

C₃-C₁₂ carbocyclyl,

C₁-C₂₀ heteroaryl,

—(C₁-C₁₂ alkylene)-(C₃-C₁₂ carbocyclyl),

—(C₁-C₁₂ alkylene)-(C₂-C₂₀ heterocyclyl),

—(C₁-C₁₂ alkylene)-(C₂-C₂₀ heterocyclyl)-(C₂-C₂₀ heterocyclyl),

—(C₁-C₁₂ alkylene)-(C₂-C₂₀ heterocyclyl)-(C₃-C₁₂ carbocyclyl),

—(C₁-C₁₂ alkylene)-(C₂-C₂₀ heterocyclyl)-C(═O)—(C₂-C₂₀ heterocyclyl),

—(C₁-C₁₂ alkylene)-(C₁-C₂₀ heteroaryl),

—(C₁-C₁₂ alkylene)-(C₂-C₂₀ heterocyclyl)-(C₁-C₁₂ alkyl),

—(C₁-C₁₂ alkylene)-(C₆-C₂₀ aryl)-(C₁-C₁₂ alkyl),

—(C₁-C₁₂ alkylene)-(C₁-C₂₀ heteroaryl)-(C₁-C₁₂ alkyl),

—(C₁-C₁₂ alkylene)-C(═O)—(C₂-C₂₀ heterocyclyl),

—(C₁-C₁₂ alkylene)-NHR^(2′),

—(C₁-C₁₂ alkylene)-NR^(2′)—(C₁-C₁₂ alkyl),

—(C₁-C₁₂ alkylene)-NR^(2′)—(C₃-C₁₂ carbocyclyl),

—(C₁-C₁₂ alkylene)-NR^(2″)—(C₂-C₂₀ heterocyclyl),

—(C₁-C₁₂ alkylene)-NR^(2′)—(C₁-C₂₀ heteroaryl),

—(C₁-C₁₂ alkylene)-NR^(2′)—(C₆-C₂₀ aryl),

—(C₁-C₁₂ alkylene)-NR^(2′)—(C₁-C₁₂ alkylene)-(C₃-C₁₂ carbocyclyl),

—(C₁-C₁₂ alkylene)-NR^(2′)—(C₁-C₁₂ alkylene)-(C₁-C₂₀ heteroaryl),

—(C₁-C₁₂ alkylene)-NR^(2′)—(C₁-C₁₂ alkylene)-(C₁-C₂₀ heterocyclyl),

—(C₁-C₁₂ alkylene)-NR^(2′)—(C₁-C₁₂ alkylene)-(C₆-C₂₀ aryl),

—(C₁-C₁₂ alkylene)-NR^(2′)—(C₁-C₁₂ alkylene)-NHC(═O)—(C₁-C₂₀heteroaryl),

—(C₁-C₁₂ alkylene)-(C₂-C₂₀ heterocyclyl)-N(C₁-C₁₂ alkyl)R^(2′),

—(C₁-C₁₂ alkylene)-(C₂-C₂₀ heterocyclyl)-(C₁-C₁₂ alkyl)-N(C₁-C₁₂alkyl)R^(2′),

—(C₂-C₁₂ alkenylene)-(C₂-C₂₀ heterocyclyl),

—(C₁-C₂₀ heteroaryl)-(C₂-C₂₀ heterocyclyl),

—(C₁-C₂₀ heteroaryl)-(C₃-C₁₂ carbocyclyl),

—C(═O)—(C₂-C₂₀ heterocyclyl),

—C(═O)—(C₁-C₂₀ heteroaryl),

—C(═O)—(C₂-C₂₀ heterocyclyl)-(C₂-C₂₀ heterocyclyl),

—C(═O)—(C₂-C₂₀ heterocyclyl)-(C₁-C₂₀ heteroaryl),

—C(═O)—(C₁-C₁₂ alkyl),

—C(═O)—NR^(2′)—(C₁-C₁₂ alkyl), and

—CR⁴═CR⁵R⁶ where R⁴ is selected from H, F, Cl, Br, I, and C₁-C₁₂ alkyl,and R⁵ and R⁶ form C₂-C₂₀ heterocyclyl, C₁-C₂₀ heteroaryl, or C₃-C₁₂carbocyclyl,

where alkyl, alkenyl, alkynyl, alkylene, carbocyclyl, heterocyclyl,aryl, and heteroaryl are optionally substituted with one or more groupsindependently selected from F, Cl, Br, I, —CH₃, —CH₂CH₃, —CH₂CH(CH₃)₂,—CH₂NH₂, —CH₂N(CH₃)₂, —CH₂CH₂NH₂, —CH₂CH₂N(CH₃)₂, —CH₂OH, —CH₂OCH₃,—CH₂CH₂OH, —C(CH₃)₂OH, —CH₂C(CH₃)₂OH, —CH(OH)CH(CH₃)₂, —C(CH₃)₂CH₂OH,—CH₂CH₂SO₂CH₃, —CN, —CF₃, —CO₂H, —CHO, —COCH₃, —CO₂CH₃, —CO₂C(CH₃)₃,—COCH₂OH, —COC(OH)(CH₃)₂, —COCH(OH)CH₃, —CONH₂, —CONHCH₃, —CON(CH₃)₂,—CH₂CONH₂, —CH₂CON(CH₃)₂, —C(CH₃)₂CONH₂, —NO₂, —NH₂, —NHCH₃, —N(CH₃)₂,—NHCOCH₃, —N(CH₃)COCH₃, —NHS(O)₂CH₃, —N(CH₃)C(CH₃)₂CONH₂,—N(CH₃)CH₂CH₂S(O)₂CH₃, ═O, —OH, —OCH₃, —S(O)₂N(CH₃)₂, —SCH₃, —CH₂OCH₃,—S(O)₂CH₃, —C(O)-cyclopropyl, cyclopropyl, cyclobutyl, oxetanyl, andmorpholino;

R² and R^(2′) are independently selected from H, C₁-C₁₂ alkyl, C₂-C₈alkenyl, C₂-C₈ alkynyl, —(C₁-C₁₂ alkylene)-(C₃-C₁₂ carbocyclyl),—(C₁-C₁₂ alkylene)-(C₂-C₂₀ heterocyclyl), —(C₁-C₁₂alkylene)-C(═O)—(C₂-C₂₀ heterocyclyl), —(C₁-C₁₂ alkylene)-(C₆-C₂₀ aryl),and —(C₁-C₁₂ alkylene)-(C₁-C₂₀ heteroaryl), where alkyl, alkenyl,alkynyl, alkylene, carbocyclyl, heterocyclyl, aryl, and heteroaryl areoptionally substituted with one or more groups independently selectedfrom F, Cl, Br, I, —CH₃, —CH₂OH, —CN, —CF₃, —CO₂H, —COCH₃, —CO₂CH₃,—CONH₂, —CONHCH₃, —CON(CH₃)₂, —NO₂, —NH₂, —NHCH₃, —NHCOCH₃, —NHS(O)₂CH₃,—OH, —OCH₃, —S(O)₂N(CH₃)₂, —SCH₃, —CH₂OCH₃, and —S(O)₂CH₃;

R³ is a bicyclic heteroaryl group selected from:

where the wavy line indicates the site of attachment;

optionally substituted with one or more groups independently selectedfrom C₁-C₁₂ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, C₃-C₁₂ carbocyclyl,C₂-C₂₀ heterocyclyl, C₆-C₂₀ aryl, C₁-C₂₀ heteroaryl, —(C₁-C₁₂alkylene)-(C₂-C₂₀ heterocyclyl), —NH—(C₁-C₁₂ alkylene)-(C₂-C₂₀heterocyclyl), —N(C₁-C₁₂ alkyl)-(C₁-C₁₂ alkylene)-(C₂-C₂₀ heterocyclyl),—NH—(C₂-C₂₀ heterocyclyl), —O—(C₂-C₂₀ heterocyclyl), —NH—(C₃-C₁₂carbocyclyl), —O—(C₃-C₁₂ carbocyclyl), F, Cl, Br, I, —CN, —CO₂H, —CONH₂,—CONH(C₁-C₁₂ alkyl), —CON(C₁-C₁₂ alkyl)₂, —CO(C₁-C₁₂ alkyl), —NO₂, —NH₂,—NH(C₁-C₁₂ alkyl), —N(C₁-C₁₂ alkyl)₂, —NHCO(C₁-C₁₂ alkyl),—NHS(O)₂(C₁-C₁₂ alkyl), —N(C₁-C₁₂ alkyl)S(O)₂(C₁-C₁₂ alkyl), —OH,—O(C₁-C₁₂ alkyl), —NHC(═O)NH(C₁-C₁₂ alkyl), —SH, —S(C₁-C₁₂ alkyl),—S(O)(C₁-C₁₂ alkyl), —S(O)₂(C₁-C₁₂ alkyl), —S(O)₂NH₂, —S(O)₂NH(C₁-C₁₂alkyl), and —S(O)₂N(C₁-C₁₂ alkyl)₂, where alkyl, alkenyl, alkynyl,alkylene, carbocyclyl, heterocyclyl, aryl, and heteroaryl are optionallysubstituted with one or more groups independently selected from F, Cl,Br, I, —CN, —CF₃, —CO₂H, —COCH₃, —CO₂CH₃, —CONH₂, —CONHCH₃, —CON(CH₃)₂,—NO₂, —NH₂, —NHCH₃, —NHCOCH₃, —NHS(O)₂CH₃, ═O, —OH, —OCH₃,—S(O)₂N(CH₃)₂, —SH, —SCH₃, —CH₂OCH₃, and —S(O)₂CH₃;

R⁷ is selected from H, C₁-C₁₂ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl,—(C₁-C₁₂ alkylene)-(C₃-C₁₂ carbocyclyl), —(C₁-C₁₂ alkylene)-(C₂-C₂₀heterocyclyl), —(C₁-C₁₂ alkylene)-C(═O)—(C₂-C₂₀ heterocyclyl), —(C₁-C₁₂alkylene)-(C₆-C₂₀ aryl), and —(C₁-C₁₂ alkylene)-(C₁-C₂₀ heteroaryl),where alkyl, alkenyl, alkynyl, alkylene, carbocyclyl, heterocyclyl,aryl, and heteroaryl are optionally substituted with one or more groupsindependently selected from F, Cl, Br, I, —CH₃, —CH₂OH, —CN, —CF₃,—CO₂H, —COCH₃, —CO₂CH₃, —CONH₂, —CONHCH₃, —CON(CH₃)₂, —NO₂, —NH₂,—NHCH₃, —NHCOCH₃, —NHS(O)₂CH₃, ═O, —OH, —OCH₃, —S(O)₂N(CH₃)₂, —SCH₃,—CH₂OCH₃, and —S(O)₂CH₃;

mor is a morpholine group or a bicyclic structure selected from:

optionally substituted with one or more groups selected from F, Cl, Br,I, —CH₃, —CH₂CH₃, —CH₂CH₂CH₃, —CH(CH₃)₂, —C(CH₃)₃, —CH₂OCH₃, —CHF₂, —CN,—CF₃, —CH₂OH, —CH₂OCH₃, —CH₂CH₂OH, —CH₂C(CH₃)₂OH, —CH(CH₃)OH,—CH(CH₂CH₃)OH, —CH₂CH(OH)CH₃, —C(CH₃)₂OH, —C(CH₃)₂OCH₃, —CH(CH₃)F,—C(CH₃)F₂, —CH(CH₂CH₃)F, —C(CH₂CH₃)₂F, —CO₂H, —CONH₂, —CON(CH₂CH₃)₂,—COCH₃, —CON(CH₃)₂, —NO₂, —NH₂, —NHCH₃, —N(CH₃)₂, —NHCH₂CH₃,—NHCH(CH₃)₂, —NHCH₂CH₂OH, —NHCH₂CH₂OCH₃, —NHCOCH₃, —NHCOCH₂CH₃,—NHCOCH₂OH, —NHS(O)₂CH₃, —N(CH₃)S(O)₂CH₃, ═O, —OH, —OCH₃, —OCH₂CH₃,—OCH(CH₃)₂, —SH, —NHC(═O)NHCH₃, —NHC(═O)NHCH₂CH₃, —S(O)CH₃, —S(O)CH₂CH₃,—S(O)₂CH₃, —S(O)₂NH₂, —S(O)₂NHCH₃, —S(O)₂N(CH₃)₂, —CH₂S(O)₂CH₃;

and wherein the IC50 binding activity to p110 delta is ten or more timeslower than the binding activity to p110 alpha;

with the proviso that a Formula Ib compound wherein (ii) X¹ is CR⁷ andX² is S, R¹ is —(C₁-C₁₂ alkylene)-(C₂-C₂₀ heterocyclyl), R³ isoptionally substituted benzo[d]imidazol-1-yl, and R⁷ is H, excludes theC₂-C₂₀ heterocyclyl of R¹ substituted with —S(O)₂CH₃.

Exemplary Formula I compounds include where mor is an unsubstitutedmorpholine group, having the structures Ic and Id:

Exemplary Formula I compounds include thiazolopyrimidines where (i) X isN and X² is S:

Exemplary Formula I compounds include thienopyrimidines where (ii) X¹ isCR⁷ and X² is S:

Exemplary Formula I compounds include purines where (iii) X¹ is N and X²is NR²:

Exemplary Formula I compounds include furanopyrimidines where (iv) X¹ isCR⁷ and X² is O:

In additional exemplary embodiments, mor is selected from thestructures:

where the wavy line indicates the attachment to the 4-position of thepyrimidine ring.

Exemplary embodiments of R¹ include the groups:

where the wavy line indicates the site of attachment to the Formula Istructure.

Exemplary embodiments of R¹ also include the groups:

Exemplary embodiments include the R³ bicyclic heteroaryl substitutedwith one or more groups independently selected from F, Cl, Br, I, —CH₃,—CH₂CH₃, —CH₂CH₂CH₃, —CH(CH₃)₂, —C(CH₃)₃, —CH₂OCH₃, —CHF₂, —CH₂CN, —CN,—CF₃, —CH₂OH, —CH₂OCH₃, —CH₂CH₂OH, —CH₂CH₂CH₂OH, —CH₂C(CH₃)₂OH,—CH(CH₃)OH, —CH(CH₂CH₃)OH, —CH₂CH(OH)CH₃, —CH₂CH(OCH₃)CH₃, —C(CH₃)₂OH,—CH(CH₃)OCH₃, —C(CH₃)₂OCH₃, —CH(CH₃)F, —C(CH₃)F₂, —CH(CH₂CH₃)F,—C(CH₂CH₃)₂F, —C(CH₂CH₃)F₂, —CO₂H, —CONH₂, —CON(CH₂CH₃)₂, —COCH₃,—CON(CH₃)₂, —NO₂, —NH₂, —NHCH₃, —N(CH₃)₂, —NHCH₂CH₃, —NHCH(CH₃)₂,—NHCH₂CH₂OH, —NHCH₂CH₂OCH₃, —NHCOCH₃, —NHCOCH₂CH₃, —NHCOCH₂OH,—NHS(O)₂CH₃, —N(CH₃)S(O)₂CH₃, —OH, —OCH₃, —OCH₂CH₃, —OCH(CH₃)₂, —SH,—NHC(═O)NHCH₃, —NHC(═O)NHCH₂CH₃, —S(O)CH₃, —S(O)CH₂CH₃, —S(O)₂CH₃,—S(O)₂NH₂, —S(O)₂NHCH₃, —S(O)₂N(CH₃)₂, —CH₂S(O)₂CH₃, and a groupselected from

Exemplary embodiments include where the R³ bicyclic heteroaryl is apurine having the structure:

where R⁸ is selected from H, F, Cl, Br, I, —CH₃, —CH₂CH₃, —CH₂CH₂CH₃,—CH(CH₃)₂, —C(CH₃)₃, —CH₂OCH₃, —CHF, —CH₂CN, —CN, —CF₃, —CH₂OH,—CH₂OCH₃, —CH₂CH₂OH, —CH₂C(CH₃)₂OH, —CH(CH₃)OH, —CH(CH₂CH₃)OH,—CH₂CH(OH)CH₃, —CH₂CH(OCH₃)CH₃, —C(CH₃)₂OH, —C(CH₃)₂OCH₃, —CH(CH₃)F,—C(CH₃)F₂, —CH(CH₂CH₃)F, —C(CH₂CH₃)₂F, —CO₂H, —CONH₂, —CON(CH₂CH₃)₂,—COCH₃, —CON(CH₃)₂, —NO₂, —NH₂, —NHCH₃, —N(CH₃)₂, —NHCH₂CH₃,—NHCH(CH₃)₂, —NHCH₂CH₂OH, —NHCH₂CH₂OCH₃, —NHCOCH₃, —NHCOCH₂CH₃,—NHCOCH₂OH, —NHS(O)₂CH₃, —N(CH₃)S(O)₂CH₃, —OH, —OCH₃, —OCH₂CH₃,—OCH(CH₃)₂, —SH, —NHC(═O)NHCH₃, —NHC(═O)NHCH₂CH₃, —S(O)CH₃, —S(O)CH₂CH₃,—S(O)₂CH₃, —S(O)₂NH₂, —S(O)₂NHCH₃, —S(O)₂N(CH₃)₂, —CH₂S(O)₂CH₃, and agroup selected from

R⁹ is independently selected from F, Cl, Br, I, —CH₃, —CH₂CH₃,—CH₂CH₂CH₃, —CH(CH₃)₂, —CH₂CH(CH₃)₂, —CH₂OH, —CH₂CH₂OH, —CN, —CF₃,—CO₂H, —COCH₃, —CO₂CH₃, —CONH₂, —CONHCH₃, —CON(CH₃)₂, —NO₂, —NH₂,—NHCH₃, —NHCOCH₃, —NHS(O)₂CH₃, —OH, —OCH₃, —S(O)₂N(CH₃)₂, —SCH₃,—CH₂OCH₃, and —S(O)₂CH₃; and

n is 0, 1, 2, 3, or 4.

Exemplary Formula I compounds include the structures:

Exemplary Formula I compounds include compounds selected from FormulasIe and If:

and stereoisomers, geometric isomers, tautomers, or pharmaceuticallyacceptable salts thereof,

wherein (i) X¹ is N and X² is S, (ii) X¹ is CR⁷ and X² is S, (iii) X¹ isN and X² is NR², or (iv) X¹ is CR⁷ and X² is O;

R¹ is selected from

C₁-C₁₂ alkyl,

C₂-C₈ alkenyl,

C₂-C₈ alkynyl,

C₆-C₂₀ aryl,

—(C₁-C₁₂ alkylene)-(C₃-C₁₂ carbocyclyl),

—(C₁-C₁₂ alkylene)-(C₂-C₂₀ heterocyclyl),

—(C₁-C₁₂ alkylene)-(C₂-C₂₀ heterocyclyl)-(C₂-C₂₀ heterocyclyl),

—(C₁-C₁₂ alkylene)-(C₂-C₂₀ heterocyclyl)-(C₃-C₁₂ carbocyclyl),

—(C₁-C₁₂ alkylene)-(C₂-C₂₀ heterocyclyl)-C(═O)—(C₂-C₂₀ heterocyclyl),

—(C₁-C₁₂ alkylene)-(C₁-C₂₀ heteroaryl),

—(C₁-C₁₂ alkylene)-(C₂-C₂₀ heterocyclyl)-(C₁-C₁₂ alkyl),

—(C₁-C₁₂ alkylene)-(C₆-C₂₀ aryl)-(C₁-C₁₂ alkyl),

—(C₁-C₁₂ alkylene)-(C₁-C₂₀ heteroaryl)-(C₁-C₁₂ alkyl),

—(C₁-C₁₂ alkylene)-C(═O)—(C₂-C₂₀ heterocyclyl),

—(C₁-C₁₂ alkylene)-NHR²,

—(C₁-C₁₂ alkylene)-NR²—(C₁-C₁₂ alkyl),

—(C₁-C₁₂ alkylene)-N(C₁-C₁₂ alkyl)(C₂-C₂₀ heterocyclyl),

—(C₁-C₁₂ alkylene)-NR²—(C₁-C₁₂ alkylene)-(C₁-C₂₀ heteroaryl),

—(C₁-C₁₂ alkylene)-NR²—(C₁-C₁₂ alkylene)-(C₁-C₂₀ heterocyclyl),

—(C₁-C₁₂ alkylene)-NR²—(C₁-C₁₂ alkylene)-NHC(═O)—(C₁-C₂₀ heteroaryl),

—(C₁-C₁₂ alkylene)-(C₂-C₂₀ heterocyclyl)-N(C₁-C₁₂ alkyl)R²,

—(C₁-C₁₂ alkylene)-(C₂-C₂₀ heterocyclyl)-(C₁-C₁₂ alkyl)N(C₁-C₁₂alkyl)R²,

—(C₁-C₁₂ alkylene)-NR²—(C₂-C₂₀ heterocyclyl),

—(C₂-C₁₂ alkenylene)-(C₂-C₂₀ heterocyclyl),

—NR²—(C₂-C₂₀ heterocyclyl),

—C(═O)—(C₂-C₂₀ heterocyclyl), and

—C(═O)—(C₁-C₁₂ alkyl),

where alkyl, alkenyl, alkynyl, alkylene, carbocyclyl, heterocyclyl,aryl, and heteroaryl are optionally substituted with one or more groupsindependently selected from F, Cl, Br, I, —CH₃, —CH₂CH₃, —CH₂CH(CH₃)₂,—CH₂OH, —CH₂CH₂OH, —C(CH₃)₂OH, —CH(OH)CH(CH₃)₂, —C(CH₃)₂CH₂OH,—CH₂CH₂SO₂CH₃, —CN, —CF₃, —CO₂H, —COCH₃, —CO₂CH₃, —CO₂C(CH₃)₃,—COCH(OH)CH₃, —CONH₂, —CONHCH₃, —CON(CH₃)₂, —C(CH₃)₂CONH₂, —NO₂, —NH₂,—NHCH₃, —N(CH₃)₂, —NHCOCH₃, —N(CH₃)COCH₃, —NHS(O)₂CH₃,—N(CH₃)C(CH₃)₂CONH₂, —N(CH₃)CH₂CH₂S(O)₂CH₃, ═O, —OH, —OCH₃,—S(O)₂N(CH₃)₂, —SCH₃, —CH₂OCH₃, —S(O)₂CH₃, cyclopropyl, oxetanyl, andmorpholino;

R² is selected from H, C₁-C₁₂ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl,—(C₁-C₁₂ alkylene)-(C₃-C₁₂ carbocyclyl), —(C₁-C₁₂ alkylene)-(C₂-C₂₀heterocyclyl), —(C₁-C₁₂ alkylene)-C(═O)—(C₂-C₂₀ heterocyclyl), —(C₁-C₁₂alkylene)-(C₆-C₂₀ aryl), and —(C₁-C₁₂ alkylene)-(C₁-C₂₀ heteroaryl),where alkyl, alkenyl, alkynyl, alkylene, carbocyclyl, heterocyclyl,aryl, and heteroaryl are optionally substituted with one or more groupsindependently selected from F, Cl, Br, I, —CH₃, —CH₂OH, —CN, —CF₃,—CO₂H, —COCH₃, —CO₂CH₃, —CONH₂, —CONHCH₃, —CON(CH₃)₂, —NO₂, —NH₂,—NHCH₃, —NHCOCH₃, —NHS(O)₂CH₃, —OH, —OCH₃, —S(O)₂N(CH₃)₂, —SCH₃,—CH₂OCH₃, and —S(O)₂CH₃;

R³ is selected from:

where the wavy line indicates the site of attachment;

each of which are optionally substituted with one or more groupsindependently selected from F, Cl, Br, I, —CH₃, —CH₂CH₃, —CH₂CH₂CH₃,—CH(CH₃)₂, —C(CH₃)₃, —CH₂OCH₃, —CHF₂, —CN, —CF₃, —CH₂OH, —CH₂OCH₃,—CH₂CH₂OH, —CH₂C(CH₃)₂OH, —CH(CH₃)OH, —CH(CH₂CH₃)OH, —CH₂CH(OH)CH₃,—CH₂CH(OCH₃)CH₃, —C(CH₃)₂OH, —C(CH₃)₂OCH₃, —CH(CH₃)F, —C(CH₃)F₂,—CH(CH₂CH₃)F, —C(CH₂CH₃)₂F, —CO₂H, —CONH₂, —CON(CH₂CH₃)₂, —COCH₃,—CON(CH₃)₂, —NO₂, —NH₂, —NHCH₃, —N(CH₃)₂, —NHCH₂CH₃, —NHCH(CH₃)₂,—NHCH₂CH₂OH, —NHCH₂CH₂OCH₃, —NHCOCH₃, —NHCOCH₂CH₃, —NHCOCH₂OH,—NHS(O)₂CH₃, —N(CH₃)S(O)₂CH₃, ═O, —OH, —OCH₃, —OCH₂CH₃, —OCH(CH₃)₂, —SH,—NHC(═O)NHCH₃, —NHC(═O)NHCH₂CH₃, —S(O)CH₃, —S(O)CH₂CH₃, —S(O)₂CH₃,—S(O)₂NH₂, —S(O)₂NHCH₃, —S(O)₂N(CH₃)₂, —CH₂S(O)₂CH₃, and groups selectedfrom

R⁷ is selected from H, C₁-C₁₂ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl,—(C₁-C₁₂ alkylene)-(C₃-C₁₂ carbocyclyl), —(C₁-C₁₂ alkylene)-(C₂-C₂₀heterocyclyl), —(C₁-C₁₂ alkylene)-C(═O)—(C₂-C₂₀ heterocyclyl), —(C₁-C₁₂alkylene)-(C₆-C₂₀ aryl), and —(C₁-C₁₂ alkylene)-(C₁-C₂₀ heteroaryl),where alkyl, alkenyl, alkynyl, alkylene, carbocyclyl, heterocyclyl,aryl, and heteroaryl are optionally substituted with one or more groupsindependently selected from F, Cl, Br, I, —CH₃, —CH₂OH, —CN, —CF₃,—CO₂H, —COCH₃, —CO₂CH₃, —CONH₂, —CONHCH₃, —CON(CH₃)₂, —NO₂, —NH₂,—NHCH₃, —NHCOCH₃, —NHS(O)₂CH₃, —OH, —OCH₃, —S(O)₂N(CH₃)₂, —SCH₃,—CH₂OCH₃, and —S(O)₂CH₃;

and wherein the IC50 binding activity to p110 delta is ten or more timeslower than the binding activity to p110 alpha;

with the proviso that a Formula If compound wherein (ii) X¹ is CR⁷ andX² is S, R¹ is —(C₁-C₁₂ alkylene)-(C₂-C₂₀ heterocyclyl), R³ isoptionally substituted benzo[d]imidazol-1-yl, and R⁷ is H, excludes theC₂-C₂₀ heterocyclyl of R¹ substituted with —S(O)₂CH₃.

The Formula I compounds of the invention may contain asymmetric orchiral centers, and therefore exist in different stereoisomeric forms.It is intended that all stereoisomeric forms of the compounds of theinvention, including but not limited to, diastereomers, enantiomers andatropisomers, as well as mixtures thereof such as racemic mixtures, formpart of the present invention.

In addition, the present invention embraces all geometric and positionalisomers. For example, if a Formula I compound incorporates a double bondor a fused ring, the cis- and trans-forms, as well as mixtures thereof,are embraced within the scope of the invention. Both the singlepositional isomers and mixture of positional isomers are also within thescope of the present invention.

In the structures shown herein, where the stereochemistry of anyparticular chiral atom is not specified, then all stereoisomers arecontemplated and included as the compounds of the invention. Wherestereochemistry is specified by a solid wedge or dashed linerepresenting a particular configuration, then that stereoisomer is sospecified and defined.

The compounds of the present invention may exist in unsolvated as wellas solvated forms with pharmaceutically acceptable solvents such aswater, ethanol, and the like, and it is intended that the inventionembrace both solvated and unsolvated forms.

The compounds of the present invention may also exist in differenttautomeric forms, and all such forms are embraced within the scope ofthe invention. The term “tautomer” or “tautomeric form” refers tostructural isomers of different energies which are interconvertible viaa low energy barrier. For example, proton tautomers (also known asprototropic tautomers) include interconversions via migration of aproton, such as keto-enol and imine-enamine isomerizations. Valencetautomers include interconversions by reorganization of some of thebonding electrons.

The present invention also embraces isotopically-labeled compounds ofthe present invention which are identical to those recited herein, butfor the fact that one or more atoms are replaced by an atom having anatomic mass or mass number different from the atomic mass or mass numberusually found in nature. All isotopes of any particular atom or elementas specified are contemplated within the scope of the compounds of theinvention, and their uses. Exemplary isotopes that can be incorporatedinto compounds of the invention include isotopes of hydrogen, carbon,nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine and iodine,such as 2H, ³H, ¹¹C, ¹³C, ¹⁴C, ¹³N, ¹⁵N, ¹⁵O, ¹⁷O, ¹⁸O, ³²P, ³³P, ³⁵S,¹⁸F, ³⁶Cl, ¹²³I and ¹²⁵I. Certain isotopically-labeled compounds of thepresent invention (e.g., those labeled with ³H and ¹⁴C) are useful incompound and/or substrate tissue distribution assays. Tritiated (³H) andcarbon-14 (¹⁴C) isotopes are useful for their ease of preparation anddetectability. Further, substitution with heavier isotopes such asdeuterium (i.e., ²H) may afford certain therapeutic advantages resultingfrom greater metabolic stability (e.g., increased in vivo half-life orreduced dosage requirements) and hence may be preferred in somecircumstances. Positron emitting isotopes such as ¹⁵O, ¹³N, ¹¹C and ¹⁸Fare useful for positron emission tomography (PET) studies to examinesubstrate receptor occupancy. Isotopically labeled compounds of thepresent invention can generally be prepared by following proceduresanalogous to those disclosed in the Schemes and/or in the Examplesherein below, by substituting an isotopically labeled reagent for anon-isotopically labeled reagent.

Biological Evaluation

The relative efficacies of Formula I compounds as inhibitors of anenzyme activity (or other biological activity) can be established bydetermining the concentrations at which each compound inhibits theactivity to a predefined extent and then comparing the results.Typically, the preferred determination is the concentration thatinhibits 50% of the activity in a biochemical assay, i.e., the 50%inhibitory concentration or “IC₅₀”. Determination of IC₅₀ values can beaccomplished using conventional techniques known in the art. In general,an IC₅₀ can be determined by measuring the activity of a given enzyme inthe presence of a range of concentrations of the inhibitor under study.The experimentally obtained values of enzyme activity then are plottedagainst the inhibitor concentrations used. The concentration of theinhibitor that shows 50% enzyme activity (as compared to the activity inthe absence of any inhibitor) is taken as the IC₅₀ value. Analogously,other inhibitory concentrations can be defined through appropriatedeterminations of activity. For example, in some settings it can bedesirable to establish a 90% inhibitory concentration, i.e., IC₉₀, etc.

Accordingly, a “selective PI3K delta inhibitor” can be understood torefer to a compound that exhibits a 50% inhibitory concentration (IC₅₀)with respect to PI3K delta that is at least at least 10-fold lower thanthe IC50 value with respect to any or all of the other Class I PI3Kfamily members.

Determination of the activity of PI3 kinase activity of Formula Icompounds is possible by a number of direct and indirect detectionmethods. Certain exemplary compounds described herein were assayed fortheir ability to inhibit PI3K alpha, beta, gamma, and delta isoforms(Example 901). The range of IC50 values for inhibition of PI3K delta wasless than 1 nM (nanomolar) to about 10 μM (micromolar). Certainexemplary compounds of the invention had PI3K delta inhibitory IC₅₀values less than 10 nM. The compounds are selective for the p110δ(delta) isoform, which is a class Ia PI3 kinase, over other class Ia PI3kinases, and are thus selective for the p110δ isoform over both thep110α (alpha) isoform and the p110β (beta) isoform. In particular, theyare selective for p110δ (delta) over p110α (alpha). The compounds arealso selective for the p110δ isoform over p110γ (gamma), which is aclass Ib kinase. The selectivity exhibited by Formula I compounds of theinvention for p110δ (delta) over the p110α (alpha) isoform of PI3 kinaseis at least 10 fold, as exemplified by the ratios of biochemical IC₅₀values (Example 901).

Certain Formula I compounds may have antiproliferative activity to treathyperproliferative disorders such as cancer. The Formula I compounds mayinhibit tumor growth in mammals and may be useful for treating humancancer patients. Formula I compounds may be tested for in vitro cellproliferation activity and in vivo tumor growth inhibition according tothe methods in WO 2006/046031; US 2008/0039459; US 2008/0076768; US2008/0076758; WO 2008/070740; WO 2008/073785, which are incorporated byreference herein.

Evaluation of drug-induced immunosuppression by the compounds of theinvention may be performed using in vivo functional tests, such asrodent models of induced arthritis and therapeutic or prophylactictreatment to assess disease score, T cell-dependent antibody response(TDAR), and delayed-type hypersensitivity (DTH). Other in vivo systemsincluding murine models of host defense against infections or tumorresistance (Burleson G R, Dean J H, and Munson A E. Methods inImmunotoxicology, Vol. 1. Wiley-Liss, New York, 1995) may be consideredto elucidate the nature or mechanisms of observed immunosuppression. Thein vivo test systems can be complemented by well-established in vitro orex vivo functional assays for the assessment of immune competence. Theseassays may comprise B or T cell proliferation in response to mitogens orspecific antigens, measurement of signaling through the PI3K pathway inB or T cells or immortalized B or T cell lines, measurement of cellsurface markers in response to B or T cell signaling, natural killer(NK) cell activity, mast cell activity, mast cell degranulation,macrophage phagocytosis or kill activity, and neutrophil oxidative burstand/or chemotaxis. In each of these tests determination of cytokineproduction by particular effector cells (e.g., lymphocytes, NK,monocytes/macrophages, neutrophils) may be included. The in vitro and exvivo assays can be applied in both preclinical and clinical testingusing lymphoid tissues and/or peripheral blood (House R V. “Theory andpractice of cytokine assessment in immunotoxicology” (1999) Methods19:17-27; Hubbard A K. “Effects of xenobiotics on macrophage function:evaluation in vitro” (1999) Methods; 19:8-16; Lebrec H, et al (2001)Toxicology 158:25-29).

Collagen-Induced Arthritis (CIA) 6-week detailed study using anautoimmune mechanism to mimic human arthritis; rat and mouse models(Example 902). Collagen-induced arthritis (CIA) is one of the mostcommonly used animal models of human rheumatoid arthritis (RA). Jointinflammation, which develops in animals with CIA, strongly resemblesinflammation observed in patients with RA. Blocking tumor necrosisfactor (TNF) is an efficacious treatment of CIA, just as it is a highlyefficacious therapy in treatment of RA patients. CIA is mediated by bothT-cells and antibodies (B-cells). Macrophages are believed to play animportant role in mediating tissue damage during disease development,CIA is induced by immunizing animals with collagen emulsified inComplete Freund's Adjuvant (CFA). It is most commonly induced in theDBA/1 mouse strain, but the disease can also be induced in Lewis rats.

There is good evidence that B-cells play a key role in the pathogenesisof autoimmune and/or inflammatory disease. Protein-based therapeuticsthat deplete B cells such as Rituxan are effective againstautoantibody-driven inflammatory diseases such as rheumatoid arthritis(Rastetter et al. (2004) Annu Rev Med 55:477). CD69 is the earlyactivation marker in leukocytes including T cells, thymocytes, B cells,NK cells, neutrophils, and eosinophils. The CD69 human whole blood assay(Example 903) determines the ability of compounds to inhibit theproduction of CD69 by B lymphocytes in human whole blood activated bycrosslinking surface IgM with goat F(ab′)2 anti-human IgM.

The T-cell Dependent Antibody Response (TDAR) is a predictive assay forimmune function testing when potential immunotoxic effects of compoundsneed to be studied. The IgM-Plaque Forming Cell (PFC) assay, using;Sheep Red Blood Cells (SRBC) the antigen, is currently a widely acceptedand validated standard test. TDAR has proven to be a highly predictableassay for adult exposure immunotoxicity detection in mice based on theUS National Toxicology Program (NTP) database (M. I. Luster et al (1992)Fundam. Appl. Toxicol. 18:200-210). The utility of this assay stems fromthe fact that it is a holistic measurement involving several importantcomponents of an immune response. A TDAR is dependent on functions ofthe following cellular compartments: (1) antigen-presenting cells, suchas macrophages or dendritic cells; (2) T-helper cells, which arecritical players in the genesis of the response, as well as in isotypeswitching; and (3) B-cells, which are the ultimate effector cells andare responsible for antibody production. Chemically-induced changes inany one compartment can cause significant changes in the overall TDAR(M. P. Holsapple In: G. R. Burleson, J. H. Dean and A. E. Munson,Editors, Modern Methods in Immunotoxicology, Volume 1, Wiley-LissPublishers, New York, N.Y. (1995), pp. 71-108). Usually, this assay isperformed either as an ELISA for measurement of soluble antibody (R. J.Smialowizc et al (2001) Toxicol. Sci. 61:164-175) or as a plaque (orantibody) forming cell assay (L. Guo et al (2002) Toxicol. Appl.Pharmacol. 181:219-227) to detect plasma cells secreting antigenspecific antibodies. The antigen of choice is either whole cells (e.g.sheep erythrocytes) or soluble protein antigens (T. Miller et al (1998)Toxicol. Sci. 42:129-135).

Exemplary Formula I compounds in Tables 1-3 were made, characterized,and tested for inhibition of PI3K delta and selectivity according to themethods of this invention, and have the following structures andcorresponding names (ChemDraw Ultra, Version 9.0.1, CambridgeSoft Corp.,Cambridge Mass.).

TABLE 1 No. Structure Name 101

4-(1-((2-(isoquinolin-5-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperidin-4-yl)morpholine 102

4-(6-((4-(cyclopropylmethyl)piperazin- 1-yl)methyl)-2-(1H-pyrrolo[2,3-c]pyridin-4-yl)thieno[3,2-d]pyrimidin- 4-yl)morpholine 103

4-((4-morpholino-2-(1H-pyrrolo[2,3-c]pyridin-4-yl)thieno[3,2-d]pyrimidin- 6-yl)methyl)morpholine 104

1-((2-(7-chloroquinolin-4-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)-N,N-dimethylpiperidin-4- amine 105

2-methyl-2-(4-((4-morpholino-2-(1H-pyrrolo[2,3-c]pyridin-4-yl)thieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1- yl)propanamide 106

2-methyl-2-(4-((4-morpholino-2-(1H-pyrrolo[3,2-c]pyridin-4-yl)thieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1- yl)propanamide 107

1-((2-(isoquinolin-8-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)-N,N-dimethylpiperidin-4- amine 108

2-(4-((2-(1-aminoisoquinolin-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)piperazin-1-yl)-2-methylpropanamide 109

1-((2-(isoquinolin-5-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)-N,N-dimethylpiperidin-4- amine 110

1-((2-(1H-benzo[d]imidazol-1-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)-N,N-dimethylpiperidin-4- amine 111

2-(4-((2-(7-methoxy-1H-pyrrolo[2,3- c]pyridin-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)piperazin-1-yl)-2-methylpropanamide 112

2-methyl-2-(4-((7-methyl-4- morpholino-2-(1H-pyrrolo[2,3-c]pyridin-4-yl)thieno[3,2-d]pyrimidin- 6-yl)methyl)piperazin-1-yl)propanamide 113

2-(4-((2-(7-chloro-1H-pyrrolo[2,3- c]pyridin-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)piperazin-1-yl)-2-methylpropanamide 114

4-(8-((4-tert-butylpiperidin-1- yl)methyl)-9-methyl-6-morpholino-9H-purin-2-yl)isoquinolin-1-amine 115

2-(1-((2-(1-aminoisoquinolin-4-yl)-9- methyl-6-morpholine-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol 116

1-((2-(1H-indazol-1-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)-N,N-dimethylpiperidin-4- amine 117

N,N-dimethyl-1-((2-(2-methyl-1H- benzo[d]imidazol-1-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)piperidin-4-amine 118

2-(1-((9-methyl-6-morpholino-2-(1H-pyrrolo[2,3-c]pyridin-4-yl)-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol 119

2-(1-((9-methyl-6-morpholino-2-(1H-pyrrolo[3,2-c]pyridin-4-yl)-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol 120

4-(6-((4-methylpiperazin-1-yl)methyl)- 2-(quinolin-5-yl)thieno[3,2-d]pyrimidin-4-yl)morpholine 121

2-(4-((2-(7-fluoro-1H-pyrrolo[3,2- c]pyridin-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)piperazin-1-yl)-2-methylpropanamide 122

4-(6-((4-cyclopropylpiperazin-1- yl)methyl)-2-(1H-pyrrolo[2,3-c]pyridin-4-yl)thieno[2,3-d]pyrimidin- 4-yl)morpholine 123

4-((4-morpholino-2-(1H-pyrrolo[3,2-c]pyridin-4-yl)thieno[3,2-d]pyrimidin- 6-yl)methyl)morpholine 124

4-(1-((9-methyl-6-morpholino-2-(1H-pyrrolo[2,3-c]pyridin-4-yl)-9H-purin-8-yl)methyl)piperidin-4-yl)morpholine 125

N,N-dimethyl-1-((4-morpholino-2-(1H-pyrrolo[3,2-c]pyridin-3-yl)thieno[3,2-d]pyrimidin-6-yl)methyl)piperidin-4- amine 126

2-methyl-2-(4-((7-methyl-4- morpholino-2-(1H-pyrrolo[3,2-c]pyridin-4-yl)thieno[3,2-d]pyrimidin- 6-yl)methyl)piperazin-1-yl)propanamide 127

4-(6-((4-(1-amino-2-methyl-1- oxopropan-2-yl)piperazin-1-yl)methyl)-4-morpholinothieno[3,2- d]pyrimidin-2-yl)-1H-pyrrolo[2,3-c]pyridine 6-oxide 128

2-(4-((2-(benzofuran-3-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2- methylpropanamide 129

2-(1-((2-(3-amino-1H-indazol-1-yl)-9- methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol 130

2-(1-((2-(1-aminoisoquinolin-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)piperidin-4-yl)propan-2-ol131

2-methyl-2-(4-((7-morpholino-5-(1H-pyrrolo[2,3-c]pyridin-4-yl)thiazolo[5,4-d]pyrimidin-2-yl)methyl)piperazin-1- yl)propanamide 132

2-methyl-2-(4-((2-(7-methyl-1H- pyrrolo[2,3-c]pyridin-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)piperazin-1-yl)propanamide133

4-(1-((9-methyl-6-morpholino-2-(1H-pyrrolo[3,2-c]pyridin-4-yl)-9H-purin-8-yl)methyl)piperidin-4-yl)morpholine 134

1-((2-(1H-indazol-3-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)-N,N-dimethylpiperidin-4- amine 135

2-(4-((2-(isoquinolin-8-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2- methylpropanamide 136

N,N-dimethyl-1-((4-morpholino-2-(1H-pyrrolo[2,3-b]pyridin-3-yl)thieno[3,2-d]pyrimidin-6-yl)methyl)piperidin-4- amine 137

2-(1-((2-(1-(ethylamino)isoquinolin-4- yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperidin-4- yl)propan-2-ol 138

2-(1-((2-(benzofuran-3-yl)-9-methyl-6- morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol 139

4-(9-methyl-6-morpholino-8-((4- morpholinopiperidin-1-yl)methyl)-9H-purin-2-yl)isoquinolin-1-amine 140

2-methyl-2-(4-((2-(2- methylbenzofuran-3-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)piperazin-1-yl)propanamide141

2-(2-(1-aminoisoquinolin-4-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)propan-2-ol 142

2-methyl-2-(4-((2-(2-methyl-1H- pyrrolo[2,3-c]pyridin-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)piperazin-1-yl)propanamide143

2-methyl-2-(4-((2-(2-methyl-1H- pyrrolo[3,2-c]pyridin-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)piperazin-1-yl)propanamide144

2-(4-((2-(1-acetamidoisoquinolin-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)piperazin-1-yl)-2-methylpropanamide 145

2-(1-((9-methyl-2-(2- methylbenzofuran-3-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4- yl)propan-2-ol 146

1-((2-(benzo[b]thiophen-3-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)-N,N-dimethylpiperidin-4- amine 147

2-(1-((2-(1-aminoisoquinolin-5-yl)-9- methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol 148

N-(4-(6-((4-(2-hydroxypropan-2- yl)piperidin-1-yl)methyl)-4-morpholinothieno[3,2-d]pyrimidin-2- yl)isoquinolin-1-yl)acetamide 149

N,N-dimethyl-1-((4-morpholino-2-(1H-pyrrolo[3,2-c]pyridin-1-yl)thieno[3,2-d]pyrimidin-6-yl)methyl)piperidin-4- amine 150

1-((2-(isoquinolin-4-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)-N,N-dimethylpiperidin-4- amine 151

2-(4-((2-(2-ethyl-1H-pyrrolo[2,3- c]pyridin-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)piperazin-1-yl)-2-methylpropanamide 152

4-(1-((7-morpholino-5-(1H- pyrrolo[3,2-c]pyridin-4-yl)thiazolo[5,4-d]pyrimidin-2-yl)methyl)azetidin-3- yl)morpholine 153

2-methyl-2-(4-((2-(5-methyl-1H- pyrrolo[2,3-c]pyridin-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)piperazin-1-yl)propanamide154

4-(1-((9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4- yl)morpholine 155

4-(8-((4-(2-methoxypropan-2- yl)piperidin-1-yl)methyl)-9-methyl-6-morpholino-9H-purin-2-yl)isoquinolin- 1-amine 156

1-(8-((4-(2-hydroxypropan-2- yl)piperidin-1-yl)methyl)-9-methyl-6-morpholino-9H-purin-2-yl)-1H- benzo[d]imidazol-2(3H)-one 157

2-(1-((9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4- yl)propan-2-ol 158

2-(1-((2-(2-ethyl-1H-benzo[d]imidazol- 1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4- yl)propan-2-ol 159

2-(1-((2-(2-cyclopropyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-yl)propan-2-ol 160

2-(4-((2-(isoquinolin-4-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2- methylpropanamide 161

2-(1-((2-(2-(methoxymethyl)-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-yl)propan-2-ol 162

2-(1-((2-(1H-indazol-3-yl)-9-methyl-6- morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol 163

2-(4-((2-(2-fluorobenzofuran-3-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)piperazin-1-yl)-2-methylpropanamide 164

4-(6-((4-(dimethylamino)piperidin-1- yl)methyl)-4-morpholinothieno[3,2-d]pyrimidin-2-yl)isoquinoline 2-oxide 165

2-(1-((9-methyl-2-(2-methyl-1H- pyrrolo[2,3-c]pyridin-4-yl)-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-yl)propan-2-ol 166

2-(1-((2-(2-methoxy-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-yl)propan-2-ol 167

2-(1-((2-(2-amino-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-yl)propan-2-ol 168

4-(1-((7-morpholino-5-(1H- pyrrolo[2,3-c]pyridin-4-yl)thiazolo[5,4-d]pyrimidin-2-yl)methyl)azetidin-3- yl)morpholine 169

2-methyl-2-(4-((7-morpholino-5-(1H-pyrrolo[3,2-c]pyridin-4-yl)thiazolo[5,4-d]pyrimidin-2-yl)methyl)piperazin-1- yl)propanamide 170

2-methyl-2-(4-((2-(6-methyl-1H- pyrrolo[3,2-c]pyridin-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)piperazin-1-yl)propanamide171

2-methyl-2-(4-((4-morpholino-2- (quinolin-4-yl)thieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1- yl)propanamide 172

4-(1-((2-(2-methyl-1H- benzo[d]imidazol-1-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)azetidin-3-yl)morpholine173

1-(4-morpholino-6-((3- morpholinoazetidin-1-yl)methyl)thieno[3,2-d]pyrimidin-2- yl)-1H-benzo[d]imidazol-2(3H)-one174

4-(1-((4-morpholino-2-(1H- pyrrolo[3,2-c]pyridin-4-yl)thieno[3,2-d]pyrimidin-6-yl)methyl)azetidin-3- yl)morpholine 175

2-methyl-2-(4-((2-(6- methylimidazo[1,2-a]pyridin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)piperazin-1-yl)propanamide176

2-methyl-2-(4-((2-(2-methyl-2H- indazol-3-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1- yl)propanamide 177

1-(6-((4-(dimethylamino)piperidin-1- yl)methyl)-4-morpholinothieno[3,2-d]pyrimidin-2-yl)indolin-2-one 178

2-(1-((2-(2-(hydroxymethyl)-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-yl)propan-2-ol 179

4-(8-((4-(2-methoxypropan-2- yl)piperidin-1-yl)methyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)- 9H-purin-6-yl)morpholine 180

2-(4-((2-(1-amino-6-fluoroisoquinolin- 4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1- yl)-2-methylpropanamide 181

(3S,4R)-3-fluoro-N,N-dimethyl-1-((9- methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino- 9H-purin-8-yl)methyl)piperidin-4-amine 182

4-(5-(1H-indazol-3-yl)-2-((3- morpholinoazetidin-1yl)methyl)thiazolo[5,4-d]pyrimidin-7- yl)morpholine 183

1-(7-morpholino-2-((3- morpholinoazetidin-1-yl)methyl)thiazolo[5,4-d]pyrimidin-5- yl)-1H-benzo[d]imidazol-2(3H)-one184

4-(5-(2-(difluoromethyl)-1H- benzo[d]imidazol-1-yl)-2-((3-morpholinoazetidin-1- yl)methyl)thiazolo[5,4-d]pyrimidin-7-yl)morpholine 185

2-(4-((2-(1-amino-7-fluoroisoquinolin- 4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1- yl)-2-methylpropanamide 186

2-(1-((9-methyl-6-morpholino-2-(2- (trifluoromethyl)-1H-benzo[d]imidazol-1-yl)-9H-purin-8- yl)methyl)piperidin-4-yl)propan-2-ol187

2-isobutyl-4-((9-methyl-2-(2-methyl- 1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)morpholine 188

2-(1-((2-(2-(dimethylamino)-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-yl)propan-2-ol 189

2-(1-((2-(2-ethyl-2H-indazol-3-yl)-9- methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol 190

2-(4-((2-(2-ethyl-2H-indazol-3-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)piperazin-1-yl)-2-methylpropanamide 191

2,2-diethyl-4-((9-methyl-2-(2-methyl- 1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)morpholine 192

2-methyl-2-(4-((2-(2-methyl-1H- benzo[d]imidazol-1-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)piperazin-1-yl)propanamide193

4-(5-(2-methyl-1H-benzo[d]imidazol- 1-yl)-2-((3-morpholinoazetidin-1-yl)methyl)thiazolo[5,4-d]pyrimidin-7- yl)morpholine 194

2,6-dimethyl-4-((9-methyl-2-(2- methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)morpholine 195

2-(1-((2-(2-isopropyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-yl)propan-2-ol 196

2,2-dimethyl-4-((9-methyl-2-(2- methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)morpholine 197

2-(1-((2-(2-(1,1-difluoroethyl)-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-yl)propan-2-ol 198

(R)-2-(1-((2-(2-(1-hydroxyethyl)-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-yl)propan-2-ol 199

(S)-2-(1-((2-(2-(1-hydroxyethyl)-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-yl)propan-2-ol 200

4-(8-((4-(2-methoxypropan-2- yl)piperidin-1-yl)methyl)-9-methyl-2-(2-methylbenzofuran-3-yl)-9H-purin-6- yl)morpholine 201

2-methyl-2-(4-((2-(8- methylimidazo[1,2-a]pyridin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)piperazin-1-yl)propanamide202

2-(4-((2-(imidazo[1,5-a]pyridin-8-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)piperazin-1-yl)-2-methylpropanamide 203

2-methyl-N-((2-(2-methyl-1H- benzo[d]imidazol-1-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)-2-morpholinopropan-1-amine 204

4-(6-((3,4-dihydroisoquinolin-2(1H)- yl)methyl)-2-(2-methyl-1H-benzo[d]imidazol-1-yl)thieno[3,2- d]pyrimidin-4-yl)morpholine 205

2-(1-((2-(2-(benzyl(methyl)amino)-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-yl)propan-2-ol 206

2-(1-((9-methyl-2-(2-(methylamino)- 1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-yl)propan-2-ol 207

2-(1-((9-methyl-6-morpholino-2-(2- phenyl-1H-benzo[d]imidazol-1-yl)-9H-purin-8-yl)methyl)piperidin-4- yl)propan-2-ol 208

1-(3-(6-((4-(dimethylamino)piperidin-1-yl)methyl)-4-morpholinothieno[3,2-d]pyrimidin-2-yl)benzo[b]thiophen-2- yl)ethanone 209

2-(1-((5-(1H-indazol-3-yl)-7- morpholinothiazolo[5,4-d]pyrimidin-2-yl)methyl)piperidin-4-yl)propan-2-ol 210

2-(1-((5-(2-methylbenzofuran-3-yl)-7-morpholinothiazolo[5,4-d]pyrimidin-2-yl)methyl)piperidin-4-yl)propan-2-ol 211

2-methyl-2-(4-((5-(2- methylbenzofuran-3-yl)-7-morpholinothiazolo[5,4-d]pyrimidin-2-yl)methyl)piperazin-1-yl)propanamide 212

4-((5-(2-methylbenzofuran-3-yl)-2-((3- morpholinoazetidin-1-yl)methyl)thiazolo[5,4-d]pyrimidin-7- yl)morpholine 213

4-(1-((2-(2-methylbenzofuran-3-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)azetidin-3-yl)morpholine214

2-(4-((2-(6-fluoroimidazo[1,2- a]pyridin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)piperazin-1-yl)-2-methylpropanamide 215

2-(4-((2-(1H-indazol-3-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2- methylpropanamide 216

N,N-dimethyl-1-((4-morpholino-2-(1H-pyrrolo[2,3-c]pyridin-3-yl)thieno[3,2-d]pyrimidin-6-yl)methyl)piperidin-4- amine 217

4-(6-((4-(dimethylamino)piperidin-1- yl)methyl)-4-morpholinothieno[3,2-d]pyrimidin-2-yl)isoquinolin-1(2H)- one 218

2-(1-((2-(2-(2-hydroxyethyl)-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-yl)propan-2-ol 219

2-(1-((9-methyl-6-morpholino-2-(2- (pyridin-3-yl)-1H-benzo[d]imidazol-1-yl)-9H-purin-8-yl)methyl)piperidin-4- yl)propan-2-ol 220

1-(8-((4-(2-hydroxypropan-2- yl)piperidin-1-yl)methyl)-9-methyl-6-morpholino-9H-purin-2-yl)-2-methyl- 1H-indazol-3(2H)-one 221

4-(6-((6-fluoro-3,4-dihydroisoquinolin- 2(1H)-yl)methyl)-2-(2-methyl-1H-benzo[d]imidazol-1-yl)thieno[3,2- d]pyrimidin-4-yl)morpholine 222

2-(1-((2-(imidazo[1,5-a]pyridin-8-yl)- 9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol 223

2-(1-((5-(2-methyl-1H- benzo[d]imidazol-1-yl)-7-morpholinothiazolo[5,4-d]pyrimidin-2-yl)methyl)piperidin-4-yl)propan-2-ol 224

2-(1-((9-methyl-6-morpholino-2-(2- (tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-1-yl)-9H-purin-8- yl)methyl)piperidin-4-yl)propan-2-ol225

2-(1-((2-(3-fluoroquinolin-4-yl)-9- methyl-6-morpholine-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol 226

(3R,4S)-1-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-3- fluoro-N,N-dimethylpiperidin-4-amine227

(3S,4R)-1-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-3- fluoro-N,N-dimethylpiperidin-4-amine228

N,N-dimethyl-1-((2-(3- methylisoquinolin-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)piperidin-4-amine 229

N,N-dimethyl-1-((2-(2- methylbenzo[b]thiophen-3-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)piperidin-4-amine 230

2-methyl-2-(4-((7-methyl-2-(2-methyl- 1H-benzo[d]imidazol-1-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)piperazin-1-yl)propanamide231

2-(1-((7-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)piperidin-4-yl)propan-2-ol232

4-(1-((7-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)piperidin-4-yl)morpholine233

2-(1-((9-methyl-6-morpholino-2-(2- propyl-1H-benzo[d]imidazol-1-yl)-9H-purin-8-yl)methyl)piperidin-4- yl)propan-2-ol 234

2-(4-((2-(3-methoxy-1H-indazol-1-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)piperazin-1-yl)-2-methylpropanamide 235

2-(1-((2-(3-methoxy-1H-indazol-1-yl)- 9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol 236

2-(1-((9-ethyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4- yl)propan-2-ol 237

2-(1-((2-(2-cyclobutyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-yl)propan-2-ol 238

2-(1-((9-methyl-6-morpholino-2-(2- morpholino-1H-benzo[d]imidazol-1-yl)-9H-purin-8-yl)methyl)piperidin-4- yl)propan-2-ol 239 240

2-methyl-2-(4-((2-(2-methyl-1H- benzo[d]imidazol-1-yl)-4-morpholinofuro[3,2-d]pyrimidin-6- yl)methyl)piperazin-1-yl)propanamide241

2-(1-((2-(2-methyl-1H- benzo[d]imidazol-1-yl)-4-morpholinofuro[3,2-d]pyrimidin-6- yl)methyl)piperidin-4-yl)propan-2-ol242

2-(2-methyl-1H-benzo[d]imidazol-1- yl)-4-morpholino-6-((3-morpholinoazetidin-1- yl)methyl)furo[3,2-d]pyrimidine 243

2-(4-((2-(benzo[d]isothiazol-3-yl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)piperazin-1-yl)-2-methylpropanamide 244

2-(1-((5-(8-methylimidazo[1,2- a]pyridin-5-yl)-7-morpholinothiazolo[5,4-d]pyrimidin-2-yl)methyl)piperidin-4-yl)propan-2-ol 245

2-(1-((2-(3-ethoxy-1H-indazol-1-yl)-9- methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol 246

2-(3-(6-((4-(dimethylamino)piperidin-1-yl)methyl)-4-morpholinothieno[3,2-d]pyrimidin-2-yl)benzo[b]thiophen-2- yl)propan-2-ol 247

2-(1-((9-isopropyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4- yl)propan-2-ol 248

2-(4-((5-(imidazo[1,2-a]pyridin-5-yl)-7-morpholinothiazolo[4,5-d]pyrimidin- 2-yl)methyl)piperazin-1-yl)-2-methylpropanamide 249

2-(1-((2-(imidazo[1,2-a]pyridin-5-yl)-4-morpholinofuro[3,2-d]pyrimidin-6- yl)methyl)piperidin-4-yl)propan-2-ol250

2-(imidazo[1,2-a]pyridin-5-yl)-4- morpholino-6-((3-morpholinoazetidin-1-yl)methyl)furo[3,2-d]pyrimidine 251

2-(1-((2-(cinnolin-4-yl)-9-methyl-6- morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol 252

2-ethyl-1-(8-((4-(2-hydroxypropan-2-yl)piperidin-1-yl)methyl)-9-methyl-6- morpholino-9H-purin-2-yl)-1H-indazol-3(2H)-one 253

(S)-2-(1-((9-methyl-6-morpholino-2- (2-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-1-yl)-9H-purin-8- yl)methyl)piperidin-4-yl)propan-2-ol254

(R)-2-(1-((9-((9-6-morpholino-2- (2-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-1-yl)-9H-purin-8- yl)methyl)piperidin-4-yl)propan-2-ol255

2-(1-((2-(2-(ethylamino)-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-yl)propan-2-ol 256

4-(5-(2-methyl-1H-benzo[d]imidazol- 1-yl)-2-((3-morpholinoazetidin-1-yl)methyl)thiazolo[4,5-d]pyrimidin-7- yl)morpholine 257

3-(1-((9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4- yl)oxetan-3-ol

TABLE 2 No. Structure Name 258

2,2-dimethyl-N-((9-methyl-2-(2- methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)propan-1-amine 259

1-(9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)-N-((3- methyloxetan-3- yl)methyl)methanamine260

1-(1-((9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperidin-4- yl)cyclobutanol 261

2-(1-((9-methyl-6-morpholino-2- (2-(pyrrolidin-1-yl)-1H-benzo[d]imidazol-1-yl)-9H-purin- 8-yl)methyl)piperidin-4-yl)propan- 2-ol262

2-(1-((2-(2-(3-fluorooxetan-3-yl)- 1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-yl)propan-2- ol263

3-(1-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-yl)oxetan-3- ol 264

2-methyl-2-(4-((9-methyl-2-(2- methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperazin-1-yl)propan-1- ol 265

2-(1-((9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperidin-3-yl)propan-2- ol 266

2-methyl-1-(1-((9-methyl-2-(2- methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-yl)propan-2- ol 267

4-(9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-8-((4-(2,2,2-trifluoroethyl)piperazin-1- yl)methyl)-9H-purin-6- yl)morpholine268

(4-methyl-1-((9-methyl-2-(2- methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-yl)methanol 269

(R)-2-hydroxy-1-(4-((9-methyl-2- (2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperazin-1-yl)propan-1- one 270

adamantan-1-yl-[9-methyl-2-(2- methyl-benzoimidazol-1-yl)-6-morpholin-4-yl-9H-purin-8- ylmethyl]-amine 271

N-((9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)- 2,3-dihydro-1H-inden-1-amine 272

(4R)-N-((9-methyl-2-(2-methyl- 1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)bicyclo[2.2.1]heptan-2- amine 273

1-(((9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methylamino)methyl)cyclohexan- ol 274

(1-((9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methylamino)cyclopentyl) methanol 275

N,1-dimethyl-N-((9-methyl-2-(2- methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-amine 276

4-(8-(isoindolin-2-ylmethyl)-9- methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin- 6-yl)morpholine 277

4-(8-((4- (cyclopropylmethyl)piperazin-1-yl)methyl)-9-methyl-2-(2-methyl- 1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine 278

4-(8-((4,4-difluoropiperidin-1- yl)methyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H- purin-6-yl)morpholine 279

N-((9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)- 1-phenylethanamine 280

4-(8-((4-(methoxymethyl)piperidin- 1-yl)methyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)- 9H-purin-6-yl)morpholine 281

4-((9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methylamino)cyclohexanol 282

1-(9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)-N-((1- methylpiperidin-2-yl)methyl)methanamine 283

4-(8-((dihydro-1H-pyrido[1,2- a]pyrazin-2(6H,7H,8H,9H,9aH)-yl)methyl)-9-methyl-2-(2-methyl- 1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine 284

1-methyl-N-((9-methyl-2-(2- methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-amine 285

N,2-dimethyl-N-((9-methyl-2-(2- methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)propan-1-amine 286

1-(4-((9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methylamino)piperidin-1- yl)ethanone 287

4-(1-((9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)pyrrolidin-3- yl)morpholine 288

N-((9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)tetrahydro-2H-pyran-4- amine 289

4-(9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-8-((3-(trifluoromethyl)pyrrolidin-1- yl)methyl)-9H-purin-6- yl)morpholine 290

N-methyl-1-(9-methyl-2-(2-methyl- 1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)-N- ((tetrahydrofuran-2- yl)methyl)methanamine291

1-((9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperidine-4-carbonitrile 292

2-methyl-1-((9-methyl-2-(2- methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methylamino)propan-2-ol 293

3,3,3-trifluoro-N-((9-methyl-2-(2- methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)propan-1-amine 294

4,4-difluoro-N-((9-methyl-2-(2- methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)cyclohexanamine 295

1-isopropyl-N-methyl-N-((9- methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6- morpholino-9H-purin-8-yl)methyl)piperidin-4-amine 296

N,N-diethyl-1-((9-methyl-2-(2- methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)pyrrolidin-3-amine 297

1-(9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)-N- ((tetrahydrofuran-3- yl)methyl)methanamine298

N-methyl-N-(1-((9-methyl-2-(2- methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)pyrrolidin-3- yl)acetamide 299

(R)-(1-((9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)pyrrolidin-3-yl)methanol 300

4-(8-((3,3-dimethylpyrrolidin-1- yl)methyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H- purin-6-yl)morpholine 301

4-(8-((3,3-diethylpyrrolidin-1- yl)methyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H- purin-6-yl)morpholine 302

4-(8-((3-isobutylpyrrolidin-1- yl)methyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H- purin-6-yl)morpholine 303

N-((9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)- 2-phenylpropan-2-amine 304

4-(9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-8-((1,1-dioxo-4-(tetrahydro-2H-thiopyran- 4-yl)piperazin-1-yl)methyl)-9H-purin-6-yl)morpholine 305

(S)-(1-((9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)pyrrolidin-3-yl)methanol 306

1-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)-N,N-dimethylpiperidin- 4-amine 307

2-(1-((2-(2-(1-fluorocyclopropyl)- 1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-yl)propan-2- ol308

2-(1-((2-(2-(cyclopropylmethyl)- 1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-yl)propan-2- ol309

4-(1-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)azetidin-3-yl)morpholine 310

4-(8-((3,3-dimethyl-4-(2- (methylsulfonyl)ethyl)piperazin-1-yl)methyl)-2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine 311

2-((1-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)azetidin-3- yl)(methyl)amino)-2-methylpropanamide 312

4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl- 8-((4-(2-(methylsulfonyl)ethyl)piperazin-1- yl)methyl)-9H-purin-6- yl)morpholine313

1-(1-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)azetidin-3-yl)-2- methylpropan-1-ol314

4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-8-((4-(oxetan-3-yl)piperidin-1- yl)methyl)-9H-purin-6- yl)morpholine 315

2-(1-((9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)azetidin-3-yl)propan-2-ol 316

3-(1-((9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-yl)pentan-3- ol 317

4-(1-((9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-yl)tetrahydro-2H-pyran-4-ol 318

(S)-4-(8-((3-(1,1-dioxo- isothiazolidin-2-yl)pyrrolidin-1-yl)methyl)-9-methyl-2-(2-methyl- 1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine 319

2-(1-((9-methyl-2-(2-(1-methyl- 1H-pyrazol-5-yl)-1H-benzo[d]imidazol-1-yl)-6- morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2- ol 320

(R)-4-(8-((3-(1,1-dioxo- isothiazolidin-2-yl)pyrrolidin-1-yl)methyl)-9-methyl-2-(2-methyl- 1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine 321

N-((9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)- 2-(4-methylthiazol-2-yl)ethanamine 322

N-((9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)- 2-(pyridin-2-yl)ethanamine 323

1-(1-((9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperidin-4- yl)cyclopentanol 324

7-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)-2-oxa-7- azaspiro[3.5]nonane 325

4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-8-((3-(tetrahydro-2H-pyran-4- yl)azetidin-1-yl)methyl)-9H-purin-6-yl)morpholine 326

N,N-dimethyl-1-((9-methyl-2-(2- methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperidine-4- carboxamide 327

8-((9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)- 1-oxa-3,8-diazaspiro[4.5]decan-2- one328

4-(1-((9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)azetidin-3-yl)morpholine 329

4-(9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-8-((4-(2-(methylsulfonyl)ethyl)piperazin-1- yl)methyl)-9H-purin-6- yl)morpholine330

4-(8-((3,3-dimethyl-4-(2- (methylsulfonyl)ethyl)piperazin-1-yl)methyl)-9-methyl-2-(2-methyl- 1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine 331

4-(1-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)azetidin-3-yl)-2,2-dimethylmorpholine 332

2-(1-((5-(2-ethyl-1H- benzo[d]imidazol-1-yl)-7- morpholinothiazolo[5,4-d]pyrimidin-2-yl)methyl)piperidin- 4-yl)propan-2-ol 333

(R)-N-methyl-N-(1-((9-methyl-2- (2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)pyrrolidin-3- yl)acetamide 334

(R)-4-(1-((9-methyl-2-(2-methyl- 1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)pyrrolidin-3- yl)morpholine 335

(S)-N-methyl-N-(1-((9-methyl-2- (2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)pyrrolidin-3- yl)acetamide 336

(S)-4-(1-((9-methyl-2-(2-methyl- 1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)pyrrolidin-3- yl)morpholine 337

2-(1-((2-(2-ethoxy-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-yl)propan-2- ol 338

2-(1-((2-(2-isopropoxy-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-yl)propan-2- ol 339

2-methyl-2-(1-((9-methyl-2-(2- methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-yl)propan-1- ol 340

4-(8-((4-tert-butylpiperazin-1- yl)methyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H- purin-6-yl)morpholine 341

2-(1-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-yl)-2- methylpropan-1-ol342

N-((9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)- 2-(pyrazin-2-yl)ethanamine 343

7-((9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)- 7-azaspiro[3.5]nonan-2-ol 344

2-(1-(2-(9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)ethyl)piperidin-4-yl)propan-2-ol 345

4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-8-((3-fluoro-1,3′-biazetidin-1′-yl)methyl)- 9-methyl-9H-purin-6- yl)morpholine346

2-methyl-1-(1-((9-methyl-2-(2- methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-yl)propan-1- ol 347

azetidin-1-yl(1-((9-methyl-2-(2- methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)azetidin-3-yl)methanone 348

(1-((9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)azetidin-3-yl)(pyrrolidin-1-yl)methanone 349

(R)-azetidin-1-yl(1-((9-methyl-2- (2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)pyrrolidin-3- yl)methanone 350

(R)-(1-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)pyrrolidin-3-yl)(pyrrolidin-1-yl)methanone 351

(R)-N,N-dimethyl-1-((9-methyl-2- (2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)pyrrolidine-3- carboxamide 352

(R)-1-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)-N,N-dimethylpyrrolidine-3-carboxamide 353

2,2-dimethyl-4-(1-((9-methyl-2-(2- methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)azetidin-3-yl)morpholine 354

4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl- 8-((3-(1,1-dioxo-thiomorpholino)azetidin-1- yl)methyl)-9H-purin-6- yl)morpholine 355

4-(2-(2-methyl-1H- benzo[d]imidazol-1-yl)-9-methyl- 8-((3-(1,1-dioxo-thiomorpholino)azetidin-1- yl)methyl)-9H-purin-6- yl)morpholine 356

2-methyl-2-(4-((9-methyl-2-(2- methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperazin-1-yl)propane- 1,3-diol 357

(R)-3-methyl-2-(4-((9-methyl-2-(2- methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperazin-1-yl)butan-1-ol 358

2-(1-((2-(2-(2- methoxyethylamino)-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-yl)propan-2- ol 359

(R)-1-(1-((9-methyl-2-(2-methyl- 1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-yl)propan-1- ol 360

(S)-1-(1-((9-methyl-2-(2-methyl- 1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-yl)propan-1- ol 361

(S)-3-methyl-2-(4-((9-methyl-2-(2- methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperazin-1-yl)butan-1-ol 362

2-(1-((5-(2-methyl-1H- benzo[d]imidazol-1-yl)-7- morpholinothiazolo[5,4-d]pyrimidin-2-yl)methyl)piperidin- 3-yl)propan-2-ol 363

N,N-dimethyl-1-((9-methyl-2-(2- methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)azetidine-3-carboxamide 364

(R)-(1-((9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)pyrrolidin-3-yl)(pyrrolidin-1-yl)methanone 365

(1-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)azetidin-3-yl)(pyrrolidin-1-yl)methanone 366

1-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)-N,N-dimethylazetidine- 3-carboxamide367

2-(1-(2-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)ethyl)piperidin-4-yl)propan-2-ol 368

2-methyl-2-(4-(2-(9-methyl-2-(2- methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)ethyl)piperazin-1- yl)propanamide 369

8-((9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)- 1,4-dioxa-8-azaspiro[4.5]decane 370

8-((9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)- 1-oxa-8-azaspiro[4.5]decane 371

N-(2-(1-((9-methyl-2-(2-methyl- 1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-yl)propan-2- yl)acetamide372

(S)-2-(1-((9-methyl-2-(2-methyl- 1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-yl)butan-2-ol 373

(S)-1-(1-((9-methyl-2-(2-methyl- 1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-yl)ethanol 374

(R)-1-(1-((9-methyl-2-(2-methyl- 1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-yl)ethanol 375

4-(8-((dihydro-1H-pyrido[1,2- a]pyrazin-2(6H,7H,8H,9H,9aH)-yl)methyl)-9-methyl-2-(2-methyl- 1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine 376

N,N-diethyl-1-((9-methyl-2-(2- methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)pyrrolidin-3-amine 377

4-(8-((dihydro-1H-pyrido[1,2- a]pyrazin-2(6H,7H,8H,9H,9aH)-yl)methyl)-9-methyl-2-(2-methyl- 1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine 378

N,N-diethyl-1-((9-methyl-2-(2- methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)pyrrolidin-3-amine 379

8-((9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)- 2,8-diazaspiro[4.5]decan-1-one 380

8-((9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)- 3-oxa-8-azabicyclo[3.2.1]octane 381

(R)-2-(4-((9-methyl-2-(2-methyl- 1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperazin-1-yl)butan-1-ol 382

(S)-2-(4-((9-methyl-2-(2-methyl- 1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperazin-1-yl)butan-1-ol 383

2-(1-((9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-yl)propan-2- amine 384

5-((9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)- 2-oxa-5-azabicyclo[2.2.1]heptane 385

(1-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)-4-methylpiperidin-4- yl)methanol 386

4-(9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-8-((3-(piperidin-1-yl)azetidin-1- yl)methyl)-9H-purin-6- yl)morpholine 387

4-(8-((4-tert-butylpiperazin-1- yl)methyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl- 9H-purin-6-yl)morpholine 388

(S)-1-(1-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)azetidin-3-yl)-2- methylpropan-1-ol389

N-methyl-1-((9-methyl-2-(2- methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)-N-(tetrahydrofuran-3-yl)piperidin-4-amine 390

1-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)-N-methyl-N-(tetrahydrofuran-3-yl)piperidin-4- amine 391

7-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)-2-methyl-7- azaspiro[3.5]nonan-2-ol392

4-(2-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)ethyl)-2,2-dimethylmorpholine 393

(S)-azetidin-1-yl(1-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)pyrrolidin-3- yl)methanone 394

9-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 395

4-(8-((1S,4S)-2,5- diazabicyclo[2.2.1]heptan-2- ylmethyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl- 9H-purin-6-yl)morpholine 396

(3-methyl-1-((9-methyl-2-(2- methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)pyrrolidin-3-yl)(pyrrolidin-1-yl)methanone 397

2,2-dimethyl-4-(2-(9-methyl-2-(2- methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)ethyl)morpholine 398

(S)-1-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)-N,N-dimethylpyrrolidine-3-carboxamide 399

(S)-(1-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)pyrrolidin-3-yl)(pyrrolidin-1-yl)methanone 400

9-((9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)- 1,5-dioxa-9-azaspiro[5.5]undecane 401

4-(8-((4-tert-butylpiperazin-1- yl)methyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9H-purin- 6-yl)morpholine 402

2-(4-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)piperazin-1-yl)-2- methylpropan-1-ol403

4-(8-((4-tert-butylpiperazin-1- yl)methyl)-2-(2-cyclopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl- 9H-purin-6-yl)morpholine 404

2-((1R,5S,6r)-3-((9-methyl-2-(2- methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)-3- azabicyclo[3.1.0]hexan-6-yl)propan-2-ol 405

(R)-1-(1-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)azetidin-3-yl)-2- methylpropan-1-ol406

2-methyl-2-(4-((9-methyl-2-(2- methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperazin-1- yl)propanamide 407

(R)-1-(1-(8-((4-(2-hydroxypropan- 2-yl)piperidin-1-yl)methyl)-9-methyl-6-morpholino-9H-purin-2- yl)-1H-benzo[d]imidazol-2-yl)propan-2-ol 408

(S)-1-(1-(8-((4-(2-hydroxypropan- 2-yl)piperidin-1-yl)methyl)-9-methyl-6-morpholino-9H-purin-2- yl)-1H-benzo[d]imidazol-2-yl)propan-2-ol 409

(R)-8-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)octahydropyrazino[2,1- c][1,4]oxazine410

4-methyl-5-((9-methyl-2-(2- methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methylamino)pentane-1,4-diol 411

2-(1-(8-((4-tert-butylpiperazin-1- yl)methyl)-6-morpholino-9H-purin-2-yl)-1H-benzo[d]imidazol-2- yl)ethanol 412

(1S,2R)-2-(4-((9-methyl-2-(2- methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperazin-1- yl)cyclopentanol 413

2-(4-((2-(2-cyclopropyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)piperazin-1-yl)-2- methylpropan-1-ol414

4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-8-((4-(3-methyloxetan-3- yl)piperazin-1-yl)methyl)-9H-purin-6-yl)morpholine 415

(S)-4-(8-((hexahydropyrrolo[1,2- a]pyrazin-2(1H)-yl)methyl)-9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-9H-purin- 6-yl)morpholine416

(R)-4-(8-((hexahydropyrrolo[1,2- a]pyrazin-2(1H)-yl)methyl)-9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-9H-purin- 6-yl)morpholine417

ethyl 2-((1S,4S)-5-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)-2- methylpropanoate 418

1-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)-N-methyl-N-(oxetan-3-yl)piperidin-4-amine 419

N-((1-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)azetidin-3-yl)methyl)-N-methyltetrahydrofuran-3-amine 420

2-(1-((5-(2-ethyl-1H- benzo[d]imidazol-1-yl)-7- morpholinothiazolo[4,5-d]pyrimidin-2-yl)methyl)piperidin- 4-yl)propan-2-ol 421

N-((1-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)azetidin-3-yl)methyl)-N-methyloxetan-3-amine 422

4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-8-((3-(tetrahydro-2H-pyran-4-yl)azetidin- 1-yl)methyl)-9H-purin-6-yl)morpholine 423

2-methyl-2-(4-((2-(2-methyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperazin-1- yl)propanamide 424

2-ethyl-1-(8-((4-(2-hydroxypropan- 2-yl)piperidin-1-yl)methyl)-6-morpholino-9H-purin-2-yl)-1H- indazol-3(2H)-one 425

2-(4-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-6- morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)-2- methylpropanamide 426

2-(1-((2-(2-(2-hydroxyethyl)-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-yl)propan-2- ol 427

2-(4-((2-(2-(2-hydroxyethyl)-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)piperazin-1-yl)-2- methylpropan-1-ol428

1-(8-((4-tert-butylpiperazin-1- yl)methyl)-9-methyl-6-morpholino-9H-purin-2-yl)-N-methyl-1H- benzo[d]imidazol-2-amine 429

4-methyl-1-((9-methyl-2-(2- methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)azepan-4-ol 430

2-(1-((2-(2-ethylbenzofuran-3-yl)- 9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan- 2-ol 431

N-((9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)- 2-(1H-pyrazol-1-yl)ethanamine 432

(1-aminocyclopropyl)(4-((2-(2- ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)piperazin-1- yl)methanone 433

2-(1-(2-(5-(2-ethyl-1H- benzo[d]imidazol-1-yl)-7-morpholinothiazolo[5,4- d]pyrimidin-2-yl)ethyl)piperidin-4-yl)propan-2-ol 434

2-(1-(8-((4-tert-butylpiperazin-1- yl)methyl)-9-methyl-6-morpholino-9H-purin-2-yl)-1H- benzo[d]imidazol-2-yl)ethanol 435

N-methyl-1-(9-methyl-6- morpholino-8-((3-(tetrahydro-2H-pyran-4-yl)azetidin-1-yl)methyl)- 9H-purin-2-yl)-1H-benzo[d]imidazol-2-amine 436

4-(5-(2-ethyl-1H- benzo[d]imidazol-1-yl)-2-((3-(1,1-dioxo-thiomorpholino)azetidin-1- yl)methyl)thiazolo[5,4-d]pyrimidin-7-yl)morpholine 437

2-(4-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)piperazin-1-yl)-2- methylpropanamide438

2-(4-((2-(2-cyclopropyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)piperazin-1-yl)-2- methylpropanamide439

2-(4-((2-(2-isopropyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)piperazin-1-yl)-2- methylpropanamide440

2-(4-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)piperazin-1-yl)-2-methylpropane-1,3-diol 441

4-(8-((4-isopropylpiperazin-1- yl)methyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H- purin-6-yl)morpholine 442

4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-8-((4-isopropylpiperazin-1-yl)methyl)-9- methyl-9H-purin-6-yl)morpholine 443

1-(8-((4-(2-hydroxypropan-2- yl)piperidin-1-yl)methyl)-9-methyl-6-morpholino-9H-purin-2-yl)-2- isopropyl-1H-indazol-3(2H)-one 444

4-(8-((4-cyclobutylpiperazin-1- yl)methyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl- 9H-purin-6-yl)morpholine 445

4-(8-((4-tert-butylpiperazin-1- yl)methyl)-2-(isoquinolin-4-yl)-9-methyl-9H-purin-6-yl)morpholine 446

4-(9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-8-((4-(oxetan-3-yl)piperidin-1- yl)methyl)-9H-purin-6- yl)morpholine 447

N-methyl-1-(9-methyl-6- morpholino-8-((4-(oxetan-3-yl)piperidin-1-yl)methyl)-9H- purin-2-yl)-1H-benzo[d]imidazol- 2-amine448

4-(5-(2-methyl-1H- benzo[d]imidazol-1-yl)-2-((3-(1,1-dioxo-thiomorpholino)azetidin-1- yl)methyl)thiazolo[5,4-d]pyrimidin-7-yl)morpholine 449

4-(2-(2-isopropyl-1H- benzo[d]imidazol-1-yl)-9-methyl- 8-((3-(1,1-dioxo-thiomorpholino)azetidin-1- yl)methyl)-9H-purin-6- yl)morpholine 450

4-(2-(2-cyclopropyl-1H- benzo[d]imidazol-1-yl)-9-methyl-8-((4-(oxetan-3-yl)piperidin-1- yl)methyl)-9H-purin-6- yl)morpholine 451

2-(1-(2-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)ethyl)azetidin-3-yl)propan-2-ol 452

1-(2-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)ethyl)-4-methylpiperidin-4-ol 453

2-methyl-2-(4-((9-methyl-2-(2- (methylamino)-1H- benzo[d]imidazol-yl)-6-morpholino-9H-purin-8- yl)methyl)piperazin-1-yl)propan-1- ol 454

4-(2-(2-(azetidin-1-yl)-1H- benzo[d]imidazol-1-yl)-8-((4-tert-butylpiperazin-1-yl)methyl)-9- methyl-9H-purin-6-yl)morpholine 455

2-(1-((2-(2-(azetidin-1-yl)-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-yl)propan-2- ol 456

ethyl 2-methyl-2-(4-((9-methyl-2- (2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperidin-1- yl)propanoate 457

4-(8-((4-tert-butylpiperazin-1- yl)methyl)-2-(2-(1,1-difluoroethyl)-1H-benzo[d]imidazol-1-yl)-9H- purin-6-yl)morpholine 458

1-(2-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)ethyl)-3-methylazetidin-3-ol 459

4-(2-(2-(1,1-difluoroethyl)-1H- benzo[d]imidazol-1-yl)-9-methyl-8-((4-(oxetan-3-yl)piperidin-1- yl)methyl)-9H-purin-6- yl)morpholine 460

(S)-(1-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)azetidin-3-yl)(3-hydroxypyrrolidin-1-yl)methanone 461

(R)-(1-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)azetidin-3-yl)(3-hydroxypyrrolidin-1-yl)methanone 462

2-(1-((2-(2-tert-butyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-yl)propan-2- ol 463

4-(8-((4-tert-butylpiperazin-1- yl)methyl)-2-(2-(1,1-difluoroethyl)-1H-benzo[d]imidazol-1-yl)-9- methyl-9H-purin-6-yl)morpholine 464

4-(8-((4-tert-butylpiperazin-1- yl)methyl)-9-methyl-2-(2-(trifluoromethyl)-1H- benzo[d]imidazol-1-yl)-9H-purin- 6-yl)morpholine465

7-(2-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)ethyl)-7-azaspiro[3.5]nonan-2-ol 466

1-(2-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)ethyl)-3-isopropylazetidin-3-ol 467

4-(9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-8-((3-(tetrahydro-2H-pyran-4-yl)azetidin- 1-yl)methyl)-9H-purin-6-yl)morpholine 468

4-(2-(2-(1,1-difluoroethyl)-1H- benzo[d]imidazol-1-yl)-9-methyl-8-((3-(tetrahydro-2H-pyran-4- yl)azetidin-1-yl)methyl)-9H-purin-6-yl)morpholine 469

4-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)-1-isopropylpiperazin-2- one 470

4-(5-(2-isopropyl-1H- benzo[d]imidazol-1-yl)-2-((3-(tetrahydro-2H-pyran-4-yl)azetidin- 1-yl)methyl)thiazolo[5,4-d]pyrimidin-7-yl)morpholine 471

4-(8-((4-tert-butylpiperazin-1- yl)methyl)-2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl- 9H-purin-6-yl)morpholine 472

1-(8-((4-tert-butylpiperazin-1- yl)methyl)-9-methyl-6-morpholino-9H-purin-2-yl)-2-ethyl-1H-indazol- 3(2H)-one 473

2-(4-((2-(2-(1,1-difluoroethyl)-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)piperazin-1-yl)-2- methylpropan-1-ol474

2-methyl-2-(4-((9-methyl-6- morpholino-2-(2-(trifluoromethyl)-1H-benzo[d]imidazol-1-yl)-9H- purin-8-yl)methyl)piperazin-1-yl)propan-1-ol 475

4-(8-((4-tert-butylpiperazin-1- yl)methyl)-9-methyl-2-(quinolin-4-yl)-9H-purin-6-yl)morpholine 476

2-(4-((2-(2-isopropyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)piperazin-1-yl)-2- methylpropan-1-ol477

2-(1-((2-(2-((1R,2S)-2- fluorocyclopropyl)-1H-benzo[d]imidazol-1-yl)-9-methyl- 6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2- ol 478

(R)-2-(1-((2-(2-(2,2- difluorocyclopropyl)-1H-benzo[d]imidazol-1-yl)-9-methyl- 6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2- ol 479

2-(1-((2-(2-((1S,2R)-2- fluorocyclopropyl)-1H-benzo[d]imidazol-1-yl)-9-methyl- 6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2- ol 480

2-(1-((2-(2-((1R,2R)-2- fluorocyclopropyl)-1H-benzo[d]imidazol-1-yl)-9-methyl- 6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2- ol 481

(S)-2-(1-((2-(2-(2,2- difluorocyclopropyl)-1H-benzo[d]imidazol-1-yl)-9-methyl- 6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2- ol 482

4-(5-(2-methyl-1H- benzo[d]imidazol-1-yl)-2-((3-(tetrahydro-2H-pyran-4-yl)azetidin- 1-yl)methyl)thiazolo[5,4-d]pyrimidin-7-yl)morpholine 483

4-(5-(2-ethyl-1H- benzo[d]imidazol-1-yl)-2-((3-(tetrahydro-2H-pyran-4-yl)azetidin- 1-yl)methyl)thiazolo[5,4-d]pyrimidin-7-yl)morpholine 484

4-(5-(2-cyclopropyl-1H- benzo[d]imidazol-1-yl)-2-((3-(tetrahydro-2H-pyran-4-yl)azetidin- 1-yl)methyl)thiazolo[5,4-d]pyrimidin-7-yl)morpholine 485

2-(1-((2-(2-ethyl-4-fluoro-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-yl)propan-2- ol 486

1-(1-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)azetidin-3-yl)piperidin- 4-ol 487

2-(1-((2-(2-(azetidin-1-ylmethyl)- 1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-yl)propan-2- ol488

2-(4-((2-(2-cyclopropyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperazin-1-yl)-2- methylpropan-1-ol489

2-(4-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-6- morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)-2- methylpropan-1-ol 490

2-(4-((2-(2-isopropyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperazin-1-yl)-2- methylpropan-1-ol491

4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-8-((3-(4-fluoropiperidin-1-yl)azetidin-1- yl)methyl)-9-methyl-9H-purin-6-yl)morpholine 492

4-(8-((3-(4,4-difluoropiperidin-1- yl)azetidin-1-yl)methyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9- methyl-9H-purin-6-yl)morpholine 493

4-(2-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)ethyl)-1-isopropylpiperazin-2- one 494

1′-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)-1,3′-biazetidin-3-ol 495

4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-8-((4-(tetrahydro-2H-pyran-4- yl)piperazin-1-yl)methyl)-9H-purin-6-yl)morpholine 496

4-(5-(2-ethyl-1H- benzo[d]imidazol-1-yl)-2-((4-(oxetan-3-yl)piperidin-1- yl)methyl)thiazolo[5,4-d]pyrimidin-7-yl)morpholine 497

4-(5-(2-cyclopropyl-1H- benzo[d]imidazol-1-yl)-2-((4-(oxetan-3-yl)piperidin-1- yl)methyl)thiazolo[5,4-d]pyrimidin-7-yl)morpholine 498

N-methyl-1-(7-morpholino-2-((3- (tetrahydro-2H-pyran-4-yl)azetidin-1-yl)methyl)thiazolo[5,4- d]pyrimidin-5-yl)-1H- benzo[d]imidazol-2-amine499

4-(2-(2-cyclopropyl-1H- benzo[d]imidazol-1-yl)-9-methyl-8-((3-(tetrahydro-2H-pyran-4- yl)azetidin-1-yl)methyl)-9H-purin-6-yl)morpholine 500

ethyl 2-(4-((2-(2-cyclopropyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)piperazin-1-yl)-2- methylpropanoate501

4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-8-((1-(tetrahydro-2H-(1,1-dioxo)- thiopyran-4-yl)azetidin-3-yl)methyl)-9H-purin-6- yl)morpholine 502

ethyl 2-methyl-2-(4-((9-methyl-2- (2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperazin-1- yl)propanoate 503

4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-8-((1-(tetrahydro-2H-pyran-4- yl)azetidin-3-yl)methyl)-9H-purin-6-yl)morpholine 504

4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-8-((4-(1-fluoro-2-methylpropan-2- yl)piperazin-1-yl)methyl)-9-methyl-9H-purin-6-yl)morpholine 505

tert-butyl 4-((9-methyl-2-(2- methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperidine-1-carboxylate 506

2-methyl-2-(4-((9-methyl-2-(2- methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperazin-1-yl)propanoic acid 507

methyl 2-methyl-2-(4-((9-methyl- 2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperidin-1- yl)propanoate 508

2-methyl-2-(4-((9-methyl-2-(2- methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperidin-1- yl)propanamide 509

2-methyl-2-(4-((9-methyl-2-(2- methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperidin-1-yl)propan-1- ol 510

4-(8-((4-tert-butylpiperazin-1- yl)methyl)-9-methyl-6-morpholino-9H-purin-2-yl)isoquinolin-1-amine 511

8-(2-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)ethyl)-3-oxa-8- azabicyclo[3.2.1]octane 512

2-(1-(9-methyl-6-morpholino-8- ((4-(oxetan-3-yl)piperidin-1-yl)methyl)-9H-purin-2-yl)-1H- benzo[d]imidazol-2-yl)ethanol 513

4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-8-((4-(oxetan-3-yl)piperazin-1- yl)methyl)-9H-purin-6- yl)morpholine 514

4-(1-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)azetidin-3-yl)piperazin- 2-one 515

(S)-3-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-1- isopropylpiperidin-3-ol 516

(S)-2-(1-((2-(2-(1-methoxyethyl)- 1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-yl)propan-2- ol517

N-(1-(8-((4-(2-hydroxypropan-2- yl)piperidin-1-yl)methyl)-9-methyl-6-morpholino-9H-purin-2-yl)-1H- benzo[d]imidazol-2-yl)acetamide 518

(R)-3-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-1- isopropylpiperidin-3-ol 519

(R)-2-(1-((2-(2-(1-methoxyethyl)- 1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-yl)propan-2- ol520

4-(9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-8-(piperidin-4-ylmethyl)-9H-purin-6- yl)morpholine 521

2-((1S,4S)-5-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)-2- methylpropan-1-ol 522

4-(2-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)ethyl)-6-isopropylpiperazin-2- one 523

1-(4-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)piperazin-1-yl)-2- methylpropan-2-ol524

1-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)azetidin-3-ol 525

2-methyl-2-(4-((9-methyl-2-(2- methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperidin-1-yl)propanoic acid 526

(R)-methyl 2-(4-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)(hydroxy)methyl)piperidin-1-yl)-2-methylpropanoate 527

(S)-methyl 2-(4-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)(hydroxy)methyl)piperidin-1-yl)-2-methylpropanoate 528

methyl 2-(4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purine-8- carbonyl)piperidin-1-yl)-2- methylpropanoate529

4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-8-((1-(oxetan-3-yl)azetidin-3- yl)methyl)-9H-purin-6- yl)morpholine 530

4-(8-(azetidin-3-ylmethyl)-2-(2- ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine 531

2-(3-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)azetidin-1-yl)-2- methylpropanamide532

methyl 2-(3-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)azetidin-1-yl)-2- methylpropanoate533

2-(3-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)azetidin-1-yl)-2- methylpropan-1-ol534

1-(3-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)azetidin-1-yl)-2- methylpropan-2-ol535

4-(2-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)ethyl)-3,3-dimethylmorpholine 536

(S)-1-(1-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)azetidin-3-yl)pyrrolidin- 3-ol 537

4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl- 8-(2-(3-(1,1-dioxo-thiomorpholino)azetidin-1- yl)ethyl)-9H-purin-6-yl)morpholine 538

(R)-1-(1-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)azetidin-3-yl)pyrrolidin- 3-ol 539

4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl- 8-(2-(1,1-dioxo-thiomorpholino)ethyl)-9H-purin-6- yl)morpholine 540

4-(8-(2-(4,4-difluoropiperidin-1- yl)ethyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl- 9H-purin-6-yl)morpholine 541

2-(3-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)azetidin-1-yl)acetamide 542

2-methyl-1-(4-((9-methyl-2-(2- methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperidin-1-yl)propan-2- ol 543

4-(9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-8-((1-(2-(methylsulfonyl)ethyl)azetidin-3- yl)methyl)-9H-purin-6- yl)morpholine544

4-(9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-8-((1-(2-(methylsulfonyl)ethyl)piperidin-4- yl)methyl)-9H-purin-6- yl)morpholine545

(R)-2-(3-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)azetidin-1- yl)propanamide 546

(S)-2-(3-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)azetidin-1- yl)propanamide 547

4-(1-((2-(2-isopropyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)azetidin-3-yl)morpholine 548

4-(1-((2-(2-cyclopropyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)azetidin-3-yl)morpholine 549

2-(5-(2-ethyl-1H- benzo[d]imidazol-1-yl)-7- morpholinothiazolo[5,4-d]pyrimidin-2-yl)-1-(4-(2- hydroxypropan-2-yl)piperidin-1- yl)ethanone550

1-(1-((2-(2-isopropyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)azetidin-3-yl)piperidin- 4-ol 551

1-(1-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)azetidin-3-yl)-4-methylpiperidin-4-ol 552

4-(8-((3,3-dimethylpiperazin-1- yl)methyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl- 9H-purin-6-yl)morpholine 553

4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-8-(((1S,4S)-5-(methylsulfonyl)-2,5- diazabicyclo[2.2.1]heptan-2-yl)methyl)-9H-purin-6- yl)morpholine 554

1-(1-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-yl)azetidin- 3-ol 555

1-isopropyl-4-((2-(2-isopropyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)piperazin-2-one 556

4-(1-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)azetidin-3-yl)-1-methylpiperazin-2-one 557

4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-8-(2-(4-(tetrahydro-2H-pyran-4- yl)piperazin-1-yl)ethyl)-9H-purin-6-yl)morpholine 558

2-(4-((9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperidin-1-yl)acetamide 559

(R)-2-(4-((9-methyl-2-(2-methyl- 1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperidin-1- yl)propanamide 560

(S)-2-(4-((9-methyl-2-(2-methyl- 1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperidin-1- yl)propanamide 561

(R)-4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-8-((4-(3-fluoropyrrolidin-1-yl)piperidin-1- yl)methyl)-9-methyl-9H-purin-6-yl)morpholine 562

4-(8-((3,3-difluoro-1,3′-biazetidin- 1′-yl)methyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl- 9H-purin-6-yl)morpholine 563

4-(2-(2-isopropyl-1H- benzo[d]imidazol-1-yl)-9-methyl-8-(((1S,4S)-5-(methylsulfonyl)-2,5- diazabicyclo[2.2.1]heptan-2-yl)methyl)-9H-purin-6- yl)morpholine 564

4-(2-(2-isopropyl-1H- benzo[d]imidazol-1-yl)-9-methyl-8-((4-(tetrahydro-2H-pyran-4- yl)piperazin-1-yl)methyl)-9H-purin-6-yl)morpholine 565

(S)-4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-8-((4-(3-fluoropyrrolidin-1-yl)piperidin-1- yl)methyl)-9-methyl-9H-purin-6-yl)morpholine 566

2-(4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purine-8- carbonyl)piperazin-1-yl)-2- methylpropanamide567

(4-tert-butylpiperazin-1-yl)(2-(2- ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methanone 568

3-(4-((9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperidin-1- yl)propanenitrile 569

(2-(2-ethyl-1H-benzo[d]imidazol- 1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(4-(2-hydroxypropan-2- yl)piperidin-1-yl)methanone 570

4-(8-((1-(isoxazol-5- ylmethyl)piperidin-4-yl)methyl)-9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-9H-purin- 6-yl)morpholine571

4-(8-((1-(isoxazol-5- ylmethyl)azetidin-3-yl)methyl)-9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-9H-purin- 6-yl)morpholine572

(S)-4-(9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-8-((1-(tetrahydrofuran-3-yl)azetidin-3- yl)methyl)-9H-purin-6- yl)morpholine573

(R)-4-(9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-8-((1-(tetrahydrofuran-3-yl)azetidin-3- yl)methyl)-9H-purin-6- yl)morpholine574

2-(1-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-4-morpholinothieno[3,2-d]pyrimidin- 6-yl)methyl)piperidin-4-yl)propan-2-ol 575

4-(8-(2-(3,3-dimethyl-4- (methylsulfonyl)piperazin-1-yl)ethyl)-2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine 576

4-(8-((4-(3,3-difluoroazetidin-1- yl)piperidin-1-yl)methyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9- methyl-9H-purin-6-yl)morpholine 577

1-tert-butyl-4-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)piperazin-2-one 578

(S)-2-amino-1-(4-((9-methyl-2-(2- methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperidin-1-yl)propan-1- one 579

3-methyl-2-(3-((9-methyl-2-(2- methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)azetidin-1-yl)butanamide 580

N,2-dimethyl-2-(3-((9-methyl-2-(2- methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)azetidin-1- yl)propanamide 581

(S)-3-(2-(2-isopropyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-1- methylpiperidin-3-ol 582

(R)-3-(2-(2-isopropyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-1- methylpiperidin-3-ol 583

4-(2-(2-isopropyl-1H- benzo[d]imidazol-1-yl)-8-(1-isopropyl-3-methoxypiperidin-3- yl)-9-methyl-9H-purin-6- yl)morpholine584

4-(2-(2-isopropyl-1H- benzo[d]imidazol-1-yl)-8-(1-isopropyl-3-methoxypiperidin-3- yl)-9-methyl-9H-purin-6- yl)morpholine585

N,2-dimethyl-2-(4-((9-methyl-2-(2- methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperidin-1- yl)propanamide 586

(S)-4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-8-((3-(3-fluoropyrrolidin-1-yl)azetidin-1- yl)methyl)-9-methyl-9H-purin-6-yl)morpholine 587

1′-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)-3-methyl-1,3′- biazetidin-3-ol 588

1-(1-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)azetidin-3-yl)pyrrolidin- 2-one 589

4-(8-((3-(3,3-difluoropyrrolidin-1- yl)azetidin-1-yl)methyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9- methyl-9H-purin-6-yl)morpholine 590

(R)-4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-8-((3-(3-fluoropyridin-1-yl)azetidin-1- yl)methyl)-9-methyl-9H-purin-6-yl)morpholine 591

(R)-1-isopropyl-3-(2-(2-isopropyl- 1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)piperidin-3-ol 592

(S)-1-isopropyl-3-(2-(2-isopropyl- 1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)piperidin-3-ol 593

(2-(2-ethyl-1H-benzo[d]imidazol- 1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(4-(tetrahydro-2H-(1,1- dioxo)-thiopyran-4-yl)piperazin-1-yl)methanone 594

N-tert-butyl-1-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)azetidin-3-amine 595

N-(2-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)ethyl)tetrahydro(1,1- dioxo)thiophen-3-amine596

4-(8-((2,2-dimethyl-4- (methylsulfonyl)piperazin-1-yl)methyl)-2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine 597

2-((1S,4S)-5-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)-2,5- diazabicyclo[2.2.1]heptan-2-yl)acetamide 598

4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-8-(((1S,4S)-5-(oxetan-3-yl)-2,5- diazabicyclo[2.2.1]heptan-2-yl)methyl)-9H-purin-6- yl)morpholine 599

2-methyl-2-(4-(methyl(9-methyl-2- (2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)amino)piperidin-1- yl)propanamide 600

2-(2-ethyl-1H-benzo[d]imidazol-1- yl)-N,N-bis(2-methoxyethyl)-9-methyl-6-morpholino-9H-purine-8- carboxamide 601

(4-(dimethylamino)piperidin-1- yl)(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl- 6-morpholino-9H-purin-8- yl)methanone602

2-methyl-2-(3-((9-methyl-2-(2- methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)pyrrolidin-1- yl)propanamide 603

2-methyl-2-(3-((9-methyl-2-(2- methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)pyrrolidin-1- yl)propanamide 604

1-(3-hydroxy-3-(2-(2-isopropyl- 1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)piperidin-1-yl)ethanone 605

(S)-8-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)-4,4- dimethylhexahydropyrazino[2,1-c][1,4]oxazin-3(1H)-one 606

(R)-8-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)-4,4- dimethylhexahydropyrazino[2,1-c][1,4]oxazin-3(1H)-one 607

N-(2-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)ethyl)-N-methyl-1,1-dioxo-tetrahydrothiophen-3-amine 608

4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-8-((4-(3-fluoroazetidin-1-yl)piperidin-1- yl)methyl)-9-methyl-9H-purin-6-yl)morpholine 609

2-methyl-2-(4-((9-methyl-2-(2- methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methylene)piperidin-1- yl)propanamide 610

2-methyl-2-(4-((9-methyl-2-(2- methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methylene)piperidin-1- yl)propanamide 611

(2-(2-ethyl-1H-benzo[d]imidazol- 1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(hexahydropyrrolo[1,2- a]pyrazin-2(1H)-yl)methanone 612

(2-(2-ethyl-1H-benzo[d]imidazol- 1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(hexahydropyrrolo[1,2- a]pyrazin-2(1H)-yl)methanone 613

4-(9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-8-(piperidin-4-ylidenemethyl)-9H- purin-6-yl)morpholine 614

4-(8-(((3S,5R)-3,5- dimethylpiperazin-1-yl)methyl)-2-(2-ethyl-1H-benzo[d]imidazol-1- yl)-9-methyl-9H-purin-6- yl)morpholine615

4-(9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-8-(piperidin-4-ylidenemethyl)-9H- purin-6-yl)morpholine 616

2-(3-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methylene)azetidin-1-yl)-2-methylpropanamide 617

2-(3-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methylene)azetidin-1-yl)-2-methylpropanamide 618

1-(4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purine-8- carbonyl)-1,4-diazepan-1- yl)ethanone 619

(2-(2-ethyl-1H-benzo[d]imidazol- 1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(4-hydroxypiperidin-1- yl)methanone 620

(2-(2-ethyl-1H-benzo[d]imidazol- 1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(pyrrolidin-1- yl)methanone 621

azetidin-1-yl(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methanone 622

(2-(2-ethyl-1H-benzo[d]imidazol- 1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(2- (hydroxymethyl)piperidin-1- yl)methanone 623

(2-(2-ethyl-1H-benzo[d]imidazol- 1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(4- (hydroxymethyl)piperidin-1- yl)methanone 624

4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purine-8- carbonyl)piperazine-1- carbaldehyde 625

(2-(2-ethyl-1H-benzo[d]imidazol- 1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(3- (hydroxymethyl)piperidin-1- yl)methanone 626

(2-(2-ethyl-1H-benzo[d]imidazol- 1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(4-(pyridin-3- yl)piperazin-1-yl)methanone 627

N-(2-(dimethylamino)-2-oxoethyl)- 2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-N,9-dimethyl-6-morpholino- 9H-purine-8-carboxamide 628

(2-(2-ethyl-1H-benzo[d]imidazol- 1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(4-(2- methoxyethyl)piperazin-1- yl)methanone 629

(2-(2-ethyl-1H-benzo[d]imidazol- 1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(4-fluoropiperidin-1- yl)methanone 630

2-(2-ethyl-1H-benzo[d]imidazol-1- yl)-N-(2-methoxyethyl)-N,9-dimethyl-6-morpholino-9H-purine- 8-carboxamide 631

4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purine-8- carbonyl)-N,N-dimethylpiperazine-1-carboxamide 632

(S)-(3-(dimethylamino)pyrrolidin- 1-yl)(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl- 6-morpholino-9H-purin-8- yl)methanone633

(R)-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(3- hydroxypiperidin-1-yl)methanone 634

(2-(2-ethyl-1H-benzo[d]imidazol- 1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(1,4-oxazepan-4- yl)methanone 635

2-(2-ethyl-1H-benzo[d]imidazol-1- yl)-N,9-dimethyl-N-(1-methylpyrrolidin-3-yl)-6- morpholino-9H-purine-8- carboxamide 636

N-(2-cyanoethyl)-2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-N,9-dimethyl-6-morpholino-9H-purine- 8-carboxamide 637

N-(cyanomethyl)-2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-N,9-dimethyl-6-morpholino-9H-purine- 8-carboxamide 638

2-(2-ethyl-1H-benzo[d]imidazol-1- yl)-N-(2-hydroxyethyl)-N,9-dimethyl-6-morpholino-9H-purine- 8-carboxamide 639

(2-(2-ethyl-1H-benzo[d]imidazol- 1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(3- (trifluoromethyl)piperidin-1- yl)methanone 640

(4,4-difluoropiperidin-1-yl)(2-(2- ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methanone 641

(2-(2-ethyl-1H-benzo[d]imidazol- 1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(4- (methoxymethyl)piperidin-1- yl)methanone 642

(2-(2-ethyl-1H-benzo[d]imidazol- 1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(3- (trifluoromethyl)pyrrolidin-1- yl)methanone 643

2-(2-ethyl-1H-benzo[d]imidazol-1- yl)-N,9-dimethyl-6-morpholino-N-(1,1-dioxo-tetrahydrothiophen-3- yl)-9H-purine-8-carboxamide 644

(R)-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(2- (hydroxymethyl)pyrrolidin-1- yl)methanone645

1-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purine-8- carbonyl)piperidine-4-carboxamide 646

tert-butyl 3-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)pyrrolidine-1-carboxylate 647

tert-butyl 4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)piperidine-1-carboxylate 648

4-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)-3-isopropylpiperazin-2- one 649

4-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)-3,3-dimethylpiperazin- 2-one 650

(2-(2-ethyl-1H-benzo[d]imidazol- 1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(4-methylpiperazin-1- yl)methanone 651

(2-(2-ethyl-1H-benzo[d]imidazol- 1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(4-isopropylpiperazin-1- yl)methanone 652

1-(4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purine-8- carbonyl)piperazin-1-yl)ethanone 653

(4-(cyclopropylmethyl)piperazin-1- yl)(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl- 6-morpholino-9H-purin-8- yl)methanone654

1-(4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purine-8- carbonyl)piperazin-1-yl)-2- methylpropan-1-one655

(4-cyclobutylpiperazin-1-yl)(2-(2- ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methanone 656

(4- (cyclopropanecarbonyl)piperazin- 1-yl)(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl- 6-morpholino-9H-purin-8- yl)methanone657

(2-(2-ethyl-1H-benzo[d]imidazol- 1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(4- (methylsulfonyl)piperazin-1- yl)methanone 658

2-(3-hydroxy-3-(2-(2-isopropyl- 1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)piperidin-1-yl)-2- methylpropanamide659

(2-(2-ethyl-1H-benzo[d]imidazol- 1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(4-(2-hydroxy-2- methylpropyl)piperazin-1- yl)methanone 660

(2-(2-ethyl-1H-benzo[d]imidazol- 1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(4-(pyridin-2- yl)piperazin-1-yl)methanone 661

2-(3-hydroxy-3-(2-(2-isopropyl- 1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)piperidin-1-yl)-2- methylpropanamide662

(R)-2-(3-(2-(2-isopropyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-3- methoxypiperidin-1-yl)-2-methylpropanamide 663

(S)-2-(3-(2-(2-isopropyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-3- methoxypiperidin-1-yl)-2-methylpropanamide 664

(R)-1-(3-(2-(2-isopropyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-3- methoxypiperidin-1-yl)ethanone 665

(S)-1-(3-(2-(2-isopropyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-3- methoxypiperidin-1-yl)ethanone 666

(2-(2-ethyl-1H-benzo[d]imidazol- 1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(4-(oxetan-3- yl)piperazin-1-yl)methanone 667

2-(4-(2-(2-isopropyl-1H- benzo[d]imidazol-1-yl)-4-morpholinofuro[3,2-d]pyrimidine- 6-carbonyl)piperazin-1-yl)-2-methylpropanamide 668

2-(4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-4-morpholinofuro[3,2-d]pyrimidine- 6-carbonyl)piperazin-1-yl)-2-methylpropanamide 669

(2-(2-ethyl-1H-benzo[d]imidazol- 1-yl)-4-morpholinofuro[3,2-d]pyrimidin-6-yl)(4-(2- hydroxypropan-2-yl)piperidin-1- yl)methanone 670

(4-(2-hydroxypropan-2- yl)piperidin-1-yl)(2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-4- morpholinofuro[3,2-d]pyrimidin-6-yl)methanone 671

(2-(2-(1,1-difluoroethyl)-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(4-(2- hydroxypropan-2-yl)piperidin-1-yl)methanone 672

(2-(2-ethyl-1H-benzo[d]imidazol- 1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(4-(1-hydroxy-2- methylpropan-2-yl)piperazin-1- yl)methanone673

(R)-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(2- methylpiperidin-1-yl)methanone 674

(S)-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(2- methylpiperidin-1-yl)methanone 675

(2-(2-ethyl-1H-benzo[d]imidazol- 1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(3-(1,1- dioxo)thiomorpholinoazetidin-1- yl)methanone 676

4-(2-(2-isopropyl-1H- benzo[d]imidazol-1-yl)-9-methyl-8-(pyridin-3-yl)-9H-purin-6- yl)morpholine 677

2-(4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)piperidin-1-yl)acetamide 678

tert-butyl 3-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)azetidine-1-carboxylate 679

(R)-1-(3-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)azetidin-1-yl)-2- hydroxypropan-1-one680

4-(8-(azetidin-3-yl)-2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine 681

1-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8- yl)methyl)-3-isopropylpiperazin-2- one 682

(2-(2-ethyl-2H-indazol-3-yl)-9- methyl-6-morpholino-9H-purin-8-yl)(4-(2-hydroxypropan-2- yl)piperidin-1-yl)methanone 683

4-(2-(2-isopropyl-1H- benzo[d]imidazol-1-yl)-8-(3-methoxyphenyl)-9-methyl-9H- purin-6-yl)morpholine 684

4-(8-(3-ethoxy-1- isopropylpiperidin-3-yl)-2-(2-isopropyl-1H-benzo[d]imidazol-1- yl)-9-methyl-9H-purin-6- yl)morpholine685

(2-(2-ethyl-1H-benzo[d]imidazol- 1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(3-morpholinoazetidin- 1-yl)methanone 686

(2-(2-ethyl-1H-benzo[d]imidazol- 1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(4-(oxazol-2- ylmethyl)piperazin-1-yl)methanone 687

4-(1-((2-(imidazo[1,2-a]pyridin-5- yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperidin- 4-yl)morpholine 688

1-((2-(imidazo[1,2-a]pyridin-5-yl)- 4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)-N,N- dimethylpiperidin-4-amine 689

5-(6-((4-(dimethylamino)piperidin- 1-yl)methyl)-4-morpholinothieno[3,2-d]pyrimidin- 2-yl)imidazo[1,2-a]pyridin-8-ol 690

2-(4-((2-([1,2,4]triazolo[4,3- a]pyridin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin- 6-yl)methyl)piperazin-1-yl)-2-methylpropanamide 691

2-(4-((2-(imidazo[1,2-a]pyridin-5- yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin- 6-yl)methyl)piperazin-1-yl)-2-methylpropanamide 692

2-(1-((9-methyl-2-(2- methylimidazo[1,2-a]pyridin-5-yl)-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-yl)propan-2- ol 693

2-methyl-2-(4-((2-(2- methylimidazo[1,2-a]pyridin-5-yl)-4-morpholinothieno[3,2- d]pyrimidin-6-yl)methyl)piperazin-1-yl)propanamide 694

2-methyl-2-(4-((2-(7- methylimidazo[1,2-a]pyridin-5-yl)-4-morpholinothieno[3,2- d]pyrimidin-6-yl)methyl)piperazin-1-yl)propanamide 695

2-methyl-2-(4-((4-morpholino-2- 1H-pyrrolo[2,3-b]pyridin-4-yl)thieno[3,2-d]pyrimidin-6- yl)methyl)piperazin-1- yl)propanamide 696

2-methyl-2-(4-((7-methyl-4- morpholino-2-(1H-pyrrolo[2,3-b]pyridin-4-yl)thieno[3,2- d]pyrimidin-6-yl)methyl)piperazin-1-yl)propanamide 697

2-(4-((2-(imidazo[1,2-a]pyridin-5- yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin- 1-yl)-2-methylpropanamide 698

2-(1-((2-(imidazo[1,2-a]pyridin-5- yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4- yl)propan-2-ol 699

2-(1-((5-(imidazo[1,2-a]pyridin-5- yl)-7-morpholinothiazolo[5,4-d]pyrimidin-2-yl)methyl)piperidin- 4-yl)propan-2-ol 700

4-(5-(imidazo[1,2-a]pyridin-5-yl)- 2-((3-morpholinoazetidin-1-yl)methyl)thiazolo[5,4- d]pyrimidin-7-yl)morpholine 701

2-(1-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-6- morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2- ol 702

2-(1-((2-(2-methyl-1H- benzo[d]imidazol-1-yl)-6- morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2- ol

TABLE 3 No. Structure Name 703

2-(4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)piperidin-1-yl)-2- methylpropanamide704

(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)(4-(2- hydroxypropan-2-yl)piperidin-1- yl)methanone 705

(R)-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)(3-fluoropyrrolidin-1- yl)methanone706

(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9- methyl-6-morpholino-9H-purin-8-yl)(3-(tetrahydro-2H-pyran-4- yl)azetidin-1-yl)methanone 707

N-ethyl-4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H- purine-8-carbonyl)piperazine-1- carboxamide 708

(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9- methyl-6-morpholino-9H-purin-8-yl)(pyridin-3-yl)methanone 709

(S)-N-(2-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)ethyl)-N-methyl-(1,1-dioxo)-tetrahydrothiophen-3- amine 710

(R)-N-(2-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)ethyl)-N-methyl-(1,1-dioxo)-tetrahydrothiophen-3- amine 711

1-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)methyl)-4- isopropylpiperazin-2-one712

2-(5-(2-ethyl-1H- benzo[d]imidazol-1-yl)-7- morpholinothiazolo[5,4-d]pyrimidin-2-yl)-1-(4-(1- hydroxy-2-methylpropan-2-yl)piperazin-1-yl)ethanone 713

4-(2-(2-isopropyl-1H- benzo[d]imidazol-1-yl)-8-(3- methoxy-1-(2-(methylsulfonyl)ethyl)piperidin- 3-yl)-9-methyl-9H-purin-6-yl)morpholine 714

tert-butyl 3-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)-3-methoxyazetidine-1- carboxylate715

(2,2-dimethyl-4- (methylsulfonyl)piperazin-1- yl)(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9- methyl-6-morpholino-9H-purin- 8-yl)methanone716

2-(3-(2-(2-isopropyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)-3-methoxypiperidin-1- yl)acetamide717

2-(4-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)methyl)-3,3- dimethylpiperazin-1-yl)acetamide 718

(S)-1-(3-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)methyl)azetidin-1-yl)-2-hydroxypropan-1-one 719

(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-7- methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)(4-(2- hydroxypropan-2-yl)piperidin-1- yl)methanone 720

3-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)-1-(tetrahydro-2H-pyran-4-yl)azetidin-3-ol 721

1-(3-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)methyl)azetidin-1-yl)-2-hydroxy-2-methylpropan-1-one 722

(R)-1-(4-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)methyl)-3,3-dimethylpiperazin-1-yl)-2- hydroxypropan-1-one 723

(S)-1-(4-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)methyl)-3,3-dimethylpiperazin-1-yl)-2- hydroxypropan-1-one 724

1-(4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9- methyl-6-morpholino-9H-purine-8-carbonyl)piperazin-1- yl)propan-1-one 725

methyl 4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H- purine-8-carbonyl)piperazine-1- carboxylate 726

(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9- methyl-6-morpholino-9H-purin-8-yl)(4-(2,2,2- trifluoroethyl)piperazin-1- yl)methanone 727

(R)-1-(4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H- purine-8-carbonyl)piperazin-1-yl)-2-hydroxypropan-1-one 728

(S)-1-(4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H- purine-8-carbonyl)piperazin-1-yl)-2-hydroxypropan-1-one 729

(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9- methyl-6-morpholino-9H-purin-8-yl)(4-(1,1- dioxotetrahydrothiophen-3- yl)piperazin-1-yl)methanone 730

4-(9-methyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-8-((1-(1,1-dioxo-tetrahydrothiophen-3- yl)piperidin-4-yl)methyl)-9H-purin-6-yl)morpholine 731

2-(4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-7-methyl-4-morpholinothieno[3,2- d]pyrimidine-6-carbonyl)piperazin-1-yl)-2- methylpropanamide 732

(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9- methyl-6-morpholino-9H-purin-8-yl)(3-methylpyrrolidin-1- yl)methanone 733

2-(1-((2-(2-isopropyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-yl)propan- 2-ol 734

2-(1-(1-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)ethyl)piperidin-4-yl)propan- 2-ol 735

2-(1-(1-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)ethyl)piperidin-4-yl)propan- 2-ol 736

(4-(2-hydroxypropan-2- yl)piperidin-1-yl)(2-(2-isopropyl-1H-benzo[d]imidazol- 1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methanone 737

4-(8-(((2R,6S)-2,6-dimethyl-4- (methylsulfonyl)piperazin-1-yl)methyl)-2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9- methyl-9H-purin-6-yl)morpholine 738

3-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)-1-isopropylazetidin-3-ol 739

4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-8-(1-isopropyl-3-methoxyazetidin-3- yl)-9-methyl-9H-purin-6- yl)morpholine740

4-(8-((2,2-dimethyl-4-(oxetan-3- yl)piperazin-1-yl)methyl)-2-(2-ethyl-1H-benzo[d]imidazol-1- yl)-9-methyl-9H-purin-6- yl)morpholine 741

1-(4-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)methyl)-3,3-dimethylpiperazin-1-yl)-2- hydroxy-2-methylpropan-1-one 742

2-(3-(2-(2-isopropyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)-3-methoxypiperidin-1- yl)acetamide743

2-(3-(2-(2-isopropyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)-3-methoxypiperidin-1- yl)acetamide744

4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-8-((7-(oxetan-3-yl)-4,7- diazaspiro[2.5]octan-4-yl)methyl)-9H-purin-6- yl)morpholine 745

2-(3-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)-3-hydroxypiperidin-1-yl)-N,N-dimethylacetamide 746

3-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)-1-(2-hydroxy-2-methylpropyl)piperidin-3-ol 747

4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9- methyl-8-(1-(tetrahydro-2H-pyran-4-yl)azetidin-3-yl)-9H- purin-6-yl)morpholine 748

N-(2-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)ethyl)-N,3-dimethyl-1,1-dioxotetrahydrothiophen-3- amine 749

2-(4-(9-ethyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purine-8- carbonyl)piperazin-1-yl)-2- methylpropanamide750

4-(8-((2,2-dimethyl-4- (methylsulfonyl)piperazin-1-yl)methyl)-2-(2-isopropyl-1H- benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine 751

2-(1-((2-(2-(1,1-difluoroethyl)- 1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-yl)propan- 2-ol 752

2-(1-((2-(2-cyclopropyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)piperidin-4-yl)propan- 2-ol 753

4-(1-((2-(2-(1,1-difluoroethyl)- 1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)azetidin-3- yl)morpholine 754

(4-(2-hydroxypropan-2- yl)piperidin-1-yl)(2-(2-isopropyl-1H-benzo[d]imidazol- 1-yl)-6-morpholino-9H-purin-8-yl)methanone 755

4-(2-(2-(1,1-difluoroethyl)-1H- benzo[d]imidazol-1-yl)-8-((3-(tetrahydro-2H-pyran-4- yl)azetidin-1-yl)methyl)-9H-purin-6-yl)morpholine 756

4-(2-(2-isopropyl-1H- benzo[d]imidazol-1-yl)-8-((3-(tetrahydro-2H-pyran-4- yl)azetidin-1-yl)methyl)-9H-purin-6-yl)morpholine 757

(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)(4-(2- hydroxypropan-2-yl)piperidin-1-yl)methanone 758

4-(1-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-6- morpholino-9H-purin-8-yl)methyl)azetidin-3- yl)morpholine 759

(9-ethyl-2-(2-methyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)(4-(2- hydroxypropan-2-yl)piperidin-1-yl)methanone 760

(4-(2-hydroxypropan-2- yl)piperidin-1-yl)(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1- yl)-6-morpholine-9H-purin-8- yl)methanone761

2-(4-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-6- morpholino-9H-purin-8-yl)methyl)piperidin-1-yl)-2- methylpropanamide 762

4-(1-((2-(2-isopropyl-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)methyl)azetidin-3- yl)morpholine 763

2-(4-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)fluoromethylene)piperidin-1-yl)-2-methylpropanamide 764

(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9- methyl-6-morpholino-9H-purin-8-yl)(piperazin-1-yl)methanone 765

3-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)-1- (methylsulfonyl)piperidin-3-ol766

4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-8-(3- methoxy-1-(methylsulfonyl)piperidin-3-yl)- 9-methyl-9H-purin-6- yl)morpholine 767

1-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9- methyl-6-morpholino-9H-purine-8-carbonyl)piperidine-4- carbonitrile 768

(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9- methyl-6-morpholino-9H-purin-8-yl)(4-(2- hydroxyethyl)piperazin-1- yl)methanone 769

(9-(2-hydroxyethyl)-2-(2- isopropyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8- yl)(4-(2-hydroxypropan-2-yl)piperidin-1-yl)methanone 770

2-(1-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-6-(octadeuterio)morpholino-9H- purin-8-yl)methyl)piperidin-4-yl)propan-2-ol 771

(5-(2-ethyl-1H- benzo[d]imidazol-1-yl)-7- morpholinothiazolo[5,4-d]pyrimidin-2-yl)(4-(2- hydroxypropan-2-yl)piperidin-1- yl)methanone 772

3-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)-1-(tetrahydro-2H-pyran-4-yl)piperidin-3-ol 773

2-amino-1-(4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H- purine-8-carbonyl)piperazin-1- yl)ethanone 774

(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9- methyl-6-morpholino-9H-purin-8-yl)(4-(1- hydroxyethyl)piperidin-1- yl)methanone 775

(S)-2-(1-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-(3-methylmorpholino)- 9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol 776

(4-(1,3-dihydroxypropan-2- yl)piperazin-1-yl)(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9- methyl-6-morpholino-9H-purin- 8-yl)methanone777

(4- (cyclopropanecarbonyl)piperazin- 1-yl)(2-(2-(dimethylamino)-1H-benzo[d]imidazol-1-yl)-9- methyl-6-morpholino-9H-purin- 8-yl)methanone778

(R)-1-(4-(2-(2-(dimethylamino)- 1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H- purine-8-carbonyl)piperazin-1-yl)-2-hydroxypropan-1-one 779

N-(1-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9- methyl-6-morpholino-9H-purine-8-carbonyl)piperidin-4- yl)acetamide 780

(1-aminocyclopropyl)(4-((2-(2- ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H- purin-8-yl)methyl)-3,3-dimethylpiperazin-1- yl)methanone 781

(R)-2-(1-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-(3-methylmorpholino)- 9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol 782

N-(1-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9- methyl-6-morpholino-9H-purine-8-carbonyl)piperidin-4- yl)propionamide 783

N-(1-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9- methyl-6-morpholino-9H-purine-8-carbonyl)piperidin-4- yl)-2-hydroxy-2- methylpropanamide 784

4-(2-(2-isopropyl-1H- benzo[d]imidazol-1-yl)-7-methyl-6-((1-(tetrahydro-2H- pyran-4-yl)azetidin-3-yl)methyl)thieno[3,2- d]pyrimidin-4-yl)morpholine 785

4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-8-(1-isopropyl-1H-1,2,4-triazol-5-yl)- 9-methyl-9H-purin-6- yl)morpholine 786

(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9- methyl-6-morpholino-9H-purin-8-yl)(3-(oxetan-3- ylamino)azetidin-1- yl)methanone 787

N-(1-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9- methyl-6-morpholino-9H-purine-8-carbonyl)azetidin-3- yl)propionamide 788

(2-(2-(dimethylamino)-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)(4-(2- hydroxypropan-2-yl)piperidin-1-yl)methanone 789

(S)-(4-(2-hydroxypropan-2- yl)piperidin-1-yl)(2-(2-(1- methoxyethyl)-1H-benzo[d]imidazol-1-yl)-9- methyl-6-morpholino-9H-purin- 8-yl)methanone790

1-(4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)-4-hydroxypiperidin-1-yl)-2-hydroxy-2-methylpropan-1- one 791

1-(3-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)-3-methoxypiperidin-1-yl)-2-methylpropan-2-ol 792

4-(6-((2,2-dimethyl-4-(oxetan-3- yl)piperazin-1-yl)methyl)-2-(2-ethyl-1H-benzo[d]imidazol-1- yl)thieno[3,2-d]pyrimidin-4- yl)morpholine793

(2,2-dimethyl-4-(oxetan-3- yl)piperazin-1-yl)(5-(2-ethyl-1H-benzo[d]imidazol-1-yl)-7- morpholinothiazolo[5,4-d]pyrimidin-2-yl)methanone 794

(R)-(4-(2-hydroxypropan-2- yl)piperidin-1-yl)(2-(2-(1- methoxyethyl)-1H-benzo[d]imidazol-1-yl)-9- methyl-6-morpholino-9H-purin- 8-yl)methanone795

1-(4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9- methyl-6-morpholino-9H-purine-8-carbonyl)piperazin-1- yl)-2-hydroxy-2-methylpropan- 1-one 796

4-(1-((5-(2-ethyl-1H- benzo[d]imidazol-1-yl)-7- morpholinothiazolo[5,4-d]pyrimidin-2- yl)methyl)azetidin-3- yl)piperazin-2-one 797

(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9- methyl-6-morpholino-9H-purin-8-yl)(3-(4-hydroxypiperidin-1- yl)azetidin-1-yl)methanone 798

(2-(2-cyclopropyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)(4-(2-hydroxypropan-2-yl)piperidin-1-yl)methanone 799

(2-(2-cyclopropyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)(3-morpholinoazetidin-1- yl)methanone800

1-(4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)-4-methoxypiperidin-1-yl)-2-hydroxy-2-methylpropan-1- one 801

(4-(2-hydroxypropan-2- yl)piperidin-1-yl)(2-(2- (methoxymethyl)-1H-benzo[d]imidazol-1-yl)-9- methyl-6-morpholino-9H-purin- 8-yl)methanone802

(2-(2-(2-hydroxypropan-2-yl)- 1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)(4-(2-hydroxypropan-2-yl)piperidin-1-yl)methanone 803

(R)-(2-(2-(1-methoxyethyl)-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)(3-morpholinoazetidin-1- yl)methanone804

N,N-diethyl-4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H- purine-8-carbonyl)piperazine-1- carboxamide 805

(S)-(4-tert-butylpiperazin-1- yl)(2-(2-(1-methoxyethyl)-1H-benzo[d]imidazol-1-yl)-9- methyl-6-morpholino-9H-purin- 8-yl)methanone806

N-(1-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9- methyl-6-morpholino-9H-purine-8-carbonyl)piperidin-4- yl)-N-methylacetamide 807

(4- (cyclopropanecarbonyl)piperazin- 1-yl)(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-6- morpholino-9H-purin-8- yl)methanone 808

1-(4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-6- morpholino-9H-purine-8-carbonyl)piperazin-1-yl)propan- 1-one 809

4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-8-(1-(1-methylpiperidin- 4-yl)-1H-1,2,4-triazol-5-yl)-9H-purin-6-yl)morpholine 810

(2-(2-(1,1-difluoroethyl)-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)(3-morpholinoazetidin-1- yl)methanone811

1-(3-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)-3-methoxyazetidin-1-yl)-2-hydroxy-2-methylpropan-1-one 812

4-(1-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-6- morpholino-9H-purin-8-yl)methyl)azetidin-3- yl)piperazin-2-one 813

4-(2-((2,2-dimethyl-4-(oxetan-3- yl)piperazin-1-yl)methyl)-5-(2-ethyl-1H-benzo[d]imidazol-1- yl)thiazolo[5,4-d]pyrimidin-7-yl)morpholine 814

1-(3-((5-(2-ethyl-1H- benzo[d]imidazol-1-yl)-7- morpholinothiazolo[5,4-d]pyrimidin-2- yl)methyl)azetidin-1-yl)-2- hydroxy-2-methylpropan-1-one815

4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9- methyl-6-morpholino-9H-purine-8-carbonyl)-N- isopropylpiperazine-1- carboxamide 816

4-(8-(1-cyclopentyl-1H-1,2,4- triazol-5-yl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9- methyl-9H-purin-6- yl)morpholine 817

4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-8-(1-isopropyl-1H-imidazol-2-yl)-9- methyl-9H-purin-6- yl)morpholine 818

1-(4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-6- morpholino-9H-purine-8-carbonyl)piperazin-1-yl)-2- methylpropan-1-one 819

1-(4-(2-(2-ethyl-1H benzo[d]imidazol-1-yl)-6- morpholino-9H-purine-8-carbonyl)piperazin-1-yl)-2,2- dimethylpropan-1-one 820

(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-6- morpholino-9H-purin-8-yl)(3-(1,1-dioxo)- thiomorpholinoazetidin-1- yl)methanone 821

(2-(2-(hydroxymethyl)-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)(4-(2-hydroxypropan-2-yl)piperidin-1-yl)methanone 822

4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-8-(1-isobutyl-1H-1,2,4-triazol-5-yl)- 9-methyl-9H-purin-6- yl)morpholine 823

1-(4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)-4-methoxypiperidin-1-yl)-2-hydroxyethanone 824

1-(3-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)methyl)azetidin-1-yl)-2-methylpropan-1-one 825

cyclopropyl(3-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)methyl)azetidin-1- yl)methanone 826

4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-8-(3- methoxy-1-(2-(methylsulfonyl)ethyl)azetidin- 3-yl)-9-methyl-9H-purin-6- yl)morpholine827

4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-8-(3- methoxy-1-(tetrahydro-2H-pyran-4-yl)azetidin-3-yl)-9- methyl-9H-purin-6- yl)morpholine 828

tert-butyl 3-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)-3-fluoroazetidine-1- carboxylate 829

(S)-1-(4-((5-(2-ethyl-1H- benzo[d]imidazol-1-yl)-7-morpholinothiazolo[5,4- d]pyrimidin-2-yl)methyl)-3,3-dimethylpiperazin-1-yl)-2- hydroxypropan-1-one 830

(S)-(2-(2-(1-methoxyethyl)-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)(3-morpholinoazetidin-1- yl)methanone831

2-(5-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)-1H-1,2,4-triazol-1-yl)-N,N-dimethylethanamine 832

1-(8-(1-isopropyl-1H-1,2,4- triazol-5-yl)-9-methyl-6-morpholino-9H-purin-2-yl)-N,N- dimethyl-1H-benzo[d]imidazol- 2-amine 833

1-(3-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)-3-methoxyazetidin-1-yl)-2-methylpropan-2-ol 834

4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-8-(3-fluoroazetidin-3-yl)-9-methyl- 9H-purin-6-yl)morpholine 835

(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-6- morpholino-9H-purin-8-yl)(3-morpholinoazetidin-1- yl)methanone 836

4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-8-(1-isopropyl-4-methyl-1H-pyrazol- 5-yl)-9-methyl-9H-purin-6- yl)morpholine837

1-(5-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)-4-methyl-1H-pyrazol-1-yl)-2-methylpropan-2-ol 838

1-(5-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)-1H-1,2,4-triazol-1-yl)-2-methylpropan-2-ol 839

1-(3-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)-3-fluoroazetidin-1-yl)-2-methylpropan-2-ol 840

(S)-1-(3-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)-3-methoxyazetidin-1-yl)-2-hydroxypropan-1-one 841

(4-(2-hydroxypropan-2- yl)piperidin-1-yl)(9-methyl-2-(2-(methylamino)-1H- benzo[d]imidazol-1-yl)-6- morpholino-9H-purin-8-yl)methanone 842

1-(4-(2-(2-(dimethylamino)-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H- purine-8-carbonyl)piperazin-1- yl)propan-1-one843

(2-(2-(dimethylamino)-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)(3-morpholinoazetidin-1- yl)methanone844

(2-(2-(dimethylamino)-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)(4-(2-hydroxypropan-2-yl)piperidin-1-yl)methanone 845

1-(4-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)methyl)piperidin-1-yl)-2-hydroxy-2-methylpropan-1-one 846

(5-(2-ethyl-1H- benzo[d]imidazol-1-yl)-7- morpholinothiazolo[5,4-d]pyrimidin-2-yl)(3- morpholinoazetidin-1- yl)methanone 847

(S)-1-(4-(2-(2-(1-methoxyethyl)- 1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H- purine-8-carbonyl)piperazin-1- yl)propan-1-one848

1-(4-(9-methyl-2-(2- (methylamino)-1H- benzo[d]imidazol-1-yl)-6-morpholino-9H-purine-8- carbonyl)piperazin-1-yl)propan- 1-one 849

2-(3-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)-3-methoxyazetidin-1- yl)ethanol 850

2-(3-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)-3-fluoroazetidin-1-yl)-2-methylpropan-1-ol 851

1-(4-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)methyl)piperidin-1-yl)-2-methylpropan-1-one 852

cyclopropyl(4-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)methyl)piperidin-1- yl)methanone 853

4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9- methyl-8-(pyridin-2-yl)-9H-purin-6-yl)morpholine 854

2-hydroxy-1-(3-((2-(2-isopropyl- 1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)methyl)azetidin-1-yl)-2-methylpropan-1-one 855

2-hydroxy-2-methyl-1-(3-((9- methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6- morpholino-9H-purin-8-yl)methyl)azetidin-1-yl)propan- 1-one 856

2-(1-(8-(4-(2-hydroxypropan-2- yl)piperidine-1-carbonyl)-9-methyl-6-morpholino-9H-purin- 2-yl)-1H-benzo[d]imidazol-2-yl)acetonitrile 857

(4-(2-hydroxypropan-2- yl)piperidin-1-yl)(9-methyl-6- morpholino-2-(2-(trifluoromethyl)-1H- benzo[d]imidazol-1-yl)-9H- purin-8-yl)methanone858

(2-(2-(difluoromethyl)-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)(4-(2-hydroxypropan-2-yl)piperidin-1-yl)methanone 859

(S)-1-(3-((2-(2-(1- hydroxyethyl)-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)methyl)azetidin-1-yl)-2-methylpropan-1-one 860

(R)-1-(3-((2-(2-(1- hydroxyethyl)-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)methyl)azetidin-1-yl)-2-methylpropan-1-one 861

(R)-2-hydroxy-1-(3-((2-(2-(1- hydroxyethyl)-1H-benzo[d]imidazol-1-yl)-9- methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-1-yl)-2- methylpropan-1-one 862

(S)-1-(4-((2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)methyl)piperidin-1-yl)-2-hydroxypropan-1-one 863

1-(4-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9- methyl-6-morpholino-9H-purine-8-carbonyl)piperidin-1- yl)-2-methylpropan-1-one 864

(1- (cyclopropanecarbonyl)piperidin- 4-yl)(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9- methyl-6-morpholino-9H-purin- 8-yl)methanone865

cyclopropyl(4-(1-(2-(2-ethyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)-1-hydroxyethyl)piperidin-1-yl)methanone 866

(9-methyl-2-(2-(methylamino)- 1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)(3- morpholinoazetidin-1- yl)methanone 867

(R)-(2-(2-(1-hydroxyethyl)-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)(3-morpholinoazetidin-1- yl)methanone868

(S)-(2-(2-(1-hydroxyethyl)-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)(3-morpholinoazetidin-1- yl)methanone869

(2-(2-isopropyl-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)(3-morpholinoazetidin-1- yl)methanone870

(2-(2-(2-hydroxyethyl)-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)(3-morpholinoazetidin-1- yl)methanone871

(4-(2-hydroxypropan-2- yl)piperidin-1-yl)(9-methyl-2-(2-methyl-3H-imidazo[4,5- c]pyridin-3-yl)-6-morpholino-9H-purin-8-yl)methanone 872

(9-methyl-2-(2-methyl-3H- imidazo[4,5-c]pyridin-3-yl)-6-morpholino-9H-purin-8-yl)(3- morpholinoazetidin-1- yl)methanone 873

(4-(2-hydroxypropan-2- yl)piperidin-1-yl)(9-methyl-2-(2-methyl-1H-imidazo[4,5- c]pyridin-1-yl)-6-morpholino-9H-purin-8-yl)methanone 874

(9-methyl-2-(2-methyl-1H- imidazo[4,5-c]pyridin-1-yl)-6-morpholino-9H-purin-8-yl)(3- morpholinoazetidin-1- yl)methanone 875

(4-(2-hydroxypropan-2- yl)piperidin-1-yl)(2-(imidazo[1,2-a]pyridin-5-yl)-9- methyl-6-morpholino-9H-purin-8-yl)methanone 876

1-(4-((5-(2-ethyl-1H- benzo[d]imidazol-1-yl)-7- morpholinothiazolo[5,4-d]pyrimidin-2- yl)methyl)piperidin-1-yl)-2- hydroxy-2-methylpropan-1-one877

(2-(2-methoxy-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)(3-morpholinoazetidin-1- yl)methanone878

(2-(2-(difluoromethyl)-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)(3-morpholinoazetidin-1- yl)methanone879

(2-(2-(2-hydroxyethyl)-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin- 8-yl)(4-(2-hydroxypropan-2-yl)piperidin-1-yl)methanone 880

1-(4-(2-(2-(2-hydroxyethyl)-1H- benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H- purine-8-carbonyl)piperazin-1- yl)propan-1-one881

1-(4-(9-methyl-2-(2-methyl-3H- imidazo[4,5-c]pyridin-3-yl)-6-morpholino-9H-purine-8- carbonyl)piperazin-1-yl)propan- 1-one 882

1-(4-(9-methyl-2-(2-methyl-1H- imidazo[4,5-c]pyridin-1-yl)-6-morpholino-9H-purine-8- carbonyl)piperazin-1-yl)propan- 1-one 883

1-(8-(4-(2-hydroxypropan-2- yl)piperidine-1-carbonyl)-9-methyl-6-morpholino-9H-purin- 2-yl)-1H-benzo[d]imidazol- 2(3H)-one 884

(4-(2-hydroxypropan-2- yl)piperidin-1-yl)(2-(2-methoxy-1H-benzo[d]imidazol-1-yl)-9- methyl-6-morpholino-9H-purin-8-yl)methanone 885

1-(4-(2-(2-methoxy-1H- benzo[d]imidazol-1-yl)-9- methyl-6-morpholino-9H-purine-8-carbonyl)piperazin-1- yl)propan-1-one

Administration of Formula I Compounds

The Formula I compounds of the invention may be administered by a routeappropriate to the condition to be treated. Suitable routes includeoral, parenteral (including subcutaneous, intramuscular, intravenous,intraarterial, intradermal, intrathecal and epidural), transdermal,rectal, nasal, topical (including buccal and sublingual), vaginal,intraperitoneal, intrapulmonary and intranasal. For localimmunosuppressive treatment, the compounds may be administered byintralesional administration, including perfusing or otherwisecontacting the graft with the inhibitor before transplantation. It willbe appreciated that the preferred route may vary with for example thecondition of the recipient. Where the compound is administered orally,it may be formulated as a pill, capsule, tablet, etc. with apharmaceutically acceptable carrier or excipient. Where the compound isadministered parenterally, it may be formulated with a pharmaceuticallyacceptable parenteral vehicle and in a unit dosage injectable form, asdetailed below.

A dose to treat human patients may range from about 10 mg to about 1000mg of Formula I compound. A typical dose may be about 100 mg to about300 mg of the compound. A dose may be administered once a day (QID),twice per day (BID), or more frequently, depending on thepharmacokinetic and pharmacodynamic properties, including absorption,distribution, metabolism, and excretion of the particular compound. Inaddition, toxicity factors may influence the dosage and administrationregimen. When administered orally, the pill, capsule, or tablet may beingested daily or less frequently for a specified period of time. Theregimen may be repeated for a number of cycles of therapy.

Methods of Treatment with Formula I Compounds

Formula I compounds of the present invention are useful for treating ahuman or animal patient suffering from a disease or disorder arisingfrom abnormal cell growth, function or behavior associated with PI3kinase, in particular with the p110δ (delta) isoform of PI3 kinase suchas an immune disorder, cardiovascular disease, viral infection,inflammation, a metabolism/endocrine disorder or a neurologicaldisorder, may thus be treated by a method comprising the administrationthereto of a compound of the present invention as defined above. A humanor animal patient suffering from cancer may also be treated by a methodcomprising the administration thereto of a compound of the presentinvention as defined above. The condition of the patient may thereby beimproved or ameliorated.

Formula I compounds may be useful for in vitro, in situ, and in vivodiagnosis or treatment of mammalian cells, organisms, or associatedpathological conditions, such as systemic and local inflammation,immune-inflammatory diseases such as rheumatoid arthritis, immunesuppression, organ transplant rejection, allergies, ulcerative colitis,Crohn's disease, dermatitis, asthma, systemic lupus erythematosus,Sjögren's Syndrome, multiple sclerosis, scleroderma/systemic sclerosis,idiopathic thrombocytopenic purpura (ITP), anti-neutrophil cytoplasmicantibodies (ANCA) vasculitis, chronic obstructive pulmonary disease(COPD), psoriasis, and for general joint protective effects.

Methods of the invention also include treating such diseases asarthritic diseases, such as rheumatoid arthritis, monoarticulararthritis, osteoarthritis, gouty arthritis, spondylitis; Behcet disease;sepsis, septic shock, endotoxic shock, gram negative sepsis, grampositive sepsis, and toxic shock syndrome; multiple organ injurysyndrome secondary to septicemia, trauma, or hemorrhage; ophthalmicdisorders such as allergic conjunctivitis, vernal conjunctivitis,uveitis, and thyroid-associated ophthalmopathy; eosinophilic granuloma;pulmonary or respiratory disorders such as asthma, chronic bronchitis,allergic rhinitis, ARDS, chronic pulmonary inflammatory disease (e.g.,chronic obstructive pulmonary disease), silicosis, pulmonarysarcoidosis, pleurisy, alveolitis, vasculitis, emphysema, pneumonia,bronchiectasis, and pulmonary oxygen toxicity; reperfusion injury of themyocardium, brain, or extremities; fibrosis such as cystic fibrosis;keloid formation or scar tissue formation; atherosclerosis; autoimmunediseases, such as systemic lupus erythematosus (SLE), autoimmunethyroiditis, multiple sclerosis, some forms of diabetes, and Reynaud'ssyndrome; and transplant rejection disorders such as GVHD and allograftrejection; chronic glomerulonephritis; inflammatory bowel diseases suchas chronic inflammatory bowel disease (CIBD), Crohn's disease,ulcerative colitis, and necrotizing enterocolitis; inflammatorydermatoses such as contact dermatitis, atopic dermatitis, psoriasis, orurticaria; fever and myalgias due to infection; central or peripheralnervous system inflammatory disorders such as meningitis, encephalitis,and brain or spinal cord injury due to minor trauma; Sjogren's syndrome;diseases involving leukocyte diapedesis; alcoholic hepatitis; bacterialpneumonia; antigen-antibody complex mediated diseases; hypovolemicshock; Type I diabetes mellitus; acute and delayed hypersensitivity;disease states due to leukocyte dyscrasia and metastasis; thermalinjury; granulocyte transfusion-associated syndromes; andcytokine-induced toxicity.

The methods of the invention can have utility in treating subjects whoare or can be subject to reperfusion injury, i.e., injury resulting fromsituations in which a tissue or organ experiences a period of ischemiafollowed by reperfusion. The term “ischemia” refers to localized tissueanemia due to obstruction of the inflow of arterial blood. Transientischemia followed by reperfusion characteristically results inneutrophil activation and transmigration through the endothelium of theblood vessels in the affected area. Accumulation of activatedneutrophils in turn results in generation of reactive oxygenmetabolites, which damage components of the involved tissue or organ.This phenomenon of “reperfusion injury” is commonly associated withconditions such as vascular stroke (including global and focalischemia), hemorrhagic shock, myocardial ischemia or infarction, organtransplantation, and cerebral vasospasm. To illustrate, reperfusioninjury occurs at the termination of cardiac bypass procedures or duringcardiac arrest when the heart, once prevented from receiving blood,begins to reperfuse. It is expected that inhibition of PI3K deltaactivity may result in reduced amounts of reperfusion injury in suchsituations.

Pharmaceutical Formulations

In order to use a Formula I compound for the therapeutic treatment(including prophylactic treatment) of mammals including humans, it isnormally formulated in accordance with standard pharmaceutical practiceas a pharmaceutical composition. According to this aspect of theinvention there is provided a pharmaceutical composition comprising acompound of this invention in association with a pharmaceuticallyacceptable diluent or carrier.

A typical formulation is prepared by mixing a compound of the presentinvention and a carrier, diluent or excipient. Suitable carriers,diluents and excipients are well known to those skilled in the art andinclude materials such as carbohydrates, waxes, water soluble and/orswellable polymers, hydrophilic or hydrophobic materials, gelatin, oils,solvents, water and the like. The particular carrier, diluent orexcipient used will depend upon the means and purpose for which thecompound of the present invention is being applied. Solvents aregenerally selected based on solvents recognized by persons skilled inthe art as safe (GRAS) to be administered to a mammal. In general, safesolvents are non-toxic aqueous solvents such as water and othernon-toxic solvents that are soluble or miscible in water. Suitableaqueous solvents include water, ethanol, propylene glycol, polyethyleneglycols (e.g., PEG 400, PEG 300), etc. and mixtures thereof. Theformulations may also include one or more buffers, stabilizing agents,surfactants, wetting agents, lubricating agents, emulsifiers, suspendingagents, preservatives, antioxidants, opaquing agents, glidants,processing aids, colorants, sweeteners, perfuming agents, flavoringagents and other known additives to provide an elegant presentation ofthe drug (i.e., a compound of the present invention or pharmaceuticalcomposition thereof) or aid in the manufacturing of the pharmaceuticalproduct (i.e., medicament).

The formulations may be prepared using conventional dissolution andmixing procedures. For example, the bulk drug substance (i.e., compoundof the present invention or stabilized form of the compound (e.g.,complex with a cyclodextrin derivative or other known complexationagent) is dissolved in a suitable solvent in the presence of one or moreof the excipients described above. The compound of the present inventionis typically formulated into pharmaceutical dosage forms to provide aneasily controllable dosage of the drug and to enable patient compliancewith the prescribed regimen.

The pharmaceutical composition (or formulation) for application may bepackaged in a variety of ways depending upon the method used foradministering the drug. Generally, an article for distribution includesa container having deposited therein the pharmaceutical formulation inan appropriate form. Suitable containers are well known to those skilledin the art and include materials such as bottles (plastic and glass),sachets, ampoules, plastic bags, metal cylinders, and the like. Thecontainer may also include a tamper-proof assemblage to preventindiscreet access to the contents of the package. In addition, thecontainer has deposited thereon a label that describes the contents ofthe container. The label may also include appropriate warnings.

Pharmaceutical formulations of the compounds of the present inventionmay be prepared for various routes and types of administration. Forexample, a compound of Formula I having the desired degree of purity mayoptionally be mixed with pharmaceutically acceptable diluents, carriers,excipients or stabilizers (Remington's Pharmaceutical Sciences (1980)16^(th) edition, Osol, A. Ed.), in the form of a lyophilizedformulation, milled powder, or an aqueous solution. Formulation may beconducted by mixing at ambient temperature at the appropriate pH, and atthe desired degree of purity, with physiologically acceptable carriers,i.e., carriers that are non-toxic to recipients at the dosages andconcentrations employed. The pH of the formulation depends mainly on theparticular use and the concentration of compound, but may range fromabout 3 to about 8. Formulation in an acetate buffer at pH 5 is asuitable embodiment.

The compound ordinarily can be stored as a solid composition, alyophilized formulation or as an aqueous solution.

The pharmaceutical compositions of the invention will be formulated,dosed and administered in a fashion, i.e., amounts, concentrations,schedules, course, vehicles and route of administration, consistent withgood medical practice. Factors for consideration in this context includethe particular disorder being treated, the particular mammal beingtreated, the clinical condition of the individual patient, the cause ofthe disorder, the site of delivery of the agent, the method ofadministration, the scheduling of administration, and other factorsknown to medical practitioners. The “therapeutically effective amount”of the compound to be administered will be governed by suchconsiderations, and is the minimum amount necessary to prevent,ameliorate, or treat the hyperproliferative disorder.

As a general proposition, the initial pharmaceutically effective amountof the inhibitor administered parenterally per dose will be in the rangeof about 0.01-100 mg/kg, namely about 0.1 to 20 mg/kg of patient bodyweight per day, with the typical initial range of compound used being0.3 to 15 mg/kg/day.

Acceptable diluents, carriers, excipients and stabilizers are nontoxicto recipients at the dosages and concentrations employed, and includebuffers such as phosphate, citrate and other organic acids; antioxidantsincluding ascorbic acid and methionine; preservatives (such asoctadecyldimethylbenzyl ammonium chloride; hexamethonium chloride;benzalkonium chloride, benzethonium chloride; phenol, butyl or benzylalcohol; alkyl parabens such as methyl or propyl paraben; catechol;resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecularweight (less than about 10 residues) polypeptides; proteins, such asserum albumin, gelatin, or immunoglobulins; hydrophilic polymers such aspolyvinylpyrrolidone; amino acids such as glycine, glutamine,asparagine, histidine, arginine, or lysine; monosaccharides,disaccharides and other carbohydrates including glucose, mannose, ordextrins; chelating agents such as EDTA; sugars such as sucrose,mannitol, trehalose or sorbitol; salt-forming counter-ions such assodium; metal complexes (e.g., Zn-protein complexes); and/or non-ionicsurfactants such as TWEEN™, PLURONICS™ or polyethylene glycol (PEG). Theactive pharmaceutical ingredients may also be entrapped in microcapsulesprepared, for example, by coacervation techniques or by interfacialpolymerization, for example, hydroxymethylcellulose orgelatin-microcapsules and poly-(methylmethacylate) microcapsules,respectively, in colloidal drug delivery systems (for example,liposomes, albumin microspheres, microemulsions, nano-particles andnanocapsules) or in macroemulsions. Such techniques are disclosed inRemington's Pharmaceutical Sciences 16^(th) edition, Osol, A. Ed.(1980).

Sustained-release preparations of compounds of Formula I may beprepared. Suitable examples of sustained-release preparations includesemipermeable matrices of solid hydrophobic polymers containing acompound of Formula I, which matrices are in the form of shapedarticles, e.g., films, or microcapsules. Examples of sustained-releasematrices include polyesters, hydrogels (for example,poly(2-hydroxyethyl-methacrylate), or poly(vinyl alcohol)), polylactides(U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid andgamma-ethyl-L-glutamate, non-degradable ethylene-vinyl acetate,degradable lactic acid-glycolic acid copolymers such as the LUPRONDEPOT™ (injectable microspheres composed of lactic acid-glycolic acidcopolymer and leuprolide acetate) and poly-D-(−)-3-hydroxybutyric acid.

The formulations include those suitable for the administration routesdetailed herein. The formulations may conveniently be presented in unitdosage form and may be prepared by any of the methods well known in theart of pharmacy. Techniques and formulations generally are found inRemington's Pharmaceutical Sciences (Mack Publishing Co., Easton, Pa.).Such methods include the step of bringing into association the activeingredient with the carrier which constitutes one or more accessoryingredients. In general the formulations are prepared by uniformly andintimately bringing into association the active ingredient with liquidcarriers or finely divided solid carriers or both, and then, ifnecessary, shaping the product.

Formulations of a compound of Formula I suitable for oral administrationmay be prepared as discrete units such as pills, capsules, cachets ortablets each containing a predetermined amount of a compound of FormulaI. Compressed tablets may be prepared by compressing in a suitablemachine the active ingredient in a free-flowing form such as a powder orgranules, optionally mixed with a binder, lubricant, inert diluent,preservative, surface active or dispersing agent. Molded tablets may bemade by molding in a suitable machine a mixture of the powdered activeingredient moistened with an inert liquid diluent. The tablets mayoptionally be coated or scored and optionally are formulated so as toprovide slow or controlled release of the active ingredient therefrom.Tablets, troches, lozenges, aqueous or oil suspensions, dispersiblepowders or granules, emulsions, hard or soft capsules, e.g., gelatincapsules, syrups or elixirs may be prepared for oral use. Formulationsof compounds of Formula I intended for oral use may be preparedaccording to any method known to the art for the manufacture ofpharmaceutical compositions and such compositions may contain one ormore agents including sweetening agents, flavoring agents, coloringagents and preserving agents, in order to provide a palatablepreparation. Tablets containing the active ingredient in admixture withnon-toxic pharmaceutically acceptable excipient which are suitable formanufacture of tablets are acceptable. These excipients may be, forexample, inert diluents, such as calcium or sodium carbonate, lactose,calcium or sodium phosphate; granulating and disintegrating agents, suchas maize starch, or alginic acid; binding agents, such as starch,gelatin or acacia; and lubricating agents, such as magnesium stearate,stearic acid or talc. Tablets may be uncoated or may be coated by knowntechniques including microencapsulation to delay disintegration andadsorption in the gastrointestinal tract and thereby provide a sustainedaction over a longer period. For example, a time delay material such asglyceryl monostearate or glyceryl distearate alone or with a wax may beemployed.

For treatment of the eye or other external tissues, e.g., mouth andskin, the formulations may be applied as a topical ointment or creamcontaining the active ingredient(s) in an amount of, for example, 0.075to 20% w/w. When formulated in an ointment, the active ingredients maybe employed with either a paraffinic or a water-miscible ointment base.Alternatively, the active ingredients may be formulated in a cream withan oil-in-water cream base. If desired, the aqueous phase of the creambase may include a polyhydric alcohol, i.e., an alcohol having two ormore hydroxyl groups such as propylene glycol, butane 1,3-diol,mannitol, sorbitol, glycerol and polyethylene glycol (including PEG 400)and mixtures thereof. The topical formulations may desirably include acompound which enhances absorption or penetration of the activeingredient through the skin or other affected areas. Examples of suchdermal penetration enhancers include dimethyl sulfoxide and relatedanalogs. The oily phase of the emulsions of this invention may beconstituted from known ingredients in a known manner, including amixture of at least one emulsifier with a fat or an oil, or with both afat and an oil. A hydrophilic emulsifier included together with alipophilic emulsifier acts as a stabilizer. Together, the emulsifier(s)with or without stabilizer(s) make up the so-called emulsifying wax, andthe wax together with the oil and fat make up the so-called emulsifyingointment base which forms the oily dispersed phase of the creamformulations. Emulsifiers and emulsion stabilizers suitable for use inthe formulation of the invention include Tween® 60, Span® 80,cetostearyl alcohol, benzyl alcohol, myristyl alcohol, glycerylmono-stearate and sodium lauryl sulfate.

Aqueous suspensions of Formula I compounds contain the active materialsin admixture with excipients suitable for the manufacture of aqueoussuspensions. Such excipients include a suspending agent, such as sodiumcarboxymethylcellulose, croscarmellose, povidone, methylcellulose,hydroxypropyl methylcellulose, sodium alginate, polyvinylpyrrolidone,gum tragacanth and gum acacia, and dispersing or wetting agents such asa naturally occurring phosphatide (e.g., lecithin), a condensationproduct of an alkylene oxide with a fatty acid (e.g., polyoxyethylenestearate), a condensation product of ethylene oxide with a long chainaliphatic alcohol (e.g., heptadecaethyleneoxycetanol), a condensationproduct of ethylene oxide with a partial ester derived from a fatty acidand a hexitol anhydride (e.g., polyoxyethylene sorbitan monooleate). Theaqueous suspension may also contain one or more preservatives such asethyl or n-propyl p-hydroxybenzoate, one or more coloring agents, one ormore flavoring agents and one or more sweetening agents, such as sucroseor saccharin.

The pharmaceutical compositions of compounds of Formula I may be in theform of a sterile injectable preparation, such as a sterile injectableaqueous or oleaginous suspension. This suspension may be formulatedaccording to the known art using those suitable dispersing or wettingagents and suspending agents which have been mentioned above. Thesterile injectable preparation may also be a sterile injectable solutionor suspension in a non-toxic parenterally acceptable diluent or solvent,such as a solution in 1,3-butanediol or prepared as a lyophilizedpowder. Among the acceptable vehicles and solvents that may be employedare water, Ringer's solution and isotonic sodium chloride solution. Inaddition, sterile fixed oils may conventionally be employed as a solventor suspending medium. For this purpose any bland fixed oil may beemployed including synthetic mono- or diglycerides. In addition, fattyacids such as oleic acid may likewise be used in the preparation ofinjectables.

The amount of active ingredient that may be combined with the carriermaterial to produce a single dosage form will vary depending upon thehost treated and the particular mode of administration. For example, atime-release formulation intended for oral administration to humans maycontain approximately 1 to 1000 mg of active material compounded with anappropriate and convenient amount of carrier material which may varyfrom about 5 to about 95% of the total compositions (weight:weight). Thepharmaceutical composition can be prepared to provide easily measurableamounts for administration. For example, an aqueous solution intendedfor intravenous infusion may contain from about 3 to 500 μg of theactive ingredient per milliliter of solution in order that infusion of asuitable volume at a rate of about 30 mL/hr can occur.

Formulations suitable for parenteral administration include aqueous andnon-aqueous sterile injection solutions which may contain anti-oxidants,buffers, bacteriostats and solutes which render the formulation isotonicwith the blood of the intended recipient; and aqueous and non-aqueoussterile suspensions which may include suspending agents and thickeningagents.

Formulations suitable for topical administration to the eye also includeeye drops wherein the active ingredient is dissolved or suspended in asuitable carrier, especially an aqueous solvent for the activeingredient. The active ingredient is preferably present in suchformulations in a concentration of about 0.5 to 20% w/w, for exampleabout 0.5 to 10% w/w, for example about 1.5% w/w.

Formulations suitable for topical administration in the mouth includelozenges comprising the active ingredient in a flavored basis, usuallysucrose and acacia or tragacanth; pastilles comprising the activeingredient in an inert basis such as gelatin and glycerin, or sucroseand acacia; and mouthwashes comprising the active ingredient in asuitable liquid carrier.

Formulations for rectal administration may be presented as a suppositorywith a suitable base comprising for example cocoa butter or asalicylate.

Formulations suitable for intrapulmonary or nasal administration have aparticle size for example in the range of 0.1 to 500 microns (includingparticle sizes in a range between 0.1 and 500 microns in incrementsmicrons such as 0.5, 1, 30 microns, 35 microns, etc.), which isadministered by rapid inhalation through the nasal passage or byinhalation through the mouth so as to reach the alveolar sacs. Suitableformulations include aqueous or oily solutions of the active ingredient.Formulations suitable for aerosol or dry powder administration may beprepared according to conventional methods and may be delivered withother therapeutic agents such as compounds heretofore used in thetreatment or prophylaxis disorders as described below.

Formulations suitable for vaginal administration may be presented aspessaries, tampons, creams, gels, pastes, foams or spray formulationscontaining in addition to the active ingredient such carriers as areknown in the art to be appropriate.

The formulations may be packaged in unit-dose or multi-dose containers,for example sealed ampoules and vials, and may be stored in afreeze-dried (lyophilized) condition requiring only the addition of thesterile liquid carrier, for example water, for injection immediatelyprior to use. Extemporaneous injection solutions and suspensions areprepared from sterile powders, granules and tablets of the kindpreviously described. Preferred unit dosage formulations are thosecontaining a daily dose or unit daily sub-dose, as herein above recited,or an appropriate fraction thereof, of the active ingredient.

The invention further provides veterinary compositions comprising atleast one active ingredient as above defined together with a veterinarycarrier therefore. Veterinary carriers are materials useful for thepurpose of administering the composition and may be solid, liquid orgaseous materials which are otherwise inert or acceptable in theveterinary art and are compatible with the active ingredient. Theseveterinary compositions may be administered parenterally, orally or byany other desired route.

Combination Therapy

The compounds of Formula I may be employed alone or in combination withother therapeutic agents for the treatment of a disease or disorderdescribed herein, such as inflammation or a hyperproliferative disorder(e.g., cancer). In certain embodiments, a compound of Formula I iscombined in a pharmaceutical combination formulation, or dosing regimenas combination therapy, with a second therapeutic compound that hasanti-inflammatory or anti-hyperproliferative properties or that isuseful for treating an inflammation, immune-response disorder, orhyperproliferative disorder (e.g., cancer). The second therapeutic agentmay be an NSAID anti-inflammatory agent. The second therapeutic agentmay be a chemotherapeutic agent. The second compound of thepharmaceutical combination formulation or dosing regimen preferably hascomplementary activities to the compound of Formula I such that they donot adversely affect each other. Such compounds are suitably present incombination in amounts that are effective for the purpose intended. Inone embodiment, a composition of this invention comprises a compound ofFormula I, or a stereoisomer, tautomer, or pharmaceutically acceptablesalt or prodrug thereof, in combination with a therapeutic agent such asan NSAID.

The combination therapy may be administered as a simultaneous orsequential regimen. When administered sequentially, the combination maybe administered in two or more administrations. The combinedadministration includes coadministration, using separate formulations ora single pharmaceutical formulation, and consecutive administration ineither order, wherein preferably there is a time period while both (orall) active agents simultaneously exert their biological activities.

Suitable dosages for any of the above coadministered agents are thosepresently used and may be lowered due to the combined action (synergy)of the newly identified agent and other therapeutic agents ortreatments.

The combination therapy may provide “synergy” and prove “synergistic”,i.e., the effect achieved when the active ingredients used together isgreater than the sum of the effects that results from using thecompounds separately. A synergistic effect may be attained when theactive ingredients are: (1) co-formulated and administered or deliveredsimultaneously in a combined, unit dosage formulation; (2) delivered byalternation or in parallel as separate formulations; or (3) by someother regimen. When delivered in alternation therapy, a synergisticeffect may be attained when the compounds are administered or deliveredsequentially, e.g., by different injections in separate syringes,separate pills or capsules, or separate infusions. In general, duringalternation therapy, an effective dosage of each active ingredient isadministered sequentially, i.e., serially, whereas in combinationtherapy, effective dosages of two or more active ingredients areadministered together.

In a particular embodiment of therapy, a compound of Formula I, or astereoisomer, tautomer, or pharmaceutically acceptable salt or prodrugthereof, may be combined with other therapeutic, hormonal or antibodyagents such as those described herein, as well as combined with surgicaltherapy and radiotherapy. Combination therapies according to the presentinvention thus comprise the administration of at least one compound ofFormula I, or a stereoisomer, tautomer, or pharmaceutically acceptablesalt or prodrug thereof, and the use of at least one other cancertreatment method. The amounts of the compound(s) of Formula I and theother pharmaceutically active chemotherapeutic agent(s) and the relativetimings of administration will be selected in order to achieve thedesired combined therapeutic effect.

Metabolites of Compounds of Formula I

Also falling within the scope of this invention are the in vivometabolic products of Formula I described herein. Such products mayresult for example from the oxidation, reduction, hydrolysis, amidation,deamidation, esterification, deesterification, enzymatic cleavage, andthe like, of the administered compound. Accordingly, the inventionincludes metabolites of compounds of Formula I, including compoundsproduced by a process comprising contacting a compound of this inventionwith a mammal for a period of time sufficient to yield a metabolicproduct thereof.

Metabolite products typically are identified by preparing aradiolabelled (e.g., ¹⁴C or ³H) isotope of a compound of the invention,administering it parenterally in a detectable dose (e.g., greater thanabout 0.5 mg/kg) to an animal such as rat, mouse, guinea pig, monkey, orto man, allowing sufficient time for metabolism to occur (typicallyabout 30 seconds to 30 hours) and isolating its conversion products fromthe urine, blood or other biological samples. These products are easilyisolated since they are labeled (others are isolated by the use ofantibodies capable of binding epitopes surviving in the metabolite). Themetabolite structures are determined in conventional fashion, e.g., byMS, LC/MS or NMR analysis. In general, analysis of metabolites is donein the same way as conventional drug metabolism studies well known tothose skilled in the art. The metabolite products, so long as they arenot otherwise found in vivo, are useful in diagnostic assays fortherapeutic dosing of the compounds of the invention.

Articles of Manufacture

In another embodiment of the invention, an article of manufacture, or“kit”, containing materials useful for the treatment of the diseases anddisorders described above is provided. In one embodiment, the kitcomprises a container comprising a compound of Formula I. The kit mayfurther comprise a label or package insert, on or associated with thecontainer. The term “package insert” is used to refer to instructionscustomarily included in commercial packages of therapeutic products,that contain information about the indications, usage, dosage,administration, contraindications and/or warnings concerning the use ofsuch therapeutic products. Suitable containers include, for example,bottles, vials, syringes, blister pack, etc. The container may be formedfrom a variety of materials such as glass or plastic. The container mayhold a compound of Formula I or a formulation thereof which is effectivefor treating the condition and may have a sterile access port (forexample, the container may be an intravenous solution bag or a vialhaving a stopper pierceable by a hypodermic injection needle). At leastone active agent in the composition is a compound of Formula I. Thelabel or package insert indicates that the composition is used fortreating the condition of choice, such as cancer. In addition, the labelor package insert may indicate that the patient to be treated is onehaving a disorder such as a hyperproliferative disorder,neurodegeneration, cardiac hypertrophy, pain, migraine or aneurotraumatic disease or event. In one embodiment, the label or packageinserts indicates that the composition comprising a compound of FormulaI can be used to treat a disorder resulting from abnormal cell growth.The label or package insert may also indicate that the composition canbe used to treat other disorders. Alternatively, or additionally, thearticle of manufacture may further comprise a second containercomprising a pharmaceutically acceptable buffer, such as bacteriostaticwater for injection (BWFI), phosphate-buffered saline, Ringer's solutionand dextrose solution. It may further include other materials desirablefrom a commercial and user standpoint, including other buffers,diluents, filters, needles, and syringes.

The kit may further comprise directions for the administration of thecompound of Formula I and, if present, the second pharmaceuticalformulation. For example, if the kit comprises a first compositioncomprising a compound of Formula I and a second pharmaceuticalformulation, the kit may further comprise directions for thesimultaneous, sequential or separate administration of the first andsecond pharmaceutical compositions to a patient in need thereof.

In another embodiment, the kits are suitable for the delivery of solidoral forms of a compound of Formula I, such as tablets or capsules. Sucha kit preferably includes a number of unit dosages. Such kits caninclude a card having the dosages oriented in the order of theirintended use. An example of such a kit is a “blister pack”. Blisterpacks are well known in the packaging industry and are widely used forpackaging pharmaceutical unit dosage forms. If desired, a memory aid canbe provided, for example in the form of numbers, letters, or othermarkings or with a calendar insert, designating the days in thetreatment schedule in which the dosages can be administered.

According to one embodiment, a kit may comprise (a) a first containerwith a compound of Formula I contained therein; and optionally (b) asecond container with a second pharmaceutical formulation containedtherein, wherein the second pharmaceutical formulation comprises asecond compound with anti-hyperproliferative activity. Alternatively, oradditionally, the kit may further comprise a third container comprisinga pharmaceutically-acceptable buffer, such as bacteriostatic water forinjection (BWFI), phosphate-buffered saline, Ringer's solution anddextrose solution. It may further include other materials desirable froma commercial and user standpoint, including other buffers, diluents,filters, needles, and syringes.

In certain other embodiments wherein the kit comprises a composition ofFormula I and a second therapeutic agent, the kit may comprise acontainer for containing the separate compositions such as a dividedbottle or a divided foil packet, however, the separate compositions mayalso be contained within a single, undivided container. Typically, thekit comprises directions for the administration of the separatecomponents. The kit form is particularly advantageous when the separatecomponents are preferably administered in different dosage forms (e.g.,oral and parenteral), are administered at different dosage intervals, orwhen titration of the individual components of the combination isdesired by the prescribing physician.

Preparation of Formula I Compounds

Compounds of Formula I may be synthesized by synthetic routes thatinclude processes analogous to those well-known in the chemical arts,particularly in light of the description contained herein, and those forother heterocycles described in: Comprehensive Heterocyclic ChemistryII, Editors Katritzky and Rees, Elsevier, 1997, e.g. Volume 3; LiebigsAnnalen der Chemie, (9):1910-16, (1985); Helvetica Chimica Acta,41:1052-60, (1958); Arzneimittel-Forschung, 40(12):1328-31, (1990), eachof which are expressly incorporated by reference. Starting materials aregenerally available from commercial sources such as Aldrich Chemicals(Milwaukee, Wis.) or are readily prepared using methods well known tothose skilled in the art (e.g., prepared by methods generally describedin Louis F. Fieser and Mary Fieser, Reagents for Organic Synthesis, v.1-23, Wiley, N.Y. (1967-2006 ed.), or Beilsteins Handbuch derorganischen Chemie, 4, Aufl. ed. Springer-Verlag, Berlin, includingsupplements (also available via the Beilstein online database).

In certain embodiments, thiazolopyrimidine compounds of Formula I (X¹ isN and X² is S) may be readily prepared using procedures well-known toprepare thiazoles, pyrimidines, and thiazolopyrimidines (U.S. Pat. No.6,608,053; U.S. Pat. No. 6,492,383; U.S. Pat. No. 6,232,320; U.S. Pat.No. 6,187,777; U.S. Pat. No. 3,763,156; U.S. Pat. No. 3,661,908; U.S.Pat. No. 3,475,429; U.S. Pat. No. 5,075,305; US 2003/220365; GB 1390658;GB 1393161; WO 93/13664).

In certain embodiments, purine compounds of Formula I (X¹ is N and X² isNR²) may be readily prepared using well-known procedures to preparepurines (Hammarstrom et al (2007) Tetrahedron Lett. 48(16):2823-2827;Cerna et al (2006) Organic Letters 8(23):5389-5392; Chang et al (2006)J. Med. Chem. 49(10):2861-2867; Yang et al (2005) J. Comb. Chem.7:474-482; Liu et al (2005) J. Comb. Chem. 7:627-636; Hocek et al (2004)Synthesis 17:2869-2876; Hammarstrom et al (2003) Tetrahedron Lett.44:8361-8363; Hammarstrom et al (2002) Tetrahedron Lett. 43:8071-8073;Booth et al (1987) J. Chem. Soc, Perkin Trans. 1: Organic andBio-Organic Chem. 7:1521-1526; Booth et al (1981) J. Chem. Soc.,Chemical Communications 15:788-789; Yoneda et al (1976) J. Chem. Soc.,Perkin Trans. 1: Organic and Bio-Organic Chem. 14:1547-1550; Taylor etal (1971) J. Org. Chem. 36(21):3211-3217; Lister, J. H.; Fenn, M. D. ThePurines, Supplementary 1, John Wiley & Sons, 1996, Volume 54; TheChemistry of Heterocyclic Compounds, Editors Weissberger, A.; Taylor E.C., Wiley Interscience, 1971, Volume 24; Legraverend, M.; Grierson, D.S. (2006) Bioorg. Med. Chem. 14:3987-4006; Hocek, M. (2003) Eur. J. Org.Chem. 245-254;U.S. Pat. No. 7,122,665; U.S. Pat. No. 6,743,919; U.S.Pat. No. 5,332,744; U.S. Pat. No. 4,728,644; U.S. Pat. No. 3,016,378; US2008/0058297; US 2003/0139427; WO 2008/043031).

Synthetic chemistry transformations and protecting group methodologies(protection and deprotection) useful in synthesizing Formula I compoundsand necessary reagents and intermediates are known in the art andinclude, for example, those described in R. Larock, ComprehensiveOrganic Transformations, VCH Publishers (1989); T. W. Greene and P. G.M. Wuts, Protective Groups in Organic Synthesis, 3^(rd) Ed., John Wileyand Sons (1999); and L. Paquette, ed., Encyclopedia of Reagents forOrganic Synthesis, John Wiley and Sons (1995) and subsequent editionsthereof.

Compounds of Formula I may be prepared singly or as compound librariescomprising at least 2, for example 5 to 1,000 compounds, or 10 to 100compounds. Libraries of compounds of Formula I may be prepared by acombinatorial ‘split and mix’ approach or by multiple parallel synthesesusing either solution phase or solid phase chemistry, by proceduresknown to those skilled in the art. Thus according to a further aspect ofthe invention there is provided a compound library comprising at least 2compounds, or pharmaceutically acceptable salts thereof.

A purine compound may be prepared by using 2,4,8-trichloropurine as astarting material. The three chloro groups can be displaced by varioussubstituents. More specifically, the most reactive chloro group (i.e.,chloro at position 4) is substituted with a morpholino group to formmorpholinopurine.

For illustrative purposes, Scheme 1 shows a general method for preparingFormula I purine compounds, as well as key intermediates. For a moredetailed description of the individual reaction steps, see the GeneralProcedures and Examples sections. Those skilled in the art willappreciate that other synthetic routes may be used to synthesize theinventive compounds. Although specific starting materials and reagentsare depicted and discussed in the General Procedures, Examples, Scheme1, other starting materials and reagents can be easily substituted toprovide a variety of derivatives and/or reaction conditions. Inaddition, many of the exemplary compounds prepared by the describedmethods can be further modified in light of this disclosure usingconventional chemistry well known to those skilled in the art.

In preparing compounds of Formulas I, protection of remote functionality(e.g., primary or secondary amine) of intermediates may be necessary.The need for such protection will vary depending on the nature of theremote functionality and the conditions of the preparation methods.Suitable amino-protecting groups include acetyl, trifluoroacetyl,t-butoxycarbonyl (BOC), benzyloxycarbonyl (CBz) and9-fluorenylmethyleneoxycarbonyl (Fmoc). The need for such protection isreadily determined by one skilled in the art. For a general descriptionof protecting groups and their use, see T. W. Greene, Protective Groupsin Organic Synthesis, John Wiley & Sons, New York, 1991.

Methods of Separation

In the methods of preparing Formula I compounds, it may be advantageousto separate reaction products from one another and/or from startingmaterials. The desired products of each step or series of steps isseparated and/or purified to the desired degree of homogeneity by thetechniques common in the art. Typically such separations involvemultiphase extraction, crystallization from a solvent or solventmixture, distillation, sublimation, or chromatography. Chromatographycan involve any number of methods including, for example: reverse-phaseand normal phase; size exclusion; ion exchange; high, medium and lowpressure liquid chromatography methods and apparatus; small scaleanalytical; simulated moving bed (SMB) and preparative thin or thicklayer chromatography, as well as techniques of small scale thin layerand flash chromatography.

Another class of separation methods involves treatment of a mixture witha reagent selected to bind to or render otherwise separable a desiredproduct, unreacted starting material, reaction by product, or the like.Such reagents include adsorbents or absorbents such as activated carbon,molecular sieves, ion exchange media, or the like. Alternatively, thereagents can be acids in the case of a basic material, bases in the caseof an acidic material, binding reagents such as antibodies, bindingproteins, selective chelators such as crown ethers, liquid/liquid ionextraction reagents (LIX), or the like. Selection of appropriate methodsof separation depends on the nature of the materials involved, such as,boiling point and molecular weight in distillation and sublimation,presence or absence of polar functional groups in chromatography,stability of materials in acidic and basic media in multiphaseextraction, and the like.

Diastereomeric mixtures can be separated into their individualdiastereomers on the basis of their physical chemical differences bymethods well known to those skilled in the art, such as bychromatography and/or fractional crystallization. Enantiomers can beseparated by converting the enantiomeric mixture into a diastereomericmixture by reaction with an appropriate optically active compound (e.g.,chiral auxiliary such as a chiral alcohol or Mosher's acid chloride),separating the diastereomers and converting (e.g., hydrolyzing) theindividual diastereoisomers to the corresponding pure enantiomers. Also,some of the compounds of the present invention may be atropisomers(e.g., substituted biaryls) and are considered as part of thisinvention. Enantiomers can also be separated by use of a chiral HPLCcolumn.

A single stereoisomer, e.g., an enantiomer, substantially free of itsstereoisomer may be obtained by resolution of the racemic mixture usinga method such as formation of diastereomers using optically activeresolving agents (Eliel, E. and Wilen, S. “Stereochemistry of OrganicCompounds,” John Wiley & Sons, Inc., New York, 1994; Lochmuller, C. H.,(1975) J. Chromatogr., 113(3):283-302). Racemic mixtures of chiralcompounds of the invention can be separated and isolated by any suitablemethod, including: (1) formation of ionic, diastereomeric salts withchiral compounds and separation by fractional crystallization or othermethods, (2) formation of diastereomeric compounds with chiralderivatizing reagents, separation of the diastereomers, and conversionto the pure stereoisomers, and (3) separation of the substantially pureor enriched stereoisomers directly under chiral conditions. See: “DrugStereochemistry, Analytical Methods and Pharmacology,” Irving W. Wainer,Ed., Marcel Dekker, Inc., New York (1993).

Under method (1), diastereomeric salts can be formed by reaction ofenantiomerically pure chiral bases such as brucine, quinine, ephedrine,strychnine, α-methyl-β-phenylethylamine (amphetamine), and the like withasymmetric compounds bearing acidic functionality, such as carboxylicacid and sulfonic acid. The diastereomeric salts may be induced toseparate by fractional crystallization or ionic chromatography. Forseparation of the optical isomers of amino compounds, addition of chiralcarboxylic or sulfonic acids, such as camphorsulfonic acid, tartaricacid, mandelic acid, or lactic acid can result in formation of thediastereomeric salts.

Alternatively, by method (2), the substrate to be resolved is reactedwith one enantiomer of a chiral compound to form a diastereomeric pair(E. and Wilen, S. “Stereochemistry of Organic Compounds”, John Wiley &Sons, Inc., 1994, p. 322). Diastereomeric compounds can be formed byreacting asymmetric compounds with enantiomerically pure chiralderivatizing reagents, such as menthyl derivatives, followed byseparation of the diastereomers and hydrolysis to yield the pure orenriched enantiomer. A method of determining optical purity involvesmaking chiral esters, such as a menthyl ester, e.g., (−) menthylchloroformate in the presence of base, or Mosher ester,α-methoxy-α-(trifluoromethyl)phenyl acetate (Jacob III. J. Org. Chem.(1982) 47:4165), of the racemic mixture, and analyzing the ¹H NMRspectrum for the presence of the two atropisomeric enantiomers ordiastereomers. Stable diastereomers of atropisomeric compounds can beseparated and isolated by normal- and reverse-phase chromatographyfollowing methods for separation of atropisomeric naphthyl-isoquinolines(WO 96/15111). By method (3), a racemic mixture of two enantiomers canbe separated by chromatography using a chiral stationary phase (“ChiralLiquid Chromatography” (1989) W. J. Lough, Ed., Chapman and Hall, NewYork; Okamoto, J. Chromatogr., (1990) 513:375-378). Enriched or purifiedenantiomers can be distinguished by methods used to distinguish otherchiral molecules with asymmetric carbon atoms, such as optical rotationand circular dichroism.

General Preparative Procedures

General Procedure A C-2 Suzuki Coupling

The Suzuki-type coupling reaction is useful to attach a fused bicyclicheterocycle or a fused bicyclic heteroaryl at the 2-position of thepyrimidine ring of a 2-chloro-purine 21. The Suzuki-type couplingreaction is useful to attach a fused bicyclic heterocycle or a fusedbicyclic heteroaryl at the 2-position of the pyrimidine ring ofthiazolopyrimidines (i), thienopyrimidines (ii), furanopyrimidines (iv),and pyrrolopyrimidines (v). For example, 21 may be combined with about1.5 equivalents of4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-c]pyridine24, and dissolved in 3 equivalents of sodium carbonate as a 1 molarsolution in water and an equal volume of acetonitrile. A catalyticamount, or more, of a low valent palladium reagent, such asbis(triphenylphosphine)palladium(II) dichloride, is added. A variety ofboronic acids or boronic esters can be used in place of the indazoleboronic ester indicated. Also alternatively, a nitrogen of the fusedbicyclic heterocycle or a fused bicyclic heteroaryl may be protected,for example as N-THP. In some cases potassium acetate was used in placeof sodium carbonate to adjust the pH of the aqueous layer. The reactionis then heated to about 140-150° C. under pressure in a microwavereactor such as the Biotage Optimizer (Biotage, Inc.) for 10 to 30minutes. The contents are extracted with ethyl acetate, or anotherorganic solvent. After evaporation of the organic layer the Suzukicoupling products 22 may be purified on silica or by reverse phase HPLC.Substituents R^(1′), R^(2′), R^(4′) may be R¹, R², R⁴ as defined, orprotected forms or precursors thereof.

A variety of palladium catalysts can be used during the Suzuki couplingstep to form compounds, including exemplary embodiments 22. Suzukicoupling is a palladium mediated cross coupling reaction of aheteroarylhalide, such as 21, with a boronic acid such as 24. Lowvalent, Pd(II) and Pd(0) catalysts may be used in the Suzuki couplingreaction, including PdCl₂(PPh₃)₂, Pd(t-Bu)₃, PdCl₂ dppf CH₂Cl₂,Pd(PPh₃)₄, Pd(Oac)/PPh₃, Cl₂Pd[(Pet₃)]₂, Pd(DIPHOS)₂, Cl₂Pd(Bipy),[PdCl(Ph₂PCH₂PPh₂)]₂, Cl₂Pd[P(o-tol)₃]₂, Pd₂(dba)₃/P(o-tol)₃,Pd₂(dba)/P(furyl)₃, Cl₂Pd[P(furyl)₃]₂, Cl₂Pd(PmePh₂)₂,Cl₂Pd[P(4-F—Ph)₃]₂, Cl₂Pd[P(C₆F₆)₃]₂, Cl₂Pd[P(2-COOH-Ph)(Ph)₂]₂,Cl₂Pd[P(4-COOH-Ph)(Ph)₂]₂, and encapsulated catalysts Pd EnCat™ 30, PdEnCat™ TPP30, and Pd(II)EnCat™ BINAP30 (US 2004/0254066).

General Procedure B C-6 Nitrogen Substitution

To a 2,6-dichloro purine intermediate 27 in a solvent such as ethanol isadded a morpholine or a morpholine analog, and a non-nucleophilic basesuch as triethylamine (Net₃, 1.5 eq, 63 μl). Alternatively, acetonitrilemay be used as the solvent and potassium carbonate may be used as thebase. The reaction mixture is stirred at room temperature for about 1hour or overnight, volatiles removed in vacuo and residue partitionedbetween DCM and brine. If the mixture is insoluble it may be sonicatedand the solid product was collected by filtration. Drying with magnesiumsulfate and evaporation of the solvent gives N′-(2-chloropurin-6-yl)-amine substituted intermediate 28, often as a crystallinesolid, or by trituration. Substituents R^(1′) and R^(2′) may be R¹ andR² as defined, or protected forms or precursors thereof.

General Procedure C N-9 Nitrogen Alkylation

9-H Purine intermediate 29 is brought up into DMF and 2 equiv of cesiumcarbonate is added to the reaction mixture. The reaction is heated to50° C. whereupon 1 to 3 equivalents of an alkyl halide R^(2′)—X areadded to the reaction mixture. The reaction is monitored by TLC or LC/MSand stirred until completion, typically several hours. The reactionmixture is extracted with EtOAc and water, and the organic layer isdried, filtered and concentrated to get crude 9-alkylated purine 30which is used directly in the next reaction or purified by reverse phaseHPLC. Substituents R^(1′), R^(3′) and R^(4′) may be R¹, R³ and R⁴ asdefined, or protected forms or precursors thereof

In an embodiment of N-alkylation of a piperidine group, to a suspensionof4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidiniumchloride or4-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidiniumchloride (0.4 mmol), potassium carbonate (0.25 g, 1.8 mmol) inacetonitrile (2.0 mL) is added an electrophile (1.4 mmol). The resultingmixture is stirred in a pressure tube at about 95° C. for 5-18 hours.The reaction mixture is filtered, concentrated, and may be purified byRP-HPLC.

General Procedure D THP Deprotection

Generally, N-9-tetrahydropyranyl substituted 31 may be treated withcatalytic amounts of para-toluenesulfonic acid (PTSA) in a solution ofmethanol and heated to about 50° C. until the tetrahydropyran (THP)group is removed to afford compound 32. The reaction may be monitored byLC-MS or TLC. Substituents R^(1′) and R^(3′) may be R¹ and R³ asdefined, or protected forms or precursors thereof.

General Procedure E Displacement of Alkyl Bromide with Amines:

Generally, substituted 33 is suspended in dichloromethane whereupon 3equivalents of Hunig's base (DIPEA) and 1.5 equivalents of an amine(NHR₂) are added to the reaction mixture. Other solvents such astetrahydrofuran and methanol, or mixtures of solvents can be employed.The reaction is monitored by TLC or LC-MS until complete, usually within30 minutes. The reaction mixture is extracted with water and the organiclayer is dried, filtered and concentrated to dryness. The intermediate34 can be taken as crude into subsequent reactions or in some cases ispurified by column chromatography.

General Procedure F Amide Coupling

A 2,6,8 substituted, 9-alkylcarboxyl purine 35, where n is 1 to 12, istreated with 1.5 eq HATU(2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluroniumhexafluorophosphate), an excess (such as 3 eq) of an alkylamine(HNR¹⁰R¹¹) and an excess (such as 3 eq) of cesium carbonate indimethylformamide (DMF). Alternatively, other coupling reagents may beused. The reaction is stirred until complete and extracted inethylacetate with saturated bicarbonate solution. The organic layer isdried, filtered and concentrated to yield the acylated, crudeintermediate, which is purified via reverse phase HPLC to yield product36. Substituents R^(1′) and R^(3′) may be R¹ and R³ as defined, orprotected forms or precursors thereof.

General Procedure G Stille Coupling

To intermediate 37 in a microwave vial is added 1.2 equivalents of anaryl bromide, 1 equivalent of copper (I) iodide or copperthiophene-carboxylate, and 1,4-dioxane as solvent. The reaction mixtureis degassed under nitrogen for 5 minutes prior to addition of 0.12equivalents of tetrakis(triphenylphosphine)palladium(0). The reaction isheated in a CEM or Biotage microwave for 20-30 minutes at 140° C. Thecrude reaction mixture is filtered and periodically passed through aBiotage Isolute scx-2 basic spe cartridge before being purified vianormal or reverse phase chromatography to afford pure product 38.Substituents R^(2′) and R^(3′) may be R² and R³ as defined, or protectedforms or precursors thereof.

General Procedure H N-9 Alkylation of Purines

Scheme 1 shows a general method for preparation of polyfunctionalizedpurines begins with protection of the N-9 nitrogen of2,6-dichloro-9H-purine as the tetrahydropyranyl group (THP).Displacement of the more reactive chloro group with morpholine gives4-(2-chloro-9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-yl)morpholine. TheC-8 proton is removed with strong base and reacted with variouselectrophiles (R¹). After deprotection with mild acid, N-9 is alkylatedof N-9 with various electrophiles (R²). Suzuki coupling at C-2 chloro byGeneral Procedure A with various boronate reagents and palladiumcatalysts gives carbon-linked C₂-C₂₀ heterocyclyl and carbon-linkedC₁-C₂₀ heteroaryl as R³.

General Procedure I C-2 Halo Buchwald Coupling of Amine-Heteroaryls

A microwave tube is charged with Xphos(2-Dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl, CAS Reg. No.564483-18-7, 0.1 equiv.), tris(dibenzylideneacetone)dipalladium(0) (0.05equiv.), cesium carbonate (2 equiv.), the corresponding 2-chloropurine39 (1 equiv.) and an amine (1.2 equiv.), such as a benzimidazole. Thevessel is evacuated and refilled with nitrogen prior to the addition ofDMF or 1,4-dioxane. The mixture is heated in a microwave device, such asBiotage at about 140° C. for about 25-35 minutes. The reaction mixtureis cooled to room temperature, filtered and concentrated. Typically, thecrude product 40 is purified by flash chromatography or RP-HPLC.

Alternatively, the reaction can be performed by a modified procedure: Amicrowave tube is charged with palladium acetate (0.10 equiv.),bis(tri-t-butylphosphine)palladium (0.10 equiv.), sodium t-butoxide (2equiv.), the corresponding 2-chloropurine 39 (1 equiv.) and the amine (2equiv.). The vessel is evacuated and refilled with nitrogen prior to theaddition of toluene. The mixture is heated in a Biotage microwave atabout 140° C. for about 25-35 minutes. The reaction mixture is cooled toroom temperature, filtered and concentrated. Typically, the crudeproduct 40 is purified by flash chromatography or RP-HPLC.

The Buchwald (and Suzuki) couplings may be conducted with a variety ofpalladium catalysts and ligands, including:Chloro{[t-butylXPhos][2-(2-aminoethylphenyl)palladium(II))/[t-butylXPhos]admixture (molar PdP/P=1:1),Chloro(2-di-t-butylphosphino-2′,4′,6′-tri-1-propyl-1,1′-biphenyl)[2-(2-aminoethyl)phenyl]palladium(II),Chloro(2-dicyclohexylphosphino-2′,6′-dimethoxy-1,1′-biphenyl)[2-(2-aminoethylphenyl)]palladium(II)methyl-t-butylether adduct,Chloro[2-(dicyclohexylphosphino)-3,6-dimethoxy-2′-4′-6′-tri-1-propyl-1,1′-biphenyl][2-(2-aminoethyl)phenyl]palladium(II),Chloro(2-dicyclohexylphosphino-2′,6′-di-1-propoxy-1,1′-biphenyl)[2-(2-aminoethylphenyl)]palladium(II),methyl-t-butylether adduct,Chloro(2-dicyclohexylphosphino-2′,4′,6′-tri-1-propyl-1,1′-biphenyl)[2-(2-aminoethyl)phenyl]palladium(II)methyl-t-butylether adduct.

A variety of phosphorus ligands may also be employed in the Buchwald(and Suzuki) couplings, including:2-Dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl, Xphos (CAS Reg.No. 564483-18-7), racemic-2-Di-t-butylphosphino-1,1′-binaphthyl (CASReg. No. 255836-67-0), 2-(Di-t-butylphosphino)biphenyl, JohnPhos (CASReg. No. 224311-51-7),2-Di-t-butylphosphino-2′-(N,N-dimethylamino)biphenyl (CAS Reg. No.224311-49-3), 2-Di-t-butylphosphino-2′-methylbiphenyl (CAS Reg. No.255837-19-5),2-Di-t-butylphosphino-3,4,5,6-tetramethyl-2′,4′,6′-tri-1-propylbiphenyl(CAS Reg. No. 857356-94-6),2-Di-t-butylphosphino-2′,4′,6′-tri-1-propyl-1,1′-biphenyl, t-butylXPhos(CAS Reg. No. 564483-19-8), 2-(Dicyclohexylphosphino)biphenyl (CAS Reg.No. 247940-06-3), 2-Dicyclohexylphosphino-2′,6′-dimethoxy-1,1′-biphenyl,S-Phos (CAS Reg. No. 657408-07-6),2′-Dicyclohexylphosphino-2,6-dimethoxy-3-sulfonato-1,1′-biphenyl hydratesodium salt,2-(Dicyclohexylphosphino)-3,6-dimethoxy-2′-4′-6′-tri-1-propyl-1,1′-biphenyl(BrettPhos), 2-(Dicyclohexylphosphino)-2′-(N,N-dimethylamino)biphenyl,DavePhos (CAS Reg. No. 213697-53-1),2-Dicyclohexylphosphino-2′,6′-di-1-propoxy-1,1′-biphenyl, RuPhos (CASReg. No. 787618-22-8),2′-Dicyclohexylphosphino-2,6-di-1-propyl-4-sulfonato-1,1′-biphenylhydrate sodium salt (CAS Reg. No. 870245-84-4),2-Dicyclohexylphosphino-2′-methylbiphenyl, MePhos (CAS Reg. No.251320-86-2),2-(Dicyclohexylphosphino)-2′,4′,6′-tri-1-propyl-1,1′-biphenyl, X-Phos(CAS Reg. No. 564483-18-7)2-Diphenylphosphino-2′-(N,N-dimethylamino)biphenyl (CAS Reg. No.240417-00-9). See: Mauger, C. C. and Mignani, G. A. Aldrichimica Acta(2006) 39:17; Schlummer, B. and Scholz, U. Adv. Synth. Catal. (2004)346:1599 for reviews. Buchwald and Suzuki coupling reagents areavailable from commercial sources including Strem Chemicals, Inc., 7Mulliken Way, Newburyport, Mass. 01950-4098 USA.

General Procedure J Multi-Step Benzimidazole Formation by BuchwaldCoupling of Amino-Heteroaryls

2-Chloropurine 39 is reacted with 1,2-diaminobenzene via GeneralProcedure I for Buchwald Coupling to give 2-amino heteroarylintermediate 41 which is subsequently transformed to 42 via one of twopossible routes. In the top route; Intermediate 41 and acid with R⁸functional group (1.5 eq) and HATU (1.5 eq) are dissolved in DMF (100eq) whereupon N,N-diisopropylethylamine (3-5 eq) is added. The reactionis stirred overnight at room temperature and then concentrated todryness. The crude is dissolved in acetic acid (100 eq) and heated at90° C. for 18 hours to cyclize to product 42. In the middle route, 41 isdissolved directly in either the acid (or ester) with R⁸ functionalgroup and refluxed overnight to cyclize to product 42. In the lowerroute, 41 is acylated with anhydride (1 to 1.5 equiv.) in the presenceof a tertiary amine base such as iPr₂Net. Final products are purifiedvia reverse phase HPLC and may be subsequently purified by chiral SFC(supercritical fluid chromatography) when enantiomers are present andrequire separation (Liu et al (2003) Chromatographia 58(11/12):775-779).

General Procedure K C2-Carboxylamide Formation

To a mixture of2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purine-8-carboxylicacid 42 (1 equiv), HBTU (1.5 equiv.) in N,N-dimethylformamide is addedtriethylamine (TEA). The resulting mixture is stirred at roomtemperature for about 5 minutes before the addition of the amine (R₂NH,1 equiv.). The reaction mixture is then stirred at room temperature for2-18 hours. The reaction mixture is concentrated and purified by RP-HPLCto give the amide product 43. Other coupling agents, such as HATU, HCTU,TBTU, and PyBOP, can be used.

General Procedure L Reductive Amination

In an exemplary embodiment of the general procedure for reductiveamination of amine groups, a suspension of4-(8-(azetidin-3-ylmethyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholineor4-(8-(azetidin-3-ylmethyl)-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine(1 equiv.) in 1,2-dichloroethane is added a ketone (about 1.5-2.0equiv.). The resulting mixture is stirred at room temperature for 15minutes before the addition of sodium triacetoxyborohydride (about1.5-2.0 equiv.). The reaction is then stirred at room temperature forabout 18 hours. The reaction was then quenched by the addition ofmethanol. The mixture may be purified by chromatography, includingRP-HPLC. Also, the mixture may be loaded onto an ISOLUTE SCX-2 column,washed with MeOH, and eluted with 2M NH₃ in MeOH to give the desiredproduct.

In an exemplary embodiment of reductive amination of a 2-carboxaldehydepurine intermediate, a mixture of9-methyl-2-(2-methyl-benzoimidazol-1-yl)-6-morpholin-4-yl-9H-purine-8-carbaldehydewhere R² is methyl and R³ is 2-methyl-benzoimidazol-1-yl (0.1 g, 0.264mmol), AcOH (0.03 mL, 0.53 mmol) and amine in CH2Cl2 (4 mL) was stirredat room temperature from 2 h. Sodium triacetoxyborohydride (78 mg, 0.37mmol) was added and stirring continued for 18 h. Potassium carbonate(K2CO3) saturated solution was added and product extracted with CH2Cl2(4×). Organics combined were dried (MgSO4) and concentrated. Flashchromatography with CH2Cl2:Methanol:Ammonium hydroxide (100:5:0.5)afforded the 2-aminomethyl product.

Alternatively, to a mixture of an aldehyde (1 mmol) and amine (1-1.2mmol) in 1,2-dichloroethane (8-20 mL) was added acetic acid (2 mmol) andtrimethoxymethane (10 mmol), or micronized 4 A (angstrom) molecularsieves. The mixture was stirred at room temperature for 0.5-4 hr. Sodiumtriacetoxyborohydride (1.1-1.5 mmol) was added. The resulting mixturewas stirred at room temperature for 4-20 hr. The contents werepartitioned between DCM and diluted NaOH. The organic layer wasseparated. The aqueous layer was extracted with DCM. The combinedorganic solutions were dried (Na₂SO₄). The crude was purified bychromatography or reverse phase HPLC, or used directly if pure enoughfor subsequent transformations.

EXAMPLES

The chemical reactions described in the Examples may be readily adaptedto prepare a number of other PI3K inhibitors of the invention, andalternative methods for preparing the compounds of this invention aredeemed to be within the scope of this invention. For example, thesynthesis of non-exemplified compounds according to the invention may besuccessfully performed by modifications apparent to those skilled in theart, e.g., by appropriately protecting reactive functional groups, byutilizing other suitable reagents known in the art other than thosedescribed, and/or by making routine modifications of reactionconditions. Alternatively, other reactions disclosed herein or known inthe art will be recognized as having applicability for preparing othercompounds of the invention.

Chiral SFC (supercritical fluid chromatography) may be used to separateenantiomers (Liu et al (2003) Chromatographia 58(11/12):775-779) ¹H NMRspectra were recorded at ambient temperature using an NMR spectrometer,including a Varian Unity Inova (400 MHz) spectrometer with a tripleresonance 5 mm probe. Chemical shifts are expressed in ppm relative totetramethylsilane. The following abbreviations have been used: br=broadsignal, s=singlet, d=doublet, dd=double doublet, t=triplet, q=quartet,m=multiplet.

High Pressure Liquid Chromatography—Mass Spectrometry (LCMS) experimentsto determine retention times (R_(T)) and associated mass ions may beperformed, for example by one of the following methods. Thespectrometers have an electrospray source operating in positive andnegative ion mode. Additional detection was achieved using a Sedex 85evaporative light scattering detector.

Method A: Experiments performed on a Waters Platform LC quadrupole massspectrometer linked to a Hewlett Packard HP1100 LC system, with diodearray detector and a 100 position autosampler, using a Phenomenex Luna 3μm C₁₈(2) 30×4.6 mm and a 2 mL/minute flow rate. The mobile phaseconsisted of formic acid 0.1% in water (solvent A) and formic acid 0.1%in methanol (solvent B). The initial solvent system was 95% solvent Aand 5% solvent B for the first 0.5 minute followed by a gradient up to5% solvent A and 95% solvent B over the next 4 minutes. The finalsolvent system was held constant for a further 1 minute.

Method B: Experiments performed on a Waters Platform LC quadrupole massspectrometer linked to a Hewlett Packard HP1100 LC system, with diodearray detector and a 100 position autosampler, using a using aPhenomenex Luna 3 μm C₁₈(2) 30×4.6 mm and a 2 mL/minute flow rate Themobile phase consisted of formic acid 0.1% in water (solvent A) andformic acid 0.1% in acetonitrile (solvent B). The initial solvent systemwas 95% solvent A and 5% solvent B for the first 0.50 minute followed bya gradient up to 5% solvent A and 95% solvent B over the next 4 minutes.The final solvent system was held constant for a further 1 minute.

Method C: Experiments performed on a Waters ZMD quadrupole massspectrometer linked to a Waters 1525 LC system, with a Waters 996 diodearray detector and a Waters 2700 autosampler, using a Phenomenex Luna 3μm C₁₈(2) 30×4.6 mm and a 2 mL/minute flow rate. The mobile phaseconsisted of formic acid 0.1% in water (solvent A) and formic acid 0.1%in methanol (solvent B). The initial solvent system was 95% solvent Aand 5% solvent B for the first 0.5 minute followed by a gradient up to5% solvent A and 95% solvent B over the next 4 minutes. The finalsolvent system was held constant for a further 1 minute.

Method D: Experiments performed on a Waters ZMD quadrupole massspectrometer linked to a Waters 1525 LC system, with a Waters 996 diodearray detector and a Waters 2700 autosampler, using a Phenomenex Luna 3μm C₁₈(2) 30×4.6 mm and a 2 mL/minute flow rate. The mobile phaseconsisted of formic acid 0.1% in water (solvent A) and formic acid 0.1%in acetonitrile (solvent B). The initial solvent system was 95% solventA and 5% solvent B for the first 0.5 minute followed by a gradient up to5% solvent A and 95% solvent B over the next 4 minutes. The finalsolvent system was held constant for a further 1 minute.

Method E: Experiments performed on a Waters Micromass ZQ2000 quadrupolemass spectrometer linked to a Hewlett Packard HP1100 LC system, with aDAD UV detector and a CTC HTS PAL autosampler, using a Higgins Clipeus 5μm C18 100×3.0 mm column (at 40° C.) and a 1 mL/minute flow rate. Themobile phase consisted of formic acid 0.1% in water (solvent A) andformic acid 0.1% in methanol (solvent B). The initial solvent system was85% solvent A and 15% solvent B for the first 1 minute followed by agradient up to 5% solvent A and 95% solvent B over the next 12 minutes.The final solvent system was held constant for a further 7 minutes.

Method F: Experiments performed on a Waters Micromass ZQ2000 quadrupolemass spectrometer linked to a Hewlett Packard HP1100 LC system, with aDAD UV detector and a CTC HTS PAL autosampler, using a Higgins Clipeus 5micron C₁₈ 100×3.0 mm column and a 1 mL/minute flow rate. The mobilephase consisted of formic acid 0.1% in water (solvent A) and formic acid0.1% in acetonitrile (solvent B). The initial solvent system was 85%solvent A and 15% solvent B for the first 1 minute followed by agradient up to 5% solvent A and 95% solvent B over the next 14 minutes.The final solvent system was held constant for a further 5 minutes.

Microwave experiments were carried out using a CEM Explorer, SmithSynthesizer or a Biotage Initiator™, which uses a single-mode resonatorand dynamic field tuning, both of which give reproducibility andcontrol. Temperatures from 40-250° C. can be achieved and pressures upto 20 bar can be reached.

Unless otherwise stated, all reactions were performed under an inert,i.e. argon or nitrogen, atmosphere.

R¹ Reagents:

Example 1 3-(Tetrahydropyran-4-yl)azetidine-1-carboxylic acid tert-butylester

Step 1: Trifluoromethanesulfonic acid 3,6-dihydro-2H-pyran-4-yl ester

To a solution of diisopropylamine (35.2 mL, 0.25 mol) in anhydrous THF(200 mL) at −20° C. was added a 2.5M solution on n-buyllithium inhexanes (100 mL, 0.25 mol) over a 10 min period under an argonatmosphere. The reaction mixture was stirred at −20° C. for 15 min. Asolution of tetrahydropyran-4-one (21.0 mL, 0.23 mol) in anhydrous THF(160 mL) was added dropwise over a 20 min period (internal temperature<−65° C.). The reaction mixture was stirred for 3 hours at −78° C. thena solution of N,N-bis(trifluoromethanesulfonyl)aniline (86.4 g, 0.24mmol) in anhydrous THF (240 mL) was added dropwise over a 45 min period.The resulting mixture was stirred at −78° C. for 1.5 hours then allowedto reach room temperature and stirred for 18 hours. The solvents wereremoved in vacuo to give a residue which was partitioned between EtOAc(500 mL) and water (250 mL). The organic layer was separated and washedwith water (250 mL), 2M NaOH in water (3×300 mL) and brine (2×200 mL),dried over Na₂SO₄, filtered and concentrated to giveTrifluoromethanesulfonic acid 3,6-dihydro-2H-pyran-4-yl ester as a brownoil (43.7 g, 83%). ¹H NMR (400 MHz, CHCl₃-d): δ 5.83-5.80 (m, 1H); 4.26(dd, J=2.9, 0.4 Hz, 2H); 3.89 (t, J=5.5 Hz, 2H); 2.46 (ttd, J=5.5, 2.9,1.4 Hz, 2H).

Step 2: 3-(3,6-Dihydro-2H-pyran-4-yl)azetidine-1-carboxylic acidtert-butyl ester

Zinc activation: To a suspension of zinc powder (20.3 g, 0.31 mol) andCelpure® P65 in anhydrous DMA (48 mL) was added a 7:5 (v:v) mixture ofTMS—Cl: 1,2-dibromoethane (6.2 mL) was added dropwise. The reactionmixture was stirred at room temperature for 45 min.

Zinc insertion: A solution of 3-iodoazetidine-1-carboxylic acidtert-butyl ester (72.9 g, 0.26 mol) in anhydrous DMA (120 mL) was addeddropwise to the mixture described above over a 30 min period. Thereaction mixture was stirred for 1 hour at room temperature.

Coupling reaction: A mixture of trifluoromethanesulfonic acid3,6-dihydro-2H-pyran-4-yl ester (42.7 g, 0.18 mol), Pd(dppf)Cl₂.DCM (4.5g, 5.5 mmol) and CuI (2.1 g, 11.0 mmol) was sonicated for 5 min. Thevessel was then evacuated and back-filled with argon. The zincatemixture was quickly filtered through a grade-3 sintered funnel and addedonto the palladium-containing mixture. The resulting reaction mixturewas stirred at 85° C. for 18 hours then cooled to room temperature.EtOAc (1 L) and a 1M aqueous solution of ammonium chloride (0.5 L) wereadded and the mixture was stirred for 30 min. Water (0.5 L) was added tothe reaction mixture and the organic layer was separated, was washedwith water and brine, dried over Na₂SO₄, filtered and concentrated.

Purification: The residue was taken up in cyclohexane (ca 200 mL) andloaded onto a 600 g column of silica gel 60 pre-conditioned withcyclohexane. The product was eluted with a gradient of EtOAc incyclohexane (0%-50%). The appropriate fractions were combined andconcentrated to give the title compound as a dark-coloured oil (22.85 g,52%). The mixed fractions were combined and concentrated to give aresidue which was subjected to automated flash chromatography (Si—PPC,EtOAc:cyclohexane, gradient 5:95 to 50:50). The appropriate fractionswere combined to give3-(3,6-Dihydro-2H-pyran-4-yl)azetidine-1-carboxylic acid tert-butylester as a dark-coloured oil (7.8 g, 18%). ¹H NMR (400 MHz, CHCl₃-d): δ5.56-5.53 (m, 1H); 4.17-4.13 (m, 2H); 4.02 (t, J=8.6 Hz, 2H); 3.85-3.78(m, 4H); 3.20-3.09 (m, 1H); 2.11-2.06 (m, 2H); 1.44 (s, 9H).

Step 3: A mixture of 3-(3,6-dihydro-2H-pyran-4-yl)azetidine-1-carboxylicacid tert-butyl ester (28.6 g, 0.12 mol) and 10% palladium on charcoal(5.0 g) in IMS (500 mL) was stirred under hydrogen (4 bar) at roomtemperature for 36 hours. The reaction mixture was filtered through abed of Celite® which was washed with IMS. The filtrates were combinedand concentrated to give a residue which was reacted as above for 18hours. The reaction mixture was worked up as above to give a residuewhich was dried under reduced pressure to give3-(Tetrahydropyran-4-yl)azetidine-1-carboxylic acid tert-butyl ester asa beige solid (26.7 g, 92%). ¹H NMR (300 MHz, CHCl₃-d): δ 4.03-3.90 (m,4H); 3.63 (dd, J=8.6, 5.7 Hz, 2H); 3.37 (td, J=11.8, 2.0 Hz, 2H);2.32-2.19 (m, 1H); 1.63-1.48 (m, 3H); 1.44 (s, 9H); 1.29-1.12 (m, 2H).

Example 2 (4-Methylpiperidin-4-yl)pyrrolidin-1-ylmethanone

Step 1: 4-Methyl-4-(pyrrolidine-1-carbonyl)piperidine-1-carboxylic acidtert-butyl ester

To a solution of 4-methylpiperidine-1,4-dicarboxylic acidmono-tert-butyl ester (229 mg, 0.94 mmol) in DMF (10 mL) were addedDIPEA (0.493 mL, 2.83 mmol), pyrrolidine (0.118 mL, 1.41 mmol) and HATU(537 mg, 1.41 mmol). The reaction mixture was stirred at roomtemperature for 18 hours and then partitioned between water and EtOAc.The organic layer was separated and washed with a 0.1N aqueous HClsolution and brine, dried over Na₂SO₄, filtered and concentrated to give4-Methyl-4-(pyrrolidine-1-carbonyl)piperidine-1-carboxylic acidtert-butyl ester as a white solid (279 mg, 100%). LCMS (Method H): R_(T)4.00 min; [M+Na]⁺ 319

Step 2: A solution of4-methyl-4-(pyrrolidine-1-carbonyl)piperidine-1-carboxylic acidtert-butyl ester (296 mg, 1.0 mmol) in TFA (5 mL), DCM (5 mL) and water(0.1 mL) was stirred at room temperature for 2 hours and thenconcentrated under reduced pressure. The residue was taken up in MeOHand loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge waswashed with MeOH and the desired product was eluted with 2M NH₃ in MeOH.The solvents were removed to give the desired product as a white solid(196 mg, 66%). LCMS (Method A): R_(T) 0.31 min; [M+H]⁺ 197

Example 3 (3-Methylpyrrolidin-3-yl)pyrrolidin-1-ylmethanone

Step 1: 3-Methylpyrrolidine-1,3-dicarboxylic acid 1-tert-butyl ester

To a solution of 3-methylpyrrolidine-1,3-dicarboxylic acid 1-tert-butylester 3-methyl ester (370 mg, 1.52 mmol) in IMS (5 mL) was added a 1Maqueous solution of sodium hydroxide (2.0 mL, 2.0 mmol). The reactionmixture was stirred at room temperature for 2 hours, and thenconcentrated under reduced pressure. The residue was partitioned betweenEtOAc and a 0.1M aqueous solution of HCl. The organic layer wasseparated and washed with brine, dried over Na₂SO₄, filtered andconcentrated to give the desired product as a white solid (348 mg,100%). ¹H NMR (400 MHz, CHCl₃-d): δ 3.85-3.75 (m, 1H); 3.52-3.41 (m,2H); 3.27-3.15 (m, 1H); 2.39-2.30 (m, 1H); 1.83-1.74 (m, 1H); 1.51-1.40(m, 9H); 1.38 (s, 3H).

Step 2: 3-Methyl-3-(pyrrolidine-1-carbonyl)pyrrolidine-1-carboxylic acidtert-butyl ester

To a solution of 3-methylpyrrolidine-1,3-dicarboxylic acid 1-tert-butylester (348 mg, 1.52 mmol) in DMF (10 mL) were added DIPEA (0.53 mL, 3.04mmol), pyrrolidine (0.25 mL, 3.04 mmol) and HATU (693 mg, 1.82 mmol).The reaction mixture was stirred at room temperature for 18 hours andthen partitioned between water and EtOAc. The organic layer wasseparated and washed with a 0.1N aqueous HCl solution and brine, driedover Na₂SO₄, filtered and concentrated to give the desired product as awhite solid (334 mg, 78%). ¹H NMR (400 MHz, CHCl₃-d): δ 3.61-3.38 (m,8H); 2.00-1.79 (m, 6H); 1.47-1.44 (m, 9H); 1.33 (s, 3H).

Step 3: A solution of3-methyl-3-(pyrrolidine-1-carbonyl)pyrrolidine-1-carboxylic acidtert-butyl ester (330 mg, 1.17 mmol) in TFA (5 mL), DCM (5 mL) and water(0.1 mL) was stirred at room temperature for 2 hours and thenconcentrated under reduced pressure. The residue was taken up in MeOHand loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge waswashed with MeOH and the desired product was eluted with 2M NH₃ in MeOH.The solvents were removed to give(3-Methylpyrrolidin-3-yl)pyrrolidin-1-ylmethanone as a white solid (169mg, 79%). ¹H NMR (400 MHz, CHCl₃-d): δ 3.55-3.40 (m, 5H); 3.06-2.92 (m,2H); 2.32-2.20 (m, 2H); 2.01-1.82 (m, 5H); 1.71 (m, 1H); 1.33 (s, 3H).

Example 4 1-(2-(Methanesulfonyl)ethyl)-2,2-dimethylpiperazine

Step 1: 4-(2-(Methanesulfonyl)ethyl)-3,3-dimethylpiperazine-1-carboxylicacid tert-butyl ester

Step 2: A mixture of 3,3-dimethylpiperazine-1-carboxylic acid tert-butylester (500 mg, 2.33 mmol) and methyl vinyl sulfone (510 μL, 619 mg, 5.83mmol) in MeOH (15 mL) was heated to 65° C. for 5.5 h then stirred atroom temperature for 96 h. The reaction mixture was concentrated invacuo. The resulting residue was purified by column chromatography(Si—PCC, MeOH:DCM, 0-3%) affording1-(2-(Methanesulfonyl)ethyl)-2,2-dimethylpiperazine as a white waxysolid (550 mg, 74%). ¹H NMR (CDCl₃, 300 MHz): δ 3.47-3.40 (m, 2H); 3.15(s, 2H); 3.09 (t, J=6.4 Hz, 2H); 3.03 (s, 3H); 2.89 (t, J=6.4 Hz, 2H);2.58-2.50 (m, 2H); 1.45 (s, 9H); 1.04 (s, 6H).

Step 3: A mixture of4-(2-methanesulfonylethyl)-3,3-dimethylpiperazine-1-carboxylic acidtert-butyl ester (510 mg, 1.59 mmol) and TFA (5 mL) in DCM (10 mL) wasstirred at room temperature for 2 h. The reaction mixture was loadedonto an Isolute® SCX-2 cartridge which was washed with MeOH/DCM and theproduct eluted with 2M NH₃/MeOH affording1-(2-(Methanesulfonyl)ethyl)-2,2-dimethylpiperazine as a white solid(320 mg, 91%). ¹H NMR (CDCl₃, 300 MHz): δ 3.49 (s, 1H); 3.12-3.03 (m,5H); 2.92-2.84 (m, 4H); 2.60 (s, 2H); 2.53-2.47 (m, 2H); 1.06 (s, 6H).

Example 5 4-Azetidin-3-yl-2,2-dimethylmorpholine

Step 1: 3-(2,2-Dimethylmorpholin-4-yl)azetidine-1-carboxylic acidtert-butyl ester

A mixture of 2,2-dimethylmorpholine (260 mg, 2.26 mmol) and3-oxoazetidine-1-carboxylic acid tert-butyl ester (464 mg, 2.71 mmol) inDCE (15 mL) was stirred at room temperature for 2 h before the additionof sodium triacetoxyborohydride (957 mg, 4.52 mmol). The resultingmixture was stirred for 16 h, then diluted with DCM and washed with H₂O.The organic phase was dried (phase separator) and concentrated in vacuo.The resulting residue was purified by column chromatography (Si—PCC,EtOAc:cyclohexane, 0-40%) affording the title compound as an oil (492mg, 81%). ¹H NMR (CDCl₃, 300 MHz): δ 3.95-3.85 (m, 2H); 3.80-3.71 (m,4H); 3.07-2.88 (m, 1H); 2.32-2.22 (m, 2H); 2.14-2.06 (m, 2H); 1.44 (s,9H); 1.25 (s, 6H).

Step 2: A mixture of3-(2,2-dimethylmorpholin-4-yl)azetidine-1-carboxylic acid tert-butylester (492 mg, 1.82 mmol) and TFA (5 mL) in DCM (10 mL) was stirred atroom temperature for 2 h. The reaction mixture was loaded onto anIsolute® SCX-2 cartridge, washed with MeOH/DCM and eluted with 2MNH₃/MeOH affording 4-Azetidin-3-yl-2,2-dimethylmorpholine as a whitesolid (302 mg, 97%). ¹H NMR (CDCl₃, 300 MHz): δ 3.73 (t, J=4.8 Hz, 2H);3.64-3.51 (m, 4H); 3.18-3.11 (m, 1H); 2.23 (t, J=4.8 Hz, 2H); 2.23-2.07(m, 1H); 2.06 (s, 2H); 1.25 (s, 6H).

Example 6 4-Azetidin-3-yl-thiomorpholine 1,1-dioxide

Step 1: 3-(1,1-Dioxo-1-thiomorpholin-4-yl)azetidine-1-carboxylic acidtert-butyl ester

To a refluxing solution of 3-aminoazetidine-1-carboxylic acid tert-butylester (10.0 g, 58.1 mmol) in EtOH (50 mL) was added drop wise a solutionof divinyl sulfone (5.9 mL, 6.86 g, 58.1 mmol) in EtOH (50 mL). Theresulting mixture was stirred at reflux for 15.5 h, cooled to roomtemperature and concentrated in vacuo. The resulting beige solid wastriturated with Et₂O, affording the title compound as a white solid(10.8 g, 64%). ¹H NMR (CDCl₃, 300 MHz): δ 3.97 (dd, J=8.8, 7.1 Hz, 2H);3.76 (dd, J=8.8, 7.1 Hz, 2H); 3.36-3.26 (m, 1H); 3.13-3.05 (m, 4H);2.90-2.83 (m, 4H); 1.44 (s, 9H).

Step 2: A mixture of3-(1,1-dioxo-1-thiomorpholin-4-yl)-azetidine-1-carboxylic acidtert-butyl ester (3.35 g, 11.5 mmol) and TFA (15 mL) in DCM (30 mL) wasstirred at room temperature for 2 h. The reaction mixture was loadedonto an Isolute® SCX-2 cartridge which was washed with MeOH/DCM and theproduct eluted with 2M NH₃/MeOH affording 4-Azetidin-3-yl-thiomorpholine1,1-dioxide as a white solid (2.0 g, 91%). ¹H NMR (CDCl₃, 300 MHz): δ3.64-3.53 (m, 4H); 3.49-3.39 (m, 1H); 3.08 (m, 4H); 2.86-2.79 (m, 4H);1.83 (s, 1H).

Example 7 Methyl(piperidin-4-yl)(tetrahydro-furan-3-yl)amine

Step 1: 4-[Methyl(tetrahydrofuran-3-yl)amino]piperidine-1-carboxylicacid tert-butyl ester

A mixture of 4-(methylamino)piperidine-1-carboxylic acid tert-butylester (200 mg, 0.93 mmol), dihydrofuran-3-one (145 μl, 161 mg, 1.87mmol), 4 Å powdered molecular sieves (550 mg) and DIPEA (323 μl, 241 mg,1.87 mmol) in DCM (10 mL) was stirred at room temperature for 30 minbefore the addition of sodium triacetoxyborohydride (396 mg, 1.87 mmol).The reaction mixture was stirred at room temperature for 16 h thendiluted with DCM and washed with H₂O. The organic phase was dried(Na₂SO₄) and concentrated in vacuo. The resulting residue was purifiedby column chromatography (Si—PCC, MeOH:DCM, 0-10%) affording the titlecompound as an oil (132 mg, 50%). ¹H NMR (CDCl₃, 300 MHz): δ 4.33-4.05(m, 2H); 4.01-3.91 (m, 1H); 3.90-3.73 (m, 2H); 3.68-3.48 (m, 1H);3.47-3.23 (m, 1H); 2.72-2.56 (m, 2H); 2.21 (s, 3H); 2.11-1.94 (m, 1H);1.93-1.78 (m, 1H); 1.76-1.63 (m, 2H); 1.76-1.63 (m, 1H); 1.54-1.46 (m,2H); 1.46 (s, 9H).

Step 2: A mixture of4-[methyl(tetrahydrofuran-3-yl)amino]piperidine-1-carboxylic acidtert-butyl ester (132 mg, 0.46 mmol) and TFA (2 mL) in DCM (5 mL) wasstirred at room temperature for 2 h. The reaction mixture was loadedonto an Isolute® SCX-2 cartridge which was washed with MeOH/DCM and theproduct eluted with 2M NH₃/MeOH affordingMethyl(piperidin-4-yl)(tetrahydro-furan-3-yl)amine as a white solid (84mg, quant.). ¹H NMR (CDCl₃, 300 MHz): δ 3.98-3.91 (m, 1H); 3.88-3.83 (m,1H); 3.80-3.73 (m, 1H); 3.61-3.53 (m, 1H); 3.42-3.35 (m, 1H); 3.26-3.14(m, 2H); 2.71-2.53 (m, 2H); 2.57-2.46 (m, 1H); 2.23 (s, 3H); 2.05-1.97(m, 1H); 1.93-1.77 (m, 1H); 1.78-1.72 (m, 2H); 1.64-1.49 (m, 2H).

Example 8 Methylpiperidin-4-yl(tetrahydropyran-4-yl)amine

Step 1: 4-[Methyl(tetrahydropyran-4-yl)amino]piperidine-1-carboxylicacid tert-butyl ester

A mixture of 4-methylaminopiperidine-1-carboxylic acid tert-butyl ester(200 mg, 0.93 mmol), tetrahydropyran-3-one (187 mg, 1.87 mmol), 4 Åpowdered molecular sieves (550 mg) and DIPEA (323 μl, 241 mg, 1.87 mmol)in DCM (10 mL) was stirred at room temperature for 30 min before theaddition of sodium triacetoxyborohydride (396 mg, 1.87 mmol). Thereaction mixture was stirred at room temperature for 16 h then dilutedwith DCM and washed with H₂O. The organic phase was dried (Na₂SO₄) andconcentrated in vacuo. The resulting residue was purified by columnchromatography (Si—PCC, MeOH:DCM, 0-10%) affording4-[Methyl(tetrahydropyran-4-yl)amino]piperidine-1-carboxylic acidtert-butyl ester as an oil (101 mg, 36%). ¹H NMR (CDCl₃, 300 MHz): δ4.24-4.07 (m, 2H); 4.06-3.96 (m, 2H); 3.43-3.32 (m, 2H); 2.78-2.63 (m,4H); 2.25 (s, 3H); 1.77-1.60 (m, 8H); 1.46 (s, 9H).

Step 2: A mixture of4-[methyl(tetrahydropyran-4-yl)-amino]-piperidine-1-carboxylic acidtert-butyl ester (101 mg, 0.34 mmol) and TFA (2 mL) in DCM (5 mL) wasstirred at room temperature for 2 h. The reaction mixture was loadedonto an Isolute® SCX-2 cartridge which was washed with MeOH/DCM and theproduct eluted with 2M NH₃/MeOH affordingMethylpiperidin-4-yl(tetrahydropyran-4-yl)amine as a white solid (66 mg,97%). ¹H NMR (CDCl₃, 300 MHz): δ 4.05-3.97 (m, 2H); 3.38 (td, J=10.9,3.8 Hz, 2H); 3.19 (d, J=12.1 Hz, 2H); 2.84-2.57 (m, 5H); 2.27 (s, 3H);1.80-1.49 (m, 8H).

Example 9 Methyl(oxetan-3-yl)piperidin-4-ylamine

Step 1: 4-(Methyl(oxetan-3-yl)amino)piperidine-1-carboxylic acidtert-butyl ester

A mixture of 4-(methylamino)piperidine-1-carboxylic acid tert-butylester (200 mg, 0.93 mmol) and oxetan-3-one (56 mg, 0.78 mmol) in DCE (6mL) was stirred at room temperature for 2 h before the addition ofsodium triacetoxyborohydride (264 mg, 1.24 mmol). The resulting mixturewas stirred for 16 h, then loaded onto an Isolute® SCX-2 cartridge whichwas washed with MeOH/DCM and the product eluted with 2M NH₃/MeOH. Theresulting oil was purified by column chromatography (Si—PCC, MeOH/DCM,0-20%) affording 4-(Methyl(oxetan-3-yl)amino)piperidine-1-carboxylicacid tert-butyl ester as an oil (40 mg, 16%). ¹H NMR (CDCl₃, 300 MHz): δ4.66 (t, J=6.6 Hz, 2H); 4.61 (t, J=6.6 Hz, 2H); 4.16 (s, 2H); 3.95 (p,J=6.6 Hz, 1H); 2.63 (t, J=12.5 Hz, 2H); 2.39 (tt, J=11.7, 3.7 Hz, 1H);2.20 (s, 3H); 1.60 (d, J=12.5 Hz, 2H); 1.46 (s, 9H); 1.44-1.28 (m, 2H).

Step 2: A mixture of 4-(methyl(oxetan-3-yl)amino)piperidine-1-carboxylicacid tert-butyl ester (150 mg, 0.55 mmol) and TFA (4 mL) in DCM (10 mL)was stirred at room temperature for 2 h. The reaction mixture was loadedonto an Isolute® SCX-2 cartridge which was washed with MeOH/DCM and theproduct eluted with 2M NH₃/MeOH affordingMethyl(oxetan-3-yl)piperidin-4-ylamine as a white solid (94 mg, quant.).¹H NMR (CDCl₃, 300 MHz): δ 4.67 (t, J=6.7 Hz, 2H); 4.61 (t, J=6.7 Hz,2H); 3.97 (p, J=6.7 Hz, 1H); 3.14 (d, J=12.3 Hz, 2H); 2.56 (td, J=12.2,4.0 Hz, 2H); 2.48-2.26 (m, 2H); 2.22 (s, 3H); 1.63 (d, J=12.3 Hz, 2H);1.40 (qd, J=12.2, 4.0 Hz, 2H).

Example 10 4-Azetidin-3-ylpiperazin-2-one

Step 1: 3-(3-Oxopiperazin-1-yl)azetidine-1-carboxylic acid tert-butylester

A mixture of piperazin-2-one (1.52 g, 15.1 mmol),3-oxoazetidine-1-carboxylic acid tert-butyl ester (2.0 g, 11.6 mmol) andtrimethyl orthoformate (12.8 mL, 12.4 g, 117 mmol) in AcOH (0.7 mL) andDCE (50 mL) was stirred for 5 h before the addition oftriacetoxyborohydride (4.9 g, 23.2 mmol). The resulting mixture wasstirred for 16 h then partitioned between DCM and H₂O. The organic layerwas dried (Na₂SO₄) and concentrated in vacuo. The resulting oil waspurified by column chromatography (Si—PCC, MeOH:DCM, 0-10%) affordingthe title compound as a foam (827 mg, 28%). ¹H NMR (CDCl₃, 300 MHz): δ6.24 (s, 1H); 3.97 (dd, J=8.9, 7.1 Hz, 2H); 3.82 (dd, J=5.2, 2.2 Hz,2H); 3.40 (td, J=5.2, 2.2 Hz, 2H); 3.24-3.15 (m, 1H); 3.07 (s, 2H); 2.60(t, J=5.4 Hz, 2H); 1.44 (s, 9H).

Step 2: A mixture of 3-(3-oxopiperazin-1-yl)azetidine-1-carboxylic acidtert-butyl ester (400 mg, 1.57 mmol) and TFA (3 mL) in DCM (6 mL) wasstirred at room temperature for 2 h. The reaction mixture was loadedonto an Isolute® SCX-2 cartridge which was washed with MeOH/DCM and theproduct eluted with 2M NH₃/MeOH affording 4-Azetidin-3-ylpiperazin-2-oneas a white solid (227 mg, 93%). ¹H NMR (CDCl₃, 300 MHz): δ 6.08 (s, 1H);3.63-3.56 (m, 3H); 3.42-3.35 (m, 3H); 3.31 (t, J=6.74 Hz, 1H); 3.03 (s,2H); 2.59-2.51 (m, 2H).

Example 11 (S)-1-Azetidin-3-ylpyrrolidin-3-ol

Step 1: 3-((S)-3-Hydroxypyrrolidin-1-yl)azetidine-1-carboxylic acidtert-butyl ester

A mixture of (S)-pyrrolidin-3-ol (261 mg, 3.0 mmol),3-oxoazetidine-1-carboxylic acid tert-butyl ester (513 mg, 3.0 mmol) and4 Å powdered molecular sieves (1.0 g) in DCE (10 mL) was stirred at roomtemperature for 6 h before the addition of sodium triacetoxyborohydride(1.27 g, 6.0 mmol). The reaction mixture was filtered through celite,washing with DCM. The filtrate was concentrated in vacuo and theresulting residue was purified by column chromatography (Si—PCC,Acetone:DCM, 0-40%) affording3-((S)-3-Hydroxypyrrolidin-1-yl)azetidine-1-carboxylic acid tert-butylester as a brown oil (390 mg, 54%). LCMS (Method A): R_(T) 0.28 min[M+H]⁺ 243.0

Step 2: A mixture of3-((S)-3-hydroxypyrrolidin-1-yl)azetidine-1-carboxylic acid tert-butylester (390 mg, 1.61 mmol) and TFA (2 mL) in DCM (4 mL) was stirred atroom temperature for 2 h. The reaction mixture was loaded onto anIsolute® SCX-2 cartridge which was washed with MeOH/DCM and the producteluted with 2M NH₃/MeOH affording the title compound as a white solid(244 mg, quant.). ¹H NMR (CDCl₃, 300 MHz): δ 4.40-4.33 (m, 1H);3.70-3.60 (m, 4H); 3.44-3.34 (m, 1H); 2.88-2.77 (m, 1H); 2.73-2.52 (m,3H); 2.47 (dd, J=10.1, 5.2 Hz, 1H); 2.30-2.12 (m, 2H); 1.84-1.69 (m,1H).

Example 12 (R)-1-Azetidin-3-ylpyrrolidin-3-ol

Step 1: 3-((R)-3-Hydroxypyrrolidin-1-yl)azetidine-1-carboxylic acidtert-butyl ester

A mixture of 1-pyrrolidin-3-ol (261 mg, 3.0 mmol),3-oxoazetidine-1-carboxylic acid tert-butyl ester (513 mg, 3.0 mmol) and4 Å powdered molecular sieves (1.0 g) in DCE (10 mL) was stirred at roomtemperature for 6 h before the addition of sodium triacetoxyborohydride(1.27 g, 6.0 mmol). The reaction mixture was filtered through celite,washing with DCM. The filtrate was concentrated in vacuo and theresulting residue was purified by column chromatography (Si—PCC,Acetone:DCM, 0-40%) affording3-((R)-3-Hydroxypyrrolidin-1-yl)azetidine-1-carboxylic acid tert-butylester as a brown oil (479 mg, 66%). LCMS (Method A): R_(T) 0.28 min[M+H]⁺ 243.0

Step 2: A mixture of3-(I-3-Hydroxypyrrolidin-1-yl)azetidine-1-carboxylic acid tert-butylester (479 mg, 1.98 mmol) and TFA (3 mL) in DCM (6 mL) was stirred atroom temperature for 2 h. The reaction mixture was loaded onto anIsolute® SCX-2 cartridge, washed with MeOH/DCM and eluted with 2MNH₃/MeOH affording the title compound as a white solid (260 mg, 92%). ¹HNMR (CDCl₃, 300 MHz): δ 4.41-4.33 (m, 1H); 3.69-3.58 (m, 4H); 3.45-3.32(m, 1H); 2.88-2.79 (m, 1H); 2.65 (d, J=10.1 Hz, 1H); 2.55-2.41 (m, 3H);2.30-2.12 (m, 2H); 1.83-1.70 (m, 1H).

Example 13 1-Methylpiperazin-2-one

Step 1: 4-Methyl-3-oxopiperazine-1-carboxylic acid tert-butyl ester

To a solution of 3-oxopiperazine-1-carboxylic acid tert-butyl ester (500mg, 2.50 mmol) in DMF (20 mL) cooled on an ice-bath was added sodiumhydride (120 mg, 3.00 mmol, 60% dispersion in mineral oil) and theresulting mixture stirred for 10 min. Methyl iodide (233 μL, 532 mg,3.75 mmol) was added and the resulting mixture stirred at roomtemperature for 18 h. The reaction mixture was quenched with H₂O andextracted with EtOAc. The combined organics were dried (Na₂SO₄) andconcentrated in vacuo affording 4-Methyl-3-oxopiperazine-1-carboxylicacid tert-butyl ester as a yellow oil (300 mg, 56%). ¹H NMR (CDCl₃, 300MHz): δ 4.08 (s, 2H); 3.65 (t, J=5.4 Hz, 2H); 3.35 (t, J=5.4 Hz, 2H);3.00 (s, 3H); 1.47 (s, 9H).

Step 2: A mixture of 4-methyl-3-oxopiperazine-1-carboxylic acidtert-butyl ester (300 mg, 1.40 mmol) and TFA (1 mL) in DCM (2 mL) wasstirred at room temperature for 2 h. The reaction mixture was loadedonto an Isolute® SCX-2 cartridge, washed with MeOH/DCM and eluted with2M NH₃/MeOH affording 1-Methylpiperazin-2-one as a white solid (128 mg,80%). ¹H NMR (CDCl₃, 300 MHz): δ 3.52 (s, 2H); 3.32 (t, J=5.5 Hz, 2H);3.09 (t, J=5.5 Hz, 2H); 2.97 (s, 3H); 1.83 (s, 1H).

Example 14 4-Azetidin-3-yl-1-methylpiperazin-2-one

Step 1: 3-(4-Methyl-3-oxopiperazin-1-yl)azetidine-1-carboxylic acidtert-butyl ester

A mixture of 1-methylpiperazin-2-one (128 mg, 1.12 mmol),3-oxoazetidine-1-carboxylic acid tert-butyl ester (231 mg, 1.35 mmol)and 4 Å powdered molecular sieves (150 mg) in DCE (4 mL) was stirred atroom temperature for 1.5 h before the addition of sodiumtriacetoxyborohydride (475 mg, 2.24 mmol). The reaction mixture wasfiltered through celite, washing with DCM. The filtrate was concentratedin vacuo and the resulting residue was purified by column chromatography(Si—PCC, MeOH:EtOAc, 0-10%) affording3-(4-Methyl-3-oxopiperazin-1-yl)azetidine-1-carboxylic acid tert-butylester as an oil (211 mg, 70%). ¹H NMR (CDCl₃, 300 MHz): δ 3.99-3.92 (m,2H); 3.81 (dd, J=8.8, 5.1 Hz, 2H); 3.36 (t, J=5.5 Hz, 2H); 3.20-3.14 (m,1H); 3.08 (t, J=5.5 Hz, 2H); 2.97 (s, 3H); 2.70-2.56 (m, 2H); 1.44 (s,9H).

Step 2: A mixture of3-(4-methyl-3-oxopiperazin-1-yl)azetidine-1-carboxylic acid tert-butylester (211 mg, 0.78 mmol) and TFA (2 mL) in DCM (4 mL) was stirred atroom temperature for 2 h. The reaction mixture was loaded onto anIsolute® SCX-2 cartridge which was washed with MeOH/DCM and the producteluted with 2M NH₃/MeOH affording4-Azetidin-3-yl-1-methylpiperazin-2-one as a white solid (125 mg, 95%).¹H NMR (CDCl₃, 300 MHz): δ 3.63 (m, 4H); 3.37-3.27 (m, 3H); 3.03 (s,2H); 2.96 (s, 3H); 2.58 (t, J=5.6 Hz, 2H); 2.13-1.97 (m, 1H).

Example 15 2-Azetidin-3-ylpropan-2-ol

Step 1: 3-(1-Hydroxy-1-methylethyl)azetidine-1-carboxylic acidtert-butyl ester

A 50 mL round-bottomed flask was charged with a solution ofazetidine-1,3-dicarboxylic acid 1-tert-butyl ester 3-methyl ester (1 g,4.65 mmol) in anhydrous THF (10 mL) at 4° C., under argon. A 3.0 Msolution of methylmagnesium bromide in Et₂O (3.72 mL, 11.15 mmol) wasadded dropwise over 5 min and the reaction mixture was stirred for 5 hat room temperature. The reaction was quenched with a saturated aqueoussolution of NH₄Cl (5 mL) and water (10 mL). The aqueous phase wasextracted with EtOAc (20 mL). The organic layer was dried over sodiumsulphate and concentrated in vacuo to give3-(1-Hydroxy-1-methylethyl)azetidine-1-carboxylic acid tert-butyl esteras a colourless oil (0.8 g, 80%). ¹H NMR (CDCl₃, 400 MHz) δ 3.95-3.75(m, 4H); 2.60-2.50 (m, 1H); 1.43 (s, 9H); 1.17 (s, 6H).

Step 2: A 25 mL round-bottomed flask was charged with a solution of3-(1-hydroxy-1-methylethyl)azetidine-1-carboxylic acid tert-butyl ester(0.8 g, 3.72 mmol) in DCM/TFA (3 mL/3 mL). The reaction mixture wasstirred for 1 h at room temperature. The reaction mixture was loadedonto an Isolute® SCX-2 cartridge. The cartridge was washed with MeOH andthe desired product was eluted using 2 M NH₃ in MeOH to give2-Azetidin-3-ylpropan-2-ol as a white solid (0.36 g, 84%). ¹H NMR(CDCl₃, 400 MHz) δ 3.55-3.62 (m, 4H); 2.75-2.65 (m, 1H); 1.15 (s, 6H).

Example 16 3-Fluoro-[1,3]biazetidinyl

Step 1: 3-Fluoro-[1,3′]biazetidinyl-1′-carboxylic acid tert-butyl ester

A 10 mL round-bottomed flask was charged with a solution of3-oxoazetidine-1-carboxylic acid tert-butyl ester (0.14 g, 0.82 mmol),3-fluoroazetidine hydrochloride (0.1 g, 0.9 mmol) in DCE (3 mL),trimethoxymethane (0.88 mL, 8.5 mmol) and acetic acid (0.046 mL, 0.81mmol). The reaction mixture was stirred for 3 h at room temperature.Sodium triacetoxyborohydride (0.26 g, 1.22 mmol) was added and thereaction mixture was stirred for 18 h at room temperature. The reactionmixture was partitioned between DCM and water; the organic phase waswashed with brine, dried over sodium sulphate and concentrated. Theresidue was purified by flash chromatography (Si—PPC, EtOAc:cyclohexane,gradient 40:60 to 100:0) to give3-Fluoro-[1,3]biazetidinyl-1′-carboxylic acid tert-butyl ester as acolourless oil (0.109 g, 59%). ¹H NMR (CDCl₃, 400 MHz) δ 5.15 (dt,J=57.1, 5.3 Hz, 1H); 3.93 (dd, J=9.1, 7.0 Hz, 2H); 3.74-3.59 (m, 4H);3.45-3.38 (m, 1H); 3.31-3.25 (m, 1H); 3.23-3.17 (m, 1H); 1.43 (s, 9H).

Step 2: A 25 mL round-bottomed flask was charged with a solution of3-fluoro-[1,3′]biazetidinyl-1′-carboxylic acid tert-butyl ester (0.109g, 0.47 mmol) in DCM/TFA (2 mL/2 mL). The reaction mixture was stirredfor 90 min at room temperature. The reaction mixture was loaded onto anIsolute® SCX-2 cartridge. The cartridge was washed with MeOH and thedesired product was eluted using 2 M NH₃ in MeOH to give3-Fluoro-[1,3′]biazetidinyl as a colourless oil (0.058 g, 94%). ¹H NMR(CDCl₃, 400 MHz) δ 5.14 (dp, J=57.2, 5.3 Hz, 1H); 3.75-3.46 (m, 8H);3.34-3.24 (m, 1H); 3.27-3.10 (m, 1H).

Example 17 1-Azetidin-3-ylpiperidin-4-ol

Step 1: 3-(4-Hydroxypiperidin-1-yl)azetidine-1-carboxylic acidtert-butyl ester

A 10 mL round-bottomed flask was charged with a solution of3-oxoazetidine-1-carboxylic acid tert-butyl ester (1 g, 5.84 mmol),4-hydroxypiperidine (0.65 g, 6.42 mmol) and 4 Å molecular sieves (10 g)in DCE (50 mL). The reaction mixture was stirred for 4 h at roomtemperature. Sodium triacetoxyborohydride (2.48 g, 11.68 mmol) was addedand the reaction mixture was stirred for 18 h at room temperature. Thesuspension was filtered through Celite and the filtrate was concentratedin vacuo. The residue was purified by flash chromatography (Si—PPC,EtOAc:cyclohexane, gradient 0:100 to 100:0) to give3-(4-Hydroxypiperidin-1-yl)azetidine-1-carboxylic acid tert-butyl esteras a colourless oil (0.34 g, 23%). ¹H NMR (CDCl₃, 400 MHz) δ 3.92 (t,J=7.8 Hz, 2H); 3.87-3.72 (m, 3H); 3.07 (m, 1H); 2.68-2.63 (m, 2H);2.09-2.03 (m, 2H); 1.96-1.91 (m, 2H); 1.69-1.55 (m, 2H); 1.43 (s, 9H).

Step 2: A 25 mL round-bottomed flask was charged with a solution of3-(4-hydroxypiperidin-1-yl)azetidine-1-carboxylic acid tert-butyl ester(0.34 g, 1.33 mmol) in DCM/TFA (4 mL/4 mL). The reaction mixture wasstirred for 7 h at room temperature. The reaction mixture was loadedonto an Isolute® SCX-2 cartridge. The cartridge was washed with MeOH andthe desired product was eluted using 2 M NH₃ in MeOH to give1-Azetidin-3-ylpiperidin-4-ol as a colourless oil (0.194 g, 94%). ¹H NMR(CDCl₃, 400 MHz) δ 3.75-3.68 (m, 1H); 3.67-3.51 (m, 4H); 3.25-3.17 (m,1H); 2.66-2.56 (m, 3H); 2.03-1.84 (m, 5H); 1.65-1.53 (m, 2H).

Example 18 1-Azetidin-3-yl-4-fluoropiperidine

Step 1: 3-(4-Fluoropiperidin-1-yl)azetidine-1-carboxylic acid tert-butylester

A 10 mL round-bottomed flask was charged with a solution of3-oxoazetidine-1-carboxylic acid tert-butyl ester (1 g, 5.84 mmol),4-fluoropiperidine hydrochloride (0.97 g, 6.42 mmol) and 4 Å molecularsieves (10 g) in DCE (50 mL). The reaction mixture was stirred for 4 hat room temperature. Sodium triacetoxyborohydride (2.48 g, 11.68 mmol)was added and the reaction mixture was stirred for 18 h at roomtemperature. The suspension was filtered through Celite and the filtratewas concentrated in vacuo. The residue was purified by flashchromatography (Si—PPC, EtOAc:cyclohexane, gradient 0:100 to 100:0) then(Si—PPC, MeOH:DCM, 0:100 to 5:95) to give3-(4-Fluoropiperidin-1-yl)azetidine-1-carboxylic acid tert-butyl esteras a colourless oil (0.59 g, 39%). ¹H NMR (CDCl₃, 400 MHz) δ 4.80-4.58(m, 1H); 3.97-3.89 (m, 2H); 3.85-3.76 (m, 2H); 3.08 (t, J=6.4 Hz, 1H);2.50-2.28 (m, 4H); 1.99-1.82 (m, 4H); 1.48-1.38 (m, 9H).

Step 2: A 25 mL round-bottomed flask was charged with a solution of3-(4-fluoro-piperidin-1-yl)-azetidine-1-carboxylic acid tert-butyl ester(0.59 g, 2.26 mmol) in DCM/TFA (4 mL/4 mL). The reaction mixture wasstirred for 6 h at room temperature. The reaction mixture was loadedonto an Isolute® SCX-2 cartridge. The cartridge was washed with MeOH andthe desired product was eluted using 2 M NH₃ in MeOH to give1-Azetidin-3-yl-4-fluoropiperidine as a pale yellow oil (0.263 g, 74%).¹H NMR (CDCl₃, 400 MHz) δ 4.60 (m, 1H); 3.64-3.52 (m, 4H); 3.26-3.18 (m,1H); 2.45-2.38 (m, 2H); 2.28-2.17 (m, 2H); 1.96-1.81 (m, 4H)

Example 19 1-Azetidin-3-yl-4,4-difluoropiperidine

Step 1: 3-(4,4-Difluoropiperidin-1-yl)azetidine-1-carboxylic acidtert-butyl ester

A 10 mL round-bottomed flask was charged with a solution of3-oxoazetidine-1-carboxylic acid tert-butyl ester (0.51 g, 3 mmol),4,4-difluoropiperidine hydrochloride (0.71 g, 4.5 mmol) and 4 Åmolecular sieves (0.8 g) in DCE (8 mL). The reaction mixture was stirredfor 7 h at room temperature. Sodium triacetoxyborohydride (1.27 g, 6mmol) was added and the reaction mixture was stirred for 18 h at roomtemperature. The suspension was filtered through Celite and the filtratewas concentrated in vacuo. The residue was purified by flashchromatography (Si—PPC, EtOAc: cyclohexane, gradient 0:100 to 75:25) togive 3-(4,4-Difluoropiperidin-1-yl)azetidine-1-carboxylic acidtert-butyl ester as a yellow oil (0.69 g, 83%). ¹H NMR (CDCl₃, 400 MHz)δ 3.94 (dd, J=8.7, 7.1 Hz, 2H); 3.78 (dd, J=8.7, 5.3 Hz, 2H); 3.17-3.10(m, 1H); 2.45-2.41 (m, 4H); 2.10-1.94 (m, 4H); 1.43 (s, 9H).

Step 2: A 25 mL round-bottomed flask was charged with a solution of3-(4,4-difluoropiperidin-1-yl)azetidine-1-carboxylic acid tert-butylester (0.684 g, 2.47 mmol) in DCM/TFA (4 mL/4 mL). The reaction mixturewas stirred for 3 h at room temperature. The reaction mixture was loadedonto an Isolute® SCX-2 cartridge. The cartridge was washed with MeOH andthe desired product was eluted using 2 M NH₃ in MeOH to give1-Azetidin-3-yl-4,4-difluoropiperidine as a pale yellow oil (0.279 g,64%). ¹H NMR (CDCl₃, 400 MHz) δ 3.64-3.54 (m, 4H); 3.30-3.25 (m, 1H);2.43-2.37 (m, 4H); 2.06-1.93 (m, 5H).

Example 20 [1,3′]Biazetidinyl-3-ol

Step 1: 3-Hydroxy-[1,3′]biazetidinyl-1′-carboxylic acid tert-butyl ester

A 10 mL round-bottomed flask was charged with a solution of3-oxoazetidine-1-carboxylic acid tert-butyl ester (0.52 g, 3.1 mmol),azetidin-3-ol hydrochloride (0.5 g, 4.6 mmol) and 4 Å molecular sieves(0.7 g) in DCE (8 mL). The reaction mixture was stirred for 7 h at roomtemperature. Sodium triacetoxyborohydride (1.3 g, 6.13 mmol) was addedand the reaction mixture was stirred for 18 h at room temperature. Thesuspension was filtered through Celite and the filtrate was concentratedin vacuo. The residue was purified by flash chromatography (Si—PPC,MeOH:DCM, gradient 0:100 to 40:60) to give3-Hydroxy-[1,3]biazetidinyl-1′-carboxylic acid tert-butyl ester asyellow oil (0.69 g, 99%). ¹H NMR (CDCl₃, 400 MHz) δ 4.45-4.35 (m, 1H);3.96 (dd, J=9.3, 6.7 Hz, 2H); 3.74 (dd, J=9.3, 4.5 Hz, 2H); 3.66 (td,J=8.8, 6.7 Hz, 2H); 3.40-3.37 (m, 1H); 3.20 (td, J=8.8, 4.5 Hz, 2H);1.43 (s, 9H).

Step 2: A 25 mL round-bottomed flask was charged with a solution of3-hydroxy-[1,3′]biazetidinyl-1′-carboxylic acid tert-butyl ester (0.69g, 3.05 mmol) in DCM/TFA (4 mL/4 mL). The reaction mixture was stirredfor 30 min at room temperature. The reaction mixture was loaded onto anIsolute® SCX-2 cartridge. The cartridge was washed with MeOH and thedesired product was eluted using 2 M NH₃ in MeOH to give[1,3′]Biazetidinyl-3-ol as a colourless oil (0.225 g, 58%). LCMS (MethodA): R_(T)=0.29 min, [M+H]⁺ 288.9

Example 21 1-Azetidin-3-yl-4-methylpiperidin-4-ol

Step 1: 3-(4-Hydroxy-4-methylpiperidin-1-yl)azetidine-1-carboxylic acidtert-butyl ester

A 50 mL round-bottomed flask was charged with a solution of3-oxoazetidine-1-carboxylic acid tert-butyl ester (0.57 g, 3.33 mmol),4-methylpiperidin-4-ol (0.46 g, 3.99 mmol) and 4 Å molecular sieves(3.34 g) in DCE (20 mL). The reaction mixture was stirred for 6 h atroom temperature. Sodium triacetoxyborohydride (1.41 g, 6.66 mmol) wasadded and the reaction mixture was stirred for 18 h at room temperature.The suspension was filtered through Celite and the solution wasconcentrated in vacuo. The residue was purified by flash chromatography(Si—PPC, EtOAc:cyclohexane, 0:100 to 100:0) to give3-(4-Hydroxy-4-methylpiperidin-1-yl)azetidine-1-carboxylic acidtert-butyl ester as a colourless oil (0.49 g, 55%). ¹H NMR (CDCl₃, 400MHz) δ 3.93 (dd, J=8.7, 7.17 Hz, 2H); 3.82 (dd, J=8.7, 5.5 Hz, 2H);3.15-3.07 (m, 1H); 2.58-2.44 (m, 2H); 2.27 (td, J=11.0, 3.5 Hz, 2H);1.77-1.54 (m, 4H); 1.42 (s, 9H); 1.26 (t, J=6.7 Hz, 3H).

Step 2: A 25 mL round-bottomed flask was charged with a solution of3-(4-hydroxy-4-methylpiperidin-1-yl)azetidine-1-carboxylic acidtert-butyl ester (0.2 g, 0.74 mmol) in DCM/TFA (3 mL/3 mL). The reactionmixture was stirred for 4 h at room temperature. The reaction mixturewas loaded onto an Isolute® SCX-2 cartridge. The cartridge was washedwith MeOH and the desired product was eluted using 2 M NH₃ in MeOH togive 1-Azetidin-3-yl-4-methylpiperidin-4-ol as a colourless oil (0.107g, 85%). ¹H NMR (CDCl₃, 400 MHz) δ 3.61 (t, J=7.3 Hz, 2H); 3.54 (t,J=7.3 Hz, 2H); 3.29-3.15 (m, 1H); 3.04 (s, 2H); 2.40 (d, J=10.8 Hz, 2H);2.30-2.18 (m, 2H); 1.67-1.56 (m, 4H); 1.23 (s, 3H).

Example 22 4-Oxetan-3-ylpiperazine-1-carboxylic acid tert-butyl ester

A solution of piperazine-1-carboxylic acid tert-butyl ester (1.56 g,8.38 mmol) and oxetan-3-one (500 mg, 6.94 mmol) DCE (60 mL) was stirredat ambient temperature for 90 min. Sodium triacetoxyborohydride (2.34 g,11.04 mmol) was added and the mixture stirred for 17 h, then loaded ontoan Isolute® SCX-2 cartridge (25 g). The cartridge was then washed withmethanol and the desired product was subsequently eluted using 2 M NH₃in MeOH. The product was collected and concentrated in vacuo. Theresultant residue was purified by flash chromatography (Si—PPC,DCM:MeOH; 100:0 to 99:1 to 98:2) to afford4-Oxetan-3-ylpiperazine-1-carboxylic acid tert-butyl ester as a whitesolid (1.0 g, 59%). ¹H NMR (CDCl₃, 400 MHz) δ 4.69-4.58 (m, 4H);3.51-3.44 (m, 5H); 2.27 (m, 4H) and 1.46 (s, 9H).

Example 23 2-Hydroxy-2-methyl-7-azaspiro[3.5]nonane-7-carboxylic acidbenzyl ester

To a stirred solution of 2-oxo-7-azaspiro[3.5]nonane-7-carboxylic acidbenzyl ester (164 mg, 0.60 mmol) in dry THF (2 mL) was added dropwise a1.4 M solution of methylmagnesium bromide in toluene/THF (0.56 mL, 0.78mmol) under an atmosphere of nitrogen, at −78° C. After 1 h the solutionwas quenched with saturated NH₄Cl_((aq)) and the resulting mixturepartitioned between EtOAc and water. The organic layer was dried(Na₂SO₄) and evaporated to give a residue, which was purified by columnchromatography (Si—PCC, 0-70% EtOAc in cyclohexane) to give2-Hydroxy-2-methyl-7-azaspiro[3.5]nonane-7-carboxylic acid benzyl ester(96 mg, 55%) as a colourless oil. LCMS (Method H): R_(T) 4.13 min,[M+H]⁺ 290.4

Example 24 Azetidin-1-yl-1-pyrrolidin-3-ylmethanone

Azetidine hydrochloride (96 mg, 1.03 mmol) was added to a solution of1-pyrrolidine-1,3-dicarboxylic acid 1-tert-butyl ester (200 mg, 0.93mmol), HATU (391 mg, 1.03 mmol) and DIPEA (410 μL, 2.35 mmol) in DMF (17mL) and the resulting mixture stirred at ambient temperature for 1 h,then concentrated in vacuo. The resulting oil was partitioned betweenEtOAc and water. The organic layer was separated, washed with water andbrine, then dried (MgSO₄) and concentrated in vacuo to giveI-3-(azetidine-1-carbonyl)-pyrrolidine-1-carboxylic acid tert-butylester as a colourless oil. TFA (3 mL) was added to a solution ofI-3-(azetidine-1-carbonyl)pyrrolidine-1-carboxylic acid tert-butyl esterin DCM (10 mL) and the mixture stirred at ambient temperature for 1 h,then loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge wasthen washed with methanol and the desired product was subsequentlyeluted using 2 M NH₃ in MeOH. The product was collected and concentratedin vacuo to afford Azetidin-1-yl-1-pyrrolidin-3-ylmethanone as a brownoil (77 mg, 54%). ¹H NMR (CDCl₃, 400 MHz) δ 4.18 (t, J=7.7 Hz, 2H); 4.01(t, J=7.7 Hz, 2H); 3.18-3.04 (m, 3H); 2.96 (m, 1H); 2.88-2.71 (m, 2H);2.35-2.23 (m, 2H) and 2.04-1.84 (m, 2H).

Example 25 Azetidin-1-yl-(S)-pyrrolidin-3-ylmethanone

Azetidine hydrochloride (96 mg, 1.03 mmol) was added to a solution of1-pyrrolidine-1,3-dicarboxylic acid 1-tert-butyl ester (200 mg, 0.93mmol), HATU (391 mg, 1.03 mmol) and DIPEA (410 μL, 2.35 mmol) in DMF (17mL) and the resulting mixture stirred at ambient temperature for 1 h,then concentrated in vacuo. The resulting oil was partitioned betweenEtOAc and water. The organic layer was separated, washed with water andbrine, then dried (MgSO₄) and concentrated in vacuo to giveI-3-(azetidine-1-carbonyl)pyrrolidine-1-carboxylic acid tert-butyl esteras a colourless oil. TFA (3 mL) was added to a solution ofI-3-(azetidine-1-carbonyl)pyrrolidine-1-carboxylic acid tert-butyl esterin DCM (10 mL) and the mixture stirred at ambient temperature for 1 h,then loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge wasthen washed with methanol and the desired product was subsequentlyeluted using 2 M NH₃ in MeOH. The product was collected and concentratedin vacuo to afford Azetidin-1-yl-(S)-pyrrolidin-3-ylmethanone as a brownoil (130 mg, 91%). ¹H NMR (CDCl₃, 400 MHz) δ 4.21-4.11 (m, 2H); 4.02 (t,J=7.7 Hz, 2H); 3.18-3.07 (m, 2H); 2.95 (dd, J=11.5, 7.7 Hz, 1H);2.88-2.71 (m, 1H); 2.33-2.22 (m, 2H); 2.15 (m, 2H) and 2.05-1.82 (m,2H).

Example 26 Pyrrolidin-1-yl-(R)-pyrrolidin-3-ylmethanone

Pyrrolidine (51 μL, 1.03 mmol) was added to a solution of1-pyrrolidine-1,3-dicarboxylic acid 1-tert-butyl ester (200 mg, 0.93mmol), HATU (391 mg, 1.03 mmol) and DIPEA (410 μL, 2.35 mmol) in DMF andthe resulting mixture stirred at ambient temperature for 1 h, thenconcentrated in vacuo. The resulting oil was partitioned between EtOAcand water. The organic layer was separated, washed with water and brine,then dried (MgSO₄) and concentrated in vacuo to giveI-3-(pyrrolidine-1-carbonyl)pyrrolidine-1-carboxylic acid tert-butylester as a colourless oil. TFA (3 mL) was added to a solution ofI-3-(pyrrolidine-1-carbonyl)pyrrolidine-1-carboxylic acid tert-butylester in DCM (10 mL) and the mixture stirred at ambient temperature for1 h, then loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridgewas then washed with methanol and the desired product was subsequentlyeluted using 2 M NH₃ in MeOH. The product was collected and concentratedin vacuo to afford Pyrrolidin-1-yl-(R)-pyrrolidin-3-ylmethanone as ayellow oil (121 mg, 77%). ¹H NMR (CDCl₃, 400 MHz) δ 3.50-3.42 (m, 3H);3.19 (s, 1H); 3.14 (s, 1H); 3.00 (s, 2H); 2.96-2.59 (m, 3H); 2.04-1.92(m, 3H) and 1.89-1.81 (m, 2H).

Example 27 Pyrrolidin-1-yl-(S)-pyrrolidin-3-ylmethanone

Pyrrolidine (51 μL, 1.03 mmol) was added to a solution of(S)-pyrrolidine-1,3-dicarboxylic acid 1-tert-butyl ester (200 mg, 0.93mmol), HATU (391 mg, 1.03 mmol) and DIPEA (410 μL, 2.35 mmol) in DMF andthe resulting mixture stirred at ambient temperature for 1 h, thenconcentrated in vacuo. The resulting oil was partitioned between EtOAcand water. The organic layer was separated, washed with water and brine,then dried (MgSO₄) and concentrated in vacuo to give(S)-3-(pyrrolidine-1-carbonyl)pyrrolidine-1-carboxylic acid tert-butylester as a colourless oil. TFA (3 mL) was added to a solution of(S)-3-(pyrrolidine-1-carbonyl)pyrrolidine-1-carboxylic acid tert-butylester in DCM (10 mL) and the mixture stirred at ambient temperature for1 h, then loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridgewas then washed with methanol and the desired product was subsequentlyeluted using 2 M NH₃ in MeOH. The product was collected and concentratedin vacuo to afford the title compound as a pale brown oil (110 mg, 70%).¹H NMR (CDCl₃, 400 MHz) δ 4.01 (m, 3H); 3.52-3.41 (m, 3H); 3.25-3.11 (m,2H); 3.10-2.97 (m, 2H); 2.89 (dt, J=11.4, 7.5 Hz, 1H); 2.11-1.99 (m,1H); 2.01-1.91 (m, 2H) and 1.93-1.82 (m, 2H).

Example 28 Azetidin-3-yl-azetidin-1-ylmethanone

Azetidine hydrochloride salt (515 mg, 5.50 mmol) was added to a solutionof azetidine-1,3-dicarboxylic acid mono-tert-butyl ester (1.0 g, 4.97mmol), HATU (2.09 g, 5.50 mmol) and DIPEA (2.18 mL, 12.52 mmol) in DMF(100 mL) and the resulting mixture stirred at ambient temperature for 1h, then concentrated in vacuo. The resulting oil was partitioned betweenEtOAc and water. The organic layer was separated, washed with water andbrine, then dried (MgSO₄) and concentrated in vacuo to give3-(azetidine-1-carbonyl)azetidine-1-carboxylic acid tert-butyl ester asa colourless oil. TFA (3 mL) was added to a solution of3-(azetidine-1-carbonyl)-azetidine-1-carboxylic acid tert-butyl ester inDCM (15 mL) and the mixture stirred at ambient temperature for 1 h, thenloaded onto an Isolute® SCX-2 cartridge (25 g). The cartridge was thenwashed with methanol and the desired product was subsequently elutedusing 2 M NH₃ in MeOH. The product was collected and concentrated invacuo to afford the title compound as a colourless oil (260 mg, 37%). ¹HNMR (CD₃OD, 400 MHz) δ 4.19-4.08 (m, 2H); 4.07-3.92 (m, 2H); 3.91-3.78(m, 2H); 3.72-3.52 (m, 3H) and 2.36-2.21 (m, 2H).

Example 29 Azetidin-3-yl-pyrrolidin-1-ylmethanone

Pyrrolidine (271 μL, 5.50 mmol) was added to a solution ofazetidine-1,3-dicarboxylic acid mono-tert-butyl ester (1.0 g, 4.97mmol), HATU (2.09 g, 5.50 mmol) and DIPEA (2.18 mL, 12.52 mmol) in DMF(100 mL) and the resulting mixture stirred at ambient temperature for 1h, then concentrated in vacuo. The resulting oil was partitioned betweenEtOAc and water. The organic layer was separated, washed with water andbrine, then dried (MgSO₄) and concentrated in vacuo to give3-(pyrrolidine-1-carbonyl)azetidine-1-carboxylic acid tert-butyl esteras a colourless oil. TFA (3 mL) was added to a solution of3-(pyrrolidine-1-carbonyl)-azetidine-1-carboxylic acid tert-butyl esterin DCM (15 mL) and the mixture stirred at ambient temperature for 1 h,then loaded onto an Isolute® SCX-2 cartridge (25 g). The cartridge wasthen washed with methanol and the desired product was subsequentlyeluted using 2 M NH₃ in MeOH. The product was collected and concentratedin vacuo to afford the title compound as a colourless oil (550 mg, 72%).¹H NMR (CD₃OD, 400 MHz) δ 3.93-3.65 (m, 5H); 3.43-3.28 (m, 4H) and2.00-1.81 (m, 4H).

Example 30 4-Oxetan-3-ylpiperidine

Step 1: 2-(1-(tert-Butoxycarbonyl)piperidin-4-ylidene)malonic aciddiethyl ester

To anhydrous THF (50 mL) at 0° C. a solution of TiCl₄ (13.75 mL, 0.126mol) in CCl₄ (10 mL) was added dropwise. To the resulting yellowsuspension were a solution of 4-oxopiperidine-1-carboxylic acidtert-butyl ester (10 g, 0.05 mol) and diethylmalonate (6.85 mL, 0.05mol) in anhydrous THF (50 mL) added, followed by addition of pyridine(26 mL). The dark yellow suspension was allowed to warm to ambienttemperature and stirred at ambient temperature for 17 h, thenpartitioned between EtOAc and citric acid (10%, aq.). The organic layerwas separated and washed with water and brine, then dried (MgSO₄) andconcentrated in vacuo to afford2-(1-(tert-Butoxycarbonyl)piperidin-4-ylidene)malonic acid diethyl esteras a brown oil (17 g, 100%). ¹H NMR (CDCl₃, 400 MHz) δ 4.27-4.18 (m,4H); 3.55-3.44 (m, 4H); 2.65 (m, 4H); 1.49 (s, 9H) and 1.32-1.26 (m,6H).

Step 2: 2-(1-(tert-Butoxycarbonyl)piperidin-4-yl)malonic acid diethylester

To IMS (200 mL) at 0° C., NaBH₄ (1.87 g, 0.047 mol) and a solution of2-(1-(tert-butoxycarbonyl)piperidin-4-ylidene)malonic acid diethyl ester(17 g, 0.050 mol) in IMS (200 mL) were added. The resulting mixture wasallowed to warm to ambient temperature and stirred for 1 h, thenquenched with water and concentrated in vacuo. The resulting oil wasthen partitioned between EtOAc and water. The organic layer wasseparated and washed with brine, then dried (MgSO₄) and concentrated invacuo to afford the title compound as a yellow oil (14.6 g, 85%). LCMS(Method H): R_(T)=3.90 min, [M+Na]⁺ 366.

Step 3: 4-(2-Hydroxy-1-(hydroxymethyl)ethyl)piperidine-1-carboxylic acidtert-butyl ester

To a solution of 2-(1-(tert-butoxycarbonyl)piperidin-4-yl)malonic aciddiethyl ester (14.6 g, 0.043 mol) in anhydrous THF (100 mL) andanhydrous toluene (100 mL), LiBH₄ (2.1 g. 0.96 mol) was added portionwise. The resulting mixture was heated at 60° C. for 17 h, then stirredat ambient temperature for 24 h. The reaction mixture was slowly addedto aqueous HCl (0.1 M, 350 mL) and then extracted with EtOAc. Theorganic layer was separated and washed with brine, then dried (MgSO₄)and concentrated in vacuo. The resultant residue was purified by flashchromatography (Si—PPC, EtOAc:MeOH 100:0 to 98:2 to 95:5 to 90:10 to80:20) to afford the title compound as a colourless oil (6.91 g, 63%).¹H NMR (CDCl₃, 400 MHz) δ 3.90-3.75 (m, 4H); 2.75-2.58 (m, 4H);1.77-1.61 (m, 4H); 1.52 (m, 1H); 1.45 (s, 9H) and 1.26-1.13 (m, 1H).

Step 4: To a solution of4-(2-hydroxy-1-(hydroxymethyl)ethyl)piperidine-1-carboxylic acidtert-butyl ester (7.62 g, 0.029 mol) in anhydrous THF (100 mL) at 0° C.,a solution of n-BuLi (1.6 M in hexanes, 18.4 mL, 0.029 mol) was addeddropwise. The resulting mixture was stirred at 0° C. for 30 min, then asolution of toluenesulfonyl chloride (5.26 g, 0.028 mol) in anhydrousTHF (50 mL) was added by canula. The thick reaction mixture was allowedto warm to ambient temperature and stirred for 2 h. A solution of n-BuLi(1.6 M in hexanes, 18.4 mL, 0.029 mol) was added dropwise and thereaction mixture heated at 60° C. for 2 h, then concentrated in vacuo.The resulting oil was partitioned between EtOAc and water. The organiclayer was separated and washed with brine, then dried (MgSO₄) andconcentrated in vacuo. The resultant residue was purified by flashchromatography (Si—PPC, pentane:EtOAc; gradient from 100:0 to 20:80) toafford 4-oxetan-3-ylpiperidine-1-carboxylic acid tert-butyl ester as awhite solid (5.33 g, 75%). TFA (10 mL) was added to a solution of4-oxetan-3-yl-piperidine-1-carboxylic acid tert-butyl ester (7.1 g,0.029 mol) in DCM (100 mL) and the mixture stirred at ambienttemperature for 2 h. The reaction mixture was loaded onto an Isolute®SCX-2 cartridge (50 g), the cartridge was washed with MeOH before thedesired product was eluted using 2 M NH₃ in MeOH. The product wascollected and concentrated in vacuo. The resultant residue was purifiedby flash chromatography (Si—PPC, DCM: 2 M NH₃ in MeOH 100:0 to 98:2 to95:5 to 90:10 to 85:15 to 80:20) to afford 4-Oxetan-3-ylpiperidine as acolourless oil which solidified on standing (2.05 g, 49%). ¹H NMR(CDCl₃, 300 MHz) δ 4.75 (dd, J=7.9, 6.0 Hz, 2H); 4.52-4.42 (m, 2H);3.14-3.04 (m, 2H); 2.81-2.67 (m, 1H); 2.61 (td, J=12.2, 2.6 Hz, 2H);1.85-1.68 (m, 1H); 1.60 (m, 2H) and 1.02 (qd, J=12.2, 4.0 Hz, 2H).

Example 31 3-(Tetrahydropyran-4-yl)azetidine

To a solution of 3-(tetrahydropyran-4-yl)azetidine-1-carboxylic acidtert-butyl ester (730 mg, 3.0 mmol) in DCM (10 mL) were added water(0.15 mL) and TFA (10 mL). The reaction mixture was stirred at roomtemperature for 4 hours and the concentrated under reduced pressure togive a residue that was taken up in MeOH. The resulting solution wasloaded onto a SCX-2 cartridge (10 g) which was washed with MeOH. Thedesired product was eluted with a 2M solution of ammonia in MeOH. Theappropriate fractions were combined and concentrated to give3-(Tetrahydropyran-4-yl)azetidine as a yellow oil (393 mg, 92%). ¹H NMR(300 MHz, CDCl₃): δ 3.96 (dd, J=11.0, 4.0, 2 H); 3.65 (dd, J=8.0, 8.0Hz, 2H); 3.44 (dd, J=7.6, 7.6 Hz, 2H); 3.37 (ddd, J=11.9, 11.9, 2.1, 2H); 2.50 (m, 1H); 1.75 (m, 1H); 1.53 (m, 2H); 1.18 (ddd, J=25.0, 11.9,4.3, 2 H).

Example 32 1-Azetidin-3-ylpyrrolidin-2-one

Step 1: 3-(4-Chlorobutyrylamino)azetidine-1-carboxylic acid tert-butylester

A mixture of 3-aminoazetidine-1-carboxylic acid tert-butyl ester (730mg, 4.24 mmol) and triethylamine (1.74 mL, 1.29 g, 12.72 mmol) in DCM(10 mL) was cooled to 0° C. before the addition of4-chlorobutyrylchloride (523 μL, 657 mg, 4.66 mmol). The resultingmixture was stirred for 16 h then quenched with H₂O and extracted withDCM. The combined organic extracts were washed with brine then dried(Na₂SO₄) and concentrated in vacuo. The resulting residue was purifiedby column chromatography (Si—PCC, EtOAc:cyclohexane, 30-70%) affording3-(4-Chlorobutyrylamino)azetidine-1-carboxylic acid tert-butyl ester asa brown oil (1.04 g, 89%).

Step 2: 3-(2-Oxopyrrolidin-1-yl)azetidine-1-carboxylic acid tert-butylester

A solution of 3-(4-chlorobutyrylamino)azetidine-1-carboxylic acidtert-butyl ester (1.04 g, 3.76 mmol) in DMF (15 mL) was cooled to 0° C.before the addition of NaH (180 mg, 4.51 mmol). The resulting mixturewas allowed to stir for 2 h then quenched with H₂O and extracted withEtOAc. The organic phase was washed with H₂O and brine, then dried(Na₂SO₄) and concentrated in vacuo. The resulting residue was purifiedby column chromatography (Si—PCC, EtOAc:cyclohexane, 20-100%) affording3-(2-Oxopyrrolidin-1-yl)azetidine-1-carboxylic acid tert-butyl ester asa brown oil (320 mg, 35%). ¹H NMR (CDCl₃, 300 MHz): δ 4.99 (m, 1H), 4.15(m, 2H), 3.97 (m, 2H), 3.57 (t, J=7.0 Hz, 2H), 2.42 (t, J=8.1 Hz, 2H),2.15-2.02 (m, 2H) and 1.45 (s, 9H)

A mixture of 3-(2-oxopyrrolidin-1-yl)azetidine-1-carboxylic acidtert-butyl ester (320 mg, 1.33 mmol) and TFA (1.5 mL) in DCM (3 mL) wasstirred at room temperature for 4 h. The reaction mixture was loadedonto an Isolute® SCX-2 cartridge, washed with MeOH/DCM and eluted with2M NH₃/MeOH affording 1-Azetidin-3-ylpyrrolidin-2-one as a white solid(174 mg, 93%). ¹H NMR (CDCl₃, 300 MHz): δ 5.05 (m, 1H), 3.85-3.76 (m,4H), 3.61 (m, 2H), 2.41 (m, 2H) and 2.07 (m, 2H)

Example 33 1-Azetidin-3-yl-3,3-difluoropyrrolidine

Step 1: 3-(3,3-Difluoropyrrolidin-1-yl)azetidine-1-carboxylic acidtert-butyl ester

A mixture of 3,3-difluoropyrrolidine hydrochloride (200 mg, 1.17 mmol),3-oxoazetidine-1-carboxylic acid tert-butyl ester (284 mg, 1.99 mmol)and triethylamine (295 μL, 221 mg, 2.18 mmol) in DCE (10 mL) was stirredat room temperature for 1 h before the addition of sodiumtriacetoxyborohydride (745 mg, 3.52 mmol). The resulting mixture wasstirred for 72 h then diluted with DCM and washed with H₂O. The organicphase was dried (Na₂SO₄) and concentrated in vacuo. The resultingresidue was purified by column chromatography (Si—PCC,EtOAc:cyclohexane, 0-50%) affording3-(3,3-Difluoropyrrolidin-1-yl)azetidine-1-carboxylic acid tert-butylester as a colourless oil (193 mg, 63%). ¹H NMR (CDCl₃, 300 MHz): δ 3.95(m, 2H), 3.82 (dd, J=8.9, 4.9 Hz, 2H), 3.32 (m, 1H), 2.91 (m, 2H),2.82-2.63 (m, 2H), 2.33-2.32 (m, 2H) and 1.43 (s, 9H).

A mixture of 3-(3,3-difluoropyrrolidin-1-yl)azetidine-1-carboxylic acidtert-butyl ester (193 mg, 0.74 mmol) and TFA (1 mL) in DCM (2 mL) wasstirred at room temperature for 2 h. The reaction mixture was loadedonto an Isolute® SCX-2 cartridge, washed with MeOH/DCM and eluted with2M NH₃/MeOH affording 1-Azetidin-3-yl-3,3-difluoropyrrolidine as a whitesolid (122 mg, quant.). ¹H NMR (CDCl₃, 300 MHz): δ 3.63 (m, 4H), 3.48(m, 1H), 2.87 (t, J=13.1 Hz, 2H), 2.70 (t, J=7.0 Hz, 2H) and 2.29 (m,2H)

Example 34 3,3-Difluoro-[1,3′]biazetidinyl

Step 1: 3,3-Difluoro-[1,3′]biazetidinyl-1′-carboxylic acid tert-butylester

A 25 mL round-bottomed flask was charged with a solution of3-oxoazetidine-1-carboxylic acid tert-butyl ester (0.4 g, 2.34 mmol),3,3-difluoroazetidine hydrochloride (0.364 g, 2.80 mmol) and 4 Åmolecular sieves (2.43 g) in DCE (10 mL). The reaction mixture wasstirred for 3 h at room temperature. Sodium triacetoxyborohydride (0.99g, 4.67 mmol) was added and the reaction mixture was stirred for 18 h atroom temperature. The suspension was filtered through Celite and thefiltrate was concentrated in vacuo. The residue was purified by flashchromatography (Si—PPC, MeOH:DCM, gradient 0:100 to 10:90) to give thetitle compound as a colourless oil (0.33 g, 57%). ¹H NMR (300 MHz,CDCl₃): δ 4.02-3.69 (m, 4H), 3.65 (t, J=12.15 Hz, 4H), 3.55-3.48 (m,1H), 1.43 (s, 9H).

Step 2: 3,3-Difluoro-[1,3′]biazetidinyl

A 10 mL round-bottomed flask was charged with a solution of3,3-difluoro-[1,3′]biazetidinyl-1′-carboxylic acid tert-butyl ester(0.15 g, 0.61 mmol) in DCM/TFA (3 mL/3 mL). The reaction mixture wasstirred for 3 h at room temperature. The reaction mixture was loadedonto an Isolute® SCX-2 cartridge. The cartridge was washed with MeOH andthe desired product was eluted using 2 M NH₃ in MeOH to give3,3-Difluoro-[1,3′]biazetidinyl as a colourless oil (0.033 g, 37%). ¹HNMR (300 MHz, CDCl₃): δ 3.73-3.55 (m, 8H), 3.57-3.43 (m, 1H), 2.77 (s,1H)

Example 35 4-(3,3-Difluoroazetidin-1-yl)piperidine

Step 1: 4-(3,3-Difluoroazetidin-1-yl)piperidine-1-carboxylic acidtert-butyl ester

A 10 mL round-bottomed flask was charged with a solution of4-oxopiperidine-1-carboxylic acid tert-butyl ester (0.4 g, 0.20 mmol),3,3-difluoroazetidine hydrochloride (0.31 g, 0.24 mmol) and 4 Åmolecular sieves (2.4 g) in DCE (10 mL). The reaction mixture wasstirred for 3 h at room temperature. Sodium triacetoxyborohydride (0.85g, 4.01 mmol) was added and the reaction mixture was stirred for 18 h atroom temperature. The suspension was filtered through Celite and thefiltrate was concentrated in vacuo to give4-(3,3-Difluoroazetidin-1-yl)piperidine-1-carboxylic acid tert-butylester as a colourless oil (0.53 g, 96%). ¹H NMR (300 MHz, CDCl₃): δ3.94-3.90 (m, 2H), 3.57 (t, J=11.9 Hz, 4H), 2.96-2.81 (m, 2H), 2.34-2.23(m, 1H), 1.71-1.58 (m, 2H), 1.45 (s, 9H), 1.35-1.21 (m, 2H).

Step 2: 4-(3,3-Difluoroazetidin-1-yl)piperidine

A 25 mL round-bottomed flask was charged with a solution of4-(3,3-difluoroazetidin-1-yl)piperidine-1-carboxylic acid tert-butylester (0.265 g, 0.96 mmol) in DCM/TFA (3 mL/3 mL). The reaction mixturewas stirred for 3 h at room temperature. The reaction mixture was loadedonto an Isolute® SCX-2 cartridge. The cartridge was washed with MeOH andthe desired product was eluted using 2 M NH₃ in MeOH to give4-(3,3-Difluoroazetidin-1-yl)piperidine as a white solid (0.154 g, 91%).¹H NMR (300 MHz, CDCl₃): δ 3.54 (t, J=11.9 Hz, 4H), 3.10 (dt, J=12.7,3.9 Hz, 2H), 2.59 (td, J=11.9, 2.6 Hz, 2H), 2.24-2.13 (m, 1H), 1.76-1.65(m, 2H), 1.30-1.15 (m, 2H).

Example 36 3-Methyl-[1,3′]biazetidinyl-3-ol

Step 1: 3-Hydroxy-3-methylazetidine-1-carboxylic acid benzyl ester

To a 3.0 M solution of methylmagnesium bromide in Et₂O (0.98 mL, 2.92mmol), at 0° C., was added a solution of 3-oxoazetidine-1-carboxylicacid benzyl ester (0.5 g, 2.44 mmol) in anhydrous THF (5 mL) dropwiseover 5 min under argon. The reaction mixture was stirred for 18 h atroom temperature, and then quenched by addition of a saturated aqueoussolution of NH₄Cl (2.5 mL) and water (5 mL). The aqueous phase wasextracted with EtOAc (10 mL). The organic layer was separated, driedover sodium sulphate and concentrated in vacuo to give3-Hydroxy-3-methylazetidine-1-carboxylic acid benzyl ester as acolourless oil (0.54 g, 99%). LCMS (Method A): R_(T)=3.60 min, [M+H]⁺221.9

Step 2: 3-Methylazetidin-3-ol

A 25 mL round-bottomed flask was charged with a solution of3-hydroxy-3-methylazetidine-1-carboxylic acid benzyl ester (0.57 g, 2.58mmol) in EtOH (5 mL) and acetic acid (0.25 mL). The reaction mixture wasflushed with nitrogen and 10% Pd/C (67 mg, 0.29 mmol) was added. Thereaction mixture was stirred under a hydrogen atmosphere for 36 h atroom temperature. The reaction mixture was loaded onto an Isolute® SCX-2cartridge. The cartridge was washed with MeOH and the desired productwas eluted using 2 M NH₃ in MeOH to give the 3-Methylazetidin-3-ol as anorange oil (0.125 g, 56%). ¹H NMR (300 MHz, CDCl₃): δ 3.19-3.03 (m, 4H),1.45 (s, 3H).

Step 3: 3-Hydroxy-3-methyl-[1,3′]biazetidinyl-1′-carboxylic acidtert-butyl ester

A 10 mL round-bottomed flask was charged with a solution of3-oxoazetidine-1-carboxylic acid tert-butyl ester (0.21 g, 1.23 mmol),3-methylazetidin-3-ol (0.13 g, 1.48 mmol) and 4 Å molecular sieves (1.2g) in DCE (5 mL). The reaction mixture was stirred for 3 h at roomtemperature. Sodium triacetoxyborohydride (0.52 g, 2.47 mmol) was addedand the reaction mixture was stirred for 18 h at room temperature. Thesuspension was filtered through Celite and the solution was concentratedin vacuo. The residue was purified by flash chromatography (Si—PPC,EtOAc:cyclohexane, 0:100 to 100:0) to give3-Hydroxy-3-methyl-[1,3′]biazetidinyl-1′-carboxylic acid tert-butylester as a colourless oil (0.09 g, 30%). ¹H NMR (300 MHz, CDCl₃): δ 3.93(dd, J=9.2, 7.2 Hz, 2H), 3.82-3.70 (m, 2H), 3.50-3.40 (m, 1H), 3.32 (d,J=8.1 Hz, 2H), 3.21 (d, J=8.1 Hz, 2H), 1.51 (s, 3H), 1.43 (s, 9H).

Step 4: 3-Methyl-[1,3′]biazetidinyl-3-ol

A 10 mL round-bottomed flask was charged with a solution of3-hydroxy-3-methyl-[1,3′]biazetidinyl-1′-carboxylic acid tert-butylester (0.09 g, 0.37 mmol) in DCM/TFA (2 mL/2 mL). The reaction mixturewas stirred for 90 min at room temperature. The reaction mixture wasloaded onto an Isolute® SCX-2 cartridge. The cartridge was washed withMeOH and the desired product was eluted using 2 M NH₃ in MeOH to give3-Methyl-[1,3′]biazetidinyl-3-ol as a colourless oil (0.04 g, 76%). ¹HNMR (300 MHz, CDCl₃): δ 3.68-3.51 (m, 6H), 3.25 (d, J=7.6 Hz, 2H), 3.15(d, J=7.6 Hz, 2H), 1.49 (s, 3H).

Example 37 (R)-1-Azetidin-3-yl-3-fluoropyrrolidine

Step 1: 3-(I-3-Fluoropyrrolidin-1-yl)azetidine-1-carboxylic acidtert-butyl ester

A 25 mL round-bottomed flask was charged with a solution of3-oxoazetidine-1-carboxylic acid tert-butyl ester (0.4 g, 2.34 mmol),I-3-fluoropyrrolidine hydrochloride (0.35 g, 2.8 mmol) and 4 Å molecularsieves (2.43 g) in DCE (10 mL). The reaction mixture was stirred for 2.5h at room temperature. Sodium triacetoxyborohydride (0.99 g, 4.68 mmol)was added and the reaction mixture was stirred for 18 h at roomtemperature. The suspension was filtered through Celite and the filtratewas concentrated in vacuo. The residue was purified by flashchromatography (Si—PPC, EtOAc: cyclohexane, gradient 30:70 to 100:0) togive 3-(I-3-Fluoropyrrolidin-1-yl)azetidine-1-carboxylic acid tert-butylester as a colourless oil (0.348 g, 61%). ¹H NMR (300 MHz, CDCl₃): δ5.30-5.20 (m, 3H), 4.01-3.92 (m, 2H), 3.91-3.82 (m, 2H), 2.87-2.78 (m,2H), 2.17-2.11 (m, 3H), 1.43 (s, 9H).

Step 2: (R)-1-Azetidin-3-yl-3-fluoropyrrolidine

A 25 mL round-bottomed flask was charged with a solution of3-(I-3-fluoropyrrolidin-1-yl)azetidine-1-carboxylic acid tert-butylester (0.175 g, 0.72 mmol) in DCM/TFA (5 mL/5 mL). The reaction mixturewas stirred for 3 h at room temperature. The reaction mixture was loadedonto an Isolute® SCX-2 cartridge. The cartridge was washed with MeOH and(R)-1-Azetidin-3-yl-3-fluoropyrrolidine was eluted using 2 M NH₃ in MeOHto give the title compound as a colourless oil (0.088 g, 85%). ¹H NMR(300 MHz, CDCl₃): δ 5.31-5.07 (m, 1H), 3.73-3.56 (m, 4H), 3.55-3.21 (m,1H), 2.95-2.87 (m, 2H), 2.83-2.74 (m, 2H), 2.66 (m, 1H), 2.28-1.95 (m,2H)

Example 38 (S)-1-Azetidin-3-yl-3-fluoropyrrolidine

Step 1: 3-((S)-3-Fluoropyrrolidin-1-yl)azetidine-1-carboxylic acidtert-butyl ester

A 25 mL round-bottomed flask was charged with a solution of3-oxoazetidine-1-carboxylic acid tert-butyl ester (0.4 g, 2.34 mmol),(S)-3-fluoropyrrolidine hydrochloride (0.35 g, 2.8 mmol) and 4 Åmolecular sieves (2.43 g) in DCE (10 mL). The reaction mixture wasstirred for 2.5 h at room temperature. Sodium triacetoxyborohydride(0.99 g, 4.68 mmol) was added and the reaction mixture was stirred for18 h at room temperature. The suspension was filtered through Celite andthe filtrate was concentrated in vacuo. The residue was purified byflash chromatography (Si—PPC, EtOAc: cyclohexane, gradient 30:70 to100:0) to give 3-((S)-3-Fluoropyrrolidin-1-yl)azetidine-1-carboxylicacid tert-butyl ester as a colourless oil (0.342 g, 60%). ¹H NMR (300MHz, CDCl₃): δ 5.34-5.10 (m, 1H), 4.01-3.93 (m, 2H), 3.91-3.81 (m, 2H),3.41-3.31 (m, 1H), 2.94-2.67 (m, 3H), 2.56-2.46 (m, 1H), 2.24-2.06 (m,2H), 1.43 (s, 9H).

Step 2: (S)-1-Azetidin-3-yl-3-fluoropyrrolidine

A 25 mL round-bottomed flask was charged with a solution of3-(I-3-fluoropyrrolidin-1-yl)azetidine-1-carboxylic acid tert-butylester (0.228 g, 0.93 mmol) in DCM/TFA (6 mL/6 mL). The reaction mixturewas stirred for 4 h at room temperature. The reaction mixture was loadedonto an Isolute® SCX-2 cartridge. The cartridge was washed with MeOHand: (S)-1-Azetidin-3-yl-3-fluoropyrrolidine was eluted using 2 M NH₃ inMeOH to give the title compound as a colourless oil (0.108 g, 75%). ¹HNMR (300 MHz, CDCl₃): δ 5.46-4.86 (m, 1H), 4.05-3.79 (m, 4H), 3.78-3.20(m, 1H), 2.95-2.80 (m, 2H), 2.70-2.62 (m, 2H), 2.46-2.37 (m, 1H),2.29-1.97 (m, 2H)

Example 39 1-tert-Butylpiperazin-2-one

Step 1: 4-tert-Butyl-3-oxopiperazine-1-carboxylic acid benzyl ester

To a solution of (2-tert-butylaminoethyl)carbamic acid benzyl ester(1.44 g, 5.75 mmol) and triethylamine (2.4 mL, 17.26 mmol) in DCM (50mL), at room temperature, was added dropwise chloroacetyl chloride (0.55mL, 6.9 mmol) and the reaction mixture was stirred for 6 h at roomtemperature. The aqueous phase was extracted with EtOAc (10 mL). Thereaction mixture was partitioned between DCM and a saturated aqueoussolution of NaHCO₃. The organic layer was separated, dried over sodiumsulphate and concentrated in vacuo. The brown residue was dissolved indry THF (50 mL) and sodium hydride 60% in mineral oil (0.345 g, 8.63mmol) was added and the reaction mixture was stirred at room temperaturefor 18 h. The reaction mixture was quenched with water and partitionedbetween EtOAc and water. The organic layer was washed with brine,separated, dried over sodium sulphate and concentrated in vacuo. Theresidue was dissolved in MeOH, loaded onto an Isolute® SCX-2 cartridge,and eluted using MeOH to give 4-tert-Butyl-3-oxopiperazine-1-carboxylicacid benzyl ester as yellow oil (1.57 g, 94%). LCMS (Method A):R_(T)=3.96 min, [M+H]⁺ 291.2

Step 2: 1-tert-Butylpiperazin-2-one

A 10 mL round-bottomed flask was charged with a solution of4-tert-butyl-3-oxopiperazine-1-carboxylic acid benzyl ester (0.75 g,2.58 mmol) in EtOH (5 mL). The reaction mixture was flushed withnitrogen and 10% Pd/C (67 mg, 0.13 mmol) was added. The reaction mixturewas stirred under a hydrogen atmosphere for 18 h. The reaction mixturewas loaded onto an Isolute® SCX-2 cartridge. The cartridge was washedwith MeOH and the desired product was eluted using 2 M NH₃ in MeOH togive 1-tert-Butylpiperazin-2-one as grey oil (0.276 g, 69%). ¹H NMR (300MHz, CDCl₃): δ 3.50 (s, 2H), 3.37 (t, J=5.5 Hz, 2H), 3.06 (t, J=5.5 Hz,2H), 1.48-1.41 (m, 9H)

Example 40(2-(1S,4S)-2,5-Diazabicyclo[2.2.1]hept-2-yl-2-methylpropan-1-ol

2-Bromo-2-methylpropionic acid ethyl ester (155 μL, 1.06 mmol) was addedto a solution of potassium carbonate (145 mg, 1.05 mmol) and(1S,4S)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylic acid tert-butylester (200 mg, 1.01 mmol) in anhydrous acetonitrile (1 mL). Theresulting mixture was heated at 80° C. for 48 h, then cooled to ambienttemperature and partitioned between EtOAc and water. The organic layerwas separated, washed with brine, then dried (MgSO₄) and concentrated invacuo. The resultant residue was purified by flash chromatography(Si—PPC, DCM:MeOH; 100:0 to 98:2) to give(1S,4S)-5-(1-ethoxycarbonyl-1-methylethyl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylicacid tert-butyl ester as a pale brown oil. To a solution of(1S,4S)-5-(1-ethoxycarbonyl-1-methylethyl)-2,5-diazabicyclo[2.2.1]-heptane-2-carboxylicacid tert-butyl ester (1 mmol) in anhydrous THF (5 mL) at 0° C., asolution of LiAlH₄ (1 M in THF, 3.2 mL, 3.2 mmol) was added dropwise.The reaction mixture was allowed to warm to ambient temperature andstirred for 1 h. The reaction mixture was loaded onto an Isolute® SCX-2cartridge (10 g), washed with MeOH before the desired product was elutedusing 2 M NH₃ in MeOH. The product was collected and concentrated invacuo to afford the title compound as a brown oil (168 mg, 99%). ¹H NMR(CDCl₃, 400 MHz) δ 3.37 (bs, 1H); 3.31 (d, J=10.2 Hz, 1H); 3.21 (d,J=10.2 Hz, 1H); 3.15-3.00 (m, 2H); 2.81-2.61 (m, 2H); 2.45 (s, 2H); 1.76(d, J=10.0 Hz, 1H); 1.56 (d, J=10.0 Hz, 1H); 1.46 (t, J=5.02 Hz, 1H);1.03 (s, 3H) and 1.00 (s, 2H).

Example 41 (1S,4S)-2-Methanesulfonyl-2,5-diazabicyclo[2.2.1]heptane

Methanesulfonyl chloride (120 μL, 1.55 mmol) and DIPEA (187 μL, 1.07mmol) were added to a solution of(1S,4S)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylic acid tert-butylester (200 mg, 1.01 mmol) in DCM (20 mL) and the reaction mixturestirred at ambient temperature for 17 h, then partitioned between EtOAcand water. The organic layer was separated and washed with brine, thendried (MgSO₄) and concentrated in vacuo to give(1S,4S)-5-methanesulfonyl-2,5-diazabicyclo[2.2.1]-heptane-2-carboxylicacid tert-butyl ester. TFA (3 mL) was added to a solution of(1S,4S)-5-methanesulfonyl-2,5-diazabicyclo[2.2.1]heptane-2-carboxylicacid tert-butyl ester in DCM (10 mL) and the mixture stirred at ambienttemperature for 30 min. The reaction mixture was loaded onto an Isolute®SCX-2 cartridge (10 g); the cartridge was washed with MeOH before thedesired product was eluted using 2 M NH₃ in MeOH. The product wascollected and concentrated in vacuo to afford the title compound as awhite solid (170 mg, 96%). ¹H NMR (CDCl₃, 400 MHz) δ 4.37 (d, J=2.0 Hz,1H); 3.83 (d, J=2.0 Hz, 1H); 3.41 (dd, J=9.2, 2.19 Hz, 1H); 3.25 (d,J=9.2 Hz, 1H); 3.20 (d, J=10.3 Hz, 1H); 3.01 (dd, J=10.3, 2.14 Hz, 1H);2.89 (s, 3H); and 1.79 (bs, 2H)

Example 41a 3,3-dimethyl-1-(methylsulfonyl)piperazine

A mixture of 2,2-dimethylpiperazine-1-carboxylic acid tert-butyl ester(1.0 g, 4.60 mmol) and NEt₃ (1.3 mL, 9.34 mmol) in DCM (11 mL) wascooled to 0° C. before the drop wise addition of a solution ofmethanesulfonyl chloride (580 mg, 5.00 mmol) in DCM (2 mL). Theresulting mixture was warmed to r.t. and allowed to stir for 30 minbefore H₂O was added. The organic phase was dried (phase separator) andconcentrated in vacuo. The resulting residue was dissolved in DCM (10mL) and TFA (2 mL) was added. The resulting mixture was allowed to stirat r.t. for 30 min then concentrated in vacuo. The resulting residue waspartitioned between DCM and sat. aq. NaHCO₃ and the aqueous phase wasloaded onto an Isolute® SCX-2 cartridge which was washed with H₂O andMeOH. The product was eluted with 2M NH₃/MeOH affording the titlecompound (800 mg, 90%). LCMS (method A): R_(T) 0.29 min [M+H]⁺ 193.3

Example 41b 4-(2-Hydroxy-1,1-dimethylethyl)piperazine-1-carboxylic acidtert-butyl ester

To a solution of4-(1-ethoxycarbonyl-1-methylethyl)piperazine-1-carboxylic acidtert-butyl ester (500 mg, 1.67 mmol) in THF (5 mL) at 0° C. was addedLiAlH₄ (3 mL, 1M in THF) drop wise. The resulting mixture was allowed tostir for 2.5 h then quenched with H₂O (0.1 mL), 20% aq. NaOH (0.1 mL)and H₂O (0.3 mL). The mixture was diluted with EtOAc and H₂O, filteredthrough Celite® then the organic layer separated, dried (Na₂SO₄) andconcentrated in vacuo. The resulting residue was purified by columnchromatography (Si—PCC, MeOH:DCM, 0-10%) affording the title compound asa colourless oil (217 mg, 50%). ¹H NMR (CDCl₃, 400 MHz): δ 5.30 (1H, brds), 3.42 (6H, m), 3.35 (4H, brd s), 2.51 (6H, brd s), 1.03 (9H, s)

Example 41c 2-Methyl-2-piperazin-1-ylpropan-1-ol

To a solution of 4-(2-hydroxy-1,1-dimethylethyl)piperazine-1-carboxylicacid tert-butyl ester (110 mg, 0.43 mmol) in DCM (3 mL) was added TFA (1mL) and the resulting mixture stirred for 3 h. The reaction mixture wasloaded onto an Isolute® SCX-2 cartridge which was washed with MeOH/DCMand the product eluted with 2M NH₃/MeOH affording the title compound asan off-white solid (62 mg, 91%). ¹H NMR (CDCl₃, 400 MHz): δ 3.32 (2H,s), 2.90 (5H, t, J=4.78 Hz), 2.38-2.13 (4H, m), 1.03 (6H, s)

Example 41d 7-Oxetan-3-yl-4,7-diazaspiro[2.5]octane

Step 1: 7-Oxetan-3-yl-4,7-diazaspiro[2.5]octane-4-carboxylic acid benzylester

A mixture of 4,7-diazaspiro[2.5]octane-4-carboxylic acid benzyl esteroxalate (200 mg, 0.59 mmol), oxetan-3-one (50 mg, 0.69 mmol), NEt₃ (82μL, 0.59 mmol) and 4 Å powdered molecular sieves (1.0 g) in DCE (10 mL)was stirred at r.t. for 2 h before the addition of sodiumtriacetoxyborohydride (164 mg, 0.78 mmol). The resulting mixture wasstirred for 68 h then loaded onto an Isolute® SCX-2 cartridge which waswashed with MeOH and the product eluted with 2M NH₃/MeOH affording thetitle compound. LCMS (method H): R_(T) 2.01 min, [M+H]⁺ 303.3

Step 2: 7-Oxetan-3-yl-4,7-diazaspiro[2.5]octane

To a solution of 7-oxetan-3-yl-4,7-diazaspiro[2.5]octane-4-carboxylicacid benzyl ester in IMS (3 mL) was added 10% Pd/C (60 mg) and theresulting mixture stirred under an atmosphere of H₂ at r.t. for 20 h.The reaction mixture was filtered through Celite® and the filtrateloaded onto an Isolute® SCX-2 cartridge which was washed with MeOH andthe product eluted with 2M NH₃/MeOH affording the title compound (90 mg,90%). ¹H NMR (CDCl₃, 400 MHz): δ 4.63-4.63 (2H, m), 3.50-3.42 (2H, m),3.00-2.98 (2H, m), 2.35-2.25 (2H, m), 2.15 (2H, s), 2.05-2.03 (2H, m),0.68-0.63 (2H, m), 0.52-0.51 (2H, m)

Example 41e 1-Azetidin-3-yl-2-methylpropan-1-ol

i) 3-(Methoxymethylcarbamoyl)azetidine-1-carboxylic acid tert-butylester

A mixture of N,O-dimethylhydroxylamine hydrochloride (773 mg, 7.93 mmol)and diisopropylethylamine (1.38 mL, 7.93 mmol) in dichloromethane (5 mL)was added to a mixture of azetidine-1,3-dicarboxylic acidmono-tert-butyl ester (1.0 g, 5.30 mmol) andN-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (1.27 g,6.63 mmol) in dichloromethane (10 mL). The resulting reaction mixturewas stirred at RT under nitrogen atmosphere for 16 h. The organic phasewas washed with water (1×25 mL), 10% aqueous citric acid solution (2×25mL), brine (1×30 mL), and dried over sodium sulphate. The solvents werereduced in vacuo to afford the title compound as pale yellow oil (1.06g, 82%). ¹H NMR (400 MHz, CDCl₃): δ 4.14 (2H, m), 4.05 (2H, t, J=8.72Hz), 3.66 (4H, s), 3.20 (3H, s), 1.43 (9H, s).

ii) 3-(Isobutyryl)azetidine-1-carboxylic acid tert-butyl ester

A solution of 3-(methoxymethylcarbamoyl)azetidine-1-carboxylic acidtert-butyl ester (1.06 g, 4.34 mmol) in anhydrous tetrahydrofuran (15mL) was cooled to 4° C. under argon gas. 2M solution of isopropylmagnesium chloride (4.35 mL, 8.68 mmol) was added dropwise and theresulting reaction mixture was stirred at 4° C. for 5 min. Thetemperature was allowed to rise to RT and stirred for 1 h then themixture was stirred at 40° C. for 1 h. The reaction mixture was quenchedby addition of a saturated solution of ammonium chloride (5 mL) andwater (10 mL). The aqueous phase was extracted with ethyl acetate (3×20mL). The organic layer was dried over sodium sulfate, filtered and thesolvents reduced in vacuo to afford the title compound as a pale yellowoil (950 mg, 96%) ¹H NMR (400 MHz, CDCl₃): δ 4.03-4.01 (4H, m),3.59-3.59 (1H, m), 2.61-2.61 (1H, m), 1.43 (9H, s), 1.11 (6H, d, J=6.94Hz).

iii) 3-(1-Hydroxy-2-methylpropyl)azetidine-1-carboxylic acid tert-butylester

Sodium borohydride (237 mg, 6.26 mmol) was added to a solution of3-(isobutyryl)azetidine-1-carboxylic acid tert-butyl ester (0.95 g, 4.18mmol) in ethanol (7.5 mL). The resulting reaction mixture was stirred atRT for 2 h. Saturated hydrogen carbonate (25 mL) was added and theresulting mixture was stirred for further 15 min. The aqueous phase wasextracted with dichloromethane (3×25 mL). The organic layer was driedover sodium sulfate and the solvents reduced in vacuo to give the crudeproduct as yellow oil. The residue was purified by column chromatography(Si—PCC, ethyl acetate:cyclohexane: gradient 0:100 to 40:60). Thesolvents were reduced in vacuo to afford the title compound ascolourless oil (840 mg, 88%). ¹H NMR (400 MHz, CDCl₃): δ 3.91-3.90 (3H,m), 3.71 (1H, dd, J=8.54, 6.04 Hz), 3.51 (1H, dd, J=7.21, 4.97 Hz),2.70-2.63 (1H, m), 1.65-1.63 (1H, m), 1.44 (9H, s), 0.90 (6H, t, J=6.59Hz).

iv) Trifluoroacetic acid (3 mL) was added to a solution of3-(1-hydroxy-2-methylpropyl)azetidine-1-carboxylic acid tert-butyl ester(0.84 g, 3.66 mmol) in dichloromethane (12 mL). The resulting reactionmixture was stirred at RT for 40 min. The solvents were reduced invacuo. The resulting residue was loaded onto an Isolute® SCX-2 cartridge(5 g). The cartridge was washed with DCM/MeOH, the desired product wassubsequently eluted using a mixture of 2M NH₃ in MeOH and DCM. Thesolvents were reduced in vacuo to afford1-Azetidin-3-yl-2-methylpropan-1-ol as a white solid (0.42 g, 88%). ¹HNMR (400 MHz, CDCl₃): δ 3.63-3.62 (3H, m), 3.53-3.51 (2H, m), 2.88-2.87(1H, m), 1.62-1.62 (1H, m), 0.89 (6H, dd, J=6.84, 4.72 Hz)

Example 41f (Azetidin-3-ylmethyl)methyl(tetrahydrofuran-3-yl)amine

i) 3-{[Methyl(tetrahydrofuran-3-yl)-amino]methyl}azetidine-1-carboxylicacid tert-butyl ester

A mixture of 3-ethylaminomethyl-azetidine-1-carboxylic acid tert-butylester (200 mg, 1.0 mmol), dihydrofuran-3-one (0.155 mL, 2.0 mmol),diisopropylethylamine (0.347 mL, 2.0 mmol) and 4 Å molecular sieves (600mg) in DCM (10 mL) was stirred at RT for 30 min. Sodiumtriacetoxyborohydride (424 mg, 2 mmol) was added and the resultingreaction mixture was stirred at RT under nitrogen atmosphere for 60 h.The suspension was filtered through Celite and the filtrate wasconcentrated in vacuo. The residue was purified by column chromatography(Si—PPC, MeOH:DCM, gradient 0:100 to 5:95) to afford the title compoundas a colourless oil (257 mg, 95%). ¹H NMR (400 MHz, CDCl₃): δ 4.04-3.92(3H, m), 3.83 (1H, dd, J=8.89, 6.90 Hz), 3.75 (1H, q, J=8.07 Hz), 3.64(1H, dd, J=8.87, 6.21 Hz), 3.56-3.55 (2H, m), 3.14 (1H, m), 2.67-2.66(2H, m), 2.51 (1H, dd, J=12.33, 7.20 Hz), 2.17 (3H, s), 2.05 (1H, s),1.89-1.79 (1H, m), 1.44 (9H, s).

ii) Trifluoroacetic acid (3 mL) was added to a solution of3-{[methyl(tetrahydrofuran-3-yl)amino]methyl}azetidine-1-carboxylic acidtert-butyl ester (257 mg, 0.95 mmol) in dichloromethane (12 mL). Theresulting reaction mixture was stirred at RT for 1.5 h. The solventswere reduced in vacuo. The resulting residue was loaded onto an Isolute®SCX-2 cartridge (5 g). The cartridge was washed with DCM/MeOH, thedesired product was subsequently eluted using a mixture of 2M NH₃ inMeOH and DCM to afford(Azetidin-3-ylmethyl)methyl(tetrahydrofuran-3-yl)amine as colourless oil(140 mg, 86%). ¹H NMR (400 MHz, CDCl₃): δ 3.94 (1H, td, J=8.62, 4.35Hz), 3.84 (1H, dd, J=8.76, 6.50 Hz), 3.76-3.65 (3H, m), 3.62 (1H, dd,J=8.76, 6.50 Hz), 3.38 (2H, t, J=7.31 Hz), 3.09-3.07 (1H, m), 2.99-2.88(1H, m), 2.64 (1H, dd, J=12.50, 7.22 Hz), 2.53 (1H, dd, J=12.50, 7.22Hz), 2.15 (3H, s), 2.01 (1H, dtd, J=12.34, 7.72, 3.21 Hz), 1.83 (1H,dtd, J=12.35, 8.40, 6.96 Hz)

Example 41g (Azetidin-3-ylmethyl)methyloxetan-3-ylamine

i) 3-[(Methyl(oxetan-3-yl)amino)methyl]azetidine-1-carboxylic acidtert-butyl ester

A mixture of 3-(methylamino)methylazetidine-1-carboxylic acid tert-butylester (450 mg, 2.25 mmol), oxetan-3-one (135 mg, 1.88 mmol), indichloromethane (10 mL) was stirred at RT for 1.5 h. Sodiumtriacetoxyborohydride (797 mg, 3.76 mmol) was added and the resultingreaction mixture was stirred at RT under nitrogen atmosphere for 18 h.The mixture was diluted with water, the phases were separated and theaqueous phase was extracted with EtOAc (2×25 mL). The combined organiclayers were dried over sodium sulfate, filtered and the solvents reducedin vacuo The residue was purified by column chromatography (Si—PPC,MeOH:DCM, gradient 0:100 to 5:95) to afford the title compound as acolourless oil (330 mg, 69%). ¹H NMR (400 MHz, CDCl₃): δ 4.64 (2H, t,J=6.58 Hz), 4.57 (2H, t, J=6.26 Hz), 4.01 (2H, t, J=8.40 Hz), 3.57-3.55(3H, m), 2.71-2.61 (1H, m), 2.41 (2H, d, J=7.57 Hz), 2.08 (3H, s), 1.44(9H, s).

ii) Trifluoroacetic acid (3 mL) was added to a solution of3-[(methyl(oxetan-3-yl)amino)methyl]azetidine-1-carboxylic acidtert-butyl ester (330 mg, 1.29 mmol) in dichloromethane (12 mL) Theresulting reaction mixture was stirred at RT for 1.5 h. The solventswere reduced in vacuo. The resulting residue was loaded onto an Isolute®SCX-2 cartridge (5 g). The cartridge was washed with DCM/MeOH, thedesired product was subsequently eluted using a mixture of 2M NH₃ inMeOH and DCM to afford (Azetidin-3-ylmethyl)methyl(oxetan-3-yl)amine ascolourless oil (180 mg, 90%). ¹H NMR (400 MHz, CDCl₃): δ 4.64 (2H, t,J=6.59 Hz), 4.57 (2H, t, J=6.31 Hz), 3.72 (2H, t, J=7.87 Hz), 3.58-3.49(1H, m), 3.37 (2H, t, J=7.22 Hz), 2.92-2.82 (1H, m), 2.44 (3H, m), 2.06(3H, s)

Example 41h Azetidin-3-yl-((S)-3-hydroxypyrrolidin-1-yl)methanone

i) 3-((S)-3-Hydroxypyrrolidine-1-carbonyl)azetidine-1-carboxylic acidtert-butyl ester

(S)-Pyrrolidin-3-ol (0.276 g, 3.17 mmol) was added to a mixture ofazetidine-1,3-dicarboxylic acid mono-tert-butyl ester (0.4 g, 2.11 mmol)and N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (0.61g, 3.17 mmol) in dichloromethane (7 mL). The resulting reaction mixturewas stirred at RT under nitrogen atmosphere for 48 h. The mixture wasdiluted with DCM (10 mL) and washed with water (1×15 mL), 10% aqueouscitric acid solution (2×15 mL) and brine (2×15 mL), and dried oversodium sulphate. The solvents were reduced in vacuo to afford the titlecompound as colourless oil (0.46 g, 81%). ¹H NMR (400 MHz, CDCl₃): δ4.55-4.48 (1H, m), 4.17 (2H, s), 4.05-4.04 (2H, m), 3.50-3.47 (5H, m),2.01-2.00 (2H, m), 1.43 (9H, d, J=0.96 Hz).

ii) Trifluoroacetic acid (3 mL) was added to a solution of3-((S)-3-hydroxypyrrolidine-1-carbonyl)azetidine-1-carboxylic acidtert-butyl ester (460 mg, 1.7 mmol) in dichloromethane (12 mL). Theresulting reaction mixture was stirred at RT for 2 h. The solvents werereduced in vacuo. The resulting residue was loaded onto an Isolute®SCX-2 cartridge (10 g). The cartridge was washed with DCM/MeOH, thedesired product was subsequently eluted using a mixture of 2M NH₃ inMeOH and DCM to affordAzetidin-3-yl-((S)-3-hydroxypyrrolidin-1-yl)methanone as colourless oil(243 mg, 84%). ¹H NMR (400 MHz, DMSO, d₆): δ 4.28-4.18 (1H, m),3.72-3.17 (10H, m), 2.11-2.10 (1H, m), 1.81-1.80 (2H, m)

Example 41i Azetidin-3-yl-((R)-3-hydroxypyrrolidin-1-yl)methanone

i) 3-((R)-3-Hydroxypyrrolidine-1-carbonyl)azetidine-1-carboxylic acidtert-butyl ester

(R)-Pyrrolidin-3-ol (0.276 g, 3.17 mmol) was added to a mixture ofazetidine-1,3-dicarboxylic acid mono-tert-butyl ester (0.4 g, 2.11 mmol)and N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (0.61g, 3.17 mmol) in dichloromethane (7 mL). The resulting reaction mixturewas stirred at RT under nitrogen atmosphere for 18 h. The mixture wasdiluted with DCM (10 mL) and washed with water (1×15 mL), 10% aqueouscitric acid solution (2×15 mL) and brine (2×15 mL), and dried oversodium sulfate. The solvents were reduced in vacuo to afford the titlecompound as colourless oil (0.42 g, 74%). ¹H NMR (400 MHz, CDCl₃): δ4.54-4.52 (1H, m), 4.11-4.09 (4H, m), 3.50-3.48 (5H, m), 2.01-2.00 (2H,m), 1.43 (9H, d, J=0.78 Hz)

ii) Trifluoroacetic acid (3 mL) was added to a solution of3-((R)-3-hydroxypyrrolidine-1-carbonyl)azetidine-1-carboxylic acidtert-butyl ester (420 mg, 1.55 mmol) in dichloromethane (12 mL) Theresulting reaction mixture was stirred at RT for 2 h. The solvents werereduced in vacuo. The resulting residue was loaded onto an Isolute®SCX-2 cartridge (10 g). The cartridge was washed with DCM/MeOH, thedesired product was subsequently eluted using a mixture of 2M NH₃ inMeOH and DCM to affordAzetidin-3-yl-((R)-3-hydroxypyrrolidin-1-yl)methanone as colourless oil(225 mg, 85%). ¹H NMR (400 MHz, DMSO, d₆): δ 4.26-4.22 (1H, m),3.47-3.44 (10H, m), 2.13-2.09 (1H, m), 1.81 (2H, m)

R³ Reagents:

Example 42 4-Bromo-1H-pyrrolo[2,3-c]pyridine-1-carboxylic acidtert-butyl ester

A mixture of 4-bromo-1H-pyrrolo[2,3-c]pyridine (248 mg, 1.26 mmol),di-tert-butyl dicarbonate (302 mg, 1.38 mmol), DMAP (31 mg, 0.25 mmol),triethylamine (140 mg, 1.38 mmol) and acetonitrile (8 mL) were stirredat room temperature for 2.5 h. The reaction mixture was evaporated andthe residue was purified by column chromatography (Si—PPC,cyclohexane:EtOAc, gradient 0:100 to 50:50) to give the title compound(316 mg, 84%) as a colorless oil. LCMS (Method C): R_(T)=4.07 min,[M+H—^(t)Bu]⁺ 241 (⁷⁹Br), 243 (⁸¹Br)

Example 43 4-Bromo-6-oxypyrrolo[2,3-c]pyridine-1-carboxylic acidtert-butyl ester

To a solution of 4-bromo-1H-pyrrolo[2,3-c]pyridine-1-carboxylic acidtert-butyl ester (316 mg, 1.06 mmol) in DCM (10 mL) was added asaturated aqueous solution of NaHCO₃ (10 mL) and the resulting mixturecooled to 0° C. 3-Chloroperbenzoic acid (70-75% in H₂O) (524 mg, 2.13mmol) was added to the reaction mixture which was allowed to warm toroom temperature and stirred for a further 20 h. The mixture waspartitioned between water and DCM and the aqueous layer was extractedwith DCM (2×10 mL). The combined organic extracts were dried (phaseseparator) and evaporated to give the title compound as an orange solid(317 mg, 95%). LCMS (Method C): R_(T) 3.48 min, [M+H]⁺ 313 (⁷⁹Br), 315(⁸¹Br)

Example 44 1-Benzenesulfonyl-4-bromo-2-methyl-1H-pyrrolo[3,2-c]pyridine

Step 1: 1-Benzenesulfonyl-1H-pyrrolo[3,2-c]pyridine

A 100 mL round-bottomed flask was charged with a solution of1H-pyrrolo[3,2-c]pyridine (1.0 g, 8.4 mmol) in anhydrous THF (50 mL).NaH (60% in mineral oil, 0.41 g, 10.2 mmol) was added and the reactionmixture was stirred for 5 min at room temperature. To this solution wasadded dropwise, at 0° C., benzenesulfonyl chloride (1.35 mL, 10.2 mmol)and the resulting mixture was stirred at room temperature for 2 h. Thereaction mixture was quenched with water (30 mL) and extracted withEtOAc (3×100 mL). The organic layers were combined, dried (Na₂SO₄) andconcentrated in vacuo to give the title compound as a white solid (1.29g, 55%). ¹H NMR (DMSO, 300 MHz): δ 8.95 (s, 1H); 8.49 (d, J=5.8 Hz, 1H);8.13-8.05 (m, 2H); 8.02-7.94 (m, 2H); 7.79-7.71 (m, 1H); 7.69-7.59 (m,2H); 7.01 (dd, J=3.7, 0.9 Hz, 1H).

Step 2: 1-Benzenesulfonyl-1H-pyrrolo[3,2-c]pyridine 5-oxide

A 100 mL round-bottomed flask was charged with a solution of1-benzenesulfonyl-1H-pyrrolo[3,2-c]pyridine (0.6 g, 2.3 mmol) in dioxane(20 mL). To the resultant solution was added mCPBA (0.6 g, 3.45 mmol)and the mixture was stirred at room temperature for 30 min. The reactionmixture was concentrated in vacuo then the residue was dissolved in DCM(50 mL), and washed successively with aqueous sodium sulfite solution,aqueous sodium bicarbonate solution and brine. The organic layer wasisolated then dried (Na₂SO₄) and concentrated in vacuo to give the titlecompound as a white solid (0.6 g, 95%). ¹H NMR (DMSO, 300 MHz): δ 8.61(dd, J=1.8, 0.7 Hz, 1H); 8.13 (dd, J=7.2, 1.8 Hz, 1H); 8.09-8.04 (m,2H); 8.01 (d, J=3.7 Hz, 1H); 7.92 (d, J=7.2 Hz, 1H); 7.80-7.73 (m, 1H);7.69-7.61 (m, 2H); 6.83 (dd, J=3.7, 0.8 Hz, 1H).

Step 3: 1-Benzenesulfonyl-4-bromo-1H-pyrrolo[3,2-c]pyridine

A 250 mL round-bottomed flask, under nitrogen, fitted with a thermometerprobe and a condenser/inert gas bubbler (via a Claisen head), wascharged with a solution of 1-benzenesulfonyl-1H-pyrrolo[3,2-c]pyridine5-oxide (3.5 g, 12.8 mmol) in acetonitrile (50 mL) and dioxane (50 mL).To this solution was added dropwise phosphorus oxybromide (12 g, 40.9mmol) and the resulting mixture was stirred at 70° C. for 18 h. Theprecipitate formed was removed by filtration and washed several timeswith dioxane. The solution was concentrated in vacuo and partitionedbetween DCM, water and brine. The organic layer was isolated then dried(Na₂SO₄) and concentrated in vacuo. The resultant residue was purifiedby flash chromatography (Si—PCC, 0-20% EtOAc in cyclohexane) to give thedesired product (3.1 g, 72%). ¹H NMR (CDCl₃, 300 MHz): δ 8.23 (d, J=5.7Hz, 1H); 7.94-7.85 (m, 3H); 7.67-7.59 (m, 2H); 7.55-7.48 (m, 2H); 6.75(dd, J=3.7, 0.8 Hz, 1H).

Step 4: 1-Benzenesulfonyl-4-bromo-2-methyl-1H-pyrrolo[3,2-c]pyridine

A 50 mL round-bottomed flask, under nitrogen, fitted with a thermometerprobe and a condenser/inert gas bubbler (via a Claisen head) was chargedwith a solution of 1-benzenesulfonyl-4-bromo-1H-pyrrolo[3,2-c]pyridine(0.43 g, 1.27 mmol) in anhydrous THF (8 mL). To the resultant solution,at −35° C., was added dropwise a solution of lithium diisopropylamide(2.0M in heptane/THF/ethyl benzene, 1.27 mL, 2.54 mmol) and the mixturewas stirred at −35° C. for 30 min. Methyl iodide (0.48 mL, 7.63 mmol)was added dropwise and solution was allowed to reach room temperatureand stirred for 3 h. The reaction was quenched by addition of 1N HCl (3mL). The solution was diluted with water (7 mL), extracted with EtOAc(2×50 mL). The organic extracts were pooled, was dried (Na₂SO₄) andconcentrated in vacuo. The resultant residue was purified by flashchromatography (Si—PPC, 0-100% EtOAc:cyclohexane) to give the desiredproduct (0.43 g, 96%) as a white powder. LCMS (Method A) R_(T)=4.67 min,[M+H]⁺ 351 (⁷⁹Br), 353 (⁸Br)

Example 45 1-Benzenesulfonyl-4-bromo-2-methyl-1H-pyrrolo[2,3-c]pyridine

Step 1: 1-Benzenesulfonyl-4-bromo-1H-pyrrolo[2,3-c]pyridine

A 50 mL round-bottomed flask was charged with a solution of4-bromo-1H-pyrrolo[2,3-c]pyridine (0.7 g, 3.55 mmol) in anhydrous DCM(20 mL). NaOH (0.43 g, 10.7 mmol) and benzenetriethylammonium chloride(0.016 g, 0.07 mmol) were added and the reaction mixture was stirred for3 h at room temperature. The reaction mixture was filtered throughCelite®, the Celite bed was washed with DCM and the resulting filtratewas concentrated in vacuo. The resultant solid residue was trituratedwith diethyl ether and the precipitate collected by filtration to givethe title compound as an off-white solid (0.96 g, 80%). LCMS (Method A):R_(T)=4.29 min, [M+H]⁺ 337 (⁷⁹Br), 339 (⁸¹Br)

Step 2: 1-Benzenesulfonyl-4-bromo-2-methyl-1H-pyrrolo[2,3-c]pyridine

A 50 mL round-bottomed flask, under nitrogen fitted with a thermometerprobe, and a condenser/inert gas bubbler (via a Claisen head), wascharged with a solution of1-benzenesulfonyl-4-bromo-1H-pyrrolo[2,3-c]pyridine (0.96 g, 2.84 mmol)in anhydrous THF (10 mL). To the resultant solution, at −35° C., wasadded dropwise a solution of lithium diisopropylamide (2.0M inheptane/THF/ethyl benzene, 2.84 mL, 5.68 mmol) and the mixture thenstirred at −35° C. for 45 min. Methyl iodide (1.06 mL, 17.04 mmol) wasadded to the reaction mixture dropwise. The resulting solution wasallowed to reach room temperature and was stirred for 3 h. The reactionwas quenched by addition of a solution of 1N HCl (5 mL); the solutionwas diluted with water (15 mL) and extracted with EtOAc (2×75 mL). Theorganic layer was dried (Na₂SO₄) and concentrated in vacuo. The residuewas purified by flash chromatography (Si—PPC, 0-100% DCM:cyclohexane).The residue was triturated with EtOAc (2 mL) and the precipitate wascollected by filtration to give the title compound as a white solid(0.39 g, 39%). LCMS (Method A): R_(T)=4.47 min, [M+H]⁺ 351 (⁷⁹Br), 353(⁸¹Br)

Example 461-Benzenesulfonyl-4-tributylstannanyl-1H-pyrrolo[2,3-c]pyridine

1-Benzenesulfonyl-4-bromo-1H-pyrrolo[2,3-c]pyridine (0.34 g, 1.0 mmol)was dissolved in THF (5 mL) and diethyl ether (5 mL) and the solutioncooled to −78° C. n-Butyllithium (0.756 M in hexanes, 1.2 mL, 5.0 mmol)was added over 5 min then the mixture was stirred for 15 min beforeaddition of tributyltin chloride (0.39 g, 1.2 mmol) over 10 min. Thereaction mixture was stirred at −78° C. for 1 hour then allowed to warmto room temperature and diluted with cyclohexane (50 mL). The reactionmixture was washed with water (3×30 mL) followed by brine, before theorganic phase was dried (MgSO₄) and evaporated. The crude residue waspurified by chromatography on alumina using 30% EtOAc in cyclohexane.The material was further purified by flash chromatography (Si—PPC),eluting with 5-10% EtOAc in cyclohexane to yield the title product. ¹HNMR (CDCl₃, 300 MHz): δ 9.23 (s, 1H), 8.36 (s, 1H), 7.91-8.00 (m, 2H),7.71, d, J=1.1 Hz, 1H), 7.55-7.63 (m, 1H), 7.42-7.53 (m, 2H), 6.59 (d,J=1.1 Hz, 1H), 1.45-1.65 (m, 6H), 1.21-1.38 (m, 6H), 1.09-1.20 (m, 6H),0.85 (t, J=7.5 Hz, 9H).

Example 47 4-Bromo-7-methyl-1H-pyrrolo[2,3-c]pyridine

5-Bromo-2-methyl-3-nitropyridine (217 mg, 1 mmol) was dissolved in THF(10 mL) and the solution was cooled to −50° C. under argon.Vinylmagnesium bromide (3 mL, 1M in THF) was added immediately in oneportion, resulting in a bright orange solution. The orange solution wasstirred at −40° C. for 30 min and the reaction was quenched by theaddition of NH₄Cl (10 mL of saturated. aqueous solution). The mixturewas diluted with water and extracted with EtOAc (2×10 mL). The combinedorganic extracts were dried (MgSO₄) and concentrated. The crude materialwas purified by chromatography on silica (Si—PPC) using EtOAc incyclohexane (20-80%) as eluent to give the product as a pale yellowcrystalline solid (63 mg, 30%). ¹H NMR (CDCl₃) 8.23 (s, 1H), 7.41-7.45(m, 1H), 6.62-6.65 (m, 1H), 2.73 (s, 3H)

Example 48 4-Bromo-6-methyl-1H-pyrrolo[3,2-c]pyridine

A mixture of 6-methyl-1H-pyrrolo[3,2-c]pyridin-4-ol (J. Het. Chem.,1996, 303) (161 mg, 1.09 mmol) and phosphorus oxybromide (1.87 g,excess) was heated in a sealed tube at 120° C. for 50 minutes. Thereaction mixture was poured onto water (10 mL), basified with aqueousNaHCO₃ to pH 8 and the organic product extracted into DCM. The organiclayer was dried (phase separator), evaporated and the residue purifiedby column chromatography (Si—PCC, cyclohexane:ethyl acetate, gradient100:0 to 70:30) to give 4-bromo-6-methyl-1H-pyrrolo[3,2-c]pyridine (20mg, 12%) as a white solid. LCMS R_(T)=2.00 min, [M+H]⁺ 211

Example 49 4-Bromo-5-methyl-1H-pyrrolo[2,3-c]pyridine

To a stirred suspension of vinylmagnesium bromide (1 M in THF, 37.5 mL,37.50 mmol) was added dropwise a solution of3-bromo-2-methyl-5-nitropyridine (2.50 g, 11.52 mmol) in THF, under anatmosphere of nitrogen, at 0° C. The resulting solution was allowed towarm to RT and stirred for 1 day then quenched with saturatedNH₄Cl_((aq)). The resulting mixture was partitioned between EtOAc andwater, the organic layer separated, dried (MgSO₄) and evaporated to givea red crude oil, which was purified by column chromatography (Si—PCC,50-100% EtOAc in cyclohexane) followed by reverse phase HPLC (PhenomenexGemini 5u C18, 0.1% formic acid in water on a gradient of methanol5-75%). The relevant HPLC fractions were loaded onto an Isolute® SCX-2cartridge, the cartridge was washed with MeOH and the desired producteluted with 2 M NH₃ in MeOH to give the title compound as a pale yellowsolid (22 mg, 1%). LCMS (Method H): R_(T) 2.23 min, [M+H]⁺ 211.1 (⁷⁹Br),213.1 (⁸¹Br)

Example 50 1-Benzenesulfonyl-4-bromo-2-methyl-1H-pyrrolo[2,3-c]pyridine

Step 1: 1-Benzenesulfonyl-4-bromo-1H-pyrrolo[2,3-c]pyridine

A 50 mL round-bottomed flask was charged with a solution of4-bromo-1H-pyrrolo[2,3-c]pyridine (0.7 g, 3.55 mmol) in anhydrous DCM(20 mL). NaOH (0.43 g, 10.7 mmol) and benzenetriethylammonium chloride(0.016 g, 0.07 mmol) were added and the reaction mixture was stirred for3 h at room temperature. The reaction mixture was filtered throughCelite, the Celite bed was washed with DCM and the resulting filtratewas concentrated in vacuo. The resultant solid residue was trituratedwith diethyl ether and the precipitate collected by filtration to givethe title compound as an off-white solid (0.96 g, 80%). LCMS (Method A):R_(T)=4.29 min, [M+H]⁺ 337 (⁷⁹Br), 339 (⁸¹Br)

Step 2: 1-Benzenesulfonyl-4-bromo-2-methyl-1H-pyrrolo[2,3-c]pyridine

To a solution of 1-benzenesulfonyl-4-bromo-1H-pyrrolo[2,3-c]pyridine(0.96 g, 2.84 mmol) in anhydrous THF (10 mL), at −35° C., was added asolution of lithium diisopropylamide (2.0M in heptane/THF/ethyl benzene,2.84 mL, 5.68 mmol) dropwise. The mixture was stirred at −35° C. for 45min and then methyl iodide (1.06 mL, 17.04 mmol) was added dropwise. Theresulting solution was allowed to reach room temperature and was stirredfor 3 h. The reaction mixture was quenched by addition of an aqueoussolution of 1N HCl (5 mL); the solution was diluted with water (15 mL)and extracted with EtOAc (2×75 mL). The organic extracts were combined,dried (Na₂SO₄) and concentrated in vacuo. The residue was purified byflash chromatography (Si—PPC, DCM:cyclohexane, gradient 0:100 to 100:0).The residue was triturated in EtOAc (2 mL) and collected by filtrationto give the title compound as a white solid (0.39 g, 39%). LCMS (MethodA): R_(T)=4.47 min, [M+H]⁺ 351 (⁷⁹Br), 353 (⁸¹Br)

Example 51 1-Benzenesulfonyl-4-bromo-2-ethyl-1H-pyrrolo[2,3-c]pyridine

To a solution of 1-benzenesulfonyl-4-bromo-1H-pyrrolo[2,3-c]pyridine(0.63 g, 1.86 mmol) in anhydrous THF (10 mL), at −35° C., was added asolution of lithium diisopropylamide (2.0M in heptane/THF/ethyl benzene,1.86 mL, 3.77 mmol) dropwise. The reaction mixture was stirred at −35°C. for 30 min and then ethyl iodide (0.90 mL, 11.18 mmol) was addeddropwise. The resulting solution was allowed to reach room temperatureand was stirred for 4 h. The reaction mixture was quenched by additionof a solution of 1N HCl (5 mL); the solution was diluted with water (15mL) and extracted with EtOAc (2×75 mL). The organic extracts werecombined, washed with brine, dried (Na₂SO₄) and concentrated in vacuo.The residue was purified by flash chromatography (Si—PPC,EtOAc:cyclohexane 0:100 to 70:30). The residue was triturated in EtOAc(2 mL) and collected by filtration to give the title compound as a whitesolid (0.27 g, 40%). LCMS (Method H): R_(T)=4.65 min, [M+H]⁺ 367 (⁷⁹Br),369 (⁸¹Br)

Example 52 5-Bromo-8-methylimidazo[1,2-a]pyridine

Step 1: 2-Bromo-5-methylpyridine 1-oxide

A mixture of 2-bromo-5-methylpyridine (2.0 g, 11.6 mmol) and3-chloroperbenzoic acid (3.0 g, 14.8 mmol) in chloroform (7 mL) wasstirred at 50° C. for 3 hours, cooled down to room temperature andfiltered. The filtrate was concentrated under reduced pressure to give aresidue that was purified by flash chromatography (Si—PPC, MeOH:EtOAc,gradient 0:100 to 10:90) to give 2-Bromo-5-methylpyridine 1-oxide as awhite solid (2.0 g, 91%). ¹H NMR (400 MHz, CHCl₃-d): δ 8.24 (s, 1H);7.52 (d, J=8.3 Hz, 1H); 6.93 (d, J=8.33 Hz, 1H); 2.29 (s, 3H).

Step 2: (6-Bromo-3-methylpyridin-2-yl)-tert-butylamine

To a solution of 2-bromo-5-methylpyridine 1-oxide (2.0 g, 10.6 mmol) inDCM (40 mL) and trifluorobenzene (17 mL) at 0° C. were addedtert-butylamine (8.0 mL, 76.7 mmol) and p-toluenesulfonic anhydride(11.4 g, 35.0 mmol) portion-wise. The reaction mixture was stirred at 0°C. for 1.5 hours and then filtered. The filtrate was concentrated togive a residue that was purified by flash chromatography (Si—PPC,Et₂O:pentane, gradient 0:100 to 100:0) to give(6-Bromo-3-methylpyridin-2-yl)-tert-butylamine as a colourless oil (500mg, 19%). ¹H NMR (400 MHz, CHCl₃-d): δ 6.98 (d, J=7.5 Hz, 1H); 6.59 (d,J=7.5 Hz, 1H); 4.05 (s, 1H); 1.96 (s, 3H); 1.47 (s, 9H).

Step 3: 6-Bromo-3-methylpyridin-2-ylamine

A solution of (6-bromo-3-methylpyridin-2-yl)-tert-butylamine (500 mg,2.06 mmol) in DCE (2 mL) and TFA (2 mL) was heated at 120° C. for 10 minin a microwave reactor, and then concentrated under reduced pressure.The residue was taken up in MeOH and loaded onto an Isolute® SCX-2cartridge (10 g). The cartridge was washed with MeOH then the desiredproduct eluted with 2 M NH₃ in MeOH to give6-Bromo-3-methylpyridin-2-ylamine as a white solid (359 mg, 93%). ¹H NMR(400 MHz, CHCl₃-d): δ 7.11 (d, J=7.5 Hz, 1H); 6.77 (d, J=7.5 Hz, 1H);4.50 (s, 2H); 2.07 (s, 3H).

Step 4: A mixture of 6-bromo-3-methylpyridin-2-ylamine (359 mg, 1.92mmol) and chloroacetaldehyde (1 mL, 50 wt. % in water) in IMS (4 mL) wasstirred at 100° C. in a sealed tube for 1.5 hours, then cooled to roomtemperature and loaded onto an Isolute® SCX-2 cartridge (10 g). Thecartridge was washed with MeOH then eluted with 2 M NH₃ in MeOH to give5-Bromo-8-methylimidazo[1,2-a]pyridine as a beige solid (387 mg, 95%).¹H NMR (400 MHz, CHCl₃-d): δ 7.79 (d, J=1.3 Hz, 1H); 7.69 (d, J=1.3 Hz,1H); 6.96 (d, J=7.3 Hz, 1H); 6.91 (dq, J=7.3, 1.1 Hz, 1H); 2.61 (d,J=1.1 Hz, 3H).

Example 53 5-Bromo-6-fluoroimidazo[1,2-c]pyridine

Step 1: 2-Bromo-3-fluoropyridine 1-oxide

A mixture of 2-bromo-3-fluoropyridine (1.0 g, 5.7 mmol) and3-chloroperbenzoic acid (1.5 g, 7.4 mmol) in chloroform (3.5 mL) wasstirred at 50° C. for 18 hours, cooled down to room temperature andfiltered. The filtrate was concentrated under reduced pressure to give aresidue that was purified by flash chromatography (Si—PPC, MeOH:EtOAc,gradient 0:100 to 5:95) to give 2-Bromo-3-fluoropyridine 1-oxide as awhite solid (878 mg, 80%). ¹H NMR (400 MHz, CHCl₃-d): δ 8.25 (dt, J=6.6,1.3 Hz, 1H); 7.25-7.17 (m, 1H); 7.06 (ddd, J=8.7, 6.6, 1.3 Hz, 1H).

Step 2: (6-Bromo-5-fluoropyridin-2-yl)-tert-butylamine

To a solution of 2-bromo-3-fluoropyridine 1-oxide (511 mg, 2.7 mmol) inDCM (10 mL) and trifluorobenzene (4 mL) at 50° C. were addedtert-butylamine (2.5 mL, 23.9 mmol) and p-toluenesulfonic anhydride (3.7g, 11.4 mmol) portion-wise. The reaction mixture was stirred at 50° C.for 2 hours and then filtered. The filtrate was concentrated to give aresidue that was purified by flash chromatography (Si—PPC, Et₂O:pentane,gradient 0:100 to 5:95) to give(6-Bromo-5-fluoropyridin-2-yl)-tert-butylamine as a colourless oil (30mg, 5%). ¹H NMR (400 MHz, CHCl₃-d): δ 7.13 (dd, J=8.8, 7.3 Hz, 1H); 6.29(dd, J=8.8, 2.5 Hz, 1H); 4.49 (s, 1H); 1.40 (s, 9H).

Step 3: 6-Bromo-5-fluoropyridin-2-ylamine

A solution of (6-bromo-5-fluoropyridin-2-yl)-tert-butylamine (46 mg,0.19 mmol) in DCE (2 mL) and TFA (2 mL) was heated at 120° C. for 10 minin a microwave reactor, and then concentrated under reduced pressure.The residue was taken up in MeOH and loaded onto an Isolute® SCX-2cartridge (5 g). The cartridge was washed with MeOH then the desiredproduct eluted with 2 M NH₃ in MeOH to give6-Bromo-5-fluoropyridin-2-ylamine as an off-white solid (25 mg, 71%). ¹HNMR (400 MHz, CHCl₃-d): δ 7.21 (dd, J=8.7, 7.2 Hz, 1H); 6.39 (dd, J=8.7,2.7 Hz, 1H); 4.89-3.75 (s, 2H).

Step 4: A mixture of 6-bromo-5-fluoropyridin-2-ylamine (25 mg, 0.13mmol) and chloroacetaldehyde (0.1 mL, 50 wt. % in water) in IMS (2 mL)was stirred at 100° C. in a sealed tube for 18 hours, then cooled toroom temperature and loaded onto an Isolute® SCX-2 cartridge (5 g). Thedesired product was washed with MeOH then eluted with 2 M NH₃ in MeOH togive 5-Bromo-6-fluoroimidazo[1,2-a]pyridine as a yellow oil (25 mg,89%). ¹H NMR (400 MHz, CHCl₃-d): δ 7.84 (s, 1H); 7.76 (m, 1H); 7.61(ddd, J=9.73, 4.67, 0.71 Hz, 1H); 7.21-7.16 (m, 1H).

Example 54 5-Bromo-7-methyl-imidazo[1,2-c]pyridine

A mixture of 6-bromo-4-methyl-pyridin-2-ylamine (374 mg, 2.0 mmol) andchloroacetaldehyde (1 mL, 50 wt. % in water) in IMS (4 mL) was stirredat 100° C. in a sealed tube for 18 hours, then cooled to roomtemperature and loaded onto an Isolute® SCX-2 cartridge (10 g). Thecartridge was washed with MeOH then the product was eluted with 2 M NH₃in MeOH. After the solvents were removed, the residue was purified byflash chromatography (Si—PPC, MeOH:DCM, gradient 0:100 to 5:95) to give5-Bromo-7-methyl-imidazo[1,2-a]pyridine as an orange solid (340 mg,82%). ¹H NMR (400 MHz, CHCl₃-d): δ 7.72-7.70 (m, 1H); 7.63-7.62 (m, 1H);7.38-7.37 (m, 1H); 6.92-6.90 (m, 1H); 2.40 (m, 3H).

Example 55 5-Bromo-2-methylimidazo[1,2-a]pyridine

A mixture of 6-bromopyridin-2-ylamine (1.0 g, 5.6 mmol) and1-chloropropan-2-one (0.5 mL, 6.3 mmol) in IMS (4 mL) was stirred atreflux for 36 hours, then cooled to room temperature and loaded onto anIsolute® SCX-2 cartridge (20 g). The cartridge was washed with MeOH thenthe desired product eluted with 2 M NH₃ in MeOH. After the solvents wereremoved, the residue was purified by flash chromatography (Si—PPC,MeOH:Et₂O, gradient 0:100 to 10:100) to give5-Bromo-2-methylimidazo[1,2-a]pyridine as a yellow oil (547 mg, 45%).LCMS (Method H): R_(T)=0.31 min and 2.04 min, [M+H]⁺ 211(⁷⁹Br) and213(⁸¹Br)

Example 56 5-bromo-[1,2,4]triazolo[4,3-a]pyridine

Step 1: (6-Bromopyridin-2-yl)hydrazine

A mixture of 2,6-dibromopyridine (1.44 g, 6.1 mmol) and hydrazine (1.65mL, 32.2 mmol) in butanol (100 mL) was stirred at reflux for 18 hours.The reaction mixture was cooled to room temperature and concentratedunder reduced pressure. The residue was partitioned between an aqueoussaturated solution of sodium bicarbonate and EtOAc. The organic layerwas separated and washed with brine, dried over Na₂SO₄, filtered andconcentrated to give (6-Bromopyridin-2-yl)hydrazine as a white solid(1.0 g, 92%). ¹H NMR (400 MHz, CHCl₃-d): δ 7.36-7.28 (m, 1H); 6.82 (d,J=7.70 Hz, 1H); 6.67 (d, J=7.7 Hz, 1H); 5.97 (s, 1H); 3.80 (s, 2H).

Step 2: A solution of (6-bromopyridin-2-yl)hydrazine (500 mg, 2.66 mmol)in diethoxymethyl acetate (2.5 mL) was stirred at room temperature for18 hours. The reaction mixture was diluted with pentane and filtered.The precipitate was washed with pentane and dried at 50° C. under vacuumfor 1 hour to give 5-bromo-[1,2,4]triazolo[4,3-a]pyridine as a beigesolid (410 mg, 78%). ¹H NMR (400 MHz, CHCl₃-d): δ 8.98 (s, 1H); 7.83(dt, J=9.2, 0.9 Hz, 1H); 7.22 (dd, J=9.2, 7.0 Hz, 1H); 7.09 (dd, J=7.0,0.9 Hz, 1H).

Example 57 8-Benzyloxy-5-bromo-imidazo[1,2-c]pyridine

Step 1: 6-Bromo-2-nitropyridin-3-ol

To a suspension of 6-bromopyridin-3-ol (2.5 g, 14.4 mmol) in acetic acid(20 mL) at 0° C. was added fuming nitric acid (0.9 mL, 22.4 mmol). Thereaction mixture was stirred at room temperature for 1 hour and then at60° C. for 1 hour. The reaction mixture was cooled to 0° C. and 10Maqueous hydroxide was added dropwise until pH 4-5 (ca 25 mL). Theresulting mixture was diluted with water and partially concentratedunder reduced pressure. The residue was extracted twice with EtOAc. Theorganic fractions were combined and washed with water and brine, driedover Na₂SO₄, filtered and concentrated. The residue was azeotroped withtoluene to give 6-Bromo-2-nitropyridin-3-ol as an orange solid (2.2 g,71%). ¹H NMR (400 MHz, DMSO-d₆): δ 11.92 (s, 1H); 7.86-7.83 (d, J=8.6Hz, 1H); 7.61 (d, J=8.6 Hz, 1H).

Step 2: 3-Benzyloxy-6-bromo-2-nitropyridine

To a solution of 6-bromo-2-nitropyridin-3-ol (1.0 g, 4.6 mmol), inanhydrous DMF (15 mL) at 0° C. was added 60% sodium hydride in mineraloil (200 mg, 5.0 mmol). The reaction mixture was stirred at 0° C. for 5min and at room temperature for 15 min. Benzyl bromide (0.6 mL, 5.0mmol) was added dropwise and the resulting mixture was stirred at 60° C.for 1 hour, cooled to room temperature, diluted with water and extractedwith EtOAc. The organic layer was separated and washed with water andbrine, dried over Na₂SO₄, filtered and concentrated. The residue waspurified by flash chromatography (Si—PPC, Et₂O:pentane, gradient 0:100to 100:0) to give 3-Benzyloxy-6-bromo-2-nitropyridine as a yellow solid(956 mg, 67%). ¹H NMR (400 MHz, CHCl₃-d): δ 7.60 (d, J=8.6 Hz, 1H);7.41-7.35 (m, 6H); 5.25 (s, 2H).

Step 3: 3-Benzyloxy-6-bromopyridin-2-ylamine

A mixture of 3-benzyloxy-6-bromo-2-nitropyridine (1.6 g, 5.2 mmol) andiron powder (2.9 g, 51.8 mmol) in acetic acid (25 mL) and IMS (25 mL)was stirred at reflux for 1 hour, then cooled to room temperature andfiltered though a pad of celite. The filtrate was concentrated underreduced pressure to give a residue that was partitioned between anaqueous saturated solution of sodium bicarbonate and EtOAc. The organiclayer was separated and washed with water and brine, dried over Na₂SO₄,filtered and concentrated. The residue was purified by flashchromatography (Si—PPC, EtOAc:cyclohexane, gradient 0:100 to 40:60) togive 3-Benzyloxy-6-bromopyridin-2-ylamine as a pale yellow solid (1.0 g,71%). ¹H NMR (400 MHz, CHCl₃-d): δ 7.41-7.34 (m, 5H); 6.82 (d, J=8.1 Hz,1H); 6.71 (d, J=8.1 Hz, 1H); 5.04 (s, 2H); 4.80 (s, 2H).

Step 4: A mixture of 3-benzyloxy-6-bromopyridin-2-ylamine (1.0 g, 3.6mmol) and chloroacetaldehyde (1.2 mL, 50 wt. % in water) in IMS (12 mL)was stirred at reflux for 1 hour, then concentrated under reducedpressure. The residue was partitioned between an aqueous saturatedsolution of sodium bicarbonate and EtOAc. The organic layer wasseparated and washed with brine, dried over Na₂SO₄, filtered andconcentrated. The residue was purified by flash chromatography (Si—PPC,MeOH:Et₂O, gradient 0:100 to 1:99) to give8-Benzyloxy-5-bromo-imidazo[1,2-a]pyridine as an beige solid (960 mg,88%). LCMS (Method H) R_(T) 3.08 min; [M+H]⁺ 303 (⁷⁹Br) and 305 (⁸¹Br)

Example 58 3-Fluoro-2-nitrophenylamine

Step 1: 3-Fluoro-2-nitro-N-(triphenylphosphoranylidene)benzenamine

To a solution of 1-azido-3-fluoro-2-nitrobenzene (500 mg, 2.75 mmol) inTHF (4 mL) and water (1 mL) was added triphenylphosphine (720 mg, 2.75mmol). The reaction mixture was stirred at room temperature for 45 minthen partitioned between water and EtOAc. The organic layer wasseparated and washed with brine, dried over Na₂SO₄, filtered andconcentrated. The residue was subjected to flash chromatography (Si—PCC,Et₂O) to give the desired product as a yellow solid (844 mg, 73%). LCMS(Method A): R_(T) 4.36 min; [M+H]⁺ 417

Step 2: A 2-5 mL microwave vial equipped with a magnetic follower wascharged with 3-fluoro-2-nitro-N-(triphenylphosphoranylidene)benzenamine(585 mg, 1.4 mmol), water (3 mL) and TFA (0.1 mL). The reaction mixturewas irradiated at 160° C. for 15 min and then partitioned between waterand EtOAc. The organic layer was separated and washed with an saturatedaqueous solution of sodium bicarbonate and brine, dried over Na₂SO₄,filtered and concentrated. The residue was subjected to flashchromatography (Si—PCC, 0-100% Et₂O in pentane) to give3-Fluoro-2-nitrophenylamine as an orange solid (218 mg, 100%). ¹H NMR(CDCl₃, 400 MHz): δ 7.22 (ddd, J=8.2, 8.2, 5.5 Hz, 1H); 6.57 (ddd,J=8.5, 1.4, 1.4 Hz, 1H); 6.48 (ddd, J=11.3, 8.2, 1.4 Hz, 1H.

Example 59 2-Methylaminobenzoimidazole-1-carboxylic acid tert-butylester

Di-tert-butyl dicarbonate (951 mg, 4.36 mmol) was added to a suspensionof (1H-benzoimidazol-2-yl)methylamine (583 mg, 3.96 mmol) in water (5mL) and the resulting reaction mixture was stirred at 35° C. for 2 h.The mixture was diluted with water and extracted with DCM (2×15 mL) andEtOAc (2×15 mL). The combined organic layers were dried over sodiumsulfate, filtered and the solvents reduced in vacuo. The crude residuewas purified by column chromatography (Si—PCC, EtOAc:cyclohexane,gradient 0:100 to 30:70) to afford the title compound as a pale-brownsolid (720 mg, 74%). ¹H NMR (400 MHz, CDCl₃): δ 7.55 (1H, d, J=8.04 Hz),7.38 (1H, d, J=7.85 Hz), 7.16 (2H, td, J=7.65, 1.27 Hz), 6.99 (1H, td,J=7.75, 1.20 Hz), 3.14 (3H, d, J=4.99 Hz), 1.67 (9H, s)

Formula I(i) thiazole intermediates wherein (i) X¹ is N and X² is S

Example 65a4-(5-chloro-2-((3-morpholinoazetidin-1-yl)methyl)thiazolo[5,4-d]pyrimidin-7-yl)morpholine

A solution of5-chloro-7-morpholin-4-yl-thiazolo[5,4-d]pyrimidine-2-carbaldehyde (3.0g, 10.54 mmol) and 4-azetidin-3-ylmorpholine (1.8 g, 12.66 mmol) in DCE(200 mL) was stirred at ambient temperature for 2 h. Sodiumtriacetoxyborohydride (3.5 g, 16.5 mmol) was added and the mixturestirred for 18 h, then loaded onto an Isolute® SCX-2 cartridge (50 g).The cartridge was then washed with MeOH and the desired product wassubsequently eluted using 2 M NH₃ in MeOH. The eluent was collected andconcentrated in vacuo. The resultant residue was purified by flashchromatography (Si—PPC, DCM:MeOH 100:0 to 99:1 to 98:2 to 95:5) toafford4-(5-chloro-2-((3-morpholinoazetidin-1-yl)methyl)thiazolo[5,4-d]pyrimidin-7-yl)morpholineas a cream solid (2.66 g, 61%). LCMS (Method C): R_(T)=2.68 min, [M+H]⁺411.3

Example 65b2-methyl-2-(4-((7-morpholino-5-(tributylstannyl)thiazolo[5,4-d]pyrimidin-2-yl)methyl)piperazin-1-yl)propanamide

A mixture of2-[4-(5-chloro-7-morpholin-4-yl-thiazolo[5,4-d]pyrimidin-2-ylmethyl)-piperazin-1-yl]-isobutyramide(1.0 g, 2.2 mmol), hexabutylditin (1.4 mL, 2.7 mmol), andPdCl₂{P^(t)Bu₂(Ph-p-Nme₂)}₂ (161 mg, 0.2 mmol) in dioxane (10 mL) wasdegassed and then subjected to microwave irradiation at 150° C. for 30min. The reaction mixture was diluted with MeOH and loaded onto anIsolute® SCX-2 cartridge (25 g). The cartridge was then washed with MeOHand the desired product was subsequently eluted using 2 M NH₃ in MeOH.Appropriate fractions were combined and concentrated to give a residuewhich was subjected to flash chromatography (Si—PPC, MeOH:DCM, gradient0:100 to 10:90). Appropriate fractions were combined and concentrated togive2-methyl-2-(4-((7-morpholino-5-(tributylstannyl)thiazolo[5,4-d]pyrimidin-2-yl)methyl)piperazin-1-yl)propanamideas a yellow oil (1.1 g, 67%). LCMS (Method C) R_(T)=4.83 min;[M+H]⁺694.1 (¹¹⁶Sn) 696.1 (¹¹⁸Sn)

Example 65c5-Chloro-7-morpholin-4-yl-thiazolo[5,4-c]pyrimidine-2-carbaldehyde

5-Chloro-7-morpholin-4-yl-thiazolo[5,4-d]pyrimidine (5.1 g, 0.02 mol)was suspended in THF (200 mL) and the resulting solution was cooled to−78° C. whereupon the starting material precipitated from solution.LiHMDS (1M in THF, 25 mL, 1.25 equiv) was added dropwise to the stirredsuspension. After addition was complete, the mixture was stirred for 30min, then DMF (9 mL, 6 equiv) was added and the resulting solution wasstirred for 15 min at −78° C. and then warmed to 0° C. and stirred for15 min. The solution was re-cooled to −78° C. and then cannulated (via awide-bore double-ended needle) into a stirred solution of ˜0.5M HCl (600mL). The product precipitated from solution as a pale yellow powder.This was isolated by filtration through a sintered glass funnel, washedwith water and dried in vacuo overnight to give 5 g of5-Chloro-7-morpholin-4-yl-thiazolo[5,4-d]pyrimidine-2-carbaldehyde(87.7%). ¹H NMR (400 MHz, CDCl₃): δ 3.83-3.88 (m, 4H), 4.06-4.15 (m,2H), 4.72 (m, 2H) and 9.95 (s, 1H).

Example 65d5-Chloro-2-[3-(1,1-Dioxo-1-thiomorpholin-4-yl)azetidin-1-ylmethyl]-7-morpholin-4-ylthiazolo[5,4-c]pyrimidine

A mixture of5-chloro-7-morpholin-4-yl-thiazolo[5,4-c]pyrimidine-2-carbaldehyde (400mg, 1.40 mmol), 4-azetidin-3-ylthiomorpholine-1,1-dioxide (321 mg, 1.69mmol) and 4 Å powdered molecular sieves (600 mg) in DCE (20 mL) wasstirred at room temperature for 4 h before the addition of sodiumtriacetoxyborohydride (595 mg, 2.80 mmol). The reaction mixture wasstirred for 65 h then filtered through celite, washing with DCM. Theorganic phase was washed with brine (×1) and concentrated in vacuoaffording5-Chloro-2-[3-(1,1-Dioxo-1-thiomorpholin-4-yl)azetidin-1-ylmethyl]-7-morpholin-4-ylthiazolo[5,4-d]pyrimidineas an orange powder (572 mg, 89%). LCMS (Method H): R_(T) 2.43 min[M+H]⁺ 459.2

Example 65e5-Chloro-7-morpholin-4-yl-2-[3-(tetrahydropyran-4-yl)azetidin-1-ylmethyl]thiazolo[5,4-d]pyrimidine

A mixture of5-chloro-7-morpholin-4-yl-thiazolo[5,4-c]pyrimidine-2-carbaldehyde (650mg, 2.28 mmol), 3-(tetrahydropyran-4-yl)azetidine (313 mg, 2.22 mmol)and 4 Å powdered molecular sieves (1.2 g) in DCE (40 mL) was stirred atroom temperature for 4 h before the addition of sodiumtriacetoxyborohydride (941 mg, 4.44 mmol). The reaction mixture wasstirred for 24 h then filtered through celite, washing with DCM. Theorganic phase was washed with brine (×1) and concentrated in vacuo. Theresidue was purified by column chromatography (Si—PCC, MeOH:EtOAc,0-20%) affording5-Chloro-7-morpholin-4-yl-2-[3-(tetrahydropyran-4-yl)azetidin-1-ylmethyl]thiazolo[5,4-c]pyrimidineas an orange powder (630 mg, 67%). LCMS (Method A): R_(T) 2.54 min[M+H]⁺ 410.2

Example 65f2-[1-(5-Chloro-7-morpholin-4-ylthiazolo[5,4-d]pyrimidin-2-ylmethyl)piperidin-4-yl]propan-2-ol

A mixture of5-chloro-7-morpholin-4-yl-thiazolo[5,4-d]pyrimidine-2-carbaldehyde (5.11g, 17.9 mmol), 2-piperidin-4-ylpropan-2-ol (3.08 g, 21.5 mmol) and 4 Åpowdered molecular sieves (9 g) in DCE (85 mL) was stirred at roomtemperature for 1.5 h before the addition of sodiumtriacetoxyborohydride (7.61 g, 35.9 mmol). The reaction mixture wasstirred for 90 h then filtered through celite, washing the celite bedwith DCM. The organic phase was washed with brine and concentrated invacuo. The resulting residue was purified by column chromatography(Si—PCC, EtOAc:DCM, 0-100%) affording2-[1-(5-Chloro-7-morpholin-4-ylthiazolo[5,4-d]pyrimidin-2-ylmethyl)piperidin-4-yl]propan-2-olas an orange solid (4.96 g, 67%). LCMS (Method A): R_(T) 2.77 min [M+H]⁺412.2

Example 65g5-Chloro-2-((E)-2-methoxyvinyl)-7-morpholin-4-yl-thiazolo[5,4-d]pyrimidine

To a stirred suspension of (methoxymethyl)triphenylphosphonium chloride(3.37 g, 9.83 mmol) in dry THF (40 mL) was added dropwise a 1 M solutionof LiHMDS in THF (9.8 mL, 9.8 mmol) under an atmosphere of nitrogen, at0° C. After 15 min the solution was cooled to −78° C. and a suspensionof 5-chloro-7-morpholin-4-yl-thiazolo[5,4-d]pyrimidine-2-carbaldehyde(2.0 g, 7.02 mmol) in dry THF (40 mL) was added. The mixture was allowedto warm to RT after 5 min, stirred for a further 1.5 h then quenchedwith H₂O. The resulting precipitate was filtered, washed with EtOAc anddried under vacuum to give5-chloro-2-((E)-2-methoxyvinyl)-7-morpholin-4-yl-thiazolo[5,4-c]pyrimidine(730 mg, 33%) as a pale yellow solid. ¹H NMR (CDCl₃, 300 MHz): δ 7.48(d, J=12.8 Hz, 1H), 6.01 (d, J=12.8 Hz, 1H), 4.44-4.24 (br s, 4H), 3.83(m, 4H), 3.79 (s, 3H).

Example 65h2-{1-[2-(5-Chloro-7-morpholin-4-yl-thiazolo[5,4-d]pyrimidin-2-yl)ethyl]piperidin-4-yl}propan-2-ol

5-Chloro-2-((E)-2-methoxyvinyl)-7-morpholin-4-yl-thiazolo[5,4-c]pyrimidine(730 mg, 2.33 mmol) was stirred in 37 wt. % HCl_((aq))/THF (4:8 mL) at50° C. for 2 h. The solution was allowed to cool, partitioned betweenEtOAc and saturated NaHCO_(3(aq)), the organic layer separated andwashed with brine. The organic layer was dried (Na₂SO₄) and concentratedin vacuo to give a residue (1.4 g), which was taken up in DCE (30 mL).2-Piperidin-4-ylpropan-2-ol (300 mg, 2.10 mmol) and powdered 4 Åmolecular sieves were then added. The reaction mixture was stirred atroom temperature for 5 h, sodium triacetoxyborohydride (900 mg, 4.25mmol) was added and the resulting mixture stirred for a further 18 h.The reaction mixture was loaded onto an Isolute® SCX-2 cartridge, washedwith MeOH then the desired product eluted with 2 M NH₃ in MeOH. Theresulting residue was purified by column chromatography (Si—PCC, 0-10%MeOH in DCM) to give the title compound as an orange solid (120 mg, 12%over 2 steps). LCMS (Method H): R_(T)=2.55 min, [M+H]⁺ 426.5

Example 65i2-(5-Chloro-7-morpholin-4-yl-thiazolo[5,4-d]pyrimidin-2-yl)1-[4-(1-hydroxy-1-methylethyl)piperidin-1-yl]ethanone

To a stirred solution of5-chloro-2-methyl-7-morpholin-4-yl-thiazolo[5,4-d]pyrimidine (500 mg,1.85 mmol) in THF (30 mL) was added dropwise a 1 M solution of LiHMDS inTHF (2.80 mL, 2.80 mmol) under an atmosphere of nitrogen, at −78° C.After 2 h, the solution was poured onto a bed of CO_(2(s)) and theresulting mixture allowed to warm to RT. The mixture was partitionedbetween DCM and 0.1 M HCl_((aq)), the organic layer separated, dried(phase separator) and concentrated in vacuo. The resultant crude waspurified by flash chromatography (Si—PCC, 0-5% MeOH in DCM) to give aresidue (200 mg), a portion of which (58 mg) was taken up in DMF (2 mL)and 2-piperidin-4-ylpropan-2-ol (32 mg, 0.22 mmol), HATU (84 mg, 0.22mmol) and DIPEA (0.10 mL, 0.55 mmol) were added. The reaction mixturewas stirred at RT for 18 h, the mixture was partitioned between EtOAcand water, the organic layer dried (MgSO₄) and evaporated to give a darkorange oil.

Purification by column chromatography (Si—PCC, 0-10% MeOH in DCM) gavethe title compound (40 mg, 49%) as a dark orange solid. LCMS (Method H):R_(T) 3.96 min, [M+H]⁺ 440.4

Example 65jN1-(7-morpholino-2-((3-morpholinoazetidin-1-yl)methyl)thiazolo[5,4-d]pyrimidin-5-yl)benzene-1,2-diamine

A mixture of5-chloro-7-morpholin-4-yl-2-(3-morpholin-4-ylazetidin-1-ylmethyl)-thiazolo[5,4-d]pyrimidine(500 mg, 1.22 mmol), 1,2-diaminobenzene (300 mg, 2.77 mmol), palladiumacetate (80 mg, 0.36 mmol), BINAP (110 mg, 0.18 mmol) and cesiumcarbonate (600 mg, 1.84 mmol) in 1,4-dioxane (5 mL)) was purged withargon gas then subjected to microwave irradiation at 150° C. for 30 min.The reaction mixture was loaded onto an Isolute® SCX-2 cartridge (25 g),washed with MeOH before the desired product was eluted using 2 M NH₃ inMeOH. The product was collected and concentrated in vacuo. The resultantresidue was purified by flash chromatography (Si—PPC, DCM: 2 M NH₃ inMeOH 100:0 to 99:1 to 98:2 to 97:3) to affordN1-(7-morpholino-2-((3-morpholinoazetidin-1-yl)methyl)thiazolo[5,4-d]pyrimidin-5-yl)benzene-1,2-diamineas a white solid (283 mg, 48%). LCMS (Method H): R_(T)=2.40 min, [M+H]⁺483.

Example 65k2-[1-(7-Morpholin-4-yl-5-(tributylstannanyl)thiazolo[5,4-d]pyrimidin-2-ylmethyl)piperidin-4-yl]propan-2-ol

A mixture of2-[1-(5-chloro-7-morpholin-4-ylthiazolo[5,4-d]pyrimidin-2-ylmethyl)piperidin-4-yl]propan-2-ol(500 mg, 1.21 mmol), hexabutylditin (910 μL, 1.81 mmol), andPdCl₂{P^(t)Bu₂(Ph-p-Nme₂)}₂ (85 mg, 0.116 mmol) in 1,4-dioxane (5 mL)was purged with argon gas and then subjected to microwave irradiation at150° C. for 30 min. The reaction mixture was diluted with MeOH andloaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was thenwashed with MeOH and the desired product was subsequently eluted using 2M NH₃ in MeOH. The product was collected and concentrated in vacuo. Theresultant residue was purified by flash chromatography (Si—PPC,DCM:MeOH; 100:0 to 98:2 to 95:5) to afford to afford the title compoundas a yellow solid (681 mg, 84%). ¹H NMR (CDCl₃, 400 MHz) δ 4.31 (m, 4H);3.82 (m, 6H); 3.05 (m, 2H); 2.16 (m, 2H); 1.74 (m, 2H); 1.65-1.54 (m,7H); 1.43-1.24 (m, 9H); 1.19 (s, 6H); 1.13 (m, 6H); 0.88 (t, J=7.3 Hz,9H)

Example 65l4-(5-chloro-2-(4-(oxetan-3-yl)piperidin-1-yl)methyl)thiazolo[5,4-d]pyrimidin-7-yl)morpholine

A solution of5-chloro-7-morpholin-4-ylthiazolo[5,4-c]pyrimidine-2-carbaldehyde (1.0g, 3.52 mmol), 4-oxetan-3-ylpiperidine (536 mg, 4.23 mmol) and molecularsieves (4 Å, powdered, 6.56 g) in DCE (30 mL) was stirred at ambienttemperature for 4 h. Sodium triacetoxyborohydride (1.49 g, 7.05 mmol)was added and the mixture stirred for 6 h, then filtered through a padof Celite® and the filtrate was concentrated in vacuo. The resultantresidue was purified by flash chromatography (Si—PPC, DCM:MeOH; gradientfrom 100:0 to 97:3) to afford the title compound as a cream solid (334mg, 41%). LCMS (Method A): R_(T)=2.48 min, M+H⁺=410

Example 65m2-(5-Chloro-7-morpholin-4-ylthiazolo[5,4-d]pyrimidin-2-yl)-1-[4-(2-hydroxy-1,1-dimethylethyl)piperazin-1-yl]ethanone

A mixture of(5-chloro-7-morpholin-4-ylthiazolo[5,4-d]pyrimidin-2-yl)acetic acid (80mg, 0.25 mmol), 2-methyl-2-piperazin-1-ylpropan-1-ol (48 mg, 0.31 mmol),HATU (116 mg, 0.31 mmol) and DIPEA (133 μL, 0.76 mmol) in DMF (3 mL) wasstirred at r.t. for 65 h then loaded onto an Isolute® SCX-2 cartridgewhich was washed with MeOH and the product eluted with 2M NH₃/MeOH/DCM.The resulting residue was purified by column chromatography (Si—PCC,MeOH:DCM, 0-10%) affording the title compound as an orange solid (65 mg,56%). LCMS (method H): R_(T) 2.02 min [M+H]⁺ 455.3

Example 65n5-(2-Ethylbenzoimidazol-1-yl)-7-morpholin-4-ylthiazolo[5,4-c]pyrimidine

A mixture of 5-chloro-7-morpholin-4-ylthiazolo[5,4-d]pyrimidine (3.0 g,11.7 mmol), 2-ethylbenzimidazole (1.88 g, 12.9 mmol),tris(dibenzylideneacetone)dipalladium (534 mg, 0.60 mmol), XPhos (1.11g, 2.34 mmol) and Cs₂CO₃ (7.62 g, 23.4 mmol) in dioxane (60 mL) waspurged with argon then heated at 120° C. for 16 h in a sealed tube. Thereaction mixture was filtered through Celite®, and the filtratedpartitioned between EtOAc and H₂O. The organic phase was washed withbrine, then dried (Na₂SO₄) and concentrated in vacuo. The resultingresidue was purified by column chromatography (Si—PCC, EtOAc:DCM, 0-90%)followed by recrystallisation from ^(i)PrOAc affording the titlecompound (3.17 g, 74%). LCMS (method A): R_(T) 2.74 min [M+H]⁺ 367.1

Example 65o5-(2-Ethylbenzoimidazol-1-yl)-2-iodo-7-morpholin-4-ylthiazolo[5,4-c]pyrimidine

A solution of5-(2-ethylbenzoimidazol-1-yl)-7-morpholin-4-ylthiazolo[5,4-c]pyrimidine(1.92 g, 5.23 mmol) in THF (60 mL) was cooled to −40° C. before the dropwise addition of LiHMDS (6.3 mL, 6.28 mmol, 1 M solution in THF). Theresulting mixture was warmed to −5° C. over 30 min then mixture wascooled back to −30° C. before the addition of a solution of1-chloro-2-iodoethane (2.0 g, 10.47 mmol) in THF (6 mL). The resultingmixture was allowed to warm to 0° C. then quenched with NH₄Cl andextracted with EtOAc. The combined organics were washed with brine thendried (Na₂SO₄) and concentrated in vacuo. The resulting residue waspurified by column chromatography (Si—PCC, EtOAc:DCM, 50-80%) followedby recrystallisation from ^(i)PrOAc affording the title compound as ayellow solid (1.58 g, 62%). LCMS (method A): R_(T) 3.50 min [M+H]⁺ 493.0

Example 65p(5-Chloro-7-morpholin-4-ylthiazolo[5,4-d]pyrimidin-2-yl)-[4-(1-hydroxy-1-methylethyl)piperidin-1-yl]methanone

A mixture of5-chloro-7-morpholin-4-ylthiazolo[5,4-c]pyrimidine-2-carboxylic acid(200 mg, 0.67 mmol), 2-piperidin-4-ylpropan-2-ol (105 mg, 0.73 mmol),HATU (278 mg, 0.73 mmol) and DIPEA (130 μL, 0.75 mmol) in DCM (7 mL) wasallowed to stir at r.t. for 18 h. The reaction mixture was concentratedin vacuo and the resulting residue purified by column chromatography(Si—PCC, MeOH:DCM, 0-2%) affording the title compound as a white solid.¹H NMR (CDCl₃, 400 MHz): δ 5.15 (1H, d, J=13.36 Hz), 4.79 (1H, d,J=13.25 Hz), 4.35 (4H, brd s), 3.85 (4H, t, J=4.75 Hz), 3.16-3.13 (1H,m), 1.92 (2H, t, J=15.39 Hz), 1.75-1.60 (1H, m), 1.49-1.38 (4H, m), 1.22(6H, d, J=6.97 Hz).

Example 65q(5-Chloro-7-morpholin-4-ylthiazolo[5,4-d]pyrimidin-2-yl)-(2,2-dimethyl-4-oxetan-3-ylpiperazin-1-yl)methanone

A mixture of5-chloro-7-morpholin-4-ylthiazolo[5,4-c]pyrimidine-2-carboxylic acid(100 mg, 0.33 mmol), 3,3-dimethyl-1-oxetan-3-ylpiperazine (62 mg, 0.36mmol), HATU (278 mg, 0.37 mmol) and DIPEA (65 μL, 0.37 mmol) in DCM (3mL) was allowed to stir at r.t. for 18 h. The reaction mixture wasconcentrated in vacuo and the resulting residue purified by columnchromatography (Si—PCC, MeOH:DCM, 0-2%) affording the title compound asa yellow solid. LCMS (method H): R_(T) 2.67 min, [M+H]⁺ 453.3

Example 65r5-(2-Ethylbenzoimidazol-1-yl)-7-morpholin-4-ylthiazolo[5,4-c]pyrimidine-2-carbaldehyde

A mixture of5-chloro-7-morpholin-4-ylthiazolo[5,4-c]pyrimidine-2-carbaldehyde (1.0g, 3.51 mmol), 2-ethylbenzimidazole (512 mg, 3.71 mmol),tris(dibenzylideneacetone)dipalladium (90 mg, 2.5 mol %), XPhos (158 mg,10 mol %) and Cs₂CO₃ (1.6 g, 4.91 mmol) in dioxane (30 mL) was purgedwith argon then heated at 115° C. for 17 h. The reaction mixture wasfiltered through Celite® which was washed with hot dioxane, and thefiltrated concentrated in vacuo. The resulting residue was trituratedwith Et₂O and the resulting brown solid collected by filtration anddried in vacuo affording the title compound (1.23 g, 88%). ¹H NMR(CDCl₃, 400 MHz): δ 10.01 (1H, s), 8.09-8.09 (1H, m), 7.75-7.74 (1H, m),7.33-7.26 (2H, m), 5.00-4.00 (4H, brd s), 3.93 (4H, t, J=4.72 Hz), 3.37(2H, q, J=7.45 Hz), 1.46 (3H, t, J=7.45 Hz).

Example 65s[5-(2-Ethylbenzoimidazol-1-yl)-7-morpholin-4-ylthiazolo[5,4-c]pyrimidin-2-yl]methanol

To a solution of5-(2-ethylbenzoimidazol-1-yl)-7-morpholin-4-ylthiazolo[5,4-c]pyrimidine-2-carbaldehyde(1.2 g, 3.04 mmol) in DCE (30 mL) was added MeOH (3 mL) and NaBH₄ (119mg, 3.15 mmol) and the resulting mixture stirred at r.t. for 4 h. Thereaction mixture was concentrated in vacuo and the resulting residuetriturated with H₂O. The resulting solid was collected by filtration anddried in vacuo affording the title compound (1.18 g, 98%). LCMS (methodH): R_(T) 2.42 min, [M+H]⁺ 397.4

Example 65t2-Bromomethyl-5-(2-ethylbenzoimidazol-1-yl)-7-morpholin-4-ylthiazolo[5,4-c]pyrimidine

To a suspension of[5-(2-ethylbenzoimidazol-1-yl)-7-morpholin-4-ylthiazolo[5,4-d]pyrimidin-2-yl]methanol(1.18 g, 2.97 mmol) in DCM (60 mL) was added PBr₃ (3.36 mL, 3.36 mmol,1M solution in DCM) and the resulting mixture allowed to stir at r.t.for 1 h. The reaction mixture was diluted with DCM and the organic phasewashed with H₂O and brine, then dried (MgSO₄) and concentrated in vacuoaffording the title compound as a yellow solid (673 mg, 49%). LCMS(method H): R_(T) 3.24 min, [M+H]⁺ 459.1 and 461.1 (1:1)

Example 65u[5-(2-Ethylbenzoimidazol-1-yl)-7-morpholin-4-ylthiazolo[5,4-c]pyrimidin-2-ylmethyl]phosphonicacid dimethyl ester

A mixture of2-bromomethyl-5-(2-ethylbenzoimidazol-1-yl)-7-morpholin-4-ylthiazolo[5,4-d]pyrimidine(670 mg, 1.46 mmol) in trimethylphosphite (10 mL) was heated to reflux(120° C.) for 1 h then concentrated in vacuo. The resulting residue waspurified by column chromatography (Si—PCC, MeOH:DCM, 0-2%) then (Si—PCC,MeOH:EtOAc, 0-5%) affording the title compound as a yellow solid (620mg, 87%). LCMS (method H): R_(T) 2.46 min, [M+H]⁺ 489.3

Example 65v3-[5-(2-Ethylbenzoimidazol-1-yl)-7-morpholin-4-ylthiazolo[5,4-c]pyrimidin-2-ylmethylene]azetidine-1-carboxylicacid tert-butyl ester

To a solution of diisopropylamine (200 μL, 1.42 mmol) in THF (0.5 mL) at−78° C. was added n-BuLi (556 μL, 1.42 mmol, 2.5 M in hexanes) and theresulting mixture stirred for 20 min. The resulting solution was addedto a suspension of[5-(2-ethylbenzoimidazol-1-yl)-7-morpholin-4-ylthiazolo[5,4-c]pyrimidin-2-ylmethyl]phosphonicacid dimethyl ester (620 mg, 1.27 mmol) in THF (11 mL) at −78° C. Theresulting mixture was warmed to r.t. before a solution of3-oxo-azetidine-1-carboxylic acid tert-butyl ester (250 mg, 1.46 mmol)in THF (1.5 mL) was added. The resulting mixture was stirred at r.t. for5 h then quenched with H₂O. The mixture was concentrated in vacuo andthe residue was partitioned between DCM and brine. The organic phase wasdried (MgSO₄) and concentrated in vacuo. The resulting residue wasfiltered through a pad of silica affording the title compound (493 mg,73%). LCMS (method H): R_(T) 3.72 min, [M+H]⁺ 53.3

Example 65w2-Azetidin-3-ylmethyl-5-(2-ethylbenzoimidazol-1-yl)-7-morpholin-4-ylthiazolo[5,4-c]pyrimidine

Step 1:3-[5-(2-Ethylbenzoimidazol-1-yl)-7-morpholin-4-ylthiazolo[5,4-d]pyrimidin-2-ylmethyl]azetidine-1-carboxylicacid tert-butyl ester

To a solution of3-[5-(2-ethylbenzoimidazol-1-yl)-7-morpholin-4-ylthiazolo[5,4-d]pyrimidin-2-ylmethylene]azetidine-1-carboxylicacid tert-butyl ester (493 g, 0.92 mmol) in AcOH (20 mL) was added 10%Pd(OH)₂/C (200 mg) and the resulting mixture stirred under an atmosphereof H₂ for 2 h. The reaction mixture was filtered through Celite®,washing with EtOAc. The filtrate was loaded onto an Isolute® SCX-2cartridge which was washed with MeOH and the product eluted with 2MNH₃/MeOH affording the title compound.

Step 2: To a solution of3-[5-(2-ethylbenzoimidazol-1-yl)-7-morpholin-4-ylthiazolo[5,4-d]pyrimidin-2-ylmethyl]azetidine-1-carboxylicacid tert-butyl ester in DCM (10 mL) was added TFA (3 mL) and theresulting mixture allowed to stir at r.t. for 1 h. The reaction mixturewas loaded onto an Isolute® SCX-2 cartridge which was washed with MeOHand the product eluted with 2M NH₃/MeOH affording2-Azetidin-3-ylmethyl-5-(2-ethylbenzoimidazol-1-yl)-7-morpholin-4-ylthiazolo[5,4-d]pyrimidineas a yellow oil (209 mg, 52% over two steps). ¹H NMR (CDCl₃, 400 MHz): δ7.99-7.98 (1H, m), 7.75-7.74 (1H, m), 7.28-7.25 (2H, m), 4.41 (4H, brds), 3.89-3.84 (5H, m), 3.59 (2H, t, J=7.25 Hz), 3.48 (2H, s), 3.36-3.34(5H, m), 1.43 (3H, t, J=7.47 Hz)

Example 65x4-[1-(5-Chloro-7-morpholin-4-ylthiazolo[5,4-c]pyrimidin-2-ylmethyl)azetidin-3-yl]piperazin-2-one

A mixture of5-chloro-7-morpholin-4-ylthiazolo[5,4-c]pyrimidine-2-carbaldehyde (285mg, 1.00 mmol), 4-azetidin-3-ylpiperazin-2-one (190 mg, 1.22 mmol) and 4Å powdered molecular sieves (1.0 g) in DCE (10 mL) was allowed to stirat r.t. for 5 h before the addition of sodium triacetoxyborohydride (420mg, 1.98 mmol). The resulting mixture was allowed to stir for 16 h thenfiltered through Celite® which was washed with DCM. The filtrate wasconcentrated in vacuo and the resulting residue purified by columnchromatography (Si—PCC, MeOH:DCM, 2-10%) affording the title compound(321 mg, 75%). LCMS (method A): R_(T) 1.96 and 0.33 min [M+H]⁺ 424.3

Example 65y(5-Chloro-7-morpholin-4-ylthiazolo[5,4-d]pyrimidin-2-yl)-(3-morpholin-4-ylazetidin-1-yl)methanone

To a suspension of5-chloro-7-morpholin-4-ylthiazolo[5,4-d]pyrimidine-2-carboxylic acid(301 mg, 1.0 mmol) in DCM (6 mL) was added oxalyl chloride (847 μL,10.00 mmol) and the resulting mixture allowed to stir at r.t. for 1 hthen concentrated in vacuo and azeotroped with toluene. The resultingyellow solid was suspended in a mixture of DCM (6 mL) and NEt₃ (418 μL,3.00 mmol) at 0° C. before the addition of 4-azetidin-3-ylmorpholine(142 mg, 1.00 mmol). The resulting mixture was warmed to r.t. after 1 hthen stirred for a further 30 min. The reaction mixture was partitionedbetween DCM and H₂O, the organic phase dried (Na₂SO₄) and concentratedin vacuo. The resulting residue was triturated with EtOAc and dried invacuo affording the title compound as an off-white solid (269 mg, 63%).LCMS (method H): R_(T) 2.19 min [M+H]⁺ 425.3

Example 65z5-Chloro-7-morpholin-4-yl-thiazolo[4,5-d]pyrimidine-2-carbaldehyde

To a suspension of 5-chloro-7-morpholin-4-yl-thiazolo[4,5-d]pyrimidine(2 g, 7.79 mmol) in anhydrous tetrahydrofuran, cooled to −78° C. undernitrogen atmosphere, lithium bis(trimethylsilyl)amide (11.7 mL, 11.68mmol) was added dropwise at −78° C. and the resulting reaction mixturestirred at −78° C. for 1 h. Subsequently DMF was slowly added and themixture stirred for further 30 min. The temperature was allowed to riseto −5° C. over 10 min and then cooled again to −78° C. The resultingreaction mixture was transferred via cannula into ice-cold aqueous 1MHCl (400 mL) and stirred vigorously. The aqueous phase was extractedwith ethyl acetate (2×150 mL). The organic layer was washed with water(1×125 mL), brine (2×125 mL), dried over Na₂SO₄ and filtered. Thesolvent was reduced in vacuo to afford the title compound as anorange-brown solid (1.82 g, 82%). ¹H NMR (400 MHz, CDCl₃): δ 10.19 (1H,s), 4.03 (4H, t, J=4.90 Hz), 3.87 (4H, t, J=4.90 Hz).

Example 66a5-Chloro-7-morpholin-4-yl-2-(3-morpholin-4-yl-azetidin-1-ylmethyl)-thiazolo[4,5-d]pyrimidine

A mixture of5-chloro-7-morpholin-4-yl-thiazolo[4,5-d]pyrimidine-2-carbaldehyde (250mg, 0.88 mmol), 4-azetidin-3-yl-morpholine (150 mg, 1.05 mmol) and 4 Åmolecular sieves (1.0 g) in 1,2-dichloroethane (15 mL) was stirred at RTunder nitrogen atmosphere for 1.5 h. Sodium triacetoxyborohydride (280mg, 1.32 mmol) was added and the resulting reaction mixture was stirredat RT for 16 h. The solvent was reduced in vacuo and the residue wasloaded on an Isolute® SCX-2 cartridge (10 g). The cartridge was washedwith DCM/MeOH, the desired product was subsequently eluted using amixture of 2M NH₃ in MeOH and DCM. The resulting residue was furtherpurified by column chromatography (Si—PCC, MeOH:DCM: 0:100 to 6:94 byvolume). The solvents were reduced in vacuo to afford the title compoundas a yellow solid (165 mg, 46%). LCMS (Method A): R_(T) 2.31 min, [M+H]⁺411. ¹H NMR (400 MHz, CDCl₃): δ 4.11 (2H, s), 3.95 (4H, t, J=4.85 Hz),3.83 (4H, t, J=4.84 Hz), 3.74-3.67 (6H, m), 3.22 (2H, t, J=6.84 Hz),3.12-3.11 (1H, m), 2.34 (4H, s)

Example 66b2-[1-(5-Chloro-7-morpholin-4-yl-thiazolo[4,5-d]pyrimidin-2-ylmethyl)piperidin-4-yl]propan-2-ol

A mixture of5-chloro-7-morpholin-4-yl-thiazolo[4,5-d]pyrimidine-2-carbaldehyde (400mg, 1.4 mmol), 2-piperidin-4-yl-propan-2-ol (242 mg, 1.7 mmol), and 4 Åmolecular sieves (1.5 g) in 1,2-dichloroethane (20 mL) was stirred at RTfor 6 h. Sodium triacetoxyborohydride (593 mg, 2.8 mmol) was added andthe resulting reaction mixture was stirred at RT under nitrogenatmosphere for 18 h. The suspension was filtered through Celite and thefiltrate was concentrated in vacuo. The residue was purified by columnchromatography (Si—PPC, (10% MeOH in EtOAc): EtOAc, gradient 0:100 to20:80) to afford the title compound as an orange solid (344 mg, 60%). ¹HNMR (400 MHz, CDCl₃): δ 3.98-3.93 (6H, m), 3.85 (5H, m), 3.08 (2H, m),2.28 (2H, m), 1.79 (2H, m), 1.48 (3H, m), 1.23-1.21 (6H, m).

Example 66c2-[4-(5-Chloro-7-morpholin-4-yl-thiazolo[4,5-d]pyrimidin-2-ylmethyl)piperazin-1-yl]isobutyramide

A mixture of5-chloro-7-morpholin-4-yl-thiazolo[4,5-d]pyrimidine-2-carbaldehyde (250mg, 0.88 mmol), 2-piperazin-1-yl-isobutyramide (173 mg, 1.01 mmol) and 4Å molecular sieves (1.0 g) in 1,2-dichloroethane (15 mL) was stirred atRT under nitrogen atmosphere for 4 h. Sodium triacetoxyborohydride (280mg, 1.32 mmol) was added and the resulting reaction mixture was stirredat RT for 16 h. The solvent was reduced in vacuo and the residue wasloaded on an Isolute® SCX-2 cartridge (25 g). The cartridge was washedwith DCM/MeOH and the desired product was subsequently eluted using amixture of 2 M NH₃ in MeOH and DCM. The resulting residue was furtherpurified by column chromatography (Si—PCC, MeOH:DCM: gradient 0:100 to6:94). The solvents were reduced in vacuo to afford the title compoundas a yellow solid (275 mg, 60%). LCMS (Method H): R_(T) 2.41 min, [M+H]⁺440. ¹H NMR (400 MHz, CDCl₃): δ 7.04 (1H, br s), 5.22 (1H, br s),3.97-3.95 (6H, m), 3.85 (4H, t, J=4.80 Hz), 2.67 (8H, m), 1.25 (6H, s)

Example 66d2-[4-(7-Morpholin-4-yl-5-(tributylstannanyl)thiazolo[4,5-d]pyrimidin-2-ylmethyl)piperazin-1-yl]isobutyramide

A mixture of2-[4-(5-chloro-7-morpholin-4-yl-thiazolo[4,5-d]pyrimidin-2-ylmethyl)piperazin-1-yl]isobutyramide(120 mg, 0.27 mmol), PdCl₂{P^(t)Bu₂(Ph-p-NMe₂)}₂ (19.5 mg, 0.027 mmol)and hexabutylditin (0.203 mL, 0.405 mmol) in 1,4-dioxane (1.2 mL) waspurged with argon gas and then subjected to microwave irradiation at150° C. for 30 min. The crude residue was loaded onto an Isolute® SCX-2cartridge (20 g) and washed with DCM/MeOH, the desired product wassubsequently eluted using a mixture of 2 M NH₃ in MeOH and DCM. Theresulting residue was further purified by column chromatography (Si—PCC,cyclohexane:acetone, gradient 100:0 to 60:40). The solvents were reducedin vacuo to afford the title compound as a yellow gum (210 mg, 62%) LCMS(Method A): R_(T) 4.26 min, [M+H]⁺ 694 (¹¹⁶Sn) 696 (¹¹⁸Sn). ¹H NMR (400MHz, CDCl₃): δ 7.06 (1H, s), 5.20 (1H, s), 3.97 (2H, s), 3.92 (4H, t,J=4.60 Hz), 3.84 (4H, t, J=4.60 Hz), 2.65 (8H, m), 1.60-1.58 (6H, m),1.35-1.33 (6H, m), 1.25 (6H, s), 1.16-1.14 (6H, m), 0.87 (9H, t, J=7.32Hz)

Example 66e4-[5-(2-Ethylbenzoimidazol-1-yl)-7-morpholin-4-ylthiazolo[5,4-c]pyrimidin-2-ylmethylene]piperidine-1-carboxylicacid benzyl ester

To a solution of diisopropylamine (121 μL, 0.86 mmol) in THF (0.5 mL) at−78° C. was added n-BuLi (336 μL, 0.86 mmol, 2.5 M in hexanes) and theresulting mixture stirred for 30 min. The resulting solution was addedto a suspension of[5-(2-ethylbenzoimidazol-1-yl)-7-morpholin-4-ylthiazolo[5,4-c]pyrimidin-2-ylmethyl]phosphonicacid dimethyl ester (375 mg, 0.77 mmol) in THF (6 mL) at −78° C. Theresulting mixture was warmed to r.t. before a solution of4-oxopiperidine-1-carboxylic acid benzyl ester (206 mg, 0.88 mmol) inTHF (1 mL) was added. The resulting mixture was stirred at r.t. for 3 hthen quenched with H₂O. The mixture was concentrated in vacuo and theresidue was partitioned between EtOAc and H₂O. The organic phase wasdried (MgSO₄) and concentrated in vacuo. The resulting residue waspurified by column chromatography (Si—PCC, EtOAc:pentane, 50-75%)affording4-[5-(2-Ethylbenzoimidazol-1-yl)-7-morpholin-4-ylthiazolo[5,4-d]pyrimidin-2-ylmethylene]piperidine-1-carboxylicacid benzyl ester (300 mg, 66%). LCMS (method H): R_(T) 3.98 min, [M+H]⁺596.4

Example 66f5-(2-Ethylbenzoimidazol-1-yl)-7-morpholin-4-yl-2-piperidin-4-ylmethylthiazolo[5,4-c]pyrimidine

To a solution of4-[5-(2-ethylbenzoimidazol-1-yl)-7-morpholin-4-ylthiazolo[5,4-d]pyrimidin-2-ylmethylene]piperidine-1-carboxylicacid benzyl ester (300 mg, 0.50 mmol) in AcOH (20 mL) was added 10%Pd(OH)₂/C (200 mg) and the resulting mixture stirred under an atmosphereof H₂ for 2 h. The reaction mixture was filtered through Celite®,washing with EtOAc. The filtrate was loaded onto an Isolute® SCX-2cartridge which was washed with MeOH and the product eluted with 2MNH₃/MeOH. The resulting residue was purified by column chromatography(Si—PCC, 2M NH₃/MeOH:DCM, 0-10%) affording5-(2-Ethylbenzoimidazol-1-yl)-7-morpholin-4-yl-2-piperidin-4-ylmethylthiazolo[5,4-c]pyrimidine(96 mg, 41%). ¹H NMR (CDCl₃, 400 MHz): δ 7.99-7.98 (1H, m), 7.74-7.73(1H, m), 7.30-7.26 (2H, m), 4.43 (4H, s), 3.88 (4H, t, J=4.74 Hz), 3.33(2H, q, J=7.48 Hz), 3.12-3.08 (2H, m), 2.99 (2H, d, J=7.14 Hz), 2.63(2H, td, J=12.12, 2.54 Hz), 2.03-1.91 (1H, m), 1.79 (2H, brd d, J=13.18Hz), 1.42 (3H, t, J=7.48 Hz), 1.30-1.29 (2H, m)

Example 66g Acetic acid2-{4-[5-(2-ethylbenzoimidazol-1-yl)-7-morpholin-4-ylthiazolo[5,4-d]pyrimidin-2-ylmethyl]piperidin-1-yl}-1,1-dimethyl-2-oxoethylester

A mixture of5-(2-ethylbenzoimidazol-1-yl)-7-morpholin-4-yl-2-piperidin-4-ylmethylthiazolo[5,4-c]pyrimidine(96 mg, 0.21 mmol), acetic acid 1-chlorocarbonyl-1-methylethyl ester (40μL, 0.28 mmol) and NEt₃ (40 μL, 0.31 mmol) in DCM (1 mL) was allowed tostir at r.t. for 30 min then concentrated in vacuo. The resultingresidue was loaded onto an Isolute® SCX-2 cartridge which was washedwith MeOH and the product eluted with 2M NH₃/MeOH affording Acetic acid2-{4-[5-(2-ethylbenzoimidazol-1-yl)-7-morpholin-4-ylthiazolo[5,4-c]pyrimidin-2-ylmethyl]piperidin-1-yl}-1,1-dimethyl-2-oxoethylester. LCMS (method A): R_(T) 3.19 min [M+H]⁺ 592.2

Formula I(ii) thiophenyl intermediates wherein (ii) X¹ is CR⁷ and X² isS

Example 70a9-(2-Chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one

A solution of6-bromomethyl-2-chloro-4-morpholin-4-yl-thieno[3,2-c]pyrimidine (500 mg,1.43 mmol), 1-oxa-4,9-diaza-spiro[5.5]undecan-3-one (315 mg, 1.85 mmol)and potassium carbonate (450 mg, 3.26 mmol) in DMF (40 mL) was stirredat ambient temperature for 18 hours, then loaded onto an Isolute® SCX-2cartridge (10 g). The cartridge was washed with MeOH and the desiredproduct was subsequently eluted using 2 M NH₃ in MeOH. The eluent wascollected and concentrated in vacuo. The resultant residue was purifiedby flash chromatography (Si—PPC, DCM:MeOH 100:0 to 98:2 to 95:5) toafford9-(2-Chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-oneas a white solid (515 mg, 82%). LCMS (Method A): R_(T)=2.51 min, [M+H]⁺438.1

Example 70b2-[4-(4-Morpholin-4-yl-2-(tributylstannanyl)thieno[3,2-d]pyrimidin-6-ylmethyl)-piperazin-1-yl]isobutyramide

A mixture of2-[4-(2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)-piperazin-1-yl]isobutyramide(1.0 g, 2.3 mmol), hexabutylditin (1.4 mL, 2.7 mmol), andPdCl₂{P^(t)Bu₂(Ph-p-Nme₂)}₂ (161 mg, 0.2 mmol) in dioxane (10 mL) wasdegassed and then subjected to microwave irradiation at 150° C. for 30min. The reaction mixture was diluted with MeOH and loaded onto aIsolute® SCX-2 cartridge (25 g). The cartridge was then washed with MeOHand the desired product was subsequently eluted using 2 M NH₃ in MeOH.Appropriate fractions were combined and concentrated to give a residuewhich was subjected to flash chromatography (Si—PPC, MeOH:DCM, gradient0:100 to 10:90). Appropriate fractions were combined and concentrated togive2-[4-(4-Morpholin-4-yl-2-(tributylstannanyl)thieno[3,2-d]pyrimidin-6-ylmethyl)-piperazin-1-yl]isobutyramideas white foam (0.9 g, 56%). LCMS (Method C) R_(T)=3.88 min; [M+H]⁺693.1(¹¹⁶Sn) 695.1 (¹¹⁸Sn)

Example 70c2-[4-(2-Chloro-7-methyl-4-morpholin-4-yl-thieno[3,2-c]pyrimidin-6-ylmethyl)piperazin-1-yl]isobutyramide

To a solution of2-chloro-7-methyl-4-morpholin-4-yl-thieno[3,2-d]pyrimidine-6-carbaldehyde(1.00 g, 3.36 mmol) in DCE (50 mL) was added2-(piperazin-1-yl)isobutyramide (630 mg, 3.69 mmol), trimethylorthoformate (3.67 mL, 33.58 mmol) and acetic acid (0.19 mL, 3.36 mmol).After stirring at room temperature for 3 h sodium triacetoxyborohydride(1.10 g, 5.03 mmol) was added and the resulting mixture stirred for afurther 17 h. The reaction mixture was loaded onto an Isolute® SCX-2cartridge, washed with MeOH then eluted with 2 M NH₃ in MeOH/DCM. Theresultant residue was triturated with MeOH to give2-[4-(2-Chloro-7-methyl-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)piperazin-1-yl]isobutyramideas a white solid (1.12 g, 74%). LCMS (Method C): R_(T)=2.88 min, [M+H]⁺453

Example 70d2-[4-(7-Methyl-4-morpholin-4-yl-2-(tributylstannanyl)thieno[3,2-c]pyrimidin-6-ylmethyl)piperazin-1-yl]isobutyramide

A mixture of2-[4-(2-chloro-7-methyl-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)piperazin-1-yl]isobutyramide(194 mg, 0.43 mmol), hexabutylditin (373 mg, 0.64 mmol),PdCl₂{P^(t)Bu₂(Ph-p-Nme₂)}₂ (30 mg, 10 mol %) in dioxane (2 mL) waspurged with nitrogen gas then heated at 150° C., for 20 min, in amicrowave reactor. The reaction mixture was loaded onto an Isolute®SCX-2 cartridge, washed with MeOH then eluted with 2M NH₃ in MeOH. Theresulting residue was purified by column chromatography (Si—PPC,MeOH:DCM, gradient 0:100 to 05:95) to afford2-[4-(7-Methyl-4-morpholin-4-yl-2-(tributylstannanyl)thieno[3,2-d]pyrimidin-6-ylmethyl)piperazin-1-yl]isobutyramideas a colorless oil (192 mg, 63%). LCMS (Method D): R_(T) 2.92 min,[M+H]⁺ 705 (¹¹⁶Sn), 707 (¹¹⁸Sn)

Example 70e2-Chloro-4-morpholin-4-yl-6-(4-morpholin-4-yl-piperidin-1-ylmethyl)-thieno[3,2-d]pyrimidine

A mixture of2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidine-6-carbaldehyde (2.0 g,7.1 mmol) and 4-piperidin-4-yl-morpholine (1.4 g, 8.5 mmol) in DCE (40mL) was stirred at room temperature for 1.5 hour thentriacetoxyborohydride (2.2 g, 10.6 mmol) was added. The reaction mixturewas stirred at room temperature for 18 hours then diluted with MeOH andloaded onto an Isolute® SCX-2 cartridge (70 g). The cartridge was washedwith MeOH/DCM (1/1: v/v) and the desired product was eluted with (2M NH₃in MeOH)/DCM (1/1: v/v). The solvents were removed and the residue wastriturated in hot IMS, filtered and dried at 60° C. for 1 hour undervacuum to give2-Chloro-4-morpholin-4-yl-6-(4-morpholin-4-yl-piperidin-1-ylmethyl)-thieno[3,2-d]pyrimidineas a white solid (2.6 g, 84%). LCMS (Method C): R_(T) 0.34 min and 1.67min; [M+H]⁺ 438

Example 70f4-Morpholin-4-yl-6-(4-morpholin-4-yl-piperidin-1-ylmethyl)-2-(tributylstannanyl)thieno[3,2-c]pyrimidine

A mixture of2-chloro-4-morpholin-4-yl-6-(4-morpholin-4-yl-piperidin-1-ylmethyl)thieno[3,2-c]pyrimidine(874 mg, 2.0 mmol), hexabutylditin (1.1 mL, 2.2 mmol), andPdCl₂{P^(t)Bu₂(Ph-p-Nme₂)}₂ (71 mg, 0.1 mmol) in dioxane (10 mL) wasdegassed and then subjected to microwave irradiation at 150° C. for 20min. The reaction mixture was diluted with MeOH and loaded onto aIsolute® SCX-2 cartridge (10 g). The cartridge was then washed with MeOHand the desired product was subsequently eluted using 2 M NH₃ in MeOH.Appropriate fractions were combined and concentrated to give a residuewhich was subjected to flash chromatography (Si—PPC, MeOH:EtOAc,gradient 0:100 to 40:60). Appropriate fractions were combined andconcentrated to give4-Morpholin-4-yl-6-(4-morpholin-4-yl-piperidin-1-ylmethyl)-2-(tributylstannanyl)thieno[3,2-c]pyrimidineas pale yellow oil (823 mg, 59%). LCMS (Method C): R_(T)=2.72 min;[M+H]⁺692 (¹¹⁶Sn) 694 (¹¹⁸Sn)

Example 70g[1-(2-Chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)piperidin-4-yl]dimethylamine

A mixture of2-chloro-4-morpholin-4-ylthieno[3,2-c]pyrimidine-6-carbaldehyde (5.0 g,17.7 mmol) and dimethylpiperidin-4-ylamine (2.7 g, 21.2 mmol) in DCE(100 mL) was stirred at room temperature for 4 hours thentriacetoxyborohydride (5.6 g, 26.5 mmol) was added. The reaction mixturewas stirred at room temperature for 18 hours then diluted with MeOH andloaded onto an Isolute® SCX-2 cartridge (2×70 g). The cartridge waswashed with MeOH/DCM (1/1: v/v) and the desired product was eluted with(2M NH₃ in MeOH)/DCM (1/1: v/v). The solvents were removed and theresidue was precipitated from IMS to give[1-(2-Chloro-4-morpholin-4-yl-thieno[3,2-c]pyrimidin-6-ylmethyl)piperidin-4-yl]dimethylamineas a white solid (4.45 g, 64%). LCMS (Method B): R_(T) 0.37 min and 1.85min; [M+H]⁺ 396

Example 70hDimethyl-[1-(4-morpholin-4-yl-2-(tributylstannanyl)thieno[3,2-d]pyrimidin-6-ylmethyl)piperidin-4-yl]amine

A mixture of[1-(2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)piperidin-4-yl]dimethylamine(1.0 g, 2.5 mmol), hexabutylditin (1.5 mL, 3.0 mmol), andPdCl₂{P^(t)Bu₂(Ph-p-Nme₂)}₂ (128 mg, 0.18 mmol) in dioxane (10 mL) wasdegassed and then subjected to microwave irradiation at 160° C. for 20min. The reaction mixture was diluted with MeOH and loaded onto aIsolute® SCX-2 cartridge (25 g). The cartridge was then washed with MeOHand the desired product was subsequently eluted using 2 M NH₃ in MeOH.Appropriate fractions were combined and concentrated to give a residuewhich was subjected to flash chromatography (Si—PPC, MeOH:DCM, gradient0:100 to 40:60). Appropriate fractions were combined and concentrated togiveDimethyl-[1-(4-morpholin-4-yl-2-(tributylstannanyl)thieno[3,2-d]pyrimidin-6-ylmethyl)piperidin-4-yl]amineas pale yellow oil (879 mg, 54%). LCMS (Method C): R_(T)=2.76 min;[M+H]⁺650 (¹¹⁶Sn) 652 (¹¹⁸Sn)

Example 70i1-[1-(2-Chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-ylmethyl)azetidin-3-yl]piperidin-4-ol

A mixture of2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidine-6-carbaldehyde (136 mg,0.48 mmol), 1-azetidin-3-ylpiperidin-4-ol (90 mg, 0.58 mmol) and 4 Åpowdered molecular sieves (260 mg) in DCE (15 mL) was stirred for 5 hbefore the addition of sodium triacetoxyborohydride (202 mg, 0.96 mmol).The resulting mixture was stirred for 18 h then filtered through Celite®and the filtrate loaded onto an Isolute® SCX-2 cartridge which waswashed with MeOH and the product eluted with 2M NH₃/MeOH/DCM. Theresulting residue was purified by column chromatography (Si—PCC,MeOH:DCM, 0-10%) affording the title compound as a pale yellow oil (153mg, 75%). LCMS (method H): R_(T) 1.88 min [M+H]⁺ 424.3

Example 70j2-Chloro-6-(2,2-dimethyl-4-oxetan-3-ylpiperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-c]pyrimidine

A mixture of2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidine-6-carbaldehyde (400 mg,1.42 mmol), 3,3-dimethyl-1-oxetan-3-ylpiperazine (290 mg, 1.71 mmol) and4 Å powdered molecular sieves (500 mg) in DCE (20 mL) were allowed tostir at r.t. 3 h before the addition of sodium triacetoxyborohydride(420 mg, 1.98 mmol). The resulting mixture was allowed to stir for 18 hthen filtered through Celite®. The filtrate was loaded onto an Isolute®SCX-2 cartridge which was washed with MeOH and the product eluted with2M NH₃/MeOH. The resulting residue was purified by column chromatography(Si—PCC, MeOH:EtOAc, 0-10%) affording the title compound as a creamsolid (305 mg, 49%). LCMS (method H): R_(T) 2.12 min, [M+H]⁺ 438.3

Example 70k3-(2-Chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-ylmethylene)azetidine-1-carboxylicacid tert-butyl ester

To a suspension of(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-ylmethyl)phosphonicacid dimethyl ester (3.0 g, 7.94 mmol) in THF (150 mL) at −78° C. wasadded LiHMDS (8.8 mL, 8.80 mmol, 1M solution in THF) and the resultingmixture stirred for 30 min then warmed to r.t. before the addition of asolution of 3-oxo-azetidine-1-carboxylic acid tert-butyl ester (1.51 g,8.82 mmol) in THF (20 mL). The reaction mixture was stirred at r.t. for16 h then quenched with H₂O and MeOH and concentrated in vacuo. Theresulting residue was purified by column chromatography (Si—PCC,EtOAc:DCM, 5-100%) affording the title compound as a yellow solid (2.14g, 63%). LCMS (method A): R_(T) 3.97 min [M+H]⁺ 423.3

Example 70l3-[2-(2-Ethylbenzoimidazol-1-yl)-4-morpholin-4-ylthieno[3,2-c]pyrimidin-6-ylmethylene]azetidine-1-carboxylicacid tert-butyl ester

A mixture of3-(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-ylmethylene)azetidine-1-carboxylicacid tert-butyl ester (1.1 g, 2.51 mmol), 2-ethylbenzimidazole (400 mg,2.74 mmol), tris(dibenzylideneacetone)dipalladium (115 mg, 0.13 mmol),XPhos (240 mg, 0.50 mmol) and Cs₂CO₃ (1.25 g, 3.84 mmol) in dioxane (25mL) was purged with argon then heated at 110° C. for 16 h. The reactionmixture was filtered through Celite®, washing with DCM, and the filtrateconcentrated in vacuo. The resulting residue was purified by columnchromatography (Si—PCC, MeOH:DCM, 0-10%) affording the title compound asan orange solid (1.5 g, quant.). LCMS (method A): R_(T) 3.40 min [M+H]⁺533.4

Example 70m3-[2-(2-Ethylbenzoimidazol-1-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-ylmethyl]azetidine-1-carboxylicacid tert-butyl ester

To a solution of3-[2-(2-ethylbenzoimidazol-1-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-ylmethylene]azetidine-1-carboxylicacid tert-butyl ester (1.5 g, 2.51 mmol) in EtOH (30 mL) was added 10%Pd/C (275 mg) and the resulting mixture stirred under an atmosphere ofH₂ for 65 h. The reaction mixture was filtered through Celite®, washingwith EtOH, and the filtrate concentrated in vacuo. The resulting residuewas purified by column chromatography (Si—PCC, MeOH:DCM, 0-10%)affording the title compound as an orange oil (0.71 g, 53%). LCMS(method A): R_(T) 3.22 min [M+H]⁺ 535.4

Example 70n6-Azetidin-3-ylmethyl-2-(2-ethylbenzoimidazol-1-yl)-4-morpholin-4-ylthieno[3,2-c]pyrimidine

To a solution of3-[2-(2-ethylbenzoimidazol-1-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-ylmethyl]azetidine-1-carboxylicacid tert-butyl ester (700 mg, 1.31 mmol) in DCM (3 mL) was added TFA(0.5 mL) and the resulting mixture stirred for 18 h at r.t. The reactionmixture was concentrated in vacuo and the resulting residue loaded ontoan Isolute® SCX-2 cartridge which was washed with MeOH/DCM and theproduct eluted with 2M NH₃/MeOH affording the title compound as anorange gum (522 mg, 91%). LCMS (method A): R_(T) 1.80 min [M+H]⁺ 435.4

Formula I(iii) purine intermediates wherein (iii) X¹ is N and X² is NR²

Example 75a 2,6-dichloro-9-methyl-9H-purine 4

The cyano group of 5-amino-1-methyl-1H-imidazole-4-carbonitrile 1 ishydrolyzed with sulfuric acid to give5-amino-1-methyl-1H-imidazole-4-carboxamide 2. Cyclization with ureagives 9-methyl-1H-purine-2,6(3H,9H)-dione 3. Chlorination withphosphorus pentachloride and phosphorusoxychloride gives2,6-dichloro-9-methyl-9H-purine 4 (CAS Registry 2382-10-7).

Example 75b2-(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol

To 4-(2-chloro-9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-yl)morpholine(100 g) in methanol (500 mL) at 50° C. was added p-toluenesulfonic acidmonohydrate (6 g). The reaction was stirred for 30 mins, whereupon whitesolid has crashed fully out of solution. The solid is filtered andcollected thru Buchner funnel, rinsed with Methanol and dried undervacuum to get 4-(2-chloro-9H-purin-6-yl)morpholine. Cesium carbonate(200 g) and iodomethane (30 mL) were subsequently added to a stirringsolution of 4-(2-chloro-9H-purin-6-yl)morpholine in DMF at 50° C. Thereaction was monitored by lc-ms until complete, about 30 minutes,whereupon the solvent was concentrated to dryness. Subsequent suspensionof the crude reaction in water precipitated4-(2-chloro-9-methyl-9H-purin-6-yl)morpholine (72 g) as a white solid,which was filtered and dried under vacuum overnight.

To stirred solution of 4-(2-chloro-9-methyl-9H-purin-6-yl)morpholine (10g) and N,N,N′,N′-tetramethylethylenediamine (9.0 mL) in tetrahydrofuran(200 mL) at −78° C. was added 2.5 M of n-butyllithium in tetrahydrofuran(35 mL). The solution was stirred at −40° C. for 30 minutes, and thenre-cooled to −78° C., whereupon DMF (8 mL) was added and the reactionstirred for another hour. The reaction was quenched into cold 0.25N HClsolution via 10 mL serological pipet aliquots. Ice was added to keepquenching solution temperature below 5° C., to avoid formation ofby-product during workup.2-Chloro-9-methyl-6-morpholino-9H-purine-8-carbaldehyde (11 g)precipitated as a light yellow solid which was filtered, rinsed withwater and dried under vacuum.

A solution of 2-chloro-9-methyl-6-morpholino-9H-purine-8-carbaldehyde(17.2 g) in MeOH (800 mL) at 0° C. was treated portion wise with sodiumborohydride (5 g). The reaction was warmed to room temperature andstirred 15 minutes. The reaction mixture was quenched with saturatedsolution of sodium bicarbonate. The aqueous layer was extracted twicewith ethyl acetate. The combined organic layers were dried overmagnesium sulfate and concentrated in vacuo to yield crude2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methanol (16.9 g) as awhite solid.

To a solution of crude2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methanol (16.5 g) in amixture of dichloroethane (600 mL) and THF (400 mL) at 0° C. was addedphosphorus tribromide (11 mL) dropwise. The reaction was stirred for 1 hwhereupon the solid that precipitated was filtered, rinsed with water,collected and dried to give4-(8-(bromomethyl)-2-chloro-9-methyl-9H-purin-6-yl)morpholine (15.6 g)as a white solid.

2-(Piperidin-4-yl)propan-2-ol (0.73 g) was reacted with4-(8-(bromomethyl)-2-chloro-9-methyl-9H-purin-6-yl)morpholine (1.6 g)via General Procedure C to yield2-(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol(1.76 g) as a white solid.

Example 75c9-Methyl-2-(2-methylbenzoimidazol-1-yl)-6-morpholin-4-yl-9H-purine-8-carbaldehyde

A mixture of Pd₂(dba)₃ (161 mg, 0.18 mmol), Xphos (CAS Reg. No.564483-18-7, 336 mg, 0.72 mmol),2-chloro-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (1.0 g, 3.52mmol), 2-ethyl-1H-benzoimidazole (500 mg, 3.73 mmol), cesium carbonate(2.3 g, 7 mmol) in dioxane (15 mL) was degassed for 5 min and heated at145° C. for 30 min under microwave irradiation. The reaction mixture wasfiltered while still hot through a pad of celite, and the pad was washedwith hot dioxane. The product precipitated immediately as a pale yellowsolid. The solid was filtered and dried at 50° C. under vacuum to give9-Methyl-2-(2-methylbenzoimidazol-1-yl)-6-morpholin-4-yl-9H-purine-8-carbaldehyde(650 mg, 50%). Additional material could be recovered from the motherliquors. LCMS (Method H): R_(T) 3.39 min; [M+MeOH]⁺ 410

Example 75d2-(2-Ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde

A mixture of Pd₂(dba)₃ (458 mg, 0.5 mmol), Xphos (954 mg, 2.0 mmol),2-chloro-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (5.64 g,20.0 mmol), 2-ethyl-1H-benzoimidazole (3.21 g, 22.0 mmol), cesiumcarbonate (9.78 g, 30.0 mmol) in dioxane (80 mL) was degassed for 5 minand heated at reflux for 18 h. The reaction mixture was filtered througha pad of celite while still hot, and the pad was washed with hotdioxane. The combined filtrate was concentrated under reduced pressureto give a residue which was triturated in Et₂O (ca 100 mL), filtered anddried at 50° C. under vacuum to give2-(2-Ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehydeas a yellow solid (4.5 g). LCMS (Method H): R_(T) 3.63 min; [M+MeOH]⁺424

Example 75e2-(2-Cyclopropylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde

A mixture of 2-chloro-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(210 mg, 0.79 mmol), 2-cyclopropylbenzimidazole (150 mg, 0.95 mmol),tris(dibenzylideneacetone)dipalladium (44 mg, 0.05 mmol), Xphos (90 mg,0.18 mmol) and Cs₂CO₃ (618 mg, 1.90 mmol) in dioxane (3 mL) and DMF (1mL) was purged with argon then heated at 145° C. for 45 min in amicrowave reactor. The reaction mixture was filtered through a pad ofcelite, washing with EtOAc. The filtrate was concentrated in vacuo andpurified by column chromatography (Si—PCC, EtOAc:cyclohexane, 0-75%)affording2-(2-Cyclopropylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehydeas an orange solid (282 mg, 89%). LCMS (Method H): R_(T) 3.79 min,[M+H]⁺ 436.4

Example 75f2-[2-(2-Hydroxyethyl)benzoimidazol-1-yl]-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde

A mixture of 2-chloro-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(500 mg, 1.78 mmol), 2-(1H-benzoimidazol-2-yl)ethanol (335 mg, 2.06mmol), Pd₂dba₃ (40 mg, 0.043 mmol), Xphos (85 mg, 0.18 mmol) and cesiumcarbonate (840 mg, 2.58 mmol) in 1,4-dioxane (10 mL) was purged withargon gas then subjected to microwave irradiation at 145° C. for 30 min.The reaction mixture was filtered through a pad of Celite® and thefiltrate was concentrated in vacuo. The resultant residue was purifiedby flash chromatography (Si—PPC, EtOAc:MeOH; 100:0 to 98:2 to 95:5 to90:10) to afford2-[2-(2-Hydroxyethyl)benzoimidazol-1-yl]-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehydeas a yellow solid (487 mg, 67%). ¹H NMR (CDCl₃, 400 MHz) δ 9.93 (s, 1H);8.16-8.12 (m, 1H); 7.76-7.72 (m, 1H); 7.35-7.29 (m, 2H); 4.52 (m, 4H);4.20 (t, J=5.3 Hz, 2H); 4.14 (s, 3H); 3.91 (m, 5H) and 3.57 (t, J=5.3Hz, 2H).

Example 75g8-Chloromethyl-2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine

To a suspension of[2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-yl]methanol(200 mg, 0.51 mmol) in DCM (6 mL) and DMF (100 μL) was added oxalylchloride (129 μL, 1.52 mmol) and the resulting solution was stirred atroom temperature for 19 h. The reaction mixture was concentrated invacuo to an oil which was purified by column chromatography (Si—PCC,MeOH:DCM, 0-10%) affording8-Chloromethyl-2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purineas an impure mixture which was used directly in subsequent reactions.

Example 75h2-Chloro-8-[3-(1,1-Dioxo-1-thiomorpholin-4-yl)azetidin-1-ylmethyl]-9-methyl-6-morpholin-4-yl-9H-purine

A mixture of 2-chloro-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(400 mg, 1.42 mmol), 4-azetidin-3-ylthiomorpholine-1,1-dioxide (324 mg,1.70 mmol) and 4 Å powdered molecular sieves (900 mg) in DCE (20 mL) wasstirred at room temperature for 4 h before the addition of sodiumtriacetoxyborohydride (602 mg, 2.84 mmol). The reaction mixture wasstirred for 40 h then filtered through celite, washing with DCM. Theorganic phase was washed with brine (×1) and concentrated in vacuo. Theresulting residue was purified by column chromatography (Si—PCC,MeOH:EtOAc, 0-15%) affording2-Chloro-8-[3-(1,1-Dioxo-1-thiomorpholin-4-yl)azetidin-1-ylmethyl]-9-methyl-6-morpholin-4-yl-9H-purineas a cream solid (587 mg, 91%). LCMS (Method H): R_(T) 2.25 min [M+H]⁺456.3

Example 75i2-Chloro-9-methyl-6-morpholin-4-yl-8-(3-morpholin-4-ylazetidin-1-ylmethyl)-9H-purine

A mixture of 2-chloro-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(235 mg, 0.82 mmol), 4-azetidin-3-ylmorpholine (122 mg, 0.86 mmol) and 4Å powdered molecular sieves (300 mg) in DCE (8 mL) was stirred at roomtemperature for 3 h before the addition of sodium triacetoxyborohydride(346 mg, 1.63 mmol). The reaction mixture was stirred for 65 h thenfiltered through celite, washing with DCM. The organic phase was washedwith brine and concentrated in vacuo. The resulting residue was purifiedby column chromatography (Si—PCC, MeOH:EtOAc, 0-20%) affording2-Chloro-9-methyl-6-morpholin-4-yl-8-(3-morpholin-4-ylazetidin-1-ylmethyl)-9H-purineas a cream solid (165 mg, 49%). LCMS (Method A): R_(T) 2.22 min [M+H]⁺408.2

Example 75j2-(2-Ethylbenzoimidazol-1-yl)-6-morpholin-4-yl-9-(tetrahydropyran-2-yl)-8-[3-(tetrahydropyran-4-yl)azetidin-1-ylmethyl]-9H-purine

Step 1:2-(2-Ethylbenzoimidazol-1-yl)-6-morpholin-4-yl-9-(tetrahydropyran-2-yl)-9H-purine-8-carbaldehyde

Step 1: A mixture of2-chloro-6-morpholin-4-yl-9-(tetrahydropyran-2-yl)-9H-purine-8-carbaldehyde(0.8 g, 2.27 mmol), 2-ethyl-1H-benzoimidazole (0.4 g, 2.72 mmol), Xphos(0.216 g, 0.45 mmol), Pd₂(dba)₃ (0.104 g, 0.11 mmol) and Cs₂CO₃ (1.48 g,4.54 mmol) in dioxane (10 mL) was subjected to microwave irradiation at145° C. for 45 min. The suspension was filtered through Celite and thefiltrate was concentrated in vacuo. The residue was purified by flashchromatography (Si—PPC, EtOAc:Cyclohexane, gradient 0:100 to 75:25) togive2-(2-Ethylbenzoimidazol-1-yl)-6-morpholin-4-yl-9-(tetrahydropyran-2-yl)-8-[3-(tetrahydropyran-4-yl)azetidin-1-ylmethyl]-9H-purineas a yellow foam (0.444 g, 43%). LCMS (Method A): R_(T)=4.05 min, [M+H]⁺494.4

Step 2: A 10 mL round-bottomed flask was charged with a solution of2-(2-ethylbenzoimidazol-1-yl)-6-morpholin-4-yl-9-(tetrahydropyran-2-yl)-9H-purine-8-carbaldehyde(0.22 g, 0.48 mmol), 3-(tetrahydropyran-4-yl)azetidine hydrochloride(0.093 g, 0.53 mmol) in DCE (5 mL), trimethoxymethane (0.518 mL, 4.8mmol) and acetic acid (0.03 mL, 0.48 mmol). The reaction mixture wasstirred for 4 h at room temperature. Sodium triacetoxyborohydride (0.152g, 0.72 mmol) was added and the reaction mixture was stirred for afurther 72 h at room temperature. The suspension was partitioned betweenDCM and water; the organic layer was separated and washed with brine,dried with sodium sulphate and concentrated to give2-(2-Ethylbenzoimidazol-1-yl)-6-morpholin-4-yl-9-(tetrahydropyran-2-yl)-8-[3-(tetrahydropyran-4-yl)azetidin-1-ylmethyl]-9H-purineas an orange oil (0.356 g, 99%). LCMS (Method A): R_(T)=2.97 min, [M+H]⁺587.4

Example 75kN-[9-Methyl-6-morpholin-4-yl-8-(4-oxetan-3-yl-piperidin-1-ylmethyl)-9H-purin-2-yl]benzene-1,2-diamine

A mixture of2-chloro-9-methyl-6-morpholin-4-yl-8-(4-oxetan-3-yl-piperidin-1-ylmethyl)-9H-purine(0.2 g, 0.49 mmol), benzene-1,2-diamine (0.106 g, 0.98 mmol), Xphos(0.047 g, 0.098 mmol), Pd₂(dba)₃ (0.022 g, 0.025 mmol) and Cs₂CO₃ (0.32g, 0.98 mmol) in DMF (2 mL) was subjected to microwave irradiation at150° C. for 30 min. The suspension was filtered through Celite and thesolution was concentrated in vacuo. The residue was purified by flashchromatography (Si—PPC, MeOH:DCM, gradient 0:100 to 10:90) to giveN-[9-Methyl-6-morpholin-4-yl-8-(4-oxetan-3-yl-piperidin-1-ylmethyl)-9H-purin-2-yl]benzene-1,2-diamineas yellow foam (0.117 g, 50%). LCMS (Method A): R_(T)=2.14 min, [M+H]⁺479.2

Example 75l2-Chloro-9-methyl-6-morpholin-4-yl-8-[3-(tetrahydropyran-4-yl)azetidin-1-ylmethyl]-9H-purine

A 25 mL round-bottomed flask was charged with a solution of2-chloro-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (0.173 g,0.65 mmol), 3-(tetrahydropyran-4-yl)azetidine hydrochloride (0.138 g,0.78 mmol) and 4 Å molecular sieves (0.9 g) in DCE (7 mL). The reactionmixture was stirred for 5 h at room temperature. Sodiumtriacetoxyborohydride (0.274 g, 1.29 mmol) was added and the reactionmixture was stirred for 18 h at room temperature. The suspension wasfiltered through Celite and the filtrate was concentrated in vacuo. Theresidue was purified by flash chromatography (Si—PPC, MeOH:EtOAc,gradient 0:100 to 10:90) to give2-Chloro-9-methyl-6-morpholin-4-yl-8-[3-(tetrahydropyran-4-yl)azetidin-1-ylmethyl]-9H-purineas a white foam (0.117 g, 45%). LCMS (Method A): R_(T)=2.40 min, [M+H]⁺407.2

Example 75mN-{9-Methyl-6-morpholin-4-yl-8-[3-(tetrahydropyran-4-yl)azetidin-1-ylmethyl]-9H-purin-2-yl}benzene-1,2-diamine

A mixture of2-chloro-9-methyl-6-morpholin-4-yl-8-[3-(tetrahydropyran-4-yl)azetidin-1-ylmethyl]-9H-purine(0.25 g, 0.61 mmol), benzene-1,2-diamine (0.133 g, 1.23 mmol), Xphos(0.059 g, 0.123 mmol), Pd₂(dba)₃ (0.028 g, 0.031 mmol) and Cs₂CO₃ (0.17g, 1.23 mmol) in DMF (2.5 mL) was subjected to microwave irradiation at150° C. for 30 min. The suspension was filtered through Celite and thefiltrate was concentrated in vacuo. The residue was purified by flashchromatography (Si—PPC, MeOH:DCM, gradient 0:100 to 10:90) to give thetitle compound as a brown foam (0.234 g, 80%). LCMS (Method A):R_(T)=2.20 min, [M+H]⁺ 479.4

Example 75n2-[1-(9-Methyl-6-morpholin-4-yl-2-(tributylstannanyl)-9H-purin-8-ylmethyl)piperidin-4-yl]propan-2-ol

A mixture of2-[1-(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl)-piperidin-4-yl]propan-2-ol(500 mg, 1.23 mmol), hexabutylditin (0.928 mL, 1.84 mmol),PdCl₂{P^(t)Bu₂(Ph-p-Nme₂)}₂ (88 mg, 0.122 mmol) in dioxane (2.5 mL) andNMP (0.25 mL) was degassed and then subjected to microwave irradiationat 150° C. for 45 min. The reaction mixture was filtered through Celiteand the filtrate was concentrated in vacuo. The residue was dissolved inDCM (10 mL), washed with water (10 mL). The organic layer was separated,dried with sodium sulphate and concentrated in vacuo. The residue wasdiluted with MeOH and loaded onto a Isolute® SCX-2 cartridge (10 g). Thecartridge was then washed with MeOH and the desired product wassubsequently eluted using 2 M NH₃ in MeOH. The solution was concentratedto give a residue which was subjected to flash chromatography (Si—PPC,MeOH:DCM, gradient 0:100 to 7.5:92.5) followed by (Si—PPC,EtOAc:cyclohexane, gradient 0:100 to 100:0). Appropriate fractions werecombined and concentrated to give the title compound as pale yellow oil(236 mg, 29%). LCMS (Method A) R_(T)=4.58 min; [M+H]⁺663.3 (¹¹⁶Sn) 665.3(¹¹⁸Sn)

Example 75o(2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)acetaldehyde

To a stirred suspension of (methoxymethyl)triphenylphosphonium chloride(1.49 g, 4.35 mmol) in dry THF (10 mL) was added dropwise a 1 M solutionof LiHMDS in THF (4.35 mL, 4.35 mmol) under an atmosphere of nitrogen,at 0° C. After 15 min a suspension of2-chloro-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (1.02 g,3.62 mmol) in dry THF (10 mL) was added. The mixture was allowed to warmto RT after 30 min and stirred for a further 1 h then quenched with H₂O.The mixture was partitioned between EtOAc and 0.5 M HCl_((aq)), theorganic layer separated and washed with water and then brine. Theorganic layer was dried (Na₂SO₄) and evaporated to give a residue (2.2g), which was dissolved in MeOH, loaded onto an Isolute® SCX-2cartridge, the cartridge was washed with MeOH then the desired producteluted with 2 M NH₃ in MeOH to give a residue (860 mg) which was takenup in 37 wt. % HCl_((aq))/THF (8:16 mL). The resulting mixture wasstirred at 50° C. for 2 h then allowed to cool, partitioned betweenEtOAc and saturated NaHCO₃(aq). The organic layer was separated andwashed with brine then dried (Na₂SO₄) and concentrated in vacuo. Theresultant residue was purified by flash chromatography (Si—PCC, 0-100%EtOAc in cyclohexane) to give the title compound (451 mg, 42% over 2steps) as an orange solid. LCMS (Method H): R_(T) 3.29 min, [M+H]⁺ 296.2

Example 75p2-{1-[2-(2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)ethyl]piperidin-4-yl}propan-2-ol

To a solution of(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)acetaldehyde (150 mg,0.51 mmol) in DCE (10 mL) was added 2-piperidin-4-ylpropan-2-ol (110 mg,0.77 mmol), trimethyl orthoformate (0.55 mL, 5.02 mmol) and acetic acid(0.03 mL, 0.52 mmol). The reaction mixture was stirred at roomtemperature for 5 h, sodium triacetoxyborohydride (154 mg, 0.73 mmol)was added and the resulting mixture stirred for a further 2 h. Thereaction mixture was loaded onto an Isolute® SCX-2 cartridge, thecartridge was washed with MeOH then the desired product eluted with 2 MNH₃ in MeOH. The resulting residue was purified by column chromatography(Si—PCC, 0-10% MeOH in DCM) to give the title compound as an off whitesolid (109 mg, 51%). LCMS (Method H): R_(T)=2.54 min, [M+H]⁺ 423.5

Example 75q2-{4-[2-(2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)ethyl]piperazin-1-yl}isobutyramide

To a solution of(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)acetaldehyde (110 mg,0.37 mmol) in DCE (10 mL) was added 2-piperazin-1-ylisobutyramide (90mg, 0.53 mmol), trimethyl orthoformate (0.20 mL, 1.86 mmol) and aceticacid (0.02 mL, 0.37 mmol). The reaction mixture was stirred at roomtemperature for 3 h, sodium triacetoxyborohydride (118 mg, 0.56 mmol)was added and the resulting mixture stirred for a further 2 days. Thereaction mixture was loaded onto an Isolute® SCX-2 cartridge, thecartridge was washed with MeOH then the desired product eluted with 2 MNH₃ in MeOH. The resulting residue was purified by column chromatography(Si—PCC, 0-20% MeOH in EtOAc) to give the title compound as a paleyellow solid (71 mg, 42%). LCMS (Method H): R_(T)=2.40 min, [M+H]⁺ 451.5

Example 75r2-Chloro-8-[2-(2,2-dimethylmorpholin-4-yl)ethyl]-9-methyl-6-morpholin-4-yl-9H-purine

To a solution of(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)acetaldehyde (116 mg,0.39 mmol) in DCE (10 mL) was added 2,2-dimethylmorpholine (68 mg, 0.59mmol), trimethyl orthoformate (0.22 mL, 1.96 mmol) and acetic acid (0.02mL, 0.39 mmol). The reaction mixture was stirred at room temperature for3 h, sodium triacetoxyborohydride (125 mg, 0.59 mmol) was added and theresulting mixture stirred for a further 18 h. The reaction mixture wasloaded onto an Isolute® SCX-2 cartridge, the cartridge was washed withMeOH then the desired product eluted with 2 M NH₃ in MeOH. The resultingresidue was purified by column chromatography (Si—PCC, 0-10% MeOH inEtOAc) to give the title compound as a pale yellow solid (100 mg, 65%).LCMS (Method H): R_(T)=2.51 min, [M+H]⁺ 395.4

Example 75s2-{1-[2-(2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)ethyl]azetidin-3-yl}propan-2-ol

To a solution of(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)acetaldehyde (300 mg,1.01 mmol) in DCE (20 mL) was added 2-azetidin-3-ylpropan-2-ol (118 mg,1.02 mmol), trimethyl orthoformate (1.11 mL, 10.14 mmol) and acetic acid(0.06 mL, 1.01 mmol). The reaction mixture was stirred at roomtemperature for 6 h, sodium triacetoxyborohydride (323 mg, 1.52 mmol)was added and the resulting mixture stirred for a further 18 h. Thereaction mixture was loaded onto an Isolute® SCX-2 cartridge, thecartridge was washed with MeOH then the desired product eluted with 2 MNH₃ in MeOH. The resulting residue was purified by column chromatography(Si—PCC, 0-10% MeOH in DCM) to give the title compound as a pale yellowoil (90 mg, 23%). LCMS (Method A): R_(T)=2.37 min, [M+H]⁺ 395.2

Example 75t1-[2-(2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)ethyl]-4-methylpiperidin-4-ol

To a solution of(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)acetaldehyde (200 mg,0.68 mmol) in DCE (15 mL) was added 4-methylpiperidin-4-ol (117 mg, 1.01mmol), trimethyl orthoformate (0.74 mL, 6.76 mmol) and acetic acid (0.04mL, 0.68 mmol). The reaction mixture was stirred at room temperature for1.5 h, sodium triacetoxyborohydride (187 mg, 1.35 mmol) was added andthe resulting mixture stirred for a further 18 h. The reaction mixturewas loaded onto an Isolute® SCX-2 cartridge, washed with MeOH then thedesired product eluted with 2 M NH₃/MeOH in DCM. The resulting residuewas purified by column chromatography (Si—PCC, 0-20% 2 M NH₃/MeOH inDCM) to give the title compound as a colourless oil (45 mg, 17%). LCMS(Method H): R_(T)=2.24 min, [M+H]⁺ 395.5

Example 75u1-[2-(2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)ethyl]-3-methyl-azetidin-3-ol

To a solution of(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)acetaldehyde (150 mg,0.51 mmol) in DCE (10 mL) was added 3-methyl-azetidin-3-ol (65 mg, 0.75mmol) and powdered 4 Å molecular sieves. The reaction mixture wasstirred at room temperature for 2 h, sodium triacetoxyborohydride (215mg, 1.01 mmol) was added and the resulting mixture stirred for a further17 h. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge,washed with MeOH then the desired product eluted with 2 M NH₃ in MeOH.The resulting residue was purified by column chromatography (Si—PCC,0-10% MeOH in DCM) to give the title compound as a pale yellow oil (83mg, 45%). LCMS (Method H): R_(T)=2.29 min, [M+H]⁺ 367.5

Example 75v7-[2-(2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)ethyl]-7-azaspiro[3.5]nonan-2-ol

To a solution of(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)acetaldehyde (157 mg,0.53 mmol) in DCE (10 mL) was added 7-azaspiro[3.5]nonan-2-ol (109 mg,0.77 mmol) and powdered 4 Å molecular sieves. The reaction mixture wasstirred at room temperature for 4 h, sodium triacetoxyborohydride (225mg, 1.06 mmol) was added and the resulting mixture stirred for a further16 h. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge,washed with MeOH then the desired product eluted with 2 M NH₃ in MeOH.The resulting residue was purified by column chromatography (Si—PCC,0-10% 2 M NH₃/MeOH in DCM) to give the title compound as a colourlessoil (155 mg, 69%). LCMS (Method H): R_(T)=2.41 min, [M+H]⁺ 421.5

Example 75w1-[2-(2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)ethyl]-3-isopropyl-azetidin-3-ol

To a solution of(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)acetaldehyde (69 mg,0.23 mmol) in DCE (5 mL) was added 3-isopropyl-azetidin-3-ol (27 mg,0.23 mmol) and powdered 4 Å molecular sieves. The reaction mixture wasstirred at room temperature for 2 h, sodium triacetoxyborohydride (99mg, 0.47 mmol) was added and the resulting mixture stirred for a further2 days. The reaction mixture was loaded onto an Isolute® SCX-2cartridge, washed with MeOH then the desired product eluted with 2 M NH₃in MeOH. The resulting residue was purified by column chromatography(Si—PCC, 0-10% 2 M NH₃/MeOH in DCM) to give the title compound as a paleyellow oil (30 mg, 33%). LCMS (Method H): R_(T)=2.65 min, [M+H]⁺ 395.5

Example 75x4-[2-(2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)ethyl]-1-isopropylpiperazin-2-one

To a solution of(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)acetaldehyde (167 mg,0.57 mmol) in DCE (10 mL) was added 1-isopropylpiperazin-2-one (87 mg,0.61 mmol) and powdered 4 Å molecular sieves. The reaction mixture wasstirred at room temperature for 1 h, sodium triacetoxyborohydride (239mg, 1.13 mmol) was added and the resulting mixture stirred for a further16 h. The reaction mixture was filtered through Celite®, loaded onto anIsolute® SCX-2 cartridge, washed with MeOH then the desired producteluted with 2 M NH₃ in MeOH. The resulting residue was purified bycolumn chromatography (Si—PCC, 0-10% 2 M NH₃/MeOH in DCM) to give thetitle compound as a pale yellow oil (51 mg, 33%). LCMS (Method H):R_(T)=3.31 min, [M+H]⁺ 422.5

Example 75xx2-Chloro-9-methyl-6-morpholin-4-yl-8-[2-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)ethyl]-9H-purine

To a solution of(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)acetaldehyde (117 mg,0.40 mmol) in DCE (10 mL) was added 3-oxa-8-azabicyclo[3.2.1]octane (54mg, 0.48 mmol) and powdered 4 Å molecular sieves. The reaction mixturewas stirred at room temperature for 2 h, sodium triacetoxyborohydride(168 mg, 0.79 mmol) was added and the resulting mixture stirred for afurther 16 h. The reaction mixture was filtered through Celite®, loadedonto an Isolute® SCX-2 cartridge, washed with MeOH then the desiredproduct eluted with 2 M NH₃ in MeOH. The resulting residue was purifiedby column chromatography (Si—PCC, 0-10% MeOH in DCM) to give the titlecompound as a pale yellow oil (80 mg, 51%). LCMS (Method H): R_(T)=2.34min, [M+H]⁺ 393.5

Example 75y4-[2-(2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)ethyl]-6-isopropylpiperazin-2-one

To a solution of(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)acetaldehyde (184 mg,0.62 mmol) in DCE (15 mL) was added 6-isopropylpiperazin-2-one (106 mg,0.75 mmol) and powdered 4 Å molecular sieves. The reaction mixture wasstirred at room temperature for 6 h, sodium triacetoxyborohydride (364mg, 1.72 mmol) was added and the resulting mixture stirred for a further18 h. The reaction mixture was filtered through Celite®, loaded onto anIsolute® SCX-2 cartridge, washed with MeOH then the desired producteluted with 2 M NH₃/MeOH in DCM. The resulting residue was purified bycolumn chromatography (Si—PCC, 0-10% MeOH in DCM) to give the titlecompound as a pale yellow oil (93 mg, 35%). LCMS (Method H): R_(T)=3.44min, [M+H]⁺ 422.4

Example 75z2-Chloro-8-[2-(3,3-dimethylmorpholin-4-yl)ethyl]-9-methyl-6-morpholin-4-yl-9H-purine

To a solution of(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)acetaldehyde (119 mg,0.40 mmol) in DCE (10 mL) was added 3,3-dimethylmorpholine.HCl (61 mg,0.40 mmol), triethylamine (0.06 mL, 0.40 mmol) and powdered 4 Åmolecular sieves. After stirring at room temperature for 4 h, sodiumtriacetoxyborohydride (171 mg, 0.80 mmol) was added and the resultingmixture stirred for a further 16 h. The reaction mixture was filteredthrough Celite®, loaded onto an Isolute® SCX-2 cartridge, the cartridgewas washed with MeOH then the desired product eluted with 2 M NH₃/MeOHin DCM. The resulting residue was purified by column chromatography(Si—PCC, 0-7% MeOH in DCM) to give the title compound as a pale yellowoil (44 mg, 28%). LCMS (Method H): R_(T)=2.45 min, [M+H]⁺ 395.5

Example 75aa2-Chloro-8-{2-[3-(1,1-dioxo-1-thiomorpholin-4-yl)azetidin-1-yl]-ethyl}-9-methyl-6-morpholin-4-yl-9H-purine

To a solution of(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)acetaldehyde (115 mg,0.39 mmol) in DCE (10 mL) was added 4-azetidin-3-yl-thiomorpholine,1-1-dioxide (74 mg, 0.39 mmol) and powdered 4 Å molecular sieves. Thereaction mixture was stirred at room temperature for 4 h, sodiumtriacetoxyborohydride (165 mg, 0.78 mmol) was added and the resultingmixture stirred for a further 2 days. The reaction mixture was filteredthrough Celite®, loaded onto an Isolute® SCX-2 cartridge, washed withMeOH then the desired product eluted with 2 M NH₃/MeOH in DCM. Theresulting residue was purified by column chromatography (Si—PCC, 0-10% 2M NH₃/MeOH in DCM) to give the title compound as a pale yellow oil (93mg, 51%). LCMS (Method H): R_(T)=2.25 min, [M+H]⁺ 470.3

Example 75bb2-Chloro-8-[2-(4,4-difluoropiperidin-1-yl)ethyl]-9-methyl-6-morpholin-4-yl-9H-purine

To a solution of(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)acetaldehyde (60 mg,0.20 mmol) in DCE (10 mL) was added 4,4-difluoropiperidine.HCl (42 mg,0.26 mmol), triethylamine (0.04 mL, 0.26 mmol), powdered 4 Å molecularsieves and sodium triacetoxyborohydride (86 mg, 0.41 mmol). The reactionmixture was stirred at room temperature for 5 h, the reaction mixturewas loaded onto an Isolute® SCX-2 cartridge, washed with MeOH then thedesired product eluted with 2 M NH₃/MeOH in DCM. The resulting residuewas purified by column chromatography (Si—PCC, 0-5% MeOH in DCM) to givethe title compound as a pale yellow oil (30 mg, 37%). LCMS (Method H):R_(T)=2.61 min, [M+H]⁺ 401.5

Example 75cc2-Chloro-9-methyl-6-morpholin-4-yl-8-{2-[4-(tetrahydropyran-4-yl)piperazin-1-yl]ethyl}-9H-purine

To a solution of(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)acetaldehyde (72 mg,0.24 mmol) in DCE (15 mL) was added 1-(tetrahydropyran-4-yl)piperazine(60 mg, 0.35 mmol), powdered 4 Å molecular sieves and sodiumtriacetoxyborohydride (103 mg, 0.49 mmol). The reaction mixture wasstirred at room temperature for 17 h. The reaction mixture was loadedonto an Isolute® SCX-2 cartridge, the cartridge was washed with MeOHthen the desired product eluted with 2 M NH₃/MeOH in DCM. The resultingresidue was purified by column chromatography (Si—PCC, 0-10% MeOH inDCM) to give the title compound as a yellow solid (37 mg, 34%). LCMS(Method H): R_(T)=2.46 min, [M+H]⁺ 450.5

Example 75dd2-[(1S,4S)-5-(2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]-2-methylpropan-1-ol

A solution of2-chloro-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (235 mg,0.83 mmol),(2-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-2-methylpropan-1-ol (168 mg,0.99 mmol) and molecular sieves (4 Å, powdered, 1 g) in DCE (10 mL) wasstirred at ambient temperature for 4 h. Sodium triacetoxyborohydride(265 mg, 1.25 mmol) was added and the mixture stirred for 18 h, thenloaded onto an Isolute® SCX-2 cartridge (25 g). The cartridge was thenwashed with methanol and the desired product was subsequently elutedusing 2 M NH₃ in MeOH. The product was collected and concentrated invacuo. The resultant residue was purified by flash chromatography(Si—PPC, DCM:MeOH; 90:10) to afford the title compound as a tan solid(50 mg, 14%). LCMS (Method H): R_(T)=2.39 min, M+H⁺=436.

Example 75ee2-Chloro-8-((1S,4S)-5-methanesulfonyl-2,5-diazabicyclo[2.2.1]hept-2-ylmethyl)-9-methyl-6-morpholin-4-yl-9H-purine

A solution of2-chloro-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (227 mg,0.81 mmol), (1S,4S)-2-methanesulfonyl-2,5-diazabicyclo[2.2.1]heptane(170 mg, 0.97 mmol) and molecular sieves (4 Å, powdered, 1 g) in DCE (12mL) was stirred at ambient temperature for 3 h. Sodiumtriacetoxyborohydride (255 mg, 1.20 mmol) was added and the mixturestirred for 17 h, then loaded onto an Isolute® SCX-2 cartridge (25 g).The cartridge was then washed with methanol and the desired product wassubsequently eluted using 2 M NH₃ in MeOH. The product was collected andconcentrated in vacuo. The resultant residue was purified by flashchromatography (Si—PPC, DCM:MeOH; 98:2) to afford the title compound asa white solid (350 mg, 98%). LCMS (Method H): R_(T)=2.51 min, M+H⁺=442.

Example 75ff2-Chloro-9-methyl-6-morpholin-4-yl-8-(4-oxetan-3-ylpiperidin-1-ylmethyl)-9H-purine

A solution of2-chloro-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (1.0 g, 3.55mmol), 4-oxetan-3-ylpiperidine (600 mg, 4.25 mmol) and molecular sieves(4 Å, powdered, 5 g) in anhydrous THF (25 mL) was stirred at ambienttemperature for 5 h. Sodium triacetoxyborohydride (1.5 g, 7.08 mmol) wasadded and the mixture stirred for 18 h, then loaded onto an Isolute®SCX-2 cartridge (25 g). The cartridge was then washed with methanol andthe desired product was subsequently eluted using 2 M NH₃ in MeOH. Theproduct was collected and concentrated in vacuo. The resultant residuewas purified by flash chromatography (Si—PPC, DCM:MeOH; 100:0 to 99:1 to98:2 to 95:5 to 90:10) to afford the title compound as a white foam(0.82 g, 57%). LCMS (Method H): R_(T)=2.38 min, M+H⁺=408.

Example 75gg2-Chloro-8-[2-(4-methanesulfonyl-3,3-dimethylpiperazin-1-yl)-ethyl]-9-methyl-6-morpholin-4-yl-9H-purine

To a solution of(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)acetaldehyde (137 mg,0.46 mmol) in DCE (10 mL) was added 2,2-dimethylpiperazine-1-carboxylicacid tert-butyl ester (99 mg, 0.46 mmol), powdered 4 Å molecular sievesand sodium triacetoxyborohydride (146 mg, 0.69 mmol). After stirring atrt for 20 h, the reaction mixture was filtered through Celite®, loadedonto an Isolute® SCX-2 cartridge, washed with MeOH then the desiredproduct eluted with 2 M NH₃/MeOH in DCM. The resulting residue waspurified by column chromatography (Si—PCC, 0-10% MeOH in DCM) to give aresidue, which was taken up in DCM (3 mL). TFA (1 mL) was then added andthe reaction mixture stirred at RT for 2 h. The reaction mixture wasloaded onto an Isolute® SCX-2 cartridge, washed with MeOH then thedesired product eluted with 2 M NH₃ in MeOH. The resulting residue waspurified by column chromatography (Si—PCC, 0-10% MeOH in DCM) to give aresidue (28 mg), which was taken up in DCM (4 mL). The solution wascooled to 0° C. and Net₃ (0.03 mL, 0.21 mmol) and methanesulfonylchloride (0.03 mL, 0.39 mmol) were added. After 10 min the reactionmixture was allowed to warm to RT then stirred for 60 h. The reactionmixture was partitioned between DCM and sat. NaHCO₃(aq), the organiclayer separated and passed through a hydrophobic frit, then evaporatedin vacuo. This residue was taken up in MeOH/DCM, loaded onto an Isolute®SCX-2 cartridge, washed with MeOH then eluted with 2 M NH₃/MeOH in DCM)to give2-Chloro-8-[2-(4-methanesulfonyl-3,3-dimethylpiperazin-1-yl)-ethyl]-9-methyl-6-morpholin-4-yl-9H-purine(35 mg, 16% over 3 steps) as a yellow oil. LCMS (Method H): R_(T)=2.82min, [M+H]⁺ 472.4

Example 75hh[2-(2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)-ethyl]-(1,1-dioxo-tetrahydro-1-thiophen-3-yl)amine

To a solution of(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)acetaldehyde (118 mg,0.40 mmol) in DCE (15 mL) was added1,1-dioxo-tetrahydro-1-thiophen-3-ylamine (107 mg, 0.80 mmol) andpowdered 4 Å molecular sieves. The reaction mixture was stirred at roomtemperature for 30 min, sodium triacetoxyborohydride (169 mg, 0.80 mmol)was added and the resulting mixture stirred for a further 18 h. Thereaction mixture was filtered through Celite®, loaded onto an Isolute®SCX-2 cartridge, washed with MeOH then the desired product eluted with 2M NH₃/MeOH in DCM. The resulting residue was purified by columnchromatography (Si—PCC, 0-7% MeOH in DCM) to give[2-(2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)-ethyl]-(1,1-dioxo-tetrahydro-1-thiophen-3-yl)amineas a yellow oil (45 mg, 27%). LCMS (Method H): R_(T)=2.38 min, [M+H]⁺415.4

Example 75ii3-(2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)-pyrrolidine-1-carboxylicacid tert-butyl ester

Zinc activation: To a suspension of zinc powder (128 mg, 0.99 mmol) andCelpure® P65 in anhydrous DMA (4 mL) was added a 7:5 (v:v) mixture ofTMS—Cl: 1,2-dibromoethane (25 μL). The reaction mixture was stirred atroom temperature for 10 min.

Zinc insertion: A solution of 3-iodopyrrolidine-1-carboxylic acidtert-butyl ester (470 g, 1.58 mmol) in anhydrous DMA (2 mL) was addeddropwise. The reaction mixture was stirred for 45 min at roomtemperature.

Coupling reaction: A mixture of2-chloro-8-iodo-9-methyl-6-morpholin-4-yl-9H-purine (400 mg, 1.05 mmol),Pd(dppf)Cl₂.DCM (42 mg, 5 mol %) and CuI (20 mg, 10 mol %) in DMA (4 mL)was evacuated and back-filled with argon. The zincate mixture wasquickly filtered (PTFE) and added onto the palladium-containing mixture.The resulting reaction mixture was stirred at 85° C. for 18 hours thencooled to room temperature. The mixture was partitioned between EtOAcand a 1M aqueous solution of ammonium chloride, the organic layerseparated, washed with water, brine and dried (Na₂SO₄). The resultingresidue was purified by column chromatography (Si—PCC, 0-100% EtOAc incyclohexane) to give3-(2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)-pyrrolidine-1-carboxylicacid tert-butyl ester as an orange oil (79 mg, 18%). LCMS (Method H):R_(T)=4.48 min, [M+H]⁺ 423.5

Example 75jj4-(2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl)-3-isopropylpiperazin-2-one

A mixture of 2-chloro-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(212 mg, 0.75 mmol), 3-isopropylpiperazin-2-one (128 mg, 0.90 mmol) andpowdered 4 Å molecular sieves in DCE (18 mL) were stirred at RT. After 4h, sodium triacetoxyborohydride (318 mg, 1.50 mmol) was added and theresulting mixture stirred for a further 17 h. The reaction mixture wasfiltered through Celite®, loaded onto an Isolute® SCX-2 cartridge,washed with MeOH then the desired product eluted with 2 M NH₃/MeOH inDCM. Trituration of the resulting residue with EtOAc gave4-(2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl)-3-isopropylpiperazin-2-oneas a yellow oil (198 mg, 65%). LCMS (Method H): R_(T)=2.82 min, [M+H]⁺408.4

Example 75kk 2-Chloro-8-iodo-9-methyl-6-morpholin-4-yl-9H-purine

A suspension of 2-chloro-9-methyl-6-morpholin-4-yl-9H-purine (2.95 g,11.7 mmol) and TMEDA (2.6 mL, 2.03 g, 17.5 mmol) in THF (80 mL) wascooled to −78° C. before the drop wise addition of n-BuLi (9.8 mL, 24.5mmol, 2.5 M solution in hexanes). The resulting mixture was warmed to−40° C. and stirred for 40 mins. The mixture was cooled back to −78° C.before the addition of 1-chloro-2-iodoethane (3.7 mL, 7.8 g, 40.8 mmol).The resulting mixture was allowed to warm to r.t. over 2 h then quenchedwith NH₄Cl and extracted with EtOAc (×4). The combined organics weredried (Na₂SO₄) and concentrated in vacuo affording2-Chloro-8-iodo-9-methyl-6-morpholin-4-yl-9H-purine as a yellow solid(4.02 g, 91%). LCMS (method H): R_(T) 4.09 min [M+H]⁺ 379.9

Example 75ll2-(2-Ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine

A mixture of 2-chloro-9-methyl-6-morpholin-4-yl-9H-purine (4.0 g, 15.8mmol), 2-ethylbenzimidazole (2.8 g, 19.0 mmol),tris(dibenzylideneacetone)dipalladium (724 mg, 0.79 mmol), Xphos (1.5 g,3.16 mmol) and Cs₂CO₃ (10.3 g, 31.6 mmol) in dioxane (90 mL) was purgedwith argon then heated at 120° C. for 16 h in a sealed reactor. Thereaction mixture was filtered through a pad of celite, washing withEtOAc. The filtrate was concentrated in vacuo and purified by columnchromatography (Si—PCC, MeOH:EtOAc, 0-10%) affording2-(2-Ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine as anorange solid (3.49 g, 96%). LCMS (method H): R_(T) 3.46 min, [M+H]⁺364.5

Example 75mm2-(2-Ethylbenzoimidazol-1-yl)-8-iodo-9-methyl-6-morpholin-4-yl-9H-purine

A suspension of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine (1.67g, 4.58 mmol) and TMEDA (1.0 mL, 799 mg, 6.88 mmol) in THF (25 mL) wascooled to −78° C. before the drop wise addition of n-BuLi (2.8 mL, 6.88mmol, 2.5 M solution in hexanes). The resulting mixture was stirred for40 mins before the addition of 1-chloro-2-iodoethane (629 μL, 1.3 g,6.88 mmol). The resulting mixture was stirred at −78° C. for 1 h thenquenched with H₂O and warmed to r.t. The pale yellow precipitate wascollected by filtration washing with further H₂O and dried under vacuumat 50° C.2-(2-Ethylbenzoimidazol-1-yl)-8-iodo-9-methyl-6-morpholin-4-yl-9H-purinewas afforded as a pale yellow powder (2.0 g, 90%). LCMS (method H):R_(T) 2.74 min [M+H]⁺ 490.2

Example 75nn2-Chloro-9-methyl-6-morpholin-4-yl-8-[4-(tetrahydropyran-4-yl)piperazin-1-ylmethyl]-9H-purine

A mixture of 2-chloro-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(165 mg, 0.59 mmol), 1-(tetrahydropyran-4-yl)piperazine (110 mg, 0.65mmol) and molecular sieves (4 Å, powdered, 750 mg) in DCE (10 mL) wasstirred at ambient temperature for 4 h. Sodium triacetoxyborohydride(170 mg, 0.80 mmol) was added and the mixture stirred for 18 h, thenloaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was thenwashed with methanol and the desired product was subsequently elutedusing 2 M NH₃ in MeOH. The product was collected and concentrated invacuo. The resultant residue was purified by flash chromatography(Si—PPC, DCM:MeOH, 100:0 to 98:2 to 95:5 to 90:10) to afford2-Chloro-9-methyl-6-morpholin-4-yl-8-[4-(tetrahydropyran-4-yl)piperazin-1-ylmethyl]-9H-purineas a white solid (250 mg, 98%). ¹H NMR (CDCl₃, 400 MHz) δ 4.27 (m, 4H),4.01 (dd, J=11.5, 4.2 Hz, 2H), 3.81 (m, 7H), 3.69 (s, 2H), 3.36 (dd,J=12.5, 10.9 Hz, 2H), 2.55 (m, 8H), 2.40 (m, 1H), 1.75 (d, J=12.5 Hz,2H) and 1.56 (m, 2H)

Example 76a(2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl)phosphonic aciddimethyl ester

A mixture of 8-bromomethyl-2-chloro-9-methyl-6-morpholin-4-yl-9H-purine(3.92 g, 11.3 mmol) and trimethylphosphite (20 mL, mmol) was heated toreflux (120° C.) for 2 h. The reaction mixture was concentrated in vacuoto a fluorescent green solid which was triturated with H₂O. Theresulting pale green solid was purified by column chromatography(Si—PCC, MeOH:EtOAc, 0-10%) affording the title compound as a greensolid (3.36 g, 79%). LCMS (method A): R_(T) 3.45 min [M+H]⁺ 376.1

Example 76b3-(2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethylene)azetidine-1-carboxylicacid tert-butyl ester

To a solution of diisopropylamine (1.4 mL, 9.8 mmol) in THF (3 mL) at−78° C. was added n-BuLi (3.9 mL, 9.8 mmol, 2.5 M in hexanes) and theresulting mixture allowed to stir for 20 min. The resulting solution wasadded to a pale green solution of(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl)phosphonic aciddimethyl ester (3.36 g, 8.9 mmol) in THF (80 mL) at −78° C. Theresulting mixture was warmed to r.t. before a solution of3-oxo-azetidine-1-carboxylic acid tert-butyl ester (1.76 g, 10.2 mmol)in THF (10 mL) was added. The resulting pink mixture was stirred for 16h then quenched with H₂O. The mixture was concentrated in vacuo and theresidue was partitioned between DCM and brine. The organic phase wasdried (Na₂SO₄) and concentrated in vacuo. The resulting residue waspurified by column chromatography (Si—PCC, EtOAc:cyclohexane, 0-70%)affording the title compound as a green powder (3.46 g, 92%). ¹H NMR(CDCl₃, 400 MHz): δ 6.33-6.32 (1H, m), 4.91-4.90 (2H, m), 4.71-4.70 (2H,m), 4.28 (4H, brd s), 3.81 (4H, t, J=4.74 Hz), 3.71 (3H, s), 1.48 (9H,s).

Example 76c3-[2-(2-Ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethylene]azetidine-1-carboxylicacid tert-butyl ester

A mixture of3-(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethylene)azetidine-1-carboxylicacid tert-butyl ester (1.4 g, 3.33 mmol), 2-ethylbenzimidazole (584 mg,3.99 mmol), tris(dibenzylideneacetone)dipalladium (152 mg, 0.17 mmol),XPhos (317 mg, 0.66 mmol) and Cs₂CO₃ (2.17 g, 6.65 mmol) in dioxane (15mL) was purged with argon then heated at 120° C. for 16 h in a sealedtube. The reaction mixture was filtered through Celite®, washing withEtOAc, and the filtrate concentrated in vacuo. The resulting residue waspurified by column chromatography (Si—PCC, EtOAc:cyclohexane, 0-100%)affording the title compound as a cream solid (1.1 g, 62%). LCMS (methodH): R_(T) 3.20 min [M+H]⁺ 531.4

Example 76d3-[2-(2-Ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl]azetidine-1-carboxylicacid tert-butyl ester

To a solution of3-[2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethylene]azetidine-1-carboxylicacid tert-butyl ester (1.1 g, 2.07 mmol) in EtOH (40 mL) and AcOH (15mL) was added 10% Pd/C (200 mg) and the resulting mixture stirred underan atmosphere of H₂ for 65 h. The reaction mixture was filtered throughCelite®, washing with EtOAc, and the filtrate concentrated in vacuo. Theresulting residue was purified by column chromatography (Si—PCC,EtOAc:cyclohexane, 70-100%) affording the title compound as an orangeoil (0.92 g, 83%). LCMS (method H): R_(T) 3.01 min [M+H]⁺ 533.4

Example 76e8-Azetidin-3-ylmethyl-2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine

To a solution of3-[2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl]azetidine-1-carboxylicacid tert-butyl ester (917 mg, 1.72 mmol) in DCM (6 mL) was added TFA (3mL) and the resulting mixture stirred for 3 h at r.t. The reactionmixture was loaded onto an Isolute® SCX-2 cartridge which was washedwith MeOH/DCM and the product eluted with 2M NH₃/MeOH affording thetitle compound as a colourless oil (647 mg, 87%). LCMS (method H): R_(T)1.83 min [M+H]⁺ 433.3

Example 76f4-[2-(2-Ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl]-2-isopropyl-3-oxopiperazine-1-carboxylicacid tert-butyl ester

To a solution of 2-isopropyl-3-oxopiperazine-1-carboxylic acidtert-butyl ester (58 mg, 0.24 mmol) in DMF (1.5 mL) at 0° C. was addedNaH (11 mg, 0.29 mmol, 60% dispersion in mineral oil) and the resultingmixture stirred at r.t. for 30 min before the addition of8-bromomethyl-2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine(100 mg, 0.22 mmol) in DMF (1.5 mL). The resulting mixture was allowedto stir for 19 h then partitioned between EtOAc and H₂O. The organicphase was dried (MgSO₄) and concentrated in vacuo. The resulting residuewas purified by column chromatography (Si—PCC, MeOH:EtOAc, 0-10%)affording the title compound as a yellow oil (104 mg, 77%), LCMS (methodH): R_(T) 3.03 min [M+H]⁺ 618.4

Example 76g[2-(2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)ethyl]methyl-(3-methyl-1,1-dioxotetrahydrothiophen-3-yl)amine

A mixture of(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)acetaldehyde (210 mg,0.71 mmol), methyl-(3-methyl-1,1-dioxotetrahydrothiophen-3-yl)amine (116mg, 0.71 mmol), sodium triacetoxyborohydride (301 mg, 1.42 mmol) and 4 Åpowdered molecular sieves (280 mg) in DCE (15 mL) was stirred for 23 h.The reaction mixture was filtered through Celite® and the filtrateloaded onto an Isolute® SCX-2 cartridge which was washed with MeOH andthe product eluted with 2M NH₃/MeOH/DCM. The resulting residue waspurified by column chromatography (Si—PCC, MeOH:EtOAc, 0-10%) affordingthe title compound as a pale yellow solid (87 mg, 28%). LCMS (method H):R_(T) 2.01 min [M+H]⁺ 443.2

Example 76h4-(2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl)-3,3-dimethyl-piperazine-1-carboxylicacid tert-butyl ester

A mixture of 8-bromomethyl-2-chloro-9-methyl-6-morpholin-4-yl-9H-purine(400 mg, 1.16 mmol), 3,3-dimethylpiperazine-1-carboxylic acid tert-butylester (250 mg, 1.17 mmol) and K₂CO₃ (176 mg, 1.28 mmol) in DMF (20 mL)was allowed to stir at r.t. for 16 h. The reaction mixture was loadedonto an Isolute® SCX-2 cartridge which was washed with MeOH and theproduct eluted with 2M NH₃/MeOH. The resulting residue was purified bycolumn chromatography (Si—PCC, MeOH:DCM, 0-10%) affording the titlecompound (150 mg, 27%). ¹H NMR (CDCl₃, 400 MHz): δ 4.26 (4H, brd s),3.82-3.80 (9H, m), 3.33 (2H, brd s), 3.22 (2H, brd s), 2.42-2.35 (2H,m), 1.45 (9H, s), 1.15 (6H, s).

Example 76i2-Chloro-8-(2,2-dimethylpiperazin-1-ylmethyl)-9-methyl-6-morpholin-4-yl-9H-purine

To a solution of4-(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl)-3,3-dimethyl-piperazine-1-carboxylicacid tert-butyl ester (288 mg, 0.60 mmol) in DCM (30 mL) was added TFA(3 mL) and the mixture stirred at r.t for 1 h. The reaction mixture wasloaded onto an Isolute® SCX-2 cartridge which was washed with MeOH andthe product eluted with 2M NH₃/MeOH affording the title compound as awhite solid (199 mg, 87%). ¹H NMR (CDCl₃, 400 MHz): δ 4.26 (4H, brd s),3.84-3.77 (9H, m), 2.84 (2H, t, J=4.87 Hz), 2.74 (2H, s), 2.43 (2H, t,J=4.89 Hz), 1.21 (6H, s).

Example 76j2-Chloro-8-(2,2-dimethyl-4-oxetan-3-ylpiperazin-1-ylmethyl)-9-methyl-6-morpholin-4-yl-9H-purine

A mixture of2-chloro-8-(2,2-dimethylpiperazin-1-ylmethyl)-9-methyl-6-morpholin-4-yl-9H-purine(198 mg, 0.52 mmol), oxetan-3-one (42 mg, 0.58 mmol) and 4 Å powderedmolecular sieves in DCE (10 mL) was allowed to stir at r.t for 4 hbefore the addition of sodium triacetoxyborohydride (144 mg, 0.68 mmol).The resulting mixture was allowed to stir for 16 h then loaded onto anIsolute® SCX-2 cartridge which was washed with MeOH and the producteluted with 2M NH₃/MeOH affording the title compound (192 mg, 85%). ¹HNMR (CDCl₃, 400 MHz): δ 4.63 (2H, t, J=6.48 Hz), 4.55 (2H, t, J=6.08Hz), 4.27 (4H, brd s), 3.84-3.80 (7H, m), 3.49 (2H, s), 3.38-3.37 (1H,m), 2.50-2.40 (2H, m), 2.23-2.04 (4H, m), 1.20 (6H, s)

Example 76k(1-{4-[2-(2-Ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl]-3,3-dimethylpiperazine-1-carbonyl}cyclopropyl)carbamicacid tert-butyl ester

A mixture of8-(2,2-dimethylpiperazin-1-ylmethyl)-2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine(140 mg, 0.29 mmol), 1-aminocyclopropanecarboxylic acid (64 mg, 0.32mmol), HATU (120 mg, 0.32 mmol) and DIPEA (56 μL, 0.32 mmol) in DCM (3mL) was allowed to stir at r.t. for 60 h. The reaction mixture wasloaded onto an Isolute® SCX-2 cartridge which was washed with MeOH andthe product eluted with 2M NH₃/MeOH. The resulting residue was purifiedby column chromatography (Si—PCC, MeOH:DCM, 0-2%) affording the titlecompound. LCMS (method H): R_(T) 2.56 min, [M+H]⁺ 673.7

Example 76l2-(2-Cyclopropylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carboxylicacid

To a suspension of2-(2-cyclopropylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(500 mg, 1.24 mmol) in EtOH (16 mL) was added AgNO₃ (265 mg, 1.56 mmol)followed by a solution of NaOH (302 mg, 7.5 mmol) in H₂O (5 mL). Theresulting black suspension was allowed to stir at r.t. for 30 min thenfiltered through Celite® and the resulting filtrate concentrated invacuo. The resulting residue was dissolved in H₂O and basified by theaddition of aq. NaOH. The aqueous phase was extracted with DCM thenacidified to pH 2 with HCl. The aqueous phase was concentrated in vacuoto half volume then cooled on ice. The resulting precipitate wascollected by filtration and dried in vacuo affording the title compound(280 mg, 55%). ¹H NMR (DMSO, 400 MHz): δ 8.12-8.11 (1H, m), 7.72-7.68(1H, m), 7.44-7.43 (2H, m), 4.60 (4H, brd s), 4.04 (3H, s), 3.90-3.70(4H, m), 3.06-3.00 (1H, m), 1.33-1.31 (4H, m)

Example 76m4-{1-[2-Chloro-6-morpholin-4-yl-9-(tetrahydropyran-2-yl)-9H-purin-8-ylmethyl]azetidin-3-yl}piperazin-2-one

A mixture of2-chloro-6-morpholin-4-yl-9-(tetrahydropyran-2-yl)-9H-purine-8-carbaldehyde(1.06 g, 3.01 mmol) and 4-azetidin-3-ylpiperazin-2-one (560 mg, 3.61mmol) in DCE (60 mL) and DMF (20 mL) was allowed to stir at r.t. for 10min before the addition of 4 Å powdered molecular sieves (3.0 g)followed by sodium triacetoxyborohydride (1.28 g, 6.04 mmol). Theresulting mixture was allowed to stir for 64 h then filtered throughCelite® which was washed with DCM. The filtrate was concentrated invacuo and the resulting residue dissolved in EtOAc and washed withNaHCO₃, H₂O and brine. The organic phase was dried (Na₂SO₄) andconcentrated in vacuo affording the title compound as a yellow gum (997mg, 67%). LCMS (method A): R_(T) 2.19 and 2.11 min [M−C₅H₉O+H]⁺407.3

Example 76n4-{1-[2-(2-Ethylbenzoimidazol-1-yl)-6-morpholin-4-yl-9-(tetrahydropyran-2-yl)-9H-purin-8-ylmethyl]azetidin-3-yl}piperazin-2-one

A mixture of4-{1-[2-chloro-6-morpholin-4-yl-9-(tetrahydropyran-2-yl)-9H-purin-8-ylmethyl]azetidin-3-yl}piperazin-2-one(990 mg, 2.00 mmol), 2-ethylbenzimidazole (322 mg, 2.20 mmol),tris(dibenzylideneacetone)dipalladium (46 mg, 0.05 mmol), XPhos (95 mg,0.20 mmol) and Cs₂CO₃ (980 mg, 3.01 mmol) in dioxane (30 mL) was purgedwith argon then heated at 115° C. for 6 h then stirred at r.t. for 16 h.The reaction mixture was filtered through Celite®, washing with dioxane,and the filtrate concentrated in vacuo. The resulting residue waspurified by column chromatography (Si—PCC, MeOH:DCM, 0-10%) affordingthe title compound (470 mg, 39%). LCMS (method A): R_(T) 2.01 and 1.92min [M+H]⁺ 601.6

Example 76o2-Chloro-8-iodo-6-morpholin-4-yl-9-(tetrahydropyran-2-yl)-9H-purine

A solution of2-chloro-6-morpholin-4-yl-9-(tetrahydropyran-2-yl)-9H-purine (1.50 g,4.63 mmol) and TMEDA (1.72 mL, 6.94 mmol) in THF (30 mL) was cooled to−78° C. before the drop wise addition of n-BuLi (6.08 mL, 9.73 mmol, 1.6M solution in hexanes). The resulting mixture was allowed to stir at−78° C. for 485 min before the addition of 1-chloro-2-iodoethane (902μL, 16.22 mmol). The resulting mixture was allowed to warm to 0° C. over2.5 h then quenched with H₂O and extracted with DCM. The combinedorganics were washed with brine then dried (Na₂SO₄) and concentrated invacuo. The residue was triturated with ^(i)PrOAc and the resulting solidcollected by filtration affording the title compound (1.80 g, 87%). LCMS(method A): R_(T) 3.90 min [M+H]⁺ 450.3

Example 76p3-[2-(2-Methylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethylene]azetidine-1-carboxylicacid tert-butyl ester

A mixture of3-(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethylene)azetidine-1-carboxylicacid tert-butyl ester (200 mg, 0.48 mmol), 2-methylbenzimidazole (76 mg,0.57 mmol), tris(dibenzylideneacetone)dipalladium (44 mg, 0.06 mmol),XPhos (58 mg, 0.10 mmol) and Cs₂CO₃ (320 mg, 0.95 mmol) in toluene (4mL) was purged with argon then heated at 140° C. for 2 h in a microwavereactor. The reaction mixture was filtered through Celite®, washing withMeOH, and the filtrate concentrated in vacuo. The resulting residue waspurified by column chromatography (Si—PCC, EtOAc:cyclohexane, 0-100%)affording the title compound as an off-white solid (156 mg, 64%). LCMS(method A): R_(T) 3.11 min [M+H]⁺ 517.3

Example 76q3-[2-(2-Methylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl]azetidine-1-carboxylicacid tert-butyl ester

To a solution of3-[2-(2-methylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethylene]azetidine-1-carboxylicacid tert-butyl ester (205 mg, 0.40 mmol) in EtOH (10 mL) and AcOH (3mL) was added 10% Pd/C (40 mg) and the resulting mixture stirred underan atmosphere of H₂ for 65 h. The reaction mixture was filtered throughCelite®, washing with MeOH, and the filtrate concentrated in vacuoaffording the title compound (207 mg, quant.). LCMS (method H): R_(T)2.92 min [M+H]⁺ 519.4

Example 76r8-Azetidin-3-ylmethyl-2-(2-methylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine

To a solution of3-[2-(2-methylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl]azetidine-1-carboxylicacid tert-butyl ester (207 mg, 0.40 mmol) in DCM (5 mL) was added TFA (5mL) and the resulting mixture stirred for 2 h at r.t. The reactionmixture was loaded onto an Isolute® SCX-2 cartridge which was washedwith MeOH/DCM and the product eluted with 2M NH₃/MeOH affording thetitle compound as a white foam (131 mg, 80%). LCMS (method H): R_(T)1.81 min [M+H]⁺ 419.4

Example 76s Acetic acid1,1-dimethyl-2-{3-[9-methyl-2-(2-methylbenzoimidazol-1-yl)-6-morpholin-4-yl-9H-purin-8-ylmethyl]azetidin-1-yl}-2-oxoethylester

A mixture of8-azetidin-3-ylmethyl-2-(2-methylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine(131 mg, 0.31 mmol), acetic acid 1-chlorocarbonyl-1-methylethyl ester(45 μL, 0.31 mmol) and NEt₃ (40 μL, 0.31 mmol) in THF (3 mL) was allowedto stir at r.t. for 16 h then concentrated in vacuo. The resultingresidue was partitioned between DCM and H₂O, the organic phase dried(Na₂SO₄) and concentrated in vacuo. The residue was purified by columnchromatography (Si—PCC, MeOH:EtOAc, 0-10%) affording the title compoundas a white solid (125 mg, 73%). LCMS (method H): R_(T) 2.50 min [M+H]⁺547.5

Example 76t3-[2-(2-Isopropylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethylene]azetidine-1-carboxylicacid tert-butyl ester

A mixture of3-(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethylene)azetidine-1-carboxylicacid tert-butyl ester (200 mg, 0.48 mmol), 2-isopropylbenzimidazole (92mg, 0.57 mmol), tris(dibenzylideneacetone)dipalladium (44 mg, 0.06mmol), XPhos (58 mg, 0.10 mmol) and Cs₂CO₃ (310 mg, 0.95 mmol) intoluene (4 mL) was purged with argon then heated at 140° C. for 45 minin a microwave reactor. The reaction mixture was filtered throughCelite®, washing with MeOH, and the filtrate concentrated in vacuo. Theresulting residue was purified by column chromatography (Si—PCC,EtOAc:cyclohexane, 0-100%) affording the title compound as an off-whitesolid (255 mg, 99%). LCMS (method A): R_(T) 3.40 min [M+H]⁺ 545.3

Example 76u3-[2-(2-Isopropylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl]azetidine-1-carboxylicacid tert-butyl ester

To a solution of3-[2-(2-isopropylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethylene]azetidine-1-carboxylicacid tert-butyl ester (255 mg, 0.47 mmol) in EtOH (15 mL) and AcOH (5mL) was added 10% Pd/C (55 mg) and the resulting mixture stirred underan atmosphere of H₂ for 65 h. The reaction mixture was filtered throughCelite®, washing with MeOH, and the filtrate concentrated in vacuoaffording the title compound (256 mg, quant.). LCMS (method A): R_(T)3.16 min [M+H]⁺ 547.4

Example 76v8-Azetidin-3-ylmethyl-2-(2-isopropylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine

To a solution of3-[2-(2-isopropylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl]azetidine-1-carboxylicacid tert-butyl ester (256 mg, 0.47 mmol) in DCM (5 mL) was added TFA (5mL) and the resulting mixture stirred for 2 h at r.t. The reactionmixture was loaded onto an Isolute® SCX-2 cartridge which was washedwith MeOH/DCM and the product eluted with 2M NH₃/MeOH affording thetitle compound as an orange foam (205 mg, 97%). LCMS (method H): R_(T)1.91 min [M+H]⁺ 447.4

Example 76w Acetic acid1,1-dimethyl-2-{3-[9-methyl-2-(2-methylbenzoimidazol-1-yl)-6-morpholin-4-yl-9H-purin-8-ylmethyl]azetidin-1-yl}-2-oxoethylester

A mixture of8-azetidin-3-ylmethyl-2-(2-isopropylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine(100 mg, 0.22 mmol), acetic acid 1-chlorocarbonyl-1-methylethyl ester(32 μL, 0.22 mmol) and NEt₃ (29 μL, 0.22 mmol) in THF (3 mL) was allowedto stir at r.t. for 16 h then concentrated in vacuo. The resultingresidue was partitioned between DCM and H₂O, the organic phase dried(Na₂SO₄) and concentrated in vacuo. The residue was purified by columnchromatography (Si—PCC, MeOH:EtOAc, 0-7%) affording the title compoundas a white foam (97 mg, 75%). LCMS (method A): R_(T) 2.65 min [M+H]⁺575.3

Example 77a4-[2-(2-Ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbonyl]piperidine-1-carboxylicacid tert-butyl ester

To a solution of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine (500mg, 1.38 mmol) and TMEDA (312 μL, 2.07 mmol) in THF (10 mL) at −78° C.was added n-BuLi (660 μL, 1.65 mmol, 2.5M solution in hexanes) and theresulting mixture stirred for 30 min before the addition of a solutionof 4-(methoxymethylcarbamoyl)piperidine-1-carboxylic acid tert-butylester (564 mg, 2.07 mmol) in THF (5 mL). The resulting mixture wasstirred for 2 h then quenched with H₂O and extracted with EtOAc. Thecombined organic phases were dried (MgSO₄) and concentrated in vacuo.The resulting residue was triturated with EtOAc:cyclohexane and themother liquors concentrated in vacuo affording the title compound as anoil (760 mg, 96%). LCMS (method A): R_(T) 3.67 min [M+H]⁺ 557.3

Example 77b4-{1-[2-(2-Ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-yl]-1-hydroxyethyl}piperidine-1-carboxylicacid tert-butyl ester

To a solution of4-[2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbonyl]piperidine-1-carboxylicacid tert-butyl ester (177 mg, 0.31 mmol) in THF (3 mL) at 0° C. wasadded methylmagnesium bromide (130 μL, 0.37 mmol, 3M solution in Et₂O)and the resulting mixture stirred for 1 h before further methylmagnesiumbromide (130 μL, 0.37 mmol) was added. The resulting mixture was warmedto r.t. and stirred for 16 h then concentrated in vacuo. The resultingresidue was purified by column chromatography (Si—PCC, MeOH:EtOAc,0-10%) affording the title compound as a clear oil (104 mg, 57%). LCMS(method A): R_(T) 3.09 min [M+H]⁺ 591.2

Example 77c3-{2-[2-((R)-1-Hydroxyethyl)benzoimidazol-1-yl]-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethylene}azetidine-1-carboxylicacid tert-butyl ester

A mixture of3-(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethylene)azetidine-1-carboxylicacid tert-butyl ester (180 mg, 0.43 mmol),(R)-1-(1H-benzoimidazol-2-yl)ethanol (84 mg, 0.52 mmol),tris(dibenzylideneacetone) dipalladium (40 mg, 0.04 mmol), XPhos (82 mg,0.17 mmol) and Cs₂CO₃ (279 mg, 0.86 mmol) in toluene (3 mL) was purgedwith argon then heated at 140° C. for 1 h in a microwave reactor. Thereaction mixture was filtered through Celite®, washing with EtOAc andthe filtrate concentrated in vacuo. The resulting residue was purifiedby column chromatography (Si—PCC, MeOH:EtOAc, 0-15%) affording the titlecompound (167 mg, 72%). LCMS (method A): R_(T) 3.24 min [M+H]⁺ 547.4

Example 77d3-{2-[2-((R)-1-Hydroxyethyl)benzoimidazol-1-yl]-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl}azetidine-1-carboxylicacid tert-butyl ester

To a solution of3-{2-[2-((R)-1-hydroxyethyl)benzoimidazol-1-yl]-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethylene}azetidine-1-carboxylicacid tert-butyl ester (167 mg, 0.31 mmol) in EtOAc (5 mL) and EtOH (5mL) was added 20% Pd(OH)₂/C (160 mg) and the resulting mixture stirredunder an atmosphere of H₂ for 16 h. The reaction mixture was filteredthrough Celite® and the filtrate concentrated in vacuo affording thetitle compound (156 mg, 93%). LCMS (method A): R_(T) 3.07 min [M+H]⁺549.4

Example 77e(R)-1-[1-(8-Azetidin-3-ylmethyl-9-methyl-6-morpholin-4-yl-9H-purin-2-yl)-1H-benzoimidazol-2-yl]ethanol

To a solution of3-{2-[2-((R)-1-hydroxyethyl)benzoimidazol-1-yl]-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl}azetidine-1-carboxylicacid tert-butyl ester (156 mg, 0.28 mmol) in DCM (5 mL) was added TFA (2mL) and the resulting mixture stirred at r.t. for 45 min. The reactionmixture was concentrated in vacuo and the resulting residue loaded ontoan Isolute® SCX-2 cartridge which was washed with MeOH and the producteluted with 2M NH₃/MeOH affording the title compound (114 mg, 90%). LCMS(method A): R_(T) 1.80 min [M+H]⁺ 449.4

Example 77f3-{2-[2-((S)-1-Hydroxyethyl)benzoimidazol-1-yl]-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethylene}azetidine-1-carboxylicacid tert-butyl ester

A mixture of3-(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethylene)azetidine-1-carboxylicacid tert-butyl ester (180 mg, 0.43 mmol),(S)-1-(1H-benzoimidazol-2-yl)ethanol (84 mg, 0.52 mmol),tris(dibenzylideneacetone) dipalladium (40 mg, 0.04 mmol), XPhos (82 mg,0.17 mmol) and Cs₂CO₃ (279 mg, 0.86 mmol) in toluene (3 mL) was purgedwith argon then heated at 140° C. for 1 h in a microwave reactor.Further tris(dibenzylideneacetone) dipalladium (40 mg, 0.04 mmol) andXPhos (82 mg, 0.17 mmol) were added and the mixture heated at 140° C.for a further 1 h. The reaction mixture was filtered through Celite®,washing with EtOAc and the filtrate concentrated in vacuo. The resultingresidue was purified by column chromatography (Si—PCC, MeOH:EtOAc,0-15%) affording the title compound (127 mg, 55%). LCMS (method A):R_(T) 3.27 min [M+H]⁺ 547.4

Example 77g3-{2-[2-((S)-1-Hydroxyethyl)benzoimidazol-1-yl]-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl}azetidine-1-carboxylicacid tert-butyl ester

To a solution of3-{2-[2-((S)-1-hydroxyethyl)benzoimidazol-1-yl]-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethylene}azetidine-1-carboxylicacid tert-butyl ester (127 mg, 0.23 mmol) in EtOAc (5 mL) and EtOH (5mL) was added 20% Pd(OH)₂/C (130 mg) and the resulting mixture stirredunder an atmosphere of H₂ for 18 h. The reaction mixture was filteredthrough Celite® and the filtrate concentrated in vacuo affording thetitle compound (109 mg, 86%). LCMS (method A): R_(T) 3.06 min [M+H]⁺549.4

Example 77h(S)-1-[1-(8-Azetidin-3-ylmethyl-9-methyl-6-morpholin-4-yl-9H-purin-2-yl)-1H-benzoimidazol-2-yl]ethanol

To a solution of3-{2-[2-((S)-1-hydroxyethyl)benzoimidazol-1-yl]-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl}azetidine-1-carboxylicacid tert-butyl ester (109 mg, 0.20 mmol) in DCM (5 mL) was added TFA (2mL) and the resulting mixture stirred at r.t. for 45 min. The reactionmixture was concentrated in vacuo and the resulting residue loaded ontoan Isolute® SCX-2 cartridge which was washed with MeOH and the producteluted with 2M NH₃/MeOH affording the title compound (70 mg, 80%). LCMS(method A): R_(T) 1.87 min [M+H]⁺ 449.4

Formula I(iv) furan intermediates wherein (iv) X¹ is CR⁷ and X² is O

Example 80a2-[4-(2-Chloro-4-morpholin-4-ylfuro[3,2-c]pyrimidin-6-ylmethyl)piperazin-1-yl]-isobutyramide

A solution of2-chloro-4-morpholin-4-yl-furo[3,2-c]pyrimidine-6-carbaldehyde (300 mg,1.12 mmol) and 2-piperazin-1-ylisobutyramide dihydrochloride (327 mg,1.33 mmol) in DCE (12 mL) was stirred at ambient temperature for 1 h.Sodium triacetoxyborohydride (358 mg, 1.69 mmol) was added and themixture stirred for 6 h, then loaded onto an Isolute® SCX-2 cartridge(25 g). The cartridge was then washed with methanol and the desiredproduct was subsequently eluted using 2 M NH₃ in MeOH. The product wascollected and concentrated in vacuo. The resultant residue was purifiedby flash chromatography (Si—PPC, DCM:MeOH; gradient from 100:0 to 90:10)to afford the title compound as a tan solid (390 mg, 82%). LCMS (MethodH): R_(T)=2.39 min, M+H⁺=423

Example 80b2-Chloro-4-morpholin-4-yl-6-(3-morpholin-4-ylazetidin-1-ylmethyl)furo[3,2-d]-pyrimidine

A solution of2-chloro-4-morpholin-4-ylfuro[3,2-c]pyrimidine-6-carbaldehyde (300 mg,1.12 mmol) and 4-azetidin-3-yl-morpholine (191 mg, 1.34 mmol) in DCE (12mL) was stirred at ambient temperature for 1 h. Sodiumtriacetoxyborohydride (358 mg, 1.69 mmol) was added and the mixturestirred for 6 h, then loaded onto an Isolute® SCX-2 cartridge (10 g).The cartridge was then washed with methanol and the desired product wassubsequently eluted using 2 M NH₃ in MeOH. The product was collected andconcentrated in vacuo. The resultant residue was purified by flashchromatography (Si—PPC, DCM:MeOH; gradient from 100:0 to 90:10) toafford the title compound as a tan solid (357 mg, 81%). LCMS (Method H):R_(T)=2.26 min, M+H⁺=394

Example 80c2-[1-(2-Chloro-4-morpholin-4-ylfuro[3,2-c]pyrimidin-6-ylmethyl)piperidin-4-yl]-propan-2-ol

A solution of2-chloro-4-morpholin-4-ylfuro[3,2-c]pyrimidine-6-carbaldehyde (78 mg,0.29 mmol) and 2-piperidin-4-ylpropan-2-ol (50 mg, 0.35 mmol) in DCE (3mL) was stirred at ambient temperature for 45 min. Sodiumtriacetoxyborohydride (93 mg, 0.44 mmol) was added and the mixturestirred for 2 h, then loaded onto an Isolute® SCX-2 cartridge (10 g).The cartridge was then washed with methanol and the desired product wassubsequently eluted using 2 M NH₃ in MeOH. The product was collected andconcentrated in vacuo. The resultant residue was purified by flashchromatography (Si—PPC, DCM:MeOH; 100:0 to 98:2 to 95:5) to afford thetitle compound as a tan solid (110 mg, 96%). LCMS (Method H): R_(T)=2.33min, M+H⁺=395.

Example 80d2-[1-(4-Morpholin-4-yl-2-(tributylstannanyl)furo[3,2-d]pyrimidin-6-ylmethyl)-piperidin-4-yl]-propan-2-ol

A mixture of2-[1-(2-chloro-4-morpholin-4-ylfuro[3,2-d]pyrimidin-6-ylmethyl)piperidin-4-yl]propan-2-ol(140 mg, 0.36 mmol), hexabutylditin (266 μL, 0.53 mmol), andPdCl₂{P^(t)Bu₂(Ph-p-Nme₂)}₂ (25 mg, 0.034 mmol) in 1,4-dioxane (1.6 mL)was purged with argon gas and then subjected to microwave irradiation at150° C. for 30 min. The reaction mixture was diluted with MeOH andloaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was thenwashed with MeOH and the desired product was subsequently eluted using 2M NH₃ in MeOH. The product was collected and concentrated in vacuo toafford the title compound which was used without further purification(147 mg, 54%). LCMS (Method H) R_(T)=3.72 min; [M+H]⁺649 (¹¹⁶Sn) 651(¹¹⁸Sn)

Example 80e4-Morpholin-4-yl-6-(3-morpholin-4-yl-azetidin-1-ylmethyl)-2-(tributylstannanyl)furo[3,2-c]pyrimidine

A mixture of2-chloro-4-morpholin-4-yl-6-(3-morpholin-4-ylazetidin-1-ylmethyl)furo[3,2-c]pyrimidine(200 mg, 0.51 mmol), hexabutylditin (380 μL, 0.75 mmol), andPdCl₂{P^(t)Bu₂(Ph-p-Nme₂)}₂ (36 mg, 0.051 mmol) in 1,4-dioxane (2.3 mL)was purged with argon gas and then subjected to microwave irradiation at150° C. for 30 min. The reaction mixture was diluted with MeOH andloaded onto a Isolute® SCX-2 cartridge (10 g). The cartridge was thenwashed with MeOH and the desired product was subsequently eluted using 2M NH₃ in MeOH. The product was collected and concentrated in vacuo. Theresultant residue was purified by flash chromatography (Si—PPC,DCM:MeOH; 100:0 to 98:2 to 95:5) to afford to afford the title compoundas a yellow oil (227 mg, 69%). LCMS (Method H) R_(T)=3.72 min; [M+H]⁺648(¹¹⁶Sn) 650 (¹¹⁸Sn)

Example 81a 2-Chloro-6-((R)-3-methylmorpholin-4-yl)-9H-purine

A mixture of 2,6-dichloro-9H-purine (2.18 g, 11.53 mmol),(R)-3-methylmorpholine (1.40 g, 13.84 mmol) and DIPEA (2.57 mL, 14.99mmol) in IMS (50 mL) were heated at 80° C. for 8 h. The reaction mixturewas concentrated in vacuo to a reduced volume and the residuepartitioned between EtOAc and H₂O. The organic phase was dried (Na₂SO₄)and concentrated in vacuo. The resulting residue was purified by columnchromatography (Si—PCC, MeOH:EtOAc, 0-10%) affording the title compoundas an off-white solid (914 mg, 31%). LCMS (method H): R_(T) 2.53 min[M+H]⁺ 254.3

Example 81b 2-Chloro-9-methyl-6-((R)-3-methylmorpholin-4-yl)-9H-purine

A mixture of 2-chloro-6-((R)-3-methylmorpholin-4-yl)-9H-purine (635 mg,2.50 mmol), methyl iodide (187 μL, 3.00 mmol) and K₂CO₃ (484 mg, 3.50mmol) in THF (15 mL) were stirred at r.t. for 18 h before further methyliodide (187 μL, 3.00 mmol) was added. The resulting mixture was allowedto stir for 65 h then concentrated in vacuo. The resulting residue waspartitioned between EtOAc and H₂O, the organic phase washed with brine,then dried (Na₂SO₄) and concentrated in vacuo affording the titlecompound as an off-white solid (552 mg, 83%). LCMS (method H): R_(T)2.76 min [M+H]⁺ 268.3

Example 81c2-Chloro-9-methyl-6-((R)-3-methylmorpholin-4-yl)-9H-purine-8-carbaldehyde

To a solution of2-chloro-9-methyl-6-((R)-3-methylmorpholin-4-yl)-9H-purine (550 mg, 2.05mmol) in THF (20 mL) at −78° C. was added LiHMDS (3.1 mL, 3.08 mmol, 1Msolution in THF). The resulting mixture was allowed to stir for 45 minbefore the addition of DMF (800 μL, 10.33 mmol). The reaction mixturewas warmed to r.t. over 1.5 h then poured onto 0.5M HCl. The resultingprecipitate was collected by filtration and washed with H₂O then Et₂Oaffording the title compound as a yellow solid (406 mg, 67%). LCMS(method H): R_(T) 3.35 min [M+H]⁺ 296.3

Example 81d2-{1-[2-Chloro-9-methyl-6-((R)-3-methylmorpholin-4-yl)-9H-purin-8-ylmethyl]piperidin-4-yl}propan-2-ol

A mixture of2-chloro-9-methyl-6-((R)-3-methylmorpholin-4-yl)-9H-purine-8-carbaldehyde(279 mg, 0.94 mmol), 2-piperidin-4-ylpropan-2-ol (149 mg, 1.04 mmol) and4 Å powdered molecular sieves (700 mg) in DCE (15 mL) was stirred for5.5 h before the addition of sodium triacetoxyborohydride (400 mg, 1.89mmol). The resulting mixture was allowed to stir for 17 h then filteredthrough Celite®, washing with MeOH. The resulting filtrate was loadedonto an Isolute® SCX-2 cartridge which was washed with MeOH and theproduct eluted with 2M NH₃/MeOH/DCM. The resulting residue was purifiedby column chromatography (Si—PCC, MeOH:EtOAc, 0-15%) affording the titlecompound as a pale yellow solid (366 mg, 92%). LCMS (method H): R_(T)2.11 min [M+H]⁺ 423.4

Example 82a 2-Chloro-6-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)-9H-purine

A mixture of 2,6-dichloro-9H-purine (527 Mg, 2.79 mmol),3-Oxa-8-aza-bicyclo[3.2.1]octane hydrochloride (500 mg, 3.34 mmol) andDIPEA (1.2 mL, 6.98 mmol) in IMS (15 mL) were heated at 80° C. for 3 hthen stirred at r.t. for 18 h. The resulting precipitate was collectedby filtration and washed with further IMS. The resulting solid was driedin vacuo affording the title compound (663 mg, 90%). ¹H NMR (CDCl₃, 400MHz): δ 8.14 (1H, s), 5.60 (1H, brd s), 4.80 (1H, brd s), 3.66 (4H, brds), 2.00 (4H, s)

Example 82b2-Chloro-9-methyl-6-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)-9H-purine

A mixture of 2-chloro-6-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)-9H-purine(650 mg, 2.45 mmol), methyl iodide (183 μL, 2.94 mmol) and K₂CO₃ (473mg, 3.43 mmol) in THF (15 mL) was stirred at r.t. for 18 h beforefurther methyl iodide (50 μL, 0.80 mmol) was added. The resultingmixture was allowed to stir for 65 h then concentrated in vacuo. Theresulting residue was partitioned between EtOAc and H₂O, the organicphase washed with brine, then dried (Na₂SO₄) and concentrated in vacuoaffording the title compound as an off-white solid (673 mg, 98%). LCMS(method H): R_(T) 2.63 min [M+H]⁺ 280.3

Example 82c2-Chloro-9-methyl-6-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)-9H-purine-8-carbaldehyde

To a solution of2-chloro-9-methyl-6-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)-9H-purine (620mg, 2.22 mmol) and TMEDA (498 μL, 3.33 mmol) in THF (11 mL) at −78° C.was added n-BuLi (1.3 mL, 3.33 mmol, 2.5M solution in hexanes). Theresulting mixture was warmed to −40° C. and allowed to stir for 30 minbefore cooling back to −78° C. DMF (517 μL, 6.65 mmol) was added and theresulting mixture was stirred at −78° C. for 30 min then poured onto 1MHCl. The aqueous layer was extracted with EtOAc and the organic phasewashed with brine, then dried (Na₂SO₄) and concentrated in vacuo. Theresulting residue was purified by column chromatography (Si—PCC,MeOH:DCM, 0-10%) affording the title compound as a pale yellow solid(500 mg, 73%). ¹H NMR (CDCl₃, 400 MHz): δ 9.88 (1H, s), 5.79 (1H, d,J=6.14 Hz), 5.05 (1H, d, J=6.84 Hz), 4.05 (3H, s), 3.80-3.78 (4H, m),2.29-2.01 (4H, m)

Example 82d2-{1-[2-Chloro-9-methyl-6-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)-9H-purin-8-ylmethyl]piperidin-4-yl}propan-2-ol

A mixture of2-chloro-9-methyl-6-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)-9H-purine-8-carbaldehyde(500 mg, 1.63 mmol), 2-piperidin-4-ylpropan-2-ol (256 mg, 1.79 mmol) and4 Å powdered molecular sieves (500 mg) in DCE (11 mL) was stirred for 4h before the addition of sodium triacetoxyborohydride (690 mg, 3.26mmol). The resulting mixture was allowed to stir for 17 h then filteredthrough Celite®, washing with MeOH. The resulting filtrate was loadedonto an Isolute® SCX-2 cartridge which was washed with MeOH and theproduct eluted with 2M NH₃/MeOH/DCM. The resulting residue was purifiedby column chromatography (Si—PCC, MeOH:DCM, 0-10%) affording the titlecompound as a pale yellow solid (577 mg, 82%). LCMS (method H): R_(T)0.30 and 2.00 min [M+H]⁺ 435.4

Example 83a 2-Chloro-6-((S)-3-methylmorpholin-4-yl)-9H-purine

A mixture of 2,6-dichloro-9H-purine (5.2 g, 27.51 mmol),(S)-3-methylmorpholine (3.30 g, 32.62 mmol) and DIPEA (5.0 mL, 28.71mmol) in IMS (130 mL) were heated at 80° C. for 3 h then stirred at r.t.for 17 h. The resulting white precipitate was collected by filtrationand the filtrate concentrated in vacuo to a reduced volume and theresulting precipitate also collected by filtration. Both batches ofsolid were combined in DCM and the organic phase washed with H₂O andbrine, then dried (MgSO₄) and concentrated in vacuo affording the titlecompound as a white powder (5.3 g, 76%). LCMS (method H): R_(T) 2.54 min[M+H]⁺ 254.1

Example 83b 2-Chloro-9-methyl-6-((S)-3-methylmorpholin-4-yl)-9H-purine

A mixture of 2-chloro-6-((S)-3-methylmorpholin-4-yl)-9H-purine (5.3 g,20.89 mmol), methyl iodide (1.6 mL, 25.70 mmol) and K₂CO₃ (4.0 g, 28.94mmol) in THF (100 mL) were stirred at r.t. for 18 h then concentrated invacuo. The resulting residue was partitioned between EtOAc and H₂O, theorganic phase washed with brine, then dried (Na₂SO₄) and concentrated invacuo affording the title compound (4.84 g, 87%). LCMS (method H): R_(T)2.74 min [M+H]⁺ 268.2

Example 83c2-Chloro-9-methyl-6-((S)-3-methylmorpholin-4-yl)-9H-purine-8-carbaldehyde

To a solution of2-chloro-9-methyl-6-((S)-3-methylmorpholin-4-yl)-9H-purine (500 mg, 1.67mmol) and TMEDA (419 μL, 2.80 mmol) in THF (10 mL) at −78° C. was addedn-BuLi (1.12 mL, 2.80 mmol, 2.5M solution in hexanes). The resultingmixture was allowed to warm to −40° C. and stir for 30 min then cooledback to −78° C. before the addition of DMF (435 μL, 5.61 mmol). Thereaction mixture was allowed to stir at −78° C. for 30 min then pouredonto 1M HCl. The aqueous phase was extracted with EtOAc and the combinedorganic phases were washed with H₂O and brine, then dried (MgSO₄) andconcentrated in vacuo. The resulting residue was purified by columnchromatography (Si—PCC, EtOAc:cyclohexane, 0-50%) affording the titlecompound as a white solid (450 mg, 81%). LCMS (method H): R_(T) 3.28 min[M+H]⁺ 296.3

Example 83d2-{1-[2-Chloro-9-methyl-6-((S)-3-methylmorpholin-4-yl)-9H-purin-8-ylmethyl]piperidin-4-yl}propan-2-ol

A mixture of2-chloro-9-methyl-6-((S)-3-methylmorpholin-4-yl)-9H-purine-8-carbaldehyde(450 mg, 1.52 mmol), 2-piperidin-4-ylpropan-2-ol (239 mg, 1.67 mmol) and4 Å powdered molecular sieves (450 mg) in DCE (10 mL) was stirred for 6h before the addition of sodium triacetoxyborohydride (644 mg, 3.04mmol). The resulting mixture was allowed to stir for 17 h then filteredthrough Celite®, washing with MeOH. The resulting filtrate was loadedonto an Isolute® SCX-2 cartridge which was washed with MeOH and theproduct eluted with 2M NH₃/MeOH/DCM. The resulting residue was purifiedby column chromatography (Si—PCC, MeOH:DCM, 0-4%) affording the titlecompound as a cream solid (538 mg, 84%). LCMS (method H): R_(T) 2.02 min[M+H]⁺ 423.3

Example 1014-(1-((2-(isoquinolin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperidin-4-yl)morpholine101

A sealable tube was charged with2-chloro-4-morpholin-4-yl-6-(4-morpholin-4-yl-piperidin-1-ylmethyl)-thieno[3,2-d]pyrimidine(0.100 g, 0.229 mmol), isoquinoline-5-boronic acid (0.048 g, 0.275mmol), dichlorobis(triphenylphosphine)palladium(II) (0.008 g, 0.012mmol), 1 N aqueous sodium carbonate solution (1 mL) and acetonitrile (3mL). The vessel was evacuated and back-filled with argon three timesthen sealed and heated at 130° C. for 90 min. The reaction mixture wascooled, concentrated, redissolved in ethyl acetate and filtered throughcelite. The filtrates were concentrated then purified by chromatography(silica, 10 to 20% methanol in dichloromethane) to give 101 (0.033 g,27%) as a yellow solid. MS m/e 531 [M+H]⁺; ¹H NMR (300 MHz, CDCl₃) δ ppm1.54-1.71 (m, 2H) 1.87 (d, J=11.3 Hz, 2H) 2.09-2.30 (m, 3H) 2.52-2.63(m, 4H) 3.01-3.11 (m, 2H) 3.70-3.78 (m, 4H) 3.85 (s, 2H) 3.87-3.94 (m,4H) 4.03-4.12 (m, 4H) 7.35 (s, 1H) 7.67-7.75 (m, 1H) 8.06 (d, J=8.3 Hz,1H) 8.31-8.37 (m, 1H) 8.52-8.58 (m, 1H) 8.61-8.67 (m, 1H) 9.30 (s, 1H)

Example 1024-(6-((4-(cyclopropylmethyl)piperazin-1-yl)methyl)-2-(1H-pyrrolo[2,3-c]pyridin-4-yl)thieno[3,2-d]pyrimidin-4-yl)morpholine102

Step 1:6-(4-(Cyclopropylmethyl)piperazin-1-ylmethyl)-2-methylsulfanyl-4-morpholin-4-yl-thieno[3,2-d]pyrimidine

2-Chloro-6-(4-(cyclopropylmethyl)piperazin-1-ylmethyl)-4-morpholin-4-ylthieno[3,2-d]pyrimidine(0.2 g, 0.49 mmol) in DMF (3 mL) was treated with sodium thiomethoxide(0.12 g, 1.71 mmol) in a sealed tube and the reaction mixture heated at100° C. with stirring. After 2 hours the contents of the tube werediluted with EtOAc then washed with saturated aqueous NaHCO₃ (×2)followed by brine and the organic phase was isolated, dried (Na₂SO₄),filtered and concentrated to afford6-(4-(cyclopropylmethyl)piperazin-1-ylmethyl)-2-methylsulfanyl-4-morpholin-4-yl-thieno[3,2-d]pyrimidineas a pale yellow solid (0.2 g, 97%). LCMS (Method D): R_(T)=2.04 min,[M+H]⁺ 419

Step 2: A solution of6-(4-cyclopropylmethylpiperazin-1-ylmethyl)-2-methylsulfanyl-4-morpholin-4-yl-thieno[3,2-d]pyrimidine(46 mg, 0.11 mmol) and1-benzenesulfonyl-4-tributylstannanyl-1H-pyrrolo[2,3-c]pyridine (129 mg,0.24 mmol) in DME (2 mL) was treated with copper (I) bromide-dimethylsulfide complex (50 mg, 2.43 mmol) in a sealed tube then the solutionwas degassed with argon for 5 min. Pd(PPh₃)₄ (20 mg, 0.016 mmol) wasadded and the reaction mixture heated at 100° C. for 3 hours. Themixture was filtered through Celite®, which was washed with DME and thecombined filtrate was evaporated to give a yellow gum. The gum waspurified by flash chromatography on silica, eluting with EtOAc to afford2-(1-benzenesulfonyl-6-(4-cyclopropylmethylpiperazin-1-ylmethyl)-4-morpholin-4-yl-2-(1H-pyrrolo[2,3-c]pyridin-4-yl)thieno[3,2-c]pyrimidine(34 mg, 54%). This intermediate was dissolved in IMS (1 mL) and1,4-dioxane (1 mL) and the stirring solution was treated with NaOHsolution (0.1 mL from 2.5 g NaOH in 5 mL H₂O). After 10 min the reactionmixture was treated with HCl (10 N) until at pH 7. The reaction mixturewas filtered to remove insoluble material. The solids were washed with1,4-dioxane, and the filtrate was evaporated. The resulting residue wastaken up in DCM and washed with brine; the isolated organic phase wasdried (MgSO₄), filtered and evaporated. Purification was carried out byflash chromatography, eluting with 3-12% MeOH in DCM to afford 102 (22mg, 41%). ¹H NMR (DMSO, 400 MHz): δ 11.76 (s, 1H); 9.13 (s, 1H); 8.81(s, 1H); 7.71 (d, J=2.71 Hz, 1H); 7.45 (s, 1H); 7.40-7.36 (m, 1H); 3.99(t, J=4.6 Hz, 4H); 3.87 (s, 2H); 3.83 (t, J=4.65 Hz, 4H); 3.30 (br s,4H); 2.54 (br s, 4H); 2.24 (br s, 2H); 0.89-0.77 (m, 1H); 0.50-0.41 (m,2H); 0.12-0.04 (m, 2H). LCMS (Method F): R_(T)=4.63 min, [M+H]⁺ 490.1

Example 1034-((4-morpholino-2-(1H-pyrrolo[2,3-c]pyridin-4-yl)thieno[3,2-d]pyrimidin-6-yl)methyl)morpholine103

Step 1:2-Methylsulfanyl-4-morpholin-4-yl-6-morpholin-4-ylmethyl-thieno[3,2-c]pyrimidine

2-Chloro-4-morpholin-4-yl-6-morpholin-4-ylmethyl-thieno[3,2-c]pyrimidine(0.2 g, 0.56 mmol) in DMF (3 mL) was treated with sodium thiomethoxide(0.12 g, 1.71 mmol) in a sealed tube and the reaction mixture heated at100° C. with stirring. After 2 h the contents of the tube were dilutedwith EtOAc, washed with saturated aqueous NaHCO₃ (×2) then brine, andthe organic phase was isolated, dried (Na₂SO₄), filtered andconcentrated to afford the title compound as a light brown solid (0.205g, 100%). LCMS (Method D): R_(T)=1.80 min, [M+H]⁺ 366.

Step 2: A solution of2-methylsulfanyl-4-morpholin-4-yl-6-morpholin-4-ylmethyl-thieno[3,2-d]pyrimidine(40 mg, 0.11 mmol) and1-benzenesulfonyl-4-(tributylstannanyl)-1H-pyrrolo[2,3-c]pyridine (129mg, 0.24 mmol) in DME (2 mL) was treated with copper (I)bromide-dimethyl sulfide complex (50 mg, 2.43 mmol) in a sealed tube andthe solution was degassed with argon for 5 min. Pd(PPh₃)₄ (19 mg, 0.016mmol) was added and the reaction mixture heated at 100° C. for 3 hours.The mixture was filtered through celite, which was washed with DME andthe combined filtrate was evaporated to give a yellow gum. The gum waspurified by flash chromatography on silica, eluting with EtOAc to afford2-(1-benzenesulfonyl-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-morpholin-4-yl-6-morpholin-4-ylmethyl-thieno[3,2-c]pyrimidine(34 mg, 54%). The sulfone intermediate was dissolved in IMS (1 mL) and1,4-dioxane (1 mL) and the stirring solution was treated with NaOHsolution (0.1 mL from 2.5 g NaOH in 5 mL H₂O). After 10 min the reactionmixture was treated with HCl (10 N) until at pH 7. The reaction mixturewas filtered to remove insoluble material. The solids were washed with1,4-dioxane, and the filtrate was evaporated. The resulting residue wastaken up in DCM and washed with brine; the isolated organic phase wasdried (MgSO₄), filtered and evaporated. The resultant crude residue waspurified by flash chromatography, (Si—PPC) eluting with 2-8% MeOH in DCMto afford 103 as a white solid (14 mg, 29%). ¹H NMR (MeOD, 400 MHz): δ8.99 (s, 1H); 8.75 (s, 1H); 7.66 (d, J=3.95 Hz, 1H); 7.40-7.36 (m, 2H);4.14-4.05 (m, 4H); 3.94-3.85 (m, 6H); 3.73 (t, J=4.6 Hz, 4H); 2.59 (t,J=4.35 Hz, 4H). LCMS (Method F): R_(T)=4.59 min, [M+H]⁺ 437.2

Example 1041-((2-(7-chloroquinolin-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)-N,N-dimethylpiperidin-4-amine104

A sealable tube was charged with[1-(2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)-piperidin-4-yl]-dimethyl-amine(0.150 g, 0.380 mmol), 7-chloroquinoline-4-boronic acid pinacol ester(0.132 g, 0.456 mmol), dichlorobis(triphenylphosphine) palladium(II)(0.013 g, 0.02 mmol), 1 N aqueous sodium carbonate solution (1 mL) andacetonitrile (3 mL). The vessel was evacuated and back-filled with argonthree times then sealed and heated at 130° C. for 90 min. The reactionmixture was cooled, concentrated, redissolved in ethyl acetate andfiltered through celite. The filtrates were concentrated then purifiedby chromatography (silica, 10 to 20% methanol in dichloromethane) togive 104 (0.085 g, 43%) as a yellow solid. MS m/e 531 [M+H]⁺; ¹H NMR(300 MHz, METHANOL-d₄) δ ppm 1.48-1.67 (m, 2H) 1.82-1.96 (m, 2H)2.07-2.26 (m, 3H) 2.30 (s, 6H) 3.07 (d, J=11.7 Hz, 2H) 3.82-3.91 (m, 6H)4.02-4.11 (m, 4H) 7.36 (s, 1H) 7.60 (dd, J=9.1, 2.3 Hz, 1H) 7.95 (d,J=4.5 Hz, 1H) 8.10 (d, J=2.3 Hz, 1H) 8.67 (d, J=9.4 Hz, 1H) 8.98 (d,J=4.9 Hz, 1H)

Example 1052-methyl-2-(4-((4-morpholino-2-(1H-pyrrolo[2,3-c]pyridin-4-yl)thieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)propanamide105

A mixture of2-[4-(4-morpholin-4-yl-2-(tributlystannanyl)thieno[3,2-d]pyrimidin-6-ylmethyl)piperazin-1-yl]isobutyramide(1.17 g, 1.69 mmol), 4-bromo-1H-pyrrolo[2,3-c]pyridine (432 mg, 2.19mmol), tetrakis(triphenylphosphine)palladium (194 mg, 10 mol %) and CuI(385 mg, 2.02 mmol) in dioxane (20 mL) was purged with argon gas thenheated at 140° C., for 20 min, in a microwave reactor. The reactionmixture was loaded onto an Isolute® SCX-2 cartridge, washed withMeOH/DCM then eluted with 2 M NH₃ in MeOH/DCM. The resulting residue waspurified by column chromatography (Si—PPC, MeOH:DCM, gradient 0:100 to20:80). The resulting solid was dissolved in MeOH, loaded onto anIsolute® SCX-2 cartridge, washed with MeOH then eluted with 2 M NH₃ inMeOH to afford 105 as a pale yellow solid (242 mg, 39%). LCMS (MethodF): R_(T) 4.51 min, [M+H]⁺ 521.2. ¹H NMR (DMSO, 400 MHz): δ 11.75 (s,1H); 9.13 (s, 1H); 8.81 (s, 1H); 7.71 (t, J=2.7 Hz, 1H); 7.45 (s, 1H);7.40-7.37 (m, 1H); 7.07 (d, J=3.5 Hz, 1H); 6.95 (d, J=3.5 Hz, 1H); 4.01(t, J=4.6 Hz, 4H); 3.87 (s, 2H); 3.83 (t, J=4.6 Hz, 4H); 2.58 (s, 4H);2.49 (s, 4H); 1.10 (s, 6H)

Example 1062-methyl-2-(4-((4-morpholino-2-(1H-pyrrolo[3,2-c]pyridin-4-yl)thieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)propanamide106

A mixture of2-[4-(4-morpholin-4-yl-2-(tributylstannanyl)thieno[3,2-d]pyrimidin-6-ylmethyl)piperazin-1-yl]isobutyramide(150 mg, 0.22 mmol), 1-benzenesulfonyl-4-bromo-1H-pyrrolo[3,2-c]pyridine(90 mg, 0.27 mmol), Pd(PPh₃)₄ (25 mg, 10 mol %) and CuI (50 mg, 0.25mmol) in dioxane (2.5 mL) was purged with argon gas then heated at 140°C., for 20 min, in a microwave reactor. The reaction mixture was loadedonto an Isolute® SCX-2 cartridge, washed with MeOH/DCM then eluted with2 M NH₃ in MeOH. The resulting residue was dissolved in IMS/dioxane (1:1mL) and 12.5 M aqueous NaOH solution (0.1 mL) added. After stirring for1 h the reaction mixture was loaded onto an Isolute® SCX-2 cartridge,washed with MeOH/DCM then eluted with 2 M NH₃ in MeOH/DCM. The resultingresidue was purified by flash chromatography (Si—PPC, MeOH:DCM, gradient0:100 to 05:95) to give 106 (28 mg, 24%) as a pale yellow solid. LCMS(Method F) R_(T) 4.86 min; [M+H]⁺ 521.3. ¹H NMR (CDCl₃, 400 MHz): δ 9.11(s, 1H); 8.54 (d, J=5.6 Hz, 1H); 7.45 (s, 1H); 7.41 (dd, J=3.3, 0.9 Hz,1H); 7.38 (dd, J=5.6, 0.95 Hz, 1H); 7.36 (d, J=3.3 Hz, 1H); 7.10 (d,J=5.3 Hz, 1H); 5.25 (d, J=5.2 Hz, 1H); 4.10 (t, J=4.75 Hz, 4H); 3.91 (t,J=4.7 Hz, 4H); 3.85 (s, 2H); 2.60 (s, 8H); 1.24 (s, 6H)

Example 1071-((2-(isoquinolin-8-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)-N,N-dimethylpiperidin-4-amine107

A microwave vessel was charged withdimethyl-[1-(4-morpholin-4-yl-2-tributylstannanyl-thieno[3,2-d]pyrimidin-6-methyl)-piperidin-4-yl]-amine(0.106 g, 0.163 mmol), 8-bromoisoquinoline (0.041 g, 0.196 mmol),copper(I) iodine (0.037 g, 0.196 mmol), palladiumtetrakis(triphenylphosphine) (0.019 g, 0.016 mmol) and tetrahydrofuran(2 mL). The vessel was evacuated and back-filled with argon three timesthen sealed and heated at 140° C. under microwave irradiation for 20min. The reaction mixture was cooled to room temperature and filteredthrough celite. The filtrates were concentrated then purified bychromatography (silica, 1 to 20% of a 49:1 MeOH:NH₄OH mixture indichloromethane) to give a colorless residue. This residue was dissolvedin dichloromethane (3 mL) then 1 N HCl in ether (0.2 mL) added dropwise.The resulting precipitate was collected by filtration to furnish 107(0.028 g, 29%) as a pale yellow powder and as a tetrahydrochloride salt.MS m/e 489 [M+H]⁺. ¹H NMR (300 MHz, methanol-d₄) δ ppm 2.45 (br. s., 4H)2.94 (s, 6H) 3.47 (br. s., 2H) 3.64-4.09 (m, 7H) 4.35 (br. s., 4H) 4.98(br. s., 2H) 8.14 (br. s., 1H) 8.45 (br. s., 1H) 8.64 (d, J=7.9 Hz, 1H)8.70 (d, J=6.0 Hz, 1H) 8.73-8.86 (m, 1H) 10.37 (br. s., 1H).

Example 1082-(4-((2-(1-aminoisoquinolin-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-methylpropanamide108

Step 1: 4-bromoisoquinolin-1-amine

To a mixture of 4-bromoisoquinoline (1.102 g, 7.644 mmol), potassiumbromide (0.9369 g, 7.873 mmol), and phosphomolybdic acid (70 mg) inacetic acid (23 mL) was added 30% of hydrogen peroxide in water (0.88mL) over 5 min. The mixture formed a suspension and was stirred at roomtemperature for 2 h. Water (50 mL) was added. The suspension wasextracted with EtOAc (2×100 mL). The combined EtOAc extracts were washedwith water (2×50 mL), saturated NaHCO₃ (2×50 mL), and brine (20 mL), anddried (Na₂SO₄). The crude (1.322 g) was purified with flashchromatography to give the product as off-white powder (71 mg, 65%).LCMS: M+H⁺=223.

Step 2: A mixture of 4-bromoisoquinolin-1-amine (126 mg, 0.565 mmol),bispinacol ester boronate (358 mg, 1.41 mmol), and potassium acetate(333 mg, 3.39 mmol) in 1,4-dioxane (4.6 mL) was sparged with N₂ for 10min. [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II),complex with dichloromethane (1:1) (23.1 mg, 0.0282 mmol) was added. Themixture was sealed under N₂ and heated at 80° C. for 20 h, diluted withDCM, the contents were filtered, washed with DCM, and concentrated. Thecrude product was mixed with2-(4-((2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-methylpropanamide(124 mg, 0.282 mmol), a 1 M solution of sodium carbonate (0.85 mL) and1,4-dioxane (3.4 mL, 44 mmol). The mixture was sparged with N₂ for 10min. Palladium acetate (6.342 mg, 0.02825 mmol) and a 1.0 M solution oftri-tert-butylphosphine in toluene (0.0565 mL) were added. The mixturewas sealed under N₂ and heated at 85° C. for 6 h, diluted with DCM, thecontents were filtered, and concentrated. The residue was purified withflash chromatography. The fractions containing the desired product werecollected, concentrated, and purified with reverse-phase HPLC to give108 (25 mg, 16%). LCMS: M+H⁺=467. ¹H NMR (400 MHz, CDCl₃) δ 8.91 (d,J=8.6, 1H), 8.67 (s, 1H), 7.85 (d, J=8.3, 1H), 7.71-7.64 (m, 1H), 7.53(t, J=7.3, 1H), 7.34 (s, 1H), 7.10 (s, 1H), 5.29 (s, 2H), 5.20 (s, 1H),4.10-3.99 (m, 4H), 3.87 (dd, J=9.1, 4.6, 6H), 2.61 (s, 8H), 1.24 (s, 6H)

Example 1091-((2-(isoquinolin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)-N,N-dimethylpiperidin-4-amine109

A sealable tube was charged with[1-(2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)-piperidin-4-yl]-dimethyl-amine(0.630 g, 1.59 mmol), isoquinoline-5-boronic acid (0.331 g, 1.91 mmol),dichlorobis(triphenylphosphine) palladium(II) (0.056 g, 0.08 mmol), 1 Naqueous sodium carbonate solution (2.5 mL) and acetonitrile (7.5 mL).The vessel was evacuated and back-filled with argon three times thensealed and heated at 130° C. for 90 min. The reaction mixture wascooled, concentrated, redissolved in methanol and filtered throughcelite. The filtrates were concentrated then purified by chromatography(C-18 reverse phase column, 5 to 95% acetonitrile in water containing0.1% TFA). The fractions containing the desired product wereconcentrated then dissolved in MeOH/dichloromethane, basified with solidsodium carbonate then filtered and concentrated to furnish 109 (0.386 g,50%) as a white foam. MS m/e 489 [M+H]; ¹H NMR (300 MHz, MeOH-d₄) δ ppm1.61-1.91 (m, 2H) 1.99-2.15 (m, 2H) 2.17-2.36 (m, 2H) 2.88 (s, 6H)3.04-3.28 (m, 3H) 3.73-3.87 (m, 4H) 3.91 (s, 2H) 3.96-4.07 (m, 4H) 7.33(s, 1H) 7.69-7.83 (m, 1H) 8.18 (d, J=8.3 Hz, 1H) 8.30 (d, J=7.2 Hz, 1H)8.43 (d, J=6.4 Hz, 1H) 8.57 (d, J=6.0 Hz, 1H) 9.28 (s, 1H)

Example 1101-((2-(1H-benzo[d]imidazol-1-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)-N,N-dimethylpiperidin-4-amine110

A mixture of[1-(2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)-piperidin-4-yl]dimethylamine(50 mg, 0.13 mmol), benzimidazole (32 mg, 0.27 mmol) and concentratedHCl (53 μL, 0.64 mmol) in 1,4-dioxane (1 mL) was subjected to microwaveirradiation at 150° C. for 40 min. The reaction mixture was cooled toambient temperature and loaded onto an Isolute® SCX-2 cartridge (2 g).The cartridge was then washed with MeOH and the desired product wassubsequently eluted using 2 M NH₃ in MeOH. The eluent was collected andconcentrated in vacuo. The resultant residue was purified by flashchromatography (Si—PPC, DCM: 2 M NH₃ in MeOH 100:0 to 98:2 to 95:5 to90:10) to afford 110 as a white solid (38 mg, 63%). LCMS (Method F):R_(T)=5.12 min, [M+H]⁺ 478.2. ¹H NMR (CDCl₃, 400 MHz): δ 9.04 (s, 1H);8.61-8.57 (m, 1H); 7.86-7.82 (m, 1H); 7.43-7.31 (m, 2H); 7.27 (s, 1H);4.07 (t, J=4.8 Hz, 4H); 3.92 (t, J=4.8 Hz, 4H); 3.82 (s, 2H); 3.08-2.99(m, 2H); 2.30 (s, 6H); 2.20-2.10 (m, 3H); 1.88-1.78 (m, 2H); 1.66-1.54(m, 2H)

Example 1122-methyl-2-(4-((7-methyl-4-morpholino-2-(1H-pyrrolo[2,3-c]pyridin-4-yl)thieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)propanamide112

A mixture of2-[4-(7-methyl-4-morpholin-4-yl-2-(tributylstannanyl)thieno[3,2-c]pyrimidin-6-ylmethyl)piperazin-1-yl]isobutyramide(109 mg, 0.15 mmol), 4-bromo-1H-pyrrolo[2,3-c]pyridine (39 mg, 0.20mmol), tetrakis(triphenylphosphine)palladium (18 mg, 10 mol %) and CuI(32 mg, 0.17 mmol) in toluene (2 mL) was purged with argon gas, thenheated at 150° C. for 30 min in a microwave reactor. The reactionmixture was loaded onto an Isolute® SCX-2 cartridge, washed with MeOHthen eluted with 2 M NH₃ in MeOH/DCM. The resulting residue was purifiedby column chromatography (Si—PPC, MeOH:DCM, gradient 0:100 to 05:95)followed by reverse phase HPLC (Phenomenex Gemini 5u C18, 20 mMtriethylamine in water on a gradient of acetonitrile 80:20 to 2:98) togive 112 as an off-white solid (17 mg, 21%). LCMS (Method F): R_(T) 4.93min, [M+H]⁺ 535.3. ¹H NMR (MeOD plus CDCl₃, 400 MHz): δ 9.17 (s, 1H);8.75 (s, 1H); 7.61 (d, J=3.0 Hz, 1H); 7.56 (d, J=3.0 Hz, 1H); 4.11 (t,J=4.7 Hz, 4H); 3.94 (t, J=4.7 Hz, 4H); 3.88 (s, 2H); 2.74-2.56 (m, 8H);2.53 (s, 3H); 1.24 (s, 6H)

Example 1144-(8-((4-tert-butylpiperidin-1-yl)methyl)-9-methyl-6-morpholino-9H-purin-2-yl)isoquinolin-1-amine114

4-tert-butylpiperidine (0.45 g) was reacted with4-(8-(bromomethyl)-2-chloro-9-methyl-9H-purin-6-yl)morpholine (1.0 g)via General Procedure C to yield4-(8-((4-tert-butylpiperidin-1-yl)methyl)-2-chloro-9-methyl-9H-purin-6-yl)morpholine(0.80 g) as a white solid.

A mixture of4-(8-((4-tert-butylpiperidin-1-yl)methyl)-2-chloro-9-methyl-9H-purin-6-yl)morpholine(697 mg), bis-tributyltin (1.71 mL) and PdCl₂[t-Bu₂P(Ph-p-Nme₂)₂] (190mg, in 1,4-dioxane (8.5 mL) was heated in a CEM microwave at 140° C. for40 minutes. The reaction mixture was then concentrated and the crudeproduct was then purified by flash chromatography (0-30% hexanes/ethylacetate over 15 minutes) to give intermediate4-(8-((4-tert-butylpiperidin-1-yl)methyl)-9-methyl-2-(tributylstannyl)-9H-purin-6-yl)morpholine(627 mg).

4-(8-((4-tert-butylpiperidin-1-yl)methyl)-9-methyl-2-(tributylstannyl)-9H-purin-6-yl)morpholine(0.1 g) was reacted with 4-bromoisoquinolin-1-amine via GeneralProcedure D to afford 114 (10 mg) following reverse phase purification.MS (Q1) 515.3 (M)+. ¹H NMR (500 MHz, CDCl₃) δ 9.02 (d, 1H), 7.94-7.45(m, 6H), 4.35 (s, 4H), 4.02-3.61 (m, 9H), 2.97 (s, 2H), 2.13 (s, 2H),1.92-1.52 (m, 5H), 1.52-0.68 (m, 26H)

Example 1152-(1-((2-(1-aminoisoquinolin-4-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol115

2-(1-((9-Methyl-6-morpholino-2-(tributylstannyl)-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol(0.1 g) was reacted with 4-bromoisoquinolin-1-amine via GeneralProcedure G to afford 115 following reverse phase purification. MS (Q1)517.3 (M)+. ¹H NMR (400 MHz, DMSO) δ 9.01 (d, 1H), 8.56 (s, 1H), 8.25(d, 1H), 7.67 (t, 1H), 7.49 (t, 1H), 7.07 (s, 2H), 4.23 (s, 4H), 4.02(s, 1H), 3.87-3.66 (m, 10H), 2.89 (d, 3H), 1.99 (t, 2H), 1.66 (d, 2H),1.35-1.10 (m, 3H), 1.02 (s, 6H).

Example 1161-((2-(1H-indazol-1-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)-N,N-dimethylpiperidin-4-amine116

A solution of indazole (0.118 g) in DMF (8 mL) was cooled to 0° C. thensodium hydride (0.06 g) added. After 15 min,[1-(2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)-piperidin-4-yl]-dimethyl-amine(0.395 g) was added and the reaction vessel sealed and heated at 150° C.After 1 h the reaction mixture was cooled to room temperature thendiluted with water. The resulting precipitate was collected byfiltration then purified by chromatography (silica, 0 to 20% of a 49:1MeOH:NH₄OH mixture in dichloromethane) to furnish 116 (0.233 g, 49%) asa white solid after trituration with ethyl acetate. MS m/e 478 [M+H]⁺;¹H NMR (300 MHz, DMSO-d₆) δ ppm 1.41 (dd, J=11.68, 3.39 Hz, 2H) 1.73 (d,J=10.93 Hz, 2H) 2.07 (t, J=10.74 Hz, 3H) 2.17 (s, 6H) 2.94 (d, J=11.68Hz, 2H) 3.75-3.90 (m, 6H) 3.93-4.13 (m, 4H) 7.31 (t, J=7.54 Hz, 1H) 7.39(s, 1H) 7.56 (dd, J=7.91, 6.40 Hz, 1H) 7.88 (d, J=7.91 Hz, 1H) 8.39 (s,1H) 8.68 (d, J=8.67 Hz, 1H).

Example 117N,N-dimethyl-1-((2-(2-methyl-1H-benzo[d]imidazol-1-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperidin-4-amine117

A mixture ofN-[6-(4-dimethylaminopiperidin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-c]pyrimidin-2-yl]benzene-1,2-diamine(80 mg, 0.17 mmol) and triethyl orthoformate (1 mL, 6.0 mmol) in DMF (1mL) was heated at 150° C. for 6 h. The reaction mixture was cooled toambient temperature and loaded onto an Isolute® SCX-2 cartridge (10 g).The cartridge was then washed with MeOH and the desired product wassubsequently eluted using 2 M NH₃ in MeOH. The eluent was collected andconcentrated in vacuo. The resultant residue was purified by flashchromatography (Si—PPC, DCM: 2 M NH₃ in MeOH 100:0 to 98:2 to 95:5)followed by reverse phase HPLC (Phenomenex Luna C₁₈, 20 mM Et₃N in wateron a gradient of 20 mM Et₃N in acetonitrile 95:5 to 2:98) to afford 117as a white solid (20 mg, 24%). LCMS (Method F): R_(T)=4.24 min, [M+H]⁺492.3. ¹H NMR (CDCl₃, 400 MHz): δ 8.09-8.04 (m, 1H); 7.74-7.68 (m, 1H);7.29-7.24 (m, 3H); 4.08-4.02 (m, 4H); 3.91-3.86 (m, 4H); 3.83 (s, 2H);3.08-3.00 (m, 2H); 2.93 (s, 3H); 2.30 (s, 6H); 2.21-2.10 (m, 3H);1.88-1.79 (m, 2H); 1.68-1.53 (m, 2H)

Example 1182-(1-((9-methyl-6-morpholino-2-(1H-pyrrolo[2,3-c]pyridin-4-yl)-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol118

2-(1-((9-methyl-6-morpholino-2-(tributylstannyl)-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol(150 mg) was reacted with 4-bromo-6-azaindole via General Procedure G toafford 118 (31.8 mg) following reverse phase purification. MS (Q1) 491.2(M)+. ¹H NMR (400 MHz, DMSO) δ 11.70 (s, 1H), 9.14 (s, 1H), 8.79 (s,1H), 7.70 (t, 1H), 7.43 (s, 1H), 4.30 (s, 4H), 4.02 (s, 1H), 3.89 (s,3H), 3.83-3.76 (m, 4H), 3.73 (s, 2H), 2.92 (t, 2H), 1.97 (dd, 16.9, 2H),1.69 (t, 2H), 1.40-1.09 (m, 3H), 1.02 (s, 6H)

Example 1192-(1-((9-methyl-6-morpholino-2-(1H-pyrrolo[3,2-c]pyridin-4-yl)-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol119

2-(1-((9-Methyl-6-morpholino-2-(tributylstannyl)-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol(150 mg) was reacted with 4-bromo-5-azaindole via General Procedure G toafford 119 (20 mg) following reverse phase purification. MS (Q1) 491.2(M)+. ¹H NMR (400 MHz, MeOD) δ 8.31 (d, 1H), 7.51 (d, 1H), 7.45 (d, 1H),7.34 (d, 1H), 4.39 (s, 4H), 4.03-3.69 (m, 10H), 3.31 (d, 5H), 3.01 (d,2H), 2.10 (t, 2H), 2.03 (s, 2H), 1.75 (d, 2H), 1.53-1.22 (m, 4H), 1.13(s, 6H)

Example 1204-(6-((4-methylpiperazin-1-yl)methyl)-2-(quinolin-5-yl)thieno[3,2-d]pyrimidin-4-yl)morpholine120

Following General Procedure L for reductive amination,4-morpholino-2-(quinolin-5-yl)thieno[3,2-d]pyrimidine-6-carbaldehyde and1-methylpiperazine were reacted to give 120. LCMS m/z: 461.6 (MH+)

Example 1212-(4-((2-(7-fluoro-1H-pyrrolo[3,2-c]pyridin-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-methylpropanamide121

Following the procedures for 142,2-[4-(4-morpholin-4-yl-2-(tributylstannanyl)thieno[3,2-c]pyrimidin-6-ylmethyl)piperazin-1-yl]isobutyramidewas converted to 121. LCMS m/z: 539.2 (MH+)

Example 1234-((4-morpholino-2-(1H-pyrrolo[3,2-c]pyridin-4-yl)thieno[3,2-d]pyrimidin-6-yl)methyl)morpholine123

Following General Procedure L for reductive amination,4-morpholino-2-(1H-pyrrolo[3,2-c]pyridin-4-yl)thieno[3,2-d]pyrimidine-6-carbaldehydeand morpholine were reacted to give 123. LCMS: M+H⁺=437.5

Example 1244-(1-((9-methyl-6-morpholino-2-(1H-pyrrolo[2,3-c]pyridin-4-yl)-9H-purin-8-yl)methyl)piperidin-4-yl)morpholine124

Step 1:4-(1-((9-methyl-6-morpholino-2-(tributylstannyl)-9H-purin-8-yl)methyl)piperidin-4-yl)morpholine

A mixture of4-(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)morpholine(593 mg, 1.36 mmol), bis(tributyltin) (1.36 mL, 2.72 mmol) andPdCl₂[t-Bu₂P(Ph-p-Nme₂)₂] (150 mg, 0.21 mmol) in 1,4-dioxane (5 mL) washeated in a microwave at 140° C. for 40 minutes. The reaction mixturewas then concentrated. The crude product was then purified by flashchromatography (10% MeOH in DCM) to give the title compound (859 mg,91.4%). LCMS: M+H⁺=691.4.

Step 2: To a degassed mixture of4-(1-((9-methyl-6-morpholino-2-(tributylstannyl)-9H-purin-8-yl)methyl)piperidin-4-yl)morpholine(859 mg, 1.24 mmol),4-bromo-1-(phenylsulfonyl)-1H-pyrrolo[2,3-c]pyridine (385 mg, 1.14mmol), copper(I) iodide (326 mg, 1.71 mmol) in 1,4-dioxane (10 mL) wasadded Pd(PPh₃)₄ (100 mg, 0.09 mmol). The reaction mixture was stirred at110° C. for 18 hours. The reaction mixture was concentrated and thendissolved in DCM and filtered through a column of silica gel (20% MeOHin DCM). The elutant was concentrated to give a yellow paste which wastaken up in ethanol (2 mL) and 1,4-dioxane (3 mL). A 12 M aqueous NaOHsolution (0.5 mL) was then added and the resulting mixture was stirredat room temperature for 1 hour. The reaction mixture was thenconcentrated and the crude product was purified by flash chromatographyusing a Biotage KP—NH column (10% MeOH in DCM) followed by RP-HPLC togive 124. LCMS: M+H⁺=518.3. ¹H-NMR (400 MHz, DMSO-d₆): δ 11.70 (s, 1H),9.14 (s, 1H), 8.79 (s, 1H), 7.70 (m, 1H), 7.43 (m, 1H), 4.30 (s, br,4H), 3.88 (s, 3H), 3.78 (m, 4H), 3.70 (s, 2H), 3.54 (m, 4H), 2.86 (m,2H), 2.43 (m, 4H), 2.09 (m, 2H), 1.75 (m, 2H), 1.36 (m, 3H).

Example 125N,N-dimethyl-1-((4-morpholino-2-(1H-pyrrolo[3,2-c]pyridin-3-yl)thieno[3,2-d]pyrimidin-6-yl)methyl)piperidin-4-amine125

A microwave vessel was charged withdimethyl-[1-(4-morpholin-4-yl-2-tributylstannanyl-thieno[3,2-d]pyrimidin-6-methyl)-piperidin-4-yl]-amine(0.4 g) in dioxane (8 mL). The vessel was evacuated and back filled withargon. To this mixture was added3-iodo-pyrrolo[3,2-c]pyridine-1-carboxylic acid tert-butyl ester (0.254g), copper iodide (0.14 g) and tetrakistriphenylphosphine palladium(0.08 g). The vessel was evacuated and back filled with argon again,then the mixture was then irradiated with microwaves at 150° C. for 35min. The reaction mixture was cooled to room temperature then filteredthrough HPLC filter. The filtrate was concentrated and the residueobtained was purified by chromatography (silica, 0 to 10% of a 49:1MeOH:NH₄OH mixture in dichloromethane). The residue obtained wasdissolved in anhydrous methanol (2 mL) and 4.0 N HCl in dioxane (6 mL)was added. The mixture was stirred at room temperature overnight. Theprecipitated solid was collected by filtration and the residue obtainedwas dried at 50° C. under vacuum overnight to furnish 125 (0.086 g, 22%)as a white solid. MS m/e 478 [M+H]⁺. ¹H NMR (300 MHz, DMSO-d₆) δ ppm2.19-2.34 (m, 4H) 2.71 (s, 6H) 3.06 (br. s., 2H) 3.43 (br. s., 1H)3.50-3.57 (m, 2H) 3.81-3.90 (m, 4H) 4.01-4.11 (m, 4H) 4.64 (s, 2H) 7.93(s, 1H) 8.07 (d, J=6.78 Hz, 1H) 8.50 (d, J=6.78 Hz, 1H) 8.75 (s, 1H)9.76 (s, 1H)

Example 1262-methyl-2-(4-((7-methyl-4-morpholino-2-(1H-pyrrolo[3,2-c]pyridin-4-yl)thieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)propanamide126

A degassed solution of2-[4-(7-methyl-4-morpholin-4-yl-2-(tributylstannanyl)thieno[3,2-c]pyrimidin-6-ylmethyl)piperazin-1-yl]isobutyramide(100 mg, 0.14 mmol), 1-benzenesulfonyl-4-bromo-1H-pyrrolo[3,2-c]pyridine(60 mg, 0.18 mmol), Pd(PPh₃)₄ (16 mg, 0.014 mmol) and CuI (33 mg, 0.17mmol) in 1,4-dioxane (1.5 mL) was subjected to microwave irradiation at140° C. for 20 min. The reaction mixture was cooled to ambienttemperature and loaded onto an Isolute® SCX-2 cartridge (10 g). Thecartridge was then washed with MeOH and the desired product wassubsequently eluted using 2 M NH₃ in MeOH. The eluent was collected andconcentrated to give2-{4-[2-(1-benzenesulfonyl-1H-pyrrolo[3,2-c]pyridin-4-yl)-7-methyl-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl]-piperazin-1-yl}-isobutyramideas a crude oil. Aqueous NaOH (12.5 M, 0.2 mL) was added to a solution ofthis intermediate in 1,4-dioxane (2 mL) and IMS (2 mL). The reactionmixture was stirred at ambient temperature for 1 h, and thenconcentrated in vacuo. The residue was dissolved in MeOH then loadedonto an Isolute® SCX-2 cartridge (10 g). The cartridge was then washedwith MeOH and the desired product was subsequently eluted using 2 M NH₃in MeOH. The eluent was collected and concentrated to afford a crudesolid. The solid was purified by flash chromatography (Si—PPC, DCM: 2 MNH₃ in MeOH, 100:0 to 99:1 to 98:2 to 95:5 to 90:0) to afford 126 as acream solid (36 mg, 48%). LCMS (Method F): R_(T)=5.04 min, [M+H]⁺ 535.2.¹H NMR (CDCl₃, 400 MHz): δ 9.76 (s, 1H); 8.46 (d, J=5.6 Hz, 1H); 7.49(dd, J=3.2, 1.0 Hz, 1H); 7.34 (d, J=3.25 Hz, 1H); 7.31 (dd, J=5.6, 1.0Hz, 1H); 7.12 (d, J=5.3 Hz, 1H); 5.35 (d, J=5.25 Hz, 1H); 4.08 (t, J=4.7Hz, 4H); 3.86 (t, J=4.7 Hz, 4H); 3.82 (s, 2H); 2.60 (s, 8H); 2.58-2.45(m, 3H); 1.33-1.17 (m, 6H)

Example 1274-(6-((4-(1-amino-2-methyl-1-oxopropan-2-yl)piperazin-1-yl)methyl)-4-morpholinothieno[3,2-d]pyrimidin-2-yl)-1H-pyrrolo[2,3-c]pyridine6-oxide 127

A mixture of2-[4-(4-morpholin-4-yl-2-(tributylstannanyl)thieno[3,2-d]pyrimidin-6-ylmethyl)piperazin-1-yl]isobutyramide(170 mg, 0.25 mmol), 4-bromo-6-oxy-pyrrolo[2,3-c]pyridine-1-carboxylicacid tert-butyl ester (100 mg, 0.32 mmol),tetrakis(triphenylphosphine)palladium (28 mg, 10 mol %) and CuI (55 mg,0.28 mmol) in dioxane (2.5 mL) was purged with argon gas then heated at140° C., for 20 min, in a microwave reactor. The reaction mixture wasloaded onto an Isolute® SCX-2 cartridge, washed with MeOH/DCM theneluted with 2 M NH₃ in MeOH/DCM. The resulting residue was dissolved inDCM (3 mL) and trifluoroacetic acid (0.4 mL) added. After stirring for 3h the reaction mixture was loaded onto an Isolute® SCX-2 cartridge,washed with MeOH/DCM then eluted with 2 M NH₃ in MeOH/DCM. The resultingresidue was purified by column chromatography (Si—PPC, MeOH:DCM,gradient 0:100 to 15:85) to give 127 (30 mg, 17%) as a pale yellowsolid. LCMS (Method F): R_(T) 4.95 min, [M+H]⁺ 537.9. ¹H NMR (CDCl₃, 400MHz): δ 12.52 (s, 1H); 9.07 (s, 1H); 8.79 (s, 1H); 7.65 (d, J=2.8 Hz,1H); 7.56 (d, J=2.8 Hz, 1H); 7.34 (s, 1H); 7.09 (d, J=5.3 Hz, 1H); 5.38(d, J=5.3 Hz, 1H); 4.05 (t, J=4.6 Hz, 4H); 3.89 (t, J=4.7 Hz, 4H); 3.84(s, 2H); 2.60 (s, 8H); 1.24 (m, 6 H)

Example 1282-(4-((2-(benzofuran-3-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-methylpropanamide128

Following the procedures for 140,2-(benzofuran-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane wasconverted to 128. LCMS: M+H⁺=521.2. ¹H-NMR (400 MHz, DMSO-d₆): δ 8.73(s, 1H), 8.52 (m, 1H), 7.66 (m, 1H), 7.39 (m, 3H), 7.05 (s, 1H), 6.93(s, 1H), 3.99 (m, 4H), 3.86 (s, 2H), 2.83 (m, 4H), 2.39-2.61 (m, 8H),1.08 (s, 6H)

Example 1292-(1-((2-(3-amino-1H-indazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol129

Sodium hydride (1.5 eq) was added to 3-iodoindazole (0.5 g) in DMF (5mL) and the reaction was stirred for 30 minutes at 0° C.2-(1-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-olwas subsequently added to the reaction mixture and heated in a Biotagemicrowave for 10 minutes at 180° C. The reaction was purified by flashcolumn chromatography to afford2-(1-((2-(3-iodo-1H-indazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol(0.4 g) as a brown solid.

To a solution of2-(1-((2-(3-iodo-1H-indazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol(0.1 g), tris(dibenzylideneacetone)dipalladium(0) (3 mg),4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (5.6 mg) and cesiumcarbonate (74 mg) in 1,4-dioxane (0.5 mL) was added benzophenone imine(40 μL). The reaction was heated at 120° C. until complete, about 90minutes. The crude reaction mixture was loaded onto silica and purifiedby flash column chromatography to afford2-(1-((2-(3-(diphenylmethyleneamino)-1H-indazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol.

2-(1-((2-(3-(Diphenylmethyleneamino)-1H-indazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-oland hydroxylamine hydrochloride (12.4 mg) in MeOH (2 mL) were stirredovernight at room temperature. The crude was purified by reverse phaseHPLC to give 129 as a white solid (32.6 mg). MS (Q1) 506.3 (M)+. ¹H NMR(400 MHz, DMSO) δ 8.56 (d, 1H), 7.83 (d, 1H), 7.47 (t, 1H), 7.17 (t,1H), 6.05 (s, 2H), 4.26 (s, 5H), 4.02 (s, 1H), 3.79 (s, 7H), 3.68 (s,4H), 2.86 (t, 2H), 1.97 (t, J=2H), 1.66 (d, 2H), 1.33-1.11 (m, 4H), 1.02(s, 6H).

Example 1302-(1-((2-(1-aminoisoquinolin-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperidin-4-yl)propan-2-ol130

Following the procedures for 108,2-(1-((2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperidin-4-yl)propan-2-oland 4-bromoisoquinolin-1-amine were converted to 130. LCMS: M+H⁺=519. ¹HNMR (400 MHz, DMSO) δ 8.99 (d, J=8.5, 1H), 8.58 (s, 1H), 8.26 (d, J=8.5,1H), 8.17 (s, 2H), 7.68 (t, J=7.6, 1H), 7.50 (t, J=7.5, 1H), 7.37 (s,1H), 7.12 (s, 1H), 4.00-3.89 (m, 4H), 3.86-3.75 (m, 6H), 2.99 (d,J=11.0, 2H), 1.97 (t, J=11.2, 2H), 1.65 (t, J=15.4, 2H), 1.37-1.11 (m,3H), 1.04 (s, 6H)

Example 1312-methyl-2-(4-((7-morpholino-5-(1H-pyrrolo[2,3-c]pyridin-4-yl)thiazolo[5,4-d]pyrimidin-2-yl)methyl)piperazin-1-yl)propanamide131

A mixture of2-[4-(7-morpholin-4-yl-5-(tributylstannanyl)thiazolo[5,4-d]pyrimidin-2-ylmethyl)piperazin-1-yl]isobutyramide(167 mg, 0.24 mmol), 4-bromo-1H-pyrrolo[2,3-c]pyridine (62 mg, 0.31mmol), tetrakis(triphenylphosphine)palladium (28 mg, 10 mol %) and CuI(55 mg, 0.28 mmol) in dioxane (2.5 mL) was purged with argon gas thenheated at 140° C., for 20 min, in a microwave reactor. The reactionmixture was loaded onto an Isolute® SCX-2 cartridge, washed withMeOH/DCM then eluted with 2 M NH₃ in MeOH/DCM. The resulting residue waspurified by column chromatography (Si—PPC, MeOH:DCM, gradient 0:100 to15:85) to give 131 as an pale yellow solid (12 mg, 10%). LCMS (MethodF): R_(T) 4.70 min, [M+H]⁺ 522.2. ¹H NMR (DMSO, 400 MHz): δ 11.94 (s,1H); 9.10 (s, 1H); 8.88 (s, 1H); 7.82 (s, 1H); 7.35 (s, 1H); 7.15 (s,1H); 7.04 (s, 1H); 4.37 (s, 4H); 3.95 (s, 2H); 3.82 (t, J=4.6 Hz, 4H);2.68 (s, 4H); 2.56 (s, 4H); 1.13 (s, 6H)

Example 1322-methyl-2-(4-((2-(7-methyl-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)propanamide132

A mixture of2-[4-(4-morpholin-4-yl-2-(tributylstannanyl)thieno[3,2-d]pyrimidin-6-ylmethyl)-piperazin-1-yl]isobutyramide(197 mg, 0.28 mmol), 4-bromo-7-methyl-1H-pyrrolo[2,3-c]pyridine (60 mg,0.28 mmol), copper(I) 2-thiophene carboxylate (11 mg, 0.056 mmol), andPd(PPh₃)₄ (32 mg, 0.028 mmol) in dioxane (3 mL) was placed in amicrowave tube which was sealed and evacuated. The reaction vessel wasdegassed and purged with argon (×3). The reaction mixture was irradiatedat 140° C. for 20 min. The cooled mixture was then poured onto anIsolute® SCX-II cartridge and the cartridge was washed with MeOH (100mL). The product was eluted with 2 M NH₃ in MeOH. The pooled fractionswere evaporated and the product was further purified by chromatographyon silica (Si—PPC), using MeOH in DCM (0-10%) as eluent. The pooledproduct-containing fractions were evaporated and the residue wascrystallized from hot EtOAc to afford 132 as a white crystalline solid(70 mg, 46%). LCMS: (Method F): R_(T) 5.02 min; [M+H]⁺ 535.2. ¹H NMR(DMSO, 400 MHz): δ 11.71 (s, 1H); 9.02 (s, 1H); 7.66 (t, J=2.7 Hz, 1H);7.44 (s, 1H); 7.38 (dd, J=2.9, 1.9 Hz, 1H); 7.08 (d, J=3.5 Hz, 1H); 6.95(d, J=3.5 Hz, 1H); 3.99 (t, J=4.6 Hz, 4H); 3.86 (s, 2H); 3.85-3.80 (m,4H); 2.73 (s, 3H); 2.62-2.53 (m, 4H); 2.47 (s, 4H); 1.08 (s, 6H)

Example 1334-(1-((9-methyl-6-morpholino-2-(1H-pyrrolo[3,2-c]pyridin-4-yl)-9H-purin-8-yl)methyl)piperidin-4-yl)morpholine133

Following the procedures to prepare 124,4-(1-((9-Methyl-6-morpholino-2-(tributylstannyl)-9H-purin-8-yl)methyl)piperidin-4-yl)morpholineand 4-bromo-1H-pyrrolo[3,2-c]pyridine were reacted to give 133. LCMS:M+H⁺=518.3. ¹H-NMR (400 MHz, DMSO-d₆): δ 11.55 (s, 1H), 8.30 (d, 1H),7.51 (d, 1H), 7.48 (d, 1H), 7.20 (d, 1H), 4.30 (m, 4H), 3.80 (s, 3H),3.78 (m, 6H), 3.55 (m, 4H), 2.88 (m, 2H), 2.44 (m, 4H), 2.09 (m, 2H),1.77 (m, 2H), 1.40 (m, 3H)

Example 1341-((2-(1H-indazol-3-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)-N,N-dimethylpiperidin-4-amine134

A microwave vessel was charged withdimethyl-[1-(4-morpholin-4-yl-2-tributylstannanyl-thieno[3,2-d]pyrimidin-6-methyl)-piperidin-4-yl]-amine(0.400 g, 0.615 mmol), 1-boc-3-bromo-1H-indazole (0.219 g, 0.737 mmol),tetrakis(triphenylpho'sphine)palladium (0.071 g, 0.061 mmol), copperiodide (0.140 g, 0.735 mmol), and THF (8 mL). The vessel was sealed,evacuated, and back filled with argon. Then the mixture was heated at140° C. under microwave irradiation for 20 min. The reaction mixture wascooled to room temperature, ethyl acetate (30 mL) was added, and themixture was filtered through celite. The filtrate was concentrated thenpurified by chromatography (silica, 0 to 20% of a 9:1 MeOH:NH₄OH mixturein dichloromethane) to yield a crude solid. This solid was dissolved indichloromethane (10 mL) and methanol (0.5 mL). Then HCl (0.80 mL, 1 N inether) was added dropwise. After stirring for 1 hr at room temperature,the mixture was concentrated then purified by chromatography (C18, 0 to90% of a 0.1% aqueous TFA mixture in methanol). The fractions containingthe title compound were combined and the volatile solvents were removedunder reduced pressure. The remaining aqueous mixture was diluted withaqueous bicarbonate and extracted with ethyl acetate. The organic layerwas dried on sodium sulfate, collected by filtration, and concentratedto give 134 (0.012 g, 9%) as a white solid. MS m/e 477 [M+H]⁺. ¹H NMR(300 MHz, DMSO-d₆) δ ppm 1.45 (dd, J=12, 23 Hz, 2H), 1.77 (d, J=12 Hz,2H), 2.04-2.11 (m, 3H), 2.25 (s, 6H), 2.96 (d, J=12 Hz, 2H), 3.81-3.85(m, 6H), 3.99-4.02 (m, 4H), 7.24 (t, J=9 Hz, 1H), 7.40 (t, J=9 Hz, 1H),7.42 (s, 1H), 7.62 (d, J=9 Hz, 1H), 8.54 (d, J=9 Hz, 1H), 13.37 (s, 1H)

Example 1352-(4-((2-(isoquinolin-8-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-methylpropanamide135

A microwave vessel was charged with2-[4-(4-morpholin-4-yl-2-tributylstannanyl-thieno[3,2-d]pyrimidin-6-ylmethyl)-piperazin-1-yl]-isobutyramide(0.200 g, 0.288 mmol), 5-bromoisoquinoline (0.072 g, 0.346 mmol),copper(I) iodine (0.066 g, 0.346 mmol), palladiumtetrakis(triphenylphosphine) (0.033 g, 0.029 mmol) and dioxane (4 mL).The vessel was evacuated and back-filled with argon three times thensealed and heated at 140° C. under microwave irradiation for 20 min. Thereaction mixture was cooled to room temperature and filtered throughcelite. The filtrates were concentrated then purified by chromatography(silica, 0 to 15% of a 9:1 MeOH:NH₄OH mixture in dichloromethane) togive a yellow residue. This residue was dissolved in dichloromethanethen 1 N HCl in ether (0.2 mL) added dropwise. The resulting precipitatewas collected by filtration to furnish 135 (0.012 g, 6%) as a paleyellow powder and as a tetrahydrochloride salt. MS m/e 532 [M+H]⁺; ¹HNMR (300 MHz, 360 K, DMSO-d₆) δ ppm 1.49 (s, 6H) 2.96-3.33 (m, 8H)3.79-3.91 (m, 4H) 3.97-4.09 (m, 4H) 4.22 (br. s., 2H) 6.00 (br. s., 2H)7.65 (s, 1H) 8.06-8.18 (m, 1H) 8.23-8.35 (m, 2H) 8.54 (d, J=7.5 Hz, 1H)8.68 (br. s., 1H) 10.57 (br. s., 1H)

Example 136N,N-dimethyl-1-((4-morpholino-2-(1H-pyrrolo[2,3-b]pyridin-3-yl)thieno[3,2-d]pyrimidin-6-yl)methyl)piperidin-4-amine136

A microwave vessel was charged withdimethyl-[1-(4-morpholin-4-yl-2-tributylstannanyl-thieno[3,2-d]pyrimidin-6-methyl)-piperidin-4-yl]-amine(0.2 g) in dioxane (8 mL). The vessel was evacuated and back filled withargon. To this mixture was added3-bromo-pyrrolo[2,3-b]pyridine-1-carboxylic acid tert-butyl ester (0.18g), copper iodide (0.07 g) and tetrakistriphenylphosphine palladium(0.04 g). The vessel was evacuated and back filled with argon again,then the mixture was then irradiated with microwaves at 150° C. for 30min. The reaction mixture was cooled to room temperature then filteredthrough HPLC filter. The filtrate was concentrated and the residueobtained was purified by chromatography (silica, 0 to 10% of a 49:1MeOH:NH₄OH mixture in dichloromethane) to furnish 136 (0.026 g, 17%) asa light brown solid. MS m/e 478 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ ppm1.41 (d, J=9.09 Hz, 2H) 1.74 (d, J=11.12 Hz, 2H) 2.06 (t, J=10.61 Hz,3H) 2.18 (s, 6H) 2.94 (d, J=11.12 Hz, 2H) 3.75-3.88 (m, 6H) 3.91-4.05(m, 4H) 7.21 (dd, J=8.08, 4.55 Hz, 1H) 7.33 (s, 1H) 8.12-8.35 (m, 2H)8.83 (dd, J=7.83, 1.77 Hz, 1H) 12.09 (br. s., 1H)

Example 1372-(1-((2-(1-(ethylamino)isoquinolin-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperidin-4-yl)propan-2-ol137

Step 1: 4-bromo-N-ethylisoquinolin-1-amine

To a suspension of 4-bromo-1 chloroisoquinoline (0.831 g, 3.43 mmol) inMeOH (10.3 mL, 254 mmol) was added ethylamine (70% in water, 1.1 mL).The mixture was heated at 50° C. for 16 h. The mixture was concentrated.The residue was partitioned between water (20 mL) and DCM (20 mL). DCMlayer was separated. The aqueous layer was extracted with DCM (10 mL).The combined DCM solutions were dried (Na₂SO₄). Filtration andconcentration gave 4-bromo-N-ethylisoquinolin-1-amine (0.761 g, 88%).LCMS: M+H⁺=251.

Step 2: Following the procedures for 108,2-(1-((2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperidin-4-yl)propan-2-oland 4-bromo-N-ethylisoquinolin-1-amine were converted to 137. LCMS:M+H+=547. ¹H NMR (400 MHz, DMSO) δ 9.03 (d, J=8.5, 1H), 8.67 (s, 1H),8.28 (d, J=8.3, 1H), 7.68 (dd, J=16.9, 6.5, 2H), 7.51 (t, J=7.5, 1H),7.37 (s, 1H), 4.04 (s, 1H), 3.93 (d, J=4.8, 4H), 3.80 (d, J=6.3, 6H),3.65-3.54 (m, 2H), 2.99 (d, J=10.9, 2H), 2.07 (s, 1H), 1.97 (t, J=11.5,2H), 1.67 (d, J=10.9, 2H), 1.36-1.12 (m, 6H), 1.04 (s, 6H)

Example 1382-(1-((2-(benzofuran-3-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol138

Following the procedures for 140,2-(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-oland 2-(benzofuran-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane wasconverted to 138. LCMS: M+H⁺=491.2. ¹H-NMR (400 MHz, DMSO-d₆): δ 8.75(s, 1H), 8.58 (m, 1H), 7.66 (m, 1H), 7.40 (m, 2H), 4.66 (s, 2H), 4.31(m, 4H), 3.90 (s, 3H), 3.80 (m, 4H), 3.68 (s, br, 1H), 3.12 (m, 2H),2.90 (m, 2H), 1.90 (m, 2H), 1.56 (m, 3H), 1.06 (s, 6H)

Example 1394-(9-methyl-6-morpholino-8-((4-morpholinopiperidin-1-yl)methyl)-9H-purin-2-yl)isoquinolin-1-amine139

To a degassed suspension of4-(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)morpholine(84 mg, 0.19 mmol),4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoquinolin-1-amine (52mg, 0.19 mmol), 2 M Na₂CO₃ aqueous solution (0.19 mL, 0.38 mmol) intoluene (3 mL) and ethanol (1 mL) was added Pd(PPh₃)₄ (11 mg, 0.010mmol). The suspension was then stirred under nitrogen at 100° C. for 18hours. The reaction mixture was then diluted with EtOAc and water. Theaqueous layer was extracted three times with EtOAc. The combined organicextracts were washed with water, dried over Na₂SO₄, filtered andconcentrated. The crude product was purified by flash chromatography(25% MeOH in DCM) to give 139 as a white solid (14.3 mg, 14%). LCMS:M+H⁺=544.3. ¹H-NMR (400 MHz, DMSO-d₆): δ 9.01 (d, 1H), 8.25 (d, 1H),8.16 (s, 1H), 7.67 (t, 1H), 7.49 (t, 1H), 7.08 (s, 2H), 4.23 (s, br,4H), 3.82 (s, 3H), 3.78 (m, 6H), 3.55 (m, 4H), 2.88 (m, 2H), 2.43 (m,4H), 2.07 (m, 3H), 1.75 (m, 2H), 1.38 (m, 2H)

Example 1402-methyl-2-(4-((2-(2-methylbenzofuran-3-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)propanamide140

To a degassed suspension of2-(4-((2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-methylpropanamide(90.0 mg 0.205 mmol),4,4,5,5-tetramethyl-2-(2-methylbenzofuran-3-yl)-1,3,2-dioxaborolane (120mg, 0.46 mmol) in acetonitrile (2 mL) was added 2 M aqueous solution ofsodium carbonate (0.20 mL) and 1M aqueous solution of potassium acetate(0.2 mL). The mixture was then heated in a microwave at 140° C. for 30minutes. The reaction mixture was diluted with water and EtOAc. Theaqueous layer was extracted with EtOAc. The combined extracts werewashed with brine, dried over Na₂SO₄, filtered and concentrated. Thecrude product was purified by RP-HPLC to give 140 (33.6 mg, 30.6%).LCMS: M+H⁺=535.2. ¹H-NMR (400 MHz, DMSO-d₆): δ 8.45 (m, 1H), 7.55 (m,1H), 7.42 (s, 1H), 7.31 (m, 2H), 7.05 (s, 1H), 6.93 (s, 1H), 3.95 (m,4H), 3.86 (s, 2H), 3.83 (m, 4H), 2.84 (s, 3H), 2.42-2.63 (m, 8H), 1.08(s, 6H)

Example 1412-(2-(1-aminoisoquinolin-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)propan-2-ol141

To a solution of2-(2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)propan-2-ol (63 mg,0.20 mmol) in acetonitrile (3.6 ml) in a microwave reaction vessel wasadded 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoquinolin-1-amine(110 mg, 0.40 mmol), Bis(triphenylphosphine)palladium(II) chloride (7.02mg, 0.010 mmol) and 1M sodium carbonate in water (0.60 ml). The reactionvessel was sealed and heated in the microwave at 140° C. for 20 minutes.LC-MS of the reaction mixture showed no more starting material. Thesolvent was evaporated and the resulting oil was purified on silica gel(0 to 20% of 2N NH₃ in MeOH/DCM). The resulting oil was further purifiedby reversed phase HPLC to give 141 as an off-white solid (4.7 mg, 6%) ¹HNMR (DMSO d₆, 400 MHz) 9.02 (d, 1H, J=8.4 Hz), 8.26 (s, 1H), 8.26 (d,1H, J=8.4 Hz), 7.67 (t, 1H, J=7.6 Hz), 7.50 (t, 1H, J=7.6)m 7.33 (s,1H), 7.11 (s, 2H), 5.84 (s, 1H), 3.98-3.94 (m, 4H), 3.81-3.78 (m, 4H),1.61 (m, 6H). LCMS m/z: 422 (MH⁺)

Example 1422-methyl-2-(4-((2-(2-methyl-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)propanamide142

Step 1:2-{4-[2-(1-Benzenesulfonyl-2-methyl-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-morpholin-4-yl-thieno[3,2-c]pyrimidin-6-ylmethyl]piperazine-1-yl}isobutyramide

A 5 mL microwave vial was charged with a suspension of2-[4-(4-morpholin-4-yl-2-(tributylstannanyl)thieno[3,2-c]pyrimidin-6-ylmethyl)piperazin-1-yl]isobutyramide(0.22 g, 0.31 mmol),1-benzenesulfonyl-4-bromo-2-methyl-1H-pyrrolo[2,3-c]pyridine (0.13 g,0.37 mmol), copper(I) 2-thiophene carboxylate (0.012 g, 0.062 mmol) andPd(PPh₃)₄ (0.036 g, 0.031 mmol) in dioxane (3 mL). The reaction mixturewas heated in a microwave for 20 min at 140° C. The crude reactionmixture was loaded onto a SCX-2 cartridge treated with MeOH. Thecartridge was washed with MeOH (100 mL), then the product was recoveredeluting with 2N ammonia in MeOH. The eluent was concentrated in vacuo,and the resultant residue was purified by flash chromatography (Si—PPC,0% to 10% MeOH in DCM) to give the product as white foam (0.17 g, 82%).LCMS (Method C): R_(T)=3.36 min, [M+H]⁺ 675.1

Step 2:2-{4-[2-(2-Methyl-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-morpholin-4-yl-thieno[3,2-c]pyrimidin-6-ylmethyl]piperazin-1-yl}isobutyramide

A 25 mL round-bottomed flask, under nitrogen, fitted with acondenser/inert gas bubbler (via a Claisen head), was charged with asolution of2-{4-[2-(1-benzenesulfonyl-2-methyl-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl]piperazine-1-yl}isobutyramide(0.17 g, 0.25 mmol) in dioxane (4 mL), IMS (4 mL) and NaOH 12.5M (0.4mL). The resulting mixture was stirred at room temperature for 2.5 h.The solution was concentrated in vacuo, the residue diluted with MeOHand loaded onto a Isolute® SCX-2 cartridge treated with MeOH. Thecartridge was washed with MeOH (100 mL) and the product was recoveredeluting with 2N NH₃ in MeOH, the eluent concentrated, suspended indioxane/water and freeze-dried overnight. The resultant solid wasdissolved in DMSO and purified by preparative HPLC (C18 column)gradient: (acetonitrile/20 mM triethylamine) 10% to 98% in (water/20 mMtriethylamine) over 20 min (flow rate 18 ml/min). The product wasfreeze-dried overnight yielding 142 as a white powder (0.047 g, 35%).LCMS (Method E): R_(T)=5.27 min, [M+H]⁺ 535.2. ¹H NMR (DMSO, 400 MHz): δ11.43 (s, 1H); 8.22 (d, J=5.4 Hz, 1H); 7.43 (s, 1H); 7.33 (dd, J=6.3,0.9 Hz, 1H); 7.07 (d, J=3.5 Hz, 1H); 6.95 (d, J=3.45 Hz, 1H); 6.87 (s,1H); 3.98 (t, J=4.6 Hz, 4H); 3.87 (s, 2H); 3.81 (t, J=4.6 Hz, 4H); 3.57(s, 3H); 2.61-2.53 (m, 2H); 2.49-2.45 (m, 2H); 2.44 (s, 4H); 1.08 (s,6H)

Example 1432-methyl-2-(4-((2-(2-methyl-1H-pyrrolo[3,2-c]pyridin-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)propanamide143

Step 1:2-{4-[2-(1-Benzenesulfonyl-2-methyl-1H-pyrrolo[3,2-c]pyridin-4-yl)-4-morpholin-4-yl-thieno[3,2-c]pyrimidin-6-ylmethyl]piperazine-1-yl}isobutyramide

A 20 mL microwave vial was charged with a suspension of2-[4-(4-morpholin-4-yl-2-(tributylstannanyl)thieno[3,2-c]pyrimidin-6-ylmethyl)piperazin-1-yl]isobutyramide(0.38 g, 0.54 mmol),1-benzenesulfonyl-4-bromo-2-methyl-1H-pyrrolo[3,2-c]pyridine (0.21 g,0.60 mmol), copper(I) 2-thiophene carboxylate (0.042 g, 0.22 mmol) andPd(PPh₃)₄ (0.126 g, 0.108 mmol) in dioxane (8 mL) and NMP (2 mL). Thereaction mixture was heated in a microwave for 100 min at 140° C. Thecrude reaction mixture was loaded onto a Isolute® SCX-2 cartridgetreated with MeOH. The cartridge was washed with MeOH (100 mL), then theproduct was recovered eluting with 2N NH₃ in MeOH. The eluent wasconcentrated in vacuo and the resultant residue was purified by flashchromatography (Si—PPC, 0-10% MeOH in DCM) to give the product as yellowfoam (0.24 g, 65%). LCMS (Method A): R_(T)=3.53 min, [M+H]⁺ 675.2

Step 2: A 25 mL round-bottomed flask, under nitrogen, fitted with acondenser and inert gas bubbler (via a Claisen head), was charged with asolution of1-2-{4-[2-(1-benzenesulfonyl-2-methyl-1H-pyrrolo[3,2-c]pyridin-4-yl)-4-morpholin-4-yl-thieno[3,2-c]pyrimidin-6-ylmethyl]piperazine-1-yl}isobutyramide(0.24 g, 0.35 mmol) in dioxane (5 mL), IMS (5 mL) and NaOH 12.5M (0.5mL). The resulting mixture was stirred at room temperature for 2 h andwas then concentrated in vacuo. The resultant residue was diluted withMeOH and loaded onto a Isolute® SCX-2 cartridge pre-treated with MeOH.The cartridge was washed with MeOH (100 mL) and the product wasrecovered eluting with 2N ammonia in MeOH and concentrated in vacuo. Theresidue was purified by flash chromatography (Si—PPC, 0 to 100% EtOAc incyclohexane) to give a yellow powder. The solid was dissolved in DMSOand purified by preparative HPLC (C18 column, flow rate 18 ml/min))gradient: (acetonitrile/20 mM triethylamine in water/20 mMtriethylamine) 25-98% over 20 min. The product was freeze-driedovernight yielding 143 as a yellow powder (0.035 g, 21%). LCMS (MethodE): R_(T)=5.60 min, [M+H]⁺ 535.2. ¹H NMR (DMSO, 400 MHz): δ 11.43 (s,1H); 8.22 (d, J=5.4 Hz, 1H); 7.43 (s, 1H); 7.33 (dd, J=6.3, 0.9 Hz, 1H);7.07 (d, J=3.5 Hz, 1H); 6.95 (d, J=3.45 Hz, 1H); 6.87 (s, 1H); 3.98 (t,J=4.6 Hz, 4H); 3.87 (s, 2H); 3.81 (t, J=4.6 Hz, 4H); 3.57 (s, 3H);2.61-2.53 (m, 2H); 2.49-2.45 (m, 2H); 2.44 (s, 4H); 1.08 (s, 6H)

Example 1442-(4-((2-(1-acetamidoisoquinolin-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-methylpropanamide144

Step 1: N-acetyl-N-(4-bromoisoquinolin-1-yl)acetamide

To a solution of 4-bromoisoquinolin-1-amine (403 mg, 1.81 mmol) inmethylene chloride (11 mL) at 0° C. was added N,N-diisopropylethylamine(1.57 mL, 9.03 mmol), followed by acetyl chloride (0.321 mL, 4.52 mmol)dropwise. The mixture was stirred at 0° C. for 10 min then at roomtemperature for 2 h. The mixture was diluted with DCM (10 mL). Water (20mL) was added. The organic layer was separated. The aqueous solution wasextracted with DCM (10 mL). The combined DCM solutions were dried(Na₂SO₄). After filtration and concentration, the crude was purifiedwith flash chromatography to give the desired product (470 mg, 85%). ¹HNMR (400 MHz, DMSO) δ 8.79 (s, 1H), 8.23 (d, J=8.4, 1H), 8.13 (d, J=8.4,1H), 8.05 (t, J=7.7, 1H), 7.87 (t, J=7.6, 1H), 2.23 (s, 6H).

Step 2: Following General Procedure B of Suzuki coupling,N-acetyl-N-(4-bromoisoquinolin-1-yl)acetamide (57 mg) was reacted with2-(4-((2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-methylpropanamide(107 mg). After reaction completion, 1 M Na₂CO₃ (2 mL) and 1,4-dioxane(2 mL) were added to the mixture. The suspension was heated at 60° C.for 3 h. The reaction mixture was concentrated. Water (5 mL) was added.The contents were extracted with DCM (2×10 mL). The combined DCMsolutions were dried (Na₂SO₄). The crude was purified with reverse-phaseHPLC to give 144 (20 mg, 22%). LCMS: M+H+=589. ¹H NMR (400 MHz, CDCl₃) δ8.86 (2H), 8.07 (, s, br, 2H), 7.75 (t, J=7.7, 1H), 7.64 (t, J=7.6, 1H),7.36 (s, 1H), 7.09 (s, 1H), 5.18 (s, 1H), 4.12-4.00 (m, 4H), 3.94-3.81(m, 6H), 2.62 (s, 8H), 2.44 (s, 3H), 1.25 (s, 6H)

Example 1452-(1-((9-methyl-2-(2-methylbenzofuran-3-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol145

Following the procedures for 140,2-(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-olwas converted to 145. LCMS: M+H⁺=505.3. ¹H-NMR (400 MHz, DMSO-d₆): δ8.49 (m, 1H), 7.54 (m, 1H), 7.31 (m, 2H), 4.26 (s, br, 4H), 4.05 (s,1H), 3.86 (s, 3H), 3.77 (m, 4H), 3.68 (s, 2H), 2.94 (s, 3H), 2.90 (m,2H), 2.01 (m, 2H), 1.66 (m, 2H), 1.21 (m, 3H), 0.94 (s, 6H).

Example 1461-((2-(benzo[b]thiophen-3-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)-N,N-dimethylpiperidin-4-amine146

A microwave vessel was charged with[1-(2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)-piperidin-4-yl]-dimethyl-amine(0.400 g, 1.01 mmol), benzo[b]thien-3-ylboronic acid (197 mg, 1.11mmol), 1 N sodium carbonate solution (2.5 mL), acetonitrile (7.5 mL) andPd(dppf)Cl₂ (82.4 mg. 0.100 mmol), then the mixture was degassed,sealed, and heated at 140° C. under microwave irradiation for 20 min.The reaction mixture was diluted with dichloromethane (100 mL) and 1 Nsodium carbonate solution (10 mL) then the phases were separated. Theorganic phase was washed with saturated aqueous sodium bicarbonatesolution (15 mL) then dried (MgSO₄) and concentrated in vacuo.Purification by chromatography (silica, 0 to 15% of a 9.5:0.5 MeOH:NH₄OHsolution in dichloromethane) to afford 146 (240 mg, 48.2%) as a lightbrown solid. MS m/e 494 [M+H]⁺ ¹H NMR (300 MHz, CHLOROFORM-d) δ ppm1.47-1.68 (m, 2H) 1.81 (d, J=12.43 Hz, 2H) 2.03-2.20 (m, 3H) 2.28 (s,6H) 3.02 (d, J=12.06 Hz, 2H) 3.80 (s, 2H) 3.85-3.95 (m, 4H) 3.99-4.10(m, 4H) 7.32 (s, 1H) 7.34-7.42 (m, 1H) 7.43-7.53 (m, 1H) 7.89 (d, J=7.91Hz, 1H) 8.44 (s, 1H) 9.00-9.15 (m, 1H).

Example 1472-(1-((2-(1-aminoisoquinolin-5-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol147

Step 1:2-(1-((9-methyl-6-morpholino-2-(tributylstannyl)-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol

A mixture of2-(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol(235 mg, 0.575 mmol), bis(tributyltin) (0.58 mL, 1.15 mmol) andPdCl₂[t-Bu₂P(Ph-p-Nme₂)₂] (41 mg, 0.057 mmol) in 1,4-dioxane (3 mL) washeated in a microwave at 140° C. for 40 minutes. The reaction mixturewas then concentrated. The crude product was purified by flashchromatography (0-100% gradient EtOAc-Heptane) to give the titlecompound (256 mg, 67.1%). LCMS: M+H⁺=663.2

Step 2: To a degassed mixture of2-(1-((9-methyl-6-morpholino-2-(tributylstannyl)-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol(256 mg, 0.386 mmol), 5-bromoisoquinolin-1-amine (86 mg, 0.386 mmol),copper(I) thiophene-2-carboxylate (74 mg, 0.386 mmol) in 1,4-dioxane (4mL) was added Pd(PPh₃)₄ (45 mg, 0.039 mmol). The reaction mixture washeated in the microwave at 140° C. for 35 minutes. The reaction mixturewas then loaded onto a Biotage Isolute SPE SCX-2 column. The column wasfirst washed with MeOH. The product was eluted with 2 M NH₃ in MeOH andconcentrated. The crude was further purified by RP-HPLC to give 147(36.3 mg, 18.2%). LCMS: M+H⁺=517.3. ¹H-NMR (400 MHz, DMSO-d₆): δ 8.28(d, 1H), 8.11 (d, 1H), 7.79 (d, 1H), 7.70 (d, 1H), 7.53 (t, 1H), 6.80(s, 2H), 4.23 (s, br, 4H), 4.09 (s, 1H), 3.81 (s, 3H), 3.73 (m, 6H),2.90 (m, 2H), 2.02 (m, 2H), 1.66 (m, 2H), 1.19 (m, 3H), 1.02 (s, 6H)

Example 149N,N-dimethyl-1-((4-morpholino-2-(1H-pyrrolo[3,2-c]pyridin-1-yl)thieno[3,2-d]pyrimidin-6-yl)methyl)piperidin-4-amine149

Following General Procedure I for Buchwald coupling,1-((2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)-N,N-dimethylpiperidin-4-amineand 1H-pyrrolo[3,2-c]pyridine were reacted to give 149. MS m/e 478.6[M+H]⁺

Example 1501-((2-(isoquinolin-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)-N,N-dimethylpiperidin-4-amine150

A microwave vessel was charged with2-[4-(4-morpholin-4-yl-2-tributylstannanyl-thieno[3,2-d]pyrimidin-6-ylmethyl)-piperazin-1-yl]-isobutyramide(0.226 g, 0.347 mmol), 4-bromoisoquinoline (0.086 g, 0.416 mmol),copper(I) thiophene-2-carboxylate (Cu (TC)) (0.066 g, 0.347 mmol),palladium tetrakis(triphenylphosphine) (0.040 g, 0.034 mmol) and dioxane(2 mL). The vessel was degassed, sealed, and heated at 140° C. undermicrowave irradiation for 20 min. The reaction mixture was cooled toroom temperature and filtered through celite. The filtrates wereconcentrated then purified twice by chromatography (silica, 0 to 15% ofa 9:1 MeOH:NH₄OH mixture in dichloromethane) to furnish 150 (0.026 g,15.38%) as an off-white foam. ¹H NMR (400 MHz, CDCl₃-d) δ ppm 1.60 (qd,J=12.04, 3.79 Hz, 2H) 1.83 (d, J=12.63 Hz, 2H) 2.08-2.22 (m, 3H) 2.30(s, 6H) 3.05 (d, J=12.13 Hz, 2H) 3.84 (s, 2H) 3.86-3.92 (m, 4H)4.03-4.11 (m, 4H) 7.35 (s, 1H) 7.59-7.65 (m, 1H) 7.69-7.77 (m, 1H) 8.03(d, J=8.59 Hz, 1H) 8.82 (d, J=8.08 Hz, 1H) 9.11 (s, 1H) 9.30 (s, 1H). MSm/e 489 [M+H]⁺

Example 1512-(4-((2-(2-ethyl-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-methylpropanamide151

A mixture of2-[4-(4-morpholin-4-yl-2-(tributylstannanyl)thieno[3,2-c]pyrimidin-6-ylmethyl)piperazin-1-yl]isobutyramide(0.241 g, 0.35 mmol),1-benzenesulfonyl-4-bromo-2-ethyl-1H-pyrrolo[2,3-c]pyridine (0.14 g,0.38 mmol), copper(I) 2-thiophene carboxylate (0.01 g, 0.069 mmol) andPd(PPh₃)₄ (0.040 g, 0.035 mmol) in dioxane (3 mL) was subjected tomicrowave irradiation at 150° C. for 20 min. The reaction mixture wasloaded onto an Isolute® SCX-2 cartridge. The cartridge was washed withMeOH and the desired product was eluted using 2 M NH₃ in MeOH. Theeluent was concentrated in vacuo and the residue was purified by flashchromatography (Si—PPC, MeOH:DCM, gradient 0:100 to 20:80) to give2-{4-[2-(1-benzenesulfonyl-2-ethyl-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-morpholin-4-ylthieno[3,2-c]pyrimidin-6-ylmethyl]piperazin-1-yl}isobutyramideas a yellow foam (0.15 g, 64%). LCMS (Method A): R_(T)=3.53 min, [M+H]⁺689.2

A mixture of2-{4-[2-(1-benzenesulfonyl-2-ethyl-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-morpholin-4-ylthieno[3,2-c]pyrimidin-6-ylmethyl]piperazin-1-yl}isobutyramide(0.15 g, 0.22 mmol) in dioxane (3 mL), IMS (3 mL) and NaOH 12.5M (0.34mL) was stirred at room temperature for 3 h and was then concentrated invacuo. The residue was loaded onto an Isolute® SCX-2 cartridge. Thecartridge was washed with MeOH and the desired product was eluted using2 M NH₃ in MeOH. The residue was purified by reverse phase HPLC(Phenomenex Gemini 5u C18, 20 mM triethylamine in water on a gradient ofacetonitrile 95:5 to 2:98) to give 151 as a white powder (0.034 g, 29%).LCMS (Method E): R_(T)=5.87 min, [M+H]⁺ 549.2. ¹H NMR (400 MHz,DMSO-d₆): δ 11.56 (s, 1H); 9.09 (s, 1H); 8.65 (s, 1H); 7.45 (s, 1H);7.14 (s, 1H); 7.07 (d, J=3.5 Hz, 1H); 6.95 (d, J=3.5 Hz, 1H); 3.99 (t,J=4.6 Hz, 4H); 3.86 (s, 2H); 3.82 (t, J=4.6 Hz, 4H); 2.86 (q, J=7.6 Hz,2H); 2.56-2.53 (m, 4H); 2.51-2.45 (m, 4H); 1.34 (t, J=7.6 Hz, 3H); 1.08(s, 6H)

Example 1524-(1-((7-morpholino-5-(1H-pyrrolo[3,2-c]pyridin-4-yl)thiazolo[5,4-d]pyrimidin-2-yl)methyl)azetidin-3-yl)morpholine152

A degassed solution of5-chloro-7-morpholin-4-yl-2-(3-morpholin-4-yl-azetidin-1-ylmethyl)thiazolo[5,4-d]pyrimidine(1.0 g, 2.43 mmol), PdCl₂{P^(t)Bu₂(Ph-p-Nme₂)}₂ (170 mg, 0.24 mmol) andhexamethylditin (1.85 mL, 3.66 mmol) in 1,4-dioxane (10 mL) wassubjected to microwave irradiation at 150° C. for 30 minutes. Thereaction mixture was cooled to ambient temperature and loaded onto anIsolute® SCX-2 cartridge (25 g). The cartridge was then washed with MeOHand the desired product was subsequently eluted using 2 M NH₃ in MeOH.The product was collected and concentrated to give a yellow oil. The oilwas purified by flash chromatography (Si—PPC, DCM:MeOH, 100:0 to 98:2 to95:5) to afford7-morpholin-4-yl-2-(3-morpholin-4-yl-azetidin-1-ylmethyl)-5-(tributylstannanyl)thiazolo[5,4-d]pyrimidineas a pale yellow oil (1.18 g, 73%). NMR (CDCl₃, 400 MHz) δ 4.31 (m, 4H),3.97 (s, 2H), 3.82 (t, J=4.6 Hz, 4H), 3.72 (m, 4H), 3.65-3.59 (m, 2H),3.14-3.05 (m, 3H), 2.34 (m, 4H), 1.65-1.52 (m, 6H), 1.39-1.26 (m, 6H),1.23-1.01 (m, 6H), 0.93-0.84 (m, 9H).

A degassed solution of7-morpholin-4-yl-2-(3-morpholin-4-yl-azetidin-1-ylmethyl)-5-(tributylstannanyl)thiazolo[5,4-d]pyrimidine(200 mg, 0.30 mmol), 1-benzenesulfonyl-4-bromo-1H-pyrrolo[3,2-c]pyridine(132 mg, 0.39 mmol), PdCl₂{P^(t)Bu₂(Ph-p-Nme₂)}₂ (22 mg, 0.03 mmol) andcopper(I) thiophene-2-carboxylate (12 mg, 0.06 mmol) in 1,4-dioxane (4mL) was subjected to microwave irradiation at 140° C. for 20 minutes.The reaction mixture was cooled to ambient temperature and loaded ontoan Isolute® SCX-2 cartridge (10 g). The cartridge was then washed withMeOH and the desired product was subsequently eluted using 2 M NH₃ inMeOH. The product was collected and concentrated to give5-(1-benzenesulfonyl-1H-pyrrolo[3,2-c]pyridin-4-yl)-7-morpholin-4-yl-2-(3-morpholin-4-yl-azetidin-1-ylmethyl)thioazolo[5,4-c]pyrimidineas a crude oil. Aqueous NaOH (12.5 M, 0.5 mL) was added to a solution of5-(1-benzenesulfonyl-1H-pyrrolo[3,2-c]pyridin-4-yl)-7-morpholin-4-yl-2-(3-morpholin-4-yl-azetidin-1-ylmethyl)-thiazolo[5,4-c]pyrimidinein 1,4-dioxane (4 mL) and IMS (4 mL). The reaction mixture was stirredat ambient temperature for 45 min, then concentrated in vacuo. Theresidue was dissolved in MeOH then loaded onto an Isolute® SCX-2cartridge (10 g). The cartridge was then washed with MeOH and thedesired product was subsequently eluted using 2 M NH₃ in MeOH. Theproduct was collected and concentrated to afford a solid. The solid waspurified by flash chromatography (Si—PPC, DCM:MeOH, 100:0 to 98:2 to96:4) to afford 152 as a yellow solid (56 mg, 38%). LCMS (Method E):R_(T)=4.34 min, M+H⁺=493.2. ¹H NMR (CDCl₃, 400 MHz) δ 8.72 (bs, 1H),8.56 (d, J=5.7 Hz, 1H), 7.41 (m, 2H), 7.36 (d, J=3.2 Hz, 1H), 4.49-4.44(m, 4H), 4.02 (s, 2H), 3.90 (t, J=4.7 Hz, 4H), 3.74-3.65 (m, 6H),3.16-3.07 (m, 3H), 2.35 (m, 4H)

Example 1532-methyl-2-(4-((2-(5-methyl-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)propanamide153

A mixture of2-[4-(4-morpholin-4-yl-2-(tributylstannanyl)thieno[3,2-d]pyrimidin-6-ylmethyl)piperazin-1-yl]isobutyramide(72 mg, 0.10 mmol), 4-bromo-5-methyl-1H-pyrrolo[2,3-c]pyridine (22 mg,0.10 mmol), Pd(PPh₃)₄ (12 mg, 10 mol %) andcopper(I)-thiophene-2-carboxylate (4 mg, 20 mol %) in dioxane (1 mL) waspurged with argon gas then heated at 150° C., for 20 min, in a microwavereactor. The reaction mixture was loaded onto an Isolute® SCX-2cartridge, the cartridge was washed with MeOH then the desired producteluted with 2 M NH₃ in MeOH. The resulting residue was purified bycolumn chromatography (Si—PCC, 0-20% MeOH in DCM) to give 153 as a paleyellow solid (24 mg, 43%). LCMS (Method E): R_(T)=4.19 min, [M+H]⁺535.2. ¹H NMR (400 MHz, CHCl₃-d): δ 9.14 (s, 1H), 8.73 (s, 1H),7.34-7.32 (m, 2H), 7.11 (d, J=5.3 Hz, 1H), 6.67-6.65 (m, 1H), 5.30 (d,J=4.7 Hz, 1H), 4.04 (t, J=4.7 Hz, 4H), 3.87 (d, J=4.7 Hz, 4H), 3.85 (s,2H), 2.76 (s, 3H), 2.61 (m, 8H), 1.28-1.22 (m, 6H)

Example 1544-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)morpholine154

Following the procedures for 178,4-(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)morpholineand acetic acid were converted to 154. LCMS: M+H⁺=532.3. ¹H-NMR (400MHz, DMSO-d₆): δ 8.09 (m, 1H), 7.60 (m, 1H), 7.25 (m, 2H), 4.26 (s, br,4H), 3.82 (s, 3H), 3.71 (m, 6H), 3.54 (m, 4H), 2.85 (m, 5), 2.43 (m,4H), 2.08 (m, 3H), 1.76 (m, 2H), 1.39 (m, 2H).

Example 1554-(8-((4-(2-methoxypropan-2-yl)piperidin-1-yl)methyl)-9-methyl-6-morpholino-9H-purin-2-yl)isoquinolin-1-amine155

2-(Piperidin-4-yl)propan-2-ol (1 g) was reacted with 1.1 eq of benzylchloroformate and 1.3 eq of triethylamine in 30 mL of chloroform. Thereaction was halted after 2 days at room temperature and purified byisco (0-60% Hexanes/Ethyl Acetate over 20 minutes) to afford 1.49 gbenzyl 4-(2-hydroxypropan-2-yl)piperidine-1-carboxylate.

To a suspension of sodium hydride, 60% dispersion in mineral oil (0.322g) and methyl iodide (1.00 mL) in 10 mL THF at room temp was carefullyadded portionwise benzyl4-(2-hydroxypropan-2-yl)piperidine-1-carboxylate (1.49 g, 0.00537 mol)in 15 mL THF. The reaction was heated at 50° C. for 18 hours and then itwas cooled down to 0° C. and carefully quenched by addition of sat NH4Clsolution, then extracted with EtOAc twice. The combined organics werewashed with brine, dried over MgSO4 and concentrated in vacuo. Theresidue was purified by flash chrom to get 1.2 g benzyl4-(2-methoxypropan-2-yl)piperidine-1-carboxylate as a colorless oil.

The cbz protecting group was hydrogenated off using the H-cube withpalladium on carbon. The product in a solution of methanol was thenconcentrated and run through an isolate scx-2 spe cartridge to yield0.44 g of 4-(2-methoxypropan-2-yl)piperidine as a colorless oil.

4-(2-methoxypropan-2-yl)piperidine (0.12 g) was reacted with4-(8-(bromomethyl)-2-chloro-9-methyl-9H-purin-6-yl)morpholine (0.25 g)via General Procedure E to give 300 mg of crude4-(2-chloro-8-((4-(2-methoxypropan-2-yl)piperidin-1-yl)methyl)-9-methyl-9H-purin-6-yl)morpholine,of which 0.78 g was reacted with4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoquinolin-1-amine viaGeneral Procedure A to yield 12 mg of 155 as a white solid followingreverse phase purification. MS (Q1) 531.3 (M)+

Example 1561-(8-((4-(2-hydroxypropan-2-yl)piperidin-1-yl)methyl)-9-methyl-6-morpholino-9H-purin-2-yl)-1H-benzo[d]imidazol-2(3H)-one156

A mixture of2-(1-((2-(2-aminophenylamino)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol(40 mg, 0.083 mmol) and N,N-carbonyldiimidazole (17 mg, 0.108 mmol) inacetonitrile (2 mL) was stirred at reflux for 15 hours. The reactionmixture was then filtered through paper and purified by RP-HPLC to give156 (6.7 mg, 16%). LCMS: M+H⁺=507.2. ¹H-NMR (400 MHz, DMSO-d₆): δ 11.0(s, 1H), 7.55 (d, 1H), 7.04 (m, 3H), 4.21 (s, br, 4H), 4.02 (s, 1H),3.78 (s, 3H), 3.74 (m, 6H), 2.88 (m, 2H), 2.00 (m, 2H), 1.66 (m, 2H),1.20 (m, 3H), 1.02 (s, 6H)

Example 1572-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol157

Step 1: A mixture of2-(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol(1.21 g, 2.96 mmol), benzene-1,2-diamine (520 mg, 4.8 mmol), palladiumacetate (66 mg, 0.29 mmol), bist(tri-t-butylphosphine)palladium (150 mg,0.29 mmol) and sodium tert-butoxide (620 mg, 6.4 mmol) in toluene (30mL) was stirred at 95° C. for 18 hours. The reaction mixture was thenfiltered through paper and then concentrated. The crude product was thenpurified by flash chromatography using a Biotage KP—NH column (0-10%gradient MeOH in DCM) to give2-(1-((2-(2-aminophenylamino)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol(1.2 g, 84%). LCMS: M+H⁺=481.2.

Step 2: A mixture of2-(1-((2-(2-aminophenylamino)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol(177 mg, 0.368 mmol) in acetic acid (1.5 mL) was stirred at reflux for 5hours. The reaction mixture was then concentrated and then purifiedfirst by flash chromatography (10% MeOH in DCM containing 1% 2 M ammoniain MeOH), followed by RP-HPLC to give 157 (0.0373 g, 21.1%). LCMS:M+H⁺=505.3. ¹H-NMR (400 MHz, DMSO-d₆): δ 8.09 (m, 1H), 7.60 (m, 1H),7.25 (m, 2H), 4.26 (s, br, 4H), 4.02 (s, 1H), 3.83 (s, 3H), 3.78 (m,4H), 3.73 (s, 2H), 2.90 (m, 2H), 2.84 (s, 3H), 1.99 (m, 2H), 1.66 (m,2H), 1.21 (m, 3H), 1.02 (s, 6H).

Example 1582-(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol158

Following the procedures for 180,2-(1-((2-(2-aminophenylamino)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-oland propanoic acid were reacted to give 158. LCMS: M+H⁺=519.3. ¹H-NMR(400 MHz, DMSO-d₆): δ 8.02 (m, 1H), 7.63 (m, 1H), 7.26 (m, 2H), 4.24 (s,br, 4H), 4.02 (s, 1H), 3.82 (s, 3H), 3.77 (m, 4H), 3.73 (s, 2H), 3.28(q, 2H), 2.90 (m, 2H), 2.00 (m, 2H), 1.66 (m, 2H), 1.34 (t, 3H), 1.22(m, 3H), 1.02 (s, 6H)

Example 1592-(1-((2-(2-cyclopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol159

Following the procedures for 178,2-(1-((2-(2-aminophenylamino)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-oland cyclopropanecarboxylic acid were reacted to give 159. LCMS:M+H⁺=531.3. ¹H-NMR (400 MHz, DMSO-d₆): δ 7.93 (m, 1H), 7.53 (m, 1H),7.22 (m, 2H), 4.26 (s, br, 4H), 4.08 (m, 2H), 4.03 (s, 1H), 3.82 (s,3H), 3.77 (m, 4H), 3.74 (s, 2H), 3.17 (d, 2H), 2.84-2.96 (m, 3H), 1.99(m, 2H), 1.67 (m, 2H), 1.04-1.29 (m, 3H), 1.02 (s, 6H)

Example 1602-(4-((2-(isoquinolin-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-methylpropanamide160

Following General Procedure A for Suzuki coupling,2-(4-((2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-methylpropanamideand 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoquinoline werereacted to give 160. LCMS: M+H⁺=532.2.

Example 1612-(1-((2-(2-(methoxymethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol161

Following the procedures for 178,2-(1-((2-(2-aminophenylamino)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-oland methoxyacetic acid were reacted to give 161. LCMS: M+H⁺=535.3.¹H-NMR (400 MHz, DMSO-d₆): δ 8.13 (d, 1H), 7.71 (d, 1H), 7.32 (m, 2H),5.08 (s, 2H), 4.26 (s, br, 4H), 4.02 (s, 1H), 3.83 (s, 3H), 3.78 (m,4H), 3.73 (s, 2H), 3.27 (s, 3H), 2.90 (m, 2H), 2.00 (m, 2H), 1.65 (m,2H), 1.22 (m, 3H), 1.02 (s, 6H)

Example 1622-(1-((2-(1H-indazol-3-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol162

2-(1-((9-Methyl-6-morpholino-2-(tributylstannyl)-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol(0.5 g) was reacted with 3-iodo-1H-indazole via General Procedure G togive 68.3 mg of 162 as a white solid following reverse phasepurification. MS (Q1) 491.2 (M)+

Example 1632-(4-((2-(2-fluorobenzofuran-3-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-methylpropanamide163

To a degassed mixture of2-methyl-2-(4-((4-morpholino-2-(tributylstannyl)thieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)propanamide(150 mg, 0.22 mmol), 3-bromo-2-fluorobenzofuran (0.22 mmol), copper(I)thiophene-2-carboxylate (41 mg, 0.22 mmol) in dioxane (2 mL) was addedPd(PPh₃)₄ (12 mg, 0.011 mmol). The reaction mixture was reacted in themicrowave at 140° C. for 35 min. The reaction mixture was filteredthrough paper and concentrated. The crude product was purified by flashchromatography (20% MeOH in DCM) to give a yellow paste which wasdissolved in dioxane (5 mL) and ethanol (1 mL). A 12 M aqueous solutionof NaOH was then added. The resulting mixture was then stirred at 65° C.for 15 hours. The reaction mixture was then loaded onto a BiotageIsolute SPE SCX-2 column. The column was washed with MeOH and thedesired product was then eluted with 2 M NH₃ in MeOH and furtherpurified by RP-HPLC to give 163. LCMS: M+H⁺=539.2. ¹H-NMR (400 MHz,DMSO-d₆): δ 8.46 (d, 1H), 7.63 (d, 1H), 7.41 (m, 3H), 7.05 (d, 1H), 6.93(d, 1H), 3.97 (m, 4H), 3.86 (s, 2H), 3.82 (m, 4H), 2.31-2.62 (m, 8H),1.08 (s, 6H)

Example 1644-(6-((4-(dimethylamino)piperidin-1-yl)methyl)-4-morpholinothieno[3,2-d]pyrimidin-2-yl)isoquinoline2-oxide 164

A microwave vessel was charged with2-[4-(4-morpholin-4-yl-2-tributylstannanyl-thieno[3,2-d]pyrimidin-6-ylmethyl)-piperazin-1-yl]-isobutyramide(0.206 g, 0.316 mmol), 4-bromo-isoquinoline 2-oxide (0.085 g, 0.379mmol), copper(I) thiophene-2-carboxylate (Cu (TC)) (0.060 g, 0.316mmol), palladium tetrakis(triphenylphosphine) (0.036 g, 0.031 mmol) anddioxane (2 mL). The vessel was degassed, sealed, and heated at 140° C.under microwave irradiation for 20 min. The reaction mixture was cooledto room temperature and filtered through celite. The filtrates wereconcentrated then purified twice by chromatography (silica, 0 to 15% ofa 9:1 MeOH:NH₄OH mixture in dichloromethane) to furnish 164 (0.017 g,10.7%) as a light yellow foam. ¹H NMR (400 MHz, CDCl₃-d) δ ppm 1.54-1.68(m, 3H) 1.85 (d, J=12.13 Hz, 2H) 1.97 (br. s., 2H) 2.10-2.23 (m, 3H)2.31 (s, 6H) 3.04 (d, J=11.62 Hz, 2H) 3.85 (s, 2H) 3.86-3.91 (m, 4H)4.04-4.09 (m, 4H) 7.34 (s, 1H) 7.59-7.66 (m, 2H) 7.73-7.80 (m, 1H)8.78-8.82 (m, 2H) 8.86-8.93 (m, 1H). MS m/e 505 [M+H]⁺

Example 1652-(1-((9-methyl-2-(2-methyl-1H-pyrrolo[2,3-c]pyridin-4-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol165

Step 1: A 20 mL microwave vial was charged with a suspension of2-[1-(9-methyl-6-morpholin-4-yl-2-(tributylstannanyl)-9H-purin-8-ylmethyl)piperidin-4-yl]propan-2-ol(0.5 g, 0.75 mmol), 1-benzenesulfonyl-4-bromo-1H-pyrrolo[2,3-c]pyridine(0.29 g, 0.83 mmol), CuTC (0.029 g, 0.015 mmol) and Pd(PPh₃)₄ (0.087 g,0.075 mmol) in dioxane (8 mL). The reaction mixture was heated in amicrowave for 30 min at 150° C. The cooled reaction mixture was loadedonto an SCX-2 cartridge. The cartridge was washed with 3 volumes ofMeOH, then the product was recovered eluting with 2N ammonia in MeOH.The solution was concentrated and the residue loaded onto a 40 g SiO₂column and purified by flash chromatography (Si—PCC; 40 g SiO₂ column,0% to 6% MeOH in DCM) to give2-{1-[2-(1-Benzenesulfonyl-2-methyl-1H-pyrrolo[2,3-c]pyridin-4-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl]piperidin-4-yl}propan-2-olas white foam (0.414 g, 86%). LCMS (Method A): R_(T)=3.24 min, [M+H]⁺645.3

Step 2: A 50 mL round-bottomed flask, under nitrogen, fitted with acondenser/inert gas bubbler (via a Claisen head), was charged with asolution of2-{1-[2-(1-benzenesulfonyl-2-methyl-1H-pyrrolo[2,3-c]pyridin-4-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl]piperidin-4-yl}propan-2-ol(0.41 g, 0.64 mmol) in dioxane (8 mL), IMS (8 mL) and NaOH 12.5M (0.8mL). The resulting mixture was stirred at room temperature for 2 h. Thesolution was concentrated in vacuo, the residue was dissolved in DCM anda fine solid was removed by filtration through a Celite pad. Thesolution was purified by flash chromatography (Si—PCC; 25 g SiO₂ column,0% to 20% MeOH in DCM). The residue was then purified further bypreparative HPLC [(C18 column) gradient: (acetonitrile/20 mMtriethylamine) 30% to 98% in (water/20 mM triethylamine) over 20 min(flow rate 18 ml/min)]. The product was freeze-dried overnight yielding165 as a white powder (0.136 g, 43%). LCMS (method E): R_(T)=4.89 min,[M+H]⁺ 505.24. ¹H NMR (CDCl₃, 400 MHz) δ 9.28 (s, 1H), 8.70 (s, 1H),8.30 (s, 1H), 4.40 (m, 4H), 3.96 (s, 3H), 3.89 (m, 4H), 3.74 (s, 2H),2.96 (m, 2H), 2.58 (s, 3H), 2.10 (m, 2H), 1.75 (m, 2H), 1.40-1.28 (m,3H), 1.18 (s, 6H)

Example 1662-(1-((2-(2-methoxy-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol166

Following the procedures for 179,2-(1-((2-(2-aminophenylamino)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol,tetramethylorthocarbonate and acetic acid were reacted to give 166.LCMS: M+H⁺=521.3. ¹H-NMR (400 MHz, DMSO-d₆): δ 7.83 (m, 1H), 7.48 (m,1H), 7.18 (m, 2H), 4.23 (s, br, 4H), 4.15 (s, 3H), 4.02 (s, 1H), 3.80(s, 3H), 3.76 (m, 4H), 3.72 (s, 2H), 2.87 (m, 2H), 1.99 (m, 2H), 1.65(m, 2H), 1.20 (m, 3H), 1.02 (s, 6H)

Example 1672-(1-((2-(2-amino-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol167

A mixture of2-(1-((2-(2-aminophenylamino)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol(220 mg, 0.46 mmol) and cyanogen bromide (150 mg, 1.4 mmol) in ethanol(2 mL) was stirred at 95° C. for 15 minutes. The reaction mixture wasthen loaded onto a Biotage Isolute SPE SCX-2 column. The column waswashed with MeOH and the desired product was then eluted with 2 M NH₃ inMeOH and further purified by RP-HPLC to give 167 (18.1 mg, 7.8%). LCMS:M+H⁺=506.3. ¹H-NMR (400 MHz, DMSO-d₆): δ 8.17 (d, 1H), 7.70 (s, br, 2H),7.24 (d, 1H), 7.12 (t, 1H), 7.03 (t, 1H), 4.26 (s, br, 4H), 4.10 (s,1H), 3.84 (s, 3H), 3.80 (m, 4H), 1.73 (m, 2H), 1.27 (m, 3H), 1.03 (s,6H)

Example 1684-(1-((7-morpholino-5-(1H-pyrrolo[2,3-c]pyridin-4-yl)thiazolo[5,4-d]pyrimidin-2-yl)methyl)azetidin-3-yl)morpholine168

A degassed solution of7-morpholin-4-yl-2-(3-morpholin-4-yl-azetidin-1-ylmethyl)-5-(tributylstannanyl)thiazolo[5,4-c]pyrimidine(120 mg, 0.18 mmol), 4-bromo-1H-pyrrolo[2,3-c]pyridine (46 mg, 0.23mmol), PdCl₂{P^(t)Bu₂(Ph-p-Nme₂)}₂ (13 mg, 0.018 mmol) and copper(I)thiophene-2-carboxylate (7 mg, 0.036 mmol) in 1,4-dioxane (2.5 mL) wassubjected to microwave irradiation at 140° C. for 20 minutes. Thereaction mixture was cooled to ambient temperature and loaded onto anIsolute® SCX-2 cartridge (10 g). The cartridge was then washed with MeOHand the desired product was subsequently eluted using 2 M NH₃ in MeOH.The product was collected and concentrated to give a yellow oil. The oilwas purified by chromatography (Si—PPC, DCM:MeOH, 100:0 to 98:2 to 95:5)to afford 168 as a yellow solid (12 mg, 14%). LCMS (Method E):R_(T)=4.15 min, [M+H]⁺ 493.2. ¹H NMR (CDCl₃, 400 MHz) δ 9.28 (bs, 1H),8.90 (s, 1H), 7.53 (m, 2H), 4.45 (m, 4H), 4.02 (s, 2H), 3.90 (t, J=4.7Hz, 4H), 3.76-3.65 (m, 6H), 3.19-3.09 (m, 3H), 2.36 (d, J=4.76 Hz, 4H).

Example 1692-methyl-2-(4-((7-morpholino-5-(1H-pyrrolo[3,2-c]pyridin-4-yl)thiazolo[5,4-d]pyrimidin-2-yl)methyl)piperazin-1-yl)propanamide169

A degassed solution of2-[4-(7-morpholin-4-yl-5-(tributylstannanyl)thiazolo[5,4-d]pyrimidin-2-ylmethyl)piperazin-1-yl]isobutyramide(250 mg, 0.36 mmol), 1-benzenesulfonyl-4-bromo-1H-pyrrolo[3,2-c]pyridine(130 mg, 0.39 mmol), PdCl₂{P^(t)Bu₂(Ph-p-Nme₂)}₂ (26 mg, 0.036 mmol) andcopper(I) thiophene-2-carboxylate (14 mg, 0.07 mmol) in 1,4-dioxane (4mL) was subjected to microwave irradiation at 140° C. for 20 minutes.The reaction mixture was cooled to ambient temperature and loaded ontoan Isolute® SCX-2 cartridge (10 g). The cartridge was then washed withMeOH and the desired product was subsequently eluted using 2 M NH₃ inMeOH. The product was collected and concentrated to give2-{4-[5-(1-benzenesulfonyl-1H-pyrrolo[3,2-c]pyridin-4-yl)-7-morpholin-4-ylthiazolo[5,4-c]pyrimidin-2-ylmethyl]piperazin-1-yl}isobutyramideas a crude oil. Aqueous NaOH (12.5 M, 0.4 mL) was added to a solution of2-{4-[5-(1-benzenesulfonyl-1H-pyrrolo[3,2-c]pyridin-4-yl)-7-morpholin-4-yl-thiazolo[5,4-d]pyrimidin-2-ylmethyl]-piperazin-1-yl}isobutyramidein 1,4-dioxane (4 mL) and IMS (4 mL). The reaction mixture was stirredat ambient temperature for 45 min, then concentrated in vacuo. Theresidue was dissolved in MeOH then loaded onto an Isolute® SCX-2cartridge (10 g). The cartridge was then washed with MeOH and thedesired product was subsequently eluted using 2 M NH₃ in MeOH. Theproduct was collected and concentrated to afford a solid. The solid waspurified by flash chromatography (Si—PPC, DCM:MeOH, 100:0 to 98:2 to96:4) followed by reversed phase HPLC (Phenomenex Luna C-18, 20 mM Et₃Nin water on a gradient of 20 mM Et₃N in acetonitrile 95:5 to 2:98) toafford 169 as a yellow solid (43 mg, 23%). LCMS (method E): R_(T)=5.03min, [M+H]⁺=522.2. ¹H NMR (CDCl₃, 400 MHz) δ 8.55 (d, J=5.6 Hz, 1H),7.45-7.40 (m, 2H), 7.38 (d, J=3.3 Hz, 1H), 7.11 (d, J=5.3 Hz, 1H), 5.25(d, J=5.3 Hz, 1H), 4.53-4.42 (m, 4H), 3.90 (m, 6H), 2.68 (m, 4H), 2.62(m, 4H), 1.25 (s, 6H)

Example 1702-methyl-2-(4-((2-(6-methyl-1H-pyrrolo[3,2-c]pyridin-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)propanamide170

A mixture of2-[4-(4-morpholin-4-yl-2-(tributylstannanyl)thieno[3,2-d]pyrimidin-6-ylmethyl)-piperazin-1-yl]isobutyramide(100 mg, 0.14 mmol), 4-bromo-6-methyl-1H-pyrrolo[3,2-c]pyridine (20 mg,0.09 mmol), tetrakis(triphenylphosphine)palladium (17 mg, 10 mol %) andcopper(I)-thiophene-2-carboxylate (6 mg, 20 mol %) in dioxane (1.5 mL)was purged with argon gas then heated at 150° C., for 20 min, in amicrowave reactor. The cooled reaction mixture was loaded onto anIsolute® SCX-2 cartridge, washed with MeOH/DCM then eluted with 2 M NH₃in MeOH/DCM. The resulting residue was purified by column chromatography(Si—PPC, 2 M NH₃ in MeOH:DCM, gradient 0:100 to 10:90) followed byreverse phase HPLC (Phenomenex Gemini 5 μm C18, 20 mM triethylamine inwater on a gradient of acetonitrile 90:10 to 02:98) to give 170 as anoff-white solid (11 mg, 22%). LCMS R_(T) 5.14 min, [M+H]⁺ 535. ¹H NMR(CDCl₃, 400 MHz) δ 7.41 (s, 1H), 7.29-7.25 (m, 2H), 7.14 (s, 1H), 7.09(d, J=5.3 Hz, 1H), 5.36 (d, J=5.3 Hz, 1H), 4.07 (t, J=4.6 Hz, 4H), 3.88(t, J=4.6 Hz, 4H), 3.83 (s, 2H), 2.70 (s, 3H), 2.58 (m, 8H), 1.23 (s,6H)

Example 1712-methyl-2-(4-((4-morpholino-2-(quinolin-4-yl)thieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)propanamide171

To a degassed mixture of2-methyl-2-(4-((4-morpholino-2-(tributylstannyl)thieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)propanamide(235 mg, 0.339 mmol), 4-bromoquinoline (60 mg, 0.288 mmol), copper(I)thiophene-2-carboxylate (55 mg, 0.228 mmol) in dioxane (2 mL) was addedPd(PPh₃)₄ (17 mg, 0.014 mmol). The reaction mixture was reacted in theCEM microwave at 140° C. for 30 min. The reaction mixture was thenloaded onto a Biotage Isolute SPE SCX-2 column. The column was washedwith MeOH, eluted with 2 M NH₃ in MeOH and further purified by RP-HPLCto give 171 (44 mg, 29%). LCMS: M+H⁺=532.2. ¹H-NMR (400 MHz, DMSO-d₆): δ9.39 (s, 1H), 9.04 (s, 1H), 8.86 (d, 1H), 8.22 (d, 1H), 7.84 (t, 1H),7.73 (t, 1H), 7.47 (s, 1H), 7.06 (s, 1H), 6.94 (s, 1H), 3.97 (m, 4H),3.88 (s, 2H), 3.68 (m, 4H), 2.54-2.67 (m, 8H), 1.09 (s, 6H)

Example 1724-(1-((2-(2-methyl-1H-benzo[d]imidazol-1-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)azetidin-3-yl)morpholine172

To a solution of2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidine-6-carbaldehyde (953mg, 3.36 mmol) in DCE (50 mL) was added 4-azetidin-3-ylmorpholine (525mg, 3.69 mmol), trimethyl orthoformate (3.67 mL, 33.58 mmol) and aceticacid (0.19 mL, 3.36 mmol). After stirring at room temperature for 2 hsodium triacetoxyborohydride (1.10 g, 5.03 mmol) was added and theresulting mixture stirred for a further 2 h. The reaction mixture wasloaded onto an Isolute® SCX-2 cartridge, washed with H₂O/MeOH theneluted with 2 M NH₃ in MeOH/DCM. The resulting residue was purified bycolumn chromatography (Si—PCC, MeOH:EtOAc, gradient 0:100 to 20:80) togive2-chloro-4-morpholin-4-yl-6-(3-morpholin-4-yl-azetidin-1-ylmethyl)thieno[3,2-c]pyrimidineas a pale yellow solid (856 mg, 62%). LCMS (Method C): R_(T)=2.77 min,[M+H]⁺ 410

A mixture of2-chloro-4-morpholin-4-yl-6-(3-morpholin-4-yl-azetidin-1-ylmethyl)thieno[3,2-c]pyrimidine(401 mg, 0.98 mmol), hexabutylditin (0.74 mL, 1.47 mmol), andPdCl₂{P^(t)Bu₂(Ph-p-Nme₂)}₂ (69 mg, 10 mol %) in dioxane (4 mL) waspurged with argon gas then heated at 150° C., for 25 min, in a microwavereactor. The reaction mixture was loaded onto a Isolute® SCX-2cartridge, washed with MeOH then eluted with 2 M NH₃ in MeOH. Theresulting residue was purified by column chromatography (Si—PCC,MeOH:EtOAc, gradient 0:100 to 20:80) to give4-morpholin-4-yl-6-(3-morpholin-4-yl-azetidin-1-ylmethyl)-2-(tributylstannanyl)thieno[3,2-d]pyrimidineas a colorless oil (405 mg, 62%). LCMS (Method C) R_(T) 3.87 min,[M+H]⁺664 (¹¹⁶Sn) 666 (¹¹⁸Sn).

A mixture ofN-[4-morpholin-4-yl-6-(3-morpholin-4-yl-azetidin-1-ylmethyl)thieno[3,2-c]pyrimidin-2-yl]benzene-1,2-diamine(100 mg, 0.21 mmol) and glacial acetic acid (0.5 mL) was heated at 120°C. for 3 h. The reaction mixture was cooled to ambient temperature andloaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was thenwashed with MeOH and the desired product was subsequently eluted using 2M NH₃ in MeOH. The product was collected and concentrated in vacuo. Theresultant residue was purified by flash chromatography (Si—PPC, DCM: 2 MNH₃ in MeOH 100:0 to 98:2 to 95:5) followed by reversed phase HPLC(Phenomenex Luna C-18, 20 mM Et₃N in water on a gradient of 20 mM Et₃Nin acetonitrile 95:5 to 2:98) to afford 172 as a white solid (45 mg,43%). LCMS (method A): R_(T)=5.65 min, M+H⁺=506.1. ¹H NMR (CDCl₃, 400MHz) δ 8.08-8.03 (m, 1H), 7.73-7.68 (m, 1H), 7.30-7.26 (m, 3H), 4.05 (t,J=4.8 Hz, 4H), 3.99 (s, 2H), 3.88 (t, J=4.8 Hz, 4H), 3.73 (m, 4H), 3.65(s, 2H), 3.18-2.99 (m, 3H), 2.93 (s, 3H), 2.34 (m, 4H)

Alternatively, a mixture of2-chloro-4-morpholin-4-yl-6-(3-morpholin-4-ylazetidin-1-ylmethyl)thieno[3,2-c]pyrimidine(100 mg, 0.24 mmol), 2-methylbenzimidazole (32 mg, 0.24 mmol),tris(dibenzylideneacetone)dipalladium (11 mg, 0.01 mmol), Xphos (12 mg,0.02 mmol) and Cs₂CO₃ (158 mg, 0.48 mmol) in DMF (2 mL) was purged withargon then heated at 145° C. for 30 min in a microwave reactor. Thereaction mixture was dissolved in EtOAc and washed with H₂O (×6) thenbrine (×2), then dried (Na₂SO₄) and concentrated in vacuo. The resultingresidue was purified by column chromatography (Si—PCC, MeOH:DCM, 0-5%).The resulting oil was triturated with a mixture of Et₂O and pentaneaffording 172 as a pale yellow solid (33 mg, 27%)

Example 1731-(4-morpholino-6-((3-morpholinoazetidin-1-yl)methyl)thieno[3,2-d]pyrimidin-2-yl)-1H-benzo[d]imidazol-2(3H)-one173

A degassed mixture of2-chloro-4-morpholin-4-yl-6-(3-morpholin-4-yl-azetidin-1-ylmethyl)thieno[3,2-c]pyrimidine(400 mg, 0.98 mmol), 1,2-diaminobenzene (240 mg, 2.22 mmol), Pd(Oac)₂(64 mg, 0.29 mmol), rac-BINAP (88 mg, 0.14 mmol) and Cs₂CO₃ (480 mg,1.47 mmol) in 1,4-dioxane (4 mL)) was subjected to microwave irradiationat 150° C. for 30 minutes. The reaction mixture was cooled to ambienttemperature and loaded onto an Isolute® SCX-2 cartridge (25 g). Thecartridge was then washed with MeOH and the desired product wassubsequently eluted using 2 M NH₃ in MeOH. The product was collected andconcentrated in vacuo. The resultant residue was purified by flashchromatography (Si—PPC, DCM: 2 M NH₃ in MeOH 100:0 to 98:2 to 96:4) toaffordN-[4-morpholin-4-yl-6-(3-morpholin-4-yl-azetidin-1-ylmethyl)thieno[3,2-c]pyrimidin-2-yl]benzene-1,2-diamineas a pale yellow oil (310 mg, 66%). LCMS (Method C): R_(T)=2.06 min,[M+H]⁺ 482.4

A mixture ofN-[4-morpholin-4-yl-6-(3-morpholin-4-yl-azetidin-1-ylmethyl)-thieno[3,2-d]pyrimidin-2-yl]benzene-1,2-diamine(50 mg, 0.10 mmol) and N,N′-carbonyldiimidazole (50 mg, 0.31 mmol) in1,4-dioxane (0.5 mL) was heated at 110° C. for 4 h. The reaction mixturewas cooled to ambient temperature and loaded onto an Isolute® SCX-2cartridge (10 g). The cartridge was then washed with MeOH and thedesired product was subsequently eluted using 2 M NH₃ in MeOH. Theproduct was collected and concentrated in vacuo. The resultant residuewas purified by flash chromatography (Si—PPC, DCM: 2 M NH₃ in MeOH 100:0to 98:2 to 96:4) to afford 173 as a tan solid (17 mg, 32%). LCMS (methodE): R_(T)=6.42 min, [M+H]⁺=508.1. ¹H NMR (CDCl₃, 400 MHz) δ 8.50 (bs,1H), 7.76-7.72 (m, 1H), 7.32 (s, 1H), 7.13-7.04 (m, 3H), 4.05 (t, J=4.7Hz, 4H), 3.97 (s, 2H), 3.86 (t, J=4.7 Hz, 4H), 3.73 (m, 4H), 3.62 (m,2H), 3.06 (s, 3H), 2.33 (m, 4H)

Example 1744-(1-((4-morpholino-2-(1H-pyrrolo[3,2-c]pyridin-4-yl)thieno[3,2-d]pyrimidin-6-yl)methyl)azetidin-3-yl)morpholine174

A mixture of4-morpholin-4-yl-6-(3-morpholin-4-yl-azetidin-1-ylmethyl)-2-(tributylstannanyl)thieno[3,2-c]pyrimidine(192 mg, 0.29 mmol), 1-benzenesulfonyl-4-bromo-1H-pyrrolo[3,2-c]pyridine(117 mg, 0.35 mmol), tetrakis(triphenylphosphine)palladium (34 mg, 10mol %) and copper(I)-thiophene-2-carboxylate (11 mg, 20 mol %) indioxane (2.0 mL) was purged with argon gas then heated at 150° C., for20 min, in a microwave reactor. The reaction mixture was loaded onto anIsolute® SCX-2 cartridge, washed with MeOH/DCM then eluted with 2 M NH₃in MeOH. The resulting residue was dissolved in IMS/dioxane (1:1 mL) and12.5 M aqueous NaOH solution (0.1 mL) added. After stirring for 1 h thereaction mixture was loaded onto an Isolute® SCX-2 cartridge, washedwith MeOH/DCM then eluted with 2 M NH₃ in MeOH/DCM. The resultingresidue was purified by column chromatography (Si—PCC, 2 M NH₃ inMeOH:DCM, gradient 0:100 to 10:90) followed by trituration from diethylether to give 174 (38 mg, 27%) as a pale yellow solid. LCMS R_(T) 4.52min, [M+H]⁺ 492. ¹H NMR (CDCl₃, 400 MHz) δ 8.53 (m, 1H), 7.45-7.35 (m,4H), 4.10 (t, J=4.7 Hz, 4H), 3.97 (s, 2H), 3.89 (t, J=4.7 Hz, 4H), 3.72(t, J=4.5 Hz, 4H), 3.69-3.54 (m, 2H), 3.08-3.01 (m, 3H), 2.33 (m, 4H).

Example 1762-methyl-2-(4-((2-(2-methyl-2H-indazol-3-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)propanamide176

To a degassed mixture of2-methyl-2-(4-((4-morpholino-2-(tributylstannyl)thieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)propanamide(270 mg, 0.389 mmol), 3-iodo-2-methyl-2H-indazole (95 mg, 0.368 mmol),copper(I) thiophene-2-carboxylate (70 mg, 0.368 mmol) in dioxane (2.3mL) was added Pd(PPh₃)₄ (21 mg, 0.018 mmol). The reaction mixture wasreacted in the CEM microwave at 140° C. for 30 min. The reaction mixturewas then loaded onto a Biotage Isolute SPE SCX-2 column. The column waswashed with MeOH and the desired product was then eluted with 2 M NH₃ inMeOH and further purified by RP-HPLC to give 176 (44 mg, 29%). LCMS:M+H⁺=535.2. ¹H-NMR (400 MHz, DMSO-d₆): δ 8.40 (d, 1H), 7.67 (d, 1H),7.47 (s, 1H), 7.31 (t, 1H), 7.19 (t, 1H), 7.06 (s, 1H), 6.93 (s, 1H),4.60 (s, 3H), 4.06 (m, 4H), 3.88 (s, 2H), 3.84 (m, 4H), 2.49-2.62 (m,8H), 1.08 (s, 6H)

Example 1771-(6-((4-(dimethylamino)piperidin-1-yl)methyl)-4-morpholinothieno[3,2-d]pyrimidin-2-yl)indolin-2-one177

A microwave vessel was charged with[1-(2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)-piperidin-4-yl]-dimethyl-amine(0.2 g) in dioxane (4 mL). The vessel was evacuated and back filled withargon. To this mixture was added 1,3-dihydro-indol-2-one (0.08 g), BINAP(0.015 g), cesium carbonate (0.2 g) and palladium acetate (0.009 g). Thevessel was evacuated and back filled with argon again, and the mixturewas irradiated with microwaves at 150° C. for 45 min. The reactionmixture was cooled to room temperature then filtered through HPLCfilter. The filtrate was concentrated and the residue obtained waspurified by chromatography (silica, 0 to 10% of a 49:1 MeOH:NH₄OHmixture in dichloromethane) to furnish 177 (0.022 g, 9%) as a lightbrown solid. MS m/e 493 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.44(br. s., 2H) 1.75 (d, J=11.12 Hz, 2H) 2.03-2.13 (m, 3H) 2.20 (s, 6H)2.95 (d, J=11.62 Hz, 2H) 3.71-3.83 (m, 6H) 3.85 (s, 2H) 3.89-3.98 (m,4H) 7.00-7.14 (m, 1H) 7.24 (d, J=4.04 Hz, 2H) 7.29-7.39 (m, 2H)

Example 1782-(1-((2-(2-(hydroxymethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol178

Following the procedures for synthesis of 157,2-(1-((2-(2-aminophenylamino)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-oland glycolic acid were reacted to give 178. LCMS: M+H⁺=521.3. ¹H-NMR(400 MHz, DMSO-d₆): δ 8.17 (d, 1H), 7.68 (d, 1H), 7.31 (m, 2H), 5.28 (t,1H), 5.08 (d, 2H), 4.27 (s, br, 4H), 4.02 (s, 1H), 3.82 (s, 3H), 3.78(m, 4H), 3.73 (s, 2H), 2.90 (d, 2H), 2.01 (m, 2H), 1.66 (d, 2H), 1.21(m, 3H), 1.02 (s, 6H).

Example 1794-(8-((4-(2-methoxypropan-2-yl)piperidin-1-yl)methyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine179

Step 1:N1-(8-((4-(2-methoxypropan-2-yl)piperidin-1-yl)methyl)-9-methyl-6-morpholino-9H-purin-2-yl)benzene-1,2-diamine

A mixture of4-(2-chloro-8-((4-(2-methoxypropan-2-yl)piperidin-1-yl)methyl)-9-methyl-9H-purin-6-yl)morpholine(1.21 g, 2.96 mmol), benzene-1,2-diamine (520 mg, 4.8 mmol), palladiumacetate (66 mg, 0.29 mmol), bist(tri-t-butylphosphine)palladium (150 mg,0.29 mmol) and sodium t-butoxide (620 mg, 6.4 mmol) in toluene (30 mL)was stirred at 95° C. for 18 hours. The reaction mixture was thenfiltered through paper and then concentrated. The crude product was thenpurified by flash chromatography using a Biotage KP—NH column (0-10%gradient MeOH in DCM) to giveN1-(8-((4-(2-methoxypropan-2-yl)piperidin-1-yl)methyl)-9-methyl-6-morpholino-9H-purin-2-yl)benzene-1,2-diamine(1.2 g, 84%). LCMS: M+H⁺=481.2.

Step 2: A mixture ofN1-(8-((4-(2-methoxypropan-2-yl)piperidin-1-yl)methyl)-9-methyl-6-morpholino-9H-purin-2-yl)benzene-1,2-diamine(177 mg, 0.368 mmol) in acetic acid (1.5 mL) was stirred at reflux for 5hours. The reaction mixture was then concentrated and then purifiedfirst by flash chromatography (10% MeOH in DCM containing 1% 2 M ammoniain MeOH), followed by RP-HPLC to give 179 (0.0373 g, 21.1%). LCMS:M+H⁺=519.1.

Alternatively, following General Procedure I, one-step Buchwaldcoupling, a microwave tube was charged with Xphos (0.1 equiv.),tris(dibenzylideneacetone)dipalladium(0) (0.05 equiv.), cesium carbonate(2 equiv.),4-(2-chloro-8-((4-(2-methoxypropan-2-yl)piperidin-1-yl)methyl)-9-methyl-9H-purin-6-yl)morpholine(80 mg, 1 equiv.) and 2-methyl-1H-benzo[d]imidazole (1.2 equiv.). Thevessel is evacuated and refilled with nitrogen prior to the addition ofDMF or 1,4-dioxane. The mixture is heated in a microwave device, such asBiotage at about 140° C. for about 25-35 minutes. The reaction mixtureis cooled to room temperature, filtered and concentrated, and purifiedby RP-HPLC to give 17.1 mg of 179. MS (Q1) 519.1 (M)+.

Example 1802-(4-((2-(1-amino-6-fluoroisoquinolin-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-methylpropanamide180

Following General Procedure A for Suzuki coupling,2-(4-((2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-methylpropanamideand6-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoquinolin-1-aminewere reacted to give 180. LCMS: M+H⁺=565.3

Example 181(3S,4R)-3-fluoro-N,N-dimethyl-1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-amine181

Following General Procedure I for Buchwald coupling,(3S,4R)-1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-3-fluoro-N,N-dimethylpiperidin-4-amineand 2-methyl-1H-benzo[d]imidazole were reacted to give 181. LCMS m/z:508.3 (MH+)

Example 1824-(5-(1H-indazol-3-yl)-2-((3-morpholinoazetidin-1-yl)methyl)thiazolo[5,4-d]pyrimidin-7-yl)morpholine182

A mixture of7-morpholin-4-yl-2-(3-morpholin-4-ylazetidin-1-ylmethyl)-5-(tributylstannanyl)thiazolo[5,4-c]pyrimidine(0.25 g, 0.37 mmol), 3-iodo-1H-indazole (0.2 g, 0.82 mmol), copper(I)2-thiophene carboxylate (0.030 g, 0.150 mmol) and Pd(PPh₃)₄ (0.088 g,0.075 mmol) in dioxane (3 mL) was subjected to microwave irradiation at150° C. for 90 min. The reaction mixture was loaded onto an Isolute®SCX-2 cartridge. The cartridge was washed with MeOH and the desiredproduct was eluted using 2 M NH₃ in MeOH. The eluent was concentrated invacuo and the residue was purified by flash chromatography (Si—PPC,MeOH:DCM, gradient 0:100 to 20:80) followed by reverse phase HPLC(Phenomenex Gemini 5u C18, 20 mM triethylamine in water on a gradient ofacetonitrile 95:5 to 2:98) to give 182 as an off-white solid (0.036 g,20%). LCMS (Method G): R_(T)=7.40 min, [M+H]⁺ 493.3. ¹H NMR (CDCl₃, 400MHz) δ 8.58 (d, J=8.2 Hz, 1H); 7.55 (t, J=8.2 Hz, 1H); 7.46-7.41 (m,1H); 7.34-7.29 (m, 1H); 4.48-4.33 (m, 4H); 4.02 (s, 2H); 3.92 (t, J=4.6Hz, 4H); 3.73 (t, J=4.6 Hz, 4H); 3.70-3.66 (m, 2H); 3.18-3.09 (m, 3H);2.40-2.35 (m, 4H)

Example 1831-(7-morpholino-2-((3-morpholinoazetidin-1-yl)methyl)thiazolo[5,4-d]pyrimidin-5-yl)-1H-benzo[d]imidazol-2(3H)-one183

A mixture ofN-[7-morpholin-4-yl-2-(3-morpholin-4-ylazetidin-1-ylmethyl)thiazolo[5,4-d]pyrimidin-5-yl]benzene-1,2-diamine(75 mg, 0.16 mmol) and 1,1′-carbonyldiimidazole (100 mg, 0.62 mmol) in1,4-dioxane (1 mL) was heated at 110° C. for 3 h. After cooling toambient temperature, the mixture was loaded onto an Isolute® SCX-2cartridge (10 g). The cartridge was then washed with methanol and thedesired product was subsequently eluted using 2 M NH₃ in MeOH. Theproduct was collected and concentrated in vacuo. The resultant residuewas purified by flash chromatography (Si—PPC, DCM: 2 M NH₃ in MeOH 100:0to 99:1 to 98:2) to afford 183 as a cream solid (45 mg, 57%). LCMS(Method G): R_(T)=6.72 min, M+H⁺=509. ¹H NMR (CDCl₃, 400 MHz) δ 8.71 (s,1H); 7.77 (m, 1H); 7.15-7.05 (m, 3H); 4.42 (m, 4H); 4.01 (s, 2H); 3.86(m, 4H); 3.71 (m, 6H); 3.15 (s, 3H) and 2.36 (m, 4H)

Example 1844-(5-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-2-((3-morpholinoazetidin-1-yl)methyl)thiazolo[5,4-d]pyrimidin-7-yl)morpholine184

A mixture ofN-[7-morpholin-4-yl-2-(3-morpholin-4-ylazetidin-1-ylmethyl)thiazolo[5,4-d]pyrimidin-5-yl]benzene-1,2-diamine(65 mg, 0.14 mmol) and ethyl difluoroacetate (0.3 mL, 2.8 mmol) in1,4-dioxane (0.5 mL) was heated at 100° C. for 3 days. The reactionmixture was cooled to ambient temperature and loaded onto an Isolute®SCX-2 cartridge (10 g). The cartridge was then washed with MeOH and thedesired product was subsequently eluted using 2 M NH₃ in MeOH. Theproduct was collected and concentrated in vacuo. The resultant residuewas purified by reversed phase HPLC (Phenomenex Luna C-18, 20 mM Et₃N inwater on a gradient of 20 mM Et₃N in acetonitrile 30:70 to 2:98) toafford 184 as a white solid (26 mg, 35%). LCMS (Method G): R_(T)=8.03min, M+H⁺=543. ¹H NMR (CDCl₃, 400 MHz) δ 8.29 (d, J=8.1 Hz, 1H); 7.91(d, J=7.8 Hz, 1H); 7.60 (t, J=53.8 Hz, 1H); 7.45-7.37 (m, 2H); 4.43 (m,4H); 4.02 (s, 2H); 3.89 (t, J=4.7 Hz, 4H); 3.74 (t, J=4.5 Hz, 4H); 3.69(t, J=6.2 Hz, 2H); 3.21-3.07 (m, 3H) and 2.37 (m, 4H)

Example 1852-(4-((2-(1-amino-7-fluoroisoquinolin-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-methylpropanamide185

Following General Procedure A for Suzuki coupling,2-(4-((2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-methylpropanamideand7-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoquinolin-1-aminewere reacted to give 185. LCMS: M+H⁺=565.3

Example 1862-(1-((9-methyl-6-morpholino-2-(2-(trifluoromethyl)-1H-benzo[d]imidazol-1-yl)-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol186

Following the procedures for 157,2-(1-((2-(2-aminophenylamino)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-oland trifluoroacetic acid were reacted to give 186. LCMS m/z: 559.3 (MH+)

Example 1872-isobutyl-4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)morpholine187

Following the procedures for 157, where in Step 1,4-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-2-isobutylmorpholinewas used to prepare 187. LCMS m/z: 505.3 (MH+)

Example 1882-(1-((2-(2-(dimethylamino)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol188

Following General Procedure I for Buchwald coupling,2-(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-oland N,N-dimethyl-1H-benzo[d]imidazol-2-amine were reacted to give 188.LCMS m/z: 534.3 (MH+)

Example 1892-(1-((2-(2-ethyl-2H-indazol-3-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol189

Following the procedures for 165,2-[1-(9-methyl-6-morpholin-4-yl-2-(tributylstannanyl)-9H-purin-8-ylmethyl)piperidin-4-yl]propan-2-oland 2-ethyl-3-iodo-2H-indazole were reacted to give 189. LCMS m/z: 519.3(MH+)

Example 1902-(4-((2-(2-ethyl-2H-indazol-3-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-methylpropanamide190

Following the procedures for 143,2-[4-(4-morpholin-4-yl-2-(tributylstannanyl)thieno[3,2-d]pyrimidin-6-ylmethyl)piperazin-1-yl]isobutyramideand 2-ethyl-3-iodo-2H-indazole were reacted to give 190. LCMS m/z: 549.3(MH+)

Example 1912,2-diethyl-4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)morpholine191

Following the procedures for 157 and General Procedure J,4-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-2,2-diethylmorpholineand benzene-1,2-diamine were reacted, followed by condensation withacetic acid to give 191. LCMS m/z: 505.3 (MH+)

Example 1922-methyl-2-(4-((2-(2-methyl-1H-benzo[d]imidazol-1-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)propanamide192

2-(4-((2-Chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-methylpropanamide(0.15 g) was reacted with 2-methylbenzimidazole via General Procedure Ifor Buchwald coupling to give 29.3 mg 192 following reverse phasepurification. MS (Q1) 535.2 (M)+.

Example 1934-(5-(2-methyl-1H-benzo[d]imidazol-1-yl)-2-((3-morpholinoazetidin-1-yl)methyl)thiazolo[5,4-d]pyrimidin-7-yl)morpholine193

4-(5-(2-Methyl-1H-benzo[d]imidazol-1-yl)-2-((3-morpholinoazetidin-1-yl)methyl)thiazolo[5,4-d]pyrimidin-7-yl)morpholine(75 mg) was reacted with 2-methylbenzimidazole via General Procedure Ifor Buchwald coupling to give 16.4 mg 193 following reverse phasepurification. MS (Q1) 507.2 (M)+

Example 1942,6-dimethyl-4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)morpholine194

Following the procedures for 157 and General Procedure J, where in Step1,4-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-2,6-dimethylmorpholineand benzene-1,2-diamine were reacted, followed by condensation withacetic acid to give 194. LCMS m/z: 477.2 (MH+)

Example 1952-(1-((2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol195

Following General Procedure I for Buchwald coupling,2-isopropylbenzimidazole and2-(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-olwere reacted to give 195. LCMS m/z: 533.3 (MH+). ¹H-NMR (DMSO-d₆): 7.89(m, 1H), 7.64 (m, 1H), 7.24 (m, 2H), 4.25 (s, br, 4H), 4.00 (s, 1H),3.92 (m, 1H), 3.81 (s, 3H), 3.77 (t, 4H), 3.73 (s, 2H), 2.91 (d, 2H),2.00 (t, 2H), 1.67 (t, 2H), 1.35 (d, 6H), 1.22 (m, 3H), 1.02 (s, 6H).

Example 1962,2-dimethyl-4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)morpholine196

Following the procedures for 157 and General Procedure J,4-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-2,2-dimethylmorpholineand benzene-1,2-diamine were reacted, followed by condensation withacetic acid to give 196. LCMS m/z: 477.2 (MH+)

Example 1972-(1-((2-(2-(1,1-difluoroethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol197

Following the procedures for 157 and General Procedure J,2-(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol(1.21 g, 2.96 mmol) and benzene-1,2-diamine were reacted followed bycondensation with 2,2-difluoropropionic acid to give 197. LCMS m/z:555.3 (MH+)

Example 198I-2-(1-((2-(2-(1-hydroxyethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol198

Following the procedures for 157 and General Procedure J,2-(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol(1.21 g, 2.96 mmol) and benzene-1,2-diamine were reacted followed bycondensation with lactic acid to give a racemic mixture. The enantiomerswere separated by SFC to give 198. LCMS m/z: 535.3 (MH+)

Example 199(S)-2-(1-((2-(2-(1-hydroxyethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol199

Following the procedures for 157 and General Procedure J,2-(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol(1.21 g, 2.96 mmol) and benzene-1,2-diamine were reacted followed bycondensation with lactic acid to give a racemic mixture. The enantiomerswere separated by SFC to give 199. LCMS m/z: 535.3 (MH+)

Example 2012-methyl-2-(4-((2-(8-methylimidazo[1,2-a]pyridin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)propanamide201

A mixture of2-[4-(4-morpholin-4-yl-2-(tributylstannanyl)-thieno[3,2-d]pyrimidin-6-ylmethyl)piperazin-1-yl]isobutyramide(205 mg, 0.30 mmol), 5-bromo-8-methylimidazo[1,2-a]pyridine (75 mg, 0.35mmol), Pd(PPh₃)₄ (34 mg, 0.03 mmol) and copper(I)thiophene-2-carboxylate (11 mg, 0.06 mmol) in dioxane (3 mL) was purgedwith argon gas then heated at 150° C., for 20 min, in a microwavereactor. The reaction mixture was loaded onto an Isolute® SCX-2cartridge (10 g). The cartridge was washed with MeOH then the desiredproduct was eluted with 2 M NH₃ in MeOH. The resulting residue waspurified by flash chromatography (Si—PPC, MeOH:DCM, gradient 0:100 to10:90) to give a solid that was triturated in MeOH, filtered and driedat 60° C. under vacuum for 24 hours to give 201 as a white solid (97 mg,62%). LCMS (Method G) R_(T) 5.11 min; [M+H]⁺ 535. ¹H NMR (400 MHz,CHCl₃-d): δ 9.29 (s, 1H); 7.93 (d, J=7.3 Hz, 1H); 7.75 (s, 1H); 7.37 (s,1H); 7.15 (d, J=7.3 Hz, 1H); 7.13-6.96 (m, 1H); 5.21 (s, 1H); 4.06 (t,J=4.7 Hz, 4H); 3.91 (t, J=4.7 Hz, 4H); 3.86 (s, 2H); 2.73 (s, 3H); 2.62(s, 8H); 1.25 (s, 6H)

Example 2022-(4-((2-(imidazo[1,5-a]pyridin-8-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-methylpropanamide202

A mixture of2-[4-(4-morpholin-4-yl-2-(tributylstannanyl)thieno[3,2-d]pyrimidin-6-ylmethyl)piperazin-1-yl]isobutyramide(132 mg, 0.19 mmol), 8-bromoimidazo[1,5-a]pyridine (45 mg, 0.23 mmol),Pd(PPh₃)₄ (22 mg, 0.02 mmol) and copper(I) thiophene-2-carboxylate (7mg, 0.04 mmol) in dioxane (2 mL) was purged with argon gas then heatedat 150° C., for 20 min, in a microwave reactor. The reaction mixture wasloaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was washedwith MeOH then the desired product eluted with 2 M NH₃ in MeOH. Theresulting residue was purified by flash chromatography (Si—PPC,MeOH:DCM, gradient 0:100 to 10:90) to give 202 as a yellow solid (72 mg,73%). LCMS (Method G): R_(T) 5.12 min; [M+H]⁺ 521. ¹H NMR (400 MHz,CHCl₃-d): δ 8.33 (s, 1H); 8.21 (s, 1H); 8.04 (d, J=6.9 Hz, 1H); 7.93 (d,J=6.9 Hz, 1H); 7.36 (s, 1H); 7.07 (m, 1H); 6.74-6.69 (m, 1H); 5.19 (s,1H); 4.07 (t, J=4.7 Hz, 4H); 3.96-3.86 (m, 4H); 3.88-3.83 (m, 2H); 2.61(s, 8H); 1.25 (s, 6H)

Example 2032-methyl-N-((2-(2-methyl-1H-benzo[d]imidazol-1-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)-2-morpholinopropan-1-amine203

Following the procedures for 172,2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidine-6-carbaldehyde and2-methyl-2-morpholinopropan-1-amine were reacted by reductive aminationto giveN-((2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)-2-methyl-2-morpholinopropan-1-amine,which was converted to the 2-tributylstannyl intermediate and reactedwith 2-methyl-1H-benzo[d]imidazole to give 203. LCMS m/z: 522.2 (MH+)

Example 2044-(6-((3,4-dihydroisoquinolin-2(1H)-yl)methyl)-2-(2-methyl-1H-benzo[d]imidazol-1-yl)thieno[3,2-d]pyrimidin-4-yl)morpholine204

Following General Procedure J for Multi-Step Benzimidazole Formation byBuchwald coupling,4-(2-chloro-6-((3,4-dihydroisoquinolin-2(1H)-yl)methyl)thieno[3,2-d]pyrimidin-4-yl)morpholineand 1,2-diaminobenzene were reacted to giveN1-(6-((3,4-dihydroisoquinolin-2(1H)-yl)methyl)-4-morpholinothieno[3,2-d]pyrimidin-2-yl)benzene-1,2-diaminewhich was cyclized with acetic acid to give 204. LCMS m/z: 497.6 (MH+)

Example 2052-(1-((2-(2-(benzyl(methyl)amino)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol205

Following General Procedure I for Buchwald coupling,2-(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-oland 2-(benzylmethylamino)benzimidazole were reacted to give 205. LCMSm/z: 610.4 (MH+)

Example 2062-(1-((9-methyl-2-(2-(methylamino)-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol206

A mixture of2-(1-((2-(2-(benzyl(methyl)amino)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol205 (0.2 g, 0.33 mmol) and palladium on carbon (10 wt %, 0.1 g) andacetic acid (0.1 mL) in ethanol (10 mL) was stirred under a hydrogenatmosphere at 60 degrees for 18 hours. The reaction mixture was thenfiltered though celite and concentrated. The crude product was purifiedby RP-HPLC to give 206 (28.5 mg, 17%). LCMS m/z: 520.3 (MH+)

Example 2072-(1-((9-methyl-6-morpholino-2-(2-phenyl-1H-benzo[d]imidazol-1-yl)-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol207

Following General Procedure I for Buchwald coupling,2-(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-oland 2-phenylbenzimidazole were reacted to give 207. LCMS m/z: 567.3(MH+)

Example 2081-(3-(6-((4-(dimethylamino)piperidin-1-yl)methyl)-4-morpholinothieno[3,2-d]pyrimidin-2-yl)benzo[b]thiophen-2-yl)ethanone208

Following General Procedure G for Stille coupling,N,N-dimethyl-1-((4-morpholino-2-(tributylstannyl)thieno[3,2-d]pyrimidin-6-yl)methyl)piperidin-4-amineand 1-(3-bromobenzo[b]thiophen-2-yl)ethanone were reacted to give 208.LCMS m/z: 536.7 (MH+)

Example 2092-(1-((5-(1H-indazol-3-yl)-7-morpholinothiazolo[5,4-d]pyrimidin-2-yl)methyl)piperidin-4-yl)propan-2-ol209

A mixture of2-(1-((7-morpholino-5-(tributylstannyl)thiazolo[5,4-d]pyrimidin-2-yl)methyl)piperidin-4-yl)propan-2-ol(0.211 g, 0.32 mmol), 3-iodo-1H-indazole (0.116 g, 0.48 mmol), copper(I)2-thiophene carboxylate (0.012 g, 0.064 mmol) and Pd(PPh₃)₄ (0.037 g,0.032 mmol) in dioxane (3 mL)was subjected to microwave irradiation at150° C. for 90 min. The reaction mixture was loaded onto an Isolute®SCX-2 cartridge. The cartridge was washed with MeOH and the desiredproduct was eluted using 2 M NH₃ in MeOH. The eluent was concentrated invacuo and the resultant residue was purified by flash chromatography(Si—PPC, MeOH:DCM, gradient 0:100 to 10:90) to give 209 as a yellowsolid (0.043 g, 28%). LCMS (Method G): R_(T)=7.71 min, [M+H]⁺ 494.3. ¹HNMR (400 MHz, DMSO-d₆): δ 13.45 (s, 1H); 8.48 (d, J=8.3 Hz, 1H); 7.61(d, J=8.3 Hz, 1H); 7.41 (t, J=7.6 Hz, 1H); 7.26 (t, J=7.6 Hz, 1H); 4.37(m, 4H); 3.88 (s, 2H); 3.82 (t, J=4.6 Hz, 4H); 3.02 (d, J=11.0 Hz, 2H);2.12 (t, J=11.0 Hz, 2H); 1.74-1.69 (m, 2H); 1.36-1.28 (m, 2H); 1.26-1.23(m, 2H); 1.06 (s, 6H)

Example 2102-(1-((5-(2-methylbenzofuran-3-yl)-7-morpholinothiazolo[5,4-d]pyrimidin-2-yl)methyl)piperidin-4-yl)propan-2-ol210

A mixture of2-[1-(5-chloro-7-morpholin-4-ylthiazolo[5,4-d]pyrimidin-2-ylmethyl)-piperidin-4-yl]propan-2-ol(50 mg, 0.12 mmol),2-methyl-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)benzofuran (47mg, 0.18 mmol), tetrakis(triphenylphosphine) palladium (14 mg, 0.01mmol) and Cs₂CO₃ (80 mg, 0.24 mmol) in dioxane (3 mL) and H₂O (1.5 mL)was purged with argon then heated at 140° C. for 30 min in a microwavereactor. The reaction mixture was loaded onto an Isolute® SCX-2cartridge which was washed with DCM/MeOH and the product eluted with 2MNH₃/MeOH. The resulting residue was purified by column chromatography(Si—PCC, EtOAc:cyclohexane, 0-90%) to afford 210 as a white solid (29mg, 48%). LCMS (Method G): R_(T) 10.16 min, [M+H]⁺ 508.4. ¹H NMR (CDCl₃,400 MHz): δ 8.40-8.37 (m, 1H); 7.45-7.40 (m, 1H); 7.32-7.24 (m, 2H);4.40 (m, 4H); 3.94-3.84 (m, 6H); 3.11 (m, 2H); 2.92 (s, 3H); 2.21 (m,2H); 1.78 (m, 2H); 1.48 (m, 2H) and 1.21 (m, 7H)

Example 2112-methyl-2-(4-((5-(2-methylbenzofuran-3-yl)-7-morpholinothiazolo[5,4-d]pyrimidin-2-yl)methyl)piperazin-1-yl)propanamide211

A mixture of1-amino-2-[4-(5-chloro-7-morpholin-4-ylthiazolo[5,4-d]pyrimidin-2-ylmethyl)piperazin-1-yl]-2-methylpropan-1-ol(100 mg, 0.23 mmol),2-methyl-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)benzofuran (88mg, 0.34 mmol), tetrakis(triphenylphosphine) palladium (26 mg, 0.02mmol) and Cs₂CO₃ (148 mg, 0.45 mmol) in dioxane (6 mL) and H₂O (3 mL)was purged with argon then heated at 140° C. for 30 min in a microwavereactor. The reaction mixture was loaded onto an Isolute® SCX-2cartridge which was washed with DCM/MeOH and the product eluted with 2MNH₃/MeOH. The resulting residue was purified by column chromatography(Si—PCC, EtOAc:cyclohexane, 50-100%) to afford 211 as a cream solid (75mg, 61%). LCMS (Method G): R_(T) 10.35 min, [M+H]⁺ 536.4. ¹H NMR (CDCl₃,400 MHz): δ 8.40-8.37 (m, 1H); 7.46-7.42 (m, 1H); 7.32-7.23 (m, 2H);7.10 (d, J=5.3 Hz, 1H); 5.22 (d, J=5.3 Hz, 1H); 4.40 (m, 4H); 3.93-3.87(m, 6H); 2.92 (s, 3H); 2.69 (m, 4H); 2.62 (m, 4H) and 1.26 (s, 6H)

Example 2124-(5-(2-methylbenzofuran-3-yl)-2-((3-morpholinoazetidin-1-yl)methyl)thiazolo[5,4-d]pyrimidin-7-yl)morpholine212

A mixture of5-chloro-7-morpholin-4-yl-2-(3-morpholin-4-ylazetidin-1-ylmethyl)thiazolo[5,4-c]pyrimidine(100 mg, 0.24 mmol),2-methyl-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)benzofuran (94mg, 0.37 mmol), tetrakis(triphenylphosphine)palladium (28 mg, 0.02 mmol)and Cs₂CO₃ (159 mg, 0.48 mmol) in dioxane (6 mL) and H₂O (3 mL) waspurged with argon then heated at 140° C. for 30 min in a microwavereactor. The reaction mixture was loaded onto an Isolute® SCX-2cartridge which was washed with DCM/MeOH and the product eluted with 2MNH₃/MeOH. The resulting residue was purified by column chromatography(Si—PCC, MeOH:EtOAc, 0-5%) to afford 212 as a cream solid (58 mg, 48%).LCMS (Method G): R_(T) 9.83 min, [M+H]⁺ 507.3. ¹H NMR (CDCl₃, 400 MHz):δ 8.39-8.36 (m, 1H); 7.45-7.42 (m, 1H); 7.32-7.24 (m, 2H); 4.40 (m, 4H);4.01 (s, 2H); 3.89 (m, 4H); 3.70 (m, 6H); 3.18-3.08 (m, 3H); 2.92 (s,3H) and 2.36 (m, 4H)

Example 2134-(1-((2-(2-methylbenzofuran-3-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)azetidin-3-yl)morpholine213

A mixture of2-chloro-4-morpholin-4-yl-6-(3-morpholin-4-ylazetidin-1-ylmethyl)thieno[3,2-c]pyrimidine(100 mg, 0.24 mmol),2-methyl-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)benzofuran (94mg, 0.36 mmol), tetrakis(triphenylphosphine)palladium (28 mg, 0.02 mmol)and Cs₂CO₃ (160 mg, 0.48 mmol) in dioxane (6 mL) and H₂O (3 mL) waspurged with argon then heated at 140° C. for 30 min in a microwavereactor. The reaction mixture was loaded onto an Isolute® SCX-2cartridge, washed with DCM/MeOH then eluted with 2M NH₃/MeOH. Theresulting residue was purified by column chromatography (Si—PCC,MeOH:DCM, 0-5%) to afford 213 as a white foam (98 mg, 81%). LCMS (MethodG): R_(T) 9.09 min, [M+H]⁺ 506.3. ¹H NMR (CDCl₃, 400 MHz): δ 8.42-8.39(m, 1H); 7.46-7.42 (m, 1H); 7.32-7.24 (m, 3H); 4.02 (t, J=4.7 Hz, 4H);3.97 (s, 2H); 3.89 (t, J=4.7 Hz, 4H); 3.73 (m, 4H); 3.63 (s, 2H); 3.06(m, 3H); 2.93 (s, 3H) and 2.33 (m, 4H)

Example 2142-(4-((2-(6-fluoroimidazo[1,2-a]pyridin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-methylpropanamide214

A mixture of2-[4-(4-morpholin-4-yl-2-(tributylstannanyl)thieno[3,2-d]pyrimidin-6-ylmethyl)piperazin-1-yl]isobutyramide(69 mg, 0.10 mmol), 5-bromo-6-fluoro-imidazo[1,2-a]pyridine (25 mg, 0.12mmol), Pd(PPh₃)₄ (12 mg, 0.01 mmol) and copper(I)thiophene-2-carboxylate (4 mg, 0.02 mmol) in dioxane (1 mL) was purgedwith argon gas then heated at 150° C., for 20 min, in a microwavereactor. The reaction mixture was loaded onto an Isolute® SCX-2cartridge (10 g), washed with MeOH then eluted with 2 M NH₃ in MeOH. Theresulting residue was purified by flash chromatography (Si—PPC,MeOH:DCM, gradient 0:100 to 10:90) followed by reverse phase HPLC(Phenomenex Gemini 5u C18, 20 mM triethylamine in water on a gradient ofacetonitrile 95:5 to 2:98) to give 214 as a white solid (20 mg, 37%).LCMS (Method G) R_(T) 4.52 min; [M+H]⁺ 539. ¹H NMR (400 MHz, CHCl₃-d):8.20 (s, 1H); 7.71-7.62 (m, 2H); 7.35 (s, 1H); 7.25-7.16 (t, J=9.5 Hz,1H); 7.18-6.91 (m, 1H); 5.22 (s, 1H); 4.05 (t, J=4.7 Hz, 4H); 3.87 (t+m,J=4.7 Hz, 6H); 2.62 (s, 8H); 1.25 (s, 6H)

Example 2152-(4-((2-(1H-indazol-3-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-methylpropanamide215

Following General Procedure G for Stille coupling,2-methyl-2-(4-((4-morpholino-2-(tributylstannyl)thieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)propanamideand 3-bromo-1H-indazole were reacted to give 215. LCMS m/z: 521.6 (MH+)

Example 216N,N-dimethyl-1-((4-morpholino-2-(1H-pyrrolo[2,3-c]pyridin-3-yl)thieno[3,2-d]pyrimidin-6-yl)methyl)piperidin-4-amine216

Following General Procedure G for Stille coupling,N,N-dimethyl-1-((4-morpholino-2-(tributylstannyl)thieno[3,2-d]pyrimidin-6-yl)methyl)piperidin-4-amineand 3-bromo-1H-pyrrolo[2,3-c]pyridine were reacted to give 216. LCMSm/z: 478.6 (MH+)

Example 2174-(6-((4-(dimethylamino)piperidin-1-yl)methyl)-4-morpholinothieno[3,2-d]pyrimidin-2-yl)isoquinolin-1(2H)-one217

Following General Procedure G for Stille coupling,N,N-dimethyl-1-((4-morpholino-2-(tributylstannyl)thieno[3,2-d]pyrimidin-6-yl)methyl)piperidin-4-amineand 4-bromoisoquinolin-1(2H)-one were reacted to give 217. LCMS m/z:505.7 (MH+)

Example 2182-(1-((2-(2-(2-hydroxyethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol218

Following General Procedure I for Buchwald coupling,2-(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-oland 2-(1H-benzo[d]imidazol-2-yl)ethanol were reacted to give 218. LCMSm/z: 535.3 (MH+)

Example 2192-(1-((9-methyl-6-morpholino-2-(2-(pyridin-3-yl)-1H-benzo[d]imidazol-1-yl)-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol219

Following General Procedure I for Buchwald coupling,2-(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-oland 2-(pyridin-3-yl)-1H-benzo[d]imidazole were reacted to give 219. LCMSm/z: 568.3 (MH+)

Example 2201-(8-((4-(2-hydroxypropan-2-yl)piperidin-1-yl)methyl)-9-methyl-6-morpholino-9H-purin-2-yl)-2-methyl-1H-indazol-3(2H)-one220

Following General Procedure I for Buchwald coupling,2-(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-oland 2-methyl-1,2-dihydroindazol-3-one were reacted to give 220. LCMSm/z: 521.3 (MH+)

Example 2214-(6-((6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-2-(2-methyl-1H-benzo[d]imidazol-1-yl)thieno[3,2-d]pyrimidin-4-yl)morpholine221

Following General Procedure L for reductive amination,2-(2-methyl-1H-benzo[d]imidazol-1-yl)-4-morpholinothieno[3,2-d]pyrimidine-6-carbaldehydeand 6-fluoro-1,2,3,4-tetrahydroisoquinoline were reacted to give 221.LCMS m/z: 515.6 (MH+)

Example 2222-(1-((2-(imidazo[1,5-a]pyridin-8-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol222

A mixture of2-[1-(9-methyl-6-morpholin-4-yl-2-(tributylstannanyl)-9H-purin-8-ylmethyl)piperidin-4-yl]propan-2-ol(135 mg, 0.20 mmol), 8-bromoimidazo[1,5-a]pyridine (44 mg, 0.22 mmol),Pd(PPh₃)₄ (24 mg, 10 mol %) and copper(I)-thiophene-2-carboxylate (8 mg,20 mol %) in dioxane (2 mL) was purged with argon gas then heated at150° C., for 20 min, in a microwave reactor. The reaction mixture wasloaded onto an Isolute® SCX-2 cartridge, washed with MeOH then thedesired product eluted with 2 M NH₃ in MeOH. The resulting residue waspurified by column chromatography (Si—PCC, 0-10% MeOH in DCM) to give222 as a yellow solid (58 mg, 58%). LCMS (Method G): R_(T)=4.86 min,[M+H]⁺ 491.4. ¹H NMR (400 MHz, CHCl₃-d): δ 8.42 (s, 1H), 8.19 (s, 1H),8.02 (d, J=6.9 Hz, 1H), 7.95 (dd, J=6.9, 0.9 Hz, 1H), 6.74-6.67 (m, 1H),4.38 (m, 4H), 3.96 (s, 3H), 3.91-3.87 (m, 4H), 3.80-3.66 (m, 2H), 2.97(d, J=11.0 Hz, 2H), 2.22-1.99 (m, 2H), 1.75 (d, J=11.0 Hz, 2H),1.44-1.26 (m, 4H), 1.20-1.17 (s, 6H)

Example 2232-(1-((5-(2-methyl-1H-benzo[d]imidazol-1-yl)-7-morpholinothiazolo[5,4-d]pyrimidin-2-yl)methyl)piperidin-4-yl)propan-2-ol223

A 5-20 mL microwave vial equipped with a magnetic follower was chargedwith Pd₂(dba)₃ (28 mg, 0.03 mmol), Xphos (58 mg, 0.12 mmol),2-[1-(5-chloro-7-morpholin-4-ylthiazolo[5,4-d]pyrimidin-2-ylmethyl)piperidin-4-yl]propan-2-ol(500 mg, 1.21 mmol), 2-methyl-1H-benzoimidazole (176 mg, 1.33 mmol),cesium carbonate (593 mg, 1.82 mmol) and dioxane (5 mL). The reactionmixture was degassed for 5 min and irradiated at 150° C. for 30 min. Thereaction mixture was diluted with MeOH and loaded onto an Isolute® SCX-2cartridge (25 g). The cartridge was washed with MeOH and the desiredproduct was eluted with 2M NH₃ in MeOH. The solvents were removed andthe residue was subjected to flash chromatography (Si—PCC, 0-10% (2M NH₃in MeOH) in EtOAc) to give 223 as a red oil (290 mg, 47%). LCMS: (MethodG): R_(T) 6.76 min; [M+H]⁺ 508.4. ¹H NMR (400 MHz, CHCl₃-d): δ 8.10-8.05(m, 1H); 7.73-7.69 (m, 1H); 7.32-7.26 (m, 2H); 4.42 (m 4H); 3.88 (t,J=4.6 Hz, 7H); 3.11 (d, J=10.7 Hz, 2H); 2.95 (s, 3H); 2.31-2.19 (m, 2H);1.79 (d, J=12.7 Hz, 2H); 1.50 (m, 2H); 1.34 (m, 1H); 1.22 (s, 6H)

Example 2242-(1-((9-methyl-6-morpholino-2-(2-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-1-yl)-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol224

Following General Procedure I for Buchwald coupling,2-(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-oland 2-(tetrahydrofuran-2-yl)-1H-benzimidazole were reacted to give 224.LCMS m/z: 561.3 (MH+)

Example 2252-(1-((2-(3-fluoroquinolin-4-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol225

Following the procedure for 165,2-[1-(9-methyl-6-morpholin-4-yl-2-(tributylstannanyl)-9H-purin-8-ylmethyl)piperidin-4-yl]propan-2-oland 3-fluoro-4-iodoquinoline were reacted to give 225. LCMS m/z: 520.2(MH+)

Example 226(3R,4S)-1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-3-fluoro-N,N-dimethylpiperidin-4-amine226

Following General Procedure I for Buchwald coupling, racemic1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-3-fluoro-N,N-dimethylpiperidin-4-amineand 2-ethylbenzimidazole were reacted. The enantiomers were separated bySFC to give 226. LCMS m/z: 522.3 (MH+)

Example 227(3S,4R)-1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-3-fluoro-N,N-dimethylpiperidin-4-amine227

Following General Procedure I for Buchwald coupling, racemic1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-3-fluoro-N,N-dimethylpiperidin-4-amineand 2-ethylbenzimidazole were reacted. The enantiomers were separated bySFC to give 227. LCMS m/z: 522.3 (MH+)

Example 228N,N-dimethyl-1-((2-(3-methylisoquinolin-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperidin-4-amine228

Following General Procedure G for Stille coupling,N,N-dimethyl-1-((4-morpholino-2-(tributylstannyl)thieno[3,2-d]pyrimidin-6-yl)methyl)piperidin-4-amineand 4-bromo-3-methylisoquinoline were reacted to give 228. LCMS m/z:503.7 (MH+)

Example 229N,N-dimethyl-1-((2-(2-methylbenzo[b]thiophen-3-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperidin-4-amine229

Following General Procedure G for Stille coupling,N,N-dimethyl-1-((4-morpholino-2-(tributylstannyl)thieno[3,2-d]pyrimidin-6-yl)methyl)piperidin-4-amineand 3-bromo-2-methylbenzo[b]thiophene were reacted to give 229. LCMSm/z: 508.7 (MH+)

Example 2302-methyl-2-(4-((7-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)propanamide230

Following General Procedure I for Buchwald coupling,2-(4-((2-chloro-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-methylpropanamideand 2-methyl-1H-benzo[d]imidazole were reacted to give 230. LCMS:M+H⁺=549.3

Example 2312-(1-((7-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperidin-4-yl)propan-2-ol231

2-(4-((2-chloro-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-methylpropanamidewas reduced to give2-(1-((2-chloro-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperidin-4-yl)propan-2-olwhich was reacted with 2-methyl-1H-benzo[d]imidazole following GeneralProcedure I for Buchwald coupling to give 231. LCMS: M+H⁺=521.3

Example 2324-(1-((7-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperidin-4-yl)morpholine232

Following General Procedure I for Buchwald coupling,4-(1-((2-chloro-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperidin-4-yl)morpholineand 2-methyl-1H-benzo[d]imidazole were reacted to give 232. LCMS:M+H⁺=548.3

Example 2332-(1-((9-methyl-6-morpholino-2-(2-propyl-1H-benzo[d]imidazol-1-yl)-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol233

Following General Procedure I for Buchwald coupling,2-(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-oland 2-propylbenzimidazole were reacted to give 233. LCMS m/z: 533.3(MH+)

Example 2342-(4-((2-(3-methoxy-1H-indazol-1-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-methylpropanamide234

2-(4-((2-Chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-methylpropanamide(0.1 g) was reacted with 3-methoxy-1H-indazole via General Procedure Ifor Buchwald coupling give 16.4 mg 234 following reverse phasepurification. MS (Q1) 507.2 (M)+

Example 2352-(1-((2-(3-methoxy-1H-indazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol235

2-(1-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol(0.2 g) was reacted with 3-methoxy-1H-indazole via General Procedure Ifor Buchwald coupling to give 119.5 mg 235 following reverse phasepurification. MS (Q1) 521.3 (M)+

Example 2362-(1-((9-ethyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol236

A solution of 2-chloro-9-ethyl-6-morpholino-9H-purine-8-carbaldehyde(2.4 g) in MeOH (200 mL) at 0° C. was treated portion wise with sodiumborohydride (0.84 g). The reaction was warmed to room temperature andstirred 15 minutes. The reaction mixture was quenched with saturatedsolution of sodium bicarbonate. The aqueous layer was extracted twicewith ethyl acetate. The combined organic layers were dried overmagnesium sulfate and concentrated in vacuo to yield crude(2-chloro-9-ethyl-6-morpholino-9H-purin-8-yl)methanol (2.3 g) as a whitesolid.

(2-chloro-9-ethyl-6-morpholino-9H-purin-8-yl)methanol (2.3 g) wasreacted with 2-methylbenzimidazole via General Procedure I for Buchwaldcoupling. The crude product(9-ethyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methanol(3 g) was obtained after concentration of the reaction mixture andfiltration after addition of water.

To a solution of(9-ethyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methanol(3 g, 7.65 mmol) in tetrahydrofuran (150 mL, 1800 mmol) was addedphosphorus tribromide (1.44 mL, 15.3 mmol;) dropwise. The mixture wasstirred for 2 hrs until LC/MS showed the reaction was complete. Thereaction was quenched with MeOH and extracted with Ethyl acetate andwater. The organic layer was collected, dried with Magnesium sulfate,filtered and concentrated to give a crude orange oil. The oil waspurified by flash chromatography to give 2.6 g of4-(8-(bromomethyl)-9-ethyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholineas an orange solid, of which 50 mg was reacted with2-(piperidin-4-yl)propan-2-ol via Gen Procedure E to give 34.6 mg 236following reverse phase purification. MS (Q1) 519.3 (M)+

Example 2372-(1-((2-(2-cyclobutyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol237

Following General Procedure I for Buchwald coupling,2-(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-oland 2-cyclobutylbenzimidazole were reacted to give 237. LCMS m/z: 545.3(MH+)

Example 2382-(1-((9-methyl-6-morpholino-2-(2-morpholino-1H-benzo[d]imidazol-1-yl)-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol238

Following General Procedure I for Buchwald coupling,2-(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-oland 4-(1H-benzo[d]imidazol-2-yl)morpholine were reacted to give 238.LCMS m/z: 576.4 (MH+)

Example 2402-methyl-2-(4-((2-(2-methyl-1H-benzo[d]imidazol-1-yl)-4-morpholinofuro[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)propanamide240

A mixture of2-[4-(2-chloro-4-morpholin-4-ylfuro[3,2-d]pyrimidin-6-ylmethyl)piperazin-1-yl]isobutyramide(500 mg, 1.18 mmol), 2-methyl-1H-benzoimidazole (180 mg, 1.36 mmol),Pd₂dba₃ (27 mg, 0.029 mmol), Xphos (57 mg, 0.12 mmol) and cesiumcarbonate (580 mg, 1.78 mmol) in 1,4-dioxane (10 mL) was heated at 110°C. for 18 h. The reaction mixture was cooled to ambient temperature,then loaded onto an Isolute® SCX-2 cartridge, which was washed withMeOH/DCM before the desired product was eluted with 2 M NH₃ in MeOH/DCM.The product was collected and concentrated in vacuo. The resultantresidue was purified by flash chromatography (Si—PPC, EtOAc:MeOH;gradient from 100:0 to 70:30) followed by trituration from hot EtOAc toafford 240 as a white solid (408 mg, 67%). LCMS (Method G): R_(T)=5.23min, M+H⁺=519. ¹H NMR (CDCl₃, 400 MHz) δ 8.03-7.98 (m, 1H); 7.73-7.69(m, 1H); 7.28-7.23 (m, 2H); 7.05 (bs, 1H); 6.76 (s, 1H); 5.27 (bs, 1H);4.08 (t, J=4.7 Hz, 4H); 3.89 (t, J=4.7 Hz, 4H); 3.76 (s, 2H); 2.90 (s,3H); 2.62 (m, 8H) and 1.24 (s, 6H)

Example 2412-(1-((2-(2-methyl-1H-benzo[d]imidazol-1-yl)-4-morpholinofuro[3,2-d]pyrimidin-6-yl)methyl)piperidin-4-yl)propan-2-ol241

A mixture of2-[1-(2-chloro-4-morpholin-4-ylfuro[3,2-d]pyrimidin-6-ylmethyl)piperidin-4-yl]propan-2-ol(110 mg, 0.28 mmol), 2-methyl-1H-benzoimidazole (42 mg, 0.32 mmol),Pd₂dba₃ (14 mg, 0.015 mmol), Xphos (15 mg, 0.031 mmol) and cesiumcarbonate (203 mg, 0.62 mmol) in DMF (2.5 mL) was purged with argon gasthen subjected to microwave irradiation at 145° C. for 30 min. Thereaction mixture was loaded onto an Isolute® SCX-2 cartridge, which waswashed with MeOH/DCM before the desired product was eluted with 2 M NH₃in MeOH/DCM. The product was collected and concentrated in vacuo. Theresultant residue was purified by flash chromatography (Si—PPC, DCM:MeOH100:0 to 97:3 to 95:5 to 90:10) to afford 241 as a tan solid (55 mg,40%). LCMS (Method G): R_(T)=5.19 min, M+H⁺=491. ¹H NMR (CDCl₃, 400 MHz)δ 7.99 (m, 1H); 7.71 (m, 1H); 7.25 (m, 2H); 6.77 (s, 1H); 4.09 (t, J=4.7Hz, 4H); 3.89 (t, J=4.7 Hz, 4H); 3.77 (s, 2H); 3.11 (m, 2H); 2.90 (s,3H); 2.16 (m, 2H); 1.80 (m, 2H); 1.49 (m, 2H); 1.33-1.22 (m, 2H) and1.20 (s, 6H)

Example 2422-(2-methyl-1H-benzo[d]imidazol-1-yl)-4-morpholino-6-((3-morpholinoazetidin-1-yl)methyl)furo[3,2-d]pyrimidine242

A mixture of2-chloro-4-morpholin-4-yl-6-(3-morpholin-4-ylazetidin-1-ylmethyl)furo[3,2-c]pyrimidine(100 mg, 0.25 mmol), 2-methyl-1H-benzoimidazole (38 mg, 0.29 mmol),Pd₂dba₃ (12 mg, 0.013 mmol), Xphos (13 mg, 0.027 mmol) and cesiumcarbonate (184 mg, 0.56 mmol) in DMF (2.2 mL) was purged with argon gasthen subjected to microwave irradiation at 145° C. for 30 min. Thereaction mixture was loaded onto an Isolute® SCX-2 cartridge (10 g),which was washed with MeOH/DCM before the desired product was elutedwith 2 M NH₃ in MeOH/DCM. The product was collected and concentrated invacuo. The resultant residue was purified by flash chromatography(Si—PPC, DCM:MeOH 100:0 to 97:3 to 95:5 to 90:10) to afford 242 as a tansolid (37 mg, 30%). LCMS (Method G): R_(T)=4.85 min, M+H⁺ =490. ¹H NMR(CDCl₃, 400 MHz) δ 7.99 (m, 1H); 7.70 (m, 1H); 7.26 (m, 2H); 6.72 (s,1H); 4.07 (t, J=4.7 Hz, 4H); 3.90-3.79 (m, 6H); 3.75 (m, 4H); 3.64 (m,2H); 3.17 (m, 1H); 3.11 (m, 1H); 2.89 (s, 3H) and 2.37 (m, 5H)

Example 2442-(1-((5-(8-methylimidazo[1,2-a]pyridin-5-yl)-7-morpholinothiazolo[5,4-d]pyrimidin-2-yl)methyl)piperidin-4-yl)propan-2-ol244

A mixture of2-[1-(7-morpholin-4-yl-5-(tributylstannanyl)thiazolo[5,4-d]pyrimidin-2-ylmethyl)piperidin-4-yl]propan-2-ol(118 mg, 0.18 mmol), 5-bromo-8-methylimidazo[1,2-a]pyridine (45 mg, 0.21mmol), Pd(PPh₃)₄ (20 mg, 0.02 mmol) and copper(I)thiophene-2-carboxylate (7 mg, 0.035 mmol) in dioxane (2 mL) was purgedwith argon gas then heated at 150° C., for 20 min, in a microwavereactor. The reaction mixture was loaded onto an Isolute® SCX-2cartridge (10 g). The cartridge was washed with MeOH then the desiredproduct was eluted with 2 M NH₃ in MeOH. The resulting residue waspurified by flash chromatography (Si—PPC, MeOH:DCM, gradient 0:100 to10:90) to give 244 as an off-white solid (80 mg, 89%). LCMS (Method G)R_(T) 5.09 min; [M+H]⁺ 508. ¹H NMR (400 MHz, CHCl₃-d): δ 9.22 (s, 1H);7.93 (d, J=7.4 Hz, 1H); 7.75 (d, J=1.3 Hz, 1H); 7.14 (d, J=7.4 Hz, 1H);4.43 (m, 4H); 3.90 (m, 4H); 3.87 (s, 2H); 3.10 (d, J=11.5 Hz, 2H); 2.73(s, 3H); 2.23 (t, J=11.5 Hz, 2H); 1.78 (m, 2H); 1.55-1.41 (m, 2H); 1.35(m, 2H); 1.22 (s, 6H)

Example 2462-(3-(6-((4-(dimethylamino)piperidin-1-yl)methyl)-4-morpholinothieno[3,2-d]pyrimidin-2-yl)benzo[b]thiophen-2-yl)propan-2-ol246

To1-(3-(6-((4-(dimethylamino)piperidin-1-yl)methyl)-4-morpholinothieno[3,2-d]pyrimidin-2-yl)benzo[b]thiophen-2-yl)ethanone208 (64 mg, 0.119 mmol) in anhydrous THF (3 mL) was added dropwise withstirring a solution of methylmagnesium bromide 3M in ethyl ether (0.12mL, 0.358 mmol) and mixture stirred at room temperature for 90 min. Asaturated solution of NaHCO3 (5 mL) was added and product extracted withCH2Cl2 (3×15 mL). Organics combined were dried (MgSO4) and concentrated.Flash chromatography with CH2Cl2:Methanol:Ammonium hydroxide (100:5:0.5)afforded 15 mg (21.4%) of 246. [M+H]⁺ 552

Example 2472-(1-((9-isopropyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol247

2-(1-((2-Chloro-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol(0.1 g) was reacted with isopropyl iodide via General Procedure C togive2-(1-((2-chloro-9-isopropyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-olwhich was subsequently reacted with 2-methylbenzimidazole via GeneralProcedure I for Buchwald coupling to give 43.3 g 247 following reversephase purification. MS (Q1) 533.3 (M)+

Example 2492-(1-((2-(imidazo[1,2-a]pyridin-5-yl)-4-morpholinofuro[3,2-d]pyrimidin-6-yl)methyl)piperidin-4-yl)propan-2-ol249

A mixture of2-[1-(4-morpholin-4-yl-2-tributylstannanylfuro[3,2-d]pyrimidin-6-ylmethyl)piperidin-4-yl]propan-2-ol(147 mg, 0.23 mmol), 5-bromoimidazo[1,2-a]pyridine (46 mg, 0.23 mmol),tetrakis(triphenylphosphine)palladium (22 mg, 8 mol %) and CuTC (9 mg,20 mol %) in 1,4-dioxane (2.5 mL) was purged with argon gas thensubjected to microwave irradiation at 140° C. for 30 min. The reactionmixture was loaded onto an Isolute® SCX-2 cartridge (10 g), which waswashed with MeOH/DCM before the desired product was eluted with 2 M NH₃in MeOH/DCM. The product was collected and concentrated in vacuo. Theresultant residue was purified by flash chromatography (Si—PPC,DCM:NH₃/MeOH (2 M); gradient from 100:0 to 96:4)), followed by reversephase HPLC (Phenomenex Gemini 5u C18, 20 mM triethylamine in water on agradient of acetonitrile 95:5 to 2:98) to afford 249 as a white foam (46mg, 42%). LCMS (Method G): R_(T)=3.47 min, M+H⁺=477. ¹H NMR (CDCl₃, 400MHz) 9.14 (s, 1H); δ 7.87 (dd, J=8.5, 1.19 Hz, 2H); 7.76 (d, J=8.9 Hz,1H); 7.73 (d, J=1.3 Hz, 1H); 7.30 (m, 1H); 6.79 (s, 1H); 4.11 (t, J=4.7Hz, 4H); 3.90 (t, J=4.7 Hz, 4H); 3.75 (s, 2H); 3.08 (d, J=11.0 Hz, 2H);2.12 (t, J=11.0 Hz, 2H); 1.78 (m, 2H); 1.52-1.38 (m, 3H); 1.31 (m, 1H)and 1.19 (s, 6H)

Example 2502-(imidazo[1,2-a]pyridin-5-yl)-4-morpholino-6-((3-morpholinoazetidin-1-yl)methyl)furo[3,2-d]pyrimidine250

A mixture of4-morpholin-4-yl-6-(3-morpholin-4-yl-azetidin-1-ylmethyl)-2-tributylstannanylfuro[3,2-c]pyrimidine(227 mg, 0.35 mmol), 5-bromoimidazo[1,2-a]pyridine (84 mg, 0.43 mmol),tetrakis(triphenylphosphine)palladium (40 mg, 10 mol %) and CuTC (16 mg,24 mol %) in 1,4-dioxane (4 mL) was purged with argon gas then subjectedto microwave irradiation at 140° C. for 30 min. The reaction mixture wasloaded onto an Isolute® SCX-2 cartridge (10 g); the cartridge was washedwith MeOH/DCM before the desired product was eluted with 2 M NH₃ inMeOH/DCM. The product was collected and concentrated in vacuo. Theresultant residue was purified by flash chromatography (Si—PPC,DCM:NH₃/MeOH (2 M); gradient from 100:0 to 96:4)), followed by reversephase HPLC (Phenomenex Gemini 5u C18, 20 mM triethylamine in water on agradient of acetonitrile 95:5 to 2:98) to afford 250 as a cream foam (79mg, 47%). LCMS (Method G): R_(T)=3.22 min, M+H⁺=476. ¹H NMR (CDCl₃, 400MHz) δ 9.14 (s, 1H); 7.87 (dd, J=7.2, 1.2 Hz, 1H); 7.77 (d, J=8.9 Hz,1H); 7.74 (d, J=1.2 Hz, 1H); 7.31 (dd, J=8.9, 7.2 Hz, 1H); 6.76 (s, 1H);4.10 (t, J=4.7 Hz, 4H); 3.89 (t, J=4.7 Hz, 4H); 3.84 (s, 2H); 3.74 (t,J=4.5 Hz, 4H); 3.62 (t, J=6.2 Hz, 2H); 3.15-3.02 (m, 3H) and 2.35 (m,4H)

Example 2522-ethyl-1-(8-((4-(2-hydroxypropan-2-yl)piperidin-1-yl)methyl)-9-methyl-6-morpholino-9H-purin-2-yl)-1H-indazol-3(2H)-one252

Following General Procedure I for Buchwald coupling,2-(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-oland 2-ethyl-1,2-dihydroindazol-3-one were reacted to give 252. LCMS m/z:535.3 (MH+)

Example 253(S)-2-(1-((9-methyl-6-morpholino-2-(2-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-1-yl)-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol253

Following General Procedure I for Buchwald coupling,2-(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-oland racemic 2-(tetrahydrofuran-2-yl)-1H-benzimidazole were reacted togive a racemic mixture. The enantiomers were separated by SFC to give253. LCMS m/z: 561.3 (MH+)

Example 254I-2-(1-((9-methyl-6-morpholino-2-(2-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-1-yl)-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol254

Following General Procedure I for Buchwald coupling,2-(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-oland racemic 2-(tetrahydrofuran-2-yl)-1H-benzimidazole were reacted togive a racemic mixture. The enantiomers were separated by SFC to give254. LCMS m/z: 561.3 (MH+)

Example 2552-(1-((2-(2-(ethylamino)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol255

A mixture of2-(1-((2-(2-(benzyl(ethyl)amino)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol(0.6 mmol) and palladium on carbon (10 wt %, 0.3 g) and acetic acid (0.1mL) in ethanol (20 mL) was stirred under a hydrogen atmosphere at 65° C.for 18 hours. The reaction mixture was then filtered though celite andconcentrated. The crude product was purified by RP-HPLC to give 255(28.5 mg, 17%). LCMS m/z: 534.3 (MH+)

Example 2564-(5-(2-methyl-1H-benzo[d]imidazol-1-yl)-2-((3-morpholinoazetidin-1-yl)methyl)thiazolo[4,5-d]pyrimidin-7-yl)morpholine256

A mixture of5-chloro-7-morpholin-4-yl-2-(3-morpholin-4-yl-azetidin-1-ylmethyl)thiazolo[4,5-d]pyrimidine(50 mg, 0.12 mmol), 2-methyl-1H-benzoimidazole (18 mg, 0.13 mmol),Pd₂(dba)₃ (5.5 mg, 0.006 mmol), XPhos (5.7 mg, 0.02 mmol) and cesiumcarbonate (78 mg, 0.24 mmol) in 1,4-dioxane (1.5 mL) was purged withargon gas for 15 min. The resulting reaction mixture was irradiated withmicrowaves at 145° C. for 30 min. The crude residue was loaded on anIsolute® SCX-2 cartridge (5 g). The cartridge was washed with DCM/MeOHand the desired product was subsequently eluted using a mixture of 2MNH₃ in MeOH and DCM. The resulting residue was further purified bycolumn chromatography (Si—PCC, 2 M NH₃ in MeOH:DCM: gradient 0:100 to4:96). The solvents were reduced in vacuo to afford 256 as a brown solid(43 mg, 70%). LCMS (Method G): R_(T) 5.52 min, [M+H]⁺ 507. ¹H NMR (400MHz, CDCl₃): δ 8.22-8.21 (1H, m), 7.71-7.70 (1H, m), 7.30-7.27 (2H, m),4.18 (2H, s), 4.03 (4H, t, J=4.80 Hz), 3.89 (4H, t, J=4.80 Hz),3.76-3.72 (6H, m), 3.27 (2H, m), 3.15 (1H, m), 3.00 (3H, s), 2.37 (4H,br s)

Example 2573-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)oxetan-3-ol257

Following General Procedure I for Buchwald coupling,2-methylbenzimidazole and3-(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)oxetan-3-olwere reacted to give 257. LCMS m/z: 519.3 (MH+)

Example 2582,2-dimethyl-N-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)propan-1-amine258

Following General Procedure L for reductive amination,9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purine-8-carbaldehydeand 2,2-dimethylpropan-1-amine were reacted to give 258. [M+H]⁺ 449.6.

Example 2591-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)-N-((3-methyloxetan-3-yl)methyl)methanamine259

Following General Procedure L for reductive amination,9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purine-8-carbaldehydeand (3-methyloxetan-3-yl)methanamine were reacted to give 259. [M+H]⁺463.6.

Example 2601-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)cyclobutanol260

Following General Procedure I for Buchwald coupling,2-methylbenzimidazole and1-(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)cyclobutanolwere reacted to give 260. LCMS m/z: 517.3 (MH+)

Example 2612-(1-((9-methyl-6-morpholino-2-(2-(pyrrolidin-1-yl)-1H-benzo[d]imidazol-1-yl)-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol261

Following General Procedure I for Buchwald coupling,2-(pyrrolidin-1-yl)-1H-benzo[d]imidazole and2-(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-olwere reacted to give 261. LCMS m/z: 560.3 (MH+)

Example 2622-(1-((2-(2-(3-fluorooxetan-3-yl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol262

Following General Procedure I for Buchwald coupling,2-(3-fluorooxetan-3-yl)-1H-benzimidazole and2-(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-olwere reacted to give 262. LCMS m/z: 565.3 (MH+)

Example 2633-(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)oxetan-3-ol263

Following General Procedure I for Buchwald coupling,2-ethylbenzimidazole and3-(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)oxetan-3-olwere reacted to give 263. LCMS m/z: 533.3 (MH+)

Example 2642-methyl-2-(4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)propan-1-ol264

Following General Procedure I for Buchwald coupling,2-(4-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)-2-methylpropan-1-oland 2-methyl-1H-benzo[d]imidazole were reacted to give 264. LCMS m/z:520.3 (MH+)

Example 2652-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-3-yl)propan-2-ol265

Following General Procedure E of amine alkylation,4-(8-(bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholineand 2-(piperidin-3-yl)propan-2-ol were reacted to give 265. M+H⁺=505.3

Example 2662-methyl-1-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol266

Following General Procedure E of amine alkylation,4-(8-(bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholineand 2-methyl-1-(piperidin-4-yl)propan-2-ol were reacted to give 266.LCMS: M+H⁺=519.4

Example 2674-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-8-((4-(2,2,2-trifluoroethyl)piperazin-1-yl)methyl)-9H-purin-6-yl)morpholine267

Following General Procedure E of amine alkylation,4-(8-(bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholineand 1-(2,2,2-trifluoroethyl)piperazine were reacted to give 267. LCMS:M+H⁺=530.2

Example 268(4-methyl-1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)methanol268

Following General Procedure E of amine alkylation,4-(8-(bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholineand (4-methylpiperidin-4-yl)methanol were reacted to give 268. LCMS:M+H⁺=491.3

Example 269I-2-hydroxy-1-(4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)propan-1-one269

A mixture of tert-butyl piperazine-1-carboxylate (0.367 g), L-(+)-lacticacid (0.213 g), and HBTU (0.822 g) was stirred at rt overnight. Dilutedwith DCM, the mixture was washed with water (2×), brine, and dried(Na₂SO₄). Filtration and concentration gave 1-tert-butyl4-(2-hydroxypropanoyl)piperazine-1-carboxylate as viscous oil, which wastreated with trifluoroacetic acid in dichloromethane. Afterconcentration, the residue was reacted with4-(8-(bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholinein the presence of diisopropylethylamine (10 eq) following GeneralProcedure E of amine alkylation to give 269. LCMS: M+H⁺=520.3

Example 270adamantan-1-yl-[9-methyl-2-(2-methyl-benzoimidazol-1-yl)-6-morpholin-4-yl-9H-purin-8-ylmethyl]-amine270

(2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl)methanol (4.0 g) wasreacted with 2-Methylbenzimidazole (1.96 g) via General Procedure I forBuchwald coupling. The solids were filtered from the reaction mixturewhile still warm. Water was added to the filtered reaction mixture (5times the volume of DMF) to precipitate the product out of the reactionmixture. The precipitated orange solid was filtered and dried undervacuum for quantitative yield of(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methanol.

To crude(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methanol(6 g) in anhydrous THF (400 mL) was added phosphorus tribromide (2.7mL). The reaction was monitored by LC/MS until complete. Theheterogeneous reaction mixture was passed thru a Buchner funnel and thesolid was collected and rinsed with thrice with water and twice withMeOH to get 2 g of crude4-(8-(bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholineof which 50 mg was reacted with bicyclo[2.2.2]octan-1-amine (1-adamantylamine) via General Procedure E to give 5.7 mg of 270 following reversephase purification. MS (Q1) 513.3 (M)+

Example 271N-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)-2,3-dihydro-1H-inden-1-amine271

4-(8-(Bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine(25 mg) was reacted with 2,3-dihydro-1H-inden-1-amine via GeneralProcedure E to give 10.6 mg of 271 following reverse phase purification.MS (Q1) 495.2 (M)+

Example 272(4R)—N-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)bicyclo[2.2.1]heptan-2-amine272

4-(8-(Bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine(50 mg) was reacted with (1R,4S)-bicyclo[2.2.1]heptan-2-amine viaGeneral Procedure E to give 16 mg of 272 following reverse phasepurification. MS (Q1) 473.3 (M)+

Example 2731-(((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methylamino)methyl)cyclohexanol273

4-(8-(Bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine(50 mg) was reacted with 1-(aminomethyl)cyclohexanol via GeneralProcedure E to give 22 mg of 273 following reverse phase purification.MS (Q1) 491.3 (M)+

Example 274(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methylamino)cyclopentyl)methanol274

4-(8-(Bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine(50 mg) was reacted with (1-aminocyclopentyl)methanol via GeneralProcedure E to give 10.2 mg of 274 following reverse phase purification.MS (Q1) 477.2 (M)+

Example 275N,1-dimethyl-N-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-amine275

4-(8-(Bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine(50 mg) was reacted with N,1-dimethylpiperidin-4-amine via GeneralProcedure E to give 5.2 mg of 275 following reverse phase purification.MS (Q1) 490.3 (M)+

Example 2764-(8-(isoindolin-2-ylmethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine276

4-(8-(Bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine(50 mg) was reacted with isoindoline via General Procedure E to give10.7 mg of 276 following reverse phase purification. MS (Q1) 481.2 (M)+

Example 2774-(8-((4-(cyclopropylmethyl)piperazin-1-yl)methyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine277

4-(8-(bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine(50 mg) was reacted with 1-(cyclopropylmethyl)piperazine via GeneralProcedure E to give 23.5 mg of 277 following reverse phase purification.MS (Q1) 502.3 (M)+

Example 2784-(8-((4,4-difluoropiperidin-1-yl)methyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine278

4-(8-(bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine(50 mg) was reacted with 4,4-difluoropiperidine via General Procedure Eto give 19.3 mg of 278 following reverse phase purification. MS (Q1)483.2 (M)+

Example 279N-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)-1-phenylethanamine279

4-(8-(bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine(50 mg) was reacted with 1-phenylethanamine via General Procedure E togive 10.8 mg of 279 following reverse phase purification. MS (Q1) 483.2(M)+

Example 2804-(8-((4-(methoxymethyl)piperidin-1-yl)methyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine280

4-(8-(bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine(50 mg) was reacted with 4-(methoxymethyl)piperidine via GeneralProcedure E to give 21.9 mg of 280 following reverse phase purification.MS (Q1) 491.3 (M)+

Example 2814-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methylamino)cyclohexanol281

4-(8-(bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine(50 mg) was reacted with 4-aminocyclohexanol via General Procedure E togive 11.1 mg of 281 following reverse phase purification. MS (Q1) 477.2(M)+

Example 2821-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)-N-((1-methylpiperidin-2-yl)methyl)methanamine282

4-(8-(bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine(50 mg) was reacted with (1-methylpiperidin-2-yl)methanamine via GeneralProcedure E to give 4.1 mg of 282 following reverse phase purification.MS (Q1) 490.2 (M)+

Example 2834-(8-((dihydro-1H-pyrido[1,2-a]pyrazin-2(6H,7H,8H,9H,9aH)-yl)methyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine283

4-(8-(Bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine(50 mg) was reacted with octahydro-1H-pyrido[1,2-a]pyrazine via GeneralProcedure E to give 24 mg of 284 following reverse phase purification.MS (Q1) 502.3 (M)+

Example 2841-methyl-N-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-amine284

4-(8-(Bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine(50 mg) was reacted with 1-methylpiperidin-4-amine via General ProcedureE to give 4.6 mg of 284 following reverse phase purification. MS (Q1)476.3 (M)+

Example 285N,2-dimethyl-N-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)propan-1-amine285

4-(8-(Bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine(50 mg) was reacted with N,2-dimethylpropan-1-amine via GeneralProcedure E to give 10.1 mg of 285 following reverse phase purification.MS (Q1) 449.2 (M)+

Example 2861-(4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methylamino)piperidin-1-yl)ethanone286

4-(8-(Bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine(50 mg) was reacted with 1-(4-aminopiperidin-1-yl)ethanone via GeneralProcedure E to give 19.6 mg of 286 following reverse phase purification.MS (Q1) 504.3 (M)+

Example 2874-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)pyrrolidin-3-yl)morpholine287

4-(8-(Bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine(50 mg) was reacted with 4-(pyrrolidin-3-yl)morpholine via GeneralProcedure E to give 26.9 mg of 287 following reverse phase purification.MS (Q1) 518.2 (M)+

Example 288N-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)tetrahydro-2H-pyran-4-amine288

4-(8-(Bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine(50 mg) was reacted with tetrahydro-2H-pyran-4-amine via GeneralProcedure E to give 8.6 mg of 288 following reverse phase purification.MS (Q1) 463.2 (M)+

Example 2894-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-8-((3-(trifluoromethyl)pyrrolidin-1-yl)methyl)-9H-purin-6-yl)morpholine289

4-(8-(Bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine(50 mg) was reacted with 3-(trifluoromethyl)pyrrolidine via GeneralProcedure E to give 19.9 mg of 289 following reverse phase purification.MS (Q1) 501.2 (M)+

Example 290N-methyl-1-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)-N-((tetrahydrofuran-2-yl)methyl)methanamine290

4-(8-(Bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine(50 mg) was reacted with N-methyl-1-(tetrahydrofuran-2-yl)methanaminevia General Procedure E to give 10.7 mg of 290 following reverse phasepurification. MS (Q1) 477.2 (M)+

Example 2911-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidine-4-carbonitrile291

4-(8-(Bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine(50 mg) was reacted with piperidine-4-carbonitrile via General ProcedureE to give 21.9 mg of 291 following reverse phase purification. MS (Q1)472.2 (M)+

Example 2922-methyl-1-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methylamino)propan-2-ol292

4-(8-(Bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine(50 mg) was reacted with 1-amino-2-methylpropan-2-ol via GeneralProcedure E to give 8.1 mg of 292 following reverse phase purification.MS (Q1) 451.2 (M)+

Example 2933,3,3-trifluoro-N-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)propan-1-amine293

4-(8-(Bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine(50 mg) was reacted with 3,3,3-trifluoropropan-1-amine via GeneralProcedure E to give 8 mg of 293 following reverse phase purification. MS(Q1) 475.2 (M)+

Example 2944,4-difluoro-N-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)cyclohexanamine294

4-(8-(Bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine(50 mg) was reacted with 4,4-difluorocyclohexanamine via GeneralProcedure E to give 15.4 mg of 294 following reverse phase purification.MS (Q1) 497.2 (M)+

Example 2951-isopropyl-N-methyl-N-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-amine295

4-(8-(Bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine(50 mg) was reacted with 1-isopropyl-N-methylpiperidin-4-amine viaGeneral Procedure E to give 22.1 mg of 295 following reverse phasepurification. MS (Q1) 518.3 (M)+

Example 296N,N-diethyl-1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)pyrrolidin-3-amine296

4-(8-(Bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine(50 mg) was reacted with N,N-diethylpyrrolidin-3-amine via GeneralProcedure E to give 27.8 mg of 296 following reverse phase purification.MS (Q1) 504.3 (M)+

Example 2971-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)-N-((tetrahydrofuran-3-yl)methyl)methanamine297

4-(8-(Bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine(50 mg) was reacted with (tetrahydrofuran-3-yl)methanamine via GeneralProcedure E to give 6.9 mg of 297 following reverse phase purification.MS (Q1) 463.2 (M)+

Example 298N-methyl-N-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)pyrrolidin-3-yl)acetamide298

4-(8-(Bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine(50 mg) was reacted with N-methyl-N-(pyrrolidin-3-yl)acetamide viaGeneral Procedure E to give 25.5 mg of 298 following reverse phasepurification. MS (Q1) 504.2 (M)+

Example 2991-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)pyrrolidin-3-yl)methanol299

4-(8-(Bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine(50 mg) was reacted with 1-pyrrolidin-3-ylmethanol via General ProcedureE to give 19.1 mg of 299 following reverse phase purification. MS (Q1)463.2 (M)+

Example 3004-(8-((3,3-dimethylpyrrolidin-1-yl)methyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine300

4-(8-(Bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine(50 mg) was reacted with 3,3-dimethylpyrrolidine via General Procedure Eto give 16.8 mg of 300 following reverse phase purification. MS (Q1)461.2 (M)+

Example 3014-(8-((3,3-diethylpyrrolidin-1-yl)methyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine301

4-(8-(Bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine(50 mg) was reacted with 3,3-diethylpyrrolidine via General Procedure Eto give 26.5 mg of 301 following reverse phase purification. MS (Q1)4892 (M)+

Example 3024-(8-((3-isobutylpyrrolidin-1-yl)methyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine302

4-(8-(Bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine(50 mg) was reacted with 3-isobutylpyrrolidine via General Procedure Eto give 27 mg of 302 following reverse phase purification. MS (Q1) 489.2(M)+

Example 303N-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)-2-phenylpropan-2-amine303

4-(8-(Bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine(50 mg) was reacted with 2-phenylpropan-2-amine via General Procedure Eto give 7.4 mg of 303 following reverse phase purification. MS (Q1)497.2 (M)+

Example 3044-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-8-((1,1-dioxo-4-(tetrahydro-2H-thiopyran-4-yl)piperazin-1-yl)methyl)-9H-purin-6-yl)morpholine304

4-(8-(Bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine(50 mg) was reacted with amine via General Procedure E to give 1 mg of304 following reverse phase purification. MS (Q1) 580.3 (M)+

Example 305(S)-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)pyrrolidin-3-yl)methanol305

4-(8-(Bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine(50 mg) was reacted with (S)-pyrrolidin-3-ylmethanol via GeneralProcedure E to give 18.8 mg of 305 following reverse phase purification.MS (Q1) 463.2 (M)+

Example 3061-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-N,N-dimethylpiperidin-4-amine306

According to General Procedure I for Buchwald coupling, into a vial wasadded1-((2-chloro-9-methyl-6-morpholino-8,9-dihydro-7H-purin-8-yl)methyl)-N,N-dimethylpiperidin-4-amine(0.044 g, 0.11 mmol), 2-ethyl-1H-benzo[d]imidazole (0.0171 g, 0.117mmol), Xphos (0.00692 g, 0.0145 mmol),Tris(dibenzylideneacetone)dipalladium(0) (0.00696 g, 7.60E-6 mol), andCesium Carbonate (0.0728 g, 0.223 mmol). The mixture was dissolved inN,N-Dimethylformamide (0.865 mL, 0.0112 mol). The reaction was heated at145° C. under pressure for 30 minutes in a microwave reactor. Thereaction mixture was filtered and concentrated. The crude was purifiedby reverse phase HPLC to give 306 (26.7 mg, 47%). [M+H]⁺=536.3.

Example 3072-(1-((2-(2-(1-fluorocyclopropyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol307

Following General Procedure I for Buchwald coupling,2-(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-oland 2-(1-fluorocyclopropyl)-1H-benzimidazole were reacted to give 307.LCMS m/z: 549.3 (MH+)

Example 3082-(1-((2-(2-(cyclopropylmethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol308

Following General Procedure I for Buchwald coupling,2-(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-oland 2-(cyclopropylmethyl)-benzimidazole were reacted to give 308. LCMSm/z: 545.3 (MH+)

Example 3094-(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)morpholine309

To a solution of8-chloromethyl-2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine(107 mg, 0.26 mmol) and 4-azetidin-3-ylmorpholine (44 mg, 0.31 mmol) inDMF (3 mL) was added K₂CO₃ (106 mg, 0.77 mmol). The resulting mixturewas allowed to stir at room temperature for 16 h. The reaction mixturewas dissolved in EtOAc, washed with H₂O (×4) then dried (Na₂SO₄) andconcentrated in vacuo. The resulting residue was purified by columnchromatography (Si—PCC, MeOH:DCM, 0-5%). The resulting residue wasfurther purified by Isolute® SCX-2 cartridge which was washed withMeOH/DCM and the product eluted with 2M NH₃/MeOH, followed by reversephase HPLC (Phenomenex Luna C₁₈, 20 mM Et₃N in water on a gradient of 20mM Et₃N in acetonitrile 95:5 to 2:98) to afford 309 as a white solid (14mg, 11%). LCMS (Method G): R_(T) 5.74 min, [M+H]⁺ 518.3. ¹H NMR (CDCl₃,400 MHz): δ 8.02-7.98 (m, 1H); 7.77-7.73 (m, 1H); 7.27-7.23 (m, 2H);4.35 (m, 4H); 3.89-3.82 (m, 6H); 3.83 (s, 3H); 3.72 (m, 4H); 3.56 (m,2H); 3.34 (q, J=7.5 Hz, 2H); 3.15-3.03 (m, 3H); 2.34 (m, 4H) and 1.44(t, J=7.5 Hz, 3H)

Example 3104-(8-((3,3-dimethyl-4-(2-(methylsulfonyl)ethyl)piperazin-1-yl)methyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine310

To a solution of8-chloromethyl-2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine(107 mg, 0.26 mmol) and1-(2-methanesulfonylethyl)-2,2-dimethylpiperazine (68 mg, 0.31 mmol) inDMF (3 mL) was added K₂CO₃ (106 mg, 0.77 mmol). The resulting mixturewas allowed to stir at room temperature for 16 h. The reaction mixturewas dissolved in EtOAc, washed with H₂O (×4) then dried (Na₂SO₄) andconcentrated in vacuo. The residue was purified by column chromatography(Si—PCC, MeOH:EtOAc, 0-20%) and (Si—PCC, MeOH:DCM 0-5%). The resultingresidue was further purified by reverse phase HPLC (Phenomenex Luna C₁₈,20 mM Et₃N in water on a gradient of 20 mM Et₃N in acetonitrile 95:5 to5:95) to afford 310 as a white solid (40 mg, 26%). LCMS (Method G):R_(T) 6.68 min, [M+H]⁺ 596.3. ¹H NMR (CDCl₃, 400 MHz): δ 8.04-7.99 (m,1H); 7.77-7.72 (m, 1H); 7.28-7.23 (m, 2H); 4.35 (m, 4H); 3.87 (m, 7H);3.69 (s, 2H); 3.36 (q, J=7.5 Hz, 2H); 3.11-3.03 (m, 5H); 2.92 (m, 2H);2.62 (m 2H); 2.51 (m, 2H); 2.37-2.22 (m, 2H); 1.45 (t, J=7.5 Hz, 3H) and1.09 (s, 6H)

Example 3112-((1-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)(methyl)amino)-2-methylpropanamide311

A mixture of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(0.106 g, 0.27 mmol), 2-(azetidin-3-ylmethylamino)-2-methylpropionamide(0.055 g, 0.32 mmol) in DCE (3 mL), trimethoxymethane (0.314 mL, 2.9mmol) and acetic acid (0.017 mL, 0.29 mmol) was stirred for 30 min atroom temperature. Sodium triacetoxyborohydride (0.101 g, 0.48 mmol) wasadded and the reaction mixture was stirred for 18 h at room temperature.The suspension was partitioned between DCM and water, the organic layerwas separated, washed with brine, dried over sodium sulphate andconcentrated. The residue was purified by flash chromatography (Si—PPC,MeOH:DCM gradient 0:100 to 7.5:92.5) to give 311 as a white solid (0.096g, 65%). LCMS (Method G): R_(T)=5.87 min, [M+H]⁺ 547.3. ¹H NMR (CDCl₃,400 MHz) δ 8.02-7.98 (m, 1H); 7.79-7.75 (m, 1H); 7.25-7.50 (m, 2H); 6.98(s, 1H); 5.23 (s, 1H); 4.35 (m, 4H); 3.89-3.82 (m, 7H); 3.57-3.50 (m,2H); 3.36 (q, J=7.5 Hz, 2H); 3.28-3.23 (m, 1H); 2.27-2.22 (m, 2H);1.70-1.64 (m, 6H); 1.44 (t, J=7.5 Hz, 2H); 1.20 (s, 6H)

Example 3124-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-8-((4-(2-(methylsulfonyl)ethyl)piperazin-1-yl)methyl)-9H-purin-6-yl)morpholine312

A mixture of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(65 mg, 0.17 mmol) and 1-(2-methanesulfonylethyl)piperazine (38 mg, 0.20mmol) in DCE (4 mL) was stirred at room temperature for 1.5 h before theaddition of sodium triacetoxyborohydride (70 mg, 0.33 mmol). Thereaction mixture was stirred for 16 h then partitioned between brine andDCM. The organic phase was dried (Na₂SO₄) and concentrated in vacuo. Theresulting residue was purified by column chromatography (Si—PCC,MeOH:EtOAc, 0-20%). The resulting oil was loaded onto an Isolute® SCX-2cartridge which was washed with MeOH/DCM and the product eluted with 2MNH₃/MeOH affording 312 as a cream solid (29 mg, 30%). LCMS (Method G):R_(T) 5.97 min [M+H]⁺ 568.3. ¹H NMR (CDCl₃, 400 MHz): δ 8.03-7.99 (m,1H); 7.78-7.73 (m, 1H); 7.30-7.24 (m, 2H); 4.35 (m, 4H); 3.90-3.83 (m,7H); 3.77 (s, 2H); 3.36 (q, J=7.5 Hz, 2H); 3.22-3.11 (m, 2H); 3.04 (s,3H); 2.91 (t, J=6.4 Hz, 2H); 2.59 (m, 8H) and 1.45 (t, J=7.5 Hz, 3H)

Example 3131-(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)-2-methylpropan-1-ol313

A mixture of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(125 mg, 0.32 mmol), 1-azetidin-3-yl-2-methylpropan-1-ol (50 mg, 0.38mmol) and 4 Å molecular sieves (1.0 g) in 1,2-dichloroethane (5 mL) wasstirred at RT under nitrogen atmosphere for 5 h. Sodiumtriacetoxyborohydride (102 mg, 0.48 mmol) was added and the resultingreaction mixture was stirred at RT for 16 h. The solvent was reduced invacuo and the residue was loaded onto an Isolute® SCX-2 cartridge (10g). The cartridge was washed with DCM/MeOH, the desired product wassubsequently eluted using a mixture of 2M NH₃ in MeOH and DCM. Thesolvents were reduced in vacuo to afford 313 as an off-white foam (60mg, 37%). LCMS (Method G): R_(T) 6.95 min, [M+H]⁺ 505. ¹H NMR (400 MHz,CDCl₃): δ 7.99-7.95 (1H, m), 7.72-7.71 (1H, m), 7.23 (2H, m), 4.32 (4H,br s), 3.85-3.78 (9H, m), 3.47-3.45 (3H, m), 3.32 (2H, q, J=7.48 Hz),3.25 (1H, t, J=6.66 Hz), 3.13 (1H, t, J=6.66 Hz), 2.66-2.65 (1H, m),1.62-1.60 (2H, m), 1.41 (3H, t, J=7.48 Hz), 0.87 (6H, dd, J=11.85, 6.78Hz)

Example 3144-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-8-((4-(oxetan-3-yl)piperidin-1-yl)methyl)-9H-purin-6-yl)morpholine314

A mixture of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(0.105 g, 0.27 mmol), 4-oxetan-3-ylpiperidine (0.045 g, 0.32 mmol) inDCE (2 mL), trimethoxymethane (0.314 mL, 2.9 mmol) and acetic acid(0.017 mL, 0.29 mmol) was stirred for 18 h at room temperature. Sodiumtriacetoxyborohydride (0.101 g, 0.48 mmol) was added and the reactionmixture was stirred for 5 h at room temperature. After adding sodiumtriacetoxyborohydride (0.101 g, 0.48 mmol) the reaction mixture wasstirred for a further 2 h and the suspension was partitioned between DCMand water. The organic layer was separated, washed with brine, driedover sodium sulphate and concentrated. The residue was purified by flashchromatography (Si—PPC, MeOH:DCM gradient 0:100 to 5:95) then (Si—PPC,acetone:EtOAc, 0:100 to 70:30) followed by reverse phase HPLC(Phenomenex Gemini 5u C18, 20 mM triethylamine in water on a gradient ofacetonitrile 95:5 to 2:98) to give 314 as an off-white solid (0.048 g,35%). LCMS (Method G): R_(T)=5.92 min, [M+H]⁺ 517.3. ¹H NMR (CDCl₃, 400MHz) δ 8.03-7.99 (m, 1H); 7.78-7.74 (m, 1H); 7.29-7.25 (m, 2H); 4.76(dd, J=7.9, 6.2 Hz, 2H); 4.46 (t, J=6.2 Hz, 2H); 4.44-4.35 (m, 4H);3.90-3.84 (m, 7H); 3.78-3.73 (m, 2H); 3.36 (q, J=7.5 Hz, 2H); 2.95-2.91(m, 2H); 2.79-2.71 (m, 1H); 2.21-2.17 (m, 2H); 1.81-1.50 (m, 4H);1.49-1.41 (t, J=7.5 Hz, 3H); 1.21-1.15 (m, 1H)

Example 3152-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)propan-2-ol315

A mixture of2-(2-methylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(0.075 g, 0.20 mmol), 2-azetidin-3-ylpropan-2-ol (0.023 g, 0.20 mmol) inDCE (2 mL), trimethoxymethane (0.215 mL, 2 mmol) and acetic acid (0.012mL, 0.2 mmol) was stirred for 1 h at room temperature. Sodiumtriacetoxyborohydride (0.042 g, 0.2 mmol) was added and the reactionmixture was stirred for 18 h at room temperature. The reaction mixturewas partitioned between DCM and water, and the organic layer wasseparated, washed with brine, dried over sodium sulphate andconcentrated. The residue was purified by flash chromatography (Si—PPC,MeOH:DCM, gradient 0:100 to 10:90) to give 315 as an off-white solid(0.020 g, 23%). LCMS (Method G): R_(T)=5.61 min, [M+H]⁺ 477.2. ¹H NMR(CDCl₃, 400 MHz) δ 8.11-8.07 (m, 1H); 7.72-7.69 (m, 1H); 7.35-7.26 (m,2H); 4.42-4.31 (m, 4H); 3.89-3.82 (m, 11H); 3.62-3.12 (m, 2H); 2.94 (s,3H); 2.70-2.55 (m, 1H); 1.18 (s, 6H)

Example 3163-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)pentan-3-ol316

Following General Procedure I for Buchwald coupling,2-methylbenzimidazole and3-(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)pentan-3-olwere reacted to give 316. LCMS m/z: 533.3 (MH+)

Example 3174-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)tetrahydro-2H-pyran-4-ol317

Following General Procedure I for Buchwald coupling,2-methylbenzimidazole and4-(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)-tetrahydro-2H-pyran-4-olwere reacted to give 317. LCMS m/z: 547.3 (MH+)

Example 318(S)-4-(8-((3-(1,1-dioxo-isothiazolidin-2-yl)pyrrolidin-1-yl)methyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine318

Following General Procedure I for Buchwald coupling,2-methylbenzimidazole and4-(2-chloro-8-((3-(isodioxothiazolidin-2-yl)pyrrolidin-1-yl)methyl)-9-methyl-9H-purin-6-yl)morpholinewere reacted to give 318. LCMS m/z: 552.2 (MH+)

Example 3192-(1-((9-methyl-2-(2-(1-methyl-1H-pyrazol-5-yl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol319

Following General Procedure I for Buchwald coupling,2-(1-methyl-1H-pyrazol-5-yl)-1H-benzo[d]imidazole and2-(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-olwere reacted to give 319. LCMS m/z: 571.3 (MH+)

Example 320I-4-(8-((3-(1,1-dioxo-isothiazolidin-2-yl)pyrrolidin-1-yl)methyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine320

Following General Procedure I for Buchwald coupling,2-methylbenzimidazole and4-(2-chloro-8-((3-(isodioxothiazolidin-2-yl)pyrrolidin-1-yl)methyl)-9-methyl-9H-purin-6-yl)morpholinewere reacted to give 320. LCMS m/z: 552.2 (MH+)

Example 321N-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)-2-(4-methylthiazol-2-yl)ethanamine321

Following General Procedure L for reductive amination,9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purine-8-carbaldehydeand 2-(4-methylthiazol-2-yl)ethanamine were reacted to give 321. [M+H]⁺504.6.

Example 322N-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)-2-(pyridin-2-yl)ethanamine322

Following General Procedure L for reductive amination,9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purine-8-carbaldehydeand 2-(pyridin-2-yl)ethanamine were reacted to give 322. [M+H]⁺ 484.6.

Example 3231-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)cyclopentanol323

Following General Procedure I for Buchwald coupling,2-methylbenzimidazole and1-(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)cyclopentanolwere reacted to give 323. LCMS m/z: 531.3 (MH+)

Example 3247-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-2-oxa-7-azaspiro[3.5]nonane324

A mixture of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(0.075 g, 0.19 mmol), 2-oxa-7-azaspiro[3.5]nonane trifluoroacetate (0.05g, 0.20 mmol) in DCE (2 mL), trimethoxymethane (0.204 mL, 1.9 mmol) andacetic acid (0.011 mL, 0.2 mmol) was stirred for 2 h at roomtemperature. Sodium triacetoxyborohydride (0.061 g, 0.29 mmol) was addedand the reaction mixture was stirred for 18 h at room temperature. Thereaction mixture was partitioned between DCM and water, the organiclayer was separated, washed with brine, dried over sodium sulphate andconcentrated. The residue was purified by flash chromatography (Si—PPC,MeOH:DCM gradient 0:100 to 10:90) to give 324 as a white solid (0.066 g,70%). LCMS (Method G): R_(T)=5.88 min, [M+H]⁺ 503.2. ¹H NMR (CDCl₃, 400MHz) δ 8.03-7.99 (m, 1H); 7.83-7.79 (m, 1H); 7.33-7.29 (m, 2H);4.48-4.37 (m, 4H); 4.34-4.30 (m, 4H); 3.90-3.84 (m, 7H); 3.76-3.72 (m,2H); 3.40 (d, J=8.3 Hz, 2H); 2.49-2.44 (m, 4H); 1.95-1.91 (m, 4H); 1.48(t, J=7.5 Hz, 3H)

Example 3254-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-8-((3-(tetrahydro-2H-pyran-4-yl)azetidin-1-yl)methyl)-9H-purin-6-yl)morpholine325

A mixture of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(0.10 g, 0.26 mmol), 3-(tetrahydropyran-4-yl)azetidine (0.050 g, 0.28mmol) in DCE (2 mL), trimethoxymethane (0.277 mL, 2.6 mmol) and aceticacid (0.015 mL, 0.26 mmol) was stirred for 2 h at room temperature.Sodium triacetoxyborohydride (0.090 g, 0.43 mmol) was added and thereaction mixture was stirred for 18 h at room temperature. The reactionmixture was partitioned between DCM and water, the organic phase wasseparated, washed with brine, dried over sodium sulphate andconcentrated. The residue was purified by flash chromatography (Si—PPC,MeOH:EtOAc gradient 0:100 to 10:90) to give 325 as a yellow solid (0.072g, 56%). LCMS (Method G): R_(T)=6.14 min, [M+H]⁺ 517.2. ¹H NMR (CDCl₃,400 MHz) δ 8.02-7.98 (m, 1H); 7.78-7.73 (m, 1H); 7.35-7.25 (m, 2H);4.40-4.32 (m, 4H); 3.98 (dd, J=11.7, 4.3 Hz, 2H); 3.89-3.86 (m, 9H);3.42-3.30 (m, 5H); 1.67-1.64 (m, 4H); 1.55 (d, J=11.7 Hz, 2H); 1.48-1.39(t, J=7.5 Hz, 3H); 1.29-1.16 (m, 3H)

Example 326N,N-dimethyl-1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidine-4-carboxamide326

A solution of9-methyl-2-(2-methylbenzoimidazol-1-yl)-6-morpholin-4-yl-9H-purine-8-carbaldehyde(100 mg, 0.27 mmol) and piperidine-4-carboxylic acid dimethylamide (50mg, 0.32 mmol) in DCE (3 mL) was stirred at ambient temperature for 90min. Sodium triacetoxyborohydride (86 mg, 0.41 mmol) was added and themixture stirred for 18 h, then loaded onto an Isolute® SCX-2 cartridge(10 g). The cartridge was then washed with methanol and the desiredproduct was subsequently eluted using 2 M NH₃ in MeOH. The product wascollected and concentrated in vacuo. The resultant residue was purifiedby flash chromatography (Si—PPC, DCM:MeOH; 100:0, 95:5, 90:10, to 85:15)to afford 326 as a white solid (69 mg, 51%). LCMS (Method G): R_(T)=5.48min, M+H⁺=518. ¹H NMR (CDCl₃, 400 MHz) δ 8.19 (m, 1H); 7.73-7.68 (m,1H); 7.29-7.25 (m, 2H); 4.35 (m, 4H); 3.91-3.83 (m, 7H); 3.75 (s, 2H);3.06 (s, 3H); 2.95 (s, 6H); 2.54 (m, 1H); 2.18 (m, 2H); 1.92-1.79 (m,2H) and 1.71 (m, 4H)

Example 3278-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one327

A solution of9-methyl-2-(2-methylbenzoimidazol-1-yl)-6-morpholin-4-yl-9H-purine-8-carbaldehyde(100 mg, 0.27 mmol) and 1-oxa-3,8-diazaspiro[4.5]decan-2-one (50 mg,0.32 mmol) in DCE (3 mL) was stirred at ambient temperature for 90 min.Sodium triacetoxyborohydride (86 mg, 0.41 mmol) was added and themixture stirred for 18 h, then loaded onto an Isolute® SCX-2 cartridge(10 g). The cartridge was then washed with methanol and the desiredproduct was subsequently eluted using 2 M NH₃ in MeOH. The product wascollected and concentrated in vacuo. The resultant residue was purifiedby flash chromatography (Si—PPC, DCM:MeOH; 100:0 to 95:5 to 90:10 to85:15) to afford 327 as a white solid (77 mg, 56%). LCMS (Method G):R_(T)=5.35 min, M+H⁺=518. ¹H NMR (CDCl₃, 400 MHz) δ 8.9 (m, 1H); 7.72(m, 1H); 7.29 (m, 2H); 4.99 (bs, 1H); 4.35 (m, 4H); 3.90-3.83 (m, 7H);3.80 (s, 2H); 3.36 (s, 2H); 2.95 (s, 3H); 2.76-2.65 (m, 4H); 2.03 (m,2H) and 1.82 (m, 2H)

Example 3284-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)morpholine328

A mixture of9-methyl-2-(2-methylbenzoimidazol-1-yl)-6-morpholin-4-yl-9H-purine-8-carbaldehyde(80 mg, 0.21 mmol), 4-azetidin-3-ylmorpholine (36 mg, 0.25 mmol) and 4 Åpowdered molecular sieves (100 mg) in DCE (5 mL) was stirred at roomtemperature for 4 h before the addition of sodium triacetoxyborohydride(90 mg, 0.42 mmol). The reaction mixture was stirred for 64 h thenfiltered through celite, washing with DCM. The organic phase was washedwith brine (×1) and concentrated in vacuo. The resulting residue waspurified by column chromatography (Si—PCC, MeOH:EtOAc, 0-20%). Theresulting oil was loaded onto an Isolute® SCX-2 cartridge which waswashed with MeOH/DCM and the product eluted with 2M NH₃/MeOH affording328 as a cream solid (71 mg, 67%). LCMS (Method G): R_(T) 5.18 min[M+H]⁺ 504.2. ¹H NMR (CDCl₃, 400 MHz): δ 8.10-8.05 (m, 1H); 7.73-7.69(m, 1H); 7.28-7.23 (m, 2H); 4.35 (m, 4H); 3.91-3.82 (m, 9H); 3.73 (m,4H); 3.58 (m, 2H); 3.18-3.04 (m, 3H); 2.94 (s, 3H) and 2.35 (m, 4H)

Example 3294-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-8-((4-(2-(methylsulfonyl)ethyl)piperazin-1-yl)methyl)-9H-purin-6-yl)morpholine329

A mixture of9-methyl-2-(2-methylbenzoimidazol-1-yl)-6-morpholin-4-yl-9H-purine-8-carbaldehyde(60 mg, 0.16 mmol), 1-(2-methanesulfonylethyl)piperazine (37 mg, 0.19mmol) and 4 Å powdered molecular sieves (100 mg) in DCE (4 mL) wasstirred at room temperature for 4 h before the addition of sodiumtriacetoxyborohydride (67 mg, 0.32 mmol). The reaction mixture wasstirred for 64 h then filtered through celite, washing with DCM. Theorganic phase was washed with brine (×1) and concentrated in vacuo. Theresulting residue was purified by column chromatography (Si—PCC,MeOH:EtOAc, 0-20%). The resulting oil was loaded onto an Isolute® SCX-2cartridge which was washed with MeOH/DCM and the product eluted with 2MNH₃/MeOH affording 329 as a cream solid (55 mg, 62%). LCMS (Method G):R_(T) 5.54 min [M+H]⁺ 554.3. ¹H NMR (CDCl₃, 400 MHz): δ 8.11-8.06 (m,1H); 7.74-7.70 (m, 1H); 7.30-7.25 (m, 2H); 4.35 (m, 4H); 3.90-3.82 (m,7H); 3.76 (s, 2H); 3.15 (t, J=6.4 Hz, 2H); 3.04 (s, 3H); 2.95 (s, 3H);2.90 (t, J=6.4 Hz, 2H) and 2.57 (m, 8H)

Example 3304-(8-((3,3-dimethyl-4-(2-(methylsulfonyl)ethyl)piperazin-1-yl)methyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine330

A mixture of9-methyl-2-(2-methylbenzoimidazol-1-yl)-6-morpholin-4-yl-9H-purine-8-carbaldehyde(80 mg, 0.21 mmol), 1-(2-methanesulfonylethyl)-2,2-dimethylpiperazine(56 mg, 0.25 mmol) and 4 Å powdered molecular sieves (100 mg) in DCE (5mL) was stirred at room temperature for 4 h before the addition ofsodium triacetoxyborohydride (90 mg, 0.42 mmol). The reaction mixturewas stirred for 64 h then filtered through celite, washing with DCM. Theorganic phase was washed with brine (×1) and concentrated in vacuo. Theresulting residue was purified by column chromatography (Si—PCC,MeOH:EtOAc, 0-15%). The resulting oil was loaded onto an Isolute® SCX-2cartridge which was washed with MeOH/DCM and the product eluted with 2MNH₃/MeOH affording 330 as a white solid (70 mg, 58%). LCMS (Method G):R_(T) 6.62 min [M+H]⁺ 582.3. ¹H NMR (CDCl₃, 400 MHz): δ 8.12-8.07 (m,1H); 7.74-7.70 (m, 1H); 7.29-7.25 (m, 2H); 4.35 (m, 4H); 3.91-3.83 (m,7H); 3.69 (s, 2H); 3.11 (m, 2H); 3.06 (s, 3H); 2.95 (s, 3H); 2.63 (m,2H); 2.54 (m, 2H); 2.30 (s, 2H); 1.78 (m, 2H) and 1.10 (s, 6H)

Example 3314-(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)-2,2-dimethylmorpholine331

A mixture of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(112 mg, 0.29 mmol), 4-azetidin-3-yl-2,2-dimethylmorpholine (58 mg, 0.34mmol) and 4 Å powdered molecular sieves (200 mg) in DCE (5 mL) wasstirred at room temperature for 4 h before the addition of sodiumtriacetoxyborohydride (121 mg, 0.57 mmol). The reaction mixture wasstirred for 40 h then filtered through celite, washing with DCM. Theorganic phase was washed with brine (×1) and concentrated in vacuo. Theorganic phase was dried (Na₂SO₄) and concentrated in vacuo. Theresulting residue was purified by column chromatography (Si—PCC,MeOH:EtOAc, 0-20%). The resulting oil was loaded onto an Isolute® SCX-2cartridge which was washed with MeOH/DCM and the product eluted with 2MNH₃/MeOH affording 331 as a yellow solid (121 mg, 76%). LCMS (Method G):R_(T) 6.85 min [M+H]⁺ 546.3. ¹H NMR (CDCl₃, 400 MHz): δ 8.02-7.97 (m,1H); 7.77-7.73 (m, 1H); 7.29-7.22 (m, 2H); 4.35 (m, 4H); 3.91-3.82 (m,9H); 3.73 (m, 2H); 3.57 (t, J=6.6 Hz, 2H); 3.35 (q, J=7.5 Hz, 2H); 3.10(t, J=6.6 Hz, 2H); 2.98 (p, J=6.6 Hz, 1H); 2.24 (m, 2H); 2.04 (s, 2H);1.44 (t, J=7.5 Hz, 3H) and 1.25 (s, 6H)

Example 3322-(1-((5-(2-ethyl-1H-benzo[d]imidazol-1-yl)-7-morpholinothiazolo[5,4-d]pyrimidin-2-yl)methyl)piperidin-4-yl)propan-2-ol332

A mixture2-[1-(5-chloro-7-morpholin-4-ylthiazolo[5,4-d]pyrimidin-2-ylmethyl)piperidin-4-yl]propan-2-ol(100 mg, 0.24 mmol), 2-ethyl-1H-benzoimidazole (42 mg, 0.29 mmol),copper(I) thiophene-2-carboxylate (9 mg, 0.048 mmol) and cesiumcarbonate (119 mg, 0.36 mmol) in NMP (0.5 mL) was stirred at 110° C. for18 hours. The reaction mixture was diluted with MeOH and loaded onto anIsolute® SCX-2 cartridge (5 g). The cartridge was washed with MeOH andthe desired product was eluted with 2M NH₃ in MeOH. The solvents wereremoved and the residue was subjected to flash chromatography (Si—PCC,0-20% MeOH in EtOAc) followed by reverse phase HPLC (Phenomenex Gemini5u C18, 20 mM triethylamine in water on a gradient of acetonitrile 95:5to 2:98) to give 332 as a beige solid (45 mg, 36%). LCMS (Method G):R_(T) 7.37 min; [M+H]⁺ 522. ¹H NMR (400 MHz, CHCl₃-d): δ 8.03-7.98 (m,1H); 7.77-7.73 (m, 1H); 7.32-7.24 (m, 2H); 4.41 (m, 4H); 3.90-3.85 (m,6H); 3.35 (q, J=7.5 Hz, 2H); 3.11 (m, 2H); 2.33-2.12 (m, 2H); 1.79 (m,2H); 1.57 (m, 2H); 1.44 (t, J=7.5 Hz, 3H); 1.34 (m, 1H); 1.22 (s, 6H)

Example 3372-(1-((2-(2-ethoxy-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol337

Following General Procedure I for Buchwald coupling,2-(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-oland 2-ethoxy-1H-benzo[d]imidazole were reacted to give 337. LCMS:M+H⁺=535.3

Example 3382-(1-((2-(2-isopropoxy-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol338

Following General Procedure I for Buchwald coupling,2-(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-oland 2-isopropoxy-1H-benzo[d]imidazole were reacted to give 338. LCMS:M+H⁺=549.3

Example 3392-methyl-2-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-1-ol339

Following General Procedure E for amine alkylation,4-(8-(bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholineand 2-methyl-2-(piperidin-4-yl)propan-1-ol were reacted to give 339.LCMS: M+H⁺=519.3

Example 3412-(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)-2-methylpropan-1-ol341

Following General Procedure E for amine alkylation,4-(8-(bromomethyl)-9-methyl-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholineand 2-methyl-2-(piperidin-4-yl)propan-1-ol were reacted to give 341.LCMS: M+H⁺=533.3

Example 342N-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)-2-(pyrazin-2-yl)ethanamine342

Following General Procedure L for reductive amination,9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purine-8-carbaldehydeand 2-(pyrazin-2-yl)ethanamine were reacted to give 342. [M+H]⁺ 485.6.

Example 3437-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)-7-azaspiro[3.5]nonan-2-ol343

To a solution of9-methyl-2-(2-methylbenzoimidazol-1-yl)-6-morpholin-4-yl-9H-purine-8-carbaldehyde(134 mg, 0.35 mmol) in DCE (5 mL) was added 7-azaspiro[3.5]nonan-2-ol(60 mg, 0.43 mmol), trimethyl orthoformate (0.19 mL, 1.77 mmol) andacetic acid (0.02 mL, 0.35 mmol). The reaction mixture was stirred atroom temperature for 3 h, sodium triacetoxyborohydride (113 mg, 0.53mmol) was added and the resulting mixture stirred for a further 2 h. Thereaction mixture was loaded onto an Isolute® SCX-2 cartridge, washedwith MeOH then the desired product eluted with 2 M NH₃ in MeOH. Theresulting residue was purified by column chromatography (Si—PCC, 0-20%MeOH in EtOAc) to give 343 as a white solid (80 mg, 45%). LCMS (MethodG): R_(T)=5.23 min, [M+H]⁺ 503.2. ¹H NMR (400 MHz, CHCl₃-d): δ 8.11-8.06(m, 1H), 7.73-7.68 (m, 1H), 7.30-7.24 (m, 2H), 4.37-4.24 (m, 4H),3.90-3.83 (m, 7H), 3.72 (s, 2H), 2.94 (s, 3H), 2.58-2.31 (m, 4H),2.30-2.23 (m, 2H), 1.75-1.55 (m, 8H)

Example 3442-(1-(2-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)ethyl)piperidin-4-yl)propan-2-ol344

A mixture of2-{1-[2-(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)ethyl]-piperidin-4-yl}propan-2-ol(47 mg, 0.11 mmol), 2-methylbenzimidazole (16 mg, 0.12 mmol), Pd₂(dba)₃(2.5 mg, 2.5 mol %), Xphos (5.0 mg, 10 mol %) and Cs₂CO₃ (54 mg, 0.17mmol) in dioxane (1.0 mL) was purged with argon gas then heated at 150°C., for 30 min, in a microwave reactor. The reaction mixture was loadedonto an Isolute® SCX-2 cartridge, washed with MeOH then the desiredproduct eluted with 2 M NH₃ in MeOH. The resulting residue was purifiedby flash chromatography (RediSep amine cartridge, 0-5% MeOH in DCM)followed by reverse phase HPLC (Phenomenex Gemini 5 μm C18, 20 mMtriethylamine in water on a gradient of acetonitrile 30-50%) to give 344(25 mg, 43%) as a white solid. LCMS: (Method G): R_(T) 5.64 min; [M+H]⁺519.3. ¹H NMR (400 MHz, CHCl₃-d): δ 8.09-8.04 (m, 1H), 7.73-7.69 (m,1H), 7.29-7.24 (m, 2H), 4.48-4.16 (m, 4H), 3.87 (t, J=4.7 Hz, 4H), 3.79(s, 3H), 3.23-1.05 (m, 4H), 2.93 (s, 3H), 2.93-2.75 (m, 2H), 2.11 (s,3H), 1.90-1.75 (m, 2H), 1.55-1.25 (m, 3H), 1.20 (s, 6H)

Example 3454-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-8-((3-fluoro-1,3′-biazetidin-1′-yl)methyl)-9-methyl-9H-purin-6-yl)morpholine345

A mixture of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(0.079 g, 0.20 mmol), 3-fluoro-[1,3′]biazetidinyl (0.029 g, 0.22 mmol)in DCE (3 mL), trimethoxymethane (0.22 mL, 2 mmol) and acetic acid(0.012 mL, 0.2 mmol) was stirred for 5 h at room temperature. Sodiumtriacetoxyborohydride (0.065 g, 0.30 mmol) was added and the reactionmixture was stirred for 18 h at room temperature. The reaction mixturewas partitioned between DCM and water. The organic layer was separated,washed with brine, dried over sodium sulphate and concentrated. Theresidue was purified by flash chromatography (Si—PPC, MeOH:EtOAc,gradient 0:100 to 16:84) followed by reverse phase HPLC (PhenomenexGemini 5u C18, 20 mM triethylamine in water on a gradient ofacetonitrile 95:5 to 5:95) to give 345 as an off-white solid (0.054 g,53%). LCMS (Method G): R_(T)=5.78 min, [M+H]⁺ 506.2. ¹H NMR (CDCl₃, 400MHz) δ 8.02-7.98 (m, 1H); 7.77-7.73 (m, 1H); 7.28-7.24 (m, 2H); 5.15(dt, J=57.3, 5.4 Hz, 1H); 4.38-4.33 (m, 4H); 3.90-3.85 (m, 6H); 3.83 (s,2H); 3.72-3.62 (m, 3H); 3.48-3.39 (m, 3H); 3.35 (q, J=7.5 Hz, 2H);3.35-3.19 (m, 2H); 3.17-3.15 (m, 2H); 1.44 (t, J=7.5 Hz, 3H)

Example 3462-methyl-1-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-1-ol346

A mixture of9-methyl-2-(2-methylbenzoimidazol-1-yl)-6-morpholin-4-yl-9H-purine-8-carbaldehyde(200 mg, 0.53 mmol), 2-methyl-1-piperidin-4-yl-propan-1-ol (125 mg, 0.79mmol) and 4 Å molecular sieves (1.0 g) in 1,2-dichloroethane (10 mL) wasstirred at RT under nitrogen atmosphere for 1.5 h. Sodiumtriacetoxyborohydride (167 mg, 0.79 mmol) was added and the resultingreaction mixture was stirred at RT for 16 h. The solvent was reduced invacuo and the residue was loaded onto an Isolute® SCX-2 cartridge (10g). The cartridge was washed with DCM/MeOH, the desired product wassubsequently eluted using a mixture of 2M NH₃ in MeOH and DCM. Theresidue was purified by column chromatography (Si—PCC, MeOH:DCM:gradient 0:100 to 5:95) followed by a further purification (Si—PCC,acetone:cyclohexane: gradient 10:90 to 40:60). The solvents were reducedin vacuo to afford 346 as a white solid (114 mg, 41%). LCMS (Method G):R_(T) 6.81 min, [M+H]⁺ 519. ¹H NMR (400 MHz, CH₃OH-d₄): δ 8.06-8.05 (1H,m), 7.56-7.55 (1H, m), 7.25-7.24 (2H, m), 4.29 (4H, br s), 3.84 (3H, s),3.81 (4H, t, J=4.74 Hz), 3.74 (2H, s), 2.98-2.95 (3H, m), 2.86 (3H, s),2.11 (2H, m), 1.84 (1H, m), 1.72-1.71 (1H, m), 1.57-1.20 (4H, m), 0.87(6H, dd, J=15.35, 6.73 Hz)

Example 347azetidin-1-yl(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)methanone347

A solution of9-methyl-2-(2-methylbenzoimidazol-1-yl)-6-morpholin-4-yl-9H-purine-8-carbaldehyde(100 mg, 0.27 mmol) and azetidin-3-ylazetidin-1-ylmethanone (45 mg, 0.31mmol) in DCE (3 mL) was stirred at ambient temperature for 90 min.Sodium triacetoxyborohydride (86 mg, 0.41 mmol) was added and themixture stirred for 18 h, then loaded onto an Isolute® SCX-2 cartridge(10 g). The cartridge was then washed with methanol and the desiredproduct was subsequently eluted using 2 M NH₃ in MeOH. The product wascollected and concentrated in vacuo. The resultant residue was purifiedby flash chromatography (Si—PPC, EtOAc:MeOH; 100:0 to 90:10 to 85:15) toafford 347 as a white solid (30 mg, 23%). LCMS (Method G): R_(T)=5.33min, M+H⁺=502. ¹H NMR (CDCl₃, 400 MHz) δ 8.07 (m, 1H); 7.69 (m, 1H);7.28 (m, 2H); 4.35 (m, 4H); 4.13-4.00 (m, 4H); 3.87 (m, 6H); 3.82 (s,3H); 3.68-3.58 (m, 2H); 3.53-3.45 (m, 2H); 3.34-3.26 (m, 1H); 2.96 (s,3H) and 2.33-2.23 (m, 2H)

Example 348(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)(pyrrolidin-1-yl)methanone348

A solution of9-methyl-2-(2-methylbenzoimidazol-1-yl)-6-morpholin-4-yl-9H-purine-8-carbaldehyde(100 mg, 0.27 mmol) and azetidin-3-ylpyrrolidin-1-ylmethanone (50 mg,0.32 mmol) in DCE (3 mL) was stirred at ambient temperature for 90 min.Sodium triacetoxyborohydride (86 mg, 0.41 mmol) was added and themixture stirred for 18 h, then loaded onto an Isolute® SCX-2 cartridge(10 g). The cartridge was then washed with methanol and the desiredproduct was subsequently eluted using 2 M NH₃ in MeOH. The product wascollected and concentrated in vacuo. The resultant residue was purifiedby flash chromatography (Si—PPC, EtOAc:MeOH; gradient from 100:0 to70:30) to afford 348 as a white foam (50 mg, 37%). LCMS (Method G):R_(T)=5.81 min, M+H⁺=516. ¹H NMR (CDCl₃, 400 MHz) δ 8.08 (m, 1H); 7.71(m, 1H); 7.26 (m, 2H); 4.35 (m, 4H); 3.89-3.83 (m, 9H); 3.66 (m, 2H);3.55-3.43 (m, 5H); 3.31 (m, 2H); 2.94 (s, 3H) and 1.98-1.81 (m, 4H)

Example 349I-azetidin-1-yl(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)pyrrolidin-3-yl)methanone349

A solution of9-methyl-2-(2-methylbenzoimidazol-1-yl)-6-morpholin-4-yl-9H-purine-8-carbaldehyde(141 mg, 0.37 mmol) and azetidin-1-yl-1-pyrrolidin-3-ylmethanone (77 mg,0.50 mmol) in DCE (6 mL) was stirred at ambient temperature for 2 h.Sodium triacetoxyborohydride (134 mg, 0.63 mmol) was added and themixture stirred for 18 h, then loaded onto an Isolute® SCX-2 cartridge(10 g). The cartridge was then washed with methanol and the desiredproduct was subsequently eluted using 2 M NH₃ in MeOH. The product wascollected and concentrated in vacuo. The resultant residue was purifiedby flash chromatography (Si—PPC, DCM:MeOH; gradient from 100:0 to 70:30)to afford 349 as a cream solid (157 mg, 81%). LCMS (Method G):R_(T)=5.52 min, M+H⁺=516. ¹H NMR (CDCl₃, 400 MHz) δ 8.09 (m, 1H); 7.70(m, 1H); 7.28 (m, 2H); 4.35 (m, 4H); 4.18-4.08 (m, 2H); 4.03 (m, 2H);3.92 (s, 2H); 3.92-3.81 (m, 7H); 3.08-2.71 (m, 7H); 2.69 (m, 1H);2.33-2.23 (m, 2H) and 2.10-2.03 (m, 2H)

Example 350I-(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)pyrrolidin-3-yl)(pyrrolidin-1-yl)methanone350

A solution of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(110 mg, 0.28 mmol) and pyrrolidin-1-yl-1-pyrrolidin-3-ylmethanone (60mg, 0.36 mmol) in DCE (6 mL) was stirred at ambient temperature for 2 h.Sodium triacetoxyborohydride (96 mg, 0.45 mmol) was added and themixture stirred for 18 h, then loaded onto an Isolute® SCX-2 cartridge(10 g). The cartridge was then washed with methanol and the desiredproduct was subsequently eluted using 2 M NH₃ in MeOH. The product wascollected and concentrated in vacuo. The resultant residue was purifiedby flash chromatography (Si—PPC, DCM:MeOH; gradient from 100:0 to70:30), followed by reverse phase HPLC (Phenomenex Gemini 5u C18, 20 mMtriethylamine in water on a gradient of acetonitrile 80:20 to 2:98) toafford 350 as a white solid (61 mg, 37%). LCMS (Method G): R_(T)=6.55min, M+H⁺=544. ¹H NMR (CDCl₃, 400 MHz) δ 8.00 (m, 1H); 7.75 (m, 1H);7.26 (m, 2H); 4.35 (m, 4H); 3.96 (s, 2H); 3.92-3.82 (m, 7H); 3.49-3.40(m, 4H); 3.35 (q, J=7.5 Hz, 2H); 3.25-2.70 (m, 5H); 2.13 (m, 2H);2.01-1.91 (m, 2H); 1.90-1.81 (m, 2H) and 1.47 (t, J=7.5 Hz, 3H)

Example 351I—N,N-dimethyl-1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)pyrrolidine-3-carboxamide351

A solution of9-methyl-2-(2-methylbenzoimidazol-1-yl)-6-morpholin-4-yl-9H-purine-8-carbaldehyde(135 mg, 0.36 mmol) and 1-pyrrolidine-3-carboxylic acid dimethylamide(65 mg, 0.46 mmol) in DCE (6 mL) was stirred at ambient temperature for2 h. Sodium triacetoxyborohydride (123 mg, 0.58 mmol) was added and themixture stirred for 18 h, then loaded onto an Isolute® SCX-2 cartridge(10 g). The cartridge was then washed with methanol and the desiredproduct was subsequently eluted using 2 M NH₃ in MeOH. The product wascollected and concentrated in vacuo. The resultant residue was purifiedby flash chromatography (Si—PPC, DCM:MeOH; gradient from 100:0 to 70:30)to afford 351 as a cream solid (144 mg, 80%). LCMS (Method G):R_(T)=5.48 min, M+H⁺=504. ¹H NMR (CDCl₃, 400 MHz) δ 8.09 (m, 1H); 7.70(m, 1H); 7.28 (m, 2H); 4.35 (m, 4H); 3.93 (s, 2H); 3.87 (m, 7H); 3.26(m, 1H); 3.03 (s, 3H); 3.00-2.92 (m, 7H); 2.86 (m, 2H); 2.73-2.64 (m,1H) and 2.15-2.06 (m, 2H)

Example 352I-1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-N,N-dimethylpyrrolidine-3-carboxamide352

A solution of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(140 mg, 0.36 mmol) and 1-pyrrolidine-3-carboxylic acid dimethylamide(65 mg, 0.46 mmol) in DCE (6 mL) was stirred at ambient temperature for2 h. Sodium triacetoxyborohydride (123 mg, 0.58 mmol) was added and themixture stirred for 18 h, then loaded onto an Isolute® SCX-2 cartridge(10 g). The cartridge was then washed with methanol and the desiredproduct was subsequently eluted using 2 M NH₃ in MeOH. The product wascollected and concentrated in vacuo. The resultant residue was purifiedby flash chromatography (Si—PPC, DCM:MeOH; gradient from 100:0 to 70:30)to afford 352 as a cream solid (136 mg, 74%). LCMS (Method G):R_(T)=5.90 min, M+H⁺=518. ¹H NMR (CDCl₃, 400 MHz) δ 8.02 (m, 1H); 7.80(m, 1H); 7.28 (m, 2H); 4.34 (m, 4H); 3.93 (s, 2H); 3.90-3.84 (m, 7H);3.35 (q, J=7.5 Hz, 2H); 3.26 (m, 1H); 3.07-2.93 (m, 7H); 2.87 (m, 2H);2.70 (m, 1H); 2.16-2.06 (m, 2H) and 1.45 (t, J=7.5 Hz, 3H)

Example 3532,2-dimethyl-4-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)morpholine353

A mixture of9-methyl-2-(2-methylbenzoimidazol-1-yl)-6-morpholin-4-yl-9H-purine-8-carbaldehyde(100 mg, 0.26 mmol), 4-azetidin-3-yl-2,2-dimethylmorpholine (54 mg, 0.32mmol) and 4 Å powdered molecular sieves (200 mg) in DCE (5 mL) wasstirred at room temperature for 4 h before the addition of sodiumtriacetoxyborohydride (112 mg, 0.53 mmol). The reaction mixture wasstirred for 16 h then filtered through celite, washing with DCM. Theorganic phase was washed with brine (×1) and concentrated in vacuo. Theresulting residue was purified by column chromatography (Si—PCC,MeOH:EtOAc, 0-15%). The resulting oil was loaded onto an Isolute® SCX-2cartridge which was washed with MeOH/DCM and the product eluted with 2MNH₃/MeOH affording 353 as a white solid (113 mg, 82%). LCMS (Method G):R_(T) 6.47 min [M+H]⁺ 532.3. ¹H NMR (CDCl₃, 400 MHz): δ 8.10-8.05 (m,1H); 7.73-7.69 (m, 1H); 7.29-7.24 (m, 2H); 4.35 (m, 4H); 3.89-3.83 (m,9H); 3.73 (m, 2H); 3.55 (t, J=6.5 Hz, 2H); 3.08 (t, J=6.8 Hz, 2H);3.01-2.90 (m, 4H); 2.24 (m, 2H); 2.07 (s, 2H) and 1.25 (s, 6H)

Example 3544-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-8-((3-(1,1-dioxo-thiomorpholino)azetidin-1-yl)methyl)-9H-purin-6-yl)morpholine354

A mixture of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(1.2 g, 3.07 mmol), 4-azetidin-3-ylthiomorpholine-1,1-dioxide (640 mg,3.37 mmol) and 4 Å powdered molecular sieves (2.5 g) in DCE (65 mL) wasstirred at room temperature for 6.5 h before the addition of sodiumtriacetoxyborohydride (1.3 g, 6.13 mmol). The reaction mixture wasstirred for 18 h then filtered through celite, washing with DCM. Theorganic phase was washed with brine (×1) and concentrated in vacuo. Theorganic phase was dried (Na₂SO₄) and concentrated in vacuo. Theresulting residue was purified by column chromatography (Si—PCC,MeOH:EtOAc, 0-10%). A mixture of the resulting yellow powder and3-mercaptopropyl ethyl sulphide silica (250 mg) was stirred in a mixtureof EtOH and DCM at 50° C. for 3 h. The mixture was filtered andconcentrated in vacuo. The resulting oil was loaded onto an Isolute®SCX-2 cartridge which was washed with EtOH and the product eluted with2M NH₃/EtOH. The resulting oil was triturated with Et₂O and dried invacuo at 60° C. affording 354 as a pale yellow solid (1.26 g, 73%). LCMS(Method I): R_(T) 2.43 min [M+H]⁺ 566.3. ¹H NMR (CDCl₃, 400 MHz): δ8.02-7.97 (m, 1H); 7.77-7.73 (m, 1H); 7.29-7.22 (m, 2H); 4.34 (m, 4H);3.89-3.80 (m, 9H); 3.59 (m, 2H); 3.39-3.23 (m, 3H); 3.12-3.04 (m, 6H);2.85 (m, 4H) and 1.44 (t, J=7.5 Hz, 3H)

Example 3554-(2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9-methyl-8-((3-(1,1-dioxo-thiomorpholino)azetidin-1-yl)methyl)-9H-purin-6-yl)morpholine355

A mixture of2-chloro-8-[3-(1,1-Dioxo-1-thiomorpholin-4-yl)azetidin-1-ylmethyl]-9-methyl-6-morpholin-4-yl-9H-purine(125 mg, 0.27 mmol), 2-methylbenzimidazole (402 mg, 0.30 mmol),tris(dibenzylideneacetone)dipalladium (13 mg, 0.01 mmol), Xphos (13 mg,0.02 mmol) and Cs₂CO₃ (179 mg, 0.55 mmol) in dioxane (4 mL) was purgedwith argon then heated at 145° C. for 30 min in a microwave reactor. Thereaction mixture was loaded onto an Isolute® SCX-2 cartridge, washedwith MeOH/DCM then eluted with 2M NH₃/MeOH. The resulting residue waspurified by column chromatography (Si—PCC, MeOH:EtOAc, 0-15%) followedby an Isolute® SCX-2 cartridge which was washed with MeOH/DCM and theproduct eluted with 2M NH₃/MeOH to give 355 as a cream solid (125 mg,84%). LCMS (Method G): R_(T) 4.73 min, [M+H]⁺ 552.2. ¹H NMR (CDCl₃, 400MHz): δ 8.10-8.05 (m, 1H); 7.73-7.67 (m, 1H); 7.29-7.24 (m, 2H); 4.35(m, 4H); 3.90-3.82 (m, 9H); 3.59 (m, 2H); 3.28 (m, 1H); 3.11-3.04 (m,6H); 2.94 (s, 3H) and 2.87-2.82 (m, 4H)

Example 3562-methyl-2-(4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)propane-1,3-diol356

Following General Procedure I for Buchwald coupling,2-methylbenzimidazole and2-(4-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)-2-methylpropane-1,3-diolwere reacted to give 356. LCMS m/z: 536.3 (MH+)

Example 357I-3-methyl-2-(4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)butan-1-ol357

Following General Procedure I for Buchwald coupling,2-methylbenzimidazole and racemic2-(4-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)-3-methylbutan-1-olwere reacted. The enantiomers were separated by SFC to give 357. LCMSm/z: 534.3 (MH+)

Example 3582-(1-((2-(2-(2-methoxyethylamino)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol358

A mixture of2-(1-((2-(2-(benzyl(methoxyethyl)amino)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol(0.22 g, 0.34 mmol) and palladium on carbon (10 wt %, 0.2 g) and aceticacid (0.15 mL) in ethanol (10 mL) was stirred under a hydrogenatmosphere at 70° C. for 18 hours. The reaction mixture was thenfiltered though celite and concentrated. The crude product was purifiedby RP-HPLC to give 358 (54 mg, 28%). LCMS m/z: 564.4 (MH+)

Example 361(S)-3-methyl-2-(4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)butan-1-ol361

Following General Procedure I for Buchwald coupling,2-methylbenzimidazole and racemic2-(4-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)-3-methylbutan-1-olwere reacted. The enantiomers were separated by SFC to give 361. LCMSm/z: 534.3 (MH+)

Example 3622-(1-((5-(2-methyl-1H-benzo[d]imidazol-1-yl)-7-morpholinothiazolo[5,4-d]pyrimidin-2-yl)methyl)piperidin-3-yl)propan-2-ol362

A mixture of5-(2-methylbenzoimidazol-1-yl)-7-morpholin-4-yl-thiazolo[5,4-d]pyrimidine-2-carbaldehyde(78 mg, 0.2 mmol), 2-piperidin-3-yl-propan-2-ol (43 mg, 0.3 mmol)trimethyl orthoformate (0.109 mL, 1.0 mmol) and glacial acetic acid(0.017 mL, 0.3 mmol) in 1,2-dichloroethane (2 mL) was stirred at RTunder nitrogen atmosphere for 1 h. Sodium triacetoxyborohydride (85 mg,0.4 mmol) was added and the resulting reaction mixture was stirred at RTfor 16 h. The solvent was reduced in vacuo and the residue was loadedonto an Isolute® SCX-2 cartridge (10 g). The cartridge was washed withDCM/MeOH, the desired product was subsequently eluted using a mixture of2M NH₃ in MeOH and DCM. The residue was purified by columnchromatography (Si—PCC, acetone:cyclohexane: 10:90 to 35:65 by volume).Solvents were reduced in vacuo to afford the title compound as a whitesolid. The resulting solid was further purified by reverse phase HPLC(MeOH: H₂O+0.1% HCCOH, gradient 10:90 to 90:10 over 25 min). The solventwas reduced in vacuo and the aqueous residue freeze dried to afford 362as a white solid (23 mg, 23%). LCMS (Method G): R_(T) 6.73 min, [M+H]⁺508. ¹H NMR (400 MHz, CDCl₃): δ 8.18 (1H, s), 8.04-8.03 (1H, m),7.70-7.69 (1H, m), 7.27-7.26 (2H, m), 4.38 (4H, br s), 3.90 (2H, s),3.85 (4H, t, J=4.74 Hz), 3.18 (2H, m), 2.91 (5H, m), 2.28-2.15 (2H, m),1.81 (2H, m), 1.75-1.60 (2H, m), 1.20 (3H, s), 1.15 (3H, s)

Example 363N,N-dimethyl-1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)azetidine-3-carboxamide363

A solution of9-methyl-2-(2-methylbenzoimidazol-1-yl)-6-morpholin-4-yl-9H-purine-8-carbaldehyde(100 mg, 0.27 mmol) and azetidine-3-carboxylic acid dimethylamidehydrochloride salt (53 mg, 0.32 mmol) in DCE (4 mL) was stirred atambient temperature for 1 h. Sodium triacetoxyborohydride (86 mg, 0.41mmol) was added and the mixture stirred for 18 h, then loaded onto anIsolute® SCX-2 cartridge (10 g). The cartridge was then washed withmethanol and the desired product was subsequently eluted using 2 M NH₃in MeOH. The product was collected and concentrated in vacuo. Theresultant residue was purified by flash chromatography (Si—PPC,EtOAc:MeOH; gradient from 100:0 to 70:30) to afford 363 as a white solid(83 mg, 64%). LCMS (Method G): R_(T)=5.23 min, M+H⁺=490. ¹H NMR (CDCl₃,400 MHz) δ 8.08 (m, 1H); 7.70 (m, 1H); 7.28 (m, 2H); 4.35 (m, 4H);3.89-3.82 (m, 9H); 3.69-3.62 (m, 2H); 3.57-3.46 (m, 3H); 2.96 (s, 3H);2.93 (s, 3H) and 2.90 (s, 3H)

Example 3641-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)pyrrolidin-3-yl)(pyrrolidin-1-yl)methanone364

A solution of9-methyl-2-(2-methylbenzoimidazol-1-yl)-6-morpholin-4-yl-9H-purine-8-carbaldehyde(105 mg, 0.28 mmol) and pyrrolidin-1-yl-1-pyrrolidin-3-ylmethanone (60mg, 0.36 mmol) in DCE (6 mL) was stirred at ambient temperature for 2 h.Sodium triacetoxyborohydride (96 mg, 0.45 mmol) was added and themixture stirred for 18 h, then loaded onto an Isolute® SCX-2 cartridge(10 g). The cartridge was then washed with methanol and the desiredproduct was subsequently eluted using 2 M NH₃ in MeOH. The product wascollected and concentrated in vacuo. The resultant residue was purifiedby flash chromatography (Si—PPC, DCM:MeOH; gradient from 100:0 to 70:30)to afford 364 as a white solid (110 mg, 74%). LCMS (Method G):R_(T)=6.10 min, M+H⁺=530. ¹H NMR (CDCl₃, 400 MHz) δ 8.08 (m, 1H); 7.70(m, 1H); 7.27 (m, 2H); 4.35 (m, 4H); 3.93 (s, 2H); 3.92-3.81 (m, 7H);3.50-3.38 (m, 4H); 3.19-3.08 (m, 1H); 2.99 (m, 1H); 2.94 (s, 3H); 2.86(m, 2H); 2.70 (m, 1H); 2.12 (m, 2H); 2.02-1.90 (m, 2H) and 1.91-1.81 (m,2H)

Example 365(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)(pyrrolidin-1-yl)methanone365

A solution of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(100 mg, 0.27 mmol) and azetidin-3-ylpyrrolidin-1-ylmethanone (50 mg,0.32 mmol) in DCE (3 mL) was stirred at ambient temperature for 90 min.Sodium triacetoxyborohydride (86 mg, 0.41 mmol) was added and themixture stirred for 18 h, then loaded onto an Isolute® SCX-2 cartridge(10 g). The cartridge was then washed with methanol and the desiredproduct was subsequently eluted using 2 M NH₃ in MeOH. The product wascollected and concentrated in vacuo. The resultant residue was purifiedby flash chromatography (Si—PPC, EtOAc:MeOH; gradient from 100:0 to70:30) followed by reverse phase HPLC (Phenomenex Gemini 5u C18, 20 mMtriethylamine in water on a gradient of acetonitrile 80:20 to 2:98) toafford 365 as a white solid (65 mg, 48%). LCMS (Method G): R_(T)=6.26min, M+H⁺=530. ¹H NMR (CDCl₃, 400 MHz) δ 8.01 (m, 1H); 7.73 (m, 1H);7.27 (m, 2H); 4.35 (m, 4H); 3.86 (m, 6H); 3.83 (s, 3H); 3.69-3.63 (m,2H); 3.55-3.42 (m, 5H); 3.39-3.27 (m, 4H); 1.98-1.82 (m, 4H) and 1.44(t, J=7.5 Hz, 3H)

Example 3661-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-N,N-dimethylazetidine-3-carboxamide366

A solution of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(100 mg, 0.27 mmol) and azetidine-3-carboxylic acid dimethylamidehydrochloride salt (53 mg, 0.32 mmol) in DCE (4 mL) was stirred atambient temperature for 1 h. Sodium triacetoxyborohydride (86 mg, 0.41mmol) was added and the mixture stirred for 3 h, then loaded onto anIsolute® SCX-2 cartridge (10 g). The cartridge was then washed withmethanol and the desired product was subsequently eluted using 2 M NH₃in MeOH. The product was collected and concentrated in vacuo. Theresultant residue was purified by flash chromatography (Si—PPC,EtOAc:MeOH; gradient from 100:0 to 70:30) to afford 366 as a cream solid(107 mg, 83%). LCMS (Method G): R_(T)=5.51 min, M+H⁺=504. ¹H NMR (CDCl₃,400 MHz) δ 8.00 (m, 1H); 7.75 (m, 1H); 7.28 (m, 2H); 4.34 (m, 4H);3.89-3.83 (m, 6H); 3.83 (s, 3H); 3.70-3.62 (m, 2H); 3.57-3.46 (m, 3H);3.34 (q, J=7.5 Hz, 2H); 2.96 (s, 3H); 2.90 (s, 3H) and 1.44 (t, J=7.5Hz, 3H)

Example 3672-(1-(2-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)ethyl)piperidin-4-yl)propan-2-ol367

A mixture of2-{1-[2-(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)ethyl]-piperidin-4-yl}propan-2-ol(71 mg, 0.17 mmol), 2-ethylbenzimidazole (27 mg, 0.19 mmol), Pd₂(dba)₃(3.8 mg, 2.5 mol %), Xphos (8.0 mg, 10 mol %) and Cs₂CO₃ (82 mg, 0.25mmol) in dioxane (1.0 mL) was purged with argon gas then heated at 120°C., for 19 h, in a sealed tube. The reaction mixture was loaded onto anIsolute® SCX-2 cartridge, washed with MeOH then the desired producteluted with 2 M NH₃ in MeOH. The resulting residue was purified by flashchromatography (Si—PCC, 0-10% MeOH in DCM) to give 367 (45 mg, 50%) as ayellow solid. LCMS: (Method G): R_(T) 6.09 min; [M+H]⁺ 533.3. ¹H NMR(400 MHz, CHCl₃-d): δ 8.01-7.97 (m, 1H), 7.77-7.72 (m, 1H), 7.29-7.23(m, 2H), 4.49-4.15 (m, 4H), 3.88-3.83 (m, 4H), 3.78 (s, 3H), 3.34 (q,J=7.5, 2 H), 3.14 (m, 4H), 2.93-2.75 (m, 2H), 2.20-2.08 (m, 2H),1.85-1.78 (m, 2H), 1.44 (t, J=7.5 Hz, 3H), 1.40-1.21 (m, 3H), 1.24-1.18(m, 6H)

Example 3682-methyl-2-(4-(2-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)ethyl)piperazin-1-yl)propanamide368

A mixture of2-{4-[2-(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)ethyl]piperazin-1-yl}isobutyramide(80 mg, 0.18 mmol), 2-methylbenzimidazole (26 mg, 0.20 mmol), Pd₂(dba)₃(4 mg, 2.5 mol %), Xphos (8 mg, 10 mol %) and Cs₂CO₃ (87 mg, 0.27 mmol)in dioxane (1.0 mL) was purged with argon gas then heated at 120° C.,for 19 h, in a sealed tube. The reaction mixture was loaded onto anIsolute® SCX-2 cartridge, washed with MeOH then the desired producteluted with 2 M NH₃ in MeOH. The resulting residue was purified by flashchromatography (Si—PCC, 0-10% MeOH in DCM) to give 368 (63 mg, 65%) as apale yellow solid. LCMS: (Method G): R_(T) 5.34 min; [M+H]⁺ 547.3. ¹HNMR (400 MHz, CHCl₃-d): δ 8.09-8.05 (m, 1H), 7.73-7.69 (m, 1H),7.29-7.24 (m, 1H), 7.06 (s, 1H), 5.23 (s, 1H), 4.47-4.14 (m, 4H), 3.87(t, J=4.7 Hz, 4H), 3.79 (s, 3H), 3.49 (s, 1H), 3.19-3.0 (m, 2H), 2.94(s, 3H), 2.78-2.54 (m, 6H), 1.78-1.48 (m, 4H), 1.25 (s, 6H)

Example 3698-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)-1,4-dioxa-8-azaspiro[4.5]decane369

Following General Procedure I for Buchwald coupling,8-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-1,4-dioxa-8-azaspiro[4.5]decaneand 2-methybenzimidazole were reacted to give 369. LCMS m/z: 505.2 (MH+)

Example 3708-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)-1-oxa-8-azaspiro[4.5]decane370

Following General Procedure I for Buchwald coupling,8-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-1-oxa-8-azaspiro[4.5]decaneand 2-methybenzimidazole were reacted to give 370. LCMS m/z: 503.2 (MH+)

Alternatively, following General Procedure E for Displacement of alkylbromide with amines,4-(8-(bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholineand 1-oxa-8-azaspiro[4.5]decane were reacted to give 370.

Example 3798-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)-2,8-diazaspiro[4.5]decan-1-one379

Following General Procedure I for Buchwald coupling,2-methylbenzimidazole and8-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-2,8-diazaspiro[4.5]decan-1-onewere reacted to give 379. LCMS m/z 258.6 (2M+H+)

Example 3808-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)-3-oxa-8-azabicyclo[3.2.1]octane380

Following General Procedure I for Buchwald coupling,2-methylbenzimidazole and8-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-3-oxa-8-aza-bicyclo[3.2.1]octanewere reacted to give 380. LCMS m/z: 475.2 (MH+)

Example 381I-2-(4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)butan-1-ol381

Following General Procedure I for Buchwald coupling,2-methylbenzimidazole and2-(4-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)butan-1-olwere reacted. The enantiomers were separated by SFC to give 381. LCMSm/z: 520.3 (MH+)

Example 382(S)-2-(4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)butan-1-ol382

Following General Procedure I for Buchwald coupling,2-methylbenzimidazole and2-(4-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)butan-1-olwere reacted. The enantiomers were separated by SFC to give 382. LCMSm/z: 520.3 (MH+)

Example 3832-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-amine383

According to General Procedure E, [(9H-fluoren-9-yl)methyl2-(piperidin-4-yl)propan-2-ylcarbamate (0.0923 g, 0.253 mmol) andN,N-diisopropylethylamine (0.265 mL, 0.00152 mol) were mixed in THF (0.7mL, 0.008 mol) and Methanol (0.7 mL, 0.02 mol) at room temperature, and4-(8-(bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine(0.112 g, 0.253 mmol) was added. The reaction was stirred overnight. Thereaction mixture was concentrated to dryness. The crude residue wasdissolved in N,N-Dimethylformamide (2.0 mL) and Piperidine (0.200 mL)was added. The mixture was stirred overnight at room temperature. Thereaction mixture was concentrated. The crude was purified by reversephase HPLC to give 383 (45.5 mg, 35.7%). [M+H]⁺=504.3.

Example 3845-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)-2-oxa-5-azabicyclo[2.2.1]heptane384

Following General Procedure I for Buchwald coupling,2-methylbenzimidazole and2-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-5-oxa-2-aza-bicyclo[2.2.1]heptanewere reacted to give 384. LCMS m/z: 461.2 (MH+)

Example 385(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-4-methylpiperidin-4-yl)methanol385

Following General Procedure I for Buchwald coupling,(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-4-methylpiperidin-4-yl)methanoland 2-ethyl-1H-benzo[d]imidazole were reacted to give 385. LCMS m/z:505.3 (MH+)

Example 3864-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-8-((3-(piperidin-1-yl)azetidin-1-yl)methyl)-9H-purin-6-yl)morpholine386

Following General Procedure E for amine alkylation,4-(8-(bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholineand 1-(azetidin-3-yl)piperidine were reacted to give 386. LCMS m/z:502.3 (MH+)

Example 3874-(8-((4-tert-butylpiperazin-1-yl)methyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine387

Following General Procedure I for Buchwald coupling,4-(8-((4-tert-butylpiperazin-1-yl)methyl)-2-chloro-9-methyl-9H-purin-6-yl)morpholineand 2-ethyl-1H-benzo[d]imidazole were reacted to give 387. LCMS m/z:518.3 (MH+)

Example 389N-methyl-1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)-N-(tetrahydrofuran-3-yl)piperidin-4-amine389

A mixture of9-methyl-2-(2-methylbenzoimidazol-1-yl)-6-morpholin-4-yl-9H-purine-8-carbaldehyde(72 mg, 0.19 mmol), methylpiperidin-4-yl(tetrahydrofuran-3-yl)amine (42mg, 0.23 mmol) and 4 Å powdered molecular sieves (200 mg) in DCE (5 mL)was stirred at room temperature for 4 h before the addition of sodiumtriacetoxyborohydride (81 mg, 0.38 mmol). The reaction mixture wasstirred for 16 h then filtered through celite, washing with DCM. Theorganic phase was washed with brine (×1) and concentrated in vacuo. Theresulting residue was purified by column chromatography (Si—PCC,MeOH:DCM, 0-10%). The resulting oil was loaded onto an Isolute® SCX-2cartridge which was washed with MeOH/DCM and the product eluted with 2MNH₃/MeOH affording 389 as a white solid (55 mg, 53%). LCMS (Method G):R_(T) 4.96 min [M+H]⁺ 546.3. ¹H NMR (CDCl₃, 400 MHz): δ 8.11-8.07 (m,1H); 7.73-7.69 (m, 1H); 7.29-7.24 (m, 2H); 4.35 (m, 4H); 3.96 (m, 1H);3.92-3.80 (m, 8H); 3.83-3.71 (m, 4H); 3.43 (m, 1H); 3.02-2.90 (m, 4H);2.52 (m, 1H); 2.26 (s, 3H); 2.16 (m, 2H); 2.03 (m, 1H); 1.90 (m, 1H);1.77 (s, 3H) and 1.59 (m, 2H)

Example 3901-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-N-methyl-N-(tetrahydrofuran-3-yl)piperidin-4-amine390

A mixture of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(72 g, 0.19 mmol), methylpiperidin-4-yl(tetrahydrofuran-3-yl)amine (42mg, 0.23 mmol) and 4 Å powdered molecular sieves (200 mg) in DCE (5 mL)was stirred at room temperature for 6.5 h before the addition of sodiumtriacetoxyborohydride (81 mg, 0.38 mmol). The reaction mixture wasstirred for 16 h then filtered through celite, washing with DCM. Theorganic phase was washed with brine (×1) and concentrated in vacuo. Theorganic phase was dried (Na₂SO₄) and concentrated in vacuo. Theresulting residue was purified by column chromatography (Si—PCC,MeOH:EtOAc, 0-20%). The resulting oil was loaded onto an Isolute® SCX-2cartridge which was washed with MeOH/DCM and the product eluted with 2MNH₃/MeOH affording 390 as a cream solid (55 mg, 53%). LCMS (Method G):R_(T) 4.96 min [M+H]⁺ 546.3. ¹H NMR (CDCl₃, 400 MHz): δ 8.03-7.99 (m,1H); 7.77-7.73 (m, 1H); 7.29-7.23 (m, 2H); 4.34 (m, 4H); 3.96 (m, 1H);3.91-3.69 (m, 12H); 3.45-3.26 (m, 3H); 2.97 (d, J=11.3 Hz, 2H); 2.51 (m,1H); 2.26 (s, 3H); 2.16 (t, J=11.3 Hz, 2H); 2.03 (m, 1H); 1.89 (m, 2H);1.76 (s, 2H); 1.66 (m, 1H) and 1.45 (t, J=7.5 Hz, 3H)

Example 3917-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-2-methyl-7-azaspiro[3.5]nonan-2-ol391

To a solution of 2-hydroxy-2-methyl-7-azaspiro[3.5]nonane-7-carboxylicacid benzyl ester (96 mg, 0.33 mmol) in IMS (3 mL) was added palladium(10 wt. % on carbon, 10 mg). The vessel was evacuated and back-filledwith hydrogen, and stirred at RT for 1 h under a hydrogen atmosphere.The reaction mixture was passed through a hydrophobic frit (PTFE) andthe resulting filtrate evaporated to give a residue (70 mg) that wastaken up in DCE (5 mL). To this solution was added2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(150 mg, 0.38 mmol), trimethyl orthoformate (0.42 mL, 3.83 mmol) andacetic acid (0.02 mL, 0.38 mmol). The reaction mixture was stirred atroom temperature for 2 h, sodium triacetoxyborohydride (122 mg, 0.57mmol) was added and the resulting mixture stirred for a further 2 days.The reaction mixture was loaded onto an Isolute® SCX-2 cartridge, washedwith MeOH then the desired product eluted with 2 M NH₃/MeOH in DCM. Theresulting residue was purified by reverse phase HPLC (Phenomenex Gemini5 μm C18, 20 mM triethylamine in water on a gradient of acetonitrile15-98%) to give 391 as an off white solid (69 mg, 39% over 2 steps).LCMS (Method G): R_(T)=6.29 min, [M+H]⁺ 531.3. ¹H NMR (400 MHz,CHCl₃-d): δ 8.03-7.98 (m, 1H), 7.77-7.72 (m, 1H), 7.29-7.23 (m, 2H),4.50-4.32 (m, 4H), 3.89-3.83 (m, 7H), 3.85-3.63 (m, 2H), 3.35 (q, J=7.5Hz, 2H), 2.57-2.23 (m, 4H), 2.00-1.85 (m, 4H), 1.65 (m, 5H), 1.45 (t,J=7.5 Hz, 3H), 1.39 (s, 3H)

Example 3924-(2-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)ethyl)-2,2-dimethylmorpholine392

A mixture of2-chloro-8-[2-(2,2-dimethylmorpholin-4-yl)ethyl]-9-methyl-6-morpholin-4-yl-9H-purine(57 mg, 0.14 mmol), 2-ethylbenzimidazole (23 mg, 0.16 mmol), Pd₂(dba)₃(3.3 mg, 2.5 mol %), Xphos (6.9 mg, 10 mol %) and Cs₂CO₃ (71 mg, 0.27mmol) in dioxane (1.0 mL) was purged with argon gas then heated at 120°C., for 16 h, in a sealed tube. The reaction mixture was loaded onto anIsolute® SCX-2 cartridge, washed with MeOH then the desired producteluted with 2 M NH₃ in MeOH. The resulting residue was purified by flashchromatography (Si—PCC, 0-5% MeOH in DCM) to give 392 (46 mg, 63%) as apale yellow solid. LCMS: (Method G): R_(T) 6.31 min; [M+H]⁺ 505.3. ¹HNMR (400 MHz, CHCl₃-d): δ 8.02-7.97 (m, 1H), 7.78-7.72 (m, 1H),7.27-7.22 (m, 2H), 4.48-4.20 (m, 4H), 3.89-3.83 (m, 4H), 3.79 (s, 3H),3.77-3.55 (m, 2H), 3.35 (q, J=7.5 Hz, 2H), 3.12-2.97 (m, 2H), 2.91-2.76(m, 2H), 2.57-2.43 (m, 2H), 2.42-2.29 (m, 2H), 1.44 (t, J=7.5 Hz, 3H),1.26 (s, 6H)

Example 393(S)-azetidin-1-yl(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)pyrrolidin-3-yl)methanone393

A solution of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(100 mg, 0.26 mmol) and azetidin-1-yl-(S)-pyrrolidin-3-ylmethanone (47mg, 0.31 mmol) in DCE (5 mL) was stirred at ambient temperature for 4 h.Sodium triacetoxyborohydride (81 mg, 0.38 mmol) was added and themixture stirred for 18 h, then loaded onto an Isolute® SCX-2 cartridge(10 g). The cartridge was then washed with methanol and the desiredproduct was subsequently eluted using 2 M NH₃ in MeOH. The product wascollected and concentrated in vacuo. The resultant residue was purifiedby flash chromatography (Si—PPC, DCM:MeOH; gradient from 100:0 to 70:30)followed by reverse phase HPLC (Phenomenex Gemini 5u C18, 20 mMtriethylamine in water on a gradient of acetonitrile 80:20 to 2:98) toafford 393 as a white solid (62 mg, 46%). LCMS (Method G): R_(T)=5.93min, M+H⁺=530. ¹H NMR (CDCl₃, 400 MHz) δ 8.02 (m, 1H); 7.75 (m, 1H);7.29-7.22 (m, 2H); 4.35 (m, 4H); 4.22-4.08 (m, 2H); 4.02 (t, J=7.9 Hz,2H); 3.94 (s, 2H); 3.90-3.83 (m, 7H); 3.35 (q, J=7.5 Hz, 2H); 3.09-2.57(m, 5H); 2.33-2.23 (m, 2H); 2.09 (m, 2H) and 1.45 (t, J=7.5 Hz, 3H)

Example 3949-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one394

A mixture of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(100 mg, 0.26 mmol), 1-oxa-4,9-diazaspiro[5.5]undecan-3-one (61 mg, 0.36mmol) and molecular sieves (4 Å, powdered, 255 mg) in DCE (5 mL) wasstirred at ambient temperature for 1 h. Sodium triacetoxyborohydride (81mg, 0.38 mmol) was added and the mixture stirred for 17 h, then loadedonto an Isolute® SCX-2 cartridge (10 g). The cartridge was then washedwith methanol and the desired product was subsequently eluted using 2 MNH₃ in MeOH. The product was collected and concentrated in vacuo. Theresultant residue was purified by flash chromatography (Si—PPC,EtOAc:MeOH; gradient from 100:0 to 70:30) to afford 394 as a cream solid(116 mg, 83%). LCMS (Method G): R_(T)=5.76 min, M+H⁺=546. ¹H NMR (CDCl₃,400 MHz) δ 8.01 (m, 1H); 7.77 (m, 1H); 7.32-7.24 (m, 2H); 5.93 (bs, 1H);4.35 (m, 4H); 4.18 (s, 2H); 3.90-3.84 (m, 7H); 3.82 (bs, 2H); 3.37 (q,J=7.5 Hz, 2H); 3.27 (m, 2H); 2.72 (m, 2H); 2.59 (m, 2H); 2.05-1.93 (m,2H); 1.68 (m, 2H) and 1.46 (t, J=7.5 Hz, 3H)

Example 3954-(8-((1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-ylmethyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine395

A mixture of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(200 mg, 0.51 mmol), (1S,4S)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylicacid tert-butyl ester (122 mg, 0.62 mmol) and molecular sieves (4 Å,powdered, 520 mg) in DCE (10 mL) was stirred at ambient temperature for3 h. Sodium triacetoxyborohydride (162 mg, 0.76 mmol) was added and themixture stirred for 17 h, then loaded onto an Isolute® SCX-2 cartridge(25 g). The cartridge was then washed with methanol and the desiredproduct was subsequently eluted using 2 M NH₃ in MeOH. The product wascollected and concentrated in vacuo. The resultant residue was purifiedby flash chromatography (Si—PPC, EtOAc:MeOH; gradient from 100:0 to85:15) to give(1S,4S)-5-[2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl]-2,5-diazabicyclo[2.2.1]heptane-2-carboxylicacid tert-butyl ester as a white solid. TFA (3 mL) was added to asolution of(1S,4S)-5-[2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl]-2,5-diazabicyclo[2.2.1]heptane-2-carboxylicacid tert-butyl ester in DCM (10 mL) and the mixture stirred at ambienttemperature for 30 min, then loaded onto an Isolute® SCX-2 cartridge (25g). The cartridge was then washed with methanol and the desired productwas subsequently eluted using 2 M NH₃ in MeOH. The product was collectedand concentrated in vacuo. The resultant residue was purified by flashchromatography (Si—PPC, DCM:MeOH; gradient from 100:0 to 85:15) toafford 395 as a white solid (153 mg, 63%). LCMS (Method G): R_(T)=5.78min, M+H⁺=474. ¹H NMR (CDCl₃, 400 MHz) δ 8.01 (m, 1H); 7.75 (m, 1H);7.26 (m, 2H); 4.34 (m, 4H); 4.00 (d, J=13.6 Hz, 1H); 3.92-3.83 (m, 8H);3.70 (s, 1H); 3.45 (s, 1H); 3.35 (q, J=7.5 Hz, 2H); 3.25 (d, J=10.2 Hz,1H); 2.97-2.91 (m, 2H); 2.70 (d, J=10.2 Hz, 1H); 1.85 (d, J=10.1 Hz,1H); 1.70 (d, J=10.1 Hz, 1H) and 1.45 (t, J=7.5 Hz, 3H)

Example 396(3-methyl-1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)pyrrolidin-3-yl)(pyrrolidin-1-yl)methanone396

A mixture of9-methyl-2-(2-methylbenzoimidazol-1-yl)-6-morpholin-4-yl-9H-purine-8-carbaldehyde(100 mg, 0.26 mmol), (3-methylpyrrolidin-3-yl)pyrrolidin-1-ylmethanone(58 mg, 0.32 mmol), trimethoxyorthoformate (0.29 mL, 2.65 mmol) andacetic acid (15 μL, 0.26 mmol) in DCE (5 mL) was stirred at roomtemperature for 1 hour then sodium triacetoxyborohydride (90 mg, 0.42mmol) was added. The reaction mixture was stirred at room temperaturefor 18 hours then diluted with MeOH and loaded onto an Isolute® SCX-2cartridge (10 g). The cartridge was washed with MeOH and the desiredproduct was eluted with 2M NH₃ in MeOH. The solvents were removed andthe residue was subjected to flash chromatography (Si—PCC, 0-20% MeOH inEtOAc) to give 396 as a white solid (107 mg, 76%). LCMS (Method G):R_(T) 6.69 min; [M+H]⁺ 544. ¹H NMR (400 MHz, CHCl₃-d): δ 8.12-8.07 (m,1H); 7.74-7.70 (m, 1H); 7.30-7.26 (m, 2H); 4.35 (m, 4H); 3.90 (s, 3H);3.87 (t, J=4.75 Hz, 5H); 3.49 (m, 5H); 2.96 (s, 3H); 2.64 (s, 2H);2.46-2.37 (m, 2H); 1.89 (m, 4H); 1.81 (m, 2H); 1.41 (s, 3H).

Example 398(S)-1-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-N,N-dimethylpyrrolidine-3-carboxamide398

A solution of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(100 mg, 0.26 mmol) and (S)-pyrrolidine-3-carboxylic acid dimethylamide(44 mg, 0.31 mmol) in DCE (5 mL) was stirred at ambient temperature for4 h. Sodium triacetoxyborohydride (81 mg, 0.38 mmol) was added and themixture stirred for 18 h, then loaded onto an Isolute® SCX-2 cartridge(10 g). The cartridge was then washed with methanol and the desiredproduct was subsequently eluted using 2 M NH₃ in MeOH. The product wascollected and concentrated in vacuo. The resultant residue was purifiedby flash chromatography (Si—PPC, DCM:MeOH; gradient from 100:0 to 70:30)to afford 398 as a cream solid (50 mg, 38%). LCMS (Method G): R_(T)=5.90min, M+H⁺=518. ¹H NMR (CDCl₃, 400 MHz) δ 8.01 (m, 1H); 7.75 (m, 1H);7.28 (m, 2H); 4.35 (m, 4H); 3.98-3.80 (m, 9H); 3.40-3.25 (m, 3H);3.20-2.78 (m, 10H); 2.15-2.07 (m, 2H) and 1.50-1.41 (m, 3H)

Example 399(S)-(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)pyrrolidin-3-yl)(pyrrolidin-1-yl)methanone399

A solution of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(100 mg, 0.26 mmol) and pyrrolidin-1-yl-(S)-pyrrolidin-3-ylmethanone (51mg, 0.30 mmol) in DCE (5 mL) was stirred at ambient temperature for 2 h.Sodium triacetoxyborohydride (96 mg, 0.45 mmol) was added and themixture stirred for 18 h, then loaded onto an Isolute® SCX-2 cartridge(10 g). The cartridge was then washed with methanol and the desiredproduct was subsequently eluted using 2 M NH₃ in MeOH. The product wascollected and concentrated in vacuo. The resultant residue was purifiedby flash chromatography (Si—PPC, DCM:MeOH; gradient from 100:0 to 70:30)to afford 399 as a white solid (132 mg, 86%). LCMS (Method G):R_(T)=6.43 min, M+H⁺=544. ¹H NMR (CDCl₃, 400 MHz) δ 7.99 (m, 1H); 7.75(m, 1H); 7.27 (m, 2H); 4.35 (m, 4H); 3.94 (s, 2H); 3.87 (m, 7H);3.50-3.38 (m, 4H); 3.35 (q, J=7.5 Hz, 2H); 3.20-3.10 (m, 1H); 3.01 (m,1H); 2.87 (m, 2H); 2.72 (m, 1H); 2.16-2.07 (m, 2H); 2.01-1.90 (m, 2H);1.91-1.81 (m, 2H) and 1.45 (t, J=7.5 Hz, 3H)

Example 4009-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)-1,5-dioxa-9-azaspiro[5.5]undecane400

Following General Procedure I for Buchwald coupling,2-methylbenzimidazole and9-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-1,5-dioxa-9-azaspiro[5.5]undecanewere reacted to give 400. LCMS m/z: 519.2 (MH+)

Example 4014-(8-((4-tert-butylpiperazin-1-yl)methyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine401

To stirred solution of4-(2-chloro-9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-yl)morpholine (10.0g, 0.0309 mol;) in THF (400 mL, 5 mol) at −78° C. was added 2.5 M ofn-Butyllithium in hexane (18 mL). The solution was stirred at −78° C.for 30 minutes. N,N-Dimethylformamide (5.3 mL, 0.068 mol) was added andstirring continued at −78° C. for 1 hours. The reaction was slowlyquenched using 0.1N HCl cold solution. The product was extracted withDCM. The organic extracts were combined, washed with brine, filtered,and concentrated to dryness to give2-chloro-6-morpholino-9-(tetrahydro-2H-pyran-2-yl)-9H-purine-8-carbaldehyde(10.76 g, 99%) as a yellow solid. The crude was carried on withoutfurther purification.

2-Chloro-6-morpholino-9-(tetrahydro-2H-pyran-2-yl)-9H-purine-8-carbaldehyde(0.148 g, 0.422 mmol) was dissolved in 1,2-dichloroethane (3.7 mL, 0.047mol). 1-tert-butylpiperazine (0.060 g, 0.42 mmol) was added followed bymicronized 4 Å molecular sieves (0.450 g). After 2 hours sodiumtriacetoxyborohydride (0.179 g, 0.844 mmol) was added and the reactionwas stirred at room temperature overnight. The reaction mixture wasfiltered. The filter cake was washed with additional DCM and MeOH. Thecombined organics were concentrated to dryness. The crude was purifiedby flash column chromatography (Si—PPC; MeOH:DCM gradient 0:100 to10:90) to give4-(8-((4-tert-butylpiperazin-1-yl)methyl)-2-chloro-9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-yl)morpholine(126 mg, 62%). [M+H]⁺=478.3

Into a vial was added4-(8-((4-tert-butylpiperazin-1-yl)methyl)-2-chloro-9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-yl)morpholine(126 mg, 0.264 mmol), 2-ethyl-1H-benzo[d]imidazole (40.4 mg, 0.277mmol), Xphos (16.3 mg, 0.0343 mmol),tris(dibenzylideneacetone)dipalladium(0) (16.4 mg, 0.0179 mmol), andcesium carbonate (172 mg, 0.527 mmol;). The mixture was dissolved inN,N-dimethylformamide (2.02 mL, 0.0261 mol) and heated at 145° C. underpressure for 30 minutes in a microwave reactor. The reaction mixture wasfiltered and concentrated. The crude residue was dissolved in MeOH (5.0mL) and para-toluenesulfonic acid (90.8 mg, 0.527 mmol) was added. Thereaction was heated overnight at 40° C. The reaction mixture wasconcentrated to dryness and purified by reverse phase HPLC to give 401(50.9 mg, 38.3%). [M+H]⁺=504.3

Example 4042-((1R,5S,6r)-3-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)-3-azabicyclo[3.1.0]hexan-6-yl)propan-2-ol404

Following General Procedure I for Buchwald coupling,2-methylbenzimidazole and2-((1R,5S,6r)-3-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-3-azabicyclo[3.1.0]hexan-6-yl)propan-2-olwere reacted to give 404. LCMS m/z: 503.3 (MH+)

Example 407I-1-(1-(8-((4-(2-hydroxypropan-2-yl)piperidin-1-yl)methyl)-9-methyl-6-morpholino-9H-purin-2-yl)-1H-benzo[d]imidazol-2-yl)propan-2-ol407

Following General Procedure I for Buchwald coupling,1-(1H-benzmidazol-2-yl)propan-2-ol and racemic2-(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-olwere reacted. The enantiomers were separated by SFC to give 407. LCMSm/z: 549.3 (MH+)

Example 408(S)-1-(1-(8-((4-(2-hydroxypropan-2-yl)piperidin-1-yl)methyl)-9-methyl-6-morpholino-9H-purin-2-yl)-1H-benzo[d]imidazol-2-yl)propan-2-ol408

Following General Procedure I for Buchwald coupling,1-(1H-benzmidazol-2-yl)propan-2-ol and racemic2-(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-olwere reacted. The enantiomers were separated by SFC to give 408. LCMSm/z: 549.3 (MH+)

Example 409I-8-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)octahydropyrazino[2,1-c][1,4]oxazine409

A mixture of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(97 g, 0.25 mmol), (R)-octahydropyrazino[2,1-c][1,4]oxazine (42 mg, 0.30mmol) and 4 Å powdered molecular sieves (200 mg) in DCE (6 mL) wasstirred at room temperature for 5 h before the addition of sodiumtriacetoxyborohydride (106 mg, 0.50 mmol). The reaction mixture wasstirred for 64 h then filtered through celite, washing with DCM. Theorganic phase was washed with brine (×1) and concentrated in vacuo. Theorganic phase was dried (Na₂SO₄) and concentrated in vacuo. Theresulting residue was purified by column chromatography (Si—PCC,MeOH:DCM, 0-15%). The resulting oil was loaded onto an Isolute® SCX-2cartridge which was washed with MeOH/DCM and the product eluted with 2MNH₃/MeOH affording 409 as a cream solid (31 mg, 24%). LCMS (Method I):R_(T) 2.49 min [M+H]⁺ 518.3. ¹H NMR (CDCl₃, 400 MHz): δ 8.03-7.98 (m,1H); 7.78-7.74 (m, 1H); 7.29-7.23 (m, 2H); 4.34 (m, 4H); 3.89-3.82 (m,7H); 3.84-3.70 (m, 2H); 3.70-3.63 (m, 1H); 3.42-3.32 (m, 3H); 2.85 (d,J=11.0 Hz, 2H); 2.74 (m, 1H); 2.63 (d, J=11.4 Hz, 2H); 2.56 (m, 1H);2.43 (m, 3H); 2.08 (m, 1H) and 1.68 (s, 1H); 1.50-1.42 (m, 3H)

Example 4104-methyl-5-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methylamino)pentane-1,4-diol410

Following General Procedure E for Displacement of alkyl bromide withamines,4-(8-(bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholineand 5-amino-4-methylpentane-1,4-diol were reacted to give 410. [M+H]⁺495.6

Example 4132-(4-((2-(2-cyclopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)-2-methylpropan-1-ol413

Following General Procedure I for Buchwald coupling,4-(8-((4-tert-butylpiperazin-1-yl)methyl)-2-chloro-9-methyl-9H-purin-6-yl)morpholineand 2-cyclopropyl-1H-benzo[d]imidazole were reacted to give 413. LCMS:M+H⁺=546.3

Example 415(S)-4-(8-((hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)methyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine415

Following General Procedure I for Buchwald coupling,2-methylbenzimidazole and racemic4-(2-chloro-8-((hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)methyl)-9-methyl-9H-purin-6-yl)morpholinewere reacted. The enantiomers were separated by SFC to give 415. LCMSm/z: 488.2 (MH+)

Example 416I-4-(8-((hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)methyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine416

Following General Procedure I for Buchwald coupling,2-methylbenzimidazole and racemic4-(2-chloro-8-((hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)methyl)-9-methyl-9H-purin-6-yl)morpholinewere reacted. The enantiomers were separated by SFC to give 416. LCMSm/z: 488.2 (MH+)

Example 417 ethyl2-((1S,4S)-5-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)-2-methylpropanoate417

2-Bromo-2-methylpropionic acid ethyl ester (90 μL, 0.61 mmol) was addedto a solution of potassium carbonate (84 mg, 0.61 mmol) and8-[(1S,4S)-1-(2,5-diazabicyclo[2.2.1]hept-2-yl)methyl]-2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine(140 mg, 0.30 mmol) in anhydrous acetonitrile. The resulting mixture washeated at 80° C. for 48 h, then cooled to ambient temperature andpartitioned between EtOAc and water. The organic layer was separated,washed with brine, then dried (MgSO₄) and concentrated in vacuo. Theresultant residue was purified by flash chromatography (Si—PPC,DCM:MeOH; gradient from 100:0 to 85:15) to afford 417 as a cream solid(100 mg, 58%). LCMS (Method I): R_(T)=2.92 min, M+H⁺=588. ¹H NMR (CDCl₃,400 MHz) δ 8.01 (m, 1H); 7.75 (m, 1H); 7.29-7.23 (m, 2H); 4.34 (m, 4H);4.15 (m, 2H); 3.93-3.82 (m, 9H); 3.64 (m, 1H); 3.35 (q, J=7.5 Hz, 2H);3.19 (m, 1H); 2.81-2.63 (m, 3H); 1.58 (m, 4H); 1.45 (t, J=7.5 Hz, 3H);1.36 (m, 2H) and 1.32-1.23 (m, 6H)

Example 4181-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-N-methyl-N-(oxetan-3-yl)piperidin-4-amine418

A mixture of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(179 mg, 0.46 mmol), methyloxetan-3-ylpiperidin-4-ylamine (94 mg, 0.55mmol) and 4 Å powdered molecular sieves (400 mg) in DCE (10 mL) wasstirred at room temperature for 5 h before the addition of sodiumtriacetoxyborohydride (233 mg, 0.92 mmol). The reaction mixture wasstirred for 16 h then filtered through celite, washing with DCM. Theorganic phase was washed with brine (×1) and concentrated in vacuo. Theorganic phase was dried (Na₂SO₄) and concentrated in vacuo. Theresulting residue was purified by column chromatography (Si—PCC,MeOH:DCM, 0-15%) affording 418 as a cream solid (93 mg, 37%). LCMS(Method I): R_(T) 2.31 min [M+H]⁺ 546.4. ¹H NMR (CDCl₃, 400 MHz): δ8.03-7.99 (m, 1H); 7.78-7.72 (m, 1H); 7.29-7.22 (m, 2H); 4.67 (t, J=6.5Hz, 2H); 4.60 (t, J=6.6 Hz, 2H); 4.34 (m, 4H); 3.98-3.88 (m, 1H);3.89-3.82 (m, 7H); 3.72 (s, 2H); 3.35 (q, J=7.5 Hz, 2H); 2.94 (d, J=11.2Hz, 2H); 2.35-2.24 (m, 1H); 2.21 (s, 3H); 2.13 (t, J=11.2 Hz, 2H); 1.64(d, J=12.2 Hz, 2H); 1.54 (m, 2H) and 1.45 (t, J=7.5 Hz, 3H)

Example 419N-((1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)methyl)-N-methyltetrahydrofuran-3-amine419

A mixture of9-methyl-2-(2-methylbenzoimidazol-1-yl)-6-morpholin-4-yl-9H-purine-8-carbaldehyde(78 mg, 0.2 mmol),(azetidin-3-ylmethyl)methyl(tetrahydrofuran-3-yl)amine (51 mg, 0.3 mmol)and 4 Å molecular sieves (250 mg) in 1,2-dichloroethane (2 mL) wasstirred at RT under nitrogen atmosphere for 6 h. Sodiumtriacetoxyborohydride (85 mg, 0.4 mmol) was added and the resultingreaction mixture was stirred at RT for 36 h. The solvent was reduced invacuo and the residue was loaded onto an Isolute® SCX-2 cartridge (5 g).The cartridge was washed with DCM/MeOH, the desired product wassubsequently eluted using a mixture of 2M NH₃ in MeOH and DCM. Theresidue was purified by column chromatography (Si—PCC, MeOH:DCM:gradient 0:100 to 10:90) to afford 419 as a white foam (80 mg, 73%).LCMS (Method I): R_(T) 2.05 min, [M+H]⁺ 546. ¹H NMR (400 MHz, CDCl₃): δ7.99-7.95 (1H, m), 7.73-7.70 (1H, m), 7.23 (2H, m), 4.32 (4H, s), 3.92(1H, m), 3.82-3.80 (7H, m), 3.72 (1H, q, J=8.06 Hz), 3.61 (1H, m), 3.51(2H, t, J=7.19 Hz), 3.31 (2H, q, J=7.48 Hz), 3.08 (1H, m), 2.95 (2H, t,J=6.81 Hz), 2.76-2.44 (2H, m), 2.14 (3H, s), 2.03-1.93 (1H, m),1.85-1.75 (1H, m), 1.63 (4H, br s), 1.41 (3H, t, J=7.48 Hz)

Example 4202-(1-((5-(2-ethyl-1H-benzo[d]imidazol-1-yl)-7-morpholinothiazolo[4,5-d]pyrimidin-2-yl)methyl)piperidin-4-yl)propan-2-ol420

A mixture of2-[1-(5-chloro-7-morpholin-4-yl-thiazolo[4,5-d]pyrimidin-2-ylmethyl)piperidin-4-yl]propan-2-ol(100 mg, 0.243 mmol), 2-ethyl-1H-benzoimidazole (39 mg, 0.267 mmol),Pd₂(dba)₃ (11 mg, 0.0122 mmol), XPhos (23 mg, 0.049 mmol) and cesiumcarbonate (158 mg, 0.486 mmol) in 1,4-dioxane (1.5 mL) was purged withargon gas for 15 min. The resulting reaction mixture was irradiated withmicrowaves at 150° C. for 30 min. The crude residue was loaded on anIsolute® SCX-2 cartridge (5 g). The cartridge was washed with DCM/MeOHand the desired product was subsequently eluted using a mixture of 2MNH₃ in MeOH and DCM. The resulting residue was further purified bycolumn chromatography (Si—PCC, 2 M NH₃ in MeOH:DCM: gradient 0:100 to5:95) to afford 420 as a brown solid (47 mg, 37%) LCMS (Method I): R_(T)2.53 min, [M+H]⁺ 522. ¹H NMR (400 MHz, CDCl₃): δ 8.11 (1H, m), 7.77-7.70(1H, m), 7.23 (2H, m), 4.01-3.99 (6H, m), 3.87 (5H, m), 3.42-3.39 (2H,m), 3.10 (2H, m), 2.27 (2H, m), 1.79 (2H, m), 1.50 (2H, d, m), 1.46-1.40(3H, m), 1.32 (1H, m), 1.20 (6H, s)

Example 421N-((1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)methyl)-N-methyloxetan-3-amine421

A mixture of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(78 mg, 0.2 mmol), (azetidin-3-ylmethyl)methyloxetan-3-yl-amine (47 mg,0.3 mmol), and 4 Å molecular sieves (250 mg) in 1,2-dichloroethane (2mL) was stirred at RT for 6 h. Sodium triacetoxyborohydride (85 mg, 0.4mmol) was added and the resulting reaction mixture was stirred at RTunder nitrogen atmosphere for 16 h. The suspension was filtered throughCelite and the filtrate was concentrated in vacuo. The crude residue wasloaded on an Isolute® SCX-2 cartridge (5 g). The cartridge was washedwith DCM/MeOH and the desired product was subsequently eluted using amixture of 2M NH₃ in MeOH and DCM. The residue was purified by columnchromatography (Si—PPC, MeOH:DCM, gradient 0:100 to 8:92) to afford 421as an off-white foam (63 mg, 59%). LCMS (Method I): R_(T) 2.11 min,[M+H]⁺ 532. ¹H NMR (400 MHz, CDCl₃): δ 7.97-7.96 (1H, m), 7.72-7.71 (1H,m), 7.23 (2H, t, J=3.78 Hz), 4.61 (2H, t, J=6.53 Hz), 4.53 (2H, t,J=6.23 Hz), 4.32 (4H, s), 3.82-3.81 (9H, m), 3.51-3.50 (3H, m), 3.32(2H, q, J=7.48 Hz), 3.03-2.89 (2H, m), 2.68-2.57 (1H, m), 2.40 (2H, d,J=7.26 Hz), 2.04 (3H, s), 1.41 (3H, t, J=7.47 Hz)

Example 4224-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-8-((3-(tetrahydro-2H-pyran-4-yl)azetidin-1-yl)methyl)-9H-purin-6-yl)morpholine422

A mixture of2-(2-ethylbenzoimidazol-1-yl)-6-morpholin-4-yl-9-(tetrahydropyran-2-yl)-8-[3-(tetrahydropyran-4-yl)azetidin-1-ylmethyl]-9H-purine(0.28 g, 0.48 mmol) in 1.25 M HCl (10 mL) was stirred for 48 h at roomtemperature. The reaction mixture was concentrated in vacuo. The residuewas loaded in MeOH onto an Isolute® SCX-2 cartridge. The cartridge waswashed with MeOH, then the desired product was eluted with DCM, 20-80%MeOH in DCM and 10-40% 2 M NH₃ in MeOH in DCM. The residue was purifiedby flash chromatography (Si—PPC, 2 M NH₃ in MeOH:DCM, gradient 0:100 to4:96) followed by (Si—PPC, 2M NH₃ in MeOH:EtOAc, gradient 2.5:97.5 to10:90 then 2 M NH₃ in MeOH:DCM, gradient 2:98 to 10:90) to give 422 as awhite solid (0.14 g, 59%). LCMS (Method I): R_(T)=2.50 min, [M+H]⁺503.4. ¹H NMR (400 MHz, DMSO-d₆): δ 7.96-7.92 (m, 1H); 7.64-7.60 (m,1H); 7.25-7.20 (m, 2H); 4.28-4.19 (m, 4H); 3.83 (dd, J=11.3, 4.3 Hz,2H); 3.77 (t, J=4.6 Hz, 2H); 3.72 (s, 2H); 3.43-3.38 (m, 7H); 3.27-3.19(q, J=7.4 Hz, 2H); 2.96 (t, J=6.9 Hz, 2H); 2.19-2.11 (m, 1H); 1.69-1.57(m, 1H); 1.50 (d, J=13.0 Hz, 2H); 1.31 (t, J=7.4 Hz, 3H); 1.06 (td,J=12.2, 4.3 Hz, 2H)

Example 4272-(4-((2-(2-(2-hydroxyethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)-2-methylpropan-1-ol427

Following General Procedure I for Buchwald coupling,2-(4-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)-2-methylpropan-1-oland 2-(1H-benzo[d]imidazol-2-yl)ethanol were reacted to give 427. LCMSm/z: 550.3 (MH+)

Example 4281-(8-((4-tert-butylpiperazin-1-yl)methyl)-9-methyl-6-morpholino-9H-purin-2-yl)-N-methyl-1H-benzo[d]imidazol-2-amine428

Following General Procedure I for Buchwald coupling,4-(8-((4-tert-butylpiperazin-1-yl)methyl)-2-chloro-9-methyl-9H-purin-6-yl)morpholineand N-methyl-1H-benzo[d]imidazol-2-amine were reacted to give 428. LCMS:M+H⁺=519.3

Example 4294-methyl-1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)azepan-4-ol429

Following General Procedure E for Displacement of alkyl bromide withamines,4-(8-(bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholineand 4-methylazepan-4-ol were reacted to give 429. [M+H]⁺ 491.6

Example 4302-(1-((2-(2-ethylbenzofuran-3-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol430

Following General Procedure L for reductive amination,2-(2-ethylbenzofuran-3-yl)-9-methyl-6-morpholino-9H-purine-8-carbaldehydeand 2-(piperidin-4-yl)propan-2-ol were reacted to give 430. [M+H]⁺ 519.6

Example 431N-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)-2-(1H-pyrazol-1-yl)ethanamine431

Following General Procedure L for reductive amination,9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purine-8-carbaldehydeand 2-(1H-pyrazol-1-yl)ethanamine were reacted to give 431. [M+H]⁺ 473.3

Example 432(1-aminocyclopropyl)(4-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)methanone432

A mixture of(1-{4-[2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl]piperazine-1-carbonyl}cyclopropyl)carbamicacid tert-butyl ester (0.123 g, 0.19 mmol) in DCM/TFA (5 mL/5 mL) wasstirred for 4 h at room temperature. The reaction mixture was loadedonto an Isolute® SCX-2 cartridge. The cartridge was washed with MeOH andthe desired product was eluted using 2 M NH₃ in MeOH. The eluent wasconcentrated in vacuo and the residue was purified by flashchromatography (Si—PPC, MeOH:DCM, gradient 0:100 to 10:90) to give 432as a white solid (0.066 g, 64%). LCMS (Method I): R_(T)=2.47 min, [M+H]⁺462.3. ¹H NMR (400 MHz, DMSO-d₆): δ 8.04-8.00 (m, 1H); 7.66-7.61 (m,1H); 7.28-7.21 (m, 2H); 4.18-4.22 (m, 4H); 3.85 (s, 3H); 3.82 (s, 2H);3.78 (t, J=4.6 Hz, 4H); 3.58-3.53 (m, 4H); 3.27 (q, J=7.4 Hz, 2H);2.55-2.45 (m, 4H); 1.34 (t, J=7.4 Hz, 3H); 0.92-0.87 (m, 2H); 0.82-0.75(m, 2H)

Example 4332-(1-(2-(5-(2-ethyl-1H-benzo[d]imidazol-1-yl)-7-morpholinothiazolo[5,4-d]pyrimidin-2-yl)ethyl)piperidin-4-yl)propan-2-ol433

A mixture of2-{1-[2-(5-chloro-7-morpholin-4-yl-thiazolo[5,4-d]pyrimidin-2-yl)ethyl]-piperidin-4-yl}propan-2-ol(56 mg, 0.13 mmol), 2-ethylbenzimidazole (21 mg, 0.15 mmol), Pd₂(dba)₃(3.0 mg, 2.5 mol %), Xphos (6.3 mg, 10 mol %) and Cs₂CO₃ (64 mg, 0.20mmol) in dioxane (1.0 mL) was purged with argon gas then heated at 120°C., for 18 h, in a sealed tube. The reaction mixture was loaded onto anIsolute® SCX-2 cartridge, washed with MeOH then the desired producteluted with 2 M NH₃ in MeOH. The resulting residue was purified by flashchromatography (Si—PCC, 0-10% MeOH in DCM) to give 433 (39 mg, 56%) asan orange solid. LCMS: (Method I): R_(T) 2.71 min; [M+H]⁺ 536.4. ¹H NMR(400 MHz, CHCl₃-d): δ 8.01-7.97 (m, 1H), 7.76-7.71 (m, 1H), 7.29-7.24(m, 2H), 4.52-4.32 (m, 4H), 3.90-3.85 (m, 4H), 3.34 (q, 7.5 Hz, 2H),3.35-3.23 (m, 2H), 3.21-3.10 (m, 2H), 2.87-2.83 (m, 2H), 2.17-2.05 (m,2H), 1.86-1.75 (m, 2H), 1.43 (t, J=7.5 Hz, 3H), 1.38-1.23 (m, 3H), 1.22(s, 6H)

Example 4342-(1-(8-((4-tert-butylpiperazin-1-yl)methyl)-9-methyl-6-morpholino-9H-purin-2-yl)-1H-benzo[d]imidazol-2-yl)ethanol434

A mixture of9-methyl-2-(2-methylbenzoimidazol-1-yl)-6-morpholin-4-yl-9H-purine-8-carbaldehyde(100 mg, 0.26 mmol), (4-methylpiperidin-4-yl)pyrrolidin-1-ylmethanone(62 mg, 0.32 mmol), trimethoxyorthoformate (0.29 mL, 2.65 mmol) andacetic acid (40 μL, 0.70 mmol) in DCE (5 mL) was stirred at roomtemperature for 1 hour then sodium triacetoxyborohydride (90 mg, 0.42mmol) was added. The reaction mixture was stirred at room temperaturefor 18 hours then diluted with MeOH and loaded onto an Isolute® SCX-2cartridge (5 g). The cartridge was washed with MeOH and the desiredproduct was eluted with 2M NH₃ in MeOH. The solvents were removed andthe residue was subjected to flash chromatography (Si—PCC, 0-20% MeOH inEtOAc) to give 434 as a white solid (98 mg, 68%). LCMS (Method I): R_(T)2.64 min; [M+H]⁺ 558. ¹H NMR (400 MHz, CHCl₃-d): δ 8.11-8.07 (m, 1H);7.73-7.68 (m, 1H); 7.31-7.26 (m, 2H); 4.34 (m, 4H); 3.90 (s, 3H);3.90-3.79 (m, 5H); 3.76 (m, 2H); 3.58-3.50 (m, 5H); 2.95 (s, 3H); 2.66(m, 2H); 2.49 (m, 2H); 2.28 (m, 4H); 1.87 (m, 2H); 1.33 (s, 3H)

Example 435N-methyl-1-(9-methyl-6-morpholino-8-((3-(tetrahydro-2H-pyran-4-yl)azetidin-1-yl)methyl)-9H-purin-2-yl)-1H-benzo[d]imidazol-2-amine435

A mixture of2-chloro-9-methyl-6-morpholin-4-yl-8-[3-(tetrahydropyran-4-yl)azetidin-1-ylmethyl]-9H-purine(120 mg, 0.29 mmol), (1H-benzoimidazol-2-yl)methylamine (52 mg, 0.35mmol), tris(dibenzylideneacetone)dipalladium (14 mg, 0.01 mmol), Xphos(28 mg, 0.06 mmol) and Cs₂CO₃ (192 mg, 0.59 mmol) in DMF (2.5 mL) waspurged with argon then heated at 150° C. for 30 min in a microwavereactor. The reaction mixture was filtered through a pad of celite,washing with EtOAc. The filtrate was concentrated in vacuo and purifiedby column chromatography (Si—PCC, MeOH:EtOAc, 0-15%) affording 435 as afoam (104 mg, 69%). LCMS (Method I): R_(T) 2.45 min, [M+H]⁺ 518.4. ¹HNMR (CDCl₃, 400 MHz): δ 8.48 (d, J=5.0 Hz, 1H); 8.28 (d, J=8.0 Hz, 1H);7.49 (d, J=7.8 Hz, 1H); 7.19 (m, 1H); 7.10-7.04 (m, 1H); 4.34 (m, 4H);3.97 (dd, J=11.5, 4.1 Hz, 2H); 3.90 (t, J=4.7 Hz, 4H); 3.85 (s, 3H);3.82 (s, 2H); 3.51 (t, J=7.3 Hz, 2H); 3.42-3.32 (m, 2H); 3.26 (d, J=5.0Hz, 3H); 3.03 (t, J=7.0 Hz, 2H); 2.34-2.25 (m, 1H); 1.74-1.62 (m, 1H);1.54 (m, 2H) and 1.27-1.13 (m, 2H)

Example 4364-(5-(2-ethyl-1H-benzo[d]imidazol-1-yl)-2-((3-(1,1-dioxo-thiomorpholino)azetidin-1-yl)methyl)thiazolo[5,4-d]pyrimidin-7-yl)morpholine436

A mixture of5-chloro-2-[3-(1,1-Dioxo-1-thiomorpholin-4-yl)azetidin-1-ylmethyl]-7-morpholin-4-ylthiazolo[5,4-c]pyrimidine(150 mg, 0.33 mmol), 2-ethylbenzimidazole (58 mg, 0.39 mmol),tris(dibenzylideneacetone)dipalladium (15 mg, 0.02 mmol), Xphos (31 mg,0.07 mmol) and Cs₂CO₃ (213 mg, 0.65 mmol) in dioxane (3 mL) was purgedwith argon then heated at 145° C. for 45 min in a microwave reactor. Thereaction mixture was filtered through a pad of celite, washing withEtOAc. The filtrate was concentrated in vacuo and purified by columnchromatography (Si—PCC, MeOH:EtOAc, 0-10%) affording 436 as a foam (113mg, 60%). LCMS (Method I): R_(T) 2.59 min, [M+H]⁺ 569.3. ¹H NMR (CDCl₃,400 MHz): δ 8.02-7.97 (m, 1H); 7.79-7.75 (m, 1H); 7.33-7.27 (m, 2H);4.41 (m, 4H); 4.02 (s, 2H); 3.91-3.81 (m, 4H); 3.72 (m, 2H); 3.39-3.30(m, 3H); 3.16 (m, 2H); 3.08 (m, 4H); 2.90-2.85 (m, 4H) and 1.44 (t,J=7.5 Hz, 3H)

Example 4372-(4-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)-2-methylpropanamide437

2-(4-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)-2-methylpropanamide(75 mg) was reacted with 2-methylbenzimidazole via General Procedure Ifor Buchwald coupling to give 39.9 mg 437 following reverse phasepurification. MS (Q1) 547.1 (M)+

Example 4382-(4-((2-(2-cyclopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)-2-methylpropanamide438

2-(4-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)-2-methylpropanamide(75 mg) was reacted with 2-cyclopropylbenzimidazole via GeneralProcedure I for Buchwald coupling to give 38.7 mg 438 following reversephase purification. MS (Q1) 559.1 (M)+

Example 4392-(4)(2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)-2-methylpropanamide439

2-(4-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)-2-methylpropanamide(75 mg) was reacted with 2-isopropylbenzimidazole via General ProcedureI for Buchwald coupling to give 24.9 mg 439 following reverse phasepurification. MS (Q1) 561.7 (M)+

Example 4402-(4-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)-2-methylpropane-1,3-diol440

Following General Procedure I for Buchwald coupling,2-ethylbenzimidazole and2-(4-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)-2-methylpropane-1,3-diolwere reacted to give 440. LCMS m/z: 550.3 (MH+)

Example 4414-(8-((4-isopropylpiperazin-1-yl)methyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine441

Following General Procedure E for Displacement of alkyl bromide withamines,4-(8-(bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholineand 1-isopropylpiperazine were reacted to give 441. LCMS m/z: 490.3(MH+)

Example 4431-(8-((4-(2-hydroxypropan-2-yl)piperidin-1-yl)methyl)-9-methyl-6-morpholino-9H-purin-2-yl)-2-isopropyl-1H-indazol-3(2H)-one443

Following General Procedure I for Buchwald coupling,2-isopropyl-1,2-dihydroindazol-3-one and2-(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-olwere reacted to give 443. LCMS m/z: 549.3 (MH+)

Example 4444-(8-((4-cyclobutylpiperazin-1-yl)methyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine444

Following General Procedure I for Buchwald coupling,2-ethylbenzimidazole and4-(2-chloro-8-((4-cyclobutylpiperazin-1-yl)methyl)-9-methyl-9H-purin-6-yl)morpholinewere reacted to give 444. LCMS m/z: 516.3 (MH+)

Example 4454-(8-((4-tert-butylpiperazin-1-yl)methyl)-2-(isoquinolin-4-yl)-9-methyl-9H-purin-6-yl)morpholine445

4-(8-((4-tert-butylpiperazin-1-yl)methyl)-2-chloro-9-methyl-9H-purin-6-yl)morpholinewas prepared following General Procedure E of amine SN₂ alkylation.Following General Procedure A Suzuki coupling,4-(8-((4-tert-butylpiperazin-1-yl)methyl)-2-chloro-9-methyl-9H-purin-6-yl)morpholineand 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoquinoline werereacted to give 445. LCMS: M+H⁺=501.3

Example 4464-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-8-((4-(oxetan-3-yl)piperidin-1-yl)methyl)-9H-purin-6-yl)morpholine446

A mixture of2-chloro-9-methyl-6-morpholin-4-yl-8-(4-oxetan-3-yl-piperidin-1-ylmethyl)-9H-purine(100 mg, 0.25 mmol), 2-methyl-1H-benzoimidazole (38 mg, 0.29 mmol),Pd₂dba₃ (6 mg, 0.006 mmol), Xphos (12 mg, 0.025 mmol) and cesiumcarbonate (121 mg, 0.37 mmol) in DMF (2 mL) was purged with argon gasthen subjected to microwave irradiation at 145° C. for 30 min. Thereaction mixture was loaded onto an Isolute® SCX-2 cartridge (10 g),which was washed with MeOH/DCM before the desired product was elutedwith 2 M NH₃ in MeOH/DCM. The product was collected and concentrated invacuo. The resultant residue was purified by flash chromatography(Si—PPC, DCM:MeOH 100:0 to 99:1 to 98:2) to afford 446 as a white solid(29 mg, 23%). LCMS (Method I): R_(T)=2.37 min, M+H⁺=503. ¹H NMR (CDCl₃,400 MHz) δ 8.09 (m, 1H); 7.72 (m, 1H); 7.39 (m, 2H); 4.76 (dd, J=7.9,6.0 Hz, 2H); 4.46 (t, J=6.0 Hz, 2H); 4.35 (m, 4H); 3.90-3.84 (m, 7H);3.78 (s, 2H); 2.96 (m, 5H); 2.80-2.71 (m, 1H); 2.22 (m, 2H) and 1.69 (m,5H)

Example 447N-methyl-1-(9-methyl-6-morpholino-8-((4-(oxetan-3-yl)piperidin-1-yl)methyl)-9H-purin-2-yl)-1H-benzo[d]imidazol-2-amine447

A mixture of2-chloro-9-methyl-6-morpholin-4-yl-8-(4-oxetan-3-yl-piperidin-1-ylmethyl)-9H-purine(100 mg, 0.25 mmol), (1H-benzoimidazol-2-yl)methyl-amine (43 mg, 0.29mmol), Pd₂dba₃ (6 mg, 0.006 mmol), Xphos (12 mg, 0.025 mmol) and cesiumcarbonate (121 mg, 0.37 mmol) in DMF (2 mL) was purged with argon gasthen subjected to microwave irradiation at 145° C. for 30 min. Thereaction mixture was loaded onto an Isolute® SCX-2 cartridge (10 g),which was washed with MeOH/DCM before the desired product was elutedwith 2 M NH₃ in MeOH/DCM. The product was collected and concentrated invacuo. The resultant residue was purified by flash chromatography(Si—PPC, DCM:MeOH 100:0 to 99:1 to 98:2) to afford 447 as a cream foam(58 mg, 45%). LCMS (Method I): R_(T)=2.36 min, M+H⁺=518. ¹H NMR (CDCl₃,400 MHz) δ 8.51 (bs, 1H); 8.29 (d, J=7.9 Hz, 1H); 7.51 (d, J=7.9 Hz,1H); 7.19 (t, J=7.8 Hz, 1H); 7.08 (t, J=7.8 Hz, 1H); 4.75 (dd, J=7.9,6.1 Hz, 2H); 4.46 (t, J=6.1 Hz, 2H); 4.33 (m, 4H); 3.92-3.85 (m, 7H);3.73 (s, 2H); 3.26 (d, J=4.9 Hz, 3H); 2.88 (m, 2H); 2.78-2.69 (m, 1H);2.15 (m, 2H); 1.66 (m, 3H) and 1.19-1.07 (m, 2H)

Example 4484-(5-(2-methyl-1H-benzo[d]imidazol-1-yl)-2-(3-(1,1-dioxo-thiomorpholino)azetidin-1-yl)methyl)thiazolo[5,4-d]pyrimidin-7-yl)morpholine448

A mixture of5-chloro-2-[3-(1,1-dioxo-1-thiomorpholin-4-yl)azetidin-1-ylmethyl]-7-morpholin-4-ylthiazolo[5,4-d]pyrimidine(150 mg, 0.33 mmol), 2-methylbenzimidazole (52 mg, 0.39 mmol),tris(dibenzylideneacetone)dipalladium (15 mg, 0.02 mmol), Xphos (31 mg,0.07 mmol) and Cs₂CO₃ (213 mg, 0.65 mmol) in dioxane (3 mL) was purgedwith argon then heated at 145° C. for 45 min in a microwave reactor. Thereaction mixture was filtered through a pad of celite, washing withEtOAc. The filtrate was concentrated in vacuo and purified by columnchromatography (Si—PCC, MeOH:EtOAc, 0-5%) affording 448 as a foam (74mg, 40%). LCMS (Method I): R_(T) 2.45 min, [M+H]⁺ 555.2. ¹H NMR (CDCl₃,400 MHz): δ 8.09-8.04 (m, 1H); 7.74-7.69 (m, 1H); 7.34-7.26 (m, 2H);4.41 (m, 4H); 4.01 (s, 2H); 3.88 (m, 4H); 3.71 (t, J=6.7 Hz, 2H);3.37-3.30 (m, 1H); 3.15 (t, J=6.7 Hz, 2H); 3.09 (m, 4H); 2.94 (s, 3H)and 2.88 (m, 4H)

Example 4494-(2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-8-((3-(1,1-dioxo-thiomorpholino)azetidin-1-yl)methyl)-9H-purin-6-yl)morpholine449

A mixture of2-chloro-8-[3-(1,1-dioxo-1-thiomorpholin-4-yl)azetidin-1-ylmethyl]-9-methyl-6-morpholin-4-yl-9H-purine(0.162 g, 0.36 mmol), 2-isopropyl-1H-benzoimidazole (0.068 g, 0.43mmol), Xphos (0.034 g, 0.071 mmol), Pd₂(dba)₃ (0.017 g, 0.018 mmol) andCs₂CO₃ (0.231 g, 0.71 mmol) in dioxane (2 mL) was subjected to microwaveirradiation at 145° C. for 45 min. The suspension was filtered throughCelite and the filtrate was concentrated in vacuo. The residue waspurified by flash chromatography (Si—PPC, MeOH:DCM gradient 0:100 to7.5:92.5) to give 449 as a yellow solid (0.1 g, 49%). LCMS (Method I):R_(T)=2.56 min, [M+H]⁺ 580.2. ¹H NMR (400 MHz, DMSO-d₆): δ 7.91-7.86 (m,1H); 7.66-7.61 (m, 1H); 7.26-7.21 (m, 2H); 4.30-4.23 (m, 4H); 3.97-3.86(m, 1H); 3.87 (s, 2H); 3.82-3.71 (m, 7H); 3.46 (t, J=6.6 Hz, 2H);3.26-3.18 (m, 1H); 3.12-3.08 (m, 4H); 3.00 (t, J=6.8 Hz, 2H); 2.74 (m,4H); 1.35 (d, J=6.8 Hz, 6H)

Example 4504-(2-(2-cyclopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-8-((4-(oxetan-3-yl)piperidin-1-yl)methyl)-9H-purin-6-yl)morpholine450

A mixture of2-chloro-9-methyl-6-morpholin-4-yl-8-(4-oxetan-3-ylpiperidin-1-ylmethyl)-9H-purine(100 mg, 0.25 mmol), 2-cyclopropyl-1H-benzoimidazole (47 mg, 0.30 mmol),Pd₂dba₃ (6 mg, 0.006 mmol), Xphos (12 mg, 0.025 mmol) and cesiumcarbonate (121 mg, 0.37 mmol) in DMF (2 mL) was purged with argon gasthen subjected to microwave irradiation at 145° C. for 30 min. Thereaction mixture was loaded onto an Isolute® SCX-2 cartridge (10 g),which was washed with MeOH/DCM before the desired product was elutedwith 2 M NH₃ in MeOH/DCM. The product was collected and concentrated invacuo. The resultant residue was purified by flash chromatography(Si—PPC, EtOAc:MeOH 100:0 to 99:1 to 98:2 to 95:5) to afford 450 as apale purple foam (60 mg, 46 LCMS (Method I): R_(T)=2.63 min, M+H⁺=529.¹H NMR (CDCl₃, 400 MHz) δ 7.94 (dd, J=7.1, 2.0 Hz, 1H); 7.68 (d, J=7.4Hz, 1H); 7.27-7.19 (m, 2H); 4.76 (dd, J=7.8, 6.1 Hz, 2H); 4.46 (t, J=6.1Hz, 2H); 4.35 (m, 4H); 3.89-3.82 (m, 7H); 3.76 (s, 2H); 2.91-2.81 (m,3H); 2.79-2.70 (m, 1H); 2.18 (m, 2H); 1.62 (m, 5H); 1.36 (m, 2H) and1.08-1.01 (m, 2H)

Example 4512-(1-(2-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)ethyl)azetidin-3-yl)propan-2-ol451

A mixture of2-{1-[2-(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)ethyl]azetidin-3-yl}propan-2-ol(84 mg, 0.21 mmol), 2-ethylbenzimidazole (34 mg, 0.23 mmol), Pd₂(dba)₃(4.9 mg, 2.5 mol %), Xphos (10.1 mg, 10 mol %) and Cs₂CO₃ (104 mg, 0.32mmol) in dioxane (1.5 mL) was purged with argon gas then heated at 120°C., for 23 h, in a sealed tube. The reaction mixture was loaded onto anIsolute® SCX-2 cartridge, washed with MeOH then the desired producteluted with 2 M NH₃ in MeOH. The resulting residue was purified by flashchromatography (Si—PCC, 0-20% 2 M NH₃/MeOH in DCM) to give 451 (38 mg,35%) as a yellow solid. LCMS: (Method I): R_(T) 2.53 min; [M+H]⁺ 505.3.¹H NMR (400 MHz, CHCl₃-d): δ 8.01-7.96 (m, 1H), 7.77-7.73 (m, 1H),7.27-7.22 (m, 2H), 4.49-4.24 (m, 4H), 3.88-3.83 (m, 4H), 3.76 (s, 3H),3.48-3.40 (m, 2H), 3.38-3.27 (m, 4H), 3.15-2.95 (m, 2H), 2.95-2.90 (m,2H), 2.55-2.47 (m, 1H), 1.43 (t, J=7.48 Hz, 3H), 1.17 (s, 6H)

Example 4521-(2-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)ethyl)-4-methylpiperidin-4-ol452

A mixture of1-[2-(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)ethyl]-4-methylpiperidin-4-ol(45 mg, 0.11 mmol), 2-ethylbenzimidazole (18 mg, 0.13 mmol), Pd₂(dba)₃(2.6 mg, 2.5 mol %), Xphos (5.4 mg, 10 mol %) and Cs₂CO₃ (56 mg, 0.17mmol) in dioxane (1.0 mL) was purged with argon gas then heated at 120°C., for 17 h, in a sealed tube. The reaction mixture was loaded onto anIsolute® SCX-2 cartridge, washed with MeOH then the desired producteluted with 2 M NH₃ in MeOH. The resulting residue was purified by flashchromatography (Si—PCC, 0-10% 2 M NH₃/MeOH in DCM) to give 452 (46 mg,80%) as a pale orange solid. LCMS: (Method I): R_(T) 2.46 min; [M+H]⁺505.2. ¹H NMR (400 MHz, CHCl₃-d): δ 8.01-7.96 (m, 1H), 7.77-7.73 (m,1H), 7.28-7.22 (m, 2H), 4.47-4.19 (m, 4H), 3.88-3.83 (m, 4H), 3.78 (s,3H), 3.34 (q, J=7.5 Hz, 2H), 3.15-3.05 (m, 2H), 2.98-2.80 (m, 2H),2.78-2.73 (m, 2H), 2.65-2.57 (m, 2H), 1.69-1.65 (m, 4H), 1.44 (t, J=7.5Hz, 3H), 1.33-1.27 (s, 3H)

Example 4532-methyl-2-(4-((9-methyl-2-(2-(methylamino)-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)propan-1-ol453

Following General Procedure I for Buchwald coupling,2-(4-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)-2-methylpropan-1-oland N-methyl-1H-benzo[d]imidazol-2-amine were reacted to give 453. LCMSm/z: 535.3 (MH+)

Example 4544-(2-(2-(azetidin-1-yl)-1H-benzo[d]imidazol-1-yl)-8-((4-tert-butylpiperazin-1-yl)methyl)-9-methyl-9H-purin-6-yl)morpholine454

2-Chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole (0.5g) was placed in a flask with azetidine (0.48 mL), Hunig's base(iPr2Net, 1.5 mL) in 1 mL of ethanol. The reaction was heated to 50° C.overnight and then concentrated to dryness to get 0.55 g of crude2-(azetidin-1-yl)-1-(2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole.

Into a sealed vessel was placed crude2-(azetidin-1-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1Hbenzo[d]imidazole (0.55 g) and sodium ethoxide (1.2 g) in DMF (14 mL).The reacted was heated for 30 mins at 150° C. in an oil bath. Thereaction mixture was diluted with water and extracted with ethylacetate. The organic layer was dried with magnesium sulfate, filteredand concentrated to give 310 mg of2-(azetidin-1-yl)-1H-benzo[d]imidazole as yellow solid.

4-(8-((4-tert-butylpiperazin-1-yl)methyl)-2-chloro-9-methyl-9H-purin-6-yl)morpholine(75 mg) was reacted with 2-(azetidin-1-yl)-1H-benzo[d]imidazole (33 mg)via General Procedure for Buchwald coupling to give 36.1 mg 454following reverse phase purification. MS (Q1) 545.4 (M)+

Example 4552-(1-((2-(2-(azetidin-1-yl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol455

2-(1-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol(75 mg) was reacted with 2-(azetidin-1-yl)-1H-benzo[d]imidazole (33 mg)via General Procedure I for Buchwald coupling to give 35.9 mg 455following reverse phase purification. MS (Q1) 546.3 (M)+

Example 456 ethyl2-methyl-2-(4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-1-yl)propanoate456

Following General Procedure C,4-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-8-(piperidin-4-ylmethyl)-9H-purin-6-yl)morpholinewas alkylated with 2-bromo-2-methyl-propanoic acid ethyl ester to give456. LCMS m/z: 561.3 (MH+)

Example 4574-(8-((4-tert-butylpiperazin-1-yl)methyl)-2-(2-(1,1-difluoroethyl)-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine457

N1-(8-((4-tert-butylpiperazin-1-yl)methyl)-6-morpholino-9-(tetrahydro-2H-pyran-2-yl)-9H-purin-2-yl)benzene-1,2-diamine(0.085 g, 0.15 mmol) and 2,2-difluoropropanoic acid (0.019 g, 0.17 mmol)were dissolved in N,N-dimethylformamide (2 mL, 0.02 mol).N,N-Diisopropylethylamine (0.054 mL, 0.31 mmol) was added. The resultingsolution was cooled at 0° C. for 20 minutes.N,N,N′N′-Tetramethyl-O-(7-azabenzotriazol-1-yl)uroniumhexafluorophosphate (0.070 g, 0.00018 mol) was added and the reactionstirred overnight at room temperature. The reaction mixture wasconcentrated to dryness. Acetic acid (3.0 mL, 0.053 mol) was added tothe crude residue and the reaction mixture was heated at 90° C. for 18hours. The reaction mixture was cooled, filtered and concentrated todryness. The crude was purified by reverse phase HPLC to give 457 (15.3mg, 18%). [M+H]⁺=540.3

Example 4581-(2-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)ethyl)-3-methylazetidin-3-ol458

A mixture of1-[2-(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)ethyl]-3-methylazetidin-3-ol(80 mg, 0.22 mmol), 2-ethylbenzimidazole (35 mg, 0.24 mmol), Pd₂(dba)₃(5 mg, 2.5 mol %), Xphos (10.4 mg, 10 mol %) and Cs₂CO₃ (107 mg, 0.33mmol) in dioxane (2.0 mL) was purged with argon gas then heated at 120°C., for 19 h, in a sealed tube. The reaction mixture was loaded onto anIsolute® SCX-2 cartridge, washed with MeOH then the desired producteluted with 2 M NH₃ in MeOH. The resulting residue was purified by flashchromatography (Si—PCC, 0-10% 2 M NH₃/MeOH in DCM) to give 458 (77 mg,74%) as a pale beige solid. LCMS: (Method I): R_(T) 2.39 min; [M+H]⁺477.2. ¹H NMR (400 MHz, CHCl₃-d): δ 8.01-7.96 (m, 1H), 7.76-7.72 (m,1H), 7.26-7.22 (m, 2H), 4.45-4.32 (m, 4H), 3.86 (t, J=4.8 Hz, 4H), 3.77(s, 3H), 3.40 (d, J=7.3 Hz, 2H), 3.34 (q, J=7.5 Hz, 2H), 3.14 (d, J=7.3Hz, 2H), 3.02 (t, J=7.3 Hz, 3H), 2.92 (t, J=7.3 Hz, 2H), 1.53 (s, 3H),1.44 (t, J=7.5 Hz, 3H)

Example 4594-(2-(2-(1,1-difluoroethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-8-((4-(oxetan-3-yl)piperidin-1-yl)methyl)-9H-purin-6-yl)morpholine459

To a mixture ofN-[9-methyl-6-morpholin-4-yl-8-(4-oxetan-3-ylpiperidin-1-ylmethyl)-9H-purin-2-yl]benzene-1,2-diamine(0.115 g, 0.24 mmol) and 2,2-difluoropropionic acid (0.028 g, 0.25 mmol)and DIPEA (0.091 mL, 0.53 mL) in DMF (7 mL) was added HATU (0.11 g, 0.29mmol). The reaction mixture was stirred at room temperature for 24 h,then at 90° C. for 24 h. The reaction mixture was concentrated in vacuoand the residue was loaded in MeOH onto an Isolute® SCX-2 cartridge. Thecartridge was washed with MeOH and the desired product was eluted with 2M NH₃ in MeOH. The solution was concentrated in vacuo, the residue wasdiluted in acetic acid (15 mL) and the reaction mixture was stirred at90° C. for 7 h. The reaction mixture was concentrated in vacuo and theresultant residue was purified by flash chromatography (Si—PPC,MeOH:DCM, 0:100 to 10:90) followed by reverse phase HPLC (PhenomenexGemini 5u C18, 20 mM triethylamine in water on a gradient ofacetonitrile 95:5 to 2:98) to give 459 as a white solid (0.032 g, 27%).LCMS (Method I): R_(T)=3.30 min, [M+H]⁺ 553.3. ¹H NMR (400 MHz,DMSO-d₆): δ 7.84-7.81 (m, 1H); 7.74-7.71 (m, 1H); 7.43-7.35 (m, 2H);4.40-4.15 (m, 4H); 3.84 (s, 2H); 3.81 (d, J=4.3 Hz, 2H); 3.78-3.71 (m,7H); 3.37 (t, J=6.9 Hz, 2H); 3.30-3.18 (m, 2H); 2.96 (t, J=6.9 Hz, 2H);2.34-2.21 (t, J=19.5 Hz, 3H); 2.20-2.08 (m, 1H); 1.64 (d, J=12.1 Hz,1H); 1.50 (d, J=13.0 Hz, 2H); 1.06 (td, J=12.1, 4.3 Hz, 2H)

Example 460(S)-(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)(3-hydroxypyrrolidin-1-yl)methanone460

A mixture of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(75 mg, 0.19 mmol),azetidin-3-yl-((S)-3-hydroxypyrrolidin-1-yl)methanone (65 mg, 0.38mmol), and 4 Å molecular sieves (250 mg) in 1,2-dichloroethane (2 mL)was stirred at RT for 4 h. Sodium triacetoxyborohydride (81 mg, 0.38mmol) was added and the resulting reaction mixture was stirred at RTunder nitrogen atmosphere for 60 h. The suspension was filtered throughCelite and the filtrate was concentrated in vacuo. The crude residue wasloaded on an Isolute® SCX-2 cartridge (5 g). The cartridge was washedwith DCM/MeOH and the desired product was subsequently eluted using amixture of 2M NH₃ in MeOH and DCM. The residue was purified by columnchromatography (Si—PPC, MeOH:DCM, gradient 0:100 to 10:90) to afford 460as an off-white solid (32 mg, 30%). LCMS (Method I): R_(T) 2.33 min,[M+H]⁺ 546. ¹H NMR (400 MHz, CDCl₃): δ 7.98-7.93 (1H, m), 7.71-7.70 (1H,m), 7.22 (2H, s), 4.49 (2H, s), 4.31 (4H, s), 3.83-3.81 (8H, m),3.52-3.50 (9H, m), 3.32-3.30 (2H, m), 2.04-1.88 (3H, m), 1.40 (3H, t,J=7.47 Hz)

Example 461(R)-(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)(3-hydroxypyrrolidin-1-yl)methanone461

A mixture of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(75 mg, 0.19 mmol),azetidin-3-yl-((R)-3-hydroxypyrrolidin-1-yl)methanone (65 mg, 0.38mmol), and 4 Å molecular sieves (250 mg) in 1,2-dichloroethane (2 mL)was stirred at RT for 4 h. Sodium triacetoxyborohydride (81 mg, 0.38mmol) was added and the resulting reaction mixture was stirred at RTunder nitrogen atmosphere for 60 h. The suspension was filtered throughCelite and the filtrate was concentrated in vacuo. The crude residue wasloaded on an Isolute® SCX-2 cartridge (5 g). The cartridge was washedwith DCM/MeOH and the desired product was subsequently eluted using amixture of 2M NH₃ in MeOH and DCM. The residue was purified by columnchromatography (Si—PPC, MeOH:DCM, gradient 0:100 to 10:90) to afford 461as a white solid (17 mg, 16%). LCMS (Method I): R_(T) 2.34 min, [M+H]⁺546. ¹H NMR (400 MHz, CDCl₃): δ 7.96-7.95 (1H, m), 7.73-7.69 (1H, m),7.22 (2H, s), 4.52-4.48 (2H, m), 4.31 (4H, s), 3.82-3.82 (8H, m),3.59-3.57 (9H, m), 3.32-3.30 (2H, m), 1.98-1.97 (2H, m), 1.40 (3H, t,J=7.48 Hz)

Example 4622-(1-((2-(2-tert-butyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol462

2-(1-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol(0.3 g) was reacted with tert-butylbenzimidazole via General Procedure Ifor Buchwald coupling to give 94.3 mg 462 following reverse phasepurification. MS (Q1) 547.3 (M)+

Example 4634-(8-((4-tert-butylpiperazin-1-yl)methyl)-2-(2-(1,1-difluoroethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine463

Following General Procedure J for Multi-Step Benzimidazole formation,4-(8-((4-tert-butylpiperazin-1-yl)methyl)-2-chloro-9-methyl-9H-purin-6-yl)morpholinewas converted to 463 with difluoroacetic acid. LCMS: M+H⁺=554.3

Example 4634-(8-((4-tert-butylpiperazin-1-yl)methyl)-9-methyl-2-(2-(trifluoromethyl)-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine464

Following General Procedure J for Multi-Step Benzimidazole formation,4-(8-((4-tert-butylpiperazin-1-yl)methyl)-2-chloro-9-methyl-9H-purin-6-yl)morpholinewas converted to 464 with trifluoroacetic acid. LCMS: M+H⁺=558.3

Example 4657-(2-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)ethyl)-7-azaspiro[3.5]nonan-2-ol465

A mixture of7-[2-(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)ethyl]-7-azaspiro[3.5]nonan-2-ol(75 mg, 0.18 mmol), 2-ethylbenzimidazole (29 mg, 0.20 mmol), Pd₂(dba)₃(4.1 mg, 2.5 mol %), Xphos (8.5 mg, 10 mol %) and Cs₂CO₃ (87 mg, 0.27mmol) in dioxane (2.0 mL) was purged with argon gas then heated at 120°C., for 18 h, in a sealed tube. The reaction mixture was loaded onto anIsolute® SCX-2 cartridge, washed with MeOH then the desired producteluted with 2 M NH₃ in MeOH. The resulting residue was purified by flashchromatography (Si—PCC, 0-10% 2 M NH₃/MeOH in DCM) followed by reversephase HPLC (Phenomenex Gemini 5 μm C18, 20 mM triethylamine in water ona gradient of acetonitrile 20-98%) to give 465 (42 mg, 44%) as an offwhite solid. LCMS: (Method I): R_(T) 2.47 min; [M+H]⁺ 531.3. ¹H NMR (400MHz, CHCl₃-d): δ 8.01-7.96 (m, 1H), 7.76-7.72 (m, 1H), 7.28-7.22 (m,2H), 4.37-4.27 (m, 5H), 3.86 (t, J=4.7 Hz, 4H), 3.78 (s, 3H), 3.34 (q,J=7.5 Hz, 2H), 3.17-3.02 (m, 2H), 2.99-2.81 (m, 2H), 2.71-2.39 (m, 4H),2.31-2.24 (m, 2H), 1.74-1.64 (m, 6H), 1.44 (t, J=7.5 Hz, 3H)

Example 4661-(2-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)ethyl)-3-isopropylazetidin-3-ol466

A mixture of1-[2-(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)ethyl]-3-isopropyl-azetidin-3-ol(33 mg, 0.08 mmol), 2-ethylbenzimidazole (14 mg, 0.09 mmol), Pd₂(dba)₃(1.9 mg, 2.5 mol %), Xphos (4.0 mg, 10 mol %) and Cs₂CO₃ (41 mg, 0.13mmol) in dioxane (1.0 mL) was purged with argon gas then heated at 120°C., for 18 h, in a sealed tube. The reaction mixture was loaded onto anIsolute® SCX-2 cartridge, washed with MeOH then the desired producteluted with 2 M NH₃ in MeOH. The resulting residue was purified by flashchromatography (Si—PCC, 0-10% 2 M NH₃/MeOH in DCM) followed by reversephase HPLC (Phenomenex Gemini 5 μm C18, 20 mM triethylamine in water ona gradient of acetonitrile 20-98%) to give 466 (18 mg, 42%) as an offwhite solid. LCMS: (Method I): R_(T) 2.62 min; [M+H]⁺ 505.3. ¹H NMR (400MHz, CHCl₃-d): δ 8.01-7.96 (m, 1H), 7.76-7.72 (m, 1H), 7.28-7.22 (m,2H), 4.45-4.33 (m, 4H), 3.86 (t, J=4.7 Hz, 4H), 3.77 (s, 3H), 3.41 (d,J=8.1 Hz, 2H), 3.34 (q, J=7.5 Hz, 2H), 3.18 (d, J=8.1 Hz, 2H), 3.04 (t,J=7.2 Hz, 2H), 2.93 (t, J=7.2 Hz, 2H), 2.01-1.89 (m, 1H), 1.44 (t, J=7.5Hz, 3H), 0.94 (d, J=6.8 Hz, 6H)

Example 4674-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-8-((3-(tetrahydro-2H-pyran-4-yl)azetidin-1-yl)methyl)-9H-purin-6-yl)morpholine467

A mixture of2-chloro-9-methyl-6-morpholin-4-yl-8-[3-(tetrahydropyran-4-yl)azetidin-1-ylmethyl]-9H-purine(112 mg, 0.28 mmol), 2-methylbenzimidazole (44 mg, 0.33 mmol),tris(dibenzylideneacetone)dipalladium (13 mg, 0.01 mmol), Xphos (26 mg,0.06 mmol) and Cs₂CO₃ (179 mg, 0.55 mmol) in dioxane (3 mL) was purgedwith argon then heated at 150° C. for 30 min in a microwave reactor. Thereaction mixture was filtered through a pad of celite, washing withEtOAc. The filtrate was concentrated in vacuo and purified by columnchromatography (Si—PCC, MeOH:EtOAc, 0-20%) affording 467 as a creamsolid (105 mg, 75%). LCMS (Method I): R_(T) 2.46 min, [M+H]⁺ 503.2. ¹HNMR (CDCl₃, 400 MHz): δ 8.10-8.05 (m, 1H); 7.73-7.67 (m, 1H); 7.28-7.23(m, 2H); 4.35 (m, 4H); 3.97 (dd, J=11.4, 4.1 Hz, 2H); 3.89-3.82 (m, 9H);3.54 (m, 2H); 3.37 (td, J=11.4, 2.0 Hz, 2H); 3.06 (m, 2H); 2.94 (s, 3H);2.38-2.27 (m, 1H); 1.54 (m, 2H) and 1.32-1.14 (m, 3H)

Example 4684-(2-(2-(1,1-difluoroethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-8-((3-(tetrahydro-2H-pyran-4-yl)azetidin-1-yl)methyl)-9H-purin-6-yl)morpholine468

To a mixture ofN-{9-methyl-6-morpholin-4-yl-8-[3-(tetrahydropyran-4-yl)azetidin-1-ylmethyl]-9H-purin-2-yl}benzene-1,2-diamine(0.234 g, 0.49 mmol) and 2,2-difluoropropionic acid (0.057 g, 0.51 mmol)and DIPEA (0.185 mL, 1.08 mL) in DMF (14 mL) was added HATU (0.223 g,0.59 mmol) and the reaction mixture was stirred at room temperature for24 h. The reaction mixture was concentrated in vacuo and the residuepurified by flash chromatography (Si—PPC, MeOH:DCM, gradient 0:100 to7.5:92.5). The solution was concentrated in vacuo, the residue wasdiluted in acetic acid (30 mL) and the reaction mixture was stirred at90° C. for 18 h. The reaction mixture was concentrated in vacuo and theresidue was purified by flash chromatography (Si—PPC, MeOH:DCM, 0:100 to7.5:92.5) followed by reverse phase HPLC (Phenomenex Gemini 5u C18, 20mM triethylamine in water on a gradient of acetonitrile 95:5 to 2:98) togive 468 as a white solid (0.063 g, 24%). LCMS (Method I): R_(T)=3.34min, [M+H]⁺ 553.3. ¹H NMR (400 MHz, DMSO-d₆): δ 7.84-7.82 (m, 1H);7.75-7.72 (m, 1H); 7.42-7.36 (m, 2H); 4.58 (dd, J=7.85, 6.0 Hz, 2H);4.40-4.00 (m, 4H); 4.32 (t, J=6.0 Hz, 2H); 3.78 (s, 3H); 3.77 (s, 2H);3.77-3.73 (m, 4H); 2.85 (d, J=11.1 Hz, 2H); 2.68-2.66 (m, 1H); 2.26 (t,J=19.02 Hz, 3H); 2.09 (t, J=11.1 Hz, 2H); 1.57 (d, J=12.5 Hz, 3H); 1.03(d, J=12.5 Hz, 2H)

Example 4694-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-1-isopropylpiperazin-2-one469

A mixture of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(0.15 g, 0.39 mmol), 1-isopropylpiperazin-2-one (0.082 g, 0.58 mmol) and4 Å molecular sieves (0.718 g) in DCE (5 mL) and MeOH (1 mL) was stirredfor 5 h at room temperature. Sodium triacetoxyborohydride (0.163 g, 0.77mmol) was added and the reaction mixture was stirred for 72 h at roomtemperature. The reaction mixture was filtered through Celite and thefiltrate was concentrated in vacuo. The residue was purified by flashchromatography (Si—PPC, MeOH:EtOAc, gradient 0:100 to 5:95) followed byreverse phase HPLC (Phenomenex Gemini 5u C18, 20 mM triethylamine inwater on a gradient of acetonitrile 95:5 to 2:98) to give 469 as anoff-white solid (0.044 g, 22%). LCMS (Method I): R_(T)=3.31 min, [M+H]⁺518.3. ¹H NMR (400 MHz, DMSO-d₆): δ 8.04-8.00 (m, 1H); 7.65-7.61 (m,1H); 7.28-7.21 (m, 2H); 4.64-4.58 (m, 1H); 4.28-4.25 (m, 4H); 3.86 (s,2H); 3.81 (s, 3H); 3.80-3.77 (m, 4H); 3.27 (q, 7.5 Hz, 2H); 3.17 (t,J=5.3 Hz, 2H); 3.13 (s, 2H); 2.73 (t, J=5.3 Hz, 2H); 1.34 (t, J=7.5 Hz,3H); 1.05 (d, J=6.8 Hz, 6H)

Example 4704-(5-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-2-((3-(tetrahydro-2H-pyran-4-yl)azetidin-1-yl)methyl)thiazolo[5,4-d]pyrimidin-7-yl)morpholine470

A mixture of5-chloro-7-morpholin-4-yl-2-[3-(tetrahydropyran-4-yl)azetidin-1-ylmethyl]thiazolo[5,4-c]pyrimidine(0.1 g, 0.25 mmol), 2-isopropyl-1H-benzoimidazole 0.078 g, 0.49 mmol),Xphos (0.024 g, 0.049 mmol), Pd₂(dba)₃ (0.012 g, 0.012 mmol) and Cs₂CO₃(0.159 g, 0.49 mmol) in dioxane (1.5 mL) was subjected to microwaveirradiation at 145° C. for 45 min. The reaction mixture was filteredthrough Celite and the filtrate was concentrated in vacuo. The residuewas purified by flash chromatography (Si—PPC, MeOH:DCM, gradient 0:100to 5:95) to give 470 as a yellow solid (0.044 g, 34%). LCMS (Method I):R_(T)=2.88 min, [M+H]⁺ 534.2. ¹H NMR (400 MHz, DMSO-d₆): δ 7.89-7.85 (m,1H); 7.66-7.61 (m, 1H); 7.28-7.22 (m, 2H); 4.36-4.30 (m, 4H); 4.00 (s,2H); 3.97-3.89 (m, 1H); 3.85 (dd, J=11.2, 4.0 Hz, 2H); 3.79 (t, J=4.6Hz, 4H); 3.49 (t, J=7.3 Hz, 2H); 3.39-3.35 (m, 2H); 3.07 (t, J=6.8 Hz,2H); 2.27-2.21 (m, 1H); 1.73-1.64 (m, 1H); 1.52 (d, J=13.1 Hz, 2H); 1.33(dd, J=6.8, 4.0 Hz, 6H); 1.10 (td, J=12.2, 4.6 Hz, 2H)

Example 4714-(8-((4-tert-butylpiperazin-1-yl)methyl)-2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine471

4-(8-((4-tert-Butylpiperazin-1-yl)methyl)-2-chloro-9-methyl-9H-purin-6-yl)morpholine(80 mg) was reacted with 2-isopropylbenzimidazole via General ProcedureI for Buchwald coupling to give 31.4 mg 471 following reverse phasepurification. MS (Q1) 532.4 (M)+

Example 4721-(8-((4-tert-butylpiperazin-1-yl)methyl)-9-methyl-6-morpholino-9H-purin-2-yl)-2-ethyl-1H-indazol-3(2H)-one472

Following General Procedure I for Buchwald coupling,4-(8-((4-tert-butylpiperazin-1-yl)methyl)-2-chloro-9-methyl-9H-purin-6-yl)morpholineand 2-ethyl-1H-indazol-3(2H)-one were reacted to give 472. LCMS m/z:534.3 (MH+)

Example 4732-(4-((2-(2-(1,1-difluoroethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)-2-methylpropan-1-ol473

Following General Procedure J for Multi-Step Benzimidazole formation,2-(4-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)-2-methylpropan-1-olwas converted to 473 with difluoroacetic acid. LCMS: M+H⁺=570.3

Example 4742-methyl-2-(4-((9-methyl-6-morpholino-2-(2-(trifluoromethyl)-1H-benzo[d]imidazol-1-yl)-9H-purin-8-yl)methyl)piperazin-1-yl)propan-1-ol474

Following General Procedure J for Multi-Step Benzimidazole formation,2-(4-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)-2-methylpropan-1-olwas converted to 474. LCMS: M+H⁺=574.3

Example 4754-(8-((4-tert-butylpiperazin-1-yl)methyl)-9-methyl-2-(quinolin-4-yl)-9H-purin-6-yl)morpholine475

Following General Procedure A for Suzuki coupling,4-(8-((4-tert-butylpiperazin-1-yl)methyl)-2-chloro-9-methyl-9H-purin-6-yl)morpholineand 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoline werereacted to give 475. LCMS: M+H⁺=501.3

Example 4762-(4-((2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)-2-methylpropan-1-ol476

2-(4-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)-2-methylpropan-1-ol(70 mg) was reacted with 2-isopropylbenzimidazole via General ProcedureI for Buchwald coupling to give 28 mg 476 following reverse phasepurification. MS (Q1) 548.3 (M)+

Example 4772-(1-((2-(2-((1R,2S)-2-fluorocyclopropyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol477

2-(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol(75 mg) was reacted with trans-2-fluorocyclopropanecarboxylic acid viaGeneral Procedure J for two-step Buchwald coupling to give 16.3 mg of477 following reverse phase purification and subsequent chiralseparation from 479. MS (Q1) 549.3 (M)+

Example 478I-2-(1-((2-(2-(2,2-difluorocyclopropyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol478

2-(1-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol(0.1 g) was reacted with 2,2-difluorocyclopropanecarboxylic acid viaGeneral Procedure J for two-step Buchwald coupling to give 8.8 mg of 478[MS (Q1) 567.3 (M)+] following reverse phase purification and subsequentchiral separation from 8.8 mg of enantiomer 481. MS (Q1) 567.3 (M)+].

Example 4792-(1-((2-(2-((1S,2R)-2-fluorocyclopropyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol479

2-(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol(75 mg) was reacted with trans-2-fluorocyclopropanecarboxylic acid viaGeneral Procedure J for two-step Buchwald coupling to give 16.1 mg of479 following reverse phase purification and subsequent chiralseparation from 477. MS (Q1) 549.3 (M)+

Example 4802-(1-((2-(2-((1R,2R)-2-fluorocyclopropyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol480

2-(1-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol(75 mg) was reacted with cis-2-fluorocyclopropanecarboxylic acid viaGeneral Procedure J for two-step Buchwald coupling to give 13 mg of 480.[MS (Q1) 549.3 (M)+] following reverse phase purification and subsequentchiral separation from 13.9 mg of the enantiomer,2-(1-((2-(2-((1S,2S)-2-fluorocyclopropyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol.MS (Q1) 549.3 (M)+

Example 481(S)-2-(1-((2-(2-(2,2-difluorocyclopropyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol481

2-(1-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol(0.1 g) was reacted with 2,2-difluorocyclopropanecarboxylic acid viaGeneral Procedure J for two-step Buchwald coupling to give 8.8 mg of 481[MS (Q1) 567.3 (M)+] following reverse phase purification and subsequentchiral separation from 8.8 mg of enantiomer 478. MS (Q1) 567.3 (M)+

Example 4824-(5-(2-methyl-1H-benzo[d]imidazol-1-yl)-2-((3-(tetrahydro-2H-pyran-4-yl)azetidin-1-yl)methyl)thiazolo[5,4-d]pyrimidin-7-yl)morpholine482

A mixture of5-chloro-7-morpholin-4-yl-2-(3-morpholin-4-yl-azetidin-1-ylmethyl)-thiazolo[5,4-d]pyrimidine(100 mg, 0.24 mmol), 2-methylbenzimidazole (32 mg, 0.24 mmol),tris(dibenzylideneacetone)dipalladium (11 mg, 0.01 mmol), Xphos (12 mg,0.02 mmol) and Cs₂CO₃ (159 mg, 0.48 mmol) in DMF (2 mL) was purged withargon then heated at 145° C. for 30 min in a microwave reactor. Thereaction mixture was dissolved in EtOAc and washed with H₂O (×6), thendried (Na₂SO₄) and concentrated in vacuo. The resulting residue waspurified by column chromatography (Si—PCC, MeOH:DCM, 0-5%) to afford 482as an orange solid (47 mg, 39%). LCMS (Method I): R_(T) 2.59 min, [M+H]⁺507.2. ¹H NMR (CDCl₃, 400 MHz): δ 8.09-8.04 (m, 1H); 7.73-7.68 (m, 1H);7.29-7.24 (m, 2H); 4.41 (m, 4H); 4.02 (s, 2H); 3.88 (t, J=4.7 Hz, 4H);3.71 (m, 6H); 3.17 (m, 3H); 2.92 (s, 3H) and 2.37 (m, 4H)

Example 4834-(5-(2-ethyl-1H-benzo[d]imidazol-1-yl)-2-((3-(tetrahydro-2H-pyran-4-yl)azetidin-1-yl)methyl)thiazolo[5,4-d]pyrimidin-7-yl)morpholine483

A mixture of5-chloro-7-morpholin-4-yl-2-[3-(tetrahydro-pyran-4-yl)azetidin-1-ylmethyl]thiazolo[5,4-d]pyrimidine(90 mg, 0.22 mmol), 2-ethylbenzimidazole (38 mg, 0.26 mmol),tris(dibenzylideneacetone)dipalladium (10 mg, 0.01 mmol), Xphos (21 mg,0.04 mmol) and Cs₂CO₃ (143 mg, 0.44 mmol) in dioxane (2.5 mL) was purgedwith argon then heated at 145° C. for 30 min in a microwave reactor. Thereaction mixture was filtered through a pad of celite, washing withEtOAc. The filtrate was concentrated in vacuo and purified by columnchromatography (Si—PCC, MeOH:EtOAc, 0-7%). The resulting residue wasloaded onto an Isolute® SCX-2 cartridge which was washed with MeOH/DCMand the product eluted with 2M NH₃/MeOH affording 483 as an orange solid(82 mg, 72%). LCMS (Method I): R_(T) 2.70 min, [M+H]⁺ 520.2. ¹H NMR(CDCl₃, 400 MHz): δ 8.02-7.97 (m, 1H); 7.76-7.71 (m, 1H); 7.30-7.24 (m,2H); 4.41 (m, 4H); 4.04-3.94 (m, 4H); 3.91-3.82 (m, 4H); 3.61 (m, 2H);3.44-3.30 (m, 4H); 3.10 (m, 2H); 2.40-2.30 (m, 1H); 1.70 (m, 1H); 1.55(m, 2H); 1.43 (t, J=7.5 Hz, 3H) and 1.32-1.18 (m, 2H)

Example 4844-(5-(2-cyclopropyl-1H-benzo[d]imidazol-1-yl)-2-((3-(tetrahydro-2H-pyran-4-yl)azetidin-1-yl)methyl)thiazolo[5,4-d]pyrimidin-7-yl)morpholine484

A mixture of5-chloro-7-morpholin-4-yl-2-[3-(tetrahydropyran-4-yl)azetidin-1-ylmethyl]thiazolo[5,4-d]pyrimidine(90 mg, 0.22 mmol), 2-cyclopropylbenzimidazole (42 mg, 0.26 mmol),tris(dibenzylideneacetone)dipalladium (10 mg, 0.01 mmol), Xphos (21 mg,0.04 mmol) and Cs₂CO₃ (143 mg, 0.44 mmol) in dioxane (2.5 mL) was purgedwith argon then heated at 145° C. for 30 min in a microwave reactor. Thereaction mixture was filtered through a pad of celite, washing withEtOAc. The filtrate was concentrated in vacuo and purified by columnchromatography (Si—PCC, MeOH:EtOAc, 0-7%). The resulting residue wasloaded onto an Isolute® SCX-2 cartridge which was washed with MeOH/DCMand the product eluted with 2M NH₃/MeOH affording 484 as an orange solid(83 mg, 71%). LCMS (Method I): R_(T) 2.89 min, [M+H]⁺ 532.2. ¹H NMR(CDCl₃, 400 MHz): δ 7.94-7.89 (m, 1H); 7.69-7.65 (m, 1H); 7.26-7.20 (m,2H); 4.43 (m, 4H); 3.99 (m, 4H); 3.87 (m, 4H); 3.61 (m, 2H); 3.38 (m,2H); 3.10 (m, 2H); 2.89-2.82 (m, 1H); 2.36 (m, 1H); 1.71 (m, 1H); 1.56(m, 2H); 1.37-1.31 (m, 2H); 1.30-1.18 (m, 2H) and 1.10-1.04 (m, 2H)

Example 4852-(1-((2-(2-ethyl-4-fluoro-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol485

A microwave vial equipped with a magnetic follower was charged withPd₂(dba)₃ (5.7 mg, 0.006 mmol), Xphos (11.9 mg, 0.025 mmol),2-[1-(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl)-piperidin-4-yl]-propan-2-ol(102 mg, 0.25 mmol), 3-fluoro-2-nitro-phenylamine (47 mg, 0.30 mmol),cesium carbonate (114 mg, 0.35 mmol) and DMF (1 mL). The vial wascapped, the reaction mixture was degassed for 5 min and irradiated at150° C. for 30 min. The reaction mixture was diluted with MeOH andloaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was washedwith MeOH and the desired product was eluted with 2M NH₃ in MeOH. Thesolvents were removed and the residue was subjected to flashchromatography (Si—PCC, 0-5% MeOH in EtOAc) to give2-{1-[2-(3-fluoro-2-nitrophenylamino)-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl]piperidin-4-yl}propan-2-olas a red oil (97 mg, 73%). LCMS (Method H): R_(T) 0.27 min and 3.18 min;[M+H]⁺ 529

To a mixture of2-{1-[2-(3-fluoro-2-nitrophenylamino)-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl]piperidin-4-yl}propan-2-ol(95 mg, 0.18 mmol) in IMS (5 mL) was added 10% Pd on charcoal (20 mg)under an argon atmosphere. The vessel was evacuated and backfilled withhydrogen (the process was repeated three times). The reaction mixturewas stirred at room temperature for 18 hours then filtered throughcelite. The filtrate was concentrated under reduced pressure and theresidue was subjected to flash chromatography (Si—PCC, 0-10% MeOH inEtOAc) to give2-{1-[2-(2-Amino-3-fluoro-phenylamino)-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl]piperidin-4-yl}propan-2-olas a red oil (65 mg, 72%). LCMS (Method H): R_(T)=0.28 min and 2.82 min,[M+H]⁺ 499

To a solution of2-{1-[2-(2-amino-3-fluorophenylamino)-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl]piperidin-4-yl}propan-2-ol(65 mg, 0.13 mmol), propionic acid (78 uL, 0.14 mmol) and DIPEA (49 uL,0.29 mmol) in DMF (3 mL) was added HATU (59 mg, 0.16 mmol). The reactionmixture was stirred at room temperature for 18 hours. Propionic acid (78uL, 0.14 mmol), DIPEA (49 uL, 0.29 mmol) and HATU (59 mg, 0.16 mmol)were added and the reaction mixture was stirred at room temperature for2 days, then diluted with water and extracted with EtOAc. The organiclayer was separated and washed with water, a saturated aqueous solutionof sodium bicarbonate and brine, dried over Na₂SO₄, filtered andconcentrated to give a red oil dissolved in acetic acid (2 mL). Themixture was stirred at 90° C. for 18 hours then concentrated underreduced pressure. The residue was azeotroped with toluene, then taken upin MeOH. The resulting solution was loaded onto an Isolute® SCX-2cartridge (5 g). The cartridge was washed with MeOH and the desiredproduct was eluted with 2M NH₃ in MeOH. The solvents were removed andthe residue was subjected to flash chromatography (Si—PCC, 0-20% MeOH inEtOAc) to give 485 (36 mg, 52%). LCMS (Method I): R_(T) 3.18 min; [M+H]⁺537. ¹H NMR (400 MHz, CHCl₃-d): δ 7.78-7.75 (m, 1H); 7.21-7.12 (m, 1H);6.97 (dd, J=10.3, 8.0 Hz, 1H); 4.34 (m, 4H); 3.90-3.84 (m, 7H); 3.73 (s,2H); 3.35 (q, 7.5 Hz, 2H); 2.97 (d, J=11.4 Hz, 2H); 2.12 (m, 2H); 1.77(m, 2H); 1.44 (t, J=7.5 Hz, 3H); 1.44-1.28 (m, 4H); 1.24-1.15 (m, 6H)

Example 4861-(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)piperidin-4-ol486

A mixture of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(0.167 g, 0.43 mmol), 1-azetidin-3-ylpiperidin-4-ol (0.1 g, 0.64 mmol)and 4 Å molecular sieves (0.8 g) in DCE (8 mL) was stirred for 6 h atroom temperature. Sodium triacetoxyborohydride (0.272 g, 1.28 mmol) wasadded and the reaction mixture was stirred for 18 h at room temperature.The reaction mixture was filtered through Celite and the filtrate wasconcentrated in vacuo. The residue was purified by flash chromatography(Si—PPC, MeOH:DCM, gradient 0:100 to 5:95) to give 486 as a yellow solid(0.123 g, 55%). LCMS (Method I): R_(T)=2.31 min, [M+H]⁺ 532.3. ¹H NMR(400 MHz, DMSO-d₆): δ 8.03-7.99 (m, 1H); 7.65-7.61 (m, 1H); 7.27-7.20(m, 2H); 4.54 (d, J=4.0 Hz, 1H); 4.29-4.22 (m, 4H); 3.86 (s, 2H);3.82-3.73 (m, 7H); 3.42 (t, J=6.5 Hz, 2H); 3.30-3.27 (m, 3H); 3.27 (q,J=7.4 Hz, 2H); 2.96 (t, J=6.5 Hz, 2H); 2.89-2.86 (m, 1H); 1.88-1.85 (m,2H); 1.71-1.68 (m, 2H); 1.39-1.35 (m, 2H); 1.33 (t, J=7.4 Hz, 3H)

Example 4914-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-8-((3-(4-fluoropiperidin-1-yl)azetidin-1-yl)methyl)-9-methyl-9H-purin-6-yl)morpholine491

A mixture of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(0.165 g, 0.42 mmol), 1-azetidin-3-yl-4-fluoropiperidine (0.1 g, 0.63mmol) and 4 Å molecular sieves (0.8 g) in DCE (8 mL) was stirred for 18h at room temperature. Sodium triacetoxyborohydride (0.179 g, 0.84 mmol)was added and the reaction mixture was stirred for 6 h at roomtemperature. The reaction mixture was filtered through Celite and thefiltrate was concentrated in vacuo. The residue was purified by flashchromatography (Si—PPC, MeOH:DCM, gradient 0:100 to 10:90) to give 491as a yellow solid (0.1 g, 45%). LCMS (Method I): R_(T)=2.52 min, [M+H]⁺534.2. ¹H NMR (400 MHz, DMSO-d₆): δ 8.03-7.99 (m, 1H); 7.64-7.61 (m,1H); 7.26-7.21 (m, 2H); 4.81-4.52 (m, 1H); 4.51-3.96 (m, 4H); 3.86 (s,2H); 3.79-3.76 (m, 7H); 3.43 (t, J=6.3 Hz, 2H); 3.26 (q, J=7.4 Hz, 2H);2.97 (t, J=6.3 Hz, 2H); 2.95-2.91 (m, 1H); 2.37-2.33 (m, 2H); 2.18-2.13(m, 2H); 1.90-1.75 (m, 2H); 1.76-1.64 (m, 2H); 1.33 (t, J=7.4 Hz, 3H)

Example 4924-(8-((3-(4,4-difluoropiperidin-1-yl)azetidin-1-yl)methyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine492

A mixture of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(0.1 g, 0.26 mmol), 1-azetidin-3-yl-4,4-difluoropiperidine (0.087 g,0.38 mmol) and 4 Å molecular sieves (0.6 g) in DCE (6 mL)was stirred for18 h at room temperature. Sodium triacetoxyborohydride (0.109 g, 0.51mmol) was added and the reaction mixture was stirred for 5 h at roomtemperature. The reaction mixture was filtered through Celite and thefiltrate was concentrated in vacuo. The residue was purified by flashchromatography (Si—PPC, MeOH:DCM, gradient 0:100 to 3:97) to give 492 asa yellow solid (0.097 g, 69%). LCMS (Method I): R_(T)=2.82 min, [M+H]⁺552.3. ¹H NMR (400 MHz, DMSO-d₆): δ 8.03-7.99 (m, 1H); 7.65-7.61 (m,1H); 7.28-7.21 (m, 2H); 4.30-4.23 (m, 4H); 3.87 (s, 2H); 3.80-3.75 (m,7H); 3.46-3.43 (m, 2H); 3.25 (q, J=7.4 Hz, 2H); 3.01-2.98 (m, 3H);2.37-2.33 (m, 4H); 2.00-1.87 (m, 4H); 1.33 (t, J=7.4 Hz, 3H)

Example 4934-(2-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)ethyl)-1-isopropylpiperazin-2-one493

A mixture of4-[2-(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)ethyl]-1-isopropylpiperazin-2-one(51 mg, 0.12 mmol), 2-ethylbenzimidazole (20 mg, 0.13 mmol), Pd₂(dba)₃(2.8 mg, 2.5 mol %), Xphos (5.8 mg, 10 mol %) and Cs₂CO₃ (59 mg, 0.18mmol) in dioxane (1.5 mL) was purged with argon gas then heated at 120°C., for 19 h, in a sealed tube. The reaction mixture was loaded onto anIsolute® SCX-2 cartridge, washed with MeOH then the desired producteluted with 2 M NH₃ in MeOH. The resulting residue was purified by flashchromatography (Si—PCC, 0-10% 2 M NH₃/MeOH in DCM) followed by reversephase HPLC (Phenomenex Gemini 5 μm C18, 20 mM triethylamine in water ona gradient of acetonitrile 20-98%) to give 493 (28 mg, 44%) as an offwhite solid. LCMS: (Method I): R_(T) 2.75 min; [M+H]⁺ 532.3. ¹H NMR (400MHz, CHCl₃-d): δ 8.01-7.96 (m, 1H), 7.80-7.76 (m, 1H), 7.28 (m, 2H),4.91-4.82 (m, 1H), 4.5-4.21 (m, 4H), 3.87 (t, J=4.7 Hz, 4H), 3.77 (s,3H), 3.37 (q, J=7.5 Hz, 2H), 3.29 (s, 2H), 3.26 (t, J=5.4 Hz, 2H),3.08-3.01 (m, 2H), 3.00-2.93 (m, 2H), 2.81 (t, J=5.4 Hz, 2H), 1.45 (t,J=7.5 Hz, 3H), 1.14 (d, J=6.9 Hz, 6H)

Example 4941′-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-1,3′-biazetidin-3-ol494

A mixture of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(0.15 g, 0.38 mmol), [1,3′]biazetidinyl-3-ol (0.098 g, 0.77 mmol) and 4Å molecular sieves (0.8 g) in DCE (8 mL) was stirred for 4 h at roomtemperature. Sodium triacetoxyborohydride (0.162 g, 0.77 mmol) was addedand the reaction mixture was stirred for 18 h at room temperature. Thereaction mixture was filtered through Celite and the filtrate wasconcentrated in vacuo. The residue was purified by flash chromatography(Si—PPC, MeOH:DCM, gradient 0:100 to 20:80) to give 494 as an off-whitesolid (0.101 g, 53%). LCMS (Method I): R_(T)=2.31 min, [M+H]⁺ 504.2. ¹HNMR (400 MHz, DMSO-d₆): δ 8.03-7.98 (m, 1H); 7.65-7.60 (m, 1H);7.28-7.22 (m, 2H); 5.26 (d, J=6.8 Hz, 1H); 4.28-4.21 (m, 4H); 4.19-4.15(m, 3H); 3.83 (s, 2H); 3.79-3.75 (m, 7H); 3.47-3.35 (m, 2H); 3.20 (q,J=7.4 Hz, 2H); 3.02 (t, J=6.8 Hz, 2H); 2.82 (t, J=6.8 Hz, 3H); 1.36-1.29(q, J=7.4 Hz, 3H)

Example 4954-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-8-((4-(tetrahydro-2H-pyran-4-yl)piperazin-1-yl)methyl)-9H-purin-6-yl)morpholine495

A solution of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(360 mg, 0.92 mmol), 1-(tetrahydropyran-4-yl)piperazine (250 mg, 1.47mmol) and molecular sieves (4 Å, powdered, 1.5 g) in DCE (10 mL) wasstirred at ambient temperature for 6 h. Sodium triacetoxyborohydride(530 mg, 2.50 mmol) was added and the mixture stirred for 18 h, thenloaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was thenwashed with methanol and the desired product was subsequently elutedusing 2 M NH₃ in MeOH. The product was collected and concentrated invacuo. The resultant residue was purified by flash chromatography(Si—PPC, EtOAc:MeOH; gradient from 100:0 to 70:30) followed by reversephase HPLC (Phenomenex Gemini 5u C18, 20 mM triethylamine in water on agradient of acetonitrile 80:20 to 2:98) to afford 495 as a cream foam(439 mg, 87%). LCMS (Method I): R_(T)=2.50 min, M+H⁺=546. ¹H NMR (CDCl₃,400 MHz) δ 8.01 (m, 1H); 7.76 (m, 1H); 7.27 (m, 2H); 4.35 (m, 4H); 4.03(d, J=11.3 Hz, 2H); 3.87 (m, 7H); 3.78 (s, 2H); 3.42-3.29 (m, 4H); 2.64(m, 8H); 1.79 (m, 3H); 1.62 (m, 2H) and 1.45 (t, J=7.5 Hz, 3H)

Example 4964-(5-(2-ethyl-1H-benzo[d]imidazol-1-yl)-2-((4-(oxetan-3-yl)piperidin-1-yl)methyl)thiazole[5,4-d]pyrimidin-7-yl)morpholine496

A mixture of5-chloro-7-morpholin-4-yl-2-(4-oxetan-3-ylpiperidin-1-ylmethyl)thiazole[5,4-c]pyrimidine(200 mg, 0.49 mmol), 2-ethyl-1H-benzoimidazole (79 mg, 0.54 mmol),Pd₂dba₃ (12 mg, 0.013 mmol), Xphos (24 mg, 0.050 mmol) and cesiumcarbonate (240 mg, 0.74 mmol) in 1,4-dioxane (3 mL) was purged withargon gas then subjected to microwave irradiation at 145° C. for 30 min.The reaction mixture was loaded onto an Isolute® SCX-2 cartridge (10 g),which was washed with MeOH/DCM before the desired product was elutedwith 2 M NH₃ in MeOH/DCM. The product was collected and concentrated invacuo. The resultant residue was purified by flash chromatography(Si—PPC, DCM:MeOH 100:0 to 99:1 to 98:2) to afford 496 as a white solid(121 mg, 48%). LCMS (Method I): R_(T)=2.65 min, M+H⁺=520. ¹H NMR (CDCl₃,400 MHz) δ 8.02 (m, 1H); 7.77 (m, 1H); 7.30 (m, 2H); 4.78 (dd, J=7.8,6.1 Hz, 2H); 4.47 (t, J=6.1 Hz, 2H); 4.41 (m, 4H); 3.88 (m, 6H); 3.36(q, J=7.5 Hz, 2H); 3.05 (m, 2H); 2.84-2.76 (m, 1H); 2.30 (m, 2H);1.80-1.61 (m, 4H); 1.44 (t, J=7.5 Hz, 3H) and 1.28 (m, 1H)

Example 4974-(5-(2-cyclopropyl-1H-benzo[d]imidazol-1-yl)-2-((4-(oxetan-3-yl)piperidin-1-yl)methyl)thiazole[5,4-d]pyrimidin-7-yl)morpholine497

A mixture of5-chloro-7-morpholin-4-yl-2-(4-oxetan-3-ylpiperidin-1-ylmethyl)thiazole[5,4-c]pyrimidine(200 mg, 0.49 mmol), 2-cyclopropyl-1H-benzoimidazole (93 mg, 0.59 mmol),Pd₂dba₃ (12 mg, 0.013 mmol), Xphos (24 mg, 0.050 mmol) and cesiumcarbonate (240 mg, 0.74 mmol) in 1,4-dioxane (3 mL) was purged withargon gas then subjected to microwave irradiation at 145° C. for 30 min.The reaction mixture was loaded onto an Isolute® SCX-2 cartridge (10 g),washed with MeOH/DCM before the desired product was eluted with 2 M NH₃in MeOH/DCM. The product was collected and concentrated in vacuo. Theresultant residue was purified by flash chromatography (Si—PPC, DCM:MeOH100:0 to 99:1) to afford 497 as a salmon coloured solid (118 mg, 45%).LCMS (Method I): R_(T)=2.83 min, M+H⁺=532. ¹H NMR (CDCl₃, 400 MHz) δ7.92 (m, 1H); 7.68 (m, 1H); 7.27 (m, 2H); 4.78 (dd, J=7.9, 6.0 Hz, 2H);4.52-4.39 (m, 6H); 3.87 (m, 6H); 3.04 (m, 2H); 2.92-2.76 (m, 2H); 2.29(m, 2H); 1.79-1.61 (m, 4H); 1.43-1.18 (m, 3H) and 1.11-1.05 (m, 2H)

Example 498N-methyl-1-(7-morpholino-2-((3-(tetrahydro-2H-pyran-4-yl)azetidin-1-yl)methyl)thiazolo[5,4-d]pyrimidin-5-yl)-1H-benzo[d]imidazol-2-amine498

A mixture of5-chloro-7-morpholin-4-yl-2-[3-(tetrahydropyran-4-yl)azetidin-1-ylmethyl]thiazole[5,4-c]pyrimidine(90 mg, 0.22 mmol), (1H-benzoimidazol-2-yl)methylamine (39 mg, 0.26mmol), tris(dibenzylideneacetone)dipalladium (10 mg, 0.01 mmol), Xphos(21 mg, 0.04 mmol) and Cs₂CO₃ (143 mg, 0.44 mmol) in dioxane (2.5 mL)was purged with argon then heated at 145° C. for 30 min in a microwavereactor. The reaction mixture was filtered through a pad of celite,washing with EtOAc. The filtrate was concentrated in vacuo and purifiedby column chromatography (Si—PCC, MeOH:DCM, 0-10%). The resultingresidue was loaded onto an Isolute® SCX-2 cartridge which was washedwith MeOH/DCM and the product eluted with 2M NH₃/MeOH affording 498 asan orange solid (60 mg, 52%). LCMS (Method I): R_(T) 2.43 min, [M+H]⁺521.2. ¹H NMR (CDCl₃, 400 MHz): δ 8.37 (d, J=5.0 Hz, 1H); 8.19 (d, J=8.0Hz, 1H); 7.48 (d, J=7.8 Hz, 1H); 7.19 (t, J=7.8 Hz, 1H); 7.06 (t, J=8.0Hz, 1H); 4.41 (m, 4H); 4.02-3.88 (m, 8H); 3.58 (m, 2H); 3.38 (m, 2H);3.25 (d, J=5.0 Hz, 3H); 3.09 (m, 2H); 2.40-2.29 (m, 1H); 1.71 (m, 1H);1.56 (m, 2H) and 1.30-1.17 (m, 2H)

Example 4994-(2-(2-cyclopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-8-((3-(tetrahydro-2H-pyran-4-yl)azetidin-1-yl)methyl)-9H-purin-6-yl)morpholine499

A mixture of2-(2-cyclopropylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(100 mg, 0.25 mmol), 3-(tetrahydropyran-4-yl)azetidine (37 mg, 0.26mmol) and 4 Å powdered molecular sieves (250 mg) in DCE (5 mL) wasstirred at room temperature for 5 h before the addition of sodiumtriacetoxyborohydride (233 mg, 0.92 mmol). The reaction mixture wasstirred for 16 h then filtered through celite, washing with DCM. Theorganic phase was washed with brine (×1) and concentrated in vacuo. Theorganic phase was dried (Na₂SO₄) and concentrated in vacuo. Theresulting residue was purified by column chromatography (Si—PCC,MeOH:DCM, 0-10%). The resulting oil was loaded onto an Isolute® SCX-2cartridge which was washed with MeOH/DCM and the product eluted with 2MNH₃/MeOH affording 499 as an orange solid (76 mg, 57%). LCMS (Method I):R_(T) 2.72 min [M+H]⁺ 529.3. ¹H NMR (CDCl₃, 400 MHz): δ 7.93 (d, J=7.6Hz, 1H); 7.67 (d, J=7.4 Hz, 1H); 7.27-7.18 (m, 2H); 4.36 (m, 4H);4.00-3.93 (m, 2H); 3.88-3.83 (m, 9H); 3.55 (m, 2H); 3.37 (m, 2H); 3.06(m, 2H); 2.89-2.81 (m, 1H); 2.34 (m, 1H); 1.71 (m, 1H); 1.54 (m, 2H);1.38-1.32 (m, 2H); 1.22 (m, 2H) and 1.06 (m, 2H)

Example 500 ethyl2-(4-((2-(2-cyclopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)-2-methylpropanoate500

Following General Procedure I for Buchwald coupling,2-cyclopropylbenzimidazole and ethyl2-(4-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)-2-methylpropanoatewere reacted to give 500. LCMS m/z: 588.4 (MH+)

Example 5014-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-8-((1-(tetrahydro-2H-(1,1-dioxo)-thiopyran-4-yl)azetidin-3-yl)methyl)-9H-purin-6-yl)morpholine

Following General Procedure L, 1,1-dioxo-tetrahydrothiopyran-4-oneunderwent reductive amination with4-(8-(azetidin-3-ylmethyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholineto give 501. LCMS m/z: 565.3 (MH+)

Example 502 ethyl2-methyl-2-(4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)propanoate502

Following General Procedure C,4-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-8-(piperazin-1-ylmethyl)-9H-purin-6-yl)morpholinewas alkylated with ethyl 2-bromo-2-methyl-propionate to give 502. LCMSm/z: 281.7 (2M+H+)

Example 5034-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-8-((1-(tetrahydro-2H-pyran-4-yl)azetidin-3-yl)methyl)-9H-purin-6-yl)morpholine503

Following General Procedure L, 2H-pyran-4(3H)-one underwent reductiveamination with4-(8-(azetidin-3-ylmethyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholineto give 503. 517.3 (MH+)

Example 505 tert-butyl4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidine-1-carboxylate505

Following the procedures for 520, 505 was prepared. LCMS m/z: 547.3(MH+)

Example 5062-methyl-2-(4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)propanoicacid 506

A mixture of ethyl2-methyl-2-(4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)propanoate507 (0.14 g, 0.25 mmol) in 2M LiOH (5.0 mL) and THF (8 mL) was stirredat reflux for 18 hours. The reaction was then cooled to room temperatureand concentrated down to ⅓ of original volume. The residue was thenloaded onto a SCX-2 column. The column was first washed with MeOH. Theproduct was then eluted with 2M NH₃ in MeOH and then concentrated. Theresidue was purified by RP-HPLC to give 506. LCMS m/z: 534.3 (MH+)

Example 507 methyl2-methyl-2-(4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-1-yl)propanoate507

Following General Procedure C, 2-bromo-2-methyl-propionoic acid methylester and4-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-8-(piperidin-4-ylmethyl)-9H-purin-6-yl)morpholinewere reacted to give 507. LCMS m/z: 274.2 (2M+H)

Example 5082-methyl-2-(4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-1-yl)propanamide508

Following General Procedure C, 2-bromo-2-methyl-propionamide and4-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-8-(piperidin-4-ylmethyl)-9H-purin-6-yl)morpholinewere reacted to give 508. LCMS m/z: 532.2 (MH+)

Example 5092-methyl-2-(4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-1-yl)propan-1-ol509

To a solution of methyl2-methyl-2-(4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-1-yl)propanoate507 (0.10 g, 0.183 mmol) in THF (10 mL) was added a 1.0 M solution oflithium aluminum hydride in THF (0.18 mL, 0.18 mmol) at 0° C. Thereaction was stirred at 0° C. for 1 hour. The reaction was then quenchedby adding 2 mL of sat. NH₄Cl solution. The cloudy mixture was thenloaded onto an ISOLUTE® SCX-2 column. The column was first washed withMeOH prior to eluting the product by adding 2M NH₃ in MeOH. The crudeproduct was then concentrated and purified by RP-HPLC to give 509. LCMSm/z: 519.3 (MH+)

Example 5104-(8-((4-tert-butylpiperazin-1-yl)methyl)-9-methyl-6-morpholino-9H-purin-2-yl)isoquinolin-1-amine510

Following General Procedure A for Suzuki coupling,4-(8-((4-tert-butylpiperazin-1-yl)methyl)-2-chloro-9-methyl-9H-purin-6-yl)morpholineand 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoquinolin-1-aminewere reacted to give 510. LCMS: M+H⁺=519.3

Example 5118-(2-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)ethyl)-3-oxa-8-azabicyclo[3.2.1]octane511

A mixture of2-chloro-9-methyl-6-morpholin-4-yl-8-[2-(3-oxa-8-aza-bicyclo[3.2.1]oct-8-yl)ethyl]-9H-purine(75 mg, 0.19 mmol), 2-ethylbenzimidazole (31 mg, 0.21 mmol), Pd₂(dba)₃(4.4 mg, 2.5 mol %), Xphos (9.1 mg, 10 mol %) and Cs₂CO₃ (93 mg, 0.29mmol) in dioxane (2.0 mL) was purged with argon gas then heated at 120°C., for 18 h, in a sealed tube. The reaction mixture was loaded onto anIsolute® SCX-2 cartridge, washed with MeOH then the desired producteluted with 2 M NH₃/MeOH in DCM. The resulting residue was purified byreverse phase HPLC (Phenomenex Gemini 5 μm C18, 20 mM triethylamine inwater on a gradient of acetonitrile 30-90%) to give 511 (50 mg, 52%) asan off white solid. LCMS: (Method I): R_(T) 2.49 min; [M+H]⁺ 503.2. ¹HNMR (400 MHz, CHCl₃-d): δ 8.02-7.97 (m, 1H), 7.77-7.73 (m, 1H),7.29-7.22 (m, 2H), 4.52-4.20 (m, 4H), 3.86 (t, J=4.7 Hz, 4H), 3.82 (s,3H), 3.79-3.65 (m, 2H), 3.58-3.50 (m, 2H), 3.35 (q, J=7.5 Hz, 2H),3.18-3.09 (m, 2H), 3.09-2.99 (m, 2H), 2.90-2.76 (m, 2H), 2.07-1.88 (m,4H), 1.44 (t, J=7.5 Hz, 3H)

Example 5122-(1-((9-methyl-6-morpholino-8-((4-(oxetan-3-yl)piperidin-1-yl)methyl)-9H-purin-2-yl)-1H-benzo[d]imidazol-2-yl)ethanol512

A solution of2-[2-(2-hydroxyethyl)benzoimidazol-1-yl]-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(200 mg, 0.49 mmol), 4-oxetan-3-ylpiperidine (83 mg, 0.59 mmol) andmolecular sieves (4 Å, powdered, 1 g) in DCE (5 mL) was stirred atambient temperature for 5 h. Sodium triacetoxyborohydride (156 mg, 0.74mmol) was added and the mixture stirred for 18 h, then loaded onto anIsolute® SCX-2 cartridge (10 g). The cartridge was then washed withmethanol and the desired product was subsequently eluted using 2 M NH₃in MeOH. The product was collected and concentrated in vacuo. Theresultant residue was purified by flash chromatography (Si—PPC,DCM:MeOH; 100:0 to 99:1 to 98:2 to 97:3 to 95:5) to afford 512 as awhite solid (51 mg, 20%). LCMS (Method I): R_(T)=2.39 min, M+H⁺=533. ¹HNMR (CDCl₃, 400 MHz) δ 8.04 (m, 1H); 7.75 (m, 1H); 7.33 (m, 2H); 4.76(dd, J=7.8, 6.0 Hz, 2H); 4.45 (t, J=6.0 Hz, 2H); 4.35 (m, 4H); 4.19 (t,J=5.5 Hz, 2H); 3.94-3.80 (m, 9H); 3.54 (t, J=5.5 Hz, 2H); 3.02 (m, 2H);2.81-2.72 (m, 1H); 2.29 (m, 2H); 1.71 (m, 5H) and 1.28 (m, 1H)

Example 5134-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-8-(4-(oxetan-3-yl)piperazin-1-yl)methyl)-9H-purin-6-yl)morpholine513

TFA (2 mL) was added to a solution of4-oxetan-3-ylpiperazine-1-carboxylic acid tert-butyl ester (150 mg, 0.62mmol) in DCM (10 mL) and the mixture was stirred at ambient temperaturefor 30 min, then loaded onto an Isolute® SCX-2 cartridge (10 g). Thecartridge was then washed with methanol and the desired product wassubsequently eluted using 2 M NH₃ in MeOH. The product was collected andconcentrated in vacuo to give 1-oxetan-3-ylpiperazine as a colourlessoil. A solution of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(200 mg, 0.51 mmol), 1-oxetan-3-ylpiperazine (88 mg, 0.62 mmol) andmolecular sieves (4 Å, powdered, 1 g) in DCE (10 mL) was stirred atambient temperature for 5 h. Sodium triacetoxyborohydride (162 mg, 0.76mmol) was added and the mixture stirred for 18 h, then loaded onto anIsolute® SCX-2 cartridge (10 g). The cartridge was then washed withmethanol and the desired product was subsequently eluted using 2 M NH₃in MeOH. The product was collected and concentrated in vacuo. Theresultant residue was purified by flash chromatography (Si—PPC,DCM:MeOH; 100:0 to 99:1 to 98:2 to 95:5) to afford 513 as a white solid(98 mg, 37%). LCMS (Method I): R_(T)=2.43 min, M+H⁺=518. ¹H NMR (CDCl₃,400 MHz) δ 8.01 (dd, J=6.9, 2.4 Hz, 1H); 7.78 (m, 1H); 7.33-7.23 (m,2H); 4.70-4.60 (m, 4H); 4.35 (m, 4H); 3.97-3.75 (m, 7H); 3.79 (s, 2H);3.57-3.49 (m, 1H); 3.37 (q, J=7.5 Hz, 2H); 2.66 (m, 4H); 2.42 (m, 4H);1.46 (t, J=7.5 Hz, 3H)

Example 5144-(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)piperazin-2-one514

A mixture of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(100 mg, 0.26 mmol), 4-azetidin-3-ylpiperazin-2-one (44 mg, 0.28 mmol)and 4 Å powdered molecular sieves (250 mg) in MeOH (2 mL) and DCE (5 mL)was stirred at room temperature for 2 h before the addition of sodiumtriacetoxyborohydride (108 mg, 0.51 mmol). The reaction mixture wasstirred for 16 h then filtered through celite, washing with DCM. Theorganic phase was washed with brine (×1) and concentrated in vacuo. Theorganic phase was dried (Na₂SO₄) and concentrated in vacuo. Theresulting residue was purified by column chromatography (Si—PCC,MeOH:DCM, 0-7%). The resulting oil was loaded onto an Isolute® SCX-2cartridge which was washed with MeOH/DCM and the product eluted with 2MNH₃/MeOH affording 514 as a yellow foam (42 mg, 31%). LCMS (Method I):R_(T) 2.28 min [M+H]⁺ 531.2. ¹H NMR (CDCl₃, 400 MHz): δ 8.02-7.97 (m,1H); 7.79-7.74 (m, 1H); 7.31-7.24 (m, 2H); 5.93 (bs, 1H); 4.35 (m, 4H);3.94 (s, 2H); 3.94-3.80 (m, 7H); 3.66 (bs, 2H); 3.43-3.33 (m, 4H); 3.21(s, 3H); 3.06 (s, 2H); 2.58 (t, J=5.37 Hz, 2H) and 1.45 (t, J=7.5 Hz,3H)

Example 515(S)-3-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-1-isopropylpiperidin-3-ol515

To a stirred solution of 4-(2-chloro-9-methyl-9H-purin-6-yl)morpholine(5.0 g) and N,N,N′,N′-tetramethylethylenediamine (4.46 mL) intetrahydrofuran (80 mL) at −78° C. was added 2.5 M of n-Butyllithium inTHF (17 mL). The solution was stirred at −78° C. for 15 mins then thetemp was raised to −40° C. until the solution became clear and dark red(indicating full lithiation). The solution was lowered back to −78° C.and tert-butyl 3-oxopiperidine-1-carboxylate (8.64 g) in 10 mL THF wasadded slowly over 5 minutes and stirred for 1.5 hrs then quenched withwater. The reaction mixture was diluted with ethyl acetate and extractedwith a saturated ammonium chloride solution. The organic layer wasdried, filtered and concentrated. Any remaining starting material wasremoved by trituration with hot ether to afford the crude producttert-butyl3-(2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)-3-hydroxypiperidine-1-carboxylateas an orange oil in quantitative yield.

tert-Butyl3-(2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)-3-hydroxypiperidine-1-carboxylate(80 mg) was brought up into 1.25 M Hydrogen Chloride in ethanol andheated at 50° C. for several hours until reaction was complete. Thereaction mixture was concentrated to dryness to afford 70 mg of the HClsalt of 3-(2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)piperidin-3-ol.

The HCl salt of3-(2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)piperidin-3-ol (70 mg)was reacted with isopropyl iodide (1.5 eq), cesium carbonate (2 eq) andDIPEA (3 eq) in DMF (1 mL). The reaction was heated at 50° C. forseveral hours until complete. The reaction mixture was diluted withEthyl acetate and extracted with a saturated ammonium chloride solution.The organic layer was dried, filtered and concentrated to give 70 mg ofcrude3-(2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)-1-isopropylpiperidin-3-olwhich was reacted with 2-ethyl benzimidazole via General Procedure I forBuchwald coupling to give 515 [7.6 mg; MS (Q1) 505.3 (M)+] and 518 [7.7mg; MS (Q1) 505.2 (M)+] following reverse phase purification andsubsequent chiral separation.

Example 516(S)-2-(1-((2-(2-(1-methoxyethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol516

2-(1-chloroethyl)-1H-benzo[d]imidazole (0.39 g) and 25 wt % solution ofSodium Methoxide in Methanol (0.96 mL) in 10 mL of Methanol was heatedfor 20 minutes at 150° C. in a microwave synthesizer. The reactionmixture was extracted with EtOAc and sat NH4 chloride. The organic layerwas dried, filtered and concentrated to afford crude2-(1-methoxyethyl)-1H-benzo[d]imidazole in quantitative yield.

2-(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol(0.15 g) was reacted with 2-(1-methoxyethyl)-1H-benzo[d]imidazole (97mg) via General Procedure I for Buchwald coupling to give 32.1 mg of 516[MS (Q1) 549.4 (M)+] and 32.4 mg of 519 [MS (Q1) 549.3 (M)+] followingreverse phase purification and subsequent chiral separation.

Example 517N-(1-(8-((4-(2-hydroxypropan-2-yl)piperidin-1-yl)methyl)-9-methyl-6-morpholino-9H-purin-2-yl)-1H-benzo[d]imidazol-2-yl)acetamide517

2-Chloro-1H-benzo[d]imidazole (1 g) was added to a neat solution ofdibenzylamine (7 mL) and heated to 170° C. for 1.5 hours in a Biotagemicrowave synthesizer. The reaction mixture was concentrated to drynessand purified via flash column chromatography to afford 0.6 g ofN,N-dibenzyl-1H-benzo[d]imidazol-2-amine.

2-(1-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol(0.35 g) was reacted with N,N-dibenzyl-1H-benzo[d]imidazol-2-amine viaGeneral Procedure J for Buchwald coupling to give 255 mg of2-(1-((2-(2-(dibenzylamino)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-olfollowing flash chromatography.

To a flask of2-(1-((2-(2-(dibenzylamino)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol(125 mg) in Ethanol (5.4 mL) was added 10% Palladium on Carbon (0.2 g)and Acetic acid (83 uL). The flask was purged with a nitrogen balloonand then placed under a Hydrogen balloon. The reaction was heated at 70°C. for 48 hours. The reaction was filtered thru celite and the celitecake was rinsed with a mixture of 1% acetic acid in methanol severaltimes. The solvent was concentrated to dryness to give 70 mg of crude2-(1-((2-(2-amino-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol,70 mg of which was added to HATU (105 mg), DIPEA (0.12 mL) and aceticacid (24 uL) in DMF (0.8 mL). Upon completion, the reaction was dilutedwith Ethyl acetate and extracted with water. The organic layer wasdried, filtered and concentrated to give crude product. The crude waspurified via reverse phase HPLC to afford 11.5 mg of 517 as a whitesolid. MS (Q1) 548.3 (M)+

Example 518I-3-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-1-isopropylpiperidin-3-ol518

The HCl salt of3-(2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)piperidin-3-ol (70 mg)was reacted with isopropyl iodide (1.5 eq), cesium carbonate (2 eq) andDIPEA (3 eq) in DMF (1 mL). The reaction was heated at 50° C. forseveral hours until complete. The reaction mixture was diluted withEthyl acetate and extracted with a saturated ammonium chloride solution.The organic layer was dried, filtered and concentrated to give 70 mg ofcrude3-(2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)-1-isopropylpiperidin-3-olwhich was reacted with 2-ethyl benzimidazole via General Procedure I forBuchwald coupling to give 515 [7.6 mg; MS (Q1) 505.3 (M)+] and 518 [7.7mg; MS (Q1) 505.2 (M)+] following reverse phase purification andsubsequent chiral separation.

Example 519I-2-(1-((2-(2-(1-methoxyethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol519

2-(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol(0.15 g) was reacted with 2-(1-methoxyethyl)-1H-benzo[d]imidazole (97mg) via General Procedure I for Buchwald coupling to give 32.1 mg of 516[MS (Q1) 549.4 (M)+] and 32.4 mg of 519 [MS (Q1) 549.3 (M)+] followingreverse phase purification and subsequent chiral separation.

Example 5204-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-8-(piperidin-4-ylmethyl)-9H-purin-6-yl)morpholine520

Step 1: dimethyl(2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methylphosphonate

A mixture of4-(8-(bromomethyl)-2-chloro-9-methyl-9H-purin-6-yl)morpholine (0.25 g,0.72 mmol) and trimethylphosphite (4.0 mL, 34 mmol) was stirred at 120degree for 1.25 hours. The resulting suspension was partitioned betweenwater and dichloromethane. The aqueous layer was neutralized andextracted again with dichloromethane. The organic extracts were washedwith water, dried over MgSO₄, filtered and concentrated. The crudeproduct was purified by flash chromatography (0-5% methanol in DCM) togive the title compound (207 mg, 76%).

Step 2: tert-butyl4-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methylene)piperidine-1-carboxylate

To a cold (−78° C.) suspension of dimethyl(2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methylphosphonate (0.35 g,0.93 mmol) in THF (8.0 mL) was added a 2.0M solution of LDA in THF (0.49mL). The resulting solution was allowed to warm to room temperaturebefore the addition of a solution of 1-Boc-4-piperidone (0.19 g, 0.95mmol) in THF (3 mL). The reaction mixture was then stirred at roomtemperature for 2 hours, and partitioned between brine and DCM. Theorganic layer was isolated, washed with brine, dried over MgSO₄ andconcentrated. The crude residue was then purified by flashchromatrography (0-75% EtOAc in heptane) to give the title compound(0.38 g, 91%). LCMS m/z: 449.2 (MH+).

Step 3: tert-butyl4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methylene)piperidine-1-carboxylate

A mixture of tert-butyl4-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methylene)piperidine-1-carboxylate(0.375 g, 0.835 mmol), 2-methylbenzimidazole (0.132 g, 1.0 mmol), Xphos(0.040 g, 0.084 mmol), Pd₂(dba)₃ (0.040 g, 0.042 mmol) and cesiumcarbonate (0.54 g, 1.67 mmol) in DMF (3.5 mL) was heated in a Biotagemicrowave at 140° C. for 30 minutes. The reaction mixture was thenfiltered through paper and then partitioned between brine and EtOAc. Thecombined extracts were washed with brine, dried over Na2SO4, filteredand concentrated. The crude product was purified by flash chromatography(0-10% MeOH in DCM) to give the title compound (0.39 g, 87%). LCMS m/z:545.3 (MH+).

Step 4: tert-butyl4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidine-1-carboxylate

A suspension of tert-butyl4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methylene)piperidine-1-carboxylate(0.39 g, 0.729 mmol) and Pd/C (10 wt %, 0.1 g) in ethanol (15 mL) wasstirred under a hydrogen atmosphere (balloon) at room temperature for 18hours. The reaction mixture was then filtered through celite andconcentrated. The crude product was purified by flash chromatography(0-5% MeOH in DCM) to give the title compound (0.36 g, 90%). LCMS m/z:547.2 (MH+)

Step 5: To a solution of tert-butyl4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidine-1-carboxylate(0.36 g, 0.66 mmol) in 1,4-dioxane (10 mL) was added a 4M solution ofhydrogen chloride in 1,4-dioxane. The reaction mixture was then stirredat room temperature for 1 hour. The resulting suspension was thenfiltered. The collected solid was washed 1,4-dioxane and dried undervacuum to give 520 (hydrochloride salt) as an off-white solid (0.34 g,quant.). LCMS m/z: 484.2 (MH+)

Example 5212-((1S,4S)-5-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)-2-methylpropan-1-ol521

A mixture of2-[(1S,4S)-5-(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]-2-methylpropan-1-ol(50 mg, 0.12 mmol), 2-ethyl-1H-benzoimidazole (20 mg, 0.14 mmol),Pd₂dba₃ (3 mg, 0.003 mmol), Xphos (6 mg, 0.012 mmol) and cesiumcarbonate (56 mg, 0.17 mmol) in DMF (1 mL) was purged with argon gasthen subjected to microwave irradiation at 150° C. for 1 h. The reactionmixture was loaded onto an Isolute® SCX-2 cartridge (10 g), which waswashed with MeOH/DCM before the desired product was eluted with 2 M NH₃in MeOH/DCM. The product was collected and concentrated in vacuo. Theresultant residue was purified by flash chromatography (Si—PPC, DCM:MeOH100:0 to 95:5 to 90:10 to 80:20) to afford 521 as a tan solid (27 mg,44%). LCMS (Method I): R_(T)=2.50 min, M+H⁺=546. ¹H NMR (CDCl₃, 400 MHz)δ 8.01 (m, 1H); 7.75 (m, 1H); 7.28 (m, 2H); 4.34 (m, 4H); 4.02 (m, 2H);3.93-3.79 (m, 7H); 3.49 (m, 2H); 3.45-3.27 (m, 3H); 2.89 (m, 2H); 1.85(s, 2H); 1.64 (m, 3H); 1.48-1.42 (m, 3H) and 1.33-1.08 (m, 6H)

Example 5224-(2-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)ethyl)-6-isopropylpiperazin-2-one522

A mixture of4-[2-(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)ethyl]-6-isopropylpiperazin-2-one(90 mg, 0.21 mmol), 2-ethylbenzimidazole (35 mg, 0.24 mmol), Pd₂(dba)₃(4.9 mg, 2.5 mol %), Xphos (10.2 mg, 10 mol %) and Cs₂CO₃ (104 mg, 0.32mmol) in dioxane (2.0 mL) was purged with argon gas then heated at 120°C., for 19 h, in a sealed tube. The reaction mixture was loaded onto anIsolute® SCX-2 cartridge, washed with MeOH then the desired producteluted with 2 M NH₃/MeOH in DCM. The resulting residue was purified byreverse phase HPLC (Phenomenex Gemini 5 μm C18, 20 mM triethylamine inwater on a gradient of acetonitrile 20-90%) to give 522 (50 mg, 44%) asa pale beige solid. LCMS: (Method I): R_(T) 2.90 min; [M+H]⁺ 532.3. ¹HNMR (400 MHz, CHCl₃-d): δ 8.01-7.96 (m, 1H), 7.84-7.78 (m, 1H),7.32-7.28 (m, 2H), 5.82 (s, 1H), 4.62-4.07 (m, 4H), 3.86 (t, J=4.7 Hz,4H), 3.78 (s, 3H), 3.47-3.23 (m, 4H), 3.08-2.99 (m, 4H), 3.01-2.93 (m,2H), 2.40 (dd, J=11.7, 8.9 Hz, 1H), 1.79-1.67 (m, 1H), 1.47 (t, J=7.5Hz, 3H), 0.98 (d, J=6.8 Hz, 3H), 0.95 (d, J=6.88 Hz, 3H)

Example 5241-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-ol524

Following General Procedure I for Buchwald coupling,2-ethylbenzimidazole and1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-olwere reacted to give 524. LCMS m/z: 449.2 (MH+)

Example 5252-methyl-2-(4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-1-yl)propanoicacid 525

Following the procedure for 506, the methyl ester of methyl2-methyl-2-(4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-1-yl)propanoate507 was hydrolyzed with lithium hydroxide to give 525. LCMS m/z: 267.2(2M+H⁺)

Example 526 I-methyl2-(4-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(hydroxy)methyl)piperidin-1-yl)-2-methylpropanoate526

Step 1: tert-butyl4-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)(hydroxy)methyl)piperidine-1-carboxylate

To a solution of 4-(2-chloro-9-methyl-9H-purin-6-yl)morpholine (750 mg,3.0 mmol) and N,N,N′,N′-Tetramethylethylenediamine (0.9816 mL, 6.504mmol) in tetrahydrofuran (38 mL, 460 mmol) was added 1.6 M ofn-butyllithium in hexane (4.065 mL) at −78° C. The resulting orangecloudy mixture was stirred at −78° C. for 45 minutes and at −40° C. for5 minutes. Tert-butyl 4-formylpiperidine-1-carboxylate (1.261 g, 5.913mmol) in 2 mL of THF was then added. The resulting yellow mixture wasstirred at −78° C. for 1 hour. The reaction was then allowed to warm toroom temperature. The reaction was then stirred at room temperature for20 minutes. The reaction was then poured onto sat. NH₄Cl. the productwas extracted with EtOAc. The combined extracts were washed with brine,dried over Na2SO4, filtered and concentrated. The crude product waspurified by FCC (0-10% MeOH in DCM) to give the title compound as awhite foam. LCMS m/z 467.3 (MH+).

Step 2: tert-butyl4-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(hydroxy)methyl)piperidine-1-carboxylate

A mixture of tert-butyl4-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)(hydroxy)methyl)piperidine-1-carboxylate(0.375 g, 0.803 mmol), 2-ethylbenzimidazole (0.182 g, 1.23 mmol), Xphos(0.040 g, 0.084 mmol), Pd₂(dba)₃ (0.040 g, 0.042 mmol) and cesiumcarbonate (0.52 g, 1.67 mmol) in DMF (4.0 mL) was heated in a Biotagemicrowave at 140° C. for 30 minutes. The reaction mixture was thenfiltered through paper and then partitioned between brine and EtOAc. Thecombined extracts were washed with brine, dried over Na2SO4, filteredand concentrated. The crude product was purified by flash chromatography(0-5% MeOH in DCM) to give the title compound (0.32 g, 69%). LCMS m/z:577.2 (MH+).

Step 3:(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(piperidin-4-yl)methanol

To a solution of tert-butyl4-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(hydroxy)methyl)piperidine-1-carboxylate(0.320 g, 0.555 mmol) in Methylene chloride (10 mL, 200 mmol;) was addedTrifluoroacetic Acid (0.50 mL, 6.5 mmol;). The reaction was stirred atroom temperature for 1 hr. and the reaction mixture was evaporated todryness. To the residue was added 2M NH3 in MeOH to neutralize anyresidual acid. The mixture was then evaporated to dryness. The crude wasthen purified by flash chromatography (0-15% MeOH in DCM) to give thedesired product as pinkish paste (0.24 g, 91%). LCMS m/z 477.4 (MH+).

Step 4: 1-methyl2-(4-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(hydroxy)methyl)piperidin-1-yl)-2-methylpropanoate

Following General Procedure C,(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(piperidin-4-yl)methanolwas alkylated with 2-bromo-2-methylpropionic acid methyl ester to givethe racemate desired product (0.22 g, 83%). The enantiomers wereseparated by SFC to give 526. LCMS m/z: 289.2 (2M+H+)

Example 527 (S)-methyl2-(4-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(hydroxy)methyl)piperidin-1-yl)-2-methylpropanoate527

The procedure to prepare (R) enantiomer 526 gave (S) enantiomer 527after separation by SFC. LCMS m/z: 289.2 (2M+H+)

Example 528 methyl2-(4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purine-8-carbonyl)piperidin-1-yl)-2-methylpropanoate528

To a solution of racemic methyl2-(4-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(hydroxy)methyl)piperidin-1-yl)-2-methylpropanoate,from the procedures for 526 and 527, (0.115 g, 0.199 mmol) in methylenechloride (5.0 mL, 78 mmol) was added Dess-Martin periodinane (0.0930 g,0.219 mmol). The resulting mixture was then stirred at room temp. for 1hour. The reaction mixture was filtered though paper to remove all solidprecipitates and then concentrated. The residue was then purified byRP-HPLC to give 528 (52 mg, 64%). LCMS m/z: 288.3 (2M+H+)

Example 5294-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-8-((1-(oxetan-3-yl)azetidin-3-yl)methyl)-9H-purin-6-yl)morpholine529

Following General Procedure L for reductive amination4-(8-(azetidin-3-ylmethyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine530 and 3-oxetanone were reacted to give 529. LCMS m/z: 489.2 (MH+)

Example 5304-(8-(azetidin-3-ylmethyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine530

Step 1: tert-butyl3-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methylene)azetidine-1-carboxylate

To a cold (−78° C.) suspension of dimethyl(2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methylphosphonate (1.1 g,2.9 mmol) in THF (26 mL) was added a 2.0M solution of LDA in THF (1.6mL). The resulting solution was allowed to warm to room temperaturebefore the addition of a solution of 1-Boc-3-azetidinone (0.58 g, 3.4mmol) in THF (12 mL). The reaction mixture was stirred at roomtemperature for 2 hours and partitioned between brine and DCM. Theorganic layer was isolated, washed with brine, dried over MgSO₄ andconcentrated. The crude residue was then purified by flashchromatography (0-100% EtOAc in heptane) to give the title compound(1.15 g, 93%). LCMS m/z: 421.3 (MH+).

Step 2: tert-butyl3-((9-methyl-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methylene)azetidine-1-carboxylate

A mixture of tert-butyl3-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methylene)azetidine-1-carboxylate(0.88 g, 2.9 mmol), 2-ethylbenzimidazole (0.40 g, 2.74 mmol), Xphos(0.10 g, 0.21 mmol), Pd₂(dba)₃ (0.10 g, 0.11 mmol) and cesium carbonate(1.4 g, 4.2 mmol) in DMF (4.0 mL) was heated in a Biotage microwave at140° C. for 30 minutes. The reaction mixture was then filtered throughpaper and then partitioned between brine and EtOAc. The combinedextracts were washed with brine, dried over Na₂SO₄, filtered andconcentrated. The crude product was purified by flash chromatography(0-10% MeOH in DCM) to give the title compound (1.2 g, quant.). LCMSm/z: 531.2 (MH+).

Step 3: tert-butyl3-((9-methyl-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)azetidine-1-carboxylate

A suspension of tert-butyl3-((9-methyl-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methylene)azetidine-1-carboxylate(1.1 g, 2.1 mmol) and Pd/C (10 wt %, 0.4 g) in ethanol (25 mL) wasstirred under a hydrogen atmosphere (balloon) at room temperature for 24hours. The reaction mixture was then filtered through celite andconcentrated. The crude product was purified by flash chromatography(0-5% MeOH in DCM) to give the title compound (0.64 g, 58%). LCMS m/z:547.2 (MH+)

Step 4:4-(8-(azetidin-3-ylmethyl)-9-methyl-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine530

To a solution of tert-butyl3-((9-methyl-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)azetidine-1-carboxylate(0.64 g, 1.2 mmol) in DCM (10 mL) was added trifluoroacetic acid (1.0mL, 13 mmol) The reaction mixture was then stirred at room temperaturefor 1 hour. The reaction mixture was then evaporated to dryness. Theresidue was then re-dissolved in MeOH and neutralized by adding a 2M NH3in MeOH. The solution was then concentrated and purified by flashchromatography using a KP—NH2 column (0-10% MeOH in DCM) to give 530.LCMS m/z: 433.2 (MH+)

Example 5312-(3-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-1-yl)-2-methylpropanamide531

Following General Procedure C,4-(8-(azetidin-3-ylmethyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine530 was alkylated by 2-bromo-2-methyl-propionamide to give 531. LCMSm/z: 259.7 (2M+H+)

Example 532 methyl2-(3-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-1-yl)-2-methylpropanoate532

Following General Procedure C,4-(8-(azetidin-3-ylmethyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine530 was alkylated by 2-bromo-2-methyl-propionic acid methyl ester togive 532. LCMS m/z: 267.2 (2M+H+)

Example 5332-(3-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-1-yl)-2-methylpropan-1-ol533

Following the procedure for 509, methyl2-(3-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-1-yl)-2-methylpropanoatewas reduced with lithium aluminum hydride to give 533. LCMS m/z: 253.2(2M+H+)

Example 5341-(3-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-1-yl)-2-methylpropan-2-ol534

Following General Procedure C,4-(8-(azetidin-3-ylmethyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholineand isobutylene oxide were reacted at room temperature to give 534. LCMSm/z: 253.2 (2M+H+)

Example 5354-(2-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)ethyl)-3,3-dimethylmorpholine535

A mixture of2-chloro-8-[2-(3,3-dimethylmorpholin-4-yl)ethyl]-9-methyl-6-morpholin-4-yl-9H-purine(44 mg, 0.11 mmol), 2-ethylbenzimidazole (18 mg, 0.12 mmol), Pd₂(dba)₃(5.2 mg, 5 mol %), Xphos (5.3 mg, 10 mol %) and Cs₂CO₃ (54 mg, 0.17mmol) in dioxane (1.5 mL) was purged with argon gas then heated at 120°C., for 24 h, in a sealed tube. The reaction mixture was loaded onto anIsolute® SCX-2 cartridge, washed with MeOH then the desired producteluted with 2 M NH₃/MeOH in DCM. The resulting residue was purified byreverse phase HPLC (Phenomenex Gemini 5 μm C18, 20 mM triethylamine inwater on a gradient of acetonitrile 30-90%) to give 535 (33 mg, 59%) asa pale beige solid. LCMS: (Method I): R_(T) 2.52 min; [M+H]⁺ 505.2. ¹HNMR (400 MHz, CHCl₃-d): δ 8.02-7.97 (m, 1H), 7.77-7.72 (m, 1H),7.29-7.22 (m, 2H), 4.52-4.14 (m, 4H), 3.86 (t, J=4.8 Hz, 4H), 3.80 (s,3H), 3.79-3.67 (m, 2H), 3.35 (q, J=7.5 Hz, 2H), 3.34-3.23 (m, 2H),3.05-2.92 (m, 2H), 2.92-2.80 (m, 2H), 2.77-2.54 (m, 2H), 1.44 (t, J=7.5Hz, 3H), 0.99 (s, 6H)

Example 536(S)-1-(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)pyrrolidin-3-ol536

A mixture of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(100 mg, 0.26 mmol), (S)-1-azetidin-3-ylpyrrolidin-3-ol (41 mg, 0.28mmol) and 4 Å powdered molecular sieves (200 mg) in DCE (6 mL) wasstirred at room temperature for 2 h before the addition of sodiumtriacetoxyborohydride (108 mg, 0.51 mmol). The reaction mixture wasstirred for 65 h then filtered through celite, washing with DCM. Theorganic phase was washed with brine (×1) and concentrated in vacuo. Theorganic phase was dried (Na₂SO₄) and concentrated in vacuo. Theresulting residue was purified by column chromatography (Si—PCC,MeOH:DCM, 0-15%) affording 536 as a yellow foam (71 mg, 53%). LCMS(Method I): R_(T) 2.31 min [M+H]⁺ 518.2. ¹H NMR (CDCl₃, 400 MHz): δ8.02-7.97 (m, 1H); 7.76-7.71 (m, 1H); 7.29-7.22 (m, 2H); 4.53 (bs, 1H);4.35 (m, 4H); 3.96 (s, 2H); 3.90-3.82 (m, 7H); 3.67 (bs, 2H); 3.55 (m,3H); 3.34 (q, J=7.5 Hz, 2H); 3.17 (m, 1H); 2.99 (m, 1H); 2.30 (m, 2H);2.02 (m, 2H) and 1.44 (t, J=7.5 Hz, 3H)

Example 5374-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-8-(2-(3-(1,1-dioxo-thiomorpholino)azetidin-1-yl)ethyl)-9H-purin-6-yl)morpholine537

A mixture of2-chloro-8-{2-[3-(1,1-dioxo-1-thiomorpholin-4-yl)azetidin-1-yl]-ethyl}-9-methyl-6-morpholin-4-yl-9H-purine(93 mg, 0.20 mmol), 2-ethylbenzimidazole (32 mg, 0.22 mmol), Pd₂(dba)₃(4.5 mg, 2.5 mol %), Xphos (9.4 mg, 10 mol %) and Cs₂CO₃ (97 mg, 0.30mmol) in dioxane (2.0 mL) was purged with argon gas then heated at 120°C., for 20 h, in a sealed tube. The reaction mixture was loaded onto anIsolute® SCX-2 cartridge, washed with MeOH then the desired producteluted with 2 M NH₃/MeOH in DCM. The resulting residue was purified byreverse phase HPLC (Phenomenex Gemini 5 μm C18, 20 mM triethylamine inwater on a gradient of acetonitrile 20-90%) to give 537 (79 mg, 69%) asa beige solid. LCMS: (Method I): R_(T) 2.42 min; [M+H]⁺ 580.3. ¹H NMR(400 MHz, CHCl₃-d): δ 8.01-7.96 (m, 1H), 7.77-7.72 (m, 1H), 7.29-7.22(m, 2H), 4.57-4.09 (m, 4H), 3.86 (t, J=4.8 Hz, 4H), 3.77 (s, 3H),3.71-3.57 (m, 2H), 3.34 (q, J=7.5 Hz, 2H), 3.33-3.22 (m, 1H), 3.07 (m,8H), 3.00-2.89 (m, 2H), 2.85 (t, J=4.8 Hz, 4H), 1.44 (t, J=7.5 Hz, 3H)

Example 538I-1-(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)pyrrolidin-3-ol538

A mixture of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(100 mg, 0.26 mmol), (R)-1-azetidin-3-ylpyrrolidin-3-ol (41 mg, 0.28mmol) and 4 Å powdered molecular sieves (200 mg) in DCE (6 mL) wasstirred at room temperature for 2 h before the addition of sodiumtriacetoxyborohydride (108 mg, 0.51 mmol). The reaction mixture wasstirred for 65 h then filtered through celite, washing with DCM. Theorganic phase was washed with brine (×1) and concentrated in vacuo. Theorganic phase was dried (Na₂SO₄) and concentrated in vacuo. Theresulting residue was purified by column chromatography (Si—PCC,MeOH:DCM, 0-15%) affording 538 as a yellow foam (49 mg, 36%). LCMS(Method I): R_(T) 2.31 min [M+H]⁺ 518.2. ¹H NMR (CDCl₃, 400 MHz): δ8.02-7.97 (m, 1H); 7.76-7.71 (m, 1H); 7.30-7.23 (m, 2H); 4.60 (bs, 1H);4.35 (m, 4H); 4.00 (s, 2H); 3.89-3.81 (m, 7H); 3.72 (m, 4H); 3.34 (m,3H); 3.17 (m, 3H); 2.39-2.29 (m, 2H); 2.16-2.07 (m, 2H) and 1.44 (t,J=7.5 Hz, 3H)

Example 5394-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-8-(2-(1,1-dioxo-thiomorpholino)ethyl)-9H-purin-6-yl)morpholine539

To a solution of(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)acetaldehyde (120 mg,0.24 mmol) in DCE (15 mL) was added thiomorpholine, 1-1-dioxide (100 mg,0.74 mmol), powdered 4 Å molecular sieves and sodiumtriacetoxyborohydride (314 mg, 1.48 mmol). The reaction mixture wasstirred at room temperature for 6 h, the reaction mixture was loadedonto an Isolute® SCX-2 cartridge, washed with MeOH then the desiredproduct eluted with 2 M NH₃/MeOH in DCM. The resulting residue wastriturated with EtOAc, filtered and the mother liquor evaporated to givea yellow oil (97 mg). A mixture of this crude, 2-ethylbenzimidazole (38mg, 0.26 mmol), Pd₂(dba)₃ (5.4 mg), Xphos (11.1 mg) and Cs₂CO₃ (114 mg,0.35 mmol) in dioxane (2 mL) was purged with argon gas then heated at120° C., for 20 h, in a sealed tube. The reaction mixture was loadedonto an Isolute® SCX-2 cartridge, washed with MeOH then the desiredproduct eluted with 2 M NH₃/MeOH in DCM. The resulting residue waspurified by reverse phase HPLC (Phenomenex Gemini 5 μm C18, 20 mMtriethylamine in water on a gradient of acetonitrile 30-90%) to give 539(11 mg, 5% over 2 steps) as a pale orange solid. LCMS: (Method I): R_(T)2.94 min; [M+H]⁺ 525.2. ¹H NMR (400 MHz, CHCl₃-d): δ 8.02-7.97 (m, 1H),7.79 (d, J=7.17 Hz, 1H), 7.32-7.26 (m, 2H), 4.47-4.19 (m, 4H), 3.89-3.83(m, 4H), 3.78 (s, 3H), 3.38 (q, J=7.5 Hz, 2H), 3.18-3.12 (m, 5H),3.12-3.01 (m, 7H), 1.46 (t, J=7.5 Hz, 3H)

Example 5404-(8-(2-(4,4-difluoropiperidin-1-yl)ethyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine540

A mixture of2-chloro-8-[2-(4,4-difluoropiperidin-1-yl)ethyl]-9-methyl-6-morpholin-4-yl-9H-purine(30 mg, 0.08 mmol), 2-ethylbenzimidazole (12 mg, 0.08 mmol), Pd₂(dba)₃(1.7 mg, 2.5 mol %), Xphos (3.6 mg, 10 mol %) and Cs₂CO₃ (37 mg, 0.11mmol) in dioxane (1.0 mL) was purged with argon gas then heated at 120°C., for 20 h, in a sealed tube. The reaction mixture was loaded onto anIsolute® SCX-2 cartridge, washed with MeOH then the desired producteluted with 2 M NH₃/MeOH in DCM. The resulting residue was purified byreverse phase HPLC (Phenomenex Gemini 5 μm C18, 20 mM triethylamine inwater on a gradient of acetonitrile 30-90%) to give 540 (25 mg, 64%) asa beige solid. LCMS: (Method I): R_(T) 2.61 min; [M+H]⁺ 511.2. ¹H NMR(400 MHz, CHCl₃-d): δ 8.01-7.96 (m, 1H), 7.78-7.74 (m, 1H), 7.29-7.23(m, 2H), 4.68-4.02 (m, 4H), 3.86 (t, J=4.8 Hz, 4H), 3.78 (s, 3H), 3.35(q, J=7.5 Hz, 2H), 3.12-2.99 (m, 4H), 2.81-2.65 (m, 4H), 2.15-1.99 (m,4H), 1.44 (t, J=7.5 Hz, 3H)

Example 5412-(3-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-1-yl)acetamide541

Following General Procedure C,4-(8-(azetidin-3-ylmethyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholineand 2-bromoacetamide were reacted at room temperature to give 541. LCMSm/z: 490.3 (MH+)

Example 5422-methyl-1-(4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-1-yl)propan-2-ol542

Following General Procedure C,4-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-8-(piperidin-4-ylmethyl)-9H-purin-6-yl)morpholineand isobutylene oxide were reacted to give 542. LCMS m/z: 519.3 (MH+)

Example 5434-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-8-((1-(2-(methylsulfonyl)ethyl)azetidin-3-yl)methyl)-9H-purin-6-yl)morpholine543

Following General Procedure C,4-(8-(azetidin-3-ylmethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholineand methylvinylsulfone were reacted to give 543. LCMS m/z: 525.3 (MH+)

Example 5444-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-8-((1-(2-(methylsulfonyl)ethyl)piperidin-4-yl)methyl)-9H-purin-6-yl)morpholine544

Following General Procedure C,4-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-8-(piperidin-4-ylmethyl)-9H-purin-6-yl)morpholineand methylvinylsulfone were reacted to give 544. LCMS m/z: 553.3 (MH+)

Example 545I-2-(3-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-1-yl)propanamide545

Following General Procedure C,4-(8-(azetidin-3-ylmethyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholineand 2-bromopropionamide were reacted to give a racemic mixture. Theenantiomers were separated by SFC to give 545. LCMS m/z: 252.7 (2M+H+)

Example 546(S)-2-(3-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-1-yl)propanamide546

Following General Procedure C,4-(8-(azetidin-3-ylmethyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholineand 2-bromopropionamide were reacted to give a racemic mixture. Theenantiomers were separated by SFC to give 546. LCMS m/z: 252.7 (2M+H+)

Example 5474-(1-((2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)morpholine547

A mixture of2-chloro-9-methyl-6-morpholin-4-yl-8-(3-morpholin-4-yl-azetidin-1-ylmethyl)-9H-purine(83 mg, 0.20 mmol), 2-isopropylbenzimidazole (39 mg, 0.24 mmol),tris(dibenzylideneacetone)dipalladium (9 mg, 0.01 mmol), Xphos (19 mg,0.04 mmol) and Cs₂CO₃ (133 mg, 0.41 mmol) in dioxane (2 mL) was purgedwith argon then heated at 145° C. for 30 min in a microwave reactor. Thereaction mixture was filtered through a pad of celite, washing withEtOAc. The filtrate was concentrated in vacuo and purified by columnchromatography (Si—PCC, MeOH:DCM, 0-15%) affording 547 as a beige foam(72 mg, 68%). LCMS (Method I): R_(T) 2.50 min, [M+H]⁺ 532.3. ¹H NMR(CDCl₃, 400 MHz): δ 7.89-7.84 (m, 1H); 7.80-7.75 (m, 1H); 7.29-7.21 (m,2H); 4.34 (m, 4H); 4.00-3.92 (m, 3H); 3.88-3.81 (m, 7H); 3.76 (m, 4H);3.64 (m, 2H); 3.24 (m, 2H); 3.13 (m, 1H); 2.40 (m, 4H); 1.47 (s, 3H) and1.46 (s, 3H)

Example 5484-(1-((2-(2-cyclopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)morpholine548

A mixture of2-chloro-9-methyl-6-morpholin-4-yl-8-(3-morpholin-4-yl-azetidin-1-ylmethyl)-9H-purine(83 mg, 0.20 mmol), 2-cyclopropylbenzimidazole (39 mg, 0.24 mmol),tris(dibenzylideneacetone)dipalladium (9 mg, 0.01 mmol), Xphos (19 mg,0.04 mmol) and Cs₂CO₃ (133 mg, 0.41 mmol) in dioxane (2 mL) was purgedwith argon then heated at 145° C. for 30 min in a microwave reactor. Thereaction mixture was filtered through a pad of celite, washing withEtOAc. The filtrate was concentrated in vacuo and purified by columnchromatography (Si—PCC, MeOH:DCM, 0-20%) affording 548 as a beige foam(92 mg, 87%). LCMS (Method I): R_(T) 2.52 min, [M+H]⁺ 530.3. ¹H NMR(CDCl₃, 400 MHz): δ 7.95-7.91 (m, 1H); 7.69-7.65 (m, 1H); 7.27-7.18 (m,2H); 4.36 (m, 4H); 3.93 (s, 2H); 3.89-3.83 (m, 7H); 3.75 (m, 4H); 3.65(m, 2H); 3.24 (m, 2H); 3.13 (m, 1H); 2.89-2.81 (m, 1H); 2.39 (m, 4H);1.37-1.32 (m, 2H) and 1.08-1.02 (m, 2H)

Example 5492-(5-(2-ethyl-1H-benzo[d]imidazol-1-yl)-7-morpholinothiazolo[5,4-d]pyrimidin-2-yl)-1-(4-(2-hydroxypropan-2-yl)piperidin-1-yl)ethanone549

A mixture of2-(5-chloro-7-morpholin-4-yl-thiazolo[5,4-c]pyrimidin-2-yl)-1-[4-(1-hydroxy-1-methylethyl)piperidin-1-yl]ethanone(40 mg, 0.09 mmol), 2-ethylbenzimidazole (15 mg, 0.10 mmol), Pd₂(dba)₃(2.1 mg, 2.5 mol %), Xphos (4.3 mg, 10 mol %) and Cs₂CO₃ (44 mg, 0.14mmol) in dioxane (1.5 mL) was purged with argon gas then heated at 120°C., for 20 h, in a sealed tube. The reaction mixture diluted with EtOAc,filtered through Celite® and evaporated. The resulting residue waspurified by column chromatography (Si—PCC, 0-10% MeOH in EtOAc) to give549 as a pale beige solid (19 mg, 38%). LCMS (Method I): R_(T)=3.47 min,[M+H]⁺ 550.2. ¹H NMR (400 MHz, CHCl₃-d): δ 8.02-7.98 (m, 1H), 7.81-7.76(m, 1H), 7.33-7.29 (m, 2H), 4.81-4.75 (m, 1H), 4.52-4.29 (m, 4H), 4.19(s, 2H), 4.07 (m, 1H), 3.89-3.84 (m, 4H), 3.38 (q, J=7.5 Hz, 2H),3.15-3.06 (m, 1H), 2.63-2.54 (m, 1H), 1.90-1.92 (m, 2H), 1.92-1.80 (m,2H), 1.61-1.50 (m, 1H), 1.44 (t, J=7.5 Hz, 3H), 1.36-1.23 (m, 1H), 1.20(d, J=11.0 Hz, 6H)

Example 5501-(1-((2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)piperidin-4-ol550

A mixture of2-(2-isopropylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(0.150 g, 0.37 mmol), 1-azetidin-3-ylpiperidin-4-ol (0.069 g, 0.44 mmol)and 4 Å molecular sieves (0.37 g) in DCE (3 mL) was stirred for 2 h atroom temperature. Sodium triacetoxyborohydride (0.157 g, 0.74 mmol) wasadded and the reaction mixture was stirred for 4 h at room temperature.The reaction mixture was filtered through Celite and the filtrate wasconcentrated in vacuo. The residue was purified by flash chromatography(Si—PPC, MeOH:DCM, gradient 0:100 to 20:80) to give 550 as a white solid(0.137 g, 68%). LCMS (Method I): R_(T)=2.41 min, [M+H]⁺ 546.3. ¹H NMR(400 MHz, DMSO-d₆): δ 7.90-7.85 (m, 1H); 7.66-7.61 (m, 1H); 7.25-7.21(m, 2H); 4.53 (d, J=4.1 Hz, 1H); 4.28-4.23 (m, 4H); 3.96-3.86 (m, 1H);3.86 (s, 2H); 3.85-3.68 (m, 7H); 3.48-3.43 (m, 1H); 3.42 (t, J=6.5 Hz,2H); 2.95 (t, J=6.5 Hz, 2H); 2.90-2.82 (m, 1H); 2.45-2.55 (m, 2H); 1.85(t, J=10.6 Hz, 2H); 1.71-1.68 (m, 2H); 1.40-1.34 (m, 2H); 1.35 (d,J=6.80 Hz, 6H)

Example 5511-(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)-4-methylpiperidin-4-ol551

A mixture of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(0.207 g, 0.53 mmol), 1-azetidin-3-yl-4-methylpiperidin-4-ol (0.108 g,0.63 mmol) and 4 Å molecular sieves (0.5 g) in DCE (5 mL)was stirred for3 h at room temperature. Sodium triacetoxyborohydride (0.224 g, 1.06mmol) was added and the reaction mixture was stirred for 18 h at roomtemperature. The reaction mixture was filtered through Celite and thefiltrate was concentrated in vacuo. The residue was purified by flashchromatography (Si—PPC, MeOH:EtOAc, gradient 0:100 to 30:70) to give 551as a white solid (0.247 g, 86%). LCMS (Method I): R_(T)=2.35 min, [M+H]⁺546.3. ¹H NMR (400 MHz, DMSO-d₆): δ 8.04-7.98 (m, 1H); 7.65-7.60 (m,1H); 7.27-7.20 (m, 2H); 4.34-3.83 (m, 4H); 3.85 (s, 2H); 3.79-3.75 (m,7H); 3.43 (t, J=7.4 Hz, 2H); 3.31-3.20 (q, J=7.4 Hz, 2H); 2.96-2.93 (m,2H); 2.92-2.83 (m, 1H); 2.27-2.23 (m, 2H); 2.18-2.14 (m, 2H); 1.48-1.36(m, 4H); 1.33 (t, J=7.4 Hz, 3H); 1.12-1.06 (s, 3H)

Example 5524-(8-((3,3-dimethylpiperazin-1-yl)methyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine552

A mixture of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(530 mg, 1.35 mmol), 2,2-dimethylpiperazine-1-carboxylic acid tert-butylester (350 mg, 1.63 mmol) and molecular sieves (4 Å, powdered, 2.5 g) inDCE (30 mL) was stirred at ambient temperature for 5 h. Sodiumtriacetoxyborohydride (427 mg, 2.02 mmol) was added and the mixturestirred for 17 h, then loaded onto an Isolute® SCX-2 cartridge (25 g).The cartridge was then washed with methanol and the desired product wassubsequently eluted using 2 M NH₃ in MeOH. The product was collected andconcentrated in vacuo. The resultant residue was purified by flashchromatography (Si—PPC, EtOAc:MeOH; 100:0 to 95:5 to 90:10) to give4-[2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl]-2,2-dimethylpiperazine-1-carboxylicacid tert-butyl ester. TFA (3 mL) was added to a solution of4-[2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl]-2,2-dimethylpiperazine-1-carboxylicacid tert-butyl ester in DCM (10 mL) and the mixture stirred at ambienttemperature for 1 h. The reaction mixture was loaded onto an Isolute®SCX-2 cartridge (10 g), which was washed with MeOH before the desiredproduct was subsequently eluted using 2 M NH₃ in MeOH. The product wascollected and concentrated in vacuo. The resultant residue was purifiedby flash chromatography (Si—PPC, DCM:MeOH 100:0 to 98:2 to 95:5 to 90:10to 80:20) to afford 552 as a cream solid (144 mg, 22%). LCMS (Method I):R_(T)=2.56 min, M+H⁺=490. ¹H NMR (CDCl₃, 400 MHz) δ 8.02 (m, 1H); 7.75(m, 1H); 7.29 (m, 2H); 4.35 (m, 4H); 3.92-3.83 (m, 7H); 3.70 (s, 2H);3.36 (q, J=7.5 Hz, 2H); 2.97 (m, 2H); 2.47 (m, 2H); 2.28 (s, 2H);1.49-1.42 (m, 3H) and 1.19 (s, 6H)

Example 5534-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-8-(((1S,4S)-5-(methylsulfonyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)methyl)-9H-purin-6-yl)morpholine

A mixture of2-chloro-8-((1S,4S)-5-methanesulfonyl-2,5-diazabicyclo[2.2.1]hept-2-ylmethyl)-9-methyl-6-morpholin-4-yl-9H-purine(150 mg, 0.34 mmol), 2-ethyl-1H-benzoimidazole (59 mg, 0.40 mmol),Pd₂dba₃ (9 mg, 0.009 mmol), Xphos (18 mg, 0.036 mmol) and cesiumcarbonate (165 mg, 0.51 mmol) in 1,4-dioxane (3 mL) was purged withargon gas then subjected to microwave irradiation at 150° C. for 30 min.The reaction mixture was loaded onto an Isolute® SCX-2 cartridge (10 g),which was washed with MeOH/DCM before the desired product was elutedwith 2 M NH₃ in MeOH/DCM. The product was collected and concentrated invacuo. The resultant residue was purified by flash chromatography(Si—PPC, EtOAc:MeOH 100:0 to 99:1 to 98:2) to afford 553 as a whitesolid (153 mg, 82%). LCMS (Method I): R_(T)=2.53 min, M+H⁺=552. ¹H NMR(CDCl₃, 400 MHz) δ 8.01 (m, 1H); 7.77 (m, 1H); 7.28 (m, 2H); 4.35 (m,5H); 4.06 (d, J=13.6 Hz, 1H); 3.96 (d, J=13.6 Hz, 1H); 3.87 (m, 7H);3.65 (d, J=9.5 Hz, 1H); 3.61 (bs, 1H); 3.37 (q, J=7.5 Hz, 2H); 3.27 (dd,J=9.5, 2.3 Hz, 1H); 3.02-2.93 (m, 2H); 2.91 (s, 3H); 1.99 (d, J=10.2 Hz,1H); 1.79 (d, J=10.2 Hz, 1H) and 1.45 (t, J=7.5 Hz, 3H)

Example 5541-(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)azetidin-3-ol554

A mixture of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(0.157 g, 0.40 mmol), 1-piperidin-4-ylazetidin-3-ol (0.075 g, 0.48 mmol)and 4 Å molecular sieves (0.4 g) in DCE (5 mL) was stirred for 3 h atroom temperature. Sodium triacetoxyborohydride (0.17 g, 0.80 mmol) wasadded and the reaction mixture was stirred for 18 h at room temperature.The reaction mixture was filtered through Celite and the filtrate wasconcentrated in vacuo. The residue was purified by flash chromatography(Si—PPC, MeOH:EtOAc, gradient 0:100 to 20:80) to give 554 as a whitesolid (0.145 g, 68%). LCMS (Method I): R_(T)=2.20 min, [M+H]⁺ 532.3. ¹HNMR (400 MHz, DMSO-d₆): δ 8.04-7.98 (m, 1H); 7.65-7.60 (m, 1H);7.27-7.20 (m, 2H); 4.27-4.19 (m, 4H); 3.80 (s, 3H); 3.77 (t, J=4.7 Hz,4H); 3.74 (s, 2H); 3.44 (t, J=7.1 Hz, 2H); 3.26 (q, J=7.4 Hz, 3H);2.78-2.70 (m, 2H); 2.62 (t, J=7.1 Hz, 2H); 2.12 (t, J=11.0 Hz, 2H);1.99-1.90 (m, 1H); 1.60 (d, J=11.0 Hz, 2H); 1.33 (t, J=7.4 Hz, 3H);1.21-1.10 (m, 2H)

Example 5551-isopropyl-4-((2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperazin-2-one555

A mixture of2-(2-isopropylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(0.15 g, 0.37 mmol), 1-isopropylpiperazin-2-one (0.078 g, 0.44 mmol) and4 Å molecular sieves (0.372 g) in DCE (3 mL) was stirred for 3 h at roomtemperature. Sodium triacetoxyborohydride (0.157 g, 0.74 mmol) was addedand the reaction mixture was stirred for 18 h at room temperature. Thereaction mixture was filtered through Celite and the filtrate wasconcentrated in vacuo. The residue was purified by flash chromatography(Si—PPC, MeOH:EtOAc, gradient 0:100 to 10:90) to give 555 as anoff-white solid (0.168 g, 84%). LCMS (Method I): R_(T)=3.43 min, [M+H]⁺532.3. ¹H NMR (400 MHz, DMSO-d₆): δ 7.93-7.89 (m, 1H); 7.68-7.63 (m,1H); 7.28-7.23 (m, 2H); 4.64-4.58 (m, 1H); 4.29-4.21 (m, 4H); 3.97-3.90(m, 1H); 3.90 (d, J=4.6 Hz, 2H); 3.80 (s, 3H); 3.78 (t, J=4.6 Hz, 4H);3.21-3.15 (m, 4H); 2.78-2.75 (m, 2H); 1.36 (d, J=6.8 Hz, 6H); 1.05 (d,J=6.8 Hz, 6H)

Example 5564-(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)-1-methylpiperazin-2-one556

A mixture of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(162 mg, 0.41 mmol), 4-azetidin-3-yl-1-methylpiperazin-2-one (77 mg,0.46 mmol) and 4 Å powdered molecular sieves (250 mg) in DCE (10 mL) wasstirred at room temperature for 2 h before the addition of sodiumtriacetoxyborohydride (175 mg, 0.83 mmol). The reaction mixture wasstirred for 16 h then filtered through celite, washing with DCM. Theorganic phase was washed with brine (×1) and concentrated in vacuo. Theorganic phase was dried (Na₂SO₄) and concentrated in vacuo. Theresulting residue was purified by column chromatography (Si—PCC,MeOH:EtOAc, 0-30%) affording 556 as a yellow foam (182 mg, 82%). LCMS(Method I): R_(T) 2.34 min [M+H]⁺ 545.3. ¹H NMR (CDCl₃, 400 MHz): δ8.02-7.97 (m, 1H); 7.77-7.72 (m, 1H); 7.29-7.22 (m, 2H); 4.35 (m, 4H);3.89-3.84 (m, 6H); 3.83 (s, 3H); 3.59 (t, J=5.3 Hz, 2H); 3.39-3.31 (m,4H); 3.18-3.10 (m, 3H); 3.05 (m, 2H); 2.96 (s, 3H); 2.59 (t, J=5.3 Hz,2H) and 1.43 (t, J=7.5 Hz, 3H)

Example 5574-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-8-(2-(4-(tetrahydro-2H-pyran-4-yl)piperazin-1-yl)ethyl)-9H-purin-6-yl)morpholine557

A mixture of2-chloro-9-methyl-6-morpholin-4-yl-8-{2-[4-(tetrahydropyran-4-yl)piperazin-1-yl]ethyl}-9H-purine(37 mg, 0.08 mmol), 2-ethylbenzimidazole (13 mg, 0.09 mmol), Pd₂(dba)₃(1.9 mg, 2.5 mol %), Xphos (3.9 mg, 10 mol %) and Cs₂CO₃ (37 mg, 0.11mmol) in dioxane (1.5 mL) was purged with argon gas then heated at 120°C., for 19 h, in a sealed tube. The reaction mixture was loaded onto anIsolute® SCX-2 cartridge, washed with MeOH then the desired producteluted with 2 M NH₃/MeOH in DCM. The resulting residue was purified byreverse phase HPLC (Phenomenex Gemini 5 μm C18, 20 mM triethylamine inwater on a gradient of acetonitrile 30-90%) to give 557 (32 mg, 70%) asa pale beige solid. LCMS: (Method I): R_(T) 2.42 min; [M+H]⁺ 560.3. ¹HNMR (400 MHz, CHCl₃-d): δ 8.01-7.97 (m, 1H), 7.77-7.72 (m, 1H),7.29-7.22 (m, 2H), 4.56-4.21 (m, 4H), 4.04 (dd, J=11.4, 4.2 Hz, 2H),3.86 (t, J=4.7 Hz, 4H), 3.77 (s, 3H), 3.38-3.34 (m, 2H), 3.34 (q, J=7.5Hz, 2H), 3.13-3.00 (m, 2H), 3.00-2.87 (m, 2H), 2.82-2.58 (m, 6H),2.57-2.42 (m, 1H), 1.88-1.75 (m, 2H), 1.71-1.55 (m, 4H), 1.44 (t, J=7.5Hz, 3H)

Example 5582-(4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-1-yl)acetamide558

Following General Procedure C,4-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-8-(piperidin-4-ylmethyl)-9H-purin-6-yl)morpholineand 2-bromoacetamide were reacted to give 558. LCMS m/z: 252.7 (2M+H+)

Example 559I-2-(4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-1-yl)propanamide559

Following General Procedure C,4-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-8-(piperidin-4-ylmethyl)-9H-purin-6-yl)morpholineand 2-bromopropionamide were reacted to give the racemic mixture. Theenantiomers were separated by SFC to give 559. LCMS m/z: 259.7 (2M+H+)

Example 560(S)-2-(4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-1-yl)propanamide560

Following General Procedure C,4-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-8-(piperidin-4-ylmethyl)-9H-purin-6-yl)morpholineand 2-bromopropionamide were reacted to give the racemic mixture. Theenantiomers were separated by SFC to give 560. LCMS m/z: 259.7 (2M+H+)

Example 561I-4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-8-((4-(3-fluoropyrrolidin-1-yl)piperidin-1-yl)methyl)-9-methyl-9H-purin-6-yl)morpholine561

A mixture of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(0.15 g, 0.383 mmol), 4-(I-3-fluoropyrrolidin-1-yl)piperidine (0.080 g,0.46 mmol) and 4 Å molecular sieves (0.4 g) in DCE (5 mL) was stirredfor 3 h at room temperature. Sodium triacetoxyborohydride (0.163 g, 0.77mmol) was added and the reaction mixture was stirred for 18 h at roomtemperature. The reaction mixture was filtered through Celite and thefiltrate was concentrated in vacuo. The residue was purified by flashchromatography (Si—PPC, MeOH:EtOAc, gradient 0:100 to 40:60) to give 561as a white solid (0.14 g, 67%). LCMS (Method I): R_(T)=2.26 min, [M+H]⁺548.2 ¹H NMR (400 MHz, DMSO-d₆): δ 8.04-7.98 (m, 1H), 7.65-7.60 (m, 1H),7.26-7.21 (m, 2H), 5.16 (dt, J=55.97, 5.52 Hz, 1H), 4.50-3.65 (m, 4H),3.82 (s, 3H), 3.80-3.74 (m, 4H), 3.75 (s, 2H), 3.27 (q, J=7.4 Hz, 2H),2.89-2.74 (m, 4H), 2.68-2.53 (m, 1H), 2.37-2.28 (m, 1H), 2.15-1.97 (m,4H), 1.94-1.76 (m, 3H), 1.45-1.34 (m, 2H), 1.34 (t, J=7.4 Hz, 3H)

Example 5624-(8-((3,3-difluoro-1,3′-biazetidin-1′-yl)methyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine562

A mixture of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(0.0725 g, 0.18 mmol), 3,3-difluoro-[1,3′]biazetidinyl (0.033 g, 0.22mmol) and 4 Å molecular sieves (0.2 g) in DCE (5 mL). The reactionmixture was stirred for 7 h at room temperature. Sodiumtriacetoxyborohydride (0.079 g, 0.37 mmol) was added and the reactionmixture was stirred for 18 h at room temperature. The suspension wasfiltered through Celite and the filtrate was concentrated in vacuo. Theresidue was purified by flash chromatography (Si—PPC, MeOH:EtOAc,gradient 0:100 to 40:60) to give 562 as a yellow solid (0.075 g, 78%).LCMS (Method I): R_(T)=2.66 min, [M+H]⁺ 524.2 ¹H NMR (400 MHz, DMSO-d₆):δ 8.03-7.98 (m, 1H), 7.65-7.60 (m, 1H), 7.27-7.20 (m, 2H), 4.50-3.96 (m,4H), 3.88 (s, 2H), 3.86-3.67 (m, 7H), 3.71-3.55 (m, 4H), 3.48-3.39 (m,1H), 3.37-3.35 (m, 2H), 3.26 (q, J=7.5 Hz, 2H), 3.06 (dd, J=7.5, 5.3 Hz,2H), 1.33 (t, J=7.5 Hz, 3H)

Example 5644-(2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-8-((4-(tetrahydro-2H-pyran-4-yl)piperazin-1-yl)methyl)-9H-purin-6-yl)morpholine564

A mixture of2-chloro-9-methyl-6-morpholin-4-yl-8-[4-(tetrahydropyran-4-yl)piperazin-1-ylmethyl]-9H-purine(180 mg, 0.41 mmol), 2-isopropyl-1H-benzoimidazole (80 mg, 0.50 mmol),Pd₂dba₃ (11 mg, 0.012 mmol), Xphos (22 mg, 0.046 mmol) and cesiumcarbonate (201 mg, 0.62 mmol) in DMF (4 mL) was purged with argon gasthen subjected to microwave irradiation at 145° C. for 30 min. Thereaction mixture was loaded onto an Isolute® SCX-2 cartridge (10 g),which was washed with MeOH/DCM before the desired product was elutedwith 2 M NH₃ in MeOH/DCM. The product was collected and concentrated invacuo. The resultant residue was purified by flash chromatography(Si—PPC, DCM:MeOH 100:0 to 95:5) followed by reverse phase HPLC(Phenomenex Gemini 5u C18, 20 mM triethylamine in water on a gradient ofacetonitrile 60:40 to 10:90) to afford 564 as a white solid (85 mg,37%). LCMS (method I): R_(T)=2.61 min, M+H⁺=560. ¹H NMR (CDCl₃, 400 MHz)δ 7.89 (d, J=7.6 Hz, 1H), 7.78 (d, J=7.5 Hz, 1H), 7.26 (m, 2H), 4.34 (m,4H), 4.03 (d, J=10.1 Hz, 2H), 3.95 (m, 1H), 3.86 (m, 7H), 3.77 (s, 2H),3.38 (t, J=11.7 Hz, 2H), 2.63 (m, 9H), 1.79 (m, 2H), 1.60 (m, 2H), 1.48(s, 3H) and 1.46 (s, 3H)

Example 565(S)-4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-8-((4-(3-fluoropyrrolidin-1-yl)piperidin-1-yl)methyl)-9-methyl-9H-purin-6-yl)morpholine565

A mixture of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(0.1 g, 0.255 mmol), 4-((S)-3-fluoropyrrolidin-1-yl)piperidine (0.053 g,0.307 mmol) and 4 Å molecular sieves (0.25 g) in DCE (4 mL) was stirredfor 3 h at room temperature. Sodium triacetoxyborohydride (0.109 g, 0.51mmol) was added and the reaction mixture was stirred for 18 h at roomtemperature. The reaction mixture was filtered through Celite and thefiltrate was concentrated in vacuo. The residue was purified by flashchromatography (Si—PPC, MeOH:EtOAc, gradient 0:100 to 40:60) to give 565as a white solid (0.121 g, 87%). LCMS (Method I): R_(T)=2.26 min, [M+H]⁺548.2 ¹H NMR (400 MHz, DMSO-d₆): δ 8.04-8.00 (m, 1H), 7.65-7.61 (m, 1H),7.26-7.21 (m, 2H), 5.16 (dt, J=56.0, 5.5 Hz, 1H), 4.50-3.96 (m, 4H),3.82 (s, 3H), 3.79-3.74 (m, 4H), 3.75 (s, 2H), 3.32-3.19 (q, J=7.4 Hz,2H), 2.89-2.74 (m, 4H), 2.69-2.55 (m, 1H), 2.37-2.28 (m, 1H), 2.15-1.97(m, 4H), 1.90-1.74 (m, 3H), 1.45-1.34 (m, 2H), 1.34 (t, J=7.4 Hz, 3H)

Example 5662-(4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purine-8-carbonyl)piperazin-1-yl)-2-methylpropanamide566

To a suspension of2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purine-8-carbaldehyde(15 g, 38 mmol) in ethanol was added silver nitrate (8.1 g, 48 mmol) anda 1.5 M NaOH solution (150 mL). The resulting mixture was stirred atroom temperature for 30 minutes prior to filtering through celite. Thesolution was then concentrated. To the residual solid was added waterand made basic by adding 1M NaOH (cloudy mixture). The mixture was thenwashed with DCM. The aqueous layer was then made acidic (pH 2) by addingconcentrated HCl. The acidic mixture was then concentrated under vacuum.A precipitate slowly formed during the concentration. After the volumewas reduced by ⅓, the suspension was cooled in an ice-bath for 15minutes before being filtered to collect the solid. The solid was thendried under vacuum to give2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purine-8-carboxylicacid as a beige powder (15.2 g, 97%). LCMS m/z: 408.3 (MH+)

2-(2-Ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purine-8-carboxylicacid was coupled with 2-methyl-2-(piperazin-1-yl)propanamidedihydrochloride according to General Procedure K to give 566. LCMS m/z:281.3 (2M+H+)

Example 567(4-tert-butylpiperazin-1-yl)(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methanone567

Following General Procedure K,2-(2-Ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purine-8-carboxylicacid was coupled with 1-tert-butylpiperazine according to GeneralProcedure K to give 567. LCMS m/z: 266.7 (2M+H+)

Example 5683-(4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-1-yl)propanenitrile568

Following General Procedure C,4-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-8-(piperidin-4-ylmethyl)-9H-purin-6-yl)morpholineand acrylonitrile were reacted to give 568. LCMS m/z: 250.7 (2M+H+)

Example 569(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(4-(2-hydroxypropan-2-yl)piperidin-1-yl)methanone569

Following General Procedure K,2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purine-8-carboxylicacid was coupled with 2-(piperidin-4-yl)propan-2-ol to give 569. LCMSm/z: 533.3 (M+H⁺)

Example 5704-(8-((1-(isoxazol-5-ylmethyl)piperidin-4-yl)methyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine570

Following General Procedure C,4-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-8-(piperidin-4-ylmethyl)-9H-purin-6-yl)morpholineand 5-(bromomethyl)isoxazole were reacted to give 570. LCMS m/z: 264.7(2M+H+)

Example 5714-(8-((1-(isoxazol-5-ylmethyl)azetidin-3-yl)methyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine571

Following General Procedure C,4-(8-(azetidin-3-ylmethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholineand 5-(bromomethyl)isoxazole were reacted to give 571. LCMS m/z: 250.7(2M+H+)

Example 572(S)-4-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-8-((1-(tetrahydrofuran-3-yl)azetidin-3-yl)methyl)-9H-purin-6-yl)morpholine572

Following General Procedure L,4-(8-(azetidin-3-ylmethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholineand dihydrofuran-3(2H)-one were reacted to give the racemic mixture. Theenantiomers were separated by SFC to give 572. LCMS m/z: 245.2 (2M+H+)

Example 573(R)-4-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-8-((1-(tetrahydrofuran-3-yl)azetidin-3-yl)methyl)-9H-purin-6-yl)morpholine573

Following General Procedure L,4-(8-(azetidin-3-ylmethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholineand dihydrofuran-3(2H)-one were reacted to give the racemic mixture. Theenantiomers were separated by SFC to give 573. LCMS m/z: 245.2 (2M+H+)

Example 5754-(8-(2-(3,3-dimethyl-4-(methylsulfonyl)piperazin-1-yl)ethyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine575

A mixture of2-chloro-8-[2-(4-methanesulfonyl-3,3-dimethylpiperazin-1-yl)ethyl]-9-methyl-6-morpholin-4-yl-9H-purine(35 mg, 0.07 mmol), 2-ethylbenzimidazole (12 mg, 0.08 mmol), Pd₂(dba)₃(1.7 mg, 2.5 mol %), Xphos (3.5 mg, 10 mol %) and Cs₂CO₃ (36 mg, 0.11mmol) in dioxane (1.5 mL) was purged with argon gas then heated at 120°C., for 24 h, in a sealed tube. The reaction mixture was loaded onto anIsolute® SCX-2 cartridge, washed with MeOH then the desired producteluted with 2 M NH₃/MeOH in DCM. The resulting residue was purified byreverse phase HPLC (Phenomenex Gemini 5 μm C18, 20 mM triethylamine inwater on a gradient of acetonitrile 30-90%) to give 575 (20 mg, 46%) asa pale beige solid. LCMS: (Method I): R_(T) 2.74 min, [M+H]⁺ 582.2 ¹HNMR (400 MHz, CDCl₃d): δ 8.01-7.96 (m, 1H), 7.79-7.75 (m, 1H), 7.28-7.25(m, 2H), 4.50-3.96 (m, 4H), 3.86 (t, J=4.7 Hz, 4H), 3.78 (s, 3H),3.50-3.44 (m, 2H), 3.36 (q, J=7.4 Hz, 2H), 3.04 (t, J=7.4 Hz, 2H), 2.94(s, 3H), 2.87 (t, J=7.4 Hz, 2H), 2.64-2.58 (m, 2H), 2.38 (s, 2H), 1.50(s, 6H), 1.45 (t, J=7.4 Hz, 3H)

Example 5764-(8-((4-(3,3-difluoroazetidin-1-yl)piperidin-1-yl)methyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine576

A mixture of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(0.139 g, 0.36 mmol), 4-(3,3-difluoroazetidin-1-yl)piperidine (0.075 g,0.43 mmol) and 4 Å molecular sieves (0.4 g) in DCE (5 mL). The reactionmixture was stirred for 3 h at room temperature. Sodiumtriacetoxyborohydride (0.15 g, 0.71 mmol) was added and the reactionmixture was stirred for 72 h at room temperature. The suspension wasfiltered through Celite and the filtrate was concentrated in vacuo. Theresidue was purified by flash chromatography (Si—PPC, MeOH:DCM, gradient0:100 to 12:88) followed by reverse phase HPLC (Phenomenex Gemini 5uC18, 20 mM triethylamine in water on a gradient of acetonitrile 95:5 to2:98) to give 576 as an off-white solid (0.104 g, 53%). LCMS (Method I):R_(T)=2.61 min, [M+H]⁺ 552.2 ¹H NMR (400 MHz, DMSO-d₆): δ 8.03-7.99 (m,1H), 7.65-7.61 (m, 1H), 7.27-7.20 (m, 2H), 4.60-3.95 (s, 4H), 3.81 (s,3H), 3.80-3.74 (m, 6H), 3.52 (t, J=12.3 Hz, 4H), 3.27 (q, J=7.4 Hz, 2H),2.79-2.70 (m, 2H), 2.20-2.10 (m, 3H), 1.68-1.59 (m, 2H), 1.34 (t, J=7.4Hz, 3H), 1.30-1.17 (m, 2H)

Example 5771-tert-butyl-4-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperazin-2-one577

A mixture of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(0.15 g, 0.39 mmol), 1-tert-butylpiperazin-2-one (0.072 g, 0.46 mmol)and 4 Å molecular sieves (0.4 g) in DCE (5 mL) was stirred for 4 h atroom temperature. Sodium triacetoxyborohydride (0.163 g, 0.77 mmol) wasadded and the reaction mixture was stirred for 18 h at room temperature.The reaction mixture was filtered through Celite and the filtrate wasconcentrated in vacuo. The residue was purified by flash chromatography(Si—PPC, MeOH:DCM, gradient 0:100 to 5:95) to give 577 as a white solid(0.178 g, 87%). LCMS (Method I): R_(T)=3.59 min, [M+H]⁺ 532.2 ¹H NMR(400 MHz, DMSO-d₆): δ 8.03-7.98 (m, 1H), 7.65-7.60 (m, 1H), 7.26-7.21(m, 2H), 4.50-3.95 (m, 5H), 3.83-3.79 (m, 6H), 3.78 (m, 4H), 3.27 (q,J=7.4 Hz, 2H), 3.08 (s, 2H), 2.69-2.64 (m, 2H), 1.36 (s, 9H), 1.34 (t,J=7.4 Hz, 3H)

Example 578(S)-2-amino-1-(4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-1-yl)propan-1-one578

To a solution of N-(tert-Butoxycarbonyl)-L-alanine (80.0 mg, 0.423 mmol)in N,N-Dimethylformamide (5.0 mL, 0.064 mol) was added HATU (0.154 g,0.404 mmol), 1-hydroxybenzotriazole (HOBt, 0.00839 g, 0.0621 mmol) andtriethylamine (0.10 mL, 0.72 mmol). The resulting yellow solution wasstirred at room temperature for 5 minutes before the addition of4-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-8-(piperidin-4-ylmethyl)-9H-purin-6-yl)morpholine520 (0.150 g, 0.310 mmol;). The reaction was stirred at room temperaturefor 2 hours. The reaction mixture was partitioned between brine andEtOAc. The organic extract was washed with brine, dried over Na₂SO₄,filtered and concentrated. The crude product was purified by flashchromatography (0-5% MeOH in DCM) to give tert-butyl4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidine-1-carboxylate(0.15 g, 78%). LCMS m/z: 618.3 (MH+).

To a solution of tert-butyl4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidine-1-carboxylate(0.18 g, 0.29 mmol) in dioxane (5 mL) was added a 2M HCl solution inether (1 mL). The reaction was then stirred at room temperature for 1hour before being concentrated. The crude was purified by RP-HPLC togive 578 (75 mg, 50%). LCMS m/z: 259.7 (2M+H+)

Example 5793-methyl-2-(3-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)azetidin-1-yl)butanamide579

Step 1: ethyl3-methyl-2-(3-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)azetidin-1-yl)butanoate

Ethyl3-methyl-2-(3-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)azetidin-1-yl)butanoatewas synthesized according to General Procedure C using ethyl2-bromo-3-methylbutanoate as the electrophile.

Step 2:3-methyl-2-(3-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)azetidin-1-yl)butanoicacid

To a solution of ethyl3-methyl-2-(3-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)azetidin-1-yl)butanoate(0.180 g, 0.329 mmol) in ethanol (1.0 mL, 17 mmol) was added 1.0 M oflithium hydroxide in water (2.0 mL). The resulting mixture was stirredat room temperature for 2 hours. The reaction mixture was neutralizedwith 1M HCl and concentrated. The residue was re-dissolved in MeOH andloaded onto a SCX-2 column. The column was first washed with MeOH. Theproduct was then eluted with 2M NH₃ in MeOH and concentrated. LCMS m/z:519.3 (MH+)

Step 3:3-methyl-2-(3-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)azetidin-1-yl)butanamide579

Following General Procedure K,3-methyl-2-(3-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)azetidin-1-yl)butanoicacid and ammonium hydroxide were coupled to give 579. LCMS m/z: 259.7(2M+H+)

Example 580N,2-dimethyl-2-(3-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)azetidin-1-yl)propanamide580

Following General Procedure C,4-(8-(azetidin-3-ylmethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholineand 2-bromo-N,2-dimethylpropanamide were reacted to give 580. LCMS m/z:259.7 (2M+H+)

Example 581(S)-3-(2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-1-methylpiperidin-3-ol581

tert-Butyl3-(2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)-3-hydroxypiperidine-1-carboxylate(1 g) was reacted with 2-isopropylbenzimidazole via General Procedure Ifor Buchwald coupling to give 0.65 g of tert-butyl3-hydroxy-3-(2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)piperidine-1-carboxylatefollowing flash column chromatography.

To a solution of tert-butyl3-hydroxy-3-(2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)piperidine-1-carboxylatein DCM (7 mL) at ambient temperature was added 4 M Hydrogen Chloride in1,4-Dioxane (2.8 mL). Upon completion the reaction mixture wasconcentrated to dryness to get the crude HCl salt of3-(2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)piperidin-3-ol.

The HCl salt of3-(2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)piperidin-3-ol(80 mg) was reacted with isopropyl iodide (1.5 eq) and potassiumcarbonate (5 eq) in a 1:1 mixture of DMF and Acetonitrile (2 mL). Thereaction was heated at 75° C. for 18 hours until complete. The reactionmixture was diluted with Ethyl acetate and extracted with a saturatedammonium chloride solution. The organic layer was dried, filtered andconcentrated to give 581 [4.6 mg; MS (Q1) 491.3 (M)+] and 582 [4.7 mg;MS (Q1) 491.3 (M)+] following reverse phase purification and subsequentchiral separation.

Example 582I-3-(2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-1-methylpiperidin-3-ol582

The HCl salt of3-(2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)piperidin-3-ol(80 mg) was reacted with isopropyl iodide (1.5 eq) and potassiumcarbonate (5 eq) in a 1:1 mixture of DMF and Acetonitrile (2 mL). Thereaction was heated at 75° C. for 18 hours until complete. The reactionmixture was diluted with Ethyl acetate and extracted with a saturatedammonium chloride solution. The organic layer was dried, filtered andconcentrated to give 581 [4.6 mg; MS (Q1) 491.3 (M)+] and 582 [4.7 mg;MS (Q1) 491.3 (M)+] following reverse phase purification and subsequentchiral separation.

Example 585N,2-dimethyl-2-(4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-1-yl)propanamide585

Following General Procedure C,4-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-8-(piperidin-4-ylmethyl)-9H-purin-6-yl)morpholineand 2-bromo-N,2-dimethylpropanamide were reacted to give 585. LCMS m/z:273.8 (2M+H+)

Example 586(S)-4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-8-((3-(3-fluoropyrrolidin-1-yl)azetidin-1-yl)methyl)-9-methyl-9H-purin-6-yl)morpholine586

A mixture of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(0.245 g, 0.627 mmol), (S)-1-azetidin-3-yl-3-fluoropyrrolidine (0.109 g,0.752 mmol) and 4 Å molecular sieves (0.5 g) in DCE (5 mL). The reactionmixture was stirred for 90 min at room temperature. Sodiumtriacetoxyborohydride (0.266 g, 1.254 mmol) was added and the reactionmixture was stirred for 18 h at room temperature. The suspension wasfiltered through Celite and the filtrate was concentrated in vacuo. Theresidue was purified by flash chromatography (Si—PPC, MeOH:DCM, gradient0:100 to 20:80) followed by reverse phase HPLC (Phenomenex Gemini 5uC18, 20 mM triethylamine in water on a gradient of acetonitrile 95:5 to2:98) to give 586 as an off-white solid (0.204 g, 63%). LCMS (Method I):R_(T)=2.46 min, [M+H]⁺ 520.2 ¹H NMR (400 MHz, DMSO-d₆): δ 8.03-7.99 (m,1H), 7.65-7.61 (m, 1H), 7.27-7.21 (m, 2H), 5.19 (dt, J=55.8, 5.4 Hz,1H), 4.50-3.95 (m, 4H), 3.87 (s, 2H), 3.81-3.72 (m, 7H), 3.40 (dd,J=7.1, 6.1 Hz, 2H), 3.26 (q, J=7.4 Hz, 2H), 3.21-3.12 (m, 1H), 3.12-3.03(m, 2H), 2.79-2.65 (m, 2H), 2.64-2.51 (m, 1H), 2.34-2.25 (m, 1H),2.15-2.03 (m, 1H), 1.76-1.95 (m, 1H), 1.33 (t, J=7.4 Hz, 3H)

Example 5871′-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-3-methyl-1,3′-biazetidin-3-ol587

A mixture of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(0.092 g, 0.234 mmol), 3-methyl-[1,3′]biazetidinyl-3-ol (0.040 g, 0.28mmol) and 4 Å molecular sieves (0.25 g) in DCE (3 mL). The reactionmixture was stirred for 90 min at room temperature. Sodiumtriacetoxyborohydride (0.099 g, 0.47 mmol) was added and the reactionmixture was stirred for 18 h at room temperature. The suspension wasfiltered through Celite and the filtrate was concentrated in vacuo. Theresidue was purified by flash chromatography (Si—PPC, MeOH:DCM, gradient0:100 to 10:90) to give 587 as a white solid (0.107 g, 89%). LCMS(Method I): R_(T)=2.33 min, [M+H]⁺ 518.2 ¹H NMR (300 MHz, DMSO-d₆): δ8.03-7.99 (m, 1H), 7.65-7.61 (m, 1H), 7.27-7.22 (m, 2H), 4.49-3.95 (m,4H), 3.84 (s, 2H), 3.80-3.74 (m, 4H), 3.36-3.31 (s, 3H), 3.31-3.20 (m,6H), 3.11-3.01 (m, 4H), 2.98-2.93 (m, 2H), 1.34 (m, 5H)

Example 5881-(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)pyrrolidin-2-one588

A mixture of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(165 mg, 0.42 mmol), 1-azetidin-3-ylpyrrolidin-2-one (65 mg, 0.46 mmol)and 4 Å powdered molecular sieves in DCE (4 mL) was stirred at roomtemperature for 2 h before the addition of sodium triacetoxyborohydride(180 mg, 0.84 mmol). The reaction mixture was stirred for 65 h thenfiltered through celite, washing with DCM. The organic phase was washedwith brine and concentrated in vacuo. The organic phase was dried(Na₂SO₄) and concentrated in vacuo. The resulting residue was purifiedby column chromatography (Si—PCC, MeOH:EtOAc, 0-15%) affording 588 as anorange foam (138 mg, 64%). LCMS (method I): R_(T) 2.42 min [M+H]⁺ 516.2¹H NMR (CDCl₃, 300 MHz): δ 8.00 (m, 1H), 7.76 (m, 1H), 7.27 (m, 2H),4.83 (t, J=6.9 Hz, 1H), 4.35 (m, 4H), 3.89-3.82 (m, 9H), 3.67-3.54 (m,4H), 3.36 (m, 4H), 2.42 (t, J=8.1 Hz, 2H), 2.07 (m, 2H) and 1.45 (t,J=7.5 Hz, 3H)

Example 5894-(8-((3-(3,3-difluoropyrrolidin-1-yl)azetidin-1-yl)methyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine589

A mixture of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(100 mg, 0.26 mmol), 1-azetidin-3-yl-3,3-difluoropyrrolidine (46 mg,0.28 mmol) and 4 Å powdered molecular sieves in DCE (6 mL) was stirredat room temperature for 2 h before the addition of sodiumtriacetoxyborohydride (108 mg, 0.52 mmol). The reaction mixture wasstirred for 16 h then filtered through celite, washing with DCM. Theorganic phase was washed with brine and concentrated in vacuo. Theorganic phase was dried (Na₂SO₄) and concentrated in vacuo. Theresulting residue was purified by column chromatography (Si—PCC,MeOH:EtOAc, 0-10%) affording 589 as an orange foam (97 mg, 69%). LCMS(method I): R_(T) 2.74 min [M+H]⁺ 538.2 ¹H NMR (CDCl₃, 300 MHz): δ 8.00(m, 1H), 7.75 (m, 1H), 7.27 (m, 2H), 4.42-4.27 (m, 4H), 3.87-3.84 (m,9H), 3.54 (t, J=6.5 Hz, 2H), 3.32-3.30 (m, 3H), 3.19 (t, J=6.5 Hz, 2H),2.89 (t, J=13.1 Hz, 2H), 2.70 (t, J=6.9 Hz, 2H), 2.29-2.28 (m, 2H) and1.44 (t, J=7.5 Hz, 3H)

Example 590I-4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-8-((3-(3-fluoropyrrolidin-1-yl)azetidin-1-yl)methyl)-9-methyl-9H-purin-6-yl)morpholine590

A mixture of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(0.188 g, 0.479 mmol), I-1-azetidin-3-yl-3-fluoropyrrolidine (0.083 g,0.575 mmol) and 4 Å molecular sieves (0.4 g) in DCE (4 mL). The reactionmixture was stirred for 3 h at room temperature. Sodiumtriacetoxyborohydride (0.203 g, 0.959 mmol) was added and the reactionmixture was stirred for 72 h at room temperature. The suspension wasfiltered through Celite and the filtrate was concentrated in vacuo. Theresidue was purified by flash chromatography (Si—PPC, MeOH:EtOAc,gradient 0:100 to 40:60) to give 590 as a yellow solid (0.2 g, 81%).LCMS (Method I): R_(T)=2.46 min, [M+H]⁺ 520.2 ¹H NMR (400 MHz, DMSO-d₆):δ 8.03-7.99 (m, 1H), 7.65-7.61 (m, 1H), 7.27-7.21 (m, 2H), 5.19 (dt,J=55.8, 5.4 Hz, 1H), 4.50-3.95 (m, 4H), 3.87 (s, 2H), 3.82-3.72 (m, 7H),3.40 (dd, J=7.1, 6.1 Hz, 2H), 3.26 (q, J=7.4 Hz, 2H), 3.22-3.12 (m, 1H),3.10-2.95 (m, 2H), 2.79-2.64 (m, 2H), 2.64-2.50 (m, 1H), 2.34-2.25 (m,1H), 2.18-2.02 (m, 1H), 1.94-1.78 (m, 1H), 1.33 (t, J=7.4 Hz, 3H)

Example 595N-(2-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)ethyl)tetrahydro(1,1-dioxo)thiophen-3-amine595

A mixture of[2-(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)-ethyl]-(1,1-dioxo-tetrahydro-1-thiophen-3-yl)amine(45 mg, 0.11 mmol), 2-ethylbenzimidazole (18 mg, 0.12 mmol), Pd₂(dba)₃(2.5 mg, 2.5 mol %), Xphos (5.2 mg, 10 mol %) and Cs₂CO₃ (53 mg, 0.16mmol) in dioxane (1.5 mL) was purged with argon gas then heated at 120°C., for 4 h, in a sealed tube. The reaction mixture was loaded onto anIsolute® SCX-2 cartridge, washed with MeOH then the desired producteluted with 2 M NH₃/MeOH in DCM. The resulting residue was purified bycolumn chromatography (Si—PCC, 0-10% MeOH in DCM) to give 595 (35 mg,62%) as a pale yellow solid. LCMS: (Method I): R_(T) 2.43 min, [M+H]⁺525.2 ¹H NMR (300 MHz, CDCl₃d): δ 8.02-7.98 (m, 1H), 7.78-7.74 (m, 1H),7.31-7.23 (m, 2H), 4.50-4.95 (m, 4H), 3.87 (t, J=4.7 Hz, 4H), 3.76 (s,3H), 3.73-3.67 (m, 1H), 3.40-3.24 (m, 4H), 3.23-3.14 (m, 2H), 3.14-3.00(m, 4H), 2.94 (dd, J=13.2, 6.0 Hz, 1H), 2.49-2.45 (m, 1H), 2.15-2.05 (m,1H), 1.44 (t, J=7.5 Hz, 3H)

Example 5964-(8-((2,2-dimethyl-4-(methylsulfonyl)piperazin-1-yl)methyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine596

A solution of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(167 mg, 0.43 mmol), 1-methanesulfonyl-3,3-dimethylpiperazine (100 mg,0.52 mmol) and molecular sieves (4 Å, powdered, 830 mg) in DCE (10 mL)was stirred at ambient temperature for 5 h. Sodium triacetoxyborohydride(136 mg, 0.64 mmol) was added and the mixture stirred for 17 h, thenloaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was thenwashed with methanol and the desired product was subsequently elutedusing 2 M NH₃ in MeOH. The product was collected and concentrated invacuo. The resultant residue was purified by flash chromatography(Si—PPC, DCM:MeOH, 100:0 to 99:1 to 98:2 to 95:5) followed by reversephase HPLC (Phenomenex Gemini 5u C18, 20 mM triethylamine in water on agradient of acetonitrile 51:49 to 49:51) to afford 596 as a cream foam(31 mg, 13%). LCMS (method I): R_(T)=3.42 min, M+H⁺=568. ¹H NMR (CDCl₃,400 MHz) δ 8.01 (m, 1H), 7.77 (m, 1H), 7.26 (m, 2H), 4.34 (m, 4H), 3.87(m, 9H), 3.36 (q, J=7.5 Hz, 2H), 3.16 (m, 2H), 3.02 (s, 2H), 2.77 (s,3H), 2.64 (m, 2H), 1.46 (t, J=7.5 Hz, 3H) and 1.29 (s, 6H)

Example 5972-((1S,4S)-5-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)acetamide597

Triethylamine (85 μL, 0.61 mmol) was added to a solution of8-[(1S,4S)-1-(2,5-diazabicyclo[2.2.1]hept-2-yl)methyl]-2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine(250 mg, 0.53 mmol) and 2-chloroacetamide (60 mg, 0.64 mmol) in DCM (10mL). The mixture was stirred at ambient temperature for 24 h, thenloaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was thenwashed with methanol and the desired product was subsequently elutedusing 2 M NH₃ in MeOH. The product was collected and concentrated invacuo. The resultant residue was purified by flash chromatography(Si—PPC, DCM:MeOH, 100:0 to 99:1 to 98:2) to afford 597 as a cream solid(175 mg, 62%). LCMS (method I): R_(T)=2.35 min, M+H⁺=531. ¹H NMR (CDCl₃,400 MHz) δ 12.12 (bs, 1H), 8.01 (m, 1H), 7.77 (m, 1H), 7.26 (m, 2H),5.62 (bs, 1H), 4.34 (m, 4H), 3.92-3.83 (m, 9H), 3.54 (m, 2H), 3.37 (q,J=7.4 Hz, 2H), 3.09 (m, 4H), 2.93 (m, 2H), 2.00 (m, 2H) and 1.42 (t,J=7.4 Hz, 3H)

Example 5984-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-8-(((1S,4S)-5-(oxetan-3-yl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)methyl)-9H-purin-6-yl)morpholine598

A solution of8-[(1S,4S)-1-(2,5-diazabicyclo[2.2.1]hept-2-yl)methyl]-2-(2-ethyl-benzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine(250 mg, 0.53 mmol), oxetan-3-one (40 mg, 0.31 mmol) and molecularsieves (4 Å, powdered, 200 mg) in DCE (7 mL) was stirred at ambienttemperature for 4 h. Sodium triacetoxyborohydride (148 mg, 0.70 mmol)was added and the mixture stirred for 16 h, then loaded onto an Isolute®SCX-2 cartridge (10 g). The cartridge was then washed with methanol andthe desired product was subsequently eluted using 2 M NH₃ in MeOH. Theproduct was collected and concentrated in vacuo. The resultant residuewas purified by flash chromatography (Si—PPC, DCM:MeOH, gradient from100:0 to 90:0) to afford 598 as a white solid (125 mg, 45%). LCMS(method I): R_(T)=2.39 min, M+H⁺=530. ¹H NMR (CDCl₃, 400 MHz) δ 8.02 (m,1H), 7.76 (m, 1H), 7.26 (m, 2H), 4.72-4.65 (m, 4H), 4.34 (m, 4H),4.01-3.86 (m, 10H), 3.35 (m, 4H), 2.99 (m, 1H), 2.82 (m, 1H), 2.76 (m,2H), 1.79 (m, 2H) and 1.45 (t, J=7.5 Hz, 3H)

Example 607N-(2-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)ethyl)-N-methyl-1,1-dioxo-tetrahydrothiophen-3-amine607

To a solution of(1,1-dioxo-tetrahydro-1-thiophen-3-yl)-{2-[2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-yl]ethyl}amine(31 mg, 0.06 mmol) in DCE (5 mL) was added formaldehyde (37 wt. % inwater, 50 μL, 0.67 mmol). The reaction mixture was stirred at roomtemperature for 5 h, sodium triacetoxyborohydride (25 mg, 0.12 mmol) wasadded and the resulting mixture stirred for a further 16 h. The reactionmixture was loaded onto an Isolute® SCX-2 cartridge, washed with MeOHthen the desired product eluted with 2 M NH₃ in MeOH. The resultingresidue was purified by column chromatography (Si—PCC, 0-10% MeOH inDCM) to give 607 as an off white solid (21 mg, 66%). LCMS (Method I):R_(T)=2.55 min, [M+H]⁺ 539.14 ¹H NMR (400 MHz, CDCl₃d): δ 8.02-7.97 (m,1H), 7.80-7.75 (m, 1H), 7.34-7.24 (m, 2H), 4.49-3.5 (m 4H), 3.87 (t,J=4.7 Hz, 4H), 3.77 (s, 3H), 3.59-3.49 (m, 1H), 3.37 (q, J=7.5 Hz, 2H),3.25 (dd, J=13.2 7.7 Hz, 2H), 3.10-2.98 (m, 6H), 2.42 (s, 3H), 2.40-2.32(m, 1H), 2.21-2.11 (m, 1H), 1.45 (t, J=7.5 Hz, 3H)

Example 6084-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-8-((4-(3-fluoroazetidin-1-yl)piperidin-1-yl)methyl)-9-methyl-9H-purin-6-yl)morpholine608

A mixture of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(0.155 g, 0.395 mmol), 4-(3-fluoroazetidin-1-yl)piperidine (0.075 g,0.474 mmol) and 4 Å molecular sieves (0.5 g) in DCE (6 mL) was stirredfor 3 h at room temperature. Sodium triacetoxyborohydride (0.168 g, 0.79mmol) was added and the reaction mixture was stirred for 72 h at roomtemperature. The reaction mixture was filtered through Celite and thefiltrate was concentrated in vacuo. The residue was purified by flashchromatography (Si—PPC, MeOH:DCM, gradient 0:100 to 15:85) to give 608as a white solid (0.177 g, 84%). LCMS (Method I): R_(T)=2.25 min, [M+H]⁺534.2 ¹H NMR (400 MHz, DMSO-d₆): δ 8.03-7.98 (m, 1H), 7.65-7.60 (m, 1H),7.27-7.21 (m, 2H), 5.20-5.00 (m, 1H), 4.50-3.96 (m, 4H), 3.80 (s, 3H),3.80-3.74 (m, 4H), 3.75 (s, 2H), 3.56-3.45 (m, 2H), 3.26 (q, J=7.4 Hz,2H), 3.06-2.94 (m, 2H), 2.78-2.68 (m, 2H), 2.19-2.09 (m, 2H), 2.07 (s,1H), 1.66-1.57 (m, 2H), 1.33 (t, J=7.4 Hz, 3H), 1.25-1.12 (m, 2H)

Example 646 tert-butyl3-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)pyrrolidine-1-carboxylate646

A mixture of3-(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)-pyrrolidine-1-carboxylicacid tert-butyl ester (44 mg, 0.10 mmol), 2-ethylbenzimidazole (17 mg,0.11 mmol), Pd₂(dba)₃ (2.4 mg, 2.5 mol %), Xphos (5.0 mg, 10 mol %) andCs₂CO₃ (51 mg, 0.16 mmol) in dioxane (1.5 mL) was purged with argon gasthen heated at 120° C., for 20 h, in a sealed tube. The reaction mixturewas loaded onto an Isolute® SCX-2 cartridge, washed with MeOH then thedesired product eluted with 2 M NH₃/MeOH in DCM. The resulting residuewas purified by column chromatography (Si—PCC, 0-100% EtOAc incyclohexane) to give 646 (37 mg, 67%) as a yellow solid. LCMS: (MethodI): R_(T) 4.34 min, [M+H]⁺ 533.2 ¹H NMR (400 MHz, CDCl₃d): δ 8.01-7.97(m, 1H), 7.78-7.73 (m, 1H), 7.29-7.22 (m, 2H), 4.55-4.10 (m, 4H), 3.86(t, J=4.67 Hz, 4H), 3.80 (s, 3H), 3.80-3.44 (m, 4H), 3.35 (q, J=7.48 Hz,2H), 2.36 (s, 3H), 1.49 (s, 9H), 1.44 (t, J=7.48 Hz, 3H)

Example 647 tert-butyl4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)piperidine-1-carboxylate647

To a suspension of zinc powder (320 mg, 4.92 mmol) and Celpure P65 inanhydrous DMA (3 mL) was added a 7:5 (v:v) mixture of TMS—Cl:1,2-dibromoethane (65 μL) drop wise. The reaction mixture was stirred atroom temperature for 15 min. A solution of 4-iodopiperidine-1-carboxylicacid tert-butyl ester (1.22 g, 3.95 mmol) in anhydrous DMA (2 mL) wasadded dropwise to the mixture described above and the reaction mixturewas stirred for 30 minutes at room temperature. The zincate mixture wasquickly filtered through a grade-3 sintered funnel and added onto amixture of 2-Chloro-8-iodo-9-methyl-6-morpholin-4-yl-9H-purine (1.0 g,2.63 mmol), Pd(dppf)Cl₂.DCM (107 mg, 0.13 mmol) and CuI (50 mg, 0.26mmol). The vessel was then evacuated and back-filled with nitrogen. Theresulting reaction mixture was stirred at 85° C. for 18 hours, after 3hours additional Pd(dppf)Cl₂.DCM and CuI was added. The mixture wascooled to room temperature and partitioned between EtOAc and sat.aqueous solution of ammonium chloride. The organic layer was washed withwater, brine, dried over Na₂SO₄, filtered and concentrated in vacuo. Theresidue was purified by column chromatography (cyclohexane:EtOAc,20-70%) affording4-(2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)-piperidine-1-carboxylicacid tert-butyl ester as a solid (375 mg, 33%). LCMS (Method H): R_(T)4.57 min, [M+H]⁺ 437.46 ¹H NMR (400 MHz, CDCl₃): δ 4.40-4.15 (m, 6H);3.81 (t, J=12.1 Hz, 4H); 3.71 (s, 3); 2.99-2.87 (m, 3H); 1.94-1.85 (m,4H); 1.71-1.59 (m, 1H); 1.48 (s, 9H).

A mixture of4-(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)piperidine-1-carboxylicacid tert-butyl ester (375 mg, 0.858 mmol), 2-ethylbenzimidazole (151mg, 1.03 mmol), Xphos (43 mg, 0.09 mmol) and Cs₂CO₃ (421 mg, 1.29 mmol)in dioxane (5 mL) was degassed with nitrogen bubbling for 15 minutes.Tris(dibenzylideneacetone)dipalladium (20 mg, 0.022 mmol) was added andthe mixture was heated to 120° C. for 20 hours. The reaction mixture wasdiluted with EtOAc, filtered, concentrated in vacuo and purified bycolumn chromatography (Si—PCC, EtOAc:cyclohexane, 40-90%) affording 647(390 mg, 83%). LCMS: R_(T) 4.54 min, [M+H]⁺ 547.24 ¹H NMR (400 MHz,DMSO): δ 8.00-7.99 (m; 1H); 7.68-7.60 (m; 1H); 7.25-7.24 (m; 2H);4.45-4.12 (m; 4H); 4.12-4.01 (d; J=13.26 Hz, 2H); 3.85-3.70 (m; 6H);3.25-3.10 (m, 4H); 3.04-2.82 (m, 2H); 2.00-1.90 (d; J=13.26 Hz, 2H);1.76-1.59 (m, 2H); 1.43 (s; 9H); 1.35 (t, J=7.44 Hz, 3H).

Example 6484-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-3-isopropylpiperazin-2-one648

A mixture of4-(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl)-3-isopropylpiperazin-2-one(198 mg, 0.49 mmol), 2-ethylbenzimidazole (78 mg, 0.53 mmol), Pd₂(dba)₃(11.1 mg, 2.5 mol %), Xphos (23.1 mg, 10 mol %) and Cs₂CO₃ (237 mg, 0.16mmol) in dioxane (4 mL) was purged with argon gas then heated at 110°C., for 17 h, in a sealed tube. The reaction mixture was loaded onto anIsolute® SCX-2 cartridge, washed with MeOH then the desired producteluted with 2 M NH₃/MeOH in DCM. The resulting residue was purified bycolumn chromatography (Si—PCC, 0-10% MeOH in EtOAc) to give 648 (196 mg,78%) as a white solid. LCMS: (Method I): R_(T) 3.37 min, [M+H]⁺ 518.2 ¹HNMR (400 MHz, CDCl₃d): δ 8.05-8.00 (m, 1H), 7.79-7.75 (m, 1H), 7.30-7.23(m, 2H), 6.02 (s, 1H), 4.50-3.96 (m, 4H), 4.09 (d, J=13.6 Hz, 1H), 3.94(d, J=13.6 Hz, 1H), 3.89 (s, 3H), 3.87 (t, J=4.80 Hz, 4H), 3.63-3.54 (m,1H), 3.37 (q, J=7.5 Hz, 2H), 3.34-3.28 (m, 1H), 3.13-3.04 (m, 1H), 3.03(d, J=5.5 Hz, 1H), 2.74-2.66 (m, 1H), 2.25-2.14 (m, 1H), 1.46 (t, J=7.5Hz, 3H), 1.11 (d, J=6.8 Hz, 3H), 1.03 (d, J=6.8 Hz, 3H)

Example 6494-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-3,3-dimethylpiperazin-2-one649

A solution of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(250 mg, 0.64 mmol), 3,3-dimethylpiperazin-2-one (100 mg, 0.78 mmol) andmolecular sieves (4 Å, powdered, 1 g) in DCE (15 mL) was stirred atambient temperature for 4 h. Sodium triacetoxyborohydride (204 mg, 0.96mmol) was added and the mixture stirred for 16 h, then loaded onto anIsolute® SCX-2 cartridge (10 g). The cartridge was then washed withmethanol and the desired product was subsequently eluted using 2 M NH₃in MeOH. The product was collected and concentrated in vacuo. Theresultant residue was purified by flash chromatography (Si—PPC,DCM:MeOH, 100:0 to 98:2 to 95:5) to afford 649 as a yellow solid (34 mg,11%). LCMS (method I): R_(T)=3.12 min, M+H⁺=504. ¹H NMR (CDCl₃, 400 MHz)δ 8.02 (m, 1H), 7.79 (m, 1H), 7.30 (m, 2H), 5.75 (bs, 1H), 4.34 (m, 4H),3.94 (s, 2H), 3.92 (s, 3H), 3.87 (m, 4H), 3.38 (q, J=7.4 Hz, 2H), 3.23(m, 2H), 2.80 (m, 2H), 1.54 (s, 6H) and, 1.47 (t, J=7.4 Hz, 3H)

Example 6772-(4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)piperidin-1-yl)acetamide677

To a solution of4-[2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-yl]piperidine-1-carboxylicacid tert-butyl ester (390 mg, 0.71 mmol) in DCM (20 mL) and MeOH (5 mL)was added 4M HCl in dioxane (20 mL). The resulting mixture was allowedto stir for 4 h at r.t. before Et₂O (80 mL) was added. The resultingprecipitate was collected by filtration, washed with Et₂O and dried invacuo affording2-(2-Ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-8-piperidin-4-yl-9H-purinehydrochloride (322 mg, 93%). LCMS (method I): R_(T) 2.43 min [M+H]⁺447.2

A mixture of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-8-piperidin-4-yl-9H-purinehydrochloride (150 mg, 0.31 mmol), 2-bromoacetamide (45 mg, 0.33 mmol),sodium iodide (5 mg, 0.03 mmol) and K₂CO₃ (90 mg, 0.65 mmol) in MeCN (3mL) was heated to 50° C. for 2 h in a sealed tube. The reaction mixturewas diluted with EtOAc, filtered and concentrated in vacuo. Theresulting residue was purified by column chromatography (Si—PCC,MeOH:EtOAc, 0-30%) affording 677 (119 mg, 76%). LCMS (method I): R_(T)2.40 min, [M+H]⁺ 504.2. ¹H NMR (DMSO, 400 MHz): δ 8.02-7.98 (1H, m),7.64-7.63 (1H, m), 7.25-7.24 (4H, m), 4.27 (4H, brd s), 3.82-3.72 (7H,m), 3.35-3.30 (2H, m), 3.26 (2H, q, J=7.45 Hz), 3.11-2.90 (4H, m),2.38-2.31 (1H, m), 1.97 (4H, s), 1.33 (3H, t, J=7.44 Hz)

Example 678 tert-butyl3-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)azetidine-1-carboxylate678

To a suspension of zinc powder (190 mg, 2.91 mmol) and Celpure® P65 (60mg) in DMA (2 mL) was added a 7:5 (v:v) mixture of TMSCl:1,2-dibromoethane (38 μL) drop wise. The reaction mixture was stirred atroom temperature for 15 min. A solution of 3-iodoazetidine-1-carboxylicacid tert-butyl ester from Example 1 (651 mg, 2.30 mmol) in DMA (2 mL)was added drop wise to the mixture described above. The resultingmixture was stirred for 1 hour at room temperature.

A mixture of2-(2-ethylbenzoimidazol-1-yl)-8-iodo-9-methyl-6-morpholin-4-yl-9H-purinefrom Example 75 mm (750 mg, 1.53 mmol), Pd(dppf)₂Cl₂.DCM (125 mg, 0.15mmol) and CuI (38 mg, 0.20 mmol) in DMA (9 mL) was purged with argon.The zincate mixture was added to the reaction mixture via a PTFE filter,and the resulting reaction mixture was stirred at 85° C. for 24 h. Thereaction mixture was partitioned between EtOAc and H₂O. The organicphase was washed with H₂O (×3) and brine, then dried (Na₂SO₄) andconcentrated in vacuo. The resulting residue was purified by columnchromatography (Si—PCC, MeOH:DCM, 0-10% and MeOH:EtOAc, 0-5%) affording678 as a solid (350 mg, 44%). LCMS (method I): R_(T) 4.16 min, [M+H]⁺519.2. ¹H NMR (CDCl₃, 400 MHz): δ 8.00 (1H, d, J=7.15 Hz), 7.76 (1H, d,J=7.06 Hz), 7.32-7.23 (2H, m), 4.57-4.24 (8H, m), 4.00-3.99 (1H, m),3.88 (4H, t, J=4.68 Hz), 3.69 (3H, s), 3.35 (2H, q, J=7.47 Hz), 1.48(12H, s).

Example 679(R)-1-(3-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-1-yl)-2-hydroxypropan-1-one679

To a mixture of8-azetidin-3-ylmethyl-2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine(57 mg, 0.13 mmol), D-lactic acid (14 mg, 0.16 mmol) and DIPEA (27 μL,0.16 mmol) in DCM (2 mL) and DMF (1.5 mL) was added HATU (60 mg, 0.16mmol). The resulting yellow mixture was stirred for 2 h at r.t. thenpartitioned between DCM and H₂O. The combined organic phases were dried(Na₂SO₄) and concentrated in vacuo. The resulting residue was purifiedby column chromatography (Si—PCC, MeOH:EtOAc, 0-10%) followed byIsolute® SCX-2 cartridge which was washed with MeOH/DCM and the producteluted with 2M NH₃/MeOH affording 679 as a cream foam (23 mg, 35%).LCMS: R_(T) 2.92 min, [M+H]⁺ 505.2. ¹H NMR (CDCl₃, 400 MHz): δ 8.00-7.98(1H, m), 7.81-7.70 (1H, m), 7.26 (2H, s), 4.49-4.20 (7H, m), 3.91 (1H,dd, J=10.38, 5.67 Hz), 3.86 (5H, t, J=4.71 Hz), 3.76-3.75 (3H, m),3.36-3.35 (4H, m), 3.18-3.15 (2H, m), 1.44 (3H, t, J=7.46 Hz), 1.34 (3H,dd, J=6.68, 4.79 Hz)

Example 6804-(8-(azetidin-3-yl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine680

To a solution of3-[2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-yl]azetidine-1-carboxylicacid tert-butyl ester 678 (325 mg, 0.63 mmol) in DCM (4 mL) was addedTFA (2 mL). The resulting mixture was stirred for 2.5 h at r.t thenloaded onto an Isolute® SCX-2 cartridge which was washed with MeOH/DCMand the product eluted with 2M NH₃/MeOH. The resulting residue waspurified by column chromatography (Si—PCC, MeOH:DCM, 0-20%) affording680 as a cream foam (224 mg, 85%). LCMS (method I): R_(T) 2.30 min,[M+H]⁺ 419.1. ¹H NMR (CDCl₃, 400 MHz): δ 8.00-8.00 (1H, m), 7.75-7.74(1H, m), 7.26 (2H, s), 4.34-4.32 (7H, m), 3.89-3.88 (6H, m), 3.71-3.69(3H, m), 3.35-3.34 (2H, m), 1.44-1.43 (3H, m)

Example 6811-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-3-isopropylpiperazin-2-one681

To a solution of4-[2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl]-2-isopropyl-3-oxopiperazine-1-carboxylicacid tert-butyl ester (104 mg, 0.17 mmol) in DCM (3 mL) was added TFA (1mL) and the resulting mixture stirred for 2 h. The reaction mixture wasloaded onto an Isolute® SCX-2 cartridge which was washed with MeOH/DCMand the product eluted with 2M NH₃/MeOH. The resulting residue waspurified by column chromatography (Si—PCC, MeOH:DCM, 0-10%) affording681 as an off-white solid (55 mg, 67%). LCMS (method I): R_(T) 2.54 min,[M+H]⁺ 518.2. ¹H NMR (CDCl₃, 400 MHz): δ 8.00-8.00 (1H, m), 7.76-7.76(1H, m), 7.32-7.22 (2H, m), 4.95-4.79 (1H, m), 4.35 (4H, brd s),3.90-3.82 (7H, m), 3.47-3.45 (3H, m), 3.35 (2H, q, J=7.48 Hz), 3.23-3.22(1H, m), 3.02 (1H, ddd, J=12.50, 11.03, 3.93 Hz), 2.57-2.56 (1H, m),1.44 (3H, t, J=7.48 Hz), 1.21 (1H, t, J=7.02 Hz), 1.04 (3H, d, J=7.12Hz), 0.93 (3H, d, J=6.80 Hz)

Example 6874-(1-((2-(imidazo[1,2-a]pyridin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperidin-4-yl)morpholine687

A mixture of4-morpholin-4-yl-6-(4-morpholin-4-ylpiperidin-1-ylmethyl)-2-(tributylstannanyl)thieno[3,2-c]pyrimidine(69 mg, 0.10 mmol), 5-bromoimidazo[1,2-a]pyridine (24 mg, 0.12 mmol),Pd(PPh₃)₄(11 mg, 0.01 mmol) and copper(I) iodide (23 mg, 0.12 mmol) inTHF (1 mL) was purged with argon gas then heated at 140° C., for 20 min,in a microwave reactor. The reaction mixture was loaded onto an Isolute®SCX-2 cartridge (10 g). The cartridge was washed with MeOH then theproduct was eluted with 2 M NH₃ in MeOH. The appropriate fractions wereevaporated and the resulting residue was purified by flashchromatography (Si—PPC, MeOH:DCM, gradient 0:100 to 3:97) followed byreverse phase HPLC (Phenomenex Gemini 5u C18, 20 mM triethylamine inwater on a gradient of acetonitrile 70:30 to 2:98) to give 687 as awhite solid (22 mg, 42%). LCMS (Method F): R_(T) 3.90 min; [M+H]⁺ 520.¹H NMR (400 MHz, CHCl₃-d): δ 9.23 (s, 1H); 7.95 (dd, J=7.2, 1.2 Hz, 1H);7.77 (d, J=8.9 Hz, 1H); 7.75 (d, J=1.2 Hz, 1H); 7.35 (s, 1H); 7.31 (dd,J=8.9, 7.2 Hz, 1H); 4.07 (t, J=4.7 Hz, 4H); 3.91 (t, J=4.7 Hz, 4H); 3.84(s, 2H); 3.74 (t, J=4.4 Hz, 4H); 3.05 (d, J=11.4 Hz, 2H); 2.57 (t, J=4.4Hz, 4H); 2.29-2.19 (m, 1H); 2.15 (t, J=11.4 Hz, 2H); 1.87 (d, J=12.5 Hz,2H); 1.65-1.59 (m, 2H)

Example 6881-((2-(imidazo[1,2-a]pyridin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)-N,N-dimethylpiperidin-4-amine688

A mixture ofdimethyl-[1-(4-morpholin-4-yl-2-(tributylstannanyl)thieno[3,2-d]pyrimidin-6-ylmethyl)piperidin-4-yl]amine(156 mg, 0.24 mmol), 5-bromoimidazo[1,2-a]pyridine (56 mg, 0.29 mmol),Pd(PPh₃)₄ (28 mg, 0.02 mmol) and copper(I) iodide (55 mg, 0.29 mmol) inTHF (2.5 mL) was purged with argon gas then heated at 140° C., for 20min, in a microwave reactor. The reaction mixture was loaded onto anIsolute® SCX-2 cartridge (5 g), washed with MeOH then eluted with 2 MNH₃ in MeOH. The resulting residue was purified by flash chromatography(Si—PPC, MeOH:DCM, gradient 0:100 to 10:90) to give 688 as a white solid(72 mg, 63%). LCMS (Method F): R_(T) 3.89 min; [M+H]⁺ 478. ¹H NMR (400MHz, CHCl₃-d): δ 9.23 (s, 1H); 7.95 (dd, J=8.6, 1.3 Hz, 1H); 7.77 (d,J=8.6 Hz, 1H); 7.75 (d, J=1.3 Hz, 1H); 7.35 (s, 1H); 7.32-7.29 (m, 1H);4.07 (t, J=4.8 Hz, 4H); 3.91 (t, J=4.8 Hz, 4H); 3.84 (s, 2H); 3.04 (d,J=11.25 Hz, 2H); 2.33-2.25 (m, 6H); 2.21-2.10 (m, 3H); 1.84 (d, J=12.5Hz, 2H); 1.61 (m, 2H)

Example 6895-(6-((4-(dimethylamino)piperidin-1-yl)methyl)-4-morpholinothieno[3,2-d]pyrimidin-2-yl)imidazo[1,2-a]pyridin-8-ol689

A mixture ofdimethyl-[1-(4-morpholin-4-yl-2-(tributylstannanyl)thieno[3,2-d]pyrimidin-6-ylmethyl)piperidin-4-yl]amine(230 mg, 0.35 mmol), 8-benzyloxy-5-bromoimidazo[1,2-a]pyridine (127 mg,0.42 mmol), Pd(PPh₃)₄ (40 mg, 0.035 mmol) and copper(I) iodide (66 mg,0.35 mmol) in dioxane (3 mL) was purged with argon gas then heated at140° C., for 20 min, in a microwave reactor. The reaction mixture wasloaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was washedwith MeOH then the desired product was eluted with 2 M NH₃ in MeOH. Theappropriate fractions were combined and evaporated. The resultingresidue was purified by flash chromatography (Si—PPC, MeOH:DCM, gradient0:100 to 20:80) to give{1-[2-(8-Benzyloxyimidazo[1,2-a]pyridin-5-yl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl]piperidin-4-yl}dimethylamineas a white solid (189 mg, 92%). LCMS (Method H): R_(T) 3.07 min; [M+H]⁺584

A mixture of{1-[2-(8-benzyloxyimidazo[1,2-a]pyridin-5-yl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl]piperidin-4-yl}dimethylamine(381 mg, 0.65 mmol) in TFA was heated at 140° C., for 10 min, in amicrowave reactor. The reaction mixture was loaded onto an Isolute®SCX-2 cartridge (10 g). The cartridge was washed with MeOH then thedesired product was eluted with 2 M NH₃ in MeOH. The appropriatefractions were combined and evaporated. The resulting residue waspurified by reverse phase HPLC (Phenomenex Gemini 5u C18, 20 mMtriethylamine in water on a gradient of acetonitrile 95:5 to 2:98) togive 689 as a yellow solid (32 mg, 10%). LCMS (Method F) R_(T) 3.98 min;[M+H]⁺ 494. ¹H NMR (400 MHz, CH₃OH-d₄): δ 9.43 (d, J=1.6 Hz, 1H); 8.04(d, J=8.2 Hz, 1H); 7.65 (d, J=1.6 Hz, 1H); 7.34 (s, 1H); 6.71 (d, J=8.2Hz, 1H); 4.03 (t, J=4.7 Hz, 4H); 3.87 (m, 7H); 3.07 (d, J=11.5 Hz, 2H);2.37 (s, 6H); 2.34 (m, 1H); 2.16 (t, J=11.5 Hz, 2H); 1.91 (d, J=12.3 Hz,2H); 1.66-1.54 (m, 2H)

Example 6902-(4-((2-([1,2,4]triazolo[4,3-a]pyridin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-methylpropanamide690

A mixture of2-[4-(4-morpholin-4-yl-2-(tributylstannanyl)thieno[3,2-c]pyrimidin-6-ylmethyl)piperazin-1-yl]isobutyramide(150 mg, 0.22 mmol), 5-bromo-[1,2,4]triazolo[4,3-a]pyridine (51 mg, 0.26mmol),bis[di-tert-butyl(4-dimethylaminophenyl)phosphine]dichloropalladium (II)(15 mg, 0.02 mmol) and copper(I) iodide (41 mg, 0.22 mmol) in dioxane(2.5 mL) was purged with argon gas then heated at 150° C., for 20 min,in a microwave reactor. The reaction mixture was loaded onto an Isolute®SCX-2 cartridge (10 g). The cartridge was washed with MeOH then thedesired product was eluted with 2 M NH₃ in MeOH. The appropriatefractions were combined and evaporated. The resulting residue waspurified by flash chromatography (Si—PPC, MeOH:DCM, gradient 0:100 to10:90) followed by reverse phase HPLC (Phenomenex Gemini 5u C18, 20 mMtriethylamine in water on a gradient of acetonitrile 95:5 to 2:98) togive 690 as a white solid (14 mg, 12%). LCMS (Method F) R_(T) 5.50 min;[M+H]⁺ 522. ¹H NMR (400 MHz, CHCl₃-d): δ 10.53 (d, J=0.9 Hz, 1H); 8.08(dd, J=7.0, 0.9 Hz, 1H); 7.93 (d, J=9.1 Hz, 1H); 7.41 (dd, J=9.1, 7.0Hz, 1H); 7.38 (s, 1H); 7.08 (d, J=5.3 Hz, 1H); 5.20 (d, J=5.3 Hz, 1H);4.07 (t, J=4.8 Hz, 4H); 3.92 (t, J=4.8 Hz, 4H); 3.88 (s, 2H); 2.62 (m,8H); 1.25 (s, 6H)

Example 6912-(4-((2-(imidazo[1,2-a]pyridin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-methylpropanamide691

A mixture of2-[4-(7-methyl-4-morpholin-4-yl-2-(tributylstannanyl)thieno[3,2-c]pyrimidin-6-ylmethyl)piperazin-1-yl]isobutyramide(150 mg, 0.21 mmol), 5-bromoimidazo[1,2-a]pyridine (50 mg, 0.25 mmol),Pd(PPh₃)₄ (24 mg, 0.02 mmol) and copper(I) thiophene-2-carboxylate (8mg, 0.04 mmol) in dioxane (2 mL) was purged with argon gas then heatedat 150° C., for 20 min, in a microwave reactor. The reaction mixture wasloaded onto an Isolute® SCX-2 cartridge (10 g), washed with MeOH theneluted with 2 M NH₃ in MeOH. The resulting residue was purified by flashchromatography (Si—PPC, MeOH:DCM, gradient 0:100 to 100:0) followed byreverse phase HPLC (Phenomenex Gemini 5u C18, 20 mM triethylamine inwater on a gradient of acetonitrile 95:5 to 2:98) to give 691 as a whitesolid (30 mg, 26%). LCMS (Method E) R_(T) 5.27 min; [M+H]⁺ 535. ¹H NMR(400 MHz, CHCl₃-d): δ 9.45 (s, 1H); 8.09-8.05 (m, 1H); 7.80-7.76 (m,2H); 7.32 (dd, J=8.9, 7.19 Hz, 1H); 7.10 (d, J=5.3 Hz, 1H); 5.20 (d,J=5.3 Hz, 1H); 4.07 (t, J=4.7 Hz, 4H); 3.91 (t, J=4.7 Hz, 4H); 3.84 (s,2H); 2.61 (m, 8H); 2.51 (s, 3H); 1.25 (s, 6H)

Example 6922-(1-((9-methyl-2-(2-methylimidazo[1,2-a]pyridin-5-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol692

A mixture of2-[1-(9-methyl-6-morpholin-4-yl-2-(tributylstannanyl)-9H-purin-8-ylmethyl)-piperidin-4-yl]propan-2-ol(127 mg, 0.19 mmol), 5-bromo-2-methyl-imidazo[1,2-a]pyridine (48 mg,0.23 mmol), Pd(PPh₃)₄(22 mg, 0.02 mmol) and copper(I)thiophene-2-carboxylate (7 mg, 0.04 mmol) in dioxane (2 mL) was purgedwith argon gas then heated at 150° C., for 20 min, in a microwavereactor. The reaction mixture was loaded onto an Isolute® SCX-2cartridge (10 g). The cartridge was washed with MeOH then the desiredproduct eluted with 2 M NH₃ in MeOH. The resulting residue was purifiedby flash chromatography (Si—PPC, MeOH:DCM, gradient 0:100 to 0:100)followed by reverse phase HPLC (Phenomenex Gemini 5u C18, 20 mMtriethylamine in water on a gradient of acetonitrile 95:5 to 2:98) togive 692 as a pale yellow solid (30 mg, 31%). LCMS (Method E) R_(T) 4.77min; [M+H]⁺ 505. ¹H NMR (400 MHz, CHCl₃-d): δ 8.98 (s, 1H); 7.91 (dd,J=7.2, 1.2 Hz, 1H); 7.66 (d, J=8.8 Hz, 1H); 7.30-7.25 (m, 1H); 4.38 (s,4H); 3.96 (s, 3H); 3.89 (t, J=4.7 Hz, 4H); 3.75 (s, 2H); 2.96 (d, J=11.0Hz, 2H); 2.54 (s, 3H); 2.12 (t, J=11.0 Hz, 2H); 1.81-1.71 (m, 1H);1.45-1.23 (m, 4H); 1.19 (s, 6H)

Example 6932-methyl-2-(4-((2-(2-methylimidazo[1,2-a]pyridin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)propanamide693

A mixture of2-[4-(4-morpholin-4-yl-2-(tributylstannanyl)thieno[3,2-d]pyrimidin-6-ylmethyl)piperazin-1-yl]isobutyramide (150 mg, 0.21 mmol),5-bromo-2-methyl-imidazo[1,2-a]pyridine (55 mg, 0.26 mmol), Pd(PPh₃)₄(24 mg, 0.02 mmol) and copper(I) thiophene-2-carboxylate (8 mg, 0.04mmol) in dioxane (2 mL) was purged with argon gas then heated at 150°C., for 20 min, in a microwave reactor. The reaction mixture was loadedonto an Isolute® SCX-2 cartridge (10 g). The cartridge was washed withMeOH then the desired product eluted with 2 M NH₃ in MeOH. The resultingresidue was purified by flash chromatography (Si—PPC, MeOH:DCM, gradient0:100 to 10:90) followed by reverse phase HPLC (Phenomenex Gemini 5uC18, 20 mM triethylamine in water on a gradient of acetonitrile 95:5 to2:98) to give 693 as a white solid (55 mg, 47%). LCMS (Method E): R_(T)4.99 min; [M+H]⁺ 535. ¹H NMR (400 MHz, CHCl₃-d): δ 8.98 (s, 1H);7.92-7.89 (m, 1H); 7.68 (d, J=8.8 Hz, 1H); 7.39 (s, 1H); 7.27-7.23 (m,1H); 7.09 (d, J=5.3 Hz, 1H); 5.22 (d, J=5.3 Hz, 1H); 4.09-4.04 (m, 4H);3.94-3.87 (m, 4H); 3.87 (s, 2H); 2.62 (m, 8H); 2.54 (s, 3H); 1.29-1.23(m, 6H)

Example 6942-methyl-2-(4-((2-(7-methylimidazo[1,2-a]pyridin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)propanamide694

A mixture of2-[4-(4-morpholin-4-yl-2-(tributylstannanyl)thieno[3,2-c]pyrimidin-6-ylmethyl)piperazin-1-yl]isobutyramide(150 mg, 0.22 mmol), 5-bromo-7-methyl-imidazo[1,2-a]pyridine (55 mg,0.26 mmol), Pd(PPh₃)₄ (25 mg, 0.02 mmol) and copper(I)thiophene-2-carboxylate (8 mg, 0.04 mmol) in dioxane (2 mL) was purgedwith argon gas then heated at 150° C., for 20 min, in a microwavereactor. The reaction mixture was loaded onto an Isolute® SCX-2cartridge (10 g). The cartridge was washed with MeOH then the desiredproduct eluted with 2 M NH₃ in MeOH. The resulting residue was purifiedby flash chromatography (Si—PPC, MeOH:DCM, gradient 0:100 to 10:90)followed by reverse phase HPLC (Phenomenex Gemini 5u C18, 20 mMtriethylamine in water on a gradient of acetonitrile 95:5 to 2:98) togive 694 as a white solid (38 mg, 32%). LCMS (Method E): R_(T) 5.09 min;[M+H]⁺ 535. ¹H NMR (400 MHz, CHCl₃-d): δ 9.05 (s, 1H); 7.76 (d, J=1.5Hz, 1H); 7.66 (d, J=1.5 Hz, 1H); 7.55 (s, 1H); 7.37 (s, 1H); 7.09 (d,J=5.3 Hz, 1H); 5.22 (d, J=5.3 Hz, 1H); 4.10-4.04 (m, 4H); 3.93-3.88 (m,4H); 3.87 (s, 2H); 2.61 (m, 8H); 2.50 (s, 3H); 1.25 (s, 6H)

Example 6952-methyl-2-(4-((4-morpholino-2-(1H-pyrrolo[2,3-b]pyridin-4-yl)thieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)propanamide695

A mixture of2-[4-(4-morpholin-4-yl-2-(tributlystannanyl)thieno[3,2-c]pyrimidin-6-ylmethyl)piperazin-1-yl]isobutyramide(0.331 g, 0.48 mmol), 4-bromopyrrolo[2,3-b]pyridine-1-carboxylic acidtert-butylester (0.170 g, 0.573 mmol), Pd(Ph₃)₄ (55.1 mg, 0.048 mmol)and CuI (109 mg, 0.573 mmol) in toluene (8 mL) was purged with argon,then subjected to microwave irradiation at 140° C. for 20 min. Thereaction mixture was loaded onto an Isolute® SCX-2 cartridge. Thecartridge was washed with MeOH and the desired product was eluted using2 M NH₃ in MeOH. The residue was then dissolved in DCM/TFA (8 mL/8 mL)and the resulting solution stirred for 2 h at room temperature. Thereaction mixture was loaded onto an Isolute® SCX-2 cartridge. Thecartridge was washed with MeOH and the desired product was eluted using2 M NH₃ in MeOH. The residue was purified by column chromatography(Si—PPC, MeOH:DCM, gradient 0:100 to 5:95) followed by reverse phaseHPLC (Phenomenex Gemini 5u C18, 20 mM triethylamine in water on agradient of acetonitrile 70:30 to 40:60) to give 695 as a white powder(0.049 g, 20%). LCMS (Method F): R_(T) 5.07 min, [M+H]⁺ 521.3. ¹H NMR(CDCl₃, 400 MHz) δ 8.93 (s, 1H); 8.43 (d, J=5.2 Hz, 1H); 8.08 (d, J=5.2Hz, 1H); 7.43 (d, J=2.2 Hz, 2H); 7.38 (s, 1H); 7.09 (d, J=5.2 Hz, 1H);5.24 (d, J=5.2 Hz, 1H); 4.10 (t, J=4.7 Hz, 4H); 3.92 (t, J=4.7 Hz, 4H);3.86 (s, 2H); 2.65-2.58 (m, 4H); 1.60-1.55 (m, 4H); 1.24 (s, 6H)

Example 6962-methyl-2-(4-((7-methyl-4-morpholino-2-(1H-pyrrolo[2,3-b]pyridin-4-yl)thieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)propanamide696

A mixture of2-[4-(7-methyl-4-morpholin-4-yl-2-(tributylstannanyl)thieno[3,2-c]pyrimidin-6-ylmethyl)piperazin-1-yl]isobutyramide(200 mg, 0.28 mmol), 4-bromo-pyrrolo[2,3-b]pyridine-1-carboxylic acidtert-butylester (100 mg, 0.34 mmol), Pd(Ph₃)₄ (33 mg, 0.028 mmol) andCuI (65 mg, 0.34 mmol) in toluene (5 mL) was purged with argon, thensubjected to microwave irradiation at 140° C. for 30 min. The reactionmixture was loaded onto an Isolute® SCX-2 cartridge. The cartridge waswashed with MeOH and the desired product was eluted using 2 M NH₃ inMeOH. The residue was then dissolved in DCM/TFA (8 mL/8 mL) and stirredfor 2 h at room temperature. The reaction mixture was loaded onto anIsolute® SCX-2 cartridge. The cartridge was washed with MeOH and thedesired product was eluted using 2 M NH₃ in MeOH. The residue waspurified by column chromatography (Si—PPC, MeOH:DCM, gradient 0:100 to05:95) to give 696 as a white powder (0.036 g, 24%). LCMS (Method F):R_(T) 5.68 min, [M+H]⁺ 535.2. ¹H NMR (CDCl₃, 400 MHz) δ 9.42-8.74 (m,1H); 8.59-7.95 (m, 1H); 7.92-7.49 (m, 1H); 7.46-7.35 (m, 2H); 7.14-7.06(m, 1H); 5.27 (s, 1H); 4.09 (t, J=4.2 Hz, 4H); 3.92 (t, J=4.2 Hz, 4H);3.85 (s, 2H); 2.66-2.61 (m, 4H); 2.53 (s, 3H); 1.63-1.58 (m, 4H); 1.26(s, 6H)

Example 6972-(4-((2-(imidazo[1,2-a]pyridin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-methylpropanamide697

A mixture of2-[4-(4-morpholin-4-yl-2-(tributylstannanyl)thieno[3,2-c]pyrimidin-6-ylmethyl)piperazin-1-yl]isobutyramide(0.35 g, 0.51 mmol), 5-bromoimidazo[1,2-a]pyridine (0.11 g, 0.56 mmol),copper(I) 2-thiophene carboxylate (0.019 g, 0.1 mmol) and Pd(PPh₃)₄(0.059 g, 0.05 mmol) in dioxane (5 mL) was subjected to microwaveirradiation at 140° C. for 20 min. The reaction mixture was loaded ontoan Isolute® SCX-2 cartridge. The cartridge was washed with MeOH and thedesired product was eluted using 2 M NH₃ in MeOH. The eluent wasconcentrated in vacuo and the residue was purified by flashchromatography (Si—PPC, MeOH:DCM, gradient 0:100 to 10:90). The residuewas loaded onto an Isolute® SCX-2 cartridge. The cartridge was washedwith MeOH and the desired product was eluted using 2 M NH₃ in MeOH. Thesolution was concentrated in vacuo and the residue was purified byreverse phase HPLC (Phenomenex Gemini 5u C18, 20 mM triethylamine inwater on a gradient of acetonitrile 75:25 to 2:98) to give 697 as awhite powder (0.117 g, 45%). LCMS: R_(T)=4.35 min, [M+H]⁺ 521.2. ¹H NMR(400 MHz, DMSO-d₆): δ 9.33 (d, J=1.1 Hz, 1H); 8.04 (dd, J=7.5, 1.2 Hz,1H); 7.78 (dd, J=8.9, 1.1 Hz, 1H); 7.74 (d, J=1.2 Hz, 1H); 7.54 (s, 1H);7.41 (dd, J=8.9, 7.5 Hz, 1H); 7.07 (d, J=3.5 Hz, 1H); 6.95 (d, J=3.5 Hz,1H); 4.00 (t, J=4.7 Hz, 4H); 3.89 (s, 2H); 3.82 (t, J=4.7 Hz, 4H);2.56-2.54 (m, 4H); 2.49-2.44 (m, 4H); 1.08 (s, 6H)

Example 6982-(1-((2-(imidazo[1,2-a]pyridin-5-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol698

A mixture of2-[1-(9-methyl-6-morpholin-4-yl-2-(tributylstannanyl)-9H-purin-8-ylmethyl)piperidin-4-yl]propan-2-ol(0.2 g, 0.30 mmol), 5-bromoimidazo[1,2-a]pyridine (0.066 g, 0.33 mmol),copper(I) 2-thiophene carboxylate (0.018 g, 0.09 mmol) and Pd(PPh₃)₄(0.052 g, 0.045 mmol) in dioxane (5 mL) was subjected to microwaveirradiation at 150° C. for 60 min. The reaction mixture was loaded ontoan Isolute® SCX-2 cartridge. The cartridge was washed with MeOH and thedesired product was eluted using 2 M NH₃ in MeOH. The eluent wasconcentrated in vacuo and the resultant residue was purified by flashchromatography (Si—PPC, MeOH:DCM, gradient 0:100 to 94:6) followed byreverse phase HPLC (Phenomenex Gemini 5u C18, 20 mM triethylamine inwater on a gradient of acetonitrile 95:5 to 2:98) to give 698 as ayellow powder (0.085 g, 58%). LCMS: R_(T)=4.17 min, [M+H]⁺ 491.2. ¹H NMR(CDCl₃, 400 MHz) δ 9.26 (d, J=1.2 Hz, 1H); 7.96 (dd, J=8.2, 1.2 Hz, 1H);7.76-7.73 (m, 2H); 7.31 (dd, J=8.2, 5.2 Hz, 1H); 4.38 (t, J=4.6 Hz, 4H);3.96 (s, 3H); 3.89 (t, J=4.6 Hz, 4H); 3.75 (s, 2H); 2.96 (d, J=11.0 Hz,2H); 2.11 (t, J=11.0 Hz, 2H); 1.76 (d, J=11.0 Hz, 2H); 1.44-1.29 (m,3H); 1.18 (s, 6H)

Example 6992-(1-((5-(imidazo[1,2-a]pyridin-5-yl)-7-morpholinothiazolo[5,4-d]pyrimidin-2-yl)methyl)piperidin-4-yl)propan-2-ol699

A mixture of2-[1-(5-imidazo[1,2-a]pyridin-5-yl-7-morpholin-4-ylthiazolo[5,4-d]pyrimidin-2-ylmethyl)piperidin-4-yl]propan-2-ol(0.25 g, 0.37 mmol), 5-bromoimidazo[1,2-a]pyridine (0.082 g, 0.41 mmol),copper(I) 2-thiophene carboxylate (0.015 g, 0.075 mmol) and Pd(PPh₃)₄(0.044 g, 0.037 mmol) in dioxane (3 mL) was subjected to microwaveirradiation at 150° C. for 60 min. The reaction mixture was loaded ontoan Isolute® SCX-2 cartridge. The cartridge was washed with MeOH and thedesired product was eluted using 2 M NH₃ in MeOH. The eluent wasconcentrated in vacuo and the residue was purified by flashchromatography (Si—PPC, MeOH:DCM, gradient 0:100 to 90:10) followed byreverse phase HPLC (Phenomenex Gemini 5u C18, 20 mM triethylamine inwater on a gradient of acetonitrile 95:5 to 2:98) to give 699 as ayellow powder (0.052 g, 28%). LCMS (Method E): R_(T)=4.38 min, [M+H]⁺494.2. ¹H NMR (CDCl₃, 400 MHz) δ 9.19 (s, 1H); 7.99 (dd, J=7.2, 1.3 Hz,1H); 7.81 (d, J=8.9 Hz, 1H); 7.76 (d, J=1.3 Hz, 1H); 7.33 (dd, J=8.9,7.2 Hz, 1H); 4.48-4.35 (m, 4H); 3.92-3.85 (m, 7H); 3.10 (d, J=11.2 Hz,2H); 2.23 (t, J=11.2 Hz, 2H); 1.83-1.77 (m, 2H); 1.54-1.41 (m, 2H);1.38-1.29 (m, 1H); 1.22 (s, 6H)

Example 7004-(5-(imidazo[1,2-a]pyridin-5-yl)-2-((3-morpholinoazetidin-1-yl)methyl)thiazolo[5,4-d]pyrimidin-7-yl)morpholine700

A mixture of7-morpholin-4-yl-2-(3-morpholin-4-ylazetidin-1-ylmethyl)-5-(tributylstannanyl)thiazolo[5,4-c]pyrimidine(0.25 g, 0.37 mmol), 5-bromoimidazo[1,2-a]pyridine (0.082 g, 0.41 mmol),copper(I) 2-thiophene carboxylate (0.015 g, 0.075 mmol) and Pd(PPh₃)₄(0.044 g, 0.037 mmol) in dioxane (3 mL) was subjected to microwaveirradiation at 150° C. for 60 min. The reaction mixture was loaded ontoan Isolute® SCX-2 cartridge. The cartridge was washed with MeOH and thedesired product was eluted using 2 M NH₃ in MeOH. The eluent wasconcentrated in vacuo and the residue was purified by flashchromatography (Si—PPC, MeOH:DCM, 0:100 to 10:90) followed by reversephase HPLC (Phenomenex Gemini 5u C18, 20 mM triethylamine in water on agradient of acetonitrile 95:5 to 2:98) to give 700 as a yellow solid(0.101 g, 55%). LCMS (Method E): R_(T)=3.98 min, [M+H]⁺ 493.15. ¹H NMR(CDCl₃, 400 MHz) δ 9.16 (s, 1H); 7.98 (dd, J=7.2, 1.2 Hz, 1H); 7.81 (d,J=8.9 Hz, 1H); 7.76 (d, J=1.2 Hz, 1H); 7.33 (dd, J=8.9, 7.2 Hz, 1H);4.47-4.32 (m, 4H); 4.04 (s, 2H); 3.89 (t, J=4.6 Hz, 4H); 3.74 (t, J=4.6Hz, 4H); 3.69 (t, J=6.4 Hz, 2H); 3.23-3.15 (m, 2H); 3.14 (t, J=6.4 Hz,1H); 2.40-2.36 (m, 4H)

Example 7032-(4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)piperidin-1-yl)-2-methylpropanamide703

To a solution of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-8-piperidin-4-yl-9H-purinehydrochloride (396 mg, 0.89 mmol) in THF (3 mL) and H₂O (4 mL) was added1M HCl to give pH 4 followed by NaCN (261 mg, 5.32 mmol) andpropan-2-one (590 μL, 7.98 mmol). The resulting mixture was allowed tostir at r.t. for 16 h then partitioned between H₂O and DCM. The organicphase was dried (phase separator) and concentrated in vacuo. Theresulting residue was triturated with Et₂O and the solid collected byfiltration and dried in vacuo affording2-{4-[2-(2-Ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-yl]piperidin-1-yl}-2-methylpropionitrile(316 mg, 69%). LCMS (method H): R_(T) 2.64 min, [M+H]⁺ 514.4

2-{4-[2-(2-Ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-yl]piperidin-1-yl}-2-methylpropionitrile(300 mg, 0.58 mmol) was added slowly to conc. H₂SO₄ (3.5 mL). Theresulting mixture was allowed to stir at r.t. for 3 h then poured ontoice and basified with K₂CO₃. The resulting mixture was extracted withDCM and the combined organic phases dried (Na₂SO₄) and concentrated invacuo. The resulting residue was purified by column chromatography(Si—PCC, MeOH:EtOAc, 0-20%) then loaded onto an Isolute® SCX-2 cartridgewhich was washed with MeOH and the product eluted with 2M NH₃/MeOHaffording 703 (177 mg, 57%). LCMS (method I): R_(T) 2.45 min, [M+H]⁺532.3. ¹H NMR (DMSO, 400 MHz): δ 8.01-7.97 (1H, m), 7.63-7.62 (1H, m),7.23-7.22 (3H, m), 6.93 (1H, d, J=3.36 Hz), 4.26 (4H, brd s), 3.79-3.74(7H, m), 3.26 (2H, q, J=7.42 Hz), 3.07-2.97 (1H, m), 2.88 (2H, d,J=10.76 Hz), 2.32-2.21 (2H, m), 1.93-1.91 (4H, m), 1.33 (3H, t, J=7.44Hz), 1.12 (6H, s)

Example 7111-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-4-isopropylpiperazin-2-one711

To a solution 4-isopropylpiperazin-2-one (56 mg, 0.35 mmol) in DMF (3mL) at 0° C. was added sodium hydride (18 mg, 0.45 mmol, 60% dispersionin mineral oil) and the resulting mixture stirred for 30 min before theaddition of a solution of8-bromomethyl-2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine(200 mg, 0.44 mmol) in DMF (2 mL). The resulting mixture was stirred atr.t. for 72 h, then partitioned between DCM and H₂O. The organic phasewas dried (Na₂SO₄) and concentrated in vacuo. The resulting residue waspurified by column chromatography (Si—PCC, MeOH:EtOAc, 0-20%) followedby reverse phase HPLC (Phenomenex Gemini 5 μm C18, 20 mM triethylaminein water on a gradient acetonitrile 30-70%) affording 711 as a whitesolid (22 mg, 15%). LCMS: R_(T) 2.43 min, [M+H]⁺ 518.2. ¹H NMR (DMSO,400 MHz): δ 8.01-8.01 (1H, m), 7.63-7.62 (1H, m), 7.25-7.24 (2H, m),4.83 (2H, s), 4.26 (4H, brd s), 3.77 (4H, t, J=4.61 Hz), 3.74 (3H, s),3.31 (2H, m), 3.26 (2H, q, J=7.45 Hz), 3.15 (2H, s), 2.69-2.68 (3H, m),1.33 (3H, t, J=7.44 Hz), 0.98 (6H, d, J=6.50 Hz)

Example 7122-(5-(2-ethyl-1H-benzo[d]imidazol-1-yl)-7-morpholinothiazolo[5,4-d]pyrimidin-2-yl)-1-(4-(1-hydroxy-2-methylpropan-2-yl)piperazin-1-yl)ethanone712

A mixture of2-(5-chloro-7-morpholin-4-ylthiazolo[5,4-c]pyrimidin-2-yl)-1-[4-(2-hydroxy-1,1-dimethylethyl)piperazin-1-yl]ethanone(65 mg, 0.14 mmol), 2-ethylbenzimidazole (23 mg, 0.16 mmol),tris(dibenzylideneacetone)dipalladium (4 mg, 2.5 mol %), XPhos (7 mg, 10mol %) and Cs₂CO₃ (70 mg, 0.21 mmol) in dioxane (2 mL) was purged withargon then heated at 110° C. for 24 h in a sealed tube. The reactionmixture was loaded onto an Isolute® SCX-2 cartridge which was washedwith MeOH and the product eluted with 2M NH₃/MeOH/DCM. The resultingresidue was purified by column chromatography (Si—PCC, MeOH:DCM, 0-10%)followed by reverse phase HPLC (Phenomenex Gemini 5 μm C18, 20 nM NEt₃in water on a gradient acetonitrile 10-95%) affording 712 as a yellowsolid (14 mg, 17%). LCMS (method I): R_(T) 2.58 min, [M+H]⁺ 565.2. ¹HNMR (CDCl₃, 400 MHz): δ 8.01-7.98 (1H, m), 7.76-7.75 (1H, m), 7.29-7.29(2H, m), 4.41 (4H, s), 4.18 (2H, s), 3.93-3.75 (9H, m), 3.56 (2H, brds), 3.34 (2H, q, J=7.47 Hz), 2.90-2.70 (4H, brd m), 1.43 (3H, t, J=7.47Hz), 1.23-1.21 (6H, m)

Example 7134-(2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-8-(3-methoxy-1-(2-(methylsulfonyl)ethyl)piperidin-3-yl)-9-methyl-9H-purin-6-yl)morpholine713

To a mixture of 2-chloro-9-methyl-6-morpholin-4-yl-9H-purine (3.5 g,13.8 mmol) and TMEDA (3.1 mL, 20.7 mmol) in THF (100 mL) at −78° C. wasadded n-BuLi (8.3 mL, 2.5 M in hexanes, 20.7 mmol). The resultingmixture was allowed to warm to −30° C. over 45 min then cooled back to−78° C. before the addition of a solution of3-oxo-piperidine-1-carboxylic acid tert-butyl ester (4.1 g, 20.7 mmol)in THF (10 mL). The reaction mixture was warmed to r.t. and stirred for2 h then quenched with H₂O and extracted with EtOAc. The combinedorganic phases were washed with brine, dried (Na₂SO₄) and concentratedin vacuo. The resulting residue was triturated with Et₂O and unreactedstarting material removed by filtration. The resulting residue waspurified by column chromatography (Si—PCC, EtOAc:cyclohexane, 30-80%)then triturated with cyclohexane affording3-(2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)-3-hydroxypiperidine-1-carboxylicacid tert-butyl ester (5.0 g, 81%). LCMS (method A): R_(T) 3.50 min[M+H]⁺ 453.3

To a solution of3-(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)-3-hydroxypiperidine-1-carboxylicacid tert-butyl ester (4.54 g, 10.02 mmol) in THF (100 mL) was added NaH(481 mg, 12.02 mmol, 60% dispersion in mineral oil) and the mixtureallowed to stir for 5 min before the addition of iodomethane (750 μL,12.02 mmol) and 15-Crown-5 (10 drops). The resulting mixture was allowedto stir for 2.5 h then concentrated in vacuo. The resulting residue waspartitioned between EtOAc and H₂O and the aqueous layer furtherextracted with 2-methyl THF. The combined organic phases were dried(Na₂SO₄) and concentrated in vacuo affording3-(2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)-3-methoxypiperidine-1-carboxylicacid tert-butyl ester (4.30 g, 92%). LCMS (method A): R_(T) 4.05 min,[M+H]⁺ 467.2

A mixture of3-(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)-3-methoxypiperidine-1-carboxylicacid tert-butyl ester (3.0 g, 6.42 mmol), 2-isopropylbenzimidazole (1.24g, 7.71 mmol), tris(dibenzylideneacetone)dipalladium (150 mg, 0.16mmol), XPhos (306 mg, 0.64 mmol) and Cs₂CO₃ (3.14 g, 9.64 mmol) indioxane (50 mL) was purged with argon then heated at 110° C. for 16 h.The reaction mixture was partitioned between EtOAc and H₂O, the organicphase washed with brine then dried (Na₂SO₄) and concentrated in vacuo.The resulting residue was purified by column chromatography (Si—PCC,EtOAc:cyclohexane, 30-70%) affording3-[2-(2-Isopropylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-yl]-3-methoxypiperidine-1-carboxylicacid tert-butyl ester (2.47 g, 65%). LCMS (method A): R_(T) 3.52 min,[M+H]⁺ 591.5

To a solution of3-[2-(2-isopropylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-yl]-3-methoxypiperidine-1-carboxylicacid tert-butyl ester (2.47 g, 4.18 mmol) in DCM (100 mL) was added 4MHCl in dioxane (10 mL). The resulting mixture was allowed to stir for 2h at r.t. before further 1.25M HCl in MeOH (20 mL) was added. Theresulting mixture was allowed to stir for 1.5 h then concentrated invacuo. The resulting residue was loaded onto an Isolute® SCX-2 cartridgewhich was washed with MeOH and the product eluted with 2M NH₃/MeOHaffording2-(2-Isopropylbenzoimidazol-1-yl)-8-(3-methoxypiperidin-3-yl)-9-methyl-6-morpholin-4-yl-9H-purine(1.83 g, 89%). LCMS (method H): R_(T) 2.12 min [M+H]⁺ 491.4

A mixture of2-(2-isopropylbenzoimidazol-1-yl)-8-(3-methoxypiperidin-3-yl)-9-methyl-6-morpholin-4-yl-9H-purine(150 mg, 0.31 mmol) and methanesulfonylethene (32 μL, 0.37 mmol) in IMS(5 mL) was allowed to stir for 4 h at room temp. before pouring thereaction mixture into H₂O. The resulting precipitate was collected byfiltration and dried under vacuum affording 713 (141 mg, 77%). LCMS(method I): R_(T) 2.82 min, [M+H]⁺ 597.2. ¹H NMR (DMSO, 400 MHz): δ7.92-7.91 (1H, m), 7.65-7.64 (1H, m), 7.24-7.23 (2H, m), 4.25 (4H, brds), 4.00-3.85 (4H, m), 3.8-3.75 (4H, m), 3.40-3.20 (2H, m), 3.15-3.00(4H, m), 2.95 (3H, s), 2.81-2.76 (4H, m), 2.30-2.20 (1H, m), 2.10-2.95(2H, m), 1.84-1.74 (2H, m), 1.36 (6H, dd, J=6.77, 2.96 Hz)

Example 714 tert-butyl3-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-3-methoxyazetidine-1-carboxylate714

To a solution of3-[2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-yl]-3-hydroxyazetidine-1-carboxylicacid tert-butyl ester (208 mg, 0.39 mmol) in THF (3 mL) was added NaH(19 mg, 0.47 mmol, 60% dispersion in mineral oil) and the mixtureallowed to stir for 5 min before the addition of iodomethane (29 μL, 66mg, 0.47 mmol). The resulting mixture was allowed to stir for 3.5 hbefore further iodomethane (29 μL, 66 mg, 0.47 mmol) was added. Themixture was stirred for 16 h then concentrated in vacuo. The resultingresidue was partitioned between EtOAc and H₂O. The organic phase wasdried (Na₂SO₄) and concentrated in vacuo. The resulting residue waspurified by column chromatography (Si—PCC, EtOAc:cyclohexane, 40-80%)affording 714 as an oil (123 mg, 57%). LCMS (method I): R_(T) 4.49 min,[M+H]⁺ 549.2. ¹H NMR (CDCl₃, 400 MHz): δ 7.99-7.90 (1H, m), 7.74-7.64(1H, m), 7.25-7.16 (2H, m), 4.60-4.40 (4H, brd m), 4.18 (2H, d, J=9.17Hz), 3.82-3.81 (6H, m), 3.71 (3H, s), 3.29 (2H, t, J=7.54 Hz), 3.07 (3H,s), 1.42-1.33 (12H, m).

Example 715(2,2-dimethyl-4-(methylsulfonyl)piperazin-1-yl)(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methanone715

To a mixture of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carboxylicacid (117 mg, 0.26 mmol), 1-methanesulfonyl-3,3-dimethylpiperazine (51mg, 0.26 mmol) and HATU (100 mg, 0.26 mmol) in DMF (1 mL) was added NEt₃(720 μL, 5.18 mmol). The resulting mixture was allowed to stir at r.t.for 16 h then partitioned between EtOAc and H₂O. The organic phase wasdried (MgSO₄) and concentrated in vacuo and the resulting residue waspurified by column chromatography (Si—PCC, MeOH:EtOAc, 0-5%). Theresulting solid was recrystallised from EtOAc and Et₂O affording 715 (50mg, 33%). LCMS (method I): R_(T) 3.68 min, [M+H]⁺ 582.2. ¹H NMR (CDCl₃,400 MHz): δ 8.03-8.03 (1H, m), 7.76-7.75 (1H, m), 7.31-7.27 (2H, m),4.35 (4H, brd s), 4.03 (2H, t, J=5.39 Hz), 3.95 (3H, s), 3.87 (4H, t,J=4.70 Hz), 3.50 (2H, t, J=5.40 Hz), 3.37 (2H, q, J=7.47 Hz), 3.31 (2H,s), 2.90 (3H, s), 1.68 (6H, s), 1.45 (3H, t, J=7.47 Hz)

Example 7162-(3-(2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-3-methoxypiperidin-1-yl)acetamide716

A mixture of2-(2-isopropylbenzoimidazol-1-yl)-8-(3-methoxypiperidin-3-yl)-9-methyl-6-morpholin-4-yl-9H-purinefrom Example 713 (1.0 g, 2.10 mmol), 2-bromoacetamide (290 mg, 2.10mmol), sodium iodide (32 mg, 0.21 mmol) and K₂CO₃ (610 mg, 4.41 mmol) inMeCN (20 mL) was stirred at r.t. for 66 h. The reaction mixture wasdiluted with EtOAc, filtered and concentrated in vacuo. The resultingresidue was purified by column chromatography (Si—PCC, MeOH:EtOAc,0-20%) then triturated with Et₂O affording 716 (675 mg, 59%). LCMS(method I): R_(T) 2.66 min, [M+H]⁺ 548.2. ¹H NMR (DMSO, 400 MHz): δ7.93-7.92 (1H, m), 7.66-7.62 (1H, m), 7.26-7.22 (2H, m), 7.14 (1H, s),7.07 (1H, s), 4.26 (4H, brd s), 3.98-3.88 (4H, m), 3.80-3.75 (4H, m),3.10-3.00 (4H, m), 3.00-2.90 (3H, m), 2.70-2.60 (1H, m), 2.45-2.35 (1H,m), 2.15-1.95 (2H, m), 1.95-1.77 (1H, m), 1.78-1.68 (1H, m), 1.37-1.37(6H, m)

Example 7172-(4-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-3,3-dimethylpiperazin-1-yl)acetamide717

A mixture of8-(2,2-dimethylpiperazin-1-ylmethyl)-2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine(120 mg, 0.25 mmol), 2-chloroacetamide (50 mg, 0.54 mmol) and NEt₃ (50μL, 0.36 mmol) in DCM (5 mL) was allowed to stir at r.t. for 5 h beforefurther 2-chloroacetamide (100 mg, 1.07 mmol) and NEt₃ (100 μL, 0.72mmol) was added. The resulting mixture was allowed to stir for 84 h thenloaded onto an Isolute® SCX-2 cartridge which was washed with MeOH andthe product eluted with 2M NH₃/MeOH. The resulting residue was purifiedby column chromatography (Si—PCC, MeOH:EtOAc, 0-5%) affording 717 (65mg, 49%). LCMS (method I): R_(T) 2.54 min, [M+H]⁺ 547.2. ¹H NMR (CDCl₃,400 MHz): δ 8.02-7.99 (1H, m), 7.77-7.74 (1H, m), 7.32-7.22 (2H, m),6.95 (1H, brd s), 5.43 (1H, brd s), 4.34 (4H, brd s), 3.90 (3H, s), 3.86(6H, t, J=4.76 Hz), 3.35 (2H, q, J=7.48 Hz), 2.96 (2H, s), 2.62-2.45(4H, m), 2.38 (2H, s), 1.45 (3H, t, J=7.48 Hz), 1.25 (6H, s)

Example 718(S)-1-(3-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-1-yl)-2-hydroxypropan-1-one718

To a mixture of8-azetidin-3-ylmethyl-2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine(100 mg, 0.23 mmol), L-lactic acid (23 mg, 0.25 mmol) and DIPEA (45 μL,0.25 mmol) in DCM (2 mL) was added HATU (96 mg, 0.25 mmol). Theresulting yellow mixture was stirred for 2.5 h at r.t. then partitionedbetween DCM and H₂O. The combined organic phases were dried (Na₂SO₄) andconcentrated in vacuo. The resulting oil was loaded onto an Isolute®SCX-2 cartridge which was washed with MeOH/DCM and the product elutedwith 2M NH₃/MeOH. The resulting residue was purified by columnchromatography (Si—PCC, MeOH:EtOAc, 0-10%) followed by reverse phaseHPLC (Phenomenex Gemini 5 μm C18, 0.1% HCO₂H in water on a gradientacetonitrile 20-35%) affording 718 as a white solid (19 mg, 16%). LCMS(method I): R_(T) 2.92 min, [M+H]⁺ 505.2. ¹H NMR (CDCl₃, 400 MHz): δ7.98-7.97 (1H, m), 7.90-7.80 (1H, m), 7.40-7.30 (2H, m), 4.33-4.32 (7H,m), 4.01-4.00 (1H, m), 3.86-3.85 (5H, m), 3.77 (3H, d, J=1.96 Hz),3.50-3.35 (4H, m), 3.19-3.17 (2H, m), 1.48 (3H, t, J=7.42 Hz), 1.34 (3H,dd, J=6.69, 4.73 Hz)

Example 7203-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-1-(tetrahydro-2H-pyran-4-yl)azetidin-3-ol720

A mixture of3-[2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-yl]-azetidin-3-ol(490 mg, 1.13 mmol), tetrahydropyran-4-one (158 mg, 1.58 mmol), AcOH(130 μL, 2.25 mmol) and 4 Å powdered molecular sieves (640 mg) in DCE(15 mL) was allowed to stir for 5 min before the addition of sodiumtriacetoxyborohydride (478 mg, 2.25 mmol) portion wise over 5 min. Theresulting mixture was allowed to stir for 4 h at r.t before the additionof further tetrahydropyran-4-one (158 mg, 1.58 mmol) and sodiumtriacetoxyborohydride (478 mg, 2.25 mmol). The mixture was stirred for 2h then diluted with DCM and washed with 1M NaOH. The organic phase wasdried (phase separator) and concentrated in vacuo. The resulting oil waspurified by column chromatography (Si—PCC, 2M NH₃/MeOH:DCM, 0-15%) then(C18, MeOH:H₂O, 7.5-25%). The resulting residue was loaded onto anIsolute® SCX-2 cartridge which was washed with DCM and MeOH and theproduct eluted with 2M NH₃/MeOH affording 720 as a white foam (309 mg,53%). LCMS (method I): R_(T) 2.40 min, [M+H]⁺ 519.3. ¹H NMR (MeOD, 400MHz): δ 8.01-8.00 (1H, m), 7.66-7.61 (1H, m), 7.28-7.27 (2H, m), 4.38(4H, s), 4.24 (2H, d, J=8.76 Hz), 3.97-3.94 (2H, m), 3.85 (7H, s), 3.56(2H, d, J=8.75 Hz), 3.31-3.31 (5H, m), 2.54-2.52 (1H, m), 1.83-1.73 (2H,m), 1.38 (5H, t, J=7.49 Hz)

Example 7211-(3-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-1-yl)-2-hydroxy-2-methylpropan-1-one721

To a mixture of8-azetidin-3-ylmethyl-2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine(60 mg, 0.14 mmol), 2-hydroxyisobutyric acid (17 mg, 0.17 mmol) andDIPEA (29 μL, 0.17 mmol) in DCM (1 mL) was added HATU (63 mg, 0.17mmol). The resulting yellow mixture was stirred for 1.5 h at r.t. thenthe reaction mixture was loaded onto an Isolute® SCX-2 cartridge whichwas washed with DCM and MeOH and the product eluted with 2M NH₃/MeOH.The resulting residue was purified by column chromatography (Si—PCC,MeOH:EtOAc, 0-6%) affording 721 as a foam (41 mg, 56%). LCMS (method I):R_(T) 3.00 min, [M+H]⁺ 519.2. ¹H NMR (CDCl₃, 400 MHz): δ 8.00-7.97 (1H,m), 7.75-7.74 (1H, m), 7.27-7.25 (2H, m), 4.62 (1H, s), 4.33 (5H, s),4.20 (1H, s), 3.93 (1H, s), 3.86 (4H, t, J=4.72 Hz), 3.76 (3H, s), 3.64(1H, s), 3.34 (3H, q, J=7.44 Hz), 3.15-3.14 (2H, m), 1.43-1.42 (9H, m)

Example 722(R)-1-(4-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-3,3-dimethylpiperazin-1-yl)-2-hydroxypropan-1-one722

A mixture of8-(2,2-dimethylpiperazin-1-ylmethyl)-2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine(100 mg, 0.20 mmol), D-Lactic acid (20 mg, 0.22 mmol), HATU (85 mg, 0.22mmol) and DIPEA (40 μL, 0.23 mmol) in DCM (2 mL) was allowed to stir atr.t. for 16 h. The reaction mixture was loaded onto an Isolute® SCX-2cartridge which was washed with MeOH and the product eluted with 2MNH₃/MeOH. The resulting residue was purified by column chromatography(Si—PCC, MeOH:DCM, 2%) affording 722 as a white solid (37 mg, 33%). LCMS(method I): R_(T) 2.90 min, [M+H]⁺ 562.2. ¹H NMR (CDCl₃, 400 MHz): δ8.04-7.99 (1H, m), 7.77-7.76 (1H, m), 7.35-7.25 (2H, m), 4.47-4.45 (1H,m), 4.34 (4H, brd s), 4.02-3.98 (1H, m), 3.91 (3H, s), 3.86 (4H, t,J=4.67 Hz), 3.82-3.68 (2H, m), 3.50-3.49 (1H, m), 3.40-3.31 (3H, m),3.27-3.16 (1H, m), 2.57-2.55 (2H, m), 1.45 (3H, t, J=7.47 Hz), 1.39-1.28(4H, m), 1.27-1.15 (5H, m)

Example 723(S)-1-(4-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-3,3-dimethylpiperazin-1-yl)-2-hydroxypropan-1-one723

A mixture of8-(2,2-dimethylpiperazin-1-ylmethyl)-2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine(100 mg, 0.20 mmol), L-Lactic acid (17 μL, 0.22 mmol), HATU (85 mg, 0.22mmol) and DIPEA (40 μL, 0.23 mmol) in DCM (2 mL) was allowed to stir atr.t. for 16 h. The reaction mixture was loaded onto an Isolute® SCX-2cartridge which was washed with MeOH and the product eluted with 2MNH₃/MeOH. The resulting residue was purified by column chromatography(Si—PCC, MeOH:DCM, 2%) affording 723 as a white solid (27 mg, 29%). LCMS(method I): R_(T) 2.90 min, [M+H]⁺ 562.3. ¹H NMR (CDCl₃, 400 MHz): δ8.02-8.00 (1H, m), 7.78-7.74 (1H, m), 7.35-7.25 (2H, s), 4.46-4.43 (1H,m), 4.34 (4H, brd s), 4.06-3.94 (1H, m), 3.91 (3H, s), 3.86 (4H, t,J=4.68 Hz), 3.76-3.75 (2H, m), 3.50-3.48 (1H, m), 3.37-3.35 (3H, m),3.24-3.22 (1H, m), 2.59-2.53 (2H, m), 1.45 (3H, t, J=7.48 Hz), 1.34-1.30(4H, m), 1.26-1.15 (5H, m)

Example 7374-(8-(((2R,6S)-2,6-dimethyl-4-(methylsulfonyl)piperazin-1-yl)methyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine737

A mixture of8-bromomethyl-2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purinehydrobromide (200 mg, 0.37 mmol),(3S,5R)-1-methanesulfonyl-3,5-dimethylpiperazine (88 mg, 0.46 mmol) andK₂CO₃ (150 mg, 1.09 mmol) in DMF (1 mL) was allowed to stir at r.t. for24 h. The reaction mixture was partitioned between EtOAc and H₂O, theorganic phase dried (MgSO₄) and concentrated in vacuo. The resultingresidue was purified by column chromatography (Si—PCC, MeOH:EtOAc,0-10%) followed by recrystallisation from EtOAc affording 737 (57 mg,28%). LCMS (method I): R_(T) 3.05 min, [M+H]⁺ 568.2. ¹H NMR (CDCl₃, 400MHz): δ 8.02-7.98 (1H, m), 7.76-7.75 (1H, m), 7.26-7.25 (2H, m), 4.34(4H, s), 4.18 (2H, s), 3.87 (4H, t, J=4.70 Hz), 3.84 (3H, s), 3.54-3.51(2H, m), 3.35 (2H, q, J=7.48 Hz), 3.29-3.23 (2H, m), 2.80 (3H, s),2.68-2.66 (2H, m), 1.45 (3H, dd, J=7.69, 7.26 Hz), 1.17 (6H, d, J=6.36Hz)

Example 7383-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-1-isopropylazetidin-3-ol738

To a mixture of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine (2.5g, 6.88 mmol) and TMEDA (1.6 mL, 10.33 mmol) in THF (40 mL) at −78° C.was added n-BuLi (4.1 mL, 2.5 M in hexanes, 10.33 mmol). The resultingmixture was allowed to warm to −40° C. over 30 min then cooled back to−78° C. before the addition of a solution of 3-oxoazetidine-1-carboxylicacid tert-butyl ester (1.8 g, 10.33 mmol) in THF (10 mL). The reactionmixture was warmed to −10° C. over 2 h then quenched with sat, aq. NH₄Cland extracted with EtOAc. The combined organic phases were washed withbrine, dried (Na₂SO₄) and concentrated in vacuo. The resulting residuewas purified by column chromatography (Si—PCC, MeOH:EtOAc, 0-5%) thenrecrystallised from ^(i)PrOAc and pentane affording3-[2-(2-Ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-yl]-3-hydroxy-azetidine-1-carboxylicacid tert-butyl ester as a cream solid (2.4 g, 64%). LCMS (method A):R_(T) 2.83 min [M+H]⁺ 535.4

To a solution of3-[2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-yl]-3-hydroxyazetidine-1-carboxylicacid tert-butyl ester (620 mg, 1.16 mmol) in DCM (5 mL) was added TFA (2mL) and the resulting mixture allowed to stir for 1.5 h at r.t. Thereaction mixture was loaded onto an Isolute® SCX-2 cartridge which waswashed with DCM and MeOH and the product eluted with 2M NH₃/MeOHaffording3-[2-(2-Ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-yl]azetidine-3-olas a yellow oil (450 mg, 89%). LCMS: (method A): R_(T) 1.84 min [M+H]⁺435.2

A mixture of3-[2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-yl]-azetidin-3-ol(100 mg, 0.23 mmol), propan-2-one (34 μL, 27 mg, 0.46 mmol) and 4 Åpowdered molecular sieves (150 mg) in DCE (3 mL) was stirred for 3 hbefore sodium triacetoxyborohydride (96 mg, 0.46 mmol) was added. Theresulting mixture was stirred for 16 h at r.t., then filtered throughCelite®, washing with DCM. The filtrate was washed with brine, dried(Na₂SO₄) and concentrated in vacuo. The resulting residue was purifiedby column chromatography (Si—PCC, MeOH:EtOAc, 0-20%) followed by reversephase HPLC (Phenomenex Gemini 5 μm C18, 20 mM triethylamine in water ona gradient of acetonitrile 50-70%) affording 738 as a white solid (15mg, 13%). LCMS (method I): R_(T) 2.43 min, [M+H]⁺ 477.2. ¹H NMR (MeOD,400 MHz): δ 8.01-8.01 (1H, m), 7.64-7.61 (1H, m), 7.29-7.28 (2H, m),4.39 (5H, s), 4.19-4.17 (2H, m), 3.85 (4H, s), 3.46 (2H, d, J=8.87 Hz),3.31-3.30 (5H, m), 2.56-2.54 (1H, m), 1.39 (3H, t, J=7.50 Hz), 1.01 (6H,d, J=6.25 Hz)

Example 7394-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-8-(1-isopropyl-3-methoxyazetidin-3-yl)-9-methyl-9H-purin-6-yl)morpholine739

To a solution of3-[2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-yl]-3-methoxyazetidine-1-carboxylicacid tert-butyl ester (109 mg, 0.20 mmol) in DCM (2 mL) was added TFA (1mL) and the resulting mixture allowed to stir for 1.5 h at r.t. Thereaction mixture was loaded onto an Isolute® SCX-2 cartridge which waswashed with DCM and MeOH and the product eluted with 2M NH₃/MeOHaffording2-(2-Ethylbenzoimidazol-1-yl)-8-(3-methoxyazetidin-3-yl)-9-methyl-6-morpholin-4-yl-9H-purineas an oil (72 mg, 80%). LCMS: (method A): R_(T) 1.86 min [M+H]⁺ 449.2

To a solution of2-(2-ethylbenzoimidazol-1-yl)-8-(3-methoxyazetidin-3-yl)-9-methyl-6-morpholin-4-yl-9H-purine(553 mg, 1.23 mmol) and propan-2-one (1.0 mL) in MeOH (20 mL) was added10% Pd/C (30 mg) as a slurry in MeOH (0.5 mL) and the resulting mixturestirred under an atmosphere of H₂ for 1.5 h at r.t. The reaction mixturewas filtered through Celite®, washing with MeOH, and the filtrateconcentrated in vacuo. The resulting residue was purified by columnchromatography (Si—PCC, 2M NH₃/MeOH:EtOAc, 0-12%) then (C18, MeOH:H₂O,5-25%). The resulting residue was loaded onto an Isolute® SCX-2cartridge which was washed with DCM and MeOH and the product eluted with2M NH₃/MeOH. The resulting colourless foam was recrystallised from^(i)PrOAc and pentane affording 739 as colourless crystals (166 mg,28%). LCMS (method I): R_(T) 2.48 min, [M+H]⁺ 491.3. ¹H NMR (CDCl₃, 400MHz): δ 8.03-8.02 (1H, m), 7.64-7.63 (1H, m), 7.29-7.28 (2H, m), 4.40(4H, s), 4.05 (2H, d, J=8.89 Hz), 3.86 (4H, s), 3.81 (3H, s), 3.57-3.55(2H, m), 3.31-3.30 (2H, m), 3.10 (3H, s), 2.54-2.53 (1H, m), 1.40 (3H,t, J=7.50 Hz), 1.02 (6H, d, J=6.24 Hz)

Example 7404-(8-((2,2-dimethyl-4-(oxetan-3-yl)piperazin-1-yl)methyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine740

A mixture of2-chloro-8-(2,2-dimethyl-4-oxetan-3-ylpiperazin-1-ylmethyl)-9-methyl-6-morpholin-4-yl-9H-purine(90 mg, 0.21 mmol), 2-ethylbenzimidazole (32 mg, 0.22 mmol),tris(dibenzylideneacetone)dipalladium (5 mg, 2.5 mol %), XPhos (9 mg, 10mol %) and Cs₂CO₃ (95 mg, 0.29 mmol) in dioxane (1 mL) was purged withargon then heated at 150° C. for 1 h in a microwave reactor. Thereaction mixture was loaded onto an Isolute® SCX-2 cartridge which waswashed with MeOH and the product eluted with 2M NH₃/MeOH. The resultingresidue was purified by column chromatography (Si—PCC, MeOH:DCM, 1-3%)followed by reverse phase HPLC (Phenomenex Gemini 5 μm C18, 20 mMtriethylamine in water on a gradient of acetonitrile 5-98%) affording740 (54 mg, 48%). LCMS (method I): R_(T) 2.62 min [M+H]⁺ 546.2. ¹H NMR(CDCl₃, 400 MHz): δ 8.01-8.01 (1H, m), 7.75-7.74 (1H, m), 7.31-7.22 (2H,m), 4.64 (2H, t, J=6.47 Hz), 4.57 (2H, t, J=6.07 Hz), 4.34 (4H, brd s),3.90 (3H, s), 3.86 (6H, t, J=4.78 Hz), 3.36-3.35 (3H, m), 2.52 (2H, s),2.24 (2H, s), 2.11 (2H, s), 1.45 (3H, t, J=7.48 Hz), 1.24 (6H, s)

Example 7411-(4-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-3,3-dimethylpiperazin-1-yl)-2-hydroxy-2-methylpropan-1-one741

A mixture of8-(2,2-dimethylpiperazin-1-ylmethyl)-2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine(100 mg, 0.20 mmol), 2-hydroxyisobutyric acid (24 mg, 0.23 mmol), HATU(85 mg, 0.22 mmol) and DIPEA (40 μL, 0.23 mmol) in DCM (2 mL) wasallowed to stir at r.t. for 17 h. The reaction mixture was loaded ontoan Isolute® SCX-2 cartridge which was washed with MeOH and the producteluted with 2M NH₃/MeOH. The resulting residue was purified by columnchromatography (Si—PCC, MeOH:DCM, 0-3%) affording 741 as a white solid(55 mg, 46%). LCMS (method I): R_(T) 2.89 min, [M+H]⁺ 576.3. ¹H NMR(CDCl₃, 400 MHz): δ 8.02-8.02 (1H, m), 7.76-7.75 (1H, m), 7.33-7.22 (2H,m), 4.40-4.20 (5H, m), 3.92 (3H, s), 3.88-3.83 (5H, m), 3.63 (2H, s),3.53 (2H, s), 3.36 (2H, q, J=7.48 Hz), 2.59-2.53 (2H, m), 1.50 (6H, s),1.45 (3H, t, J=7.48 Hz), 1.23 (6H, s)

Example 7444-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-8-((7-(oxetan-3-yl)-4,7-diazaspiro[2.5]octan-4-yl)methyl)-9H-purin-6-yl)morpholine744

A mixture of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde(183 mg, 0.47 mmol), 7-oxetan-3-yl-4,7-diazaspiro[2.5]octane (90 mg,0.54 mmol) and 4 Å powdered molecular sieves (1.0 g) in DCE (10 mL) wasallowed to stir at r.t. for 6 h before the addition of sodiumtriacetoxyborohydride (144 mg, 0.68 mmol). The resulting mixture wasallowed to stir for 16 h then loaded onto an Isolute® SCX-2 cartridgewhich was washed with MeOH and the product eluted with 2M NH₃/MeOH. Theresulting residue was purified by column chromatography (Si—PCC,MeOH:EtOAc, 5% then MeOH:DCM, 1-5%) followed by recrystallisation fromEt₂O affording 744 (156 mg, 61%). LCMS (method I): R_(T) 2.53 min [M+H]⁺544.2. ¹H NMR (DMSO, 400 MHz): δ 8.00-7.99 (1H, m), 7.65-7.61 (1H, m),7.24-7.23 (2H, m), 4.53 (2H, t, J=6.46 Hz), 4.42 (2H, t, J=6.05 Hz),4.24 (4H, brd s), 4.07 (2H, s), 3.77 (4H, t, J=4.61 Hz), 3.73 (3H, s),3.50-3.42 (1H, m), 3.26 (2H, q, J=7.44 Hz), 2.85-2.75 (2H, m), 2.32 (2H,t, J=4.72 Hz), 2.17 (2H, brd s), 1.33 (3H, t, J=7.44 Hz), 0.72-0.65 (2H,m), 0.52-0.51 (2H, m)

Example 7463-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-1-(2-hydroxy-2-methylpropyl)piperidin-3-ol746

A mixture of3-(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)-3-hydroxypiperidine-1-carboxylicacid tert-butyl ester (3.0 g, 6.62 mmol), 2-ethylbenzimidazole (1.16 g,7.94 mmol), tris(dibenzylideneacetone)dipalladium (152 mg, 0.17 mmol),XPhos (316 mg, 0.66 mmol) and K₃PO₄ (2.81 g, 13.24 mmol) in dioxane (80mL) was purged with N₂ then heated at 90° C. for 22 h before furthertris(dibenzylideneacetone)dipalladium (152 mg, 0.17 mmol) and XPhos (316mg, 0.66 mmol) were added. The resulting mixture was heated at 100° C.for 65 h then diluted with 2-methyl THF and filtered through a silicaplug. The filtrate was washed with H₂O and brine, then dried (Na₂SO₄)and concentrated in vacuo. The resulting residue was purified by columnchromatography (Si—PCC, EtOAc:cyclohexane, 20-85%) affording3-[2-(2-Ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-yl]-3-hydroxypiperidine-1-carboxylicacid tert-butyl ester (3.15 g, 85%). LCMS (method H): R_(T) 2.87 min,[M+H]⁺ 563.5

To a solution of3-[2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-yl]-3-hydroxypiperidine-1-carboxylicacid tert-butyl ester (1.0 g, 1.78 mmol) in DCM (5 mL) and MeOH (1 mL)was added 4M HCl in dioxane (5 mL). The resulting mixture was allowed tostir for 2 h at r.t. before Et₂O was added. The resulting precipitatewas collected by filtration, washed with Et₂O and dried in vacuoaffording3-[2-(2-Ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-yl]piperidin-3-oldihydrochloride (870 mg, 92%). LCMS (method H): R_(T) 1.84 min [M+H]⁺463.3

A mixture of3-[2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-yl]piperidin-3-oldihydrochloride (150 mg, 0.28 mmol), 2,2-dimethyloxirane (100 μL, 1.12mmol) and DIPEA (192 μL, 1.12 mmol) in MeCN (4 mL) was stirred at r.t.for 20 h then heated at 70° C. for 24 h. The reaction mixture wasconcentrated in vacuo and the resulting residue purified by reversephase HPLC (Phenomenex Gemini 5 μm C18, 0.1% HCO₂H in water on agradient acetonitrile 5-30%) affording 746 (35 mg, 23%). LCMS (methodI): R_(T) 2.57 min, [M+H]⁺ 535.2. ¹H NMR (DMSO, 400 MHz): δ 8.03-7.98(1H, m), 7.65-7.61 (1H, m), 7.28-7.21 (2H, m), 5.46 (1H, s), 4.45-4.05(5H, m), 3.96 (3H, s), 3.77-3.76 (4H, m), 3.30-3.22 (2H, m), 3.07-2.99(1H, m), 2.91-2.83 (1H, m), 2.70-2.60 (1H, m), 2.45-2.35 (1H, m), 2.26(2H, s), 2.15-2.00 (1H, m), 1.96-1.69 (3H, m), 1.32 (3H, t, J=7.43 Hz),1.01 (6H, d, J=15.78 Hz)

Example 7474-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-8-(1-(tetrahydro-2H-pyran-4-yl)azetidin-3-yl)-9H-purin-6-yl)morpholine747

A mixture of4-(8-(azetidin-3-yl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine680 (100 mg, 0.24 mmol), tetrahydropyran-4-one (34 mg, 0.33 mmol) and 4Å powdered molecular sieves (130 mg) in DCE (3 mL) was stirred for 5.5 hbefore the addition of sodium triacetoxyborohydride (101 mg, 0.48 mmol).The resulting mixture was allowed to stir for 16 h at r.t, then filteredthrough Celite®, washing with DCM. The filtrate was washed with brine,dried (Na₂SO₄) and concentrated in vacuo. The resulting residue waspurified by column chromatography (Si—PCC, MeOH:EtOAc, 0-30%) followedby Isolute® SCX-2 cartridge which was washed with MeOH/DCM and theproduct eluted with 2M NH₃/MeOH. The resulting solid was triturated withEtOAc affording 747 as a white powder (37 mg, 31%). LCMS (method I):R_(T) 2.46 min, [M+H]⁺ 503.1. ¹H NMR (CDCl₃, 400 MHz): δ 8.01-7.97 (1H,m), 7.75-7.74 (1H, m), 7.26 (2H, s), 4.37 (4H, s), 4.02-3.80 (9H, m),3.70 (3H, s), 3.51-3.37 (4H, m), 3.34 (2H, q, J=7.48 Hz), 2.41-2.33 (1H,m), 1.77-1.66 (3H, m), 1.43 (4H, t, J=7.47 Hz)

Example 748N-(2-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)ethyl)-N,3-dimethyl-1,1-dioxotetrahydrothiophen-3-amine748

A mixture of[2-(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)ethyl]methyl-(3-methyl-1,1-dioxotetrahydrothiophen-3-yl)amine(87 mg, 0.20 mmol), 2-ethylbenzimidazole (32 mg, 0.22 mmol),tris(dibenzylideneacetone)dipalladium (5 mg, 2.5 mol %), XPhos (9 mg, 10mol %) and Cs₂CO₃ (96 mg, 0.30 mmol) in dioxane (2 mL) was purged withargon then heated at 110° C. for 20 h in a sealed tube. The reactionmixture was loaded onto an Isolute® SCX-2 cartridge which was washedwith MeOH and the product eluted with 2M NH₃/MeOH/DCM. The resultingresidue was purified by column chromatography (Si—PCC, MeOH:DCM, 0-5%)affording 748 as an off-white solid (60 mg, 55%). LCMS (method I): R_(T)2.63 min, [M+H]⁺ 553.1. ¹H NMR (CDCl₃, 400 MHz): δ 8.01-7.98 (1H, m),7.75-7.74 (1H, m), 7.30-7.23 (2H, m), 4.34 (4H, brd s), 3.87 (4H, t,J=4.78 Hz), 3.78 (3H, s), 3.37-3.30 (3H, m), 3.01-3.00 (7H, m),2.40-2.30 (4H, m), 2.08-2.08 (1H, m), 1.44 (3H, t, J=7.48 Hz), 1.29 (3H,s)

Example 7653-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-1-(methylsulfonyl)piperidin-3-ol765

A mixture of3-[2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-yl]piperidin-3-oldihydrochloride from Example 746 (150 mg, 0.28 mmol) and DIPEA (192 μL,1.12 mmol) in THF (3 mL) was stirred for 5 min before the addition ofmethanesulfonyl chloride (22 μL, 0.28 mmol). The resulting mixture wasstirred at r.t. for 4 h then partitioned between H₂O and DCM. Theorganic phase was washed with brine, then dried (Na₂SO₄) andconcentrated in vacuo. The resulting residue was purified by columnchromatography (Si—PCC, MeOH:EtOAc, 0-20%) affording 765 (67 mg, 44%).LCMS (method I): R_(T) 3.30 min, [M+H]⁺ 541.2. ¹H NMR (DMSO, 400 MHz): δ8.02-8.01 (1H, m), 7.64-7.64 (1H, m), 7.25-7.24 (2H, m), 6.05 (1H, s),4.26 (4H, brd s), 3.96 (3H, s), 3.78 (4H, t, J=4.60 Hz), 3.61 (2H, s),3.44-3.41 (1H, m), 3.28-3.26 (2H, m), 3.06-3.03 (1H, m), 2.95 (3H, s),2.17-2.14 (1H, m), 2.09-1.92 (2H, m), 1.80-1.70 (1H, m), 1.33 (3H, t,J=7.43 Hz)

Example 7664-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-8-(3-methoxy-1-(methylsulfonyl)piperidin-3-yl)-9-methyl-9H-purin-6-yl)morpholine766

To a solution of3-[2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-yl]-3-hydroxypiperidine-1-carboxylicacid tert-butyl ester (1.0 g, 1.78 mmol) in THF (20 mL) was added NaH(86 mg, 2.14 mmol, 60% dispersion in mineral oil) and the resultingmixture allowed to stir for 5 min before the addition of iodomethane(135 μL, 2.14 mmol) and 15-Crown-5 (4 drops). The resulting mixture wasstirred for 3 h before further NaH (86 mg, 2.14 mmol) and iodomethane(135 μL, 2.14 mmol) were added. The resulting mixture was allowed tostir for 8 days then partitioned between 2-methyl THF and H₂O. Theorganic phase was washed with sat. aq. NaHCO₃ and brine, then dried(Na₂SO₄) and concentrated in vacuo affording3-[2-(2-Ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-yl]-3-methoxypiperidine-1-carboxylicacid tert-butyl ester. LCMS (method H): R_(T) 3.28 min [M+H]⁺ 577.5

To a solution of3-[2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-yl]-3-methoxypiperidine-1-carboxylicacid tert-butyl ester in DCM (10 mL) and MeOH (10 mL) was added 4M HClin dioxane (10 mL). The resulting mixture was allowed to stir at r.t.for 16 h then concentrated in vacuo. The resulting residue wastriturated with Et₂O, the solid collected by filtration and dried invacuo affording2-(2-Ethylbenzoimidazol-1-yl)-8-(3-methoxypiperidin-3-yl)-9-methyl-6-morpholin-4-yl-9H-purinedihydrochloride (1.0 g, quant.). LCMS (method H): R_(T) 2.05 min [M+H]⁺477.2

A mixture of2-(2-ethylbenzoimidazol-1-yl)-8-(3-methoxypiperidin-3-yl)-9-methyl-6-morpholin-4-yl-9H-purinedihydrochloride (150 mg, 0.27 mmol) and DIPEA (190 μL, 1.09 mmol) in THF(3 mL) was stirred for 5 min before the addition of methanesulfonylchloride (21 μL, 0.27 mmol). The resulting mixture was stirred at r.t.for 4 h then partitioned between H₂O and DCM. The organic phase waswashed with brine, then dried (Na₂SO₄) and concentrated in vacuo. Theresulting residue was purified by column chromatography (Si—PCC,EtOAc:TBME, 0-100%) affording 766 (39 mg, 26%). LCMS (method I): R_(T)3.74 min, [M+H]⁺ 555.2. ¹H NMR (DMSO, 400 MHz): δ 8.05-8.04 (1H, m),7.64-7.63 (1H, m), 7.28-7.24 (2H, m), 4.27 (4H, brd s), 3.97 (1H, d,J=13.24 Hz), 3.92 (3H, s), 3.79 (4H, t, J=4.61 Hz), 3.50-3.47 (2H, m),3.28-3.26 (2H, m), 3.08 (3H, s), 3.05-2.95 (4H, m), 2.35-2.25 (1H, m),1.98-1.95 (2H, m), 1.76-1.72 (1H, m), 1.35 (3H, t, J=7.43 Hz)

Example 771(5-(2-ethyl-1H-benzo[d]imidazol-1-yl)-7-morpholinothiazolo[5,4-d]pyrimidin-2-yl)(4-(2-hydroxypropan-2-yl)piperidin-1-yl)methanone771

A mixture of(5-chloro-7-morpholin-4-ylthiazolo[5,4-d]pyrimidin-2-yl)-[4-(1-hydroxy-1-methylethyl)piperidin-1-yl]methanone(250 mg, 0.59 mmol), 2-ethylbenzimidazole (90 mg, 0.62 mmol),tris(dibenzylideneacetone)dipalladium (15 mg, 2.5 mol %), XPhos (25 mg,10 mol %) and Cs₂CO₃ (270 mg, 0.83 mmol) in DMF (6 mL) was purged withargon then heated at 150° C. for 30 min in a microwave reactor. Thereaction mixture was purified by column chromatography (Si—PCC,MeOH:DCM, 1-5%) followed by recrystallisation from Et₂O and EtOAcaffording 771 (109 mg, 35%). LCMS (method I): R_(T) 3.96 min [M+H]⁺536.3. ¹H NMR (CDCl₃, 400 MHz): δ 8.06-8.05 (1H, m), 7.76-7.75 (1H, m),7.32-7.28 (2H, m), 5.22 (1H, d, J=13.34 Hz), 4.84 (1H, d, J=13.16 Hz),4.41 (4H, brd s), 3.89 (4H, t, J=4.74 Hz), 3.37 (2H, q, J=7.46 Hz),3.17-3.15 (1H, m), 2.84-2.82 (1H, m), 1.94 (2H, t, J=13.72 Hz),1.72-1.62 (1H, m), 1.49-1.40 (5H, m), 1.23 (6H, d, J=7.01 Hz)

Example 7723-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-1-(tetrahydro-2H-pyran-4-yl)piperidin-3-ol772

A mixture of3-[2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-yl]piperidin-3-oldihydrochloride from Example 746 (150 mg, 0.28 mmol),tetrahydropyran-2-one (39 μL, 0.42 mmol), NEt₃ (78 μL, 0.56 mmol) and 4Å powdered molecular sieves (300 mg) in DCE (3 mL) was stirred for 2 hbefore the addition of sodium triacetoxyborohydride (119 mg, 0.56 mmol).The resulting mixture was allowed to stir at r.t for 20 h then dilutedwith DCM and filtered. The filtrate was concentrated in vacuo and theresidue was purified by column chromatography (Si—PCC, MeOH:EtOAc,0-20%). The resulting residue was dissolved in DCM and treated with 4MHCl in dioxane. The resulting solid was triturated with Et₂O and driedin vacuo affording 772 (124 mg, 72%). LCMS (method I): R_(T) 2.52 min,[M+H]⁺ 547.2. ¹H NMR (DMSO, 400 MHz): δ 9.36 (1H, s), 8.18-8.14 (1H, m),7.80-7.79 (1H, m), 7.50-7.48 (2H, m), 4.28 (4H, brd s), 4.10-3.90 (6H,m), 3.78-3.77 (5H, m), 3.43-3.39 (7H, m), 3.25-3.10 (1H, m), 2.30-1.65(7H, m), 1.44-1.38 (3H, m)

Example 775(S)-2-(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-(3-methylmorpholino)-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol775

A mixture of2-{1-[2-chloro-9-methyl-6-((S)-3-methylmorpholin-4-yl)-9H-purin-8-ylmethyl]piperidin-4-yl}propan-2-ol(200 mg, 0.47 mmol), 2-ethylbenzimidazole (73 mg, 0.50 mmol),tris(dibenzylideneacetone)dipalladium (12 mg, 2.5 mol %), XPhos (20 mg,10 mol %) and Cs₂CO₃ (218 mg, 0.67 mmol) in DMF (6 mL) was purged withargon then heated at 150° C. for 1 h in a microwave reactor. Thereaction mixture was loaded onto an Isolute® SCX-2 cartridge which waswashed with MeOH and the product eluted with 2M NH₃/MeOH. The resultingresidue was purified by column chromatography (Si—PCC, MeOH:DCM, 0-5%)then (Si—PCC, MeOH:DCM, 0-3%) affording 775 (95 mg, 38%). LCMS (methodI): R_(T) 2.65 min, [M+H]⁺ 533.3. ¹H NMR (CDCl₃, 400 MHz): δ 8.03-8.02(1H, m), 7.75-7.74 (1H, m), 7.27-7.24 (2H, m), 5.40 (2H, brd s),4.09-4.03 (1H, m), 3.88 (3H, s), 3.83 (2H, s), 3.75-3.55 (4H, m), 3.36(2H, q, J=7.48 Hz), 2.98-2.95 (2H, m), 2.11 (2H, t, J=10.92 Hz),1.81-1.71 (2H, m), 1.45-1.44 (6H, m), 1.34-1.31 (4H, m), 1.19 (6H, s)

Example 780(1-aminocyclopropyl)(4-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-3,3-dimethylpiperazin-1-yl)methanone780

To a solution of(1-{-4-[2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl]-3,3-dimethylpiperazine-1-carbonyl}cyclopropyl)carbamicacid tert-butyl ester in DCM (3 mL) was added TFA (2 mL) and theresulting mixture stirred at r.t. for 30 min then loaded onto anIsolute® SCX-2 cartridge which was washed with MeOH and the producteluted with 2M NH₃/MeOH. The resulting residue was purified by columnchromatography (Si—PCC, MeOH:DCM, 0-10%) affording 780 as a white foam(99 mg, 60%). LCMS (method I): R_(T) 2.67 min, [M+H]⁺ 573.3. ¹H NMR(CDCl₃, 400 MHz): δ 8.02-8.01 (1H, m), 7.76-7.75 (1H, m), 7.32-7.22 (2H,m), 4.34 (4H, s), 3.93 (3H, s), 3.88-3.86 (6H, m), 3.65 (2H, s), 3.48(2H, s), 3.36 (2H, q, J=7.48 Hz), 2.57 (2H, t, J=5.16 Hz), 1.85-1.75(2H, brd s), 1.45 (3H, t, J=7.46 Hz), 1.23 (6H, s), 1.05-0.99 (2H, m),0.81-0.80 (2H, m)

Example 781(R)-2-(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-(3-methylmorpholino)-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol781

A mixture of2-{1-[2-chloro-9-methyl-6-((R)-3-methylmorpholin-4-yl)-9H-purin-8-ylmethyl]piperidin-4-yl}propan-2-ol(120 mg, 0.28 mmol), 2-ethylbenzimidazole (46 mg, 0.31 mmol),tris(dibenzylideneacetone)dipalladium (7 mg, 2.5 mol %), XPhos (14 mg,10 mol %) and Cs₂CO₃ (139 mg, 0.43 mmol) in dioxane (3 mL) was purgedwith argon then heated at 110° C. for 4 h in a sealed tube. The reactionmixture was loaded onto an Isolute® SCX-2 cartridge which was washedwith MeOH and the product eluted with 2M NH₃/MeOH/DCM. The resultingresidue was purified by column chromatography (Si—PCC, MeOH:EtOAc,0-20%) followed by (Si—PCC, MeOH:DCM, 0-10%) affording 781 as a whitesolid (65 mg, 43%). LCMS (method I): R_(T) 2.64 min, [M+H]⁺ 533.3. ¹HNMR (CDCl₃, 400 MHz): δ 8.03-8.02 (1H, m), 7.76-7.75 (1H, m), 7.30-7.25(2H, m), 4.06-4.05 (1H, m), 3.88 (3H, s), 3.83 (2H, s), 3.73 (2H, s),3.70-3.55 (2H, m), 3.36 (2H, q, J=7.48 Hz), 2.99-2.96 (2H, m), 2.16-2.06(2H, m), 1.81-1.71 (2H, m), 1.58 (2H, brd s), 1.48-1.42 (6H, m),1.43-1.27 (3H, m), 1.19 (6H, s)

Example 7901-(4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-4-hydroxypiperidin-1-yl)-2-hydroxy-2-methylpropan-1-one790

To a mixture of 2-chloro-9-methyl-6-morpholin-4-yl-9H-purine (2.5 g,9.86 mmol) and TMEDA (2.1 mL, 14.8 mmol) in THF (80 mL) at −78° C. wasadded n-BuLi (6 mL, 2.5 M in hexanes, 14.8 mmol). The resulting mixturewas allowed to warm to −30° C. for 30 min then cooled back to −78° C.before the addition of a solution of 4-oxo-piperidine-1-carboxylic acidtert-butyl ester (2.9 g, 14.8 mmol) in THF (20 mL). The reaction mixturewas slowly warmed to r.t. and stirred for 16 h then quenched with H₂Oand extracted with EtOAc. The combined organic phases were washed withbrine, dried (Na₂SO₄) and concentrated in vacuo. The resulting residuewas purified by column chromatography (Si—PCC, EtOAc:cyclohexane,10-75%) affording4-(2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)-4-hydroxypiperidine-1-carboxylicacid tert-butyl ester (3.2 g, 71%). LCMS (method H): R_(T) 3.52 min[M+H]⁺ 453.3

A mixture of4-(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)-4-hydroxypiperidine-1-carboxylicacid tert-butyl ester (2.5 g, 5.52 mmol), 2-ethylbenzimidazole (968 mg,6.62 mmol), tris(dibenzylideneacetone)dipalladium (126 mg, 0.14 mmol),XPhos (263 mg, 0.55 mmol) and K₃PO₄ (2.34 g, 11.04 mmol) in dioxane (50mL) was purged with N₂ then heated at 100° C. for 6 h before furthertris(dibenzylideneacetone)dipalladium (126 mg, 0.14 mmol) and XPhos (263mg, 0.55 mmol) were added. The resulting mixture was heated at 100° C.for 18 h then diluted with 2-methyl THF and filtered through Celite®.The filtrate was washed with H₂O and brine, then dried (Na₂SO₄) andconcentrated in vacuo. The resulting residue was purified by columnchromatography (Si—PCC, EtOAc:cyclohexane, 40-100%) affording4-[2-(2-Ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-yl]-4-hydroxypiperidine-1-carboxylicacid tert-butyl ester (2.6 g, 84%). LCMS (method H): R_(T) 2.99 min,[M+H]⁺ 563.4

To a solution of4-[2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-yl]-4-hydroxypiperidine-1-carboxylicacid tert-butyl ester (1.3 g, 2.31 mmol) in DCM (10 mL) was added TFA (2mL) and the resulting mixture allowed to stir at r.t. for 3 h. Thereaction mixture was concentrated in vacuo and the resulting residueloaded onto an Isolute® SCX-2 cartridge which was washed with MeOH andthe product eluted with 2M NH₃/MeOH affording4-[2-(2-Ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-yl]piperidin-4-ol(1.1 g, quant.). LCMS (method H): R_(T) 1.79 min, [M+H]⁺ 463.3

To a mixture of4-[2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-yl]piperidin-4-ol(150 mg, 0.32 mmol), 2-hydroxyisobutyric acid (41 mg, 0.39 mmol) andDIPEA (68 μL, 0.39 mmol) in DCM (2 mL) was added HATU (149 mg, 0.39mmol). The resulting mixture was allowed to stir at r.t. for 18 h thendiluted with DCM and washed with sat. aq. NaHCO₃. The organic phase wasdried (Na₂SO₄) and concentrated in vacuo. The resulting residue waspurified by column chromatography (Si—PCC, MeOH:EtOAc, 0-20%) affording790 (60 mg, 34%). LCMS (method I): R_(T) 3.09 min, [M+H]⁺ 549.3. ¹H NMR(DMSO, 400 MHz): δ 8.02-8.01 (1H, m), 7.64-7.63 (1H, m), 7.27-7.23 (2H,m), 5.84 (1H, s), 5.42 (1H, s), 4.25 (6H, brd s), 3.98 (3H, s), 3.77(4H, t, J=4.55 Hz), 3.60 (1H, brd s), 3.2-3.24 (3H, m), 2.11-2.10 (2H,m), 2.06-1.94 (2H, m), 1.38-1.30 (9H, m)

Example 7911-(3-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-3-methoxypiperidin-1-yl)-2-methylpropan-2-ol791

A mixture of2-(2-ethylbenzoimidazol-1-yl)-8-(3-methoxypiperidin-3-yl)-9-methyl-6-morpholin-4-yl-9H-purinedihydrochloride (150 mg, 0.27 mmol), 2,2-dimethyloxirane (242 μL, 2.73mmol) and DIPEA (187 μL, 1.09 mmol) in MeCN (3 mL) was heated at 70° C.r.t. for 3 h before further 2,2-dimethyloxirane (242 μL, 2.73 mmol) wasadded and the mixture heated at 90° C. for 6 h. The reaction mixture wasconcentrated in vacuo and the resulting residue purified by columnchromatography (Si—PCC, MeOH:EtOAc, 0-20%) affording 791 (51 mg, 34%).LCMS (method I): R_(T) 2.72 min, [M+H]⁺ 549.3. ¹H NMR (DMSO, 400 MHz): δ8.03-8.02 (1H, m), 7.64-7.63 (1H, m), 7.25-7.24 (2H, m), 4.26 (4H, brds), 4.08 (1H, s), 3.91 (3H, s), 3.79 (4H, t, J=4.72 Hz), 3.27-3.26 (2H,m), 3.20-3.15 (1H, m), 3.06 (3H, s), 3.01-2.97 (1H, m), 2.69-2.61 (1H,m), 2.46-2.38 (1H, m), 2.25 (2H, s), 2.17-2.14 (1H, m), 1.92-1.75 (3H,m), 1.33 (3H, t, J=7.43 Hz), 1.03 (3H, s), 0.94 (3H, s)

Example 7924-(6-((2,2-dimethyl-4-(oxetan-3-yl)piperazin-1-yl)methyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)thieno[3,2-d]pyrimidin-4-yl)morpholine792

A mixture of2-chloro-6-(2,2-dimethyl-4-oxetan-3-ylpiperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine(136 mg, 0.31 mmol), 2-ethylbenzimidazole (48 mg, 0.33 mmol),tris(dibenzylideneacetone)dipalladium (8 mg, 3 mol %), XPhos (14 mg, 9mol %) and Cs₂CO₃ (143 mg, 0.44 mmol) in DMF (4 mL) was purged withargon then heated at 150° C. for 30 min in a microwave reactor. Thereaction mixture was loaded onto an Isolute® SCX-2 cartridge which waswashed with MeOH and the product eluted with 2M NH₃/MeOH. The resultingresidue was purified by column chromatography (Si—PCC, MeOH:DCM, 0-5%)then (Si—PCC, 2M NH₃/MeOH:DCM, 0-2%) affording 792 as a cream solid (45mg, 26%). LCMS (method I): R_(T) 2.78 min [M+H]⁺ 548.3. ¹H NMR (CDCl₃,400 MHz): δ 7.97-7.96 (1H, m), 7.75-7.74 (1H, m), 7.32-7.22 (3H, m),4.66 (2H, t, J=6.47 Hz), 4.59 (2H, t, J=6.08 Hz), 4.04 (4H, t, J=4.72Hz), 3.91-3.86 (6H, m), 3.46-3.45 (1H, m), 3.33 (2H, q, J=7.48 Hz), 2.64(2H, t, J=4.98 Hz), 2.33 (2H, s), 2.14 (2H, s), 1.42 (3H, t, J=7.47 Hz),1.20 (6H, s)

Example 793(2,2-dimethyl-4-(oxetan-3-yl)piperazin-1-yl)(5-(2-ethyl-1H-benzo[d]imidazol-1-yl)-7-morpholinothiazolo[5,4-d]pyrimidin-2-yl)methanone793

A mixture of(5-chloro-7-morpholin-4-ylthiazolo[5,4-d]pyrimidin-2-yl)-(2,2-dimethyl-4-oxetan-3-ylpiperazin-1-yl)methanone(137 mg, 0.30 mmol), 2-ethylbenzimidazole (47 mg, 0.32 mmol),tris(dibenzylideneacetone)dipalladium (8 mg, 2.5 mol %), XPhos (13 mg,10 mol %) and Cs₂CO₃ (140 mg, 0.43 mmol) in DMF (4 mL) was purged withargon then heated at 150° C. for 30 min in a microwave reactor. Thereaction mixture was loaded onto an Isolute® SCX-2 cartridge which waswashed with MeOH and the product eluted with 2M NH₃/MeOH. The resultingresidue was purified by column chromatography (Si—PCC, MeOH:DCM, 1-2%)followed by triturating with EtOAc affording 793 (22 mg, 13%). LCMS(method I): R_(T) 3.79 min [M+H]⁺ 563.3. ¹H NMR (CDCl₃, 400 MHz): δ8.07-8.03 (1H, m), 7.76-7.75 (1H, m), 7.30-7.29 (2H, m), 4.72 (2H, t,J=6.51 Hz), 4.62 (2H, t, J=6.07 Hz), 4.40 (4H, brd s), 4.07-4.06 (2H,m), 3.89 (4H, t, J=4.72 Hz), 3.53-3.52 (1H, m), 3.36 (2H, q, J=7.46 Hz),2.47 (2H, t, J=5.08 Hz), 2.25 (2H, s), 1.56 (6H, s), 1.44 (3H, t, J=7.45Hz)

Example 7964-(1-((5-(2-ethyl-1H-benzo[d]imidazol-1-yl)-7-morpholinothiazolo[5,4-d]pyrimidin-2-yl)methyl)azetidin-3-yl)piperazin-2-one796

A mixture of4-[1-(5-chloro-7-morpholin-4-ylthiazolo[5,4-c]pyrimidin-2-ylmethyl)azetidin-3-yl]piperazin-2-one(315 mg, 0.74 mmol), 2-ethylbenzimidazole (120 mg, 0.82 mmol),tris(dibenzylideneacetone)dipalladium (17 mg, 0.02 mmol), XPhos (35 mg,0.07 mmol) and Cs₂CO₃ (365 mg, 1.12 mmol) in dioxane (10 mL) was purgedwith argon then heated at 115° C. for 4 h then stirred at r.t. for 16 h.The reaction mixture was filtered through Celite®, washing with dioxane,and the filtrate concentrated in vacuo. The resulting residue waspurified by column chromatography (Si—PCC, MeOH:DCM, 1-10%) affording796 (146 mg, 37%). LCMS (method G): R_(T) 4.90 min, [M+H]⁺ 534.3. ¹H NMR(DMSO, 400 MHz): δ 7.99-7.99 (1H, m), 7.75 (1H, s), 7.64-7.63 (1H, m),7.26-7.25 (2H, m), 4.32 (4H, brd s), 4.04 (2H, s), 3.79 (4H, t, J=4.61Hz), 3.57-3.52 (2H, m), 3.31 (2H, s), 3.25 (2H, q, J=7.43 Hz), 3.18-3.14(5H, m), 2.87 (2H, s), 1.32 (3H, t, J=7.42 Hz)

Example 797(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(3-(4-hydroxypiperidin-1-yl)azetidin-1-yl)methanone797

A mixture of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carboxylicacid (215 mg, 0.53 mmol), 2-chloro-1-methylpyridinium iodide (324 mg,1.27 mmol) and DIPEA (460 μL, 2.64 mmol) in DMF (2 mL) was stirred for 5min before the addition of 1-azetidin-3-ylpiperidin-4-ol (140 mg, 0.90mmol) in DMF (2 mL). The resulting mixture was allowed to stir for 2 hthen loaded onto an Isolute® SCX-2 cartridge which was washed with MeOHand the product eluted with 2M NH₃/MeOH. The resulting residue waspurified by column chromatography (Si—PCC, MeOH:DCM, 0-10%) affording797 as a pale yellow solid (76 mg, 26%). LCMS (method G): R_(T) 5.26min, [M+H]⁺ 546.4. ¹H NMR (CDCl₃, 400 MHz): δ 8.06-8.06 (1H, m),7.76-7.75 (1H, m), 7.31-7.24 (2H, m), 4.72-4.71 (1H, m), 4.50 (1H, dd,J=10.65, 5.40 Hz), 4.30-4.20 (1H, m), 4.14 (3H, s), 4.14-4.07 (1H, m),3.88 (4H, t, J=4.71 Hz), 3.81 (1H, s), 3.37 (2H, q, J=7.47 Hz),3.28-3.27 (1H, m), 2.72 (2H, d, J=27.26 Hz), 2.25-2.10 (2H, m),2.01-1.91 (2H, m), 1.68-1.60 (5H, m), 1.46-1.43 (4H, m)

Example 798(2-(2-cyclopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(4-(2-hydroxypropan-2-yl)piperidin-1-yl)methanone798

A mixture of2-(2-cyclopropylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carboxylicacid (200 mg, 0.48 mmol), 2-piperidin-4-ylpropan-2-ol (78 mg, 0.55mmol), HATU (205 mg, 0.54 mmol) and DIPEA (96 μL, 0.55 mmol) in DCM (5mL) was allowed to stir at r.t. for 19 h. The reaction mixture wasloaded onto an Isolute® SCX-2 cartridge which was washed with MeOH andthe product eluted with 2M NH₃/MeOH. The resulting residue was purifiedby column chromatography (Si—PCC, MeOH:DCM, 0-3%) then (Si—PCC,MeOH:EtOAc, 0-5%) affording 798 as a white solid (138 mg, 53%). LCMS(method G): R_(T) 7.50 min, [M+H]⁺ 545.4. ¹H NMR (CDCl₃, 400 MHz): δ7.97-7.96 (1H, m), 7.68-7.67 (1H, m), 7.28-7.20 (2H, s), 4.91-4.82 (1H,m), 4.68-4.65 (1H, m), 4.40 (4H, brd s), 3.97 (3H, s), 3.86 (4H, t,J=4.70 Hz), 3.18-3.10 (1H, m), 2.84-2.83 (2H, m), 1.94-1.92 (2H, m),1.64-1.62 (1H, m), 1.44-1.43 (2H, m), 1.35-1.34 (2H, m), 1.24-1.22 (7H,m), 1.06-1.05 (2H, m)

Example 799(2-(2-cyclopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(3-morpholinoazetidin-1-yl)methanone799

To a mixture of2-(2-cyclopropylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carboxylicacid (500 mg, 1.19 mmol), 2-chloro-1-methylpyridinium iodide (729 mg,2.86 mmol) and DIPEA (500 μL, 2.87 mmol) in DMF (10 mL) was added4-azetidin-3-ylmorpholine (288 mg, 2.0 mmol) and the resulting mixtureallowed to stir at r.t for 18 h. The reaction mixture was concentratedin vacuo and the resulting residue dissolved in EtOAc which was washedwith H₂O and brine, then dried (MgSO₄) and concentrated in vacuo. Theresulting residue was purified by column chromatography (Si—PCC,MeOH:EtOAc, 0-5%) affording 799 as a cream solid (290 mg, 45%). LCMS(method G): R_(T) 5.90 min, [M+H]⁺ 544.5. ¹H NMR (CDCl₃, 400 MHz): δ7.99-7.99 (1H, m), 7.67-7.67 (1H, m), 7.28-7.20 (2H, m), 4.73-4.72 (1H,m), 4.70-4.00 (4H, brd s), 4.53-4.51 (1H, m), 4.29-4.21 (1H, m),4.18-4.08 (4H, m), 3.87 (4H, t, J=4.67 Hz), 3.78 (4H, t, J=4.60 Hz),3.30-3.30 (1H, m), 2.88-2.88 (1H, m), 2.47-2.45 (4H, m), 1.35-1.34 (2H,m), 1.06-1.05 (2H, m)

Example 8001-(4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-4-methoxypiperidin-1-yl)-2-hydroxy-2-methylpropan-1-one800

To a solution of4-[2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-yl]-4-hydroxypiperidine-1-carboxylicacid tert-butyl ester (1.3 g, 2.31 mmol) in THF (50 mL) was added NaH(112 mg, 2.80 mmol, 60% dispersion in mineral oil) and the resultingmixture allowed to stir for 5 min before the addition of iodomethane(175 μL, 2.80 mmol) and 15-Crown-5 (5 drops). The resulting mixture wasstirred for 20 h quenched with H₂O and extracted with 2-methyl THF. Theorganic phase was washed with brine, then dried (Na₂SO₄) andconcentrated in vacuo. The resulting residue was purified by columnchromatography (Si—PCC, EtOAc:cyclohexane, 40-80%) affording4-[2-(2-Ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-yl]-4-methoxypiperidine-1-carboxylicacid tert-butyl ester (915 mg, 69%). LCMS (method H): R_(T) 3.40 min[M+H]⁺ 577.5

To a solution of4-[2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-yl]-4-methoxypiperidine-1-carboxylicacid tert-butyl ester (915 mg, 1.59 mmol) in DCM (15 mL) was added TFA(3 mL) and the resulting mixture allowed to stir at r.t. for 2 h. Thereaction mixture was concentrated in vacuo and the resulting residueloaded onto an Isolute® SCX-2 cartridge which was washed with MeOH andthe product eluted with 2M NH₃/MeOH affording2-(2-Ethylbenzoimidazol-1-yl)-8-(4-methoxypiperidin-4-yl)-9-methyl-6-morpholin-4-yl-9H-purine(775 mg, quant.). LCMS (method H): R_(T) 1.95 min, [M+H]⁺ 477.3

To a solution of 2-hydroxyisobutyric acid (49 mg, 0.47 mmol) in THF (3mL) was added2-(2-ethylbenzoimidazol-1-yl)-8-(4-methoxypiperidin-4-yl)-9-methyl-6-morpholin-4-yl-9H-purine(150 mg, 0.32 mmol), HOBt (47 mg, 0.35 mmol), NMM (77 μL, 0.69 mmol) andEDCI (91 mg, 0.47 mmol). The resulting mixture was allowed to stir atr.t. for 4 h then quenched with sat. aq. NH₄Cl and extracted with DCM.The organic phase was washed with brine, then dried (Na₂SO₄) andconcentrated in vacuo. The resulting residue was purified by columnchromatography (Si—PCC, MeOH:EtOAc, 0-20%) then triturated withMeOH/H₂O. The resulting solid was collected by filtration and dried invacuo affording 800 (111 mg, 63%). LCMS (method G): R_(T) 7.36 min,[M+H]⁺ 563.4. ¹H NMR (DMSO, 400 MHz): δ 8.05-8.04 (1H, m), 7.66-7.62(1H, m), 7.25-7.24 (2H, m), 5.44 (1H, s), 4.26 (6H, brd s), 3.92 (3H,s), 3.78 (4H, t, J=4.52 Hz), 3.30-3.23 (4H, m), 3.09 (3H, s), 2.26-2.16(2H, m), 2.19-2.02 (2H, m), 1.35-1.33 (9H, m)

Example 8111-(3-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-3-methoxyazetidin-1-yl)-2-hydroxy-2-methylpropan-1-one811

A mixture of2-(2-ethylbenzoimidazol-1-yl)-8-(3-methoxyazetidin-3-yl)-9-methyl-6-morpholin-4-yl-9H-purine(150 mg, 0.33 mmol), 2-hydroxy-2-methylpropionic acid (52 mg, 0.50mmol), HOBt (50 mg, 0.37 mmol), NMM (81 μL, 0.74 mmol) and EDCI (96 mg,0.50 mmol) in THF (3 mL) was allowed to stir at r.t. for 4 h. Theresulting mixture was diluted with DCM and washed with sat. aq. NaHCO₃,dried (phase separator) and concentrated in vacuo. The resulting residuewas purified by column chromatography (Si—PCC, THF:EtOAc, 0-50%) thentriturated with Et₂O/cyclohexane. The resulting solid was collected byfiltration and dried in vacuo affording 811 (108 mg, 60%). LCMS (methodI): R_(T) 3.21 min, [M+H]⁺ 535.3. ¹H NMR (DMSO, 400 MHz): δ 8.06-8.05(1H, m), 7.64-7.63 (1H, m), 7.26-7.25 (2H, m), 5.23 (1H, s), 5.05 (1H,d, J=10.74 Hz), 4.67 (1H, d, J=10.76 Hz), 4.55 (1H, d, J=10.69 Hz), 4.29(4H, brd s), 4.16 (1H, d, J=10.75 Hz), 3.79 (4H, t, J=4.62 Hz), 3.73(3H, s), 3.29-3.27 (2H, m), 3.09 (3H, s), 1.35 (3H, t, J=7.43 Hz), 1.30(3H, s), 1.25 (3H, s)

Example 8124-(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)piperazin-2-one812

To a solution of4-{1-[2-(2-ethylbenzoimidazol-1-yl)-6-morpholin-4-yl-9-(tetrahydropyran-2-yl)-9H-purin-8-ylmethyl]azetidin-3-yl}piperazin-2-one(470 mg, 0.78 mmol) in dioxane (20 mL) was added 4M HCl in dioxane (1mL). The resulting suspension was stirred at r.t for 24 h then theprecipitate collected by filtration, washing with dioxane. The resultingsolid was partitioned between EtOAc and H₂O and the aqueous layerbasified to pH 11 with NH₄OH. The aqueous phase was neutralised to pH 7with HCl then loaded onto an Isolute® SCX-2 cartridge which was washedwith H₂O and MeOH and the product eluted with 2M NH₃/MeOH. The resultingresidue was purified by column chromatography (C18, MeOH:H₂O, 30-95%)then loaded onto an Isolute® SCX-2 cartridge which was washed with H₂Oand MeOH and the product eluted with 2M NH₃/MeOH affording 812 (69 mg,17%). LCMS (method I): R_(T) 2.16 min, [M+H]⁺ 517.3. ¹H NMR (DMSO, 400MHz): δ 7.95-7.94 (1H, m), 7.73 (1H, s), 7.63-7.62 (1H, m), 7.25-7.22(2H, m), 4.24 (4H, brd s), 3.79-3.74 (6H, m), 3.46 (2H, s), 3.23 (3H, q,J=7.46 Hz), 3.16-3.04 (5H, m), 2.84 (2H, s), 2.45-2.44 (2H, m), 1.31(3H, t, J=7.45 Hz)

Example 8134-(2-((2,2-dimethyl-4-(oxetan-3-yl)piperazin-1-yl)methyl)-5-(2-ethyl-1H-benzo[d]imidazol-1-yl)thiazolo[5,4-d]pyrimidin-7-yl)morpholine813

A mixture of5-(2-ethylbenzoimidazol-1-yl)-7-morpholin-4-ylthiazolo[5,4-c]pyrimidine-2-carbaldehyde(200 mg, 0.51 mmol), 3,3-dimethyl-1-oxetan-3-ylpiperazine (100 mg, 0.65mmol) and 4 Å powdered molecular sieves (200 mg) in DCE (10 mL) wasallowed to stir at r.t. for 1 h before the addition of sodiumtriacetoxyborohydride (150 mg, 0.71 mmol). The resulting mixture wasallowed to stir for 5 h then loaded onto an Isolute® SCX-2 cartridgewhich was washed with MeOH and the product eluted with 2M NH₃/MeOH. Theresulting residue was purified by column chromatography (Si—PCC,MeOH:EtOAc, 0-1%) followed by reverse phase HPLC (Phenomenex Gemini 5 μmC18, 20 mM triethylamine in water on a gradient of acetonitrile 5-98%)affording 813 (111 mg, 40%). LCMS (method G): R_(T) 6.17 min [M+H]⁺549.3. ¹H NMR (CDCl₃, 400 MHz): δ 8.01-8.00 (1H, m), 7.75-7.74 (1H, m),7.32-7.22 (2H, m), 4.67 (2H, t, J=6.47 Hz), 4.59 (2H, t, J=6.08 Hz),4.40 (4H, brd s), 3.87 (6H, t, J=4.72 Hz), 3.47-3.46 (1H, m), 3.34 (2H,q, J=7.47 Hz), 2.75 (2H, t, J=4.94 Hz), 2.37 (2H, brd s), 2.15 (2H, brds), 1.43 (3H, t, J=7.47 Hz), 1.20 (6H, s)

Example 8141-(3-((5-(2-ethyl-1H-benzo[d]imidazol-1-yl)-7-morpholinothiazolo[5,4-d]pyrimidin-2-yl)methyl)azetidin-1-yl)-2-hydroxy-2-methylpropan-1-one814

A mixture of2-azetidin-3-ylmethyl-5-(2-ethylbenzoimidazol-1-yl)-7-morpholin-4-ylthiazolo[5,4-d]pyrimidine(209 mg, 0.48 mmol), 2-hydroxyisobutyric acid (56 mg, 0.54 mmol), HATU(200 mg, 0.53 mmol) and DIPEA (94 μL, 0.54 mmol) in DCM (5 mL) wasallowed to stir at r.t. for 2 h. The reaction mixture was loaded onto anIsolute® SCX-2 cartridge which was washed with MeOH and the producteluted with 2M NH₃/MeOH. The resulting residue was purified by columnchromatography (Si—PCC, MeOH:EtOAc, 0-2%) followed by reverse phase HPLC(Phenomenex Gemini 5 μm C18, 20 mM triethylamine in water on a gradientof acetonitrile 5-98%) affording 814 as a white solid (89 mg, 35%). LCMS(method I): R_(T) 3.39 min, [M+H]⁺ 522.2. ¹H NMR (CDCl₃, 400 MHz): δ8.00-7.99 (1H, m), 7.75-7.74 (1H, m), 7.28-7.28 (2H, m), 4.62-4.12 (7H,m), 4.05-3.92 (1H, m), 3.88 (4H, t, J=4.76 Hz), 3.45 (1H, s), 3.43-3.38(2H, m), 3.33 (2H, q, J=7.47 Hz), 3.27-3.21 (1H, m), 1.43-1.42 (9H, m)

Example 8231-(4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-4-methoxypiperidin-1-yl)-2-hydroxyethanone823

A mixture of2-(2-ethylbenzoimidazol-1-yl)-8-(4-methoxypiperidin-4-yl)-9-methyl-6-morpholin-4-yl-9H-purine(150 mg, 0.32 mmol), hydroxyacetic acid (36 mg, 0.47 mmol), HOBt (47 mg,0.35 mmol), NMM (77 μL, 0.69 mmol) and EDCI (91 mg, 0.47 mmol) in THF (3mL) was allowed to stir at r.t. for 4 h. The resulting mixture wasdiluted with DCM and washed with sat. aq. NaHCO₃, dried (phaseseparator) and concentrated in vacuo. The resulting residue was purifiedby column chromatography (Si—PCC, THF:EtOAc, 0-50%) then loaded onto anIsolute® SCX-2 cartridge which was washed with MeOH and the producteluted with 2M NH₃/MeOH affording 823 (88 mg, 52%). LCMS (method I):R_(T) 3.25 min, [M+H]⁺ 535.3. ¹H NMR (DMSO, 400 MHz): δ 8.05-8.04 (1H,m), 7.64-7.63 (1H, m), 7.26-7.25 (2H, m), 4.54 (1H, t, J=5.40 Hz),4.17-4.06 (6H, m), 3.92 (3H, s), 3.78 (4H, t, J=4.51 Hz), 3.65-3.55 (1H,m), 3.40-3.25 (3H, m), 3.18 (1H, m), 3.09 (3H, s), 2.17-2.14 (4H, m),1.35 (3H, t, J=7.43 Hz)

Example 8241-(3-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-1-yl)-2-methylpropan-1-one824

A mixture of8-azetidin-3-ylmethyl-2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine(121 mg, 0.28 mmol), isobutyryl chloride (30 mg, 0.29 mmol) and NEt₃ (50μL, 0.36 mmol) in DCM (1 mL) was allowed to stir at r.t. for 2 h thenconcentrated in vacuo. The resulting residue purified by columnchromatography (Si—PCC, MeOH:DCM, 0-6%) followed by triturating withEt₂O affording 824 as a white solid (86 mg, 61%). LCMS (method I): R_(T)3.42 min, [M+H]⁺ 503.2. ¹H NMR (CDCl₃, 400 MHz): δ 7.99-7.99 (1H, m),7.75-7.74 (1H, m), 7.30-7.22 (2H, m), 4.50-4.20 (4H, brd s), 4.41 (1H,t, J=8.45 Hz), 4.32-4.21 (1H, m), 3.98 (1H, dd, J=8.63, 5.41 Hz),3.90-3.80 (5H, m), 3.76 (3H, s), 3.34 (2H, q, J=7.49 Hz), 3.28-3.25 (1H,m), 3.16-3.11 (2H, m), 2.47-2.46 (1H, m), 1.44 (3H, t, J=7.48 Hz), 1.12(6H, dd, J=6.82, 2.82 Hz)

Example 825cyclopropyl(3-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-1-yl)methanone825

A mixture of8-azetidin-3-ylmethyl-2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine(108 mg, 0.25 mmol), cyclopropane carbonyl chloride (27 mg, 0.25 mmol)and NEt₃ (50 μL, 0.36 mmol) in DCM (1 mL) was allowed to stir at r.t.for 2 h then concentrated in vacuo. The resulting residue purified bycolumn chromatography (Si—PCC, MeOH:DCM, 0-10%) followed by trituratingwith Et₂O affording 825 as a white solid (107 mg, 85%). LCMS (method I):R_(T) 3.33 min, [M+H]⁺ 501.2. ¹H NMR (CDCl₃, 400 MHz): δ 7.99-7.98 (1H,m), 7.76-7.73 (1H, m), 7.32-7.22 (2H, m), 4.53 (1H, t, J=8.31 Hz),4.45-4.20 (4H, brd s), 4.28 (1H, t, J=9.30 Hz), 4.09 (1H, dd, J=8.45,5.41 Hz), 3.86 (5H, t, J=4.77 Hz), 3.77 (3H, s), 3.34-3.33 (3H, m),3.18-3.15 (2H, m), 1.45-1.43 (4H, m), 0.99-0.98 (2H, m), 0.77-0.76 (2H,m)

Example 8264-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-8-(3-methoxy-1-(2-(methylsulfonyl)ethyl)azetidin-3-yl)-9-methyl-9H-purin-6-yl)morpholine826

To a solution of2-(2-ethylbenzoimidazol-1-yl)-8-(3-methoxyazetidin-3-yl)-9-methyl-6-morpholin-4-yl-9H-purine(100 mg, 0.22 mmol) in IMS (2 mL) was added methanesulfonylethene (21μL, 0.25 mmol) and the resulting mixture allowed to stir at r.t. for 18h. The reaction mixture was concentrated in vacuo and the resultingresidue purified by column chromatography (Si—PCC, MeOH:EtOAc, 0-10%).The resulting residue was triturated with EtOAc and cyclohexane and theresulting solid dried in vacuo affording 826 (83 mg, 67%). LCMS (methodI): R_(T) 2.65 min, [M+H]⁺ 555.3. ¹H NMR (DMSO, 400 MHz): δ 8.05-8.05(1H, m), 7.64-7.63 (1H, m), 7.26-7.25 (2H, m), 4.27 (4H, brd s), 4.02(2H, d, J=7.94 Hz), 3.79 (4H, t, J=4.57 Hz), 3.72 (3H, s), 3.42 (2H, d,J=7.99 Hz), 3.28-3.25 (2H, m), 3.17 (2H, t, J=6.52 Hz), 3.05 (3H, s),2.89 (2H, t, J=6.53 Hz), 1.40 (3H, s), 1.35 (3H, t, J=7.43 Hz)

Example 8274-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-8-(3-methoxy-1-(tetrahydro-2H-pyran-4-yl)azetidin-3-yl)-9-methyl-9H-purin-6-yl)morpholine827

A mixture of2-(2-ethylbenzoimidazol-1-yl)-8-(3-methoxyazetidin-3-yl)-9-methyl-6-morpholin-4-yl-9H-purine(100 mg, 0.22 mmol), tetrahydropyran-4-one (27 mg, 0.27 mmol) and AcOH(50 μL) in DCE (2 mL) was allowed to stir at r.t. for 20 min before theaddition of sodium triacetoxyborohydride (104 mg, 0.49 mmol). Theresulting mixture was allowed to stir for 18 h then partitioned betweenDCM and H₂O. The organic phase was dried (phase separator) andconcentrated in vacuo. The resulting residue was purified by columnchromatography (Si—PCC, MeOH:EtOAc, 0-20%) then triturated with MeCN andH₂O and the resulting solid dried in vacuo affording 827 (92 mg, 82%).LCMS (method I): R_(T) 2.65 min, [M+H]⁺ 555.3. ¹H NMR (DMSO, 400 MHz): δ8.04-8.04 (1H, m), 7.65-7.62 (1H, m), 7.25-7.24 (2H, m), 4.40-4.10 (4H,brd s), 3.91 (2H, d, J=8.05 Hz), 3.80-3.79 (6H, m), 3.71 (3H, s), 3.41(2H, d, J=8.07 Hz), 3.28-3.26 (4H, m), 3.02 (3H, s), 2.37-2.28 (1H, m),1.67-1.63 (2H, m), 1.34 (3H, t, J=7.43 Hz), 1.23-1.10 (2H, m)

Example 828 tert-butyl3-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-3-fluoroazetidine-1-carboxylate828

To a solution of3-[2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-yl]-3-hydroxy-azetidine-1-carboxylicacid tert-butyl ester (300 mg, 0.56 mmol) in THF (2 mL) at 5° C. wasadded a solution of bis-(2-methoxyethyl)aminosulfur trifluoride (275 μL,0.62 mmol, 50% solution in THF) in THF (3 mL). The resulting mixture wasallowed to stir at 5° C. for 15 min then warmed to r.t. and stirred fora further 15 min. The reaction mixture was partitioned between sat. aq.NaHCO₃ and DCM, the organic phase dried (phase separator) andconcentrated in vacuo. The resulting residue was purified by columnchromatography (Si—PCC, EtOAc:cyclohexane, 35-85%) affording 828 as apale yellow solid (238 mg, 79%). LCMS (method I): R_(T) 4.65 min, [M+H]⁺537.4. ¹H NMR (DMSO, 400 MHz): δ 8.05-8.04 (1H, m), 7.64-7.64 (1H, m),7.26-7.25 (2H, m), 4.77 (2H, dd, J=20.08, 10.62 Hz), 4.60-4.10 (4H, brds), 4.48 (2H, dd, J=21.54, 10.50 Hz), 3.79 (4H, t, J=4.55 Hz), 3.76 (3H,d, J=1.32 Hz), 3.28-3.27 (2H, m), 1.42 (9H, s), 1.34 (3H, t, J=7.46 Hz)

Example 829(S)-1-(4-((5-(2-ethyl-1H-benzo[d]imidazol-1-yl)-7-morpholinothiazolo[5,4-d]pyrimidin-2-yl)methyl)-3,3-dimethylpiperazin-1-yl)-2-hydroxypropan-1-one829

A mixture of2-(2,2-dimethylpiperazin-1-ylmethyl)-5-(2-ethylbenzoimidazol-1-yl)-7-morpholin-4-ylthiazolo[5,4-d]pyrimidine(200 mg, 0.41 mmol), L-lactic acid (34 μL, 85% solution in H₂O), HATU(170 mg, 0.45 mmol) and DIPEA (80 μL, 0.46 mmol) in DCM (4 mL) wasallowed to stir at r.t. for 3 h. The reaction mixture was loaded onto anIsolute® SCX-2 cartridge which was washed with MeOH and the producteluted with 2M NH₃/MeOH. The resulting residue was purified by columnchromatography (Si—PCC, MeOH:EtOAc, 0-2%) then (C18, MeOH:H₂O, 10-20%).The resulting residue was loaded onto an Isolute® SCX-2 cartridge whichwas washed with MeOH and the product eluted with 2M NH₃/MeOH affording829 (41 mg, 18%). LCMS (method I): R_(T) 3.79 min, [M+H]⁺ 565.3. ¹H NMR(CDCl₃, 400 MHz): δ 8.03-7.98 (1H, m), 7.76-7.75 (1H, m), 7.32-7.22 (2H,m), 4.41-4.38 (5H, m), 4.08-4.01 (1H, m), 3.89-3.88 (5H, m), 3.79-3.77(1H, m), 3.59-3.44 (2H, m), 3.34 (2H, q, J=7.47 Hz), 3.27-3.25 (1H, m),2.75 (2H, s), 1.44 (3H, t, J=7.47 Hz), 1.37-1.35 (3H, m), 1.27-1.11 (6H,m)

Example 8331-(3-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-3-methoxyazetidin-1-yl)-2-methylpropan-2-ol833

To a solution of2-(2-ethylbenzoimidazol-1-yl)-8-(3-methoxyazetidin-3-yl)-9-methyl-6-morpholin-4-yl-9H-purine(100 mg, 0.22 mmol) in MeCN (2 mL) was added 2,2-dimethyloxirane (198μL, 2.23 mmol) and the resulting mixture stirred at 80° C. for 3 hbefore the addition of further 2,2-dimethyloxirane (1.0 mL, 11.15 mmol).The reaction mixture was stirred at 80° C. for a further 20 h thenconcentrated in vacuo. The resulting residue was purified by columnchromatography (Si—PCC, MeOH:EtOAc, 0-20%) then triturated with Et₂O andthe resulting solid dried in vacuo affording 833 (31 mg, 27%). LCMS(method I): R_(T) 2.59 min, [M+H]⁺ 521.3. ¹H NMR (DMSO, 400 MHz): δ8.04-8.04 (1H, m), 7.66-7.62 (1H, m), 7.25-7.24 (2H, m), 4.29 (4H, brds), 4.07 (1H, s), 3.99 (2H, d, J=8.32 Hz), 3.80 (4H, t, J=4.57 Hz), 3.70(3H, s), 3.52 (2H, d, J=8.34 Hz), 3.34-3.19 (2H, m), 3.02 (3H, s), 2.43(2H, s), 1.34 (3H, t, J=7.43 Hz), 1.05 (6H, s)

Example 8344-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-8-(3-fluoroazetidin-3-yl)-9-methyl-9H-purin-6-yl)morpholine834

To a solution of3-[2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-yl]-3-fluoroazetidine-1-carboxylicacid tert-butyl ester (235 mg, 0.44 mmol) in DCM (10 mL) was added TFA(2 mL) and the resulting mixture was allowed to stir at r.t. for 3.5 h.The reaction mixture was concentrated in vacuo and the resulting residuewas loaded onto an Isolute® SCX-2 cartridge which was washed withMeOH/DCM and the product eluted with 2M NH₃/MeOH. The resulting residuewas triturated with Et₂O and the resulting solid dried in vacuoaffording 834 (185 mg, 97%). LCMS (method I): R_(T) 2.50 min, [M+H]⁺437.3. ¹H NMR (DMSO, 400 MHz): δ 8.06-8.05 (1H, m), 7.64-7.63 (1H, m),7.28-7.24 (2H, m), 4.60-4.10 (4H, brd s), 4.26 (2H, dd, J=19.18, 10.17Hz), 4.01 (2H, dd, J=22.47, 10.23 Hz), 3.80 (4H, t, J=4.63 Hz),3.74-3.73 (3H, m), 3.28-3.27 (2H, m), 1.34 (3H, t, J=7.43 Hz)

Example 8391-(3-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-3-fluoroazetidin-1-yl)-2-methylpropan-2-ol839

A mixture of2-(2-ethylbenzoimidazol-1-yl)-8-(3-fluoroazetidin-3-yl)-9-methyl-6-morpholin-4-yl-9H-purine(90 mg, 0.21 mmol) and 2,2-dimethyloxirane (1 mL) in IMS (2 mL) washeated to 80° C. for 24 h then concentrated in vacuo. The resultingresidue was purified by column chromatography (Si—PCC, MeOH:EtOAc, 0-5%)then triturated with Et₂O. The resulting residue was further purified byreverse phase HPLC (Phenomenex Gemini 5 μm C18, 0.1% HCO₂H in water on agradient acetonitrile 5-95%) affording 839 (22 mg, 21%). LCMS (methodI): R_(T) 2.63 min, [M+H]⁺ 509.3. ¹H NMR (DMSO, 400 MHz): δ 8.04-8.03(1H, m), 7.65-7.62 (1H, m), 7.26-7.25 (2H, m), 4.28 (4H, brd s), 4.14(2H, dd, J=18.78, 9.71 Hz), 3.82-3.74 (9H, m), 3.31-3.29 (4H, m), 1.34(3H, t, J=7.43 Hz), 1.07 (6H, s)

Example 840(S)-1-(3-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-3-methoxyazetidin-1-yl)-2-hydroxypropan-1-one840

To a mixture of2-(2-ethylbenzoimidazol-1-yl)-8-(3-methoxyazetidin-3-yl)-9-methyl-6-morpholin-4-yl-9H-purine(100 mg, 0.22 mmol) and sodium L-lactate (38 mg, 0.34 mmol) in DCM (2mL) was added HOBt (33 mg, 0.25 mmol) and EDCI (64 mg, 0.34 mmol). Theresulting mixture was allowed to stir at r.t. for 18 h then partitionedbetween DCM and sat. aq. NH₄Cl. The organic phase was dried (phaseseparator), concentrated in vacuo and the resulting residue purified bycolumn chromatography (Si—PCC, MeOH:EtOAc, 0-25%). The resulting residuewas triturated with Et₂O and further purified by reverse phase HPLC(Phenomenex Gemini 5 μm C18, 0.1% HCO₂H in water on a gradient MeOH45-60%) affording 840 (29 mg, 23%). LCMS (method I): R_(T) 3.10 min,[M+H]⁺ 521.3. ¹H NMR (DMSO, 400 MHz): δ 8.44 (1H, brd s), 8.07-8.03 (1H,m), 7.64-7.63 (1H, m), 7.25-7.24 (2H, m), 5.24 (1H, brd s), 4.94 (1H,dd, J=21.10, 10.14 Hz), 4.59-4.58 (2H, m), 4.46-4.12 (4H, brd s),4.18-4.17 (2H, m), 3.79 (4H, t, J=4.51 Hz), 3.72 (3H, s), 3.34-3.32 (2H,m), 3.09 (3H, s), 1.34 (3H, t, J=7.43 Hz), 1.20 (3H, d, J=6.71 Hz)

Example 846(5-(2-ethyl-1H-benzo[d]imidazol-1-yl)-7-morpholinothiazolo[5,4-d]pyrimidin-2-yl)(3-morpholinoazetidin-1-yl)methanone846

A mixture of(5-chloro-7-morpholin-4-ylthiazolo[5,4-d]pyrimidin-2-yl)-(3-morpholin-4-ylazetidin-1-yl)methanone(98 mg, 0.23 mmol), 2-ethylbenzimidazole (36 mg, 0.25 mmol),tris(dibenzylideneacetone)dipalladium (6 mg, 2.5 mol %), XPhos (10 mg, 9mol %) and Cs₂CO₃ (107 mg, 0.33 mmol) in DMF (3 mL) was purged withargon then heated at 150° C. for 30 min in a microwave reactor. Thereaction mixture was loaded onto an Isolute® SCX-2 cartridge which waswashed with MeOH and the product eluted with 2M NH₃/MeOH. The resultingresidue was purified by column chromatography (Si—PCC, MeOH:EtOAc, 0-4%)then triturated with EtOAc affording 846 as a white solid (61 mg, 50%).LCMS (method I): R_(T) 2.96 min, [M+H]⁺ 535.3. ¹H NMR (CDCl₃, 400 MHz):δ 8.09-8.05 (1H, m), 7.80-7.75 (1H, m), 7.31-7.30 (2H, m), 4.68-4.67(1H, m), 4.60-4.20 (4H, brd s), 4.52 (1H, dd, J=10.01, 5.05 Hz),4.33-4.27 (1H, m), 4.17 (1H, dd, J=10.73, 5.02 Hz), 3.89 (4H, t, J=4.65Hz), 3.78 (4H, t, J=4.57 Hz), 3.42-3.33 (3H, m), 2.52-2.35 (4H, m), 1.46(3H, t, J=7.44 Hz)

Example 8492-(3-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-3-methoxyazetidin-1-yl)ethanol849

To a solution of1-{3-[2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-yl]-3-methoxyazetidin-1-yl}-2-hydroxyethanone(88 mg, 0.17 mmol) in THF (2 mL) at 0° C. was added BH₃.THF complex (350μL, 0.35 mmol, 1M solution) and the resulting mixture allowed to stirfor 1 h. Further BH₃.THF complex (800 μL, 0.80 mmol) was added and themixture stirred at r.t. for 17 h. The reaction mixture was quenched withH₂O, acidified with 2M HCl then loaded onto an Isolute® SCX-2 cartridgewhich was washed with MeOH and the product eluted with 2M NH₃/MeOH. Theresulting residue was dissolved in a mixture of MeCN and H₂O and allowedto freeze-dry affording 849 as a white solid (74 mg, 86%). LCMS (methodI): R_(T) 2.48 min, [M+H]⁺ 493.4. ¹H NMR (DMSO, 400 MHz): δ 8.04-8.04(1H, m), 7.64-7.63 (1H, m), 7.27-7.23 (2H, m), 4.50-4.42 (1H, m),4.39-4.14 (4H, brd m), 4.05-3.98 (2H, m), 3.80 (4H, t, J=4.56 Hz), 3.70(3H, s), 3.52-3.45 (2H, m), 3.40 (2H, q, J=5.63 Hz), 3.34-3.24 (2H, m),3.01 (3H, s), 2.65-2.57 (2H, m), 1.34 (3H, t, J=7.43 Hz)

Example 8502-(3-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-3-fluoroazetidin-1-yl)-2-methylpropan-1-ol850

To a solution of2-{3-[2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-yl]-3-fluoroazetidin-1-yl}-2-methylpropionicacid ethyl ester (40 mg, 0.07 mmol) in IMS (4 mL) was added NaBH₄ (28mg, 0.73 mmol) and the resulting mixture stirred at r.t for 3 h. FurtherNaBH₄ (28 mg, 0.73 mmol) was added and the mixture stirred for a further18 h. The reaction mixture was quenched with H₂O, extracted with EtOAcand the organic phase dried (Na₂SO₄) and concentrated in vacuo. Theresulting residue was purified by column chromatography (Si—PCC,MeOH:EtOAc, 0-10%) then dissolved in a mixture of MeCN and H₂O andallowed to freeze-dry affording 850 as a white solid (20 mg, 54%). LCMS(method I): R_(T) 2.64 min, [M+H]⁺ 509.4. ¹H NMR (DMSO, 400 MHz): δ8.05-8.04 (1H, m), 7.64-7.63 (1H, m), 7.26-7.25 (2H, m), 4.58-4.49 (1H,m), 4.44-4.14 (4H, brd m), 4.08 (2H, dd, J=18.70, 9.19 Hz), 3.81-3.74(9H, m), 3.28-3.26 (2H, m), 3.19 (2H, d, J=5.40 Hz), 1.34 (3H, t, J=7.43Hz), 0.91 (6H, s)

Example 8511-(4-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-1-yl)-2-methylpropan-1-one851

A mixture of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-8-piperidin-4-ylmethyl-9H-purine(230 mg, 0.50 mmol), isobutyryl chloride (59 mg, 0.55 mmol) and NEt₃(140 μL, 1.00 mmol) in DCM (10 mL) was allowed to stir at r.t. for 5 hthen concentrated in vacuo. The resulting residue was purified by columnchromatography (Si—PCC, MeOH:DCM, 0-5%) then further purified by reversephase HPLC (Phenomenex Gemini 5 μm C18, 20 mM triethylamine in water ona gradient of acetonitrile 40-98%) affording 851 as a white solid (57mg, 21%). LCMS (method I): R_(T) 3.69 min, [M+H]⁺ 531.4. ¹H NMR (DMSO,400 MHz): δ 8.01-8.00 (1H, m), 7.63-7.62 (1H, m), 7.27-7.23 (2H, m),4.40 (1H, d, J=13.34 Hz), 4.25 (4H, brd s), 3.94 (1H, d, J=13.78 Hz),3.77-3.74 (7H, m), 3.26 (2H, q, J=7.45 Hz), 3.01 (1H, t, J=13.02 Hz),2.87-2.85 (3H, m), 2.50-2.50 (1H, m), 2.12-2.08 (1H, m), 1.77-1.73 (2H,m), 1.33 (3H, t, J=7.44 Hz), 1.29-1.07 (2H, m), 1.00-0.98 (6H, m)

Example 852cyclopropyl(4-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-1-yl)methanone852

A mixture of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-8-piperidin-4-ylmethyl-9H-purine(230 mg, 0.50 mmol), cyclopropyl carbonyl chloride (50 μL, 0.55 mmol)and NEt₃ (140 μL, 1.00 mmol) in DCM (10 mL) was allowed to stir at r.t.for 5 h then concentrated in vacuo. The resulting residue was purifiedby column chromatography (Si—PCC, MeOH:DCM, 0-5%) then further purifiedby reverse phase HPLC (Phenomenex Gemini 5 μm C18, 20 mM triethylaminein water on a gradient of acetonitrile 40-98%) affording 852 as a whitesolid (46 mg, 17%). LCMS (method I): R_(T) 3.59 min, [M+H]⁺ 529.4. ¹HNMR (DMSO, 400 MHz): δ 8.03-7.99 (1H, m), 7.64-7.63 (1H, m), 7.25-7.24(2H, m), 4.45-4.10 (6H, m), 3.77-3.75 (6H, m), 3.27-3.24 (3H, m),3.16-3.00 (1H, m), 2.86 (2H, d, J=7.07 Hz), 2.64-2.47 (1H, m), 2.20-2.08(1H, m), 2.01-1.93 (1H, m), 1.79-1.71 (2H, m), 1.33 (3H, t, J=7.43 Hz),1.30-1.07 (2H, m), 0.74-0.66 (4H, m)

Example 8542-hydroxy-1-(3-((2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-1-yl)-2-methylpropan-1-one854

A mixture of acetic acid1,1-dimethyl-2-{3-[9-methyl-2-(2-isopropylbenzoimidazol-1-yl)-6-morpholin-4-yl-9H-purin-8-ylmethyl]azetidin-1-yl}-2-oxoethylester (56 mg, 0.17 mmol) and LiOH (84 μL, 0.33 mmol, 4M solution) in THF(3 mL) and MeOH (1 mL) was allowed to stir at r.t. for 18 h. FurtherLiOH (495 μL, 1.98 mmol, 4M solution) and the mixture stirred at 50° C.for 5 days. The reaction mixture was concentrated in vacuo and theresulting residue loaded onto an Isolute® SCX-2 cartridge which waswashed with MeOH and the product eluted with 2M NH₃/MeOH. The resultingresidue was purified by column chromatography (Si—PCC, MeOH:EtOAc, 0-5%)then partitioned between DCM and H₂O, the organic phase dried (Na₂SO₄)and concentrated in vacuo. The resulting residue was dissolved in amixture of MeCN and H₂O and allowed to freeze-dry affording 854 as awhite solid (62 mg, 70%). LCMS (method I): R_(T) 3.15 min, [M+H]⁺ 533.4.¹H NMR (DMSO, 400 MHz): δ 7.87-7.86 (1H, m), 7.65-7.64 (1H, m),7.25-7.24 (2H, m), 5.02 (1H, brd s), 4.57 (1H, t, J=8.92 Hz), 4.25 (4H,brd s), 4.18 (1H, dd, J=10.40, 5.66 Hz), 4.03 (1H, t, J=9.00 Hz),3.91-3.90 (1H, m), 3.76 (4H, t, J=4.59 Hz), 3.72 (3H, s), 3.68 (1H, dd,J=9.99, 5.41 Hz), 3.22-3.21 (3H, m), 1.36 (3H, s), 1.34 (3H, s), 1.25(6H, d, J=2.06 Hz)

Example 8552-hydroxy-2-methyl-1-(3-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)azetidin-1-yl)propan-1-one855

A mixture of acetic acid1,1-dimethyl-2-{3-[9-methyl-2-(2-methylbenzoimidazol-1-yl)-6-morpholin-4-yl-9H-purin-8-ylmethyl]azetidin-1-yl}-2-oxoethylester (125 mg, 0.23 mmol) and LiOH (114 μL, 0.46 mmol, 4M solution) inTHF (3 mL) and MeOH (1 mL) was allowed to stir at r.t. for 18 h. FurtherLiOH (343 μL, 1.37 mmol, 4M solution) and the mixture stirred at 50° C.for 5 days. The reaction mixture was concentrated in vacuo and theresulting residue loaded onto an Isolute® SCX-2 cartridge which waswashed with MeOH and the product eluted with 2M NH₃/MeOH. The resultingresidue was purified by column chromatography (Si—PCC, MeOH:EtOAc,0-10%) then dissolved in a mixture of MeCN and H₂O and allowed tofreeze-dry affording 855 as a white solid (88 mg, 77%). LCMS (method I):R_(T) 2.88 min, [M+H]⁺ 505.3. ¹H NMR (DMSO, 400 MHz): δ 8.09-8.08 (1H,m), 7.64-7.61 (1H, m), 7.28-7.27 (2H, m), 5.02 (1H, brd s), 4.57 (1H, t,J=8.94 Hz), 4.26 (4H, brd s), 4.17 (1H, dd, J=10.24, 5.60 Hz), 4.03 (1H,t, J=8.97 Hz), 3.77 (4H, t, J=4.64 Hz), 3.74 (3H, s), 3.67 (1H, dd,J=9.96, 5.41 Hz), 3.21-3.20 (3H, m), 2.85 (3H, s), 1.28-1.21 (6H, m)

Example 859(S)-1-(3-((2-(2-(1-hydroxyethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-1-yl)-2-methylpropan-1-one859

To a solution of(S)-1-[1-(8-azetidin-3-ylmethyl-9-methyl-6-morpholin-4-yl-9H-purin-2-yl)-1H-benzoimidazol-2-yl]ethanol(70 mg, 0.16 mmol) in THF (2 mL) was added DIPEA (30 μL, 0.17 mmol) andisobutyryl chloride (17 μL, 0.16 mmol) and the resulting mixture stirredat r.t. for 1 h. The reaction mixture was partitioned between DCM andsat. aq. NaHCO₃, the organic phase dried (phase separator) andconcentrated in vacuo. The resulting residue was purified by columnchromatography (Si—PCC, MeOH:EtOAc, 0-30%) then (Si—PCC, MeOH:DCM, 0-8%)affording 859 (22 mg, 27%). LCMS (method I): R_(T) 3.46 min, [M+H]⁺519.3. ¹H NMR (DMSO, 400 MHz): δ 7.95-7.95 (1H, m), 7.70-7.69 (1H, m),7.30-7.26 (2H, m), 5.59-5.57 (1H, m), 5.39 (1H, d, J=6.33 Hz), 4.39-4.10(4H, brd s), 4.34 (1H, t, J=8.25 Hz), 4.02 (1H, t, J=8.79 Hz), 3.95 (1H,dd, J=8.47, 5.27 Hz), 3.80-3.75 (4H, m), 3.72 (3H, s), 3.67-3.65 (1H,m), 3.27-3.21 (3H, m), 2.48-2.39 (1H, m), 1.60 (3H, d, J=6.48 Hz), 0.98(3H, d, J=1.76 Hz), 0.96 (3H, d, J=1.78 Hz)

Example 860(R)-1-(3-((2-(2-(1-hydroxyethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-1-yl)-2-methylpropan-1-one860

To a solution of(R)-1-[1-(8-azetidin-3-ylmethyl-9-methyl-6-morpholin-4-yl-9H-purin-2-yl)-1H-benzoimidazol-2-yl]ethanol(57 mg, 0.13 mmol) in DCM (2 mL) was added DIPEA (24 μL, 0.14 mmol) andisobutyryl chloride (14 μL, 0.13 mmol) and the resulting mixture stirredat r.t. for 1 h. The reaction mixture was partitioned between DCM andH₂O, the organic phase dried (phase separator) and concentrated invacuo. The resulting residue was purified by column chromatography(Si—PCC, MeOH:DCM, 0-8%) affording 860 (16 mg, 24%). LCMS (method I):R_(T) 3.46 min, [M+H]⁺ 519.3. ¹H NMR (DMSO, 400 MHz): δ 7.96-7.95 (1H,m), 7.70-7.69 (1H, m), 7.30-7.25 (2H, m), 5.58-5.57 (1H, m), 5.39 (1H,d, J=6.34 Hz), 4.36-4.09 (4H, brd s), 4.35 (1H, t, J=8.22 Hz), 4.02 (1H,t, J=8.79 Hz), 3.95-3.94 (1H, m), 3.80-3.75 (4H, m), 3.72 (3H, s), 3.67(1H, dd, J=9.77, 5.28 Hz), 3.24-3.23 (3H, m), 2.45-2.44 (1H, m), 1.60(3H, d, J=6.49 Hz), 0.98 (3H, d, J=1.77 Hz), 0.97 (3H, d, J=1.79 Hz)

Example 861(R)-2-hydroxy-1-(3-((2-(2-(1-hydroxyethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-1-yl)-2-methylpropan-1-one861

To a solution of(R)-1-[1-(8-azetidin-3-ylmethyl-9-methyl-6-morpholin-4-yl-9H-purin-2-yl)-1H-benzoimidazol-2-yl]ethanol(57 mg, 0.13 mmol) in DCM (2 mL) was added 2-hydroxy-2-methyl-propionicacid (15 mg, 0.14 mmol), HOBt (19 mg, 0.14 mmol), NMM (31 μL, 0.28 mmol)and EDCI (27 mg, 0.14 mmol) and the resulting mixture stirred at r.t.for 1 h. The reaction mixture was partitioned between DCM and H₂O, theorganic phase dried (phase separator) and concentrated in vacuo. Theresulting residue was purified by column chromatography (Si—PCC,MeOH:DCM, 0-10%) affording 861 (14 mg, 21%). LCMS (method I): R_(T) 3.05min, [M+H]⁺ 535.3. ¹H NMR (DMSO, 400 MHz): δ 7.97-7.94 (1H, m),7.71-7.68 (1H, m), 7.30-7.26 (2H, m), 5.58-5.57 (1H, m), 5.39 (1H, d,J=6.33 Hz), 5.02 (1H, s), 4.57-4.56 (1H, m), 4.39-4.14 (4H, brd s), 4.18(1H, dd, J=10.39, 5.70 Hz), 4.04-4.02 (1H, m), 3.80-3.75 (4H, m), 3.72(3H, s), 3.68 (1H, dd, J=9.67, 5.21 Hz), 3.23-3.20 (2H, m), 1.60 (3H, d,J=6.48 Hz), 1.25 (6H, s)

Example 862(S)-1-(4-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-1-yl)-2-hydroxypropan-1-one862

To a mixture of2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-8-piperidin-4-ylmethyl-9H-purinehydrochloride (13 mg, 0.02 mmol), sodium L-lactate (5 mg, 0.04 mmol) andHOBt (4 mg, 0.03 mmol) in THF (1 mL) was added NMM (5 μL, 0.05 mmol) andEDCI (8 mg, 0.04 mmol) and the resulting mixture was stirred at r.t. for1 h. The reaction mixture was partitioned between EtOAc and H₂O, theorganic layer washed with brine, dried (Na₂SO₄) and concentrated invacuo. The resulting residue was purified by column chromatography(Si—PCC, 2M NH₃/MeOH:DCM, 0-10%) affording 862 (12 mg, 92%). LCMS(method I): R_(T) 3.18 min, [M+H]⁺ 533.3. ¹H NMR (MeOD, 400 MHz): δ8.00-7.96 (1H, m), 7.65-7.61 (1H, m), 7.28-7.27 (2H, m), 4.56-4.54 (2H,m), 4.33 (4H, brd s), 4.04-4.04 (1H, m), 3.84 (4H, t, J=4.75 Hz), 3.79(3H, s), 3.17-3.04 (2H, m), 2.92-2.86 (2H, m), 2.76-2.64 (1H, m),2.28-2.25 (1H, m), 1.92-1.82 (2H, m), 1.38 (3H, t, J=7.51 Hz), 1.36-1.26(6H, m)

Example 8631-(4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purine-8-carbonyl)piperidin-1-yl)-2-methylpropan-1-one863

To a solution of4-[2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbonyl]piperidine-1-carboxylicacid tert-butyl ester (58 mg, 0.10 mmol) in DCM (1 mL) was added TFA (1mL) and the resulting mixture stirred at r.t. for 1 h. The reactionmixture was concentrated in vacuo and azeotroped with DCM affording[2-(2-Ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-yl]piperidin-4-ylmethanone.LCMS (method A): R_(T) 2.03 min, [M+H]⁺ 475.3

To a solution of[2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-yl]piperidin-4-ylmethanoneand NEt₃ (27 μL, 0.20 mmol) in DCM (5 mL) was added isobutyryl chloride(10 μL, 0.12 mmol) and the resulting mixture stirred at r.t. for 3 h.The reaction mixture was quenched with H₂O and extracted with DCM. Thecombined organic phases were dried (MgSO₄) and concentrated in vacuo andthe resulting residue loaded onto an Isolute® SCX-2 cartridge which waswashed with MeOH and the product eluted with 2M NH₃/MeOH. The resultingresidue was purified by reverse phase HPLC (Phenomenex Gemini 5 μm C18,0.1% NH₄OH in water on a gradient acetonitrile 40-70%) affording 863 (7mg, 13%). LCMS (method I): R_(T) 4.19 min, [M+H]⁺ 545.3. ¹H NMR (CDCl₃,400 MHz): δ 8.06-8.05 (1H, m), 7.88-7.81 (1H, m), 7.39-7.31 (2H, m),4.75-4.63 (2H, m), 4.14-4.02 (5H, m), 3.93-3.91 (5H, m), 3.51-3.40 (2H,m), 3.31-3.40 (1H, m), 2.84-2.82 (2H, m), 2.08-1.96 (2H, m), 1.89-1.62(4H, m), 1.49 (3H, t, J=7.43 Hz), 1.20-1.12 (6H, m)

Example 864(1-(cyclopropanecarbonyl)piperidin-4-yl)(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methanone864

To a solution of4-[2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbonyl]piperidine-1-carboxylicacid tert-butyl ester (58 mg, 0.10 mmol) in DCM (1 mL) was added TFA (1mL) and the resulting mixture stirred at r.t. for 1 h. The reactionmixture was concentrated in vacuo and azeotroped with DCM affording[2-(2-Ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-yl]piperidin-4-ylmethanone.LCMS (method A): R_(T) 2.03 min, [M+H]⁺ 475.3

To a solution of[2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-yl]piperidin-4-ylmethanone(47 mg, 0.10 mmol) and NEt₃ (27 μL, 0.20 mmol) in DCM (5 mL) was addedcyclopropane carbonyl chloride (10 μL, 0.12 mmol) and the resultingmixture stirred at r.t. for 3 h. The reaction mixture was quenched withH₂O and extracted with DCM. The combined organic phases were dried(MgSO₄) and concentrated in vacuo and the resulting residue loaded ontoan Isolute® SCX-2 cartridge which was washed with MeOH and the producteluted with 2M NH₃/MeOH. The resulting residue was purified by reversephase HPLC (Phenomenex Gemini 5 μm C18, 0.1% NH₄OH in water on agradient acetonitrile 30-70%) affording 864 (13 mg, 25%). LCMS (methodI): R_(T) 4.06 min, [M+H]⁺ 543.3. ¹H NMR (CDCl₃, 400 MHz): δ 8.07-8.06(1H, m), 7.89-7.82 (1H, m), 7.40-7.30 (2H, m), 4.70-4.56 (3H, m),4.39-4.28 (1H, m), 4.13 (3H, s), 3.93-3.90 (6H, m), 3.52-3.27 (3H, m),2.94-2.80 (1H, m), 2.08-1.97 (2H, m), 1.97-1.57 (4H, m), 1.50 (3H, t,J=7.40 Hz), 1.04-0.98 (2H, m), 0.79-0.78 (2H, m)

Example 865cyclopropyl(4-(1-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-1-hydroxyethyl)piperidin-1-yl)methanone865

To a solution of4-{1-[2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-yl]-1-hydroxyethyl}piperidine-1-carboxylicacid tert-butyl ester (104 mg, 0.18 mmol) in DCM (1 mL) was added TFA (1mL) and the resulting mixture stirred for 1 h. The reaction mixture wasconcentrated in vacuo and azeotroped with DCM affording1-[2-(2-Ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-yl]-1-piperidin-4-ylethanol.LCMS (method A): R_(T) 1.88 min, [M+H]⁺ 491.2

A solution of1-[2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-yl]-1-piperidin-4-ylethanoland NEt₃ (74 μL, 0.53 mmol) in DCM (5 mL) was cooled to −78° before theaddition of cyclopropane carbonyl chloride (18 μL, 0.20 mmol). Theresulting mixture was stirred for 15 min then quenched with H₂O andextracted with DCM. The combined organics were dried (phase separator)and concentrated in vacuo. The resulting residue was purified by reversephase HPLC (Phenomenex Gemini 5 μm C18, 0.1% NH₄OH in water on agradient acetonitrile 10-70%) affording 865 as a white solid (44 mg,44%). LCMS (method I): R_(T) 3.51 min, [M+H]⁺ 559.4. ¹H NMR (CDCl₃, 400MHz): δ 8.01-8.00 (1H, m), 7.80 (1H, d, J=7.13 Hz), 7.33-7.28 (2H, m),4.71 (1H, brd s), 4.32 (4H, brd s), 3.98 (3H, s), 3.87 (4H, t, J=4.69Hz), 3.40 (2H, q, J=7.47 Hz), 3.14-2.98 (1H, m), 2.60-2.43 (1H, m),2.20-2.09 (1H, m), 1.86-1.65 (6H, m), 1.62-1.36 (3H, m), 1.47 (3H, t,J=7.47 Hz), 1.00-0.93 (2H, m), 0.75-0.74 (2H, m)

Example 866(9-methyl-2-(2-(methylamino)-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)(3-morpholinoazetidin-1-yl)methanone866

A mixture of(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)-(3-morpholin-4-ylazetidin-1-yl)methanone(211 mg, 0.50 mmol), (1H-benzoimidazol-2-yl)methylamine (81 mg, 0.55mmol), tris(dibenzylideneacetone)dipalladium (12 mg, 0.01 mmol), XPhos(24 mg, 0.05 mmol) and Cs₂CO₃ (245 mg, 0.75 mmol) in dioxane (10 mL) waspurged with argon then heated at 105° C. for 65 h. The reaction mixturewas filtered through Celite®, washing with dioxane and the filtrateconcentrated in vacuo. The resulting residue was purified by columnchromatography (Si—PCC, MeOH:DCM, 0-10%) followed by reverse phase HPLC(Phenomenex Gemini 5 μm C18, 0.1% NH₄OH in water on a gradientacetonitrile 10-90%) affording 866 as a white solid (54 mg, 20%). LCMS(method I): R_(T) 2.57 min, [M+H]⁺ 533.3. ¹H NMR (CDCl₃, 400 MHz): δ8.48 (1H, brd s), 8.27 (1H, d, J=8.02 Hz), 7.51 (1H, d, J=7.84 Hz),7.20-7.19 (1H, m), 7.09-7.07 (1H, m), 4.73-4.66 (1H, m), 4.68-4.16 (4H,brd s), 4.50 (1H, dd, J=10.48, 5.14 Hz), 4.24-4.23 (1H, m), 4.16-4.08(4H, m), 3.90 (4H, t, J=4.66 Hz), 3.77 (4H, t, J=4.58 Hz), 3.30-3.26(4H, m), 2.45-2.42 (4H, m)

Example 867(R)-(2-(2-(1-hydroxyethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(3-morpholinoazetidin-1-yl)methanone

A mixture of(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)-(3-morpholin-4-ylazetidin-1-yl)methanone(164 mg, 0.39 mmol), (R)-1-(1H-benzoimidazol-2-yl)ethanol (70 mg, 0.43mmol), tris(dibenzylideneacetone)dipalladium (36 mg, 0.04 mmol), XPhos(75 mg, 0.16 mmol) and Cs₂CO₃ (255 mg, 0.78 mmol) in toluene (4 mL) waspurged with argon then heated at 140° C. for 1 h in a microwave reactor.The reaction mixture was filtered through Celite®, washing with tolueneand the filtrate concentrated in vacuo. The resulting residue waspurified by column chromatography (Si—PCC, MeOH:DCM, 0-10%) affording867 (40 mg, 18%). LCMS (method I): R_(T) 2.73 min, [M+H]⁺ 548.3. ¹H NMR(CDCl₃, 400 MHz): δ 8.13-8.12 (1H, m), 7.85-7.81 (1H, m), 7.35-7.34 (2H,m), 5.64 (1H, s), 5.41-5.40 (1H, m), 4.78-4.20 (4H, brd s), 4.76-4.68(1H, m), 4.60-4.50 (1H, m), 4.26-4.25 (1H, m), 4.20-4.10 (4H, m), 3.89(4H, t, J=4.72 Hz), 3.85-3.75 (4H, m), 3.37-3.29 (1H, m), 2.58-2.41 (4H,m), 1.80 (3H, d, J=6.53 Hz)

Example 868(S)-(2-(2-(1-hydroxyethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(3-morpholinoazetidin-1-yl)methanone

A mixture of(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)-(3-morpholin-4-ylazetidin-1-yl)methanone(164 mg, 0.39 mmol), (S)-1-(1H-benzoimidazol-2-yl)ethanol (70 mg, 0.43mmol), tris(dibenzylideneacetone)dipalladium (36 mg, 0.04 mmol), XPhos(75 mg, 0.16 mmol) and Cs₂CO₃ (255 mg, 0.78 mmol) in toluene (4 mL) waspurged with argon then heated at 140° C. for 1 h in a microwave reactor.The reaction mixture was filtered through Celite®, washing with tolueneand DCM and the filtrate concentrated in vacuo. The resulting residuewas purified by column chromatography (Si—PCC, MeOH:DCM, 0-10%)affording 868 (121 mg, 55%). LCMS (method I): R_(T) 2.74 min, [M+H]⁺548.3. ¹H NMR (CDCl₃, 400 MHz): δ 8.14-8.09 (1H, m), 7.83-7.82 (1H, m),7.37-7.33 (2H, m), 5.64 (1H, s), 5.42-5.40 (1H, m), 4.76-4.20 (4H, brds), 4.73-4.71 (1H, m), 4.59-4.51 (1H, m), 4.26-4.25 (1H, m), 4.20-4.12(4H, m), 3.88 (4H, t, J=4.71 Hz), 3.83-3.76 (4H, m), 3.37-3.29 (1H, m),2.58-2.42 (4H, m), 1.80 (3H, d, J=6.54 Hz)

Example 869(2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(3-morpholinoazetidin-1-yl)methanone

A mixture of(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)-(3-morpholin-4-ylazetidin-1-yl)methanone(211 mg, 0.50 mmol), 2-iso-propylbenzimidazole (88 mg, 0.55 mmol),tris(dibenzylideneacetone)dipalladium (12 mg, 0.01 mmol), XPhos (24 mg,0.05 mmol) and Cs₂CO₃ (245 mg, 0.75 mmol) in dioxane (10 mL) was purgedwith argon then heated at 105° C. for 22 h. The reaction mixture wasfiltered through Celite®, washing with dioxane and the filtrateconcentrated in vacuo. The resulting residue was purified by columnchromatography (Si—PCC, MeOH:DCM, 0-10%) followed by reverse phase HPLC(Phenomenex Gemini 5 μm C18, 0.1% NH₄OH in water on a gradientacetonitrile 10-90%) affording 869 as a white solid (167 mg, 61%). LCMS(method I): R_(T) 2.86 min, [M+H]⁺ 546.3. ¹H NMR (CDCl₃, 400 MHz): δ7.93-7.92 (1H, m), 7.81 (1H, d, J=7.28 Hz), 7.33-7.23 (2H, m), 4.77-4.36(4H, brd s), 4.73 (1H, dd, J=10.47, 7.11 Hz), 4.52 (1H, dd, J=10.63,5.21 Hz), 4.27-4.24 (1H, m), 4.17-4.08 (5H, m), 4.02-3.99 (1H, m), 3.87(4H, t, J=4.64 Hz), 3.78 (4H, t, J=4.60 Hz), 3.34-3.28 (1H, m),2.50-2.43 (3H, m), 1.49 (6H, d, J=6.83 Hz)

Example 875(4-(2-hydroxypropan-2-yl)piperidin-1-yl)(2-(imidazo[1,2-a]pyridin-5-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methanone

A mixture of[4-(1-hydroxy-1-methylethyl)piperidin-1-yl]-(9-methyl-6-morpholin-4-yl-2-tributylstannanyl-9H-purin-8-yl)methanone(101 mg, 0.15 mmol), 5-bromoimidazo[1,2-a]pyridine (32 mg, 0.16 mmol),Pd(PPh₃)₄ (17 mg, 10 mol %) and Cu(TC) (6 mg, 20 mol %) in dioxane (1.5mL) was purged with argon then heated at 150° C. for 20 min in amicrowave reactor. The reaction mixture was loaded onto an Isolute®SCX-2 cartridge which was washed with MeOH and the product eluted with 2M NH₃/MeOH. The resulting residue was further purified by reverse phaseHPLC (Phenomenex Gemini 5 μm C18, 0.1% NH₄OH in water on a gradientacetonitrile 10-90%) affording 875 as a white solid (22 mg, 29%). LCMS(method I): R_(T) 2.84 min, [M+H]⁺ 505.3. ¹H NMR (CDCl₃, 400 MHz): δ9.30 (1H, s), 8.07-8.05 (1H, m), 7.87 (1H, d, J=8.89 Hz), 7.78 (1H, d,J=1.39 Hz), 7.38 (1H, dd, J=8.90, 7.23 Hz), 4.89-4.86 (1H, m), 4.64-4.61(1H, m), 4.39 (4H, brd s), 4.03 (3H, s), 3.89 (4H, t, J=4.76 Hz),3.22-3.05 (1H, m), 2.81 (1H, td, J=12.92, 2.90 Hz), 1.98-1.95 (1H, m),1.90-1.87 (1H, m), 1.66-1.59 (1H, m), 1.44 (2H, qd, J=12.58, 4.23 Hz),1.24 (6H, d, J=5.99 Hz)

Example 8761-(4-((5-(2-ethyl-1H-benzo[d]imidazol-1-yl)-7-morpholinothiazolo[5,4-d]pyrimidin-2-yl)methyl)piperidin-1-yl)-2-hydroxy-2-methylpropan-1-one

A mixture of acetic acid2-{4-[5-(2-ethylbenzoimidazol-1-yl)-7-morpholin-4-ylthiazolo[5,4-c]pyrimidin-2-ylmethyl]piperidin-1-yl}-1,1-dimethyl-2-oxoethylester (122 mg, 0.21 mmol) and LiOH (500 μL, 1.96 mmol, 4M solution) inTHF (3 mL) and MeOH (3 mL) was allowed to stir at r.t. for 2 h. Thereaction mixture was loaded onto an Isolute® SCX-2 cartridge which waswashed with MeOH and the product eluted with 2M NH₃/MeOH. The resultingresidue was purified by column chromatography (Si—PCC, MeOH:DCM, 0-5%)followed by reverse phase HPLC (Phenomenex Gemini 5 μm C18, 0.1% NH₄OHin water on a gradient acetonitrile 40-80%) affording 876 as a whitesolid (45 mg, 39%). LCMS (method I): R_(T) 3.94 min, [M+H]⁺ 550.4. ¹HNMR (DMSO, 400 MHz): δ 8.00-7.99 (1H, m), 7.84-7.80 (1H, m), 7.35-7.30(2H, m), 4.43 (4H, brd s), 3.89 (4H, t, J=4.72 Hz), 3.39 (2H, q, J=7.46Hz), 3.05 (2H, d, J=7.14 Hz), 2.91 (2H, brd s), 2.17-2.15 (1H, m), 1.90(3H, d, J=13.40 Hz), 1.50 (6H, s), 1.46 (3H, t, J=7.49 Hz), 1.39-1.28(3H, m)

Example 901 PI3K Isoform Inhibition Assay (p110 Alpha, Beta, Gamma,Delta: α, β, γ, δ)

PI3K enzymatic activity was assayed by measuring the amount of productphosphatidylinositol 3,4,5-phosphate (PIP3) formed from substrate 4,5phosphatidylinositol 4,5-phosphate (PIP2) using a fluorescencepolarization displacement assay. The decrease in fluorescencepolarization of a fluorescent PIP₃ probe is measured as it is displacedfrom a PIP₃-binding protein GRP-1 detector by PI3K-catalyzed product.Assays were conducted in 384-well black Proxiplates in the presence of10 mM Tris (pH 7.5), 50 mM NaCl, 4 mM MgCl₂, 5% glycerol, 25 μM ATP, 10μM PIP₂ (Echelon Biosciences), 0.05%3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate, 1 mMdithiothreitol, and 2% DMSO. The kinase reactions were initiated by theaddition of 40 ng/mL p110α/p85α, 300 ng/mL p110β/p85α, 40 ng/mL p110γ,or 40 ng/mL p110δ/p85α (Upstate Group, Millipore; Dundee, UK), and 10 μMPIP₂ (Echelon Biosciences) to the wells. The reactions were stopped attimepoints that yielded a fixed change in fluorescence polarizationconsistent with initial rate conditions (typically 30 minutes), by theaddition of 12.5 mM EDTA, 100 nM GRP-1 detector, and 5 nMtetramethylrhodamine-labeled PIP₃ (TAMRA-PIP₃; Echelon Biosciences).After 60 minutes of incubation at room temperature to allowequilibration of labeled and unlabeled PIP3 binding, the parallel andperpendicular components of the fluorescence emissions from each samplewere measured at an excitation wavelength of 530 nm and an emissionwavelength of 590 nm using an Envision fluorescent plate reader with arhodamine filter (PerkinElmer Life and Analytical Sciences; Wellesley,Mass.). The assay is capable of detecting 0.1-2.0 μM PIP₃ product. TheIC₅₀ values were obtained by fitting the dose-dependent inhibition datato a 4-parameter equation using Assay Explorer software (MDL, San Ramon,Calif.).

Alternatively, inhibition of PI3K was determined in a radiometric assayusing purified, recombinant enzyme and ATP at a concentration of 1 uM.The Formula I compound was serially diluted in 100% DMSO. The kinasereaction was incubated for 1 h at room temperature, and the reaction wasterminated by the addition of PBS. IC₅₀ values were subsequentlydetermined using sigmoidal dose-response curve fit (variable slope).

The same protocol may be used to establish IC₅₀ values for p110α (alpha)PI3K binding.

Recombinant PI3K p110 isoforms alpha, beta, and delta may be preparedand purified according to US 2008/0275067 from recombinant PI3Kheterodimeric complexes consisting of a p110 catalytic subunit and a p85regulatory subunit overexpressed using the BAC-TO-BAC®. HT baculovirusexpression system (GIBCO/BRL), and then purified for use in biochemicalassays. The four Class I PI 3-kinases are cloned into baculovirusvectors as follows:

p110 delta: A FLAG™-tagged (Eastman Kodak Co., U.S. Pat. No. 4,703,004;U.S. Pat. No. 4,782,137; U.S. Pat. No. 4,851,341) version of humanp110.delta (Chantry et al., J. Biol. Chem. (1997) 272:19236-41) issubcloned using standard recombinant DNA techniques into the BamH1-Xba1site of the insect cell expression vector pFastbac HTb (LifeTechnologies, Gaithersburg, Md.), such that the clone is in frame withthe His tag of the vector.

p110 alpha: Similar to the method used for p110 delta, described above,a FLAG™-tagged version of p110 alpha (Volinia et al (1994) Genomics,24(3):427-77) was subcloned in BamH1-HindIII sites of pFastbac HTb (LifeTechnologies) such that the clone was in frame with the His tag of thevector.

p110 beta: A p110 beta (see Hu et al (1993) Mol. Cell. Biol.,13:7677-88) clone was amplified from the human MARATHON™ Ready spleencDNA library (Clontech, Palo Alto Calif.) according to themanufacturer's protocol using the specified primers.

The p110 delta binding IC50 values and delta/alpha selectivity ofselected compounds from Tables 1 and 2 include:

p110 delta IC50 IC50 p110 alpha/IC50 Compound No. (micromolar) p110delta 101 0.101 53 112 0.0018 29 115 0.0072 34 131 0.0013 32 149 0.006930 158 0.0016 84 162 0.0146 191 200 0.0222 54 211 0.0097 >300 2400.00274 64 248 0.0429 35 489 0.00137 157 490 0.00238 111 499 0.0063 75501 0.000589 140 521 0.00145 150 528 0.00061 136 531 0.00108 96 5350.0099 49 549 0.0094 14 676 0.0136 14 683 0.0317 23 689 0.0258 23 7010.000658 50

Example 902 Collagen Induced Arthritis Efficacy Test

The efficacy of Formula I compound inhibitors of PI3K delta to inhibitthe induction and/or progression of collagen induced arthritis wastested in mice. DBA1/J male mice (Jackson Labs; 5-6 weeks of age) areacclimatized for one week and are then injected intra-dermally at thebase of the tail with 0.1 ml of an emulsion of Bovine Type II Collagen(100 mg) and an equal volume of Complete Freunds Adjuvant (200 mgMycobacterium tuberculosis). Three weeks later, mice are injectedintra-dermally at the base of the tail with 0.1 ml of an emulsion ofBovine Type II Collagen (100 mg) and an equal volume of IncompleteFreunds Adjuvant for boost. Dosing generally starts as soon as animalsdisplay signs of joint inflammation or clinical score 1-2.

All mice are evaluated 2-3 times a week for arthritis using amacroscopic scoring system for each paw. At the end of the experimentclinical scores are obtained to evaluate the intensity of edema in thefour paws. A score of 0 to 4 is assigned to each paw. Animals are scored0 when no inflammatory signs (swelling and redness) are observed in anyof the small joints (intraphalangeal, metacarpophalangeal,metatarsophalangeal) or large joints (wrist/carpus, ankle/tarsus).Animals are scored 1 when very slight to slight inflammation wasobserved (swelling and/or redness of paw or one digit), 2 moderateedema(swelling in two or more joint), 3 severe edema(gross swelling ofthe paw with more than two joints involved), and 4 when very severeedema(severe arthritis of the entire paw and digits) is present. Thearthritic index for each mouse is evaluated by adding the four scores ofthe individual paws, giving a maximum score of 16. Plasma and serumsamples are taken at 1 hour (orbital bleed) post dose and 24 hrs(cardiac puncture) post dose. Samples are stored at −20° C. untilanalysis. At termination, the hind paws are transected at the distaltibia, just proximal to the tarsal joint. The left and right hind pawsare placed in the histology cassettes individually and fixed in 10%formalin. These paws are sent to histology dept for further process.

Materials: Bovine Type II collagen, immunization grade, 2 mg/ml (5ml/vial) in 0.05 M acetic acid (solution), store at −20° C., fromChondrex, LLC, Seattle, Wash. Adjuvant complete H37 Ra, 6×10 ml/box,contains 1 mg/ml Mycobacterium tuberculosis. For use in animalimmunological studies, for laboratory use, store at +4° C., from DifcoLaboratories, Detroit, Mich. 48232-7058 USA. Adjuvant Incomplete H37 Ra,6×10 ml/box: For use in animal immunological studies, for laboratoryuse, store at +4° C., from Difco Laboratories.

Example 903 CD69 Whole Blood Assay

Human blood is obtained from healthy volunteers, with the followingrestrictions: 1 week drug-free, non-smokers. Blood (approximately 20 mlsto test 8 compounds) is collected by venipuncture into Vacutainer tubeswith sodium heparin.

Cynomolgus monkey blood is obtained courtesy of the LAT group frommonkeys not previously exposed to, or after a washout period from,chemical dosing. Additional cyno blood draws may be collected during thecourse of pharmacokinetic or toxicology studies. Blood (25-30 mls fornaïve monkeys or 3-4 mls from monkeys on studies requiring repeateddraws) is collected by venipuncture into Vacutainer tubes with sodiumheparin.

Solutions of Formula I compounds at 1000 or 2000 μM in PBS (20×), arediluted by three-fold serial dilutions in 10% DMSO in PBS for a ninepoint dose-response curve. An aliquot of 5.5 μl of each compound isadded in duplicate to a 2 ml 96-well plate; 5.5 μl of 10% DMSO in PBS isadded as control and no-stimulus wells. Human whole blood—HWB (100 μl)is added to each well. After mixing the plates are incubated at 37° C.,5% CO₂, 100% humidity for 30 minutes. Goat F(ab′)2 anti-human IgM (10 μlof a 500 ng/ml solution, 50 μg/ml final) is added to each well (exceptthe no-stimulus wells) with mixing and the plates are incubated for anadditional 20 hours. At the end of the 20 hour incubation, samples areincubated with florescent labeled antibodies for 30 minutes, at 37° C.,5% CO₂, 100% humidity. Include induced control, unstained and singlestains for compensation adjustments and initial voltage settings.Samples are then lysed with Pharmingen Lyse according to themanufacturer's instructions. Samples are then transferred to a 96 wellplate suitable to be run on the AMS 96 well system on the BD CaliburFACs machine. Data acquired and Mean Fluorescence Intensity values wereobtained using Cell Quest Software. Results are initially analyzed byFACS analysis software (Flow Jo). The IC50 for test compounds is definedas the concentration which decreases by 50% the percent positive of CD69cells that are also CD20 positive stimulated by anti-IgM (average of 8control wells, after subtraction of the average of 8 wells for theno-stimulus background). The IC50 values are calculated by Activityl)aseusing Xlfit version 3, equation 201.

The IC50 values of selected compounds from Tables 1 and 2 in the CD69Whole Blood Assay include:

Compound No. IC50 (nanomolar) 240 17.8 314 44.1 388 51.1 403 22.0 40620.6 427 56.7 428 34.2 438 65.9 490 38.3 689 29.0 702 28.6

The foregoing description is considered as illustrative only of theprinciples of the invention. Further, since numerous modifications andchanges will be readily apparent to those skilled in the art, it is notdesired to limit the invention to the exact construction and processshown as described above. Accordingly, all suitable modifications andequivalents may be considered to fall within the scope of the inventionas defined by the claims that follow.

The words “comprise,” “comprising,” “include,” “including,” and“includes” when used in this specification and in the following claimsare intended to specify the presence of stated features, integers,components, or steps, but they do not preclude the presence or additionof one or more other features, integers, components, steps, or groupsthereof.

1. A method of treating a disease or disorder comprising administering acompound to a patient with an immune-inflammatory disease mediated bythe p110 delta isoform of PI3 kinase, wherein the compound is selectedfrom Formulas Ia and Ib:

and stereoisomers, tautomers, or pharmaceutically acceptable saltsthereof, wherein (i) X¹ is N and X² is S, (iii) X¹ is N and X² is NR²,or (iv) X¹ is CR⁷ and X² is O; R¹ is selected from C₆-C₂₀ aryl, C₂-C₂₀heterocyclyl, C₃-C₁₂ carbocyclyl, C₁-C₂₀ heteroaryl, —(C₁-C₁₂alkylene)-(C₃-C₁₂ carbocyclyl), —(C₁-C₁₂ alkylene)-(C₂-C₂₀heterocyclyl), —(C₁-C₁₂ alkylene)-(C₂-C₂₀ heterocyclyl)-(C₂-C₂₀heterocyclyl), —(C₁-C₁₂ alkylene)-(C₂-C₂₀ heterocyclyl)-(C₃-C₁₂carbocyclyl), —(C1-C₁₂ alkylene)-(C₂-C₂₀ heterocyclyl)-C(═O)—(C₂-C₂₀heterocyclyl), —(C₁-C₁₂ alkylene)-(C₁-C₂₀ heteroaryl), —(C₁-C₁₂alkylene)-(C₂-C₂₀ heterocyclyl)-(C₁-C₁₂ alkyl), —(C₁-C₁₂alkylene)-(C₆-C₂₀ aryl)-(C₁-C₁₂ alkyl), —(C₁-C₁₂ alkylene)-(C₁-C₂₀heteroaryl)-(C₁-C₁₂ alkyl), —(C₁-C₁₂ alkylene)-C(═O)—(C₂-C₂₀heterocyclyl), —(C₁-C₁₂ alkylene)-NHR^(2′), —(C₁-C₁₂alkylene)-NR^(2′)—(C₁-C₁₂ alkyl), —(C₁-C₁₂ alkylene)-NR^(2′)—(C₃-C₁₂carbocyclyl), —(C₁-C₁₂ alkylene)-NR^(2′)—(C₂-C₂₀ heterocyclyl), —(C₁-C₁₂alkylene)-NR^(2′)—(C₁-C₂₀ heteroaryl), —(C₁-C₁₂alkylene)-NR^(2′)—(C₆-C₂₀ aryl), —(C₁-C₁₂ alkylene)-NR^(2′)—(C₁-C₁₂alkylene)-(C₃-C₁₂ carbocyclyl), —(C₁-C₁₂ alkylene)-NR^(2′)—(C₁-C₁₂alkylene)-(C₁-C₂₀ heteroaryl), —(C₁-C₁₂ alkylene)-NR^(2′)—(C₁-C₁₂alkylene)-(C₁-C₂₀ heterocyclyl), —(C₁-C₁₂ alkylene)-NR^(2′)—(C₁-C₁₂alkylene)-(C₆-C₂₀ aryl), —(C₁-C₁₂ alkylene)-NR^(2′)—(C₁-C₁₂alkylene)-NHC(═O)—(C₁-C₂₀ heteroaryl), —(C₁-C₁₂ alkylene)-(C₂-C₂₀heterocyclyl)-N(C₁-C₁₂ alkyl)R^(2′), —(C₁-C₁₂ alkylene)-(C₂-C₂₀heterocyclyl)-(C₁-C₁₂ alkyl)-N(C₁-C₁₂ alkyl)R^(2′), —(C₂-C₁₂alkenylene)-(C₁-C₂₀ heterocyclyl), —(C₁-C₂₀ heteroaryl)-(C₂-C₂₀heterocyclyl), —(C₁-C₂₀ heteroaryl)-(C₃-C₁₂ carbocyclyl), —C(═O)—(C₂-C₂₀heterocyclyl), —C(═O)—(C₁-C₂₀ heteroaryl), —C(═O)—(C₂-C₂₀heterocyclyl)-(C₂-C₂₀ heterocyclyl), —C(═O)—(C₂-C₂₀heterocyclyl)-(C₁-C₂₀ heteroaryl), —C(═O)—(C₁-C₁₂ alkyl),—C(═O)—NR^(2′)—(C₁-C₁₂ alkyl), and —CR⁴═CR⁵R⁶ where R⁴ is selected fromH, F, Cl, Br, I and C₁-C₁₂ alkyl, and R⁵ and R⁶ form C₂-C₂₀heterocyclyl, C₁-C₂₀ heteroaryl, or C₃-C₁₂ carbocyclyl, where alkyl,alkenyl, alkynyl, alkylene, carbocyclyl, heterocyclyl, aryl, andheteroaryl are optionally substituted with one or more groupsindependently selected from F, Cl, Br, I, —CH₃, —CH₂CH₃, —CH₂CH(CH₃)₂,—CH₂NH₂, —CH₂N(CH₃)₂, —CH₂CH₂NH₂, —CH₂CH₂N(CH₃)₂, —CH₂OH, —CH₂OH,—CH₂OCH₃, —CH₂CH₂OH, —C(CH₃)₂OH, —CH₂C(CH₃)₂OH, —CH(OH)CH(CH₃)₂,—C(CH₃)₂CH₂OH, —CH₂CH₂SO₂CH₃, —CN, —CF₃, —CO₂H, —CHO, —COCH₃, —CO₂CH₃,—CO₂C(CH₃)₃, —COCH₂OH, —COC(OH)(CH₃)₂, —COCH(OH)CH₃, —CONH₂, —CONHCH₃,—CON(CH₃)₂, —CH₂CONH₂, —CH₂CON(CH₃)₂, —C(CH₃)₂CONH₂, —NO₂, —NH₂, —NHCH₃,—N(CH₃)₂, —NHCOCH₃, —N(CH₃)COCH₃, —NHS(O)₂CH₃, —N(CH₃)C(CH₃)₂CONH₂,—N(CH₃)CH₂CH₂S(O)₂CH₃, ═O, —OH, —OCH₃, —S(O)₂N(CH₃)₂, —SCH₃, —CH₂OCH₃,—S(O)₂CH₃, —C(O)-cyclopropyl, cyclopropyl, cyclobutyl, oxetanyl, andmorpholino; R² and R^(2′) are independently selected from H, C₁-C₁₂alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, —(C₁-C₁₂ alkylene)-(C₃-C₁₂carbocyclyl), —(C₁-C₁₂ alkylene)-(C₂-C₂₀ heterocyclyl), —(C₁-C₁₂alkylene)-C(═O)—(C₂-C₂₀ heterocyclyl), —(C₁-C₁₂ alkylene)-(C₆-C₂₀ aryl),and —(C₁-C₁₂ alkylene)-(C₁-C₂₀ heteroaryl), where alkyl, alkenyl,alkynyl, alkylene, carbocyclyl, heterocyclyl, aryl, and heteroaryl areoptionally substituted with one or more groups independently selectedfrom F, Cl, Br, I, —CH₃, —CH₂OH, —CN, —CF₃, —CO₂H, —COCH₃, —COC(CH₃)₃,—COCF₃, —CO₂CH₃, —CONH₂, —CONHCH₃, —CON(CH₃)₂, —NO₂, —NH₂, —NHCH₃,—NHCOCH₃, —NHS(O)₂CH₃, —OH, —OCH₃, —S(O)₂N(CH₃)₂, —SCH₃, —CH₂OCH₃, and—S(O)₂CH₃; R³ is:

where R⁸ is selected from H, F, Cl, Br, I, —CH₃, —CH₂CH₃, —CH₂CH₂CH₃,—CH(CH₃)₂, —C(CH₃)₃, —CH₂OCH₃, —CHF₂, —CH₂CN, —CN, —CF₃, —CH₂OH,—CH₂OCH₃, —CH₂CH₂OH, —CH₂C(CH₃)₂OH, —CH(CH₃)OH, —CH(CH₂CH₃)OH,—CH₂CH(OH)CH₃, —CH₂CH(OCH₃)CH₃, —C(CH₃)₂OH, —C(CH₃)₂OCH₃, —CH(CH₃)F,—C(CH₃)F₂, —CH(CH₂CH₃)F, —C(CH₂CH₃)₂F, —CO₂H, —CONH₂, —CON(CH₂CH₃)₂,—COCH₃, —CON(CH₃)₂, —NO₂, —NH₂, —NHCH₃, —N(CH₃)₂, —NHCH₂CH₃,—NHCH(CH₃)₂, —NHCH₂CH₂OH, —NHCH₂CH₂OCH₃, —NHCOCH₃, —NHCOCH₂CH₃,—NHCOCH₂OH, —NHS(O)₂CH₃, —N(CH₃)S(O)₂CH₃, —OH, —OCH₃, —OCH₂CH₃,—OCH(CH₃)₂, —SH, —NHC(═O)NHCH₃, —NHC(═O)NHCH₂CH₃, —S(O)CH₃, —S(O)CH₂CH₃,—S(O)₂CH₃, —S(O)₂NH₂, —S(O)₂NHCH₃, —S(O)₂N(CH₃)₂, —CH₂S(O)₂CH₃, and agroup selected from

R⁹ is independently selected from F, Cl, Br, I, —CH₃, —CH₂CH₃,—CH₂CH₂CH₃, —CH(CH₃)₂, —CH₂CH(CH₃)₂, —CH₂OH, —CH₂CH₂OH, —CN, —CF₃,—CO₂H, —COCH₃, —CO₂CH₃, —CONH₂, —CONHCH₃, —CON(CH₃)₂, —NO₂, —NH₂,—NHCH₃, —NHCOCH₃, —NHS(O)₂CH₃, —OH, —OCH₃, —S(O)₂N(CH₃)₂, —SCH₃,—CH₂OCH₃, and —S(O)₂CH₃; and n is 0, 1, 2, 3, or 4; R⁷ is selected fromH, C₁-C₁₂ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, —(C₁-C₁₂alkylene)-(C₃-C₁₂ carbocyclyl), —(C₁-C₁₂ alkylene)-(C₂-C₂₀heterocyclyl), —(C₁-C₁₂ alkylene)-C(═O)—(C₂-C₂₀ heterocyclyl), —(C₁-C₁₂alkylene)-(C₆-C₂₀ aryl), and —(C₁-C₁₂ alkylene)-(C₁-C₂₀ heteroaryl),where alkyl, alkenyl, alkynyl, alkylene, carbocyclyl, heterocyclyl,aryl, and heteroaryl are optionally substituted with one or more groupsindependently selected from F, Cl, Br, I, —CH₃, —CH₂CH₃, —CH₂OH, —CN,—CF₃, —CO₂H, —COCH₃, —CO₂CH₃, —CONH₂, —CONHCH₃, —CON(CH₃)₂, —NO₂, —NH₂,—NHCH₃, —NHCOCH₃, —NHS(O)₂CH₃, ═O, —OH, —OCH₃, —S(O)₂N(CH₃)₂, —SCH₃,—CH₂OCH₃, and —S(O)₂CH₃; mor is a morpholine group or a bicyclicstructure selected from:

optionally substituted with one or more groups selected from F, Cl, Br,I, —CH₃, —CH₂CH₃, —CH₂CH₂CH₃, —CH(CH₃)₂, —C(CH₃)₃, —CH₂OCH₃, —CHF₂, —CN,—CF₃, —CH₂OH, —CH₂OCH₃, —CH₂CH₂OH, —CH₂C(CH₃)₂OH, —CH(CH₃)OH,—CH(CH₂CH₃)OH, —CH₂CH(OH)CH₃, —C(CH₃)₂OH, —C(CH₃)₂OCH₃, —CH(CH₃)F,—C(CH₃)F₂, —CH(CH₂CH₃)F, —C(CH₂CH₃)₂F, —CO₂H, —CONH₂, —CON(CH₂CH₃)₂,—COCH₃, —CON(CH₃)₂, —NO₂, —NH₂, —NHCH₃, —N(CH₃)₂, —NHCH₂CH₃,—NHCH(CH₃)₂, —NHCH₂CH₂OH, —NHCH₂CH₂OCH₃, —NHCOCH₃, —NHCOCH₂CH₃,—NHCOCH₂OH, —NHS(O)₂CH₃, —N(CH₃)S(O)₂CH₃, ═O, —OH, —OCH₃, —OCH₂CH₃,—OCH(CH₃)₂, —SH, —NHC(═O)NHCH₃, —NHC(═O)NHCH₂CH₃, —S(O)CH₃, —S(O)CH₂CH₃,—S(O)₂CH₃, —S(O)₂NH₂, —S(O)₂NHCH₃, —S(O)₂N(CH₃)₂, CH₂S(O)₂CH₃; andwherein the IC50 binding activity to p110 delta is ten or more timeslower than the binding activity to p110 alpha.
 2. The method of claim 1wherein the immune-inflammatory disease is selected from rheumatoidarthritis, immune suppression, organ transplant rejection, allergies,ulcerative colitis, Crohn's disease, dermatitis, asthma, systemic lupuserythematosus, Sjögren's Syndrome, multiple sclerosis,scleroderma/systemic sclerosis, idiopathic thrombocytopenic purpura(ITP), anti-neutrophil cytoplasmic antibodies (ANCA) vasculitis, chronicobstructive pulmonary disease (COPD), and psoriasis.
 3. The method ofclaim 1 wherein the immune-inflammatory disease is an arthritic diseaseselected from rheumatoid arthritis, monoarticular arthritis,osteoarthritis, and gouty arthritis.
 4. The method of claim 2 whereinthe immune-inflammatory disease is rheumatoid arthritis.
 5. The methodof claim 1 further comprising administering an additional therapeuticagent selected from a chemotherapeutic agent, an anti-inflammatoryagent, an immunomodulatory agent, a neurotropic factor, an agent fortreating cardiovascular disease, an agent for treating liver disease, ananti-viral agent, an agent for treating blood disorders, an agent fortreating diabetes, and an agent for treating immunodeficiency disorders.6. The compound of claim 1 selected from the structures:


7. The compound of claim 1 selected from the structures:


8. The compound of claim 1 selected from the structures:


9. The compound of claim 1 wherein R¹ is selected from the structures

where the wavy line indicates the site of attachment.
 10. The compoundof claim 1 wherein R² is C₁-C₁₂ alkyl optionally substituted with one ormore groups independently selected from F, Cl, Br, I, —CH₃, —CH₂OH, —CN,—CF₃, —CO₂H, —COCH₃, —CO₂CH₃, —CONH₂, —CONHCH₃, —CON(CH₃)₂, —NO₂, —NH₂,—NHCH₃, —NHCOCH₃, —NHS(O)₂CH₃, —OH, —OCH₃, —S(O)₂N(CH₃)₂, —SCH₃,—CH₂OCH₃, and —S(O)₂CH₃.
 11. The compound of claim 10 wherein R² is CH₃.12. The compound of claim 1 having the structure:


13. The compound of claim 1 wherein R⁷ is H.
 14. The compound of claim 1wherein R⁷ is C₁-C₁₂ alkyl optionally substituted with one or moregroups independently selected from F, Cl, Br, I, —CH₃, —CH₂OH, —CN,—CF₃, —CO₂H, —COCH₃, —CO₂CH₃, —CONH₂, —CONHCH₃, —CON(CH₃)₂, —NO₂, —NH₂,—NHCH₃, —NHCOCH₃, —NHS(O)₂CH₃, —OH, —OCH₃, —S(O)₂N(CH₃)₂, —SCH₃,—CH₂OCH₃, and —S(O)₂CH₃.
 15. The compound of claim 14 wherein R⁷ is CH₃.16. The compound of claim 1 having the structure:


17. The compound of claim 16 wherein R² is C₁-C₁₂ alkyl optionallysubstituted with one or more groups independently selected from F, Cl,Br, I, —CH₃, —CH₂OH, —CN, —CF₃, —CO₂H, —COCH₃, —CO₂CH₃, —CONH₂,—CONHCH₃, —CON(CH₃)₂, —NO₂, —NH₂, —NHCH₃, —NHCOCH₃, —NHS(O)₂CH₃, ═O,—OH, —OCH₃, —S(O)₂N(CH₃)₂, —SCH₃, —CH₂OCH₃, and —S(O)₂CH₃.
 18. Thecompound of claim 17 wherein R² is CH₃.
 19. The compound of claim 1selected from:4-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)morpholine;1-(8-((4-(2-hydroxypropan-2-yl)piperidin-1-yl)methyl)-9-methyl-6-morpholino-9H-purin-2-yl)-1H-benzo[d]imidazol-2(3H)-one;2-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;2-(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;2-(1-((2-(2-cyclopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;2-(1-(2-(2-(methoxymethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;2-(1-((2-(2-methoxy-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;2-(1-((2-(2-amino-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;2-(1-((2-(2-(hydroxymethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;4-(8-((4-(2-methoxypropan-2-yl)piperidin-1-yl)methyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine;(3S,4R)-3-fluoro-N,N-dimethyl-1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-amine;1-(7-morpholino-2-((3-morpholinoazetidin-1-yl)methyl)thiazolo[5,4-d]pyrimidin-5-yl)-1H-benzo[d]imidazol-2(3H)-one;4-(5-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-2-((3-morpholinoazetidin-1-yl)methyl)thiazolo[5,4-d]pyrimidin-7-yl)morpholine;2-(1-((9-methyl-6-morpholino-2-(2-(trifluoromethyl)-1H-benzo[d]imidazol-1-yl)-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;2-isobutyl-4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)morpholine;2-(1-((2-(2-(dimethylamino)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;2,2-diethyl-4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)morpholine;4-(5-(2-methyl-1H-benzo[d]imidazol-1-yl)-2-((3-morpholinoazetidin-1-yl)methyl)thiazolo[5,4-d]pyrimidin-7-yl)morpholine;2,6-dimethyl-4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)morpholine;2-(1-((2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;2,2-dimethyl-4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)morpholine;2-(1-((2-(2-(1,1-difluoroethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;(R)-2-(1-((2-(2-(1-hydroxyethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;(S)-2-(1-((2-(2-(1-hydroxyethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;2-(1-((2-(2-(benzyl(methyl)amino)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;2-(1-((9-methyl-2-(2-(methylamino)-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;2-(1-((9-methyl-6-morpholino-2-(2-phenyl-1H-benzo[d]imidazol-1-yl)-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;2-(1-((2-(2-(2-hydroxyethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;2-(1-((9-methyl-6-morpholino-2-(2-(pyridin-3-yl)-1H-benzo[d]imidazol-1-yl)-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;2-(1-((5-(2-methyl-1H-benzo[d]imidazol-1-yl)-7-morpholinothiazolo[5,4-d]pyrimidin-2-yl)methyl)piperidin-4-yl)propan-2-ol;2-(1-((9-methyl-6-morpholino-2-(2-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-1-yl)-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;(3R,4S)-1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-3-fluoro-N,N-dimethylpiperidin-4-amine;(3S,4R)-1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-3-fluoro-N,N-dimethylpiperidin-4-amine;2-(1-((9-methyl-6-morpholino-2-(2-propyl-1H-benzo[d]imidazol-1-yl)-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;2-(1-((9-ethyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;2-(1-((2-(2-cyclobutyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;2-(1-((9-methyl-6-morpholino-2-(2-morpholino-1H-benzo[d]imidazol-1-yl)-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;2-methyl-2-(4-((2-(2-methyl-1H-benzo[d]imidazol-1-yl)-4-morpholinofuro[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)propanamide;2-(1-((2-(2-methyl-1H-benzo[d]imidazol-1-yl)-4-morpholinofuro[3,2-d]pyrimidin-6-yl)methyl)piperidin-4-yl)propan-2-ol;2-(2-methyl-1H-benzo[d]imidazol-1-yl)-4-morpholino-6-((3-morpholinoazetidin-1-yl)methyl)furo[3,2-d]pyrimidine;(S)-2-(1-((9-methyl-6-morpholino-2-(2-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-1-yl)-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;(R)-2-(1-((9-methyl-6-morpholino-2-(2-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-1-yl)-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;2-(1-((2-(2-(ethylamino)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;4-(5-(2-methyl-1H-benzo[d]imidazol-1-yl)-2-((3-morpholinoazetidin-1-yl)methyl)thiazolo[4,5-d]pyrimidin-7-yl)morpholine;and3-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)oxetan-3-ol.20. The compound of claim 1 selected:2,2-dimethyl-N-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)propan-1-amine;1-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)-N-((3-methyloxetan-3-yl)methyl)methanamine;1-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)cyclobutanol;2-(1-((9-methyl-6-morpholino-2-(2-(pyrrolidin-1-yl)-1H-benzo[d]imidazol-1-yl)-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;2-(1-((2-(2-(3-fluorooxetan-3-yl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;3-(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)oxetan-3-ol;2-methyl-2-(4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)propan-1-ol;2-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-3-yl)propan-2-ol;2-methyl-1-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;4-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-8-((4-(2,2,2-trifluoroethyl)piperazin-1-yl)methyl)-9H-purin-6-yl)morpholine;(4-methyl-1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)methanol;(R)-2-hydroxy-1-(4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)propan-1-one;adamantan-1-yl-[9-methyl-2-(2-methyl-benzoimidazol-1-yl)-6-morpholin-4-yl-9H-purin-8-ylmethyl]-amine;N-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)-2,3-dihydro-1H-inden-1-amine;—N-((9-methyl-2-(2-methyl-1-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)bicyclo[2.2.1]heptan-2-amine;1-(((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methylamino)methyl)cyclohexanol;(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methylamino)cyclopentyl)methanol;N,1-dimethyl-N-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-amine;4-(8-(isoindolin-2-ylmethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine;4-(8-((4-(cyclopropylmethyl)piperazin-1-yl)methyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine;4-(8-((4,4-difluoropiperidin-1-yl)methyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine;N-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)-1-phenylethanamine;4-(8-((4-(methoxymethyl)piperidin-1-yl)methyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine;4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methylamino)cyclohexanol;1-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)-N-((1-methylpiperidin-2-yl)methyl)methanamine;4-(8-((dihydro-1H-pyrido[1,2-a]pyrazin-2(6H,7H,8H,9H,9aH)-yl)methyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine;1-methyl-N-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-amine;N,2-dimethyl-N-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)propan-1-amine;1-(4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methylamino)piperidin-1-yl)ethanone;4-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)pyrrolidin-3-yl)morpholine;N-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)tetrahydro-2H-pyran-4-amine;4-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-8-((3-(trifluoromethyl)pyrrolidin-1-yl)methyl)-9H-purin-6-yl)morpholine;N-methyl-1-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)-N-((tetrahydrofuran-2-yl)methyl)methanamine;1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidine-4-carbonitrile;2-methyl-1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methylamino)propan-2-ol;3,3,3-trifluoro-N-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)propan-1-amine;4,4-difluoro-N-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)cyclohexanamine;1-isopropyl-N-methyl-N-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-amine;N,N-diethyl-1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)pyrrolidin-3-amine;1-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)-N-((tetrahydrofuran-3-yl)methyl)methanamine;N-methyl-N-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)pyrrolidin-3-yl)acetamide;(R)-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)pyrrolidin-3-yl)methanol;4-(8-((3,3-dimethylpyrrolidin-1-yl)methyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine;4-(8-((3,3-diethylpyrrolidin-1-yl)methyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine;4-(8-((3-isobutylpyrrolidin-1-yl)methyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine;N-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)-2-phenylpropan-2-amine;4-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-8-((1,1-dioxo-4-(tetrahydro-2H-thiopyran-4-yl)piperazin-1-yl)methyl)-9H-purin-6-yl)morpholine;(S)-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)pyrrolidin-3-yl)methanol;1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-N,N-dimethylpiperidin-4-amine;2-(1-((2-(2-(1-fluorocyclopropyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;2-(1-(2-(2-(cyclopropylmethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;4-(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)morpholine;4-(8-((3,3-dimethyl-4-(2-(methylsulfonyl)ethyl)piperazin-1-yl)methyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine;2-((1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)(methyl)amino)-2-methylpropanamide;4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-8-((4-(2-(methylsulfonyl)ethyl)piperazin-1-yl)methyl)-9H-purin-6-yl)morpholine;1-(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)-2-methylpropan-1-ol;4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-8-((4-(oxetan-3-yl)piperidin-1-yl)methyl)-9H-purin-6-yl)morpholine;2-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)propan-2-ol;3-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)pentan-3-ol;4-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)tetrahydro-2H-pyran-4-ol;(S)-4-(8-((3-(1,1-dioxo-isothiazolidin-2-yl)pyrrolidin-1-yl)methyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine;2-(1-((9-methyl-2-(2-(1-methyl-1H-pyrazol-5-yl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;(R)-4-(8-((3-(1,1-dioxo-isothiazolidin-2-yl)pyrrolidin-1-yl)methyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine;N-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)-2-(4-methylthiazol-2-yl)ethanamine;N-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)-2-(pyridin-2-yl)ethanamine;1-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)cyclopentanol;7-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-2-oxa-7-azaspiro[3.5]nonane;4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-8-((3-(tetrahydro-2H-pyran-4-yl)azetidin-1-yl)methyl)-9H-purin-6-yl)morpholine;N,N-dimethyl-1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidine-4-carboxamide;8-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one;4-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)morpholine;4-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-8-((4-(2-(methylsulfonyl)ethyl)piperazin-1-yl)methyl)-9H-purin-6-yl)morpholine;4-(8-((3,3-dimethyl-4-(2-(methylsulfonyl)ethyl)piperazin-1-yl)methyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine;4-(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)-2,2-dimethylmorpholine;2-(1-((5-(2-ethyl-1H-benzo[d]imidazol-1-yl)-7-morpholinothiazolo[5,4-d]pyrimidin-2-yl)methyl)piperidin-4-yl)propan-2-ol;(R)—N-methyl-N-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)pyrrolidin-3-yl)acetamide;(R)-4-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)pyrrolidin-3-yl)morpholine;(S)—N-methyl-N-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)pyrrolidin-3-yl)acetamide;(S)-4-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)pyrrolidin-3-yl)morpholine;2-(1-((2-(2-ethoxy-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;2-(1-((2-(2-isopropoxy-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;2-methyl-2-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-1-ol;4-(8-((4-tert-butylpiperazin-1-yl)methyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine;2-(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)-2-methylpropan-1-ol;N-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)-2-(pyrazin-2-yl)ethanamine;7-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)-7-azaspiro[3.5]nonan-2-ol;2-(1-(2-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)ethyl)piperidin-4-yl)propan-2-ol;4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-8-((3-fluoro-1,3′-biazetidin-1′-yl)methyl)-9-methyl-9H-purin-6-yl)morpholine;2-methyl-1-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-1-ol;azetidin-1-yl(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)methanone;(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)(pyrrolidin-1-yl)methanone;(R)-azetidin-1-yl(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)pyrrolidin-3-yl)methanone;(R)-(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)pyrrolidin-3-yl)(pyrrolidin-1-yl)methanone;(R)—N,N-dimethyl-1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)pyrrolidine-3-carboxamide;(R)-1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-N,N-dimethylpyrrolidine-3-carboxamide;2,2-dimethyl-4-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)morpholine;4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-8-((3-(1,1-dioxo-thiomorpholino)azetidin-1-yl)methyl)-9H-purin-6-yl)morpholine;4-(2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9-methyl-8-((3-(1,1-dioxo-thiomorpholino)azetidin-1-yl)methyl)-9H-purin-6-yl)morpholine;2-methyl-2-(4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)propane-1,3-diol;(R)-3-methyl-2-(4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)butan-1-ol;2-(1-((2-(2-(2-methoxyethylamino)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;(R)-1-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-1-ol;(S)-1-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-1-ol;(S)-3-methyl-2-(4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)butan-1-ol;2-(1-((5-(2-methyl-1H-benzo[d]imidazol-1-yl)-7-morpholinothiazolo[5,4-d]pyrimidin-2-yl)methyl)piperidin-3-yl)propan-2-ol;N,N-dimethyl-1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)azetidine-3-carboxamide;(R)-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)pyrrolidin-3-yl)(pyrrolidin-1-yl)methanone;(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)(pyrrolidin-1-yl)methanone;1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-N,N-dimethylazetidine-3-carboxamide;2-(1-(2-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)ethyl)piperidin-4-yl)propan-2-ol;2-methyl-2-(4-(2-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)ethyl)piperazin-1-yl)propanamide;8-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)-1,4-dioxa-8-azaspiro[4.5]decane;8-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)-1-oxa-8-azaspiro[4.5]decane;N-(2-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-yl)acetamide;(S)-2-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)butan-2-ol;(S)-1-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)ethanol;(R)-1-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)ethanol;4-(8-((dihydro-1H-pyrido[1,2-a]pyrazin-2(6H,7H,8H,9H,9aH)-yl)methyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine;N,N-diethyl-1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)pyrrolidin-3-amine;4-(8-((dihydro-1H-pyrido[1,2-a]pyrazin-2(6H,7H,8H,9H,9aH)-yl)methyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine;N,N-diethyl-1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)pyrrolidin-3-amine;8-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)-2,8-diazaspiro[4.5]decan-1-one;8-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)-3-oxa-8-azabicyclo[3.2.1]octane;(R)-2-(4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)butan-1-ol;(S)-2-(4-((9-methyl-2-(2-methyl-1-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)butan-1-ol;2-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-amine;5-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)-2-oxa-5-azabicyclo[2.2.1]heptane;(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-4-methylpiperidin-4-yl)methanol;4-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-8-((3-(piperidin-1-yl)azetidin-1-yl)methyl)-9H-purin-6-yl)morpholine;4-(8-((4-tert-butylpiperazin-1-yl)methyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine;(S)-1-(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)-2-methylpropan-1-ol;N-methyl-1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)-N-(tetrahydrofuran-3-yl)piperidin-4-amine;1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-N-methyl-N-(tetrahydrofuran-3-yl)piperidin-4-amine;7-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-2-methyl-7-azaspiro[3.5]nonan-2-ol;4-(2-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)ethyl)-2,2-dimethylmorpholine;(S)-azetidin-1-yl(1-((2-((2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)pyrrolidin-3-yl)methanone;9-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one;4-(8-((1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-ylmethyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine;(3-methyl-1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)pyrrolidin-3-yl)(pyrrolidin-1-yl)methanone;2,2-dimethyl-4-(2-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)ethyl)morpholine;(S)-1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-N,N-dimethylpyrrolidine-3-carboxamide;(S)-(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)pyrrolidin-3-yl)(pyrrolidin-1-yl)methanone;9-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)-1,5-dioxa-9-azaspiro[5.5]undecane;4-(8-((4-tert-butylpiperazin-1-yl)methyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine;2-(4-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)-2-methylpropan-1-ol;4-(8-((4-tert-butylpiperazin-1-yl)methyl)-2-(2-cyclopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine;2-((1R,5S,6r)-3-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)-3-azabicyclo[3.1.0]hexan-6-yl)propan-2-ol;(R)-1-(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)-2-methylpropan-1-ol;2-methyl-2-(4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)propanamide;(R)-1-(1-(8-((4-(2-hydroxypropan-2-yl)piperidin-1-yl)methyl)-9-methyl-6-morpholino-9H-purin-2-yl)-1H-benzo[d]imidazol-2-yl)propan-2-ol;(S)-1-(1-(8-((4-(2-hydroxypropan-2-yl)piperidin-1-yl)methyl)-9-methyl-6-morpholino-9H-purin-2-yl)-1H-benzo[d]imidazol-2-yl)propan-2-ol;(R)-8-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)octahydropyrazino[2,1-c][1,4]oxazine;4-methyl-5-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methylamino)pentane-1,4-diol;2-(1-(8-((4-tert-butylpiperazin-1-yl)methyl)-6-morpholino-9H-purin-2-yl)-1H-benzo[d]imidazol-2-yl)ethanol;(1S,2R)-2-(4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)cyclopentanol;2-(4-((2-(2-cyclopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)-2-methylpropan-1-ol;4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-8-((4-(3-methyloxetan-3-yl)piperazin-1-yl)methyl)-9H-purin-6-yl)morpholine;(S)-4-(8-((hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)methyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine;(R)-4-(8-((hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)methyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine;ethyl2-((1S,4S)-5-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)-2-methylpropanoate;1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-N-methyl-N-(oxetan-3-yl)piperidin-4-amine;N-((1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)methyl)-N-methyltetrahydrofuran-3-amine;2-(1-((5-(2-ethyl-1H-benzo[d]imidazol-1-yl)-7-morpholinothiazolo[4,5-d]pyrimidin-2-yl)methyl)piperidin-4-yl)propan-2-ol;N-((1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)methyl)-N-methyloxetan-3-amine;4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-8-((3-(tetrahydro-2H-pyran-4-yl)azetidin-1-yl)methyl)-9H-purin-6-yl)morpholine;2-methyl-2-(4-((2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)propanamide;2-(4-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)-2-methylpropanamide;2-(1-((2-(2-(2-hydroxyethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;2-(4-((2-(2-(2-hydroxyethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)-2-methylpropan-1-ol;1-(8-((4-tert-butylpiperazin-1-yl)methyl)-9-methyl-6-morpholino-9H-purin-2-yl)-N-methyl-1H-benzo[d]imidazol-2-amine;4-methyl-1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)azepan-4-ol;N-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)-2-(1H-pyrazol-1-yl)ethanamine;(1-aminocyclopropyl)(4-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)methanone;2-(1-(2-(5-(2-ethyl-1H-benzo[d]imidazol-1-yl)-7-morpholinothiazolo[5,4-d]pyrimidin-2-yl)ethyl)piperidin-4-yl)propan-2-ol;2-(1-(8-((4-tert-butylpiperazin-1-yl)methyl)-9-methyl-6-morpholino-9H-purin-2-yl)-1H-benzo[d]imidazol-2-yl)ethanol;N-methyl-1-(9-methyl-6-morpholino-8-((3-(tetrahydro-2H-pyran-4-yl)azetidin-1-yl)methyl)-9H-purin-2-yl)-1H-benzo[d]imidazol-2-amine;4-(5-(2-ethyl-1H-benzo[d]imidazol-1-yl)-2-((3-(1,1-dioxo-thiomorpholino)azetidin-1-yl)methyl)thiazolo[5,4-d]pyrimidin-7-yl)morpholine;2-(4-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)-2-methylpropanamide;2-(4-((2-(2-cyclopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)-2-methylpropanamide;2-(4-((2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)-2-methylpropanamide;2-(4-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)-2-methylpropane-1,3-diol;4-(8-((4-isopropylpiperazin-1-yl)methyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine;4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-8-((4-isopropylpiperazin-1-yl)methyl)-9-methyl-9H-purin-6-yl)morpholine;4-(8-((4-cyclobutylpiperazin-1-yl)methyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine;4-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-8-((4-(oxetan-3-yl)piperidin-1-yl)methyl)-9H-purin-6-yl)morpholine;N-methyl-1-(9-methyl-6-morpholino-8-((4-(oxetan-3-yl)piperidin-1-yl)methyl)-9H-purin-2-yl)-1H-benzo[d]imidazol-2-amine;4-(5-(2-methyl-1H-benzo[d]imidazol-1-yl)-2-((3-(1,1-dioxo-thiomorpholino)azetidin-1-yl)methyl)thiazolo[5,4-d]pyrimidin-7-yl)morpholine;4-(2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-8-((3-(1,1-dioxo-thiomorpholino)azetidin-1-yl)methyl)-9H-purin-6-yl)morpholine;4-(2-(2-cyclopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-8-((4-(oxetan-3-yl)piperidin-1-yl)methyl)-9H-purin-6-yl)morpholine;2-(1-(2-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)ethyl)azetidin-3-yl)propan-2-ol;1-(2-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)ethyl)-4-methylpiperidin-4-ol;2-methyl-2-(4-((9-methyl-2-(2-(methylamino)-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)propan-1-ol;4-(2-(2-(azetidin-1-yl)-1H-benzo[d]imidazol-1-yl)-8-((4-tert-butylpiperazin-1-yl)methyl)-9-methyl-9H-purin-6-yl)morpholine;2-(1-((2-(2-(azetidin-1-yl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;ethyl2-methyl-2-(4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-1-yl)propanoate;4-(8-((4-tert-butylpiperazin-1-yl)methyl)-2-(2-(1,1-difluoroethyl)-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine;1-(2-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)ethyl)-3-methylazetidin-3-ol;4-(2-(2-(1,1-difluoroethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-8-((4-(oxetan-3-yl)piperidin-1-yl)methyl)-9H-purin-6-yl)morpholine;(S)-(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)(3-hydroxypyrrolidin-1-yl)methanone;(R)-(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)(3-hydroxypyrrolidin-1-yl)methanone;2-(1-((2-(2-tert-butyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;4-(8-((4-tert-butylpiperazin-1-yl)methyl)-2-(2-(1,1-difluoroethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine;4-(8-((4-tert-butylpiperazin-1-yl)methyl)-9-methyl-2-(2-(trifluoromethyl)-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine;7-(2-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)ethyl)-7-azaspiro[3.5]nonan-2-ol;1-(2-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)ethyl)-3-isopropylazetidin-3-ol;4-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-8-((3-(tetrahydro-2H-pyran-4-yl)azetidin-1-yl)methyl)-9H-purin-6-yl)morpholine;4-(2-(2-(1,1-difluoroethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-8-((3-(tetrahydro-2H-pyran-4-yl)azetidin-1-yl)methyl)-9H-purin-6-yl)morpholine;4-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-1-isopropylpiperazin-2-one;4-(5-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-2-((3-(tetrahydro-2H-pyran-4-yl)azetidin-1-yl)methyl)thiazolo[5,4-d]pyrimidin-7-yl)morpholine;4-(8-((4-tert-butylpiperazin-1-yl)methyl)-2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine;2-(4-((2-(2-(1,1-difluoroethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)-2-methylpropan-1-ol;2-methyl-2-(4-((9-methyl-6-morpholino-2-(2-(trifluoromethyl)-1H-benzo[d]imidazol-1-yl)-9H-purin-8-yl)methyl)piperazin-1-yl)propan-1-ol;2-(4-((2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)-2-methylpropan-1-ol;2-(1-((2-(2-((1R,2S)-2-fluorocyclopropyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;(R)-2-(1-((2-(2-(2,2-difluorocyclopropyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;2-(1-((2-(2-((1S,2R)-2-fluorocyclopropyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;2-(1-((2-(2-((1R,2R)-2-fluorocyclopropyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;(S)-2-(1-((2-(2-(2,2-difluorocyclopropyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;4-(5-(2-methyl-1H-benzo[d]imidazol-1-yl)-2-((3-(tetrahydro-2H-pyran-4-yl)azetidin-1-yl)methyl)thiazolo[5,4-d]pyrimidin-7-yl)morpholine;4-(5-(2-ethyl-1H-benzo[d]imidazol-1-yl)-2-((3-(tetrahydro-2H-pyran-4-yl)azetidin-1-yl)methyl)thiazolo[5,4-d]pyrimidin-7-yl)morpholine;4-(5-(2-cyclopropyl-1H-benzo[d]imidazol-1-yl)-2-((3-(tetrahydro-2H-pyran-4-yl)azetidin-1-yl)methyl)thiazolo[5,4-d]pyrimidin-7-yl)morpholine;2-(1-(2-(2-ethyl-4-fluoro-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;1-(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)piperidin-4-ol;2-(1-((2-(2-(azetidin-1-ylmethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;2-(4-((2-(2-cyclopropyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)-2-methylpropan-1-ol;2-(4-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)-2-methylpropan-1-ol;2-(4-((2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)-2-methylpropan-1-ol;4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-8-((3-(4-fluoropiperidin-1-yl)azetidin-1-yl)methyl)-9-methyl-9H-purin-6-yl)morpholine;4-(8-((3-(4,4-difluoropiperidin-1-yl)azetidin-1-yl)methyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine;4-(2-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)ethyl)-1-isopropylpiperazin-2-one;1′-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-1,3′-biazetidin-3-ol;4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-8-((4-(tetrahydro-2H-pyran-4-yl)piperazin-1-yl)methyl)-9H-purin-6-yl)morpholine;4-(5-(2-ethyl-1H-benzo[d]imidazol-1-yl)-2-((4-(oxetan-3-yl)piperidin-1-yl)methyl)thiazolo[5,4-d]pyrimidin-7-yl)morpholine;4-(5-(2-cyclopropyl-1H-benzo[d]imidazol-1-yl)-2-((4-(oxetan-3-yl)piperidin-1-yl)methyl)thiazolo[5,4-d]pyrimidin-7-yl)morpholine;N-methyl-1-(7-morpholino-2-((3-(tetrahydro-2H-pyran-4-yl)azetidin-1-yl)methyl)thiazolo[5,4-d]pyrimidin-5-yl)-1H-benzo[d]imidazol-2-amine;4-(2-(2-cyclopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-8-((3-(tetrahydro-2H-pyran-4-yl)azetidin-1-yl)methyl)-9H-purin-6-yl)morpholine;ethyl2-(4-((2-(2-cyclopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)-2-methylpropanoate;4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-8-((1-(tetrahydro-2H-(1,1-dioxo)-thiopyran-4-yl)azetidin-3-yl)methyl)-9H-purin-6-yl)morpholine;ethyl2-methyl-2-(4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)propanoate;4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-8-((1-(tetrahydro-2H-pyran-4-yl)azetidin-3-yl)methyl)-9H-purin-6-yl)morpholine;4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-8-((4-(1-fluoro-2-methylpropan-2-yl)piperazin-1-yl)methyl)-9-methyl-9H-purin-6-yl)morpholine;tert-butyl4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidine-1-carboxylate;2-methyl-2-(4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)propanoicacid; methyl2-methyl-2-(4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-1-yl)propanoate;2-methyl-2-(4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-1-yl)propanamide;2-methyl-2-(4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-1-yl)propan-1-ol;8-(2-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)ethyl)-3-oxa-8-azabicyclo[3.2.1]octane;2-(1-(9-methyl-6-morpholino-8-((4-(oxetan-3-yl)piperidin-1-yl)methyl)-9H-purin-2-yl)-1H-benzo[d]imidazol-2-yl)ethanol;4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-8-((4-(oxetan-3-yl)piperazin-1-yl)methyl)-9H-purin-6-yl)morpholine;4-(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)piperazin-2-one;(S)-3-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-1-isopropylpiperidin-3-ol;(S)-2-(1-((2-(2-(1-methoxyethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;N-(1-(8-((4-(2-hydroxypropan-2-yl)piperidin-1-yl)methyl)-9-methyl-6-morpholino-9H-purin-2-yl)-1H-benzo[d]imidazol-2-yl)acetamide;(R)-3-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-1-isopropylpiperidin-3-ol;(R)-2-(1-((2-(2-(1-methoxyethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;4-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-8-(piperidin-4-ylmethyl)-9H-purin-6-yl)morpholine;2-((1S,4S)-5-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)-2-methylpropan-1-ol;4-(2-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)ethyl)-6-isopropylpiperazin-2-one;1-(4-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)-2-methylpropan-2-ol;1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-ol;2-methyl-2-(4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-1-yl)propanoicacid; (R)-methyl2-(4-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(hydroxy)methyl)piperidin-1-yl)-2-methylpropanoate;(S)-methyl2-(4-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(hydroxy)methyl)piperidin-1-yl)-2-methylpropanoate;methyl2-(4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purine-8-carbonyl)piperidin-1-yl)-2-methylpropanoate;4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-8-((1-(oxetan-3-yl)azetidin-3-yl)methyl)-9H-purin-6-yl)morpholine;4-(8-(azetidin-3-ylmethyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine;2-(3-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-1-yl)-2-methylpropanamide;methyl2-(3-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-1-yl)-2-methylpropanoate;2-(3-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-1-yl)-2-methylpropan-1-ol;1-(3-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-1-yl)-2-methylpropan-2-ol;4-(2-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)ethyl)-3,3-dimethylmorpholine;(S)-1-(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)pyrrolidin-3-ol;4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-8-(2-(3-(1,1-dioxo-thiomorpholino)azetidin-1-yl)ethyl)-9H-purin-6-yl)morpholine;(R)-1-(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)pyrrolidin-3-ol;4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-8-(2-(1,1-dioxo-thiomorpholino)ethyl)-9H-purin-6-yl)morpholine;4-(8-(2-(4,4-difluoropiperidin-1-yl)ethyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine;2-(3-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-1-yl)acetamide;2-methyl-1-(4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-1-yl)propan-2-ol;4-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-8-((1-(2-(methylsulfonyl)ethyl)azetidin-3-yl)methyl)-9H-purin-6-yl)morpholine;4-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-8-((1-(2-(methylsulfonyl)ethyl)piperidin-4-yl)methyl)-9H-purin-6-yl)morpholine;(R)-2-(3-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-1-yl)propanamide;(S)-2-(3-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-1-yl)propanamide;4-(1-((2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)morpholine;4-(1-((2-(2-cyclopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)morpholine;2-(5-(2-ethyl-1H-benzo[d]imidazol-1-yl)-7-morpholinothiazolo[5,4-d]pyrimidin-2-yl)-1-(4-(2-hydroxypropan-2-yl)piperidin-1-yl)ethanone;1-(1-((2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)piperidin-4-ol;1-(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)-4-methylpiperidin-4-ol;4-(8-((3,3-dimethylpiperazin-1-yl)methyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine;4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-8-(((1S,4S)-5-(methylsulfonyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)methyl)-9H-purin-6-yl)morpholine;1-(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)azetidin-3-ol;1-isopropyl-4-(2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperazin-2-one;4-(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)-1-methylpiperazin-2-one;4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-8-(2-(4-(tetrahydro-2H-pyran-4-yl)piperazin-1-yl)ethyl)-9H-purin-6-yl)morpholine;2-(4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-1-yl)acetamide;(R)-2-(4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-1-yl)propanamide;(S)-2-(4-((9-methyl-2-(2-methyl-1-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-1-yl)propanamide;(R)-4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-8-(4-(3-fluoropyrrolidin-1-yl)piperidin-1-yl)methyl)-9-methyl-9H-purin-6-yl)morpholine;4-(8-((3,3-difluoro-1,3′-biazetidin-1′-yl)methyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine;4-(2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-8-(((1S,4S)-5-(methylsulfonyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)methyl)-9H-purin-6-yl)morpholine;4-(2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-8-((4-(tetrahydro-2H-pyran-4-yl)piperazin-1-yl)methyl)-9H-purin-6-yl)morpholine;(S)-4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-8-((4-(3-fluoropyrrolidin-1-yl)piperidin-1-yl)methyl)-9-methyl-9H-purin-6-yl)morpholine;2-(4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purine-8-carbonyl)piperazin-1-yl)-2-methylpropanamide;(4-tert-butylpiperazin-1-yl)(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methanone;3-(4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-1-yl)propanenitrile;(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(4-(2-hydroxypropan-2-yl)piperidin-1-yl)methanone;4-(8-((1-(isoxazol-5-ylmethyl)piperidin-4-yl)methyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine;4-(8-((1-(isoxazol-5-ylmethyl)azetidin-3-yl)methyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine;(S)-4-(9-methyl-2-(2-methyl-1-benzo[d]imidazol-1-yl)-8-((1-(tetrahydrofuran-3-yl)azetidin-3-yl)methyl)-9H-purin-6-yl)morpholine;(R)-4-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-8-((1-(tetrahydrofuran-3-yl)azetidin-3-yl)methyl)-9H-purin-6-yl)morpholine;4-(8-(2-(3,3-dimethyl-4-(methylsulfonyl)piperazin-1-yl)ethyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine;4-(8-((4-(3,3-difluoroazetidin-1-yl)piperidin-1-yl)methyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine;1-tert-butyl-4-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperazin-2-one;(S)-2-amino-1-(4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-1-yl)propan-1-one;3-methyl-2-(3-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)azetidin-1-yl)butanamide;N,2-dimethyl-2-(3-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)azetidin-1-yl)propanamide;(S)-3-(2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-1-methylpiperidin-3-ol;(R)-3-(2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-1-methylpiperidin-3-ol;4-(2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-8-(1-isopropyl-3-methoxypiperidin-3-yl)-9-methyl-9H-purin-6-yl)morpholine;4-(2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-8-(1-isopropyl-3-methoxypiperidin-3-yl)-9-methyl-9H-purin-6-yl)morpholine;N,2-dimethyl-2-(4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-1-yl)propanamide;(S)-4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-8-((3-(3-fluoropyrrolidin-1-yl)azetidin-1-yl)methyl)-9-methyl-9H-purin-6-yl)morpholine;1′-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-3-methyl-1,3′-biazetidin-3-ol;1-(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)pyrrolidin-2-one;4-(8-((3-(3,3-difluoropyrrolidin-1-yl)azetidin-1-yl)methyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine;(R)-4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-8-((3-(3-fluoropyrrolidin-1-yl)azetidin-1-yl)methyl)-9-methyl-9H-purin-6-yl)morpholine;(R)-1-isopropyl-3-(2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)piperidin-3-ol;(S)-1-isopropyl-3-(2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)piperidin-3-ol;(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(4-(tetrahydro-2H-(1,1-dioxo)-thiopyran-4-yl)piperazin-1-yl)methanone;N-tert-butyl-1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-amine;N-(2-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)ethyl)tetrahydro(1,1-dioxo)thiophen-3-amine;4-(8-((2,2-dimethyl-4-(methylsulfonyl)piperazin-1-yl)methyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine;2-((1S,4S)-5-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)acetamide;4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-8-((1S,4S)-5-(oxetan-3-yl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)methyl)-9H-purin-6-yl)morpholine;2-methyl-2-(4-(methyl(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)amino)piperidin-1-yl)propanamide;2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-N,N-bis(2-methoxyethyl)-9-methyl-6-morpholino-9H-purine-8-carboxamide;(4-(dimethylamino)piperidin-1-yl)(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methanone;2-methyl-2-(3-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)pyrrolidin-1-yl)propanamide;2-methyl-2-(3-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)pyrrolidin-1-yl)propanamide;1-(3-hydroxy-3-(2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)piperidin-1-yl)ethanone;(S)-8-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-4,4-dimethylhexahydropyrazino[2,1-c][1,4]oxazin-3(1H)-one;(R)-8-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-4,4-dimethylhexahydropyrazino[2,1-c][1,4]oxazin-3(1H)-one;N-(2-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)ethyl)-N-methyl-1,1-dioxo-tetrahydrothiophen-3-amine;4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-8-((4-(3-fluoroazetidin-1-yl)piperidin-1-yl)methyl)-9-methyl-9H-purin-6-yl)morpholine;2-methyl-2-(4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methylene)piperidin-1-yl)propanamide;2-methyl-2-(4-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methylene)piperidin-1-yl)propanamide;(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)methanone;(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)methanone;4-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-8-(piperidin-4-ylidenemethyl)-9H-purin-6-yl)morpholine;4-(8-(((3S,5R)-3,5-dimethylpiperazin-1-yl)methyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine;4-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-8-(piperidin-4-ylidenemethyl)-9H-purin-6-yl)morpholine;2-(3-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methylene)azetidin-1-yl)-2-methylpropanamide;2-(3-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methylene)azetidin-1-yl)-2-methylpropanamide;1-(4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purine-8-carbonyl)-1,4-diazepan-1-yl)ethanone;(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(4-hydroxypiperidin-1-yl)methanone;(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(pyrrolidin-1-yl)methanone;azetidin-1-yl(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methanone;(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(2-(hydroxymethyl)piperidin-1-yl)methanone;(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(4-(hydroxymethyl)piperidin-1-yl)methanone;4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purine-8-carbonyl)piperazine-1-carbaldehyde;(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(3-(hydroxymethyl)piperidin-1-yl)methanone;(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(4-(pyridin-3-yl)piperazin-1-yl)methanone;N-(2-(dimethylamino)-2-oxoethyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-N,9-dimethyl-6-morpholino-9H-purine-8-carboxamide;(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(4-(2-methoxyethyl)piperazin-1-yl)methanone;(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(4-fluoropiperidin-1-yl)methanone;2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-N-(2-methoxyethyl)-N,9-dimethyl-6-morpholino-9H-purine-8-carboxamide;4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purine-8-carbonyl)-N,N-dimethylpiperazine-1-carboxamide;(S)-(3-(dimethylamino)pyrrolidin-1-yl)(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methanone;(R)-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(3-hydroxypiperidin-1-yl)methanone;(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(1,4-oxazepan-4-yl)methanone;2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-N,9-dimethyl-N-(1-methylpyrrolidin-3-yl)-6-morpholino-9H-purine-8-carboxamide;N-(2-cyanoethyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-N,9-dimethyl-6-morpholino-9H-purine-8-carboxamide;N-(cyanomethyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-N,9-dimethyl-6-morpholino-9H-purine-8-carboxamide;2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-N-(2-hydroxyethyl)-N,9-dimethyl-6-morpholino-9H-purine-8-carboxamide;(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(3-(trifluoromethyl)piperidin-1-yl)methanone;(4,4-difluoropiperidin-1-yl)(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methanone;(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(4-(methoxymethyl)piperidin-1-yl)methanone;(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(3-(trifluoromethyl)pyrrolidin-1-yl)methanone;2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-N,9-dimethyl-6-morpholino-N-(1,1-dioxo-tetrahydrothiophen-3-yl)-9H-purine-8-carboxamide;(R)-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(2-(hydroxymethyl)pyrrolidin-1-yl)methanone;1-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purine-8-carbonyl)piperidine-4-carboxamide;tert-butyl3-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)pyrrolidine-1-carboxylate;tert-butyl4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)piperidine-1-carboxylate;4-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-3-isopropylpiperazin-2-one;4-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-3,3-dimethylpiperazin-2-one;(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(4-methylpiperazin-1-yl)methanone;(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(4-isopropylpiperazin-1-yl)methanone;1-(4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purine-8-carbonyl)piperazin-1-yl)ethanone;(4-(cyclopropylmethyl)piperazin-1-yl)(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methanone;1-(4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purine-8-carbonyl)piperazin-1-yl)-2-methylpropan-1-one;(4-cyclobutylpiperazin-1-yl)(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methanone;(4-(cyclopropanecarbonyl)piperazin-1-yl)(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methanone;(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(4-(methylsulfonyl)piperazin-1-yl)methanone;2-(3-hydroxy-3-(2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)piperidin-1-yl)-2-methylpropanamide;(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)methanone;(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(4-(pyridin-2-yl)piperazin-1-yl)methanone;2-(3-hydroxy-3-(2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)piperidin-1-yl)-2-methylpropanamide;(R)-2-(3-(2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-3-methoxypiperidin-1-yl)-2-methylpropanamide;(S)-2-(3-(2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-3-methoxypiperidin-1-yl)-2-methylpropanamide;(R)-1-(3-(2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-3-methoxypiperidin-1-yl)ethanone;(S)-1-(3-(2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-3-methoxypiperidin-1-yl)ethanone;(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(4-(oxetan-3-yl)piperazin-1-yl)methanone;2-(4-(2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-4-morpholinofuro[3,2-d]pyrimidine-6-carbonyl)piperazin-1-yl)-2-methylpropanamide;2-(4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-4-morpholinofuro[3,2-d]pyrimidine-6-carbonyl)piperazin-1-yl)-2-methylpropanamide;(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-4-morpholinofuro[3,2-d]pyrimidin-6-yl)(4-(2-hydroxypropan-2-yl)piperidin-1-yl)methanone;(4-(2-hydroxypropan-2-yl)piperidin-1-yl)(2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-4-morpholinofuro[3,2-d]pyrimidin-6-yl)methanone;(2-(2-(1,1-difluoroethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(4-(2-hydroxypropan-2-yl)piperidin-1-yl)methanone;(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(4-(1-hydroxy-2-methylpropan-2-yl)piperazin-1-yl)methanone;(R)-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(2-methylpiperidin-1-yl)methanone;(S)-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(2-methylpiperidin-1-yl)methanone;(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(3-(1,1-dioxo)thiomorpholinoazetidin-1-yl)methanone;4-(2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-8-(pyridin-3-yl)-9H-purin-6-yl)morpholine;2-(4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)piperidin-1-yl)acetamide;tert-butyl3-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)azetidine-1-carboxylate;(R)-1-(3-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-1-yl)-2-hydroxypropan-1-one;4-(8-(azetidin-3-yl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine;1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-3-isopropylpiperazin-2-one;4-(2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-8-(3-methoxyphenyl)-9-methyl-9H-purin-6-yl)morpholine;4-(8-(3-ethoxy-1-isopropylpiperidin-3-yl)-2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine;(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(3-morpholinoazetidin-1-yl)methanone;(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(4-(oxazol-2-ylmethyl)piperazin-1-yl)methanone;2-(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;and2-(1-((2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol.22. The compound of claim 1 selected from2-(4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)piperidin-1-yl)-2-methylpropanamide;(R)-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(3-fluoropyrrolidin-1-yl)methanone;(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(3-(tetrahydro-2H-pyran-4-yl)azetidin-1-yl)methanone;N-ethyl-4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purine-8-carbonyl)piperazine-1-carboxamide;(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(pyridin-3-yl)methanone;(S)—N-(2-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)ethyl)-N-methyl-(1,1-dioxo)-tetrahydrothiophen-3-amine;(R)—N-(2-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)ethyl)-N-methyl-(1,1-dioxo)-tetrahydrothiophen-3-amine;1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-4-isopropylpiperazin-2-one;2-(5-(2-ethyl-1H-benzo[d]imidazol-1-yl)-7-morpholinothiazolo[5,4-d]pyrimidin-2-yl)-1-(4-(1-hydroxy-2-methylpropan-2-yl)piperazin-1-yl)ethanone;4-(2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-8-(3-methoxy-1-(2-(methylsulfonyl)ethyl)piperidin-3-yl)-9-methyl-9H-purin-6-yl)morpholine;tert-butyl3-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-3-methoxyazetidine-1-carboxylate;(2,2-dimethyl-4-(methylsulfonyl)piperazin-1-yl)(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methanone;2-(3-(2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-3-methoxypiperidin-1-yl)acetamide;2-(4-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-3,3-dimethylpiperazin-1-yl)acetamide;(S)-1-(3-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-1-yl)-2-hydroxypropan-1-one;3-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-1-(tetrahydro-2H-pyran-4-yl)azetidin-3-ol;1-(3-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-1-yl)-2-hydroxy-2-methylpropan-1-one;(R)-1-(4-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-3,3-dimethylpiperazin-1-yl)-2-hydroxypropan-1-one;(S)-1-(4-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-3,3-dimethylpiperazin-1-yl)-2-hydroxypropan-1-one;1-(4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purine-8-carbonyl)piperazin-1-yl)propan-1-one;methyl4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purine-8-carbonyl)piperazine-1-carboxylate;(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(4-(2,2,2-trifluoroethyl)piperazin-1-yl)methanone;(R)-1-(4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purine-8-carbonyl)piperazin-1-yl)-2-hydroxypropan-1-one;(S)-1-(4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purine-8-carbonyl)piperazin-1-yl)-2-hydroxypropan-1-one;(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(4-(1,1-dioxotetrahydrothiophen-3-yl)piperazin-1-yl)methanone;4-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-8-((1-(1,1-dioxo-tetrahydrothiophen-3-yl)piperidin-4-yl)methyl)-9H-purin-6-yl)morpholine;(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(3-methylpyrrolidin-1-yl)methanone;2-(1-((2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;2-(1-(1-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)ethyl)piperidin-4-yl)propan-2-ol;2-(1-(1-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)ethyl)piperidin-4-yl)propan-2-ol;(4-(2-hydroxypropan-2-yl)piperidin-1-yl)(2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methanone;4-(8-(((2R,6S)-2,6-dimethyl-4-(methylsulfonyl)piperazin-1-yl)methyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine;3-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-1-isopropylazetidin-3-ol;4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-8-(1-isopropyl-3-methoxyazetidin-3-yl)-9-methyl-9H-purin-6-yl)morpholine;4-(8-((2,2-dimethyl-4-(oxetan-3-yl)piperazin-1-yl)methyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine;1-(4-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-3,3-dimethylpiperazin-1-yl)-2-hydroxy-2-methylpropan-1-one;2-(3-(2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-3-methoxypiperidin-1-yl)acetamide;2-(3-(2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-3-methoxypiperidin-1-yl)acetamide;4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-8-((7-(oxetan-3-yl)-4,7-diazaspiro[2.5]octan-4-yl)methyl)-9H-purin-6-yl)morpholine;2-(3-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-3-hydroxypiperidin-1-yl)-N,N-dimethylacetamide;3-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-1-(2-hydroxy-2-methylpropyl)piperidin-3-ol;4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-8-(1-(tetrahydro-2H-pyran-4-yl)azetidin-3-yl)-9H-purin-6-yl)morpholine;N-(2-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)ethyl)-N,3-dimethyl-1,1-dioxotetrahydrothiophen-3-amine;2-(4-(9-ethyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purine-8-carbonyl)piperazin-1-yl)-2-methylpropanamide;4-(8-((2,2-dimethyl-4-(methylsulfonyl)piperazin-1-yl)methyl)-2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine;2-(1-((2-(2-(1,1-difluoroethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;2-(1-((2-(2-cyclopropyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;4-(1-((2-(2-(1,1-difluoroethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)morpholine;(4-(2-hydroxypropan-2-yl)piperidin-1-yl)(2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methanone;4-(2-(2-(1,1-difluoroethyl)-1H-benzo[d]imidazol-1-yl)-8-((3-(tetrahydro-2H-pyran-4-yl)azetidin-1-yl)methyl)-9H-purin-6-yl)morpholine;4-(2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-8-((3-(tetrahydro-2H-pyran-4-yl)azetidin-1-yl)methyl)-9H-purin-6-yl)morpholine;(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)(4-(2-hydroxypropan-2-yl)piperidin-1-yl)methanone;4-(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)morpholine;(9-ethyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)(4-(2-hydroxypropan-2-yl)piperidin-1-yl)methanone;(4-(2-hydroxypropan-2-yl)piperidin-1-yl)(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methanone;2-(4-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-1-yl)-2-methylpropanamide;4-(1-((2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)morpholine;2-(4-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)fluoromethylene)piperidin-1-yl)-2-methylpropanamide;(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(piperazin-1-yl)methanone;3-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-1-(methylsulfonyl)piperidin-3-ol;4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-8-(3-methoxy-1-(methylsulfonyl)piperidin-3-yl)-9-methyl-9H-purin-6-yl)morpholine;1-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purine-8-carbonyl)piperidine-4-carbonitrile;(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(4-(2-hydroxyethyl)piperazin-1-yl)methanone;(9-(2-hydroxyethyl)-2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)(4-(2-hydroxypropan-2-yl)piperidin-1-yl)methanone;2-(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-6-(octadeuterio)morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;(5-(2-ethyl-1H-benzo[d]imidazol-1-yl)-7-morpholinothiazolo[5,4-d]pyrimidin-2-yl)(4-(2-hydroxypropan-2-yl)piperidin-1-yl)methanone;3-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-1-(tetrahydro-2H-pyran-4-yl)piperidin-3-ol;2-amino-1-(4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purine-8-carbonyl)piperazin-1-yl)ethanone;(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(4-(1-hydroxyethyl)piperidin-1-yl)methanone;(S)-2-(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-(3-methylmorpholino)-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;(4-(1,3-dihydroxypropan-2-yl)piperazin-1-yl)(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methanone;(4-(cyclopropanecarbonyl)piperazin-1-yl)(2-(2-(dimethylamino)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methanone;(R)-1-(4-(2-(2-(dimethylamino)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purine-8-carbonyl)piperazin-1-yl)-2-hydroxypropan-1-one;N-(1-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purine-8-carbonyl)piperidin-4-yl)acetamide;(1-aminocyclopropyl)(4-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-3,3-dimethylpiperazin-1-yl)methanone;(R)-2-(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-(3-methylmorpholino)-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol;N-(1-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purine-8-carbonyl)piperidin-4-yl)propionamide;N-(1-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purine-8-carbonyl)piperidin-4-yl)-2-hydroxy-2-methylpropanamide;4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-8-(1-isopropyl-1H-1,2,4-triazol-5-yl)-9-methyl-9H-purin-6-yl)morpholine;(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(3-(oxetan-3-ylamino)azetidin-1-yl)methanone;N-(1-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purine-8-carbonyl)azetidin-3-yl)propionamide;(2-(2-(dimethylamino)-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)(4-(2-hydroxypropan-2-yl)piperidin-1-yl)methanone;(S)-(4-(2-hydroxypropan-2-yl)piperidin-1-yl)(2-(2-(1-methoxyethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methanone;1-(4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-4-hydroxypiperidin-1-yl)-2-hydroxy-2-methylpropan-1-one;1-(3-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-3-methoxypiperidin-1-yl)-2-methylpropan-2-ol;(2,2-dimethyl-4-(oxetan-3-yl)piperazin-1-yl)(5-(2-ethyl-1H-benzo[d]imidazol-1-yl)-7-morpholinothiazolo[5,4-d]pyrimidin-2-yl)methanone;(R)-(4-(2-hydroxypropan-2-yl)piperidin-1-yl)(2-(2-(1-methoxyethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methanone;1-(4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purine-8-carbonyl)piperazin-1-yl)-2-hydroxy-2-methylpropan-1-one;4-(1-((5-(2-ethyl-1H-benzo[d]imidazol-1-yl)-7-morpholinothiazolo[5,4-d]pyrimidin-2-yl)methyl)azetidin-3-yl)piperazin-2-one;(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(3-(4-hydroxypiperidin-1-yl)azetidin-1-yl)methanone;(2-(2-cyclopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(4-(2-hydroxypropan-2-yl)piperidin-1-yl)methanone;(2-(2-cyclopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(3-morpholinoazetidin-1-yl)methanone;1-(4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-4-methoxypiperidin-1-yl)-2-hydroxy-2-methylpropan-1-one;(4-(2-hydroxypropan-2-yl)piperidin-1-yl)(2-(2-(methoxymethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methanone;(2-(2-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(4-(2-hydroxypropan-2-yl)piperidin-1-yl)methanone;(R)-(2-(2-(1-methoxyethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(3-morpholinoazetidin-1-yl)methanone;N,N-diethyl-4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purine-8-carbonyl)piperazine-1-carboxamide;(S)-(4-tert-butylpiperazin-1-yl)(2-(2-(1-methoxyethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methanone;N-(1-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purine-8-carbonyl)piperidin-4-yl)-N-methylacetamide;(4-(cyclopropanecarbonyl)piperazin-1-yl)(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methanone;1-(4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purine-8-carbonyl)piperazin-1-yl)propan-1-one;4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-8-(1-(1-methylpiperidin-4-yl)-1H-1,2,4-triazol-5-yl)-9H-purin-6-yl)morpholine;(2-(2-(1,1-difluoroethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(3-morpholinoazetidin-1-yl)methanone;1-(3-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-3-methoxyazetidin-1-yl)-2-hydroxy-2-methylpropan-1-one4-(1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)azetidin-3-yl)piperazin-2-one;4-(2-((2,2-dimethyl-4-(oxetan-3-yl)piperazin-1-yl)methyl)-5-(2-ethyl-1H-benzo[d]imidazol-1-yl)thiazolo[5,4-d]pyrimidin-7-yl)morpholine;1-(3-((5-(2-ethyl-1H-benzo[d]imidazol-1-yl)-7-morpholinothiazolo[5,4-d]pyrimidin-2-yl)methyl)azetidin-1-yl)-2-hydroxy-2-methylpropan-1-one;4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purine-8-carbonyl)-N-isopropylpiperazine-1-carboxamide;4-(8-(1-cyclopentyl-1H-1,2,4-triazol-5-yl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine;4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-8-(1-isopropyl-1H-imidazol-2-yl)-9-methyl-9H-purin-6-yl)morpholine;1-(4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purine-8-carbonyl)piperazin-1-yl)-2-methylpropan-1-one;1-(4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purine-8-carbonyl)piperazin-1-yl)-2,2-dimethylpropan-1-one;(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)(3-(1,1-dioxo)-thiomorpholinoazetidin-1-yl)methanone;(2-(2-(hydroxymethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(4-(2-hydroxypropan-2-yl)piperidin-1-yl)methanone;4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-8-(1-isobutyl-1H-1,2,4-triazol-5-yl)-9-methyl-9H-purin-6-yl)morpholine;1-(4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-4-methoxypiperidin-1-yl)-2-hydroxyethanone;1-(3-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-1-yl)-2-methylpropan-1-one;cyclopropyl(3-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-1-yl)methanone;4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-8-(3-methoxy-1-(2-(methylsulfonyl)ethyl)azetidin-3-yl)-9-methyl-9H-purin-6-yl)morpholine;4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-8-(3-methoxy-1-(tetrahydro-2H-pyran-4-yl)azetidin-3-yl)-9-methyl-9H-purin-6-yl)morpholine;tert-butyl3-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-3-fluoroazetidine-1-carboxylate;(S)-1-(4-((5-(2-ethyl-1H-benzo[d]imidazol-1-yl)-7-morpholinothiazolo[5,4-d]pyrimidin-2-yl)methyl)-3,3-dimethylpiperazin-1-yl)-2-hydroxypropan-1-one;(S)-(2-(2-(1-methoxyethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(3-morpholinoazetidin-1-yl)methanone;2-(5-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-1H-1,2,4-triazol-1-yl)-N,N-dimethylethanamine;1-(8-(1-isopropyl-1H-1,2,4-triazol-5-yl)-9-methyl-6-morpholino-9H-purin-2-yl)-N,N-dimethyl-1H-benzo[d]imidazol-2-amine;1-(3-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-3-methoxyazetidin-1-yl)-2-methylpropan-2-ol;4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-8-(3-fluoroazetidin-3-yl)-9-methyl-9H-purin-6-yl)morpholine;(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)(3-morpholinoazetidin-1-yl)methanone;4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-8-(1-isopropyl-4-methyl-1H-pyrazol-5-yl)-9-methyl-9H-purin-6-yl)morpholine;1-(5-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-4-methyl-1H-pyrazol-1-yl)-2-methylpropan-2-ol;1-(5-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-1H-1,2,4-triazol-1-yl)-2-methylpropan-2-ol;1-(3-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-3-fluoroazetidin-1-yl)-2-methylpropan-2-ol;(S)-1-(3-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-3-methoxyazetidin-1-yl)-2-hydroxypropan-1-one;(4-(2-hydroxypropan-2-yl)piperidin-1-yl)(9-methyl-2-(2-(methylamino)-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methanone;1-(4-(2-(2-(dimethylamino)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purine-8-carbonyl)piperazin-1-yl)propan-1-one;(2-(2-(dimethylamino)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(3-morpholinoazetidin-1-yl)methanone;(2-(2-(dimethylamino)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(4-(2-hydroxypropan-2-yl)piperidin-1-yl)methanone;1-(4-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-1-yl)-2-hydroxy-2-methylpropan-1-one;(5-(2-ethyl-1H-benzo[d]imidazol-1-yl)-7-morpholinothiazolo[5,4-d]pyrimidin-2-yl)(3-morpholinoazetidin-1-yl)methanone;(S)-1-(4-(2-(2-(1-methoxyethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purine-8-carbonyl)piperazin-1-yl)propan-1-one;1-(4-(9-methyl-2-(2-(methylamino)-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purine-8-carbonyl)piperazin-1-yl)propan-1-one;2-(3-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-3-methoxyazetidin-1-yl)ethanol;2-(3-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-3-fluoroazetidin-1-yl)-2-methylpropan-1-ol;1-(4-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-1-yl)-2-methylpropan-1-one;cyclopropyl(4-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-1-yl)methanone;4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-8-(pyridin-2-yl)-9H-purin-6-yl)morpholine;2-hydroxy-1-(3-((2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-1-yl)-2-methylpropan-1-one;2-hydroxy-2-methyl-1-(3-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)azetidin-1-yl)propan-1-one;2-(1-(8-(4-(2-hydroxypropan-2-yl)piperidine-1-carbonyl)-9-methyl-6-morpholino-9H-purin-2-yl)-1H-benzo[d]imidazol-2-yl)acetonitrile;(4-(2-hydroxypropan-2-yl)piperidin-1-yl)(9-methyl-6-morpholino-2-(2-(trifluoromethyl)-1H-benzo[d]imidazol-1-yl)-9H-purin-8-yl)methanone;(2-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(4-(2-hydroxypropan-2-yl)piperidin-1-yl)methanone;(S)-1-(3-((2-(2-(1-hydroxyethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-1-yl)-2-methylpropan-1-one;(R)-1-(3-((2-(2-(1-hydroxyethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-1-yl)-2-methylpropan-1-one;(R)-2-hydroxy-1-(3-((2-(2-(1-hydroxyethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)azetidin-1-yl)-2-methylpropan-1-one;(S)-1-(4-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-1-yl)-2-hydroxypropan-1-one;1-(4-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purine-8-carbonyl)piperidin-1-yl)-2-methylpropan-1-one;(1-(cyclopropanecarbonyl)piperidin-4-yl)(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methanone;cyclopropyl(4-(1-(2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)-1-hydroxyethyl)piperidin-1-yl)methanone;(9-methyl-2-(2-(methylamino)-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)(3-morpholinoazetidin-1-yl)methanone;(R)-(2-(2-(1-hydroxyethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(3-morpholinoazetidin-1-yl)methanone;(S)-(2-(2-(1-hydroxyethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(3-morpholinoazetidin-1-yl)methanone;(2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(3-morpholinoazetidin-1-yl)methanone;(2-(2-(2-hydroxyethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(3-morpholinoazetidin-1-yl)methanone;(4-(2-hydroxypropan-2-yl)piperidin-1-yl)(9-methyl-2-(2-methyl-3H-imidazo[4,5-c]pyridin-3-yl)-6-morpholino-9H-purin-8-yl)methanone;(9-methyl-2-(2-methyl-3H-imidazo[4,5-c]pyridin-3-yl)-6-morpholino-9H-purin-8-yl)(3-morpholinoazetidin-1-yl)methanone;(4-(2-hydroxypropan-2-yl)piperidin-1-yl)(9-methyl-2-(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)-6-morpholino-9H-purin-8-yl)methanone;(9-methyl-2-(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)-6-morpholino-9H-purin-8-yl)(3-morpholinoazetidin-1-yl)methanone;1-(4-((5-(2-ethyl-1H-benzo[d]imidazol-1-yl)-7-morpholinothiazolo[5,4-d]pyrimidin-2-yl)methyl)piperidin-1-yl)-2-hydroxy-2-methylpropan-1-one;(2-(2-methoxy-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(3-morpholinoazetidin-1-yl)methanone;(2-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(3-morpholinoazetidin-1-yl)methanone;(2-(2-(2-hydroxyethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)(4-(2-hydroxypropan-2-yl)piperidin-1-yl)methanone;1-(4-(2-(2-(2-hydroxyethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purine-8-carbonyl)piperazin-1-yl)propan-1-one;1-(4-(9-methyl-2-(2-methyl-3H-imidazo[4,5-c]pyridin-3-yl)-6-morpholino-9H-purine-8-carbonyl)piperazin-1-yl)propan-1-one;1-(4-(9-methyl-2-(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)-6-morpholino-9H-purine-8-carbonyl)piperazin-1-yl)propan-1-one;1-(8-(4-(2-hydroxypropan-2-yl)piperidine-1-carbonyl)-9-methyl-6-morpholino-9H-purin-2-yl)-1H-benzo[d]imidazol-2(3H)-one;(4-(2-hydroxypropan-2-yl)piperidin-1-yl)(2-(2-methoxy-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methanone;and1-(4-(2-(2-methoxy-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purine-8-carbonyl)piperazin-1-yl)propan-1-one.